[{"id": 345, "slug": "psychological-status-of-medical-workforce-during-the-covid-19-pandemic-a-cross-s", "title": "Psychological status of medical workforce during the COVID-19 pandemic: A cross-sectional study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "L'\u00e9tude se concentre sur l'\u00e9valuation de l'\u00e9tat psychologique du personnel soignant pendant la pand\u00e9mie de COVID-19.", "verbose_date": "15.04.2020", "authors": "Lu W", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 25, "name": "Psychiatry Res"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0165178120305850?token=C8C7D4A41B27E0D131361DC547B16C75B9BCE01BD125AB5FFE98426BE0DEB471DC622C076467838E39DFAA9D4707AD56", "findings": "", "take_away": "", "relevance_level": "Le personnel soignant semble ressentir plus de peur, d'anxi\u00e9t\u00e9 et de d\u00e9pression que le personnel administratif. En outre, le personnel soignant de premi\u00e8re ligne travaillant dans les services des maladies respiratoires, des urgences, des soins intensifs et des maladies infectieuses \u00e9tait deux fois plus susceptible de souffrir d'anxi\u00e9t\u00e9 et de d\u00e9pression que le personnel non clinique.", "objectives": "Etude transversale monocentrique", "methods": "L'\u00e9tude se concentre sur l'\u00e9valuation de l'\u00e9tat psychologique du personnel soignant pendant la pand\u00e9mie de COVID-19.", "pubmed_id": "32276196\n31995857\n31782862\n32147890\n21112450\n31443480\n30343247\n32125537\n32122230\n32005675\n31988490\n29087460\n32118689\n32085839\n30366234\n15608831\n32105614\n31847898\n32133578\n32097725\n32207807\n32056751\n31991628\n32001309\n32093461\n31986264\n32146245\n32004066\n32155789\n32088508", "doi": "10.1016/j.psychres.2020.112936", "abstract": "The pandemic of 2019 coronavirus disease (COVID-19) has burdened an unprecedented psychological stress on people around the world, especially\u00a0the medical workforce. The study focuses on assess the psychological status of them. The authors conducted a single-center, cross-sectional survey via online questionnaires. Occurrence of fear, anxiety and depression were measured by the numeric rating scale (NRS) on fear, Hamilton Anxiety Scale (HAMA), and Hamilton Depression Scale (HAMD), respectively. A total of 2299 eligible participants were enrolled from the authors' institution, including 2042 medical staff and 257 administrative staff. The severity of fear, anxiety and depression were significantly different between two groups. Furthermore, as compared to the non-clinical staff, front line medical staff with close contact with infected patients, including working in the departments of respiratory,\u00a0emergency,\u00a0infectious disease, and ICU, showed higher scores on fear scale, HAMA and HAMD, and they were 1.4 times more likely to feel fear, twice more likely to suffer anxiety and depression. The medical staff especially working in above-mentioned departments made them more susceptible to psychological disorders. Effective strategies toward to improving the mental health should be provided to these individuals.", "topics": ["Epid\u00e9miologique", "Psychiatrie"], "author_list": [{"id": 331, "name": "Lu W"}], "publication_date": "2020-04-15"}, {"id": 246, "slug": "medical-masks-vs-n95-respirators-for-preventing-covid-19-in-health-care-workers-", "title": "Medical Masks vs N95 Respirators for Preventing COVID-19 in Health Care Workers A Systematic Review and Meta-Analysis of Randomized Trials", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Comparer les masques m\u00e9dicaux aux N95 dans la pr\u00e9vention de l'infection virale chez les soignants", "verbose_date": "06.04.2020", "authors": "Bartoszko JJ", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 94, "name": "Influenza Other Respir Viruses"}, "link": "https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.12745", "findings": "", "take_away": "", "relevance_level": "Faible certitude dans les preuves\r\nLes masques m\u00e9dicaux et les N95 offrent une protection similaire contre les infections respiratoires virales chez les soignants pendant les soins ne g\u00e9n\u00e9rant pas d'a\u00e9rosols.\r\nLa pr\u00e9servation des N95 pour les situations\u00a0\u00e0 haut risque (soins produisants des a\u00e9rosols) devrait \u00eatre pris en compte en cas de p\u00e9nurie.\r\nL'utilisation des N95 pour les proc\u00e9dures g\u00e9n\u00e9rant des a\u00e9rosols est unanimement recommand\u00e9e par les guidelines nationaux et internationnaux.", "objectives": "- randomisation par cluster et exhaustivit\u00e9 des \u00e9tudes - m\u00e9thodologie pr\u00e9cise - preuves indirectes et impr\u00e9cises, - niveau de certitude faible des articles - aucun des essais dans la m\u00e9ta-analyse ne concernait le SARS-CoV2 - seulement 1 article a \u00e9tudi\u00e9 \u00e0 l'\u00e9chelle individuelle les masque m\u00e9dicaux et N95 dans les infections \u00e0 coronavirus - outcome composite : infections respiratoires confirm\u00e9es au laboratoire qui incluent les infections au coronavirus - donn\u00e9es agr\u00e9g\u00e9es et pas individuelles", "methods": "Comparer les masques m\u00e9dicaux aux N95 dans la pr\u00e9vention de l'infection virale chez les soignants", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 236, "name": "Bartoszko JJ"}], "publication_date": "2020-04-06"}, {"id": 635, "slug": "remdesivir-for-5-or-10-days-in-patients-with-severe-covid-19", "title": "Remdesivir for 5 or 10 Days in Patients with Severe Covid-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les r\u00e9sultats d'un essai multicentrique ouvert et randomis\u00e9 \u00e9valuant l'efficacit\u00e9 et l'innocuit\u00e9 du traitement par remdesivir pendant 5 ou 10 jours chez des patients COVID-19 s\u00e9v\u00e8res.", "verbose_date": "28.05.2020", "authors": "Goldman JD", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2015301?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude randomis\u00e9e en ouvert, pas de diff\u00e9rence significative entre un traitement par remdesivir de 5 ou 10 jours chez les patients atteints de COVID-19 s\u00e9v\u00e8re ne n\u00e9cessitant pas de ventilation m\u00e9canique.", "objectives": "- Essai th\u00e9rapeutique de phase 3 randomis\u00e9, en ouvert - Traitement complet non obligatoire si am\u00e9lioration clinique permettant la sortie- Modification du protocole au 15 mars avec notamment modification du crit\u00e8re de jugement principal et des crit\u00e8res d'inclusion- Essai con\u00e7u et men\u00e9 par le promoteur (Gilead Sciences - laboratoire pharmaceutique commercialisant le remdesivir), qui a \u00e9galement collect\u00e9 les donn\u00e9es, surveill\u00e9 la conduite de l'essai et effectu\u00e9 les analyses statistiques. Le premier manuscrit a \u00e9t\u00e9 r\u00e9dig\u00e9 par un auteur employ\u00e9 de Gilead Sciences, avec la contribution de tous les auteurs.- Traitement complet pour 172/200 (86%) patients dans le groupe 5 jours et 86/197 (43,7%) dans le groupe 10 jours- Pas de groupe contr\u00f4le sans remdesivir", "methods": "D\u00e9crire les r\u00e9sultats d'un essai multicentrique ouvert et randomis\u00e9 \u00e9valuant l'efficacit\u00e9 et l'innocuit\u00e9 du traitement par remdesivir pendant 5 ou 10 jours chez des patients COVID-19 s\u00e9v\u00e8res.", "pubmed_id": "32459919", "doi": "10.1056/NEJMoa2015301", "abstract": "Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19).\nWe conducted a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia. Patients were randomly assigned in a 1:1 ratio to receive intravenous remdesivir for either 5 days or 10 days. All patients received 200 mg of remdesivir on day 1 and 100 mg once daily on subsequent days. The primary end point was clinical status on day 14, assessed on a 7-point ordinal scale.\nIn total, 397 patients underwent randomization and began treatment (200 patients for 5 days and 197 for 10 days). The median duration of treatment was 5 days (interquartile range, 5 to 5) in the 5-day group and 9 days (interquartile range, 5 to 10) in the 10-day group. At baseline, patients randomly assigned to the 10-day group had significantly worse clinical status than those assigned to the 5-day group (P\u2009=\u20090.02). By day 14, a clinical improvement of 2 points or more on the ordinal scale occurred in 64% of patients in the 5-day group and in 54% in the 10-day group. After adjustment for baseline clinical status, patients in the 10-day group had a distribution in clinical status at day 14 that was similar to that among patients in the 5-day group (P\u2009=\u20090.14). The most common adverse events were nausea (9% of patients), worsening respiratory failure (8%), elevated alanine aminotransferase level (7%), and constipation (7%).\nIn patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead Sciences; GS-US-540-5773 ClinicalTrials.gov number, NCT04292899.).", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 597, "name": "Goldman JD"}], "publication_date": "2020-05-28"}, {"id": 209, "slug": "potential-utilities-of-mask-wearing-and-instant-hand-hygiene-for-fighting-sarsco", "title": "Potential utilities of mask wearing and instant hand hygiene for fighting SARS\u2010CoV\u20102", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluation de l'efficacit\u00e9 du lavage de main et de 3 types de masques sur la transmission du virus de la grippe aviaire.", "verbose_date": "01.04.2020", "authors": "Ma QX ", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25805", "findings": "", "take_away": "", "relevance_level": "- Le lavage des mains semble efficace pour la d\u00e9sinfection des mains pourvu que la concentration de savon (1%) ou de chlorine active (0.25%) soit ad\u00e9quate.\r\n- La capacit\u00e9 de filtration du masque N95 semble le mieux adapt\u00e9 au milieu hospitalier (filtration 99.98%)\r\n- Le masque chirurgical semble plus adapt\u00e9 pour les occasions sociales courantes\r\n- En cas de d\u00e9faut des solutions pr\u00e9c\u00e9dentes, les masques maisons pourraient avoir une efficacit\u00e9 mod\u00e9r\u00e9e", "objectives": "- Ne prend pas en compte le fait que la totalit\u00e9 de l'air inspir\u00e9 n'est pas filtr\u00e9 par le masque chirurgical", "methods": "Evaluation de l'efficacit\u00e9 du lavage de main et de 3 types de masques sur la transmission du virus de la grippe aviaire.", "pubmed_id": "32232986\n29707364\n21477136\n31978945\n14506048\n3416941\n19652172\n16142653\n26952529\n24229526\n29140516\n31502247\n28575115", "doi": "10.1002/jmv.25805", "abstract": "The surge of patients in the pandemic of COVID-19 caused by the novel coronavirus SARS-CoV-2 may overwhelm the medical systems of many countries. Mask-wearing and handwashing can slow the spread of the virus, but currently, masks are in shortage in many countries, and timely handwashing is often impossible. In this study, the efficacy of three types of masks and instant hand wiping was evaluated using the avian influenza virus to mock the coronavirus. Virus quantification was performed using real-time reverse transcription-polymerase chain reaction. Previous studies on mask-wearing were reviewed. The results showed that instant hand wiping using a wet towel soaked in water containing 1.00% soap powder, 0.05% active chlorine, or 0.25% active chlorine from sodium hypochlorite removed 98.36%, 96.62%, and 99.98% of the virus from hands, respectively. N95 masks, medical masks, and homemade masks made of four-layer kitchen paper and one-layer cloth could block 99.98%, 97.14%, and 95.15% of the virus in aerosols. Medical mask-wearing which was supported by many studies was opposed by other studies possibly due to erroneous judgment. With these data, we propose the approach of mask-wearing plus instant hand hygiene (MIH) to slow the exponential spread of the virus. This MIH approach has been supported by the experiences of seven countries in fighting against COVID-19. Collectively, a simple approach to slow the exponential spread of SARS-CoV-2 was proposed with the support of experiments, literature review, and control experiences.", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 201, "name": "Ma QX "}], "publication_date": "2020-04-01"}, {"id": 285, "slug": "vaso-occlusive-crisis-and-acute-chest-syndrome-in-sickle-cell-disease-due-to-201", "title": "Vaso- occlusive Crisis and Acute Chest Syndrome in Sickle Cell Disease due to 2019 Novel Coronavirus Disease (COVID-19)", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire le cas de crises vaso-occlusives compliqu\u00e9es de syndrome thoracique aig\u00fc chez des dr\u00e9panocytaires atteints par le COVID-19", "verbose_date": "09.04.2020", "authors": "Nur E", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 134, "name": "Am J Hematol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/ajh.25821", "findings": "", "take_away": "", "relevance_level": "Attention au risque potentiel de crise vaso-occlusive compliqu\u00e9e de syndrome thoracique aigu\u00eb chez les patients souffrant de dr\u00e9panocytose dans le cadre d'une infection au COVID-19. L'infection peut parfois \u00eatre sans signes respiratoires ou radiologiques et avec des pr\u00e9l\u00e8vements initaux n\u00e9gatifs.", "objectives": "- 2 case-reports", "methods": "D\u00e9crire le cas de crises vaso-occlusives compliqu\u00e9es de syndrome thoracique aig\u00fc chez des dr\u00e9panocytaires atteints par le COVID-19", "pubmed_id": "32267016\n10861320\n20169545\n32171076\n32267016", "doi": "10.1002/ajh.25821", "abstract": null, "topics": ["Diagnostique", "Transversale", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 273, "name": "Nur E"}], "publication_date": "2020-04-09"}, {"id": 609, "slug": "pulmonary-arterial-thrombosis-in-covid-19-with-fatal-outcome-results-from-a-pros", "title": "Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer les changements pathologiques des syst\u00e8mes organiques et la base clinicopathologique des issues graves et mortelles.", "verbose_date": "20.05.2020", "authors": "Lax SF", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 41, "name": "Ann Intern Med"}, "link": "https://www.acpjournals.org/doi/10.7326/M20-2566", "findings": "", "take_away": "", "relevance_level": "Le COVID-19 concerne principalement les poumons, ce qui provoque une l\u00e9sion alv\u00e9olaire diffuse et conduit \u00e0 une insuffisance respiratoire aigu\u00eb\u00a0: les poumons peuvent \u00eatre consid\u00e9r\u00e9s comme le principal organe cible des COVID-19 graves, r\u00e9agissant par des dommages alv\u00e9olaires diffus et affect\u00e9s par une thrombose dans les art\u00e8res pulmonaires segmentaires et sous-segmentaires. La combinaison de ces deux ph\u00e9nom\u00e8nes pourrait expliquer la d\u00e9t\u00e9rioration clinique rapide des COVID-19 graves et pourrait n\u00e9cessiter une expansion plus proactive des strat\u00e9gies d'anticoagulation actuelles qui envisagent \u00e9galement des doses th\u00e9rapeutiques ou m\u00eame une th\u00e9rapie thrombolytique. La mort peut \u00eatre caus\u00e9e par la thrombose observ\u00e9e dans les vaisseaux art\u00e9riels pulmonaires segmentaires et sous-segmentaires malgr\u00e9 l'utilisation d'une anticoagulation prophylactique.\nCes modifications pulmonaires graves semblent entra\u00eener une d\u00e9faillance de plusieurs organes, notamment les reins et, moins fr\u00e9quemment, le foie.\nUne prophylaxie stricte de la thrombose, des \u00e9tudes rapproch\u00e9es en laboratoire et en imagerie, et un traitement anticoagulant pr\u00e9coce pour les cas suspect\u00e9s de thrombose art\u00e9rielle pulmonaire ou de thromboembolie veineuse doivent \u00eatre envisag\u00e9s. D'autres \u00e9tudes sont n\u00e9cessaires pour confirmer ces r\u00e9sultats et pour \u00e9lucider les m\u00e9canismes d\u00e9taill\u00e9s impliqu\u00e9s dans ce large spectre de l\u00e9sions organiques caus\u00e9es par le SARS-CoV-2.", "objectives": "-\t\u00c9tude prospective. -\tMonocentrique. -\t11 patients d\u00e9c\u00e9d\u00e9s atteints de COVID-19.", "methods": "\u00c9valuer les changements pathologiques des syst\u00e8mes organiques et la base clinicopathologique des issues graves et mortelles.", "pubmed_id": "32422076\n32325026\n32171076\n32073213\n32167524\n15141376\n32294809\n31215660\n32311448\n32324103\n32267998\n32015507\n32275742\n12682443\n32007145\n6859225\n32291399\n32271993\n32085846\n32324102\n12459472\n31978945\n18448259\n32213556\n32282870\n32241899\n32338827\n32163542\n23748036\n32074444\n32251539\n32272080\n32239796\n14736283\n32220112\n32156329\n32268022\n32275288\n32114094\n32142651\n32282022\n32277022\n12781536\n32330224\n32302462\n32271861", "doi": "10.7326/M20-2566", "abstract": "Coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become pandemic, with substantial mortality.\nTo evaluate the pathologic changes of organ systems and the clinicopathologic basis for severe and fatal outcomes.\nProspective autopsy study.\nSingle pathology department.\n11 deceased patients with COVID-19 (10 of whom were selected at random for autopsy).\nSystematic macroscopic, histopathologic, and viral analysis (SARS-CoV-2 on real-time polymerase chain reaction assay), with correlation of pathologic and clinical features, including comorbidities, comedication, and laboratory values.\nPatients' age ranged from 66 to 91 years (mean, 80.5 years; 8 men, 3 women). Ten of the 11 patients received prophylactic anticoagulant therapy; venous thromboembolism was not clinically suspected antemortem in any of the patients. Both lungs showed various stages of diffuse alveolar damage (DAD), including edema, hyaline membranes, and proliferation of pneumocytes and fibroblasts. Thrombosis of small and mid-sized pulmonary arteries was found in various degrees in all 11 patients and was associated with infarction in 8 patients and bronchopneumonia in 6 patients. Kupffer cell proliferation was seen in all patients, and chronic hepatic congestion in 8 patients. Other changes in the liver included hepatic steatosis, portal fibrosis, lymphocytic infiltrates and ductular proliferation, lobular cholestasis, and acute liver cell necrosis, together with central vein thrombosis. Additional frequent findings included renal proximal tubular injury, focal pancreatitis, adrenocortical hyperplasia, and lymphocyte depletion of spleen and lymph nodes. Viral RNA was detectable in pharyngeal, bronchial, and colonic mucosa but not bile.\nThe sample was small.\nCOVID-19 predominantly involves the lungs, causing DAD and leading to acute respiratory insufficiency. Death may be caused by the thrombosis observed in segmental and subsegmental pulmonary arterial vessels despite the use of prophylactic anticoagulation. Studies are needed to further understand the thrombotic complications of COVID-19, together with the roles for strict thrombosis prophylaxis, laboratory, and imaging studies and early anticoagulant therapy for suspected pulmonary arterial thrombosis or thromboembolism.\nNone.", "topics": ["Pronostique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Cardiologie et maladies m\u00e9taboliques", "Pneumologie"], "author_list": [{"id": 572, "name": "Lax SF"}], "publication_date": "2020-05-20"}, {"id": 426, "slug": "connecting-clusters-of-covid-19-an-epidemiological-and-serological-investigation", "title": "Connecting clusters of COVID-19: an epidemiological and serological investigation", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Reporter les r\u00e9sultats d'une enqu\u00eate de cas de COVID-19 rattach\u00e9s \u00e0 3 clusters \u00e0 Singapour", "verbose_date": "23.04.2020", "authors": "Yong S", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 74, "name": "Lancet Infect Dis"}, "link": "https://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(20)30273-5.pdf", "findings": "", "take_away": "", "relevance_level": "Cette \u00e9tude montre l'int\u00e9r\u00eat des enqu\u00eates de cas de COVID-19 pour en limiter la transmission. L'utilisation de tests s\u00e9rologiques est alors essentielle pour retracer au mieux le cha\u00eene de transmission notamment chez des sujets gu\u00e9ris o\u00f9 la RT-PCR peut \u00eatre n\u00e9gative. Elle montre \u00e9galement quelles sont les conditions favorables \u00e0 la transmission : contact rapproch\u00e9 et prolong\u00e9 au cours de rassemblements (offices religieux, r\u00e9unions familiales, \u00e9coles, lieux de travail).", "objectives": "- seulement 3 clusters \u00e9tudi\u00e9s- risque de biais de rappel concernant la date de d\u00e9but des sympt\u00f4mes- m\u00e9thode relativement rigoureuse", "methods": "Reporter les r\u00e9sultats d'une enqu\u00eate de cas de COVID-19 rattach\u00e9s \u00e0 3 clusters \u00e0 Singapour", "pubmed_id": "32330439\n32192580\n32064853\n12781535\n26565003\n24172901\n24670324\n5667756\n32075791\n32069388\n32065057\n32003551\n16195424", "doi": "10.1016/S1473-3099(20)30273-5", "abstract": "Elucidation of the chain of disease transmission and identification of the source of coronavirus disease 2019 (COVID-19) infections are crucial for effective disease containment. We describe an epidemiological investigation that, with use of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological assays, established links between three clusters of COVID-19.\nIn Singapore, active case-finding and contact tracing were undertaken for all COVID-19 cases. Diagnosis for acute disease was confirmed with RT-PCR testing. When epidemiological information suggested that people might have been nodes of disease transmission but had recovered from illness, SARS-CoV-2 IgG serology testing was used to establish past infection.\nThree clusters of COVID-19, comprising 28 locally transmitted cases, were identified in Singapore; these clusters were from two churches (Church A and Church B) and a family gathering. The clusters in Church A and Church B were linked by an individual from Church A (A2), who transmitted SARS-CoV-2 infection to the primary case from Church B (F1) at a family gathering they both attended on Jan 25, 2020. All cases were confirmed by RT-PCR testing because they had active disease, except for A2, who at the time of testing had recovered from their illness and tested negative. This individual was eventually diagnosed with past infection by serological testing. ELISA assays showed an optical density of more than 1\u00b74 for SARS-CoV-2 nucleoprotein and receptor binding domain antigens in titres up to 1/400, and viral neutralisation was noted in titres up to 1/320.\nDevelopment and application of a serological assay has helped to establish connections between COVID-19 clusters in Singapore. Serological testing can have a crucial role in identifying convalescent cases or people with milder disease who might have been missed by other surveillance methods.\nNational Research Foundation (Singapore), National Natural Science Foundation (China), and National Medical Research Council (Singapore).", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 405, "name": "Yong S"}], "publication_date": "2020-04-23"}, {"id": 202, "slug": "epidemiology-of-covid-19-in-a-long-term-care-facility-in-king-county-washington", "title": "Epidemiology of Covid-19 in \u00e0 Long-Term Care Facility in King County, Washington", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire le cas d'une maison de retraite m\u00e9dicalis\u00e9e touch\u00e9e par le COVID-19 aux Etats-Unis fin f\u00e9vrier 2020 : de l'identification du cas index \u00e0 la mise en place de mesures de pr\u00e9vention et contr\u00f4le de l'infection", "verbose_date": "31.03.2020", "authors": "McMichael TM", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.dropbox.com/s/j5vbbeqyljkk1vj/nejmoa2005412.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Une fois l'infection par le SARS-CoV-2 pr\u00e9sente dans une maison de retraite m\u00e9dicalis\u00e9e ou de soins de longue dur\u00e9e, elle se propage de mani\u00e8re tr\u00e8s rapide et \u00e9tendue \u00e0 la fois dans l'\u00e9tablissement et dans des structures reli\u00e9es, avec des cons\u00e9quences tr\u00e8s p\u00e9joratives sur la sant\u00e9 des r\u00e9sidents et sur la charge suppl\u00e9mentaire pour les services d'urgence alentours.\n\r\nIl semble important d'y renforcer les mesures d'hygi\u00e8ne et de protection notamment en sensibilisant et en formant leurs personnels. Il est aussi essentiel de pr\u00eater une grande attention aux personnels travaillant dans plusieurs \u00e9tablissements et aux transferts de patients. Enfin, l'id\u00e9al serait de pouvoir tester largement personnels et r\u00e9sidents pour identifier pr\u00e9coc\u00e9ment les cas.", "objectives": "1) Etude de cas2) Tous les r\u00e9sidents/visiteurs/soignants n'ont pas \u00e9t\u00e9 test\u00e9s, ne permettant pas d'estimer l'importance des cas asymptomatiques notamment3) Absence de liste exhaustive des visiteurs de la maison de retraite4) Absence d'information sur la date de d\u00e9but des sympt\u00f4mes pour de nombreux cas\"", "methods": "D\u00e9crire le cas d'une maison de retraite m\u00e9dicalis\u00e9e touch\u00e9e par le COVID-19 aux Etats-Unis fin f\u00e9vrier 2020 : de l'identification du cas index \u00e0 la mise en place de mesures de pr\u00e9vention et contr\u00f4le de l'infection", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 72, "name": "McMichael TM"}], "publication_date": "2020-03-31"}, {"id": 413, "slug": "safety-and-immunogenicity-of-a-modified-vaccinia-virus-ankara-vector-vaccine-can", "title": "Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer la s\u00e9curit\u00e9 et la tol\u00e9rance d'un vaccin candidat contre le MERS-CoV chez des adultes en bonne sant\u00e9 bas\u00e9 sur le virus modifi\u00e9 anti-MERS-CoV Ankara (MVA) qui exprime la glycoprot\u00e9ine de pointe MVA-MERS-S.", "verbose_date": "22.04.2020", "authors": "Koch T", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 74, "name": "Lancet Infect Dis"}, "link": "https://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(20)30248-6.pdf", "findings": "", "take_away": "", "relevance_level": "La vaccination avec virus modifie d'Ankara-MERS-S avait un profil de s\u00e9curit\u00e9 favorable sans \u00e9v\u00e9nements ind\u00e9sirables graves ou s\u00e9v\u00e8res.\r\nLes participants qui ont re\u00e7u la dose \u00e9lev\u00e9e de 1 \u00d7 10^8 unit\u00e9 formant plages (UFP) ont connu des \u00e9v\u00e9nements ind\u00e9sirables l\u00e9gers \u00e0 mod\u00e9r\u00e9s et 100% ont pr\u00e9sent\u00e9 une s\u00e9roconversion. 91% de ces patients ont pr\u00e9sent\u00e9 des r\u00e9ponses des lymphocytes T. Le groupe \u00e0 faible dose (1 \u00d7 10^7 UFP) a montr\u00e9 un profil d'innocuit\u00e9 similaire, une s\u00e9roconversion chez 75% des participants et une immunit\u00e9 aux lymphocytes T chez 83% des participants.\r\nL'immunisation homologue \u00e0 stimulation primaire induit des r\u00e9ponses humorales et \u00e0 m\u00e9diation cellulaire contre le MERS-CoV. Une relation dose-effet a \u00e9t\u00e9 d\u00e9montr\u00e9e pour la r\u00e9actog\u00e9nicit\u00e9, mais pas pour les r\u00e9ponses immunitaires induites par le vaccin.", "objectives": "1) Etude de phase I en ouvert, peu de participants (26 participants vaccin\u00e9s, dont 23 participants avec rappel 28 jours plus tard. 6 participants t\u00e9moins.2) Tous les patients vaccin\u00e9s inclus dans l'\u00e9tude de s\u00e9curit\u00e93) 6 mois de suivi", "methods": "\u00c9valuer la s\u00e9curit\u00e9 et la tol\u00e9rance d'un vaccin candidat contre le MERS-CoV chez des adultes en bonne sant\u00e9 bas\u00e9 sur le virus modifi\u00e9 anti-MERS-CoV Ankara (MVA) qui exprime la glycoprot\u00e9ine de pointe MVA-MERS-S.", "pubmed_id": "32325037\n29329957\n29514901\n31423970\n30938227\n23986586\n23075143\n30060038\n25787284\n27760761\n31351922\n28057259\n25714162\n24168097\n26678878\n23523410\n26565003\n27387881\n26124093\n30377284\n25455987\n26018172\n24766432\n24599590", "doi": "10.1016/S1473-3099(20)30248-6", "abstract": "The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public health emergency and the absence of efficacious drugs or vaccines, MERS is one of the WHO priority diseases warranting urgent research and development of countermeasures. We aimed to assess safety and tolerability of an anti-MERS-CoV modified vaccinia virus Ankara (MVA)-based vaccine candidate that expresses the MERS-CoV spike glycoprotein, MVA-MERS-S, in healthy adults.\nThis open-label, phase 1 trial was done at the University Medical Center Hamburg-Eppendorf (Hamburg, Germany). Participants were healthy men and women aged 18-55 years with no clinically significant health problems as determined during medical history and physical examination, a body-mass index of 18\u00b75-30\u00b70 kg/m\nVaccination with MVA-MERS-S had a favourable safety profile without serious or severe adverse events. Homologous prime-boost immunisation induced humoral and cell-mediated responses against MERS-CoV. A dose-effect relationship was demonstrated for reactogenicity, but not for vaccine-induced immune responses. The data presented here support further clinical testing of MVA-MERS-S in larger cohorts to advance MERS vaccine development.\nGerman Center for Infection Research.", "topics": ["Th\u00e9rapeutique", "Immunit\u00e9", "Virologie", "Infectiologie"], "author_list": [{"id": 394, "name": "Koch T"}], "publication_date": "2020-04-22"}, {"id": 78, "slug": "potentially-repurposing-adamantanes-for-covid-19", "title": "Potentially repurposing adamantanes for COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Utilisation de la famille des adamantanes pour traiter le SARS-CoV-2", "verbose_date": "17.03.2020", "authors": "Cimolai N", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://www.dropbox.com/s/qwp9aki9xuqtirx/jmv.25752.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Du fait d'une efficacit\u00e9 modeste in vitro de la famille des adamantanes sur les coronarovirus humain 229E, OC43, coronavirus bovin et SARS\u2010CoV, il parait int\u00e9ressant d'\u00e9valuer, dans un premier temps in vitro, l'efficacit\u00e9 de cette famille sur le SARS-CoV-2.", "objectives": "Faible :Lettre \u00e0 l'\u00e9diteur", "methods": "Utilisation de la famille des adamantanes pour traiter le SARS-CoV-2", "pubmed_id": "32176361", "doi": "10.1002/jmv.25752", "abstract": null, "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 88, "name": "Cimolai N"}], "publication_date": "2020-03-17"}, {"id": 415, "slug": "arbidol-combined-with-lpvr-versus-lpvr-alone-against-coronavirus-disease-2019-a-", "title": "Arbidol combined with LPV/r versus LPV/r alone against Coronavirus Disease 2019: A retrospective cohort study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparaison de l'\u00e9volution des patients COVID-19 trait\u00e9s par Arbidol + opinavir/ritonavir(LPV/r) versus opinavir/ritonavir(LPV/r).", "verbose_date": "22.04.2020", "authors": "Deng L", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.journalofinfection.com/article/S0163-4453(20)30113-4/pdf", "findings": "", "take_away": "", "relevance_level": "Le traitement par Arbidol + opinavir/ritonavir semblerait acc\u00e9l\u00e9rer la n\u00e9gativation de la PCR compar\u00e9 \u00e0 un traitement par opinavir/ritonavir seul. La bith\u00e9rapie semblerait aussi favoriser l'am\u00e9lioration des l\u00e9sions pulmonaires visibles au scanner.\n\r\nL'\u00e9tude est limit\u00e9e par son faible effectif et un certain nombre de biais (voir Niveau de preuve)", "objectives": "- \u00c9tude r\u00e9trospective- Pas de randomisation- Pas d'aveugle- Faible effectif (n=33)- Pas de d\u00e9tail du traitement re\u00e7u par les patients- Donn\u00e9es scanner \u00e0 l'inclusion incompl\u00e8te\"", "methods": "Comparaison de l'\u00e9volution des patients COVID-19 trait\u00e9s par Arbidol + opinavir/ritonavir(LPV/r) versus opinavir/ritonavir(LPV/r).", "pubmed_id": "32171872", "doi": "10.1016/j.jinf.2020.03.002", "abstract": "Corona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only.\nIn this retrospective cohort study, we included adults (age\u226518years) with laboratory-confirmed COVID-19 without Invasive ventilation, diagnosed between Jan 17, 2020, and Feb 13, 2020. Patients, diagnosed after Jan 17, 2020, were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5-21 days. The primary endpoint was a negative conversion rate of coronavirus from the date of COVID-19 diagnosis(day7, day14), and assessed whether the pneumonia was progressing or improving by chest CT (day7).\nWe analyzed 16 patients who received oral arbidol and LPV/r in the combination group and 17 who oral LPV/r only in the monotherapy group, and both initiated after diagnosis. Baseline clinical, laboratory, and chest CT characteristics were similar between groups. The SARS-CoV-2 could not be detected for 12(75%) of 16 patients' nasopharyngeal specimens in the combination group after seven days, compared with 6 (35%) of 17 in the monotherapy group (p < 0\u00b705). After 14 days, 15 (94%) of 16 and 9 (52\u00b79%) of 17, respectively, SARS-CoV-2 could not be detected (p < 0\u00b705). The chest CT scans were improving for 11(69%) of 16 patients in the combination group after seven days, compared with 5(29%) of 17 in the monotherapy group (p < 0\u00b705).\nIn patients with COVID-19, the apparent favorable clinical response with arbidol and LPV/r supports further LPV/r only.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 396, "name": "Deng L"}], "publication_date": "2020-04-22"}, {"id": 296, "slug": "susceptibility-of-ferrets-cats-dogs-and-other-domesticated-animals-to-sars-coron", "title": "Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer la sensibilit\u00e9 des sources interm\u00e9diaires animales au SARS-CoV-2 comme le chat, le chien, le furet, le porc, le poulet et le canard.", "verbose_date": "10.04.2020", "authors": "Shi J", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 66, "name": "Science"}, "link": "https://www.dropbox.com/s/8hct0gbpdzwsrqr/science.abb7015.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le chat et le furet semblent hautement sensibles \u00e0 l'infection au SARS-CoV-2, alors que le chien, le porc, le poulet et le canard ne semblent pas touch\u00e9s.\u00a0\r\nChez le chat et le furet, le virus est retrouv\u00e9 au niveau ORL et parfois au niveau intestinal, mais pas au niveau pulmonaire. Il se retrouve aussi dans les selles. La maladie ne semble toutefois pas caus\u00e9e de forme s\u00e9v\u00e8re et de d\u00e9c\u00e8s chez ces animaux qui sont de fait rapidement s\u00e9ropositifs.", "objectives": "- Etudes exp\u00e9rimentales animales bien men\u00e9es- Limite du mod\u00e8le de contamination- Pas de suivi long des animaux- Pas d'\u00e9valuation du risque de contagiosit\u00e9 pour l'homme\"", "methods": "Evaluer la sensibilit\u00e9 des sources interm\u00e9diaires animales au SARS-CoV-2 comme le chat, le chien, le furet, le porc, le poulet et le canard.", "pubmed_id": "32269068", "doi": "10.1126/science.abb7015", "abstract": "Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes the infectious disease COVID-19 (coronavirus disease 2019), which was first reported in Wuhan, China, in December 2019. Despite extensive efforts to control the disease, COVID-19 has now spread to more than 100 countries and caused a global pandemic. SARS-CoV-2 is thought to have originated in bats; however, the intermediate animal sources of the virus are unknown. In this study, we investigated the susceptibility of ferrets and animals in close contact with humans to SARS-CoV-2. We found that SARS-CoV-2 replicates poorly in dogs, pigs, chickens, and ducks, but ferrets and cats are permissive to infection. Additionally, cats are susceptible to airborne transmission. Our study provides insights into the animal models for SARS-CoV-2 and animal management for COVID-19 control.", "topics": ["Autres", "Transversale", "Infectiologie"], "author_list": [{"id": 285, "name": "Shi J"}], "publication_date": "2020-04-10"}, {"id": 407, "slug": "miller-fisher-syndrome-and-polyneuritis-cranialis-in-covid-19", "title": "Miller Fisher Syndrome and polyneuritis cranialis in COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Description deux cas avec une infection \u00e0 SARS-Cov-2 avec respectivement un syndrome de Miller-Fischer et une polyn\u00e9vrite cr\u00e2nienne respectivement.", "verbose_date": "21.04.2020", "authors": "Gutierrez-Ortiz C", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 18, "name": "Neurologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 171, "name": "Neurology"}, "link": "https://n.neurology.org/content/neurology/early/2020/04/17/WNL.0000000000009619.full.pdf", "findings": "", "take_away": "", "relevance_level": "Les auteurs sugg\u00e8rent de consid\u00e9rer la pr\u00e9sence d\u2019un potentiel covid-19 chez les patients avec un syndrome de Miller Fischer ou devant toute polyn\u00e9vrite cr\u00e2nienne dans ce contexte pand\u00e9mique, compte tenu que la pathog\u00e9n\u00e8se de ces deux derniers implique des m\u00e9canismes immuns ou des effets neuropathon\u00e9gique viraux directs. Ils pensent que le principal m\u00e9canisme impliqu\u00e9 ici est une r\u00e9ponse immune aberrante d\u00fb au virus.", "objectives": "-        Rapport de deux cas-        Electromyographie avec vitesses de conduction non r\u00e9alis\u00e9e vu circonstances difficiles dans un contexte pand\u00e9mique-        Profil anticorps anti gangliosides non r\u00e9alis\u00e9 pour deuxi\u00e8me patient pour les m\u00eames raisons-        Co\u00efncidence ou relation de causalit\u00e9 ?", "methods": "Description deux cas avec une infection \u00e0 SARS-Cov-2 avec respectivement un syndrome de Miller-Fischer et une polyn\u00e9vrite cr\u00e2nienne respectivement.", "pubmed_id": "32303650", "doi": "10.1212/WNL.0000000000009619", "abstract": "To report two patients infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) who acutely presented with Miller Fisher syndrome and polyneuritis cranialis, respectively.\nPatient data were obtained from medical records from the University Hospital \"Pr\u00edncipe de Asturias\", Alcal\u00e1 de Henares, Madrid, Spain and from the University Hospital \"12 de Octubre\", Madrid, Spain.\nThe first patient was a 50-year-old man who presented with anosmia, ageusia, right internuclear ophthalmoparesis, right fascicular oculomotor palsy, ataxia, areflexia, albuminocytologic dissociation and positive testing for GD1b-IgG antibodies. Five days before, he had developed a cough, malaise, headache, low back pain, and a fever. The second patient was a 39-year-old man who presented with ageusia, bilateral abducens palsy, areflexia and albuminocytologic dissociation. Three days before, he had developed diarrhea, a low-grade fever, and a poor general condition. The oropharyngeal swab test for coronavirus disease 2019 (COVID-19) by qualitative real-time reverse-transcriptase-polymerase-chain-reaction assay was positive in both patients and negative in the cerebrospinal fluid. The first patient was treated with intravenous immunoglobulin and the second, with acetaminophen. Two weeks later, both patients made a complete neurological recovery, except for residual anosmia and ageusia in the first case.\nOur two cases highlight the rare occurrence of Miller Fisher syndrome and polyneuritis cranialis during the COVID-2 pandemic. Neurological manifestations may occur because of an aberrant immune response to COVID-19. The full clinical spectrum of neurological symptoms in patients with COVID-19 remains to be characterized.", "topics": ["Diagnostique", "Infectiologie", "Neurologie"], "author_list": [{"id": 388, "name": "Gutierrez-Ortiz C"}], "publication_date": "2020-04-21"}, {"id": 366, "slug": "expected-impact-of-lockdown-in-ile-de-france-and-possible-exit-strategies", "title": "Expected impact of lockdown in Ile-de-France and possible exit strategies", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer la situation \u00e9pid\u00e9mique en Ile de France au 12 avril, \u00e9valuer l'impact attendu du confinement mis en place le 17 mars et estimer l'efficacit\u00e9 des strat\u00e9gies de sortie possibles.", "verbose_date": "18.04.2020", "authors": "Di Domenico L", "specialties": [{"id": 21, "name": "Confinement/D\u00e9confinement"}, {"id": 7, "name": "Transversale"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://drive.google.com/file/d/1YsJWztb-BU_RrZ8fxVo5jej93E6eV6uH/view", "findings": "", "take_away": "", "relevance_level": "En Ile de France, entre 1 et 6% de la population a \u00e9t\u00e9 infect\u00e9 par le covid 19 au 5 avril 2020. Le confinement a permis de r\u00e9duire drastiquement les contacts sociaux et d'abaisser le taux de reproduction de 3 \u00e0 0.68. Des mesures de distanciation sociales contraignantes restent n\u00e9cessaires dans les mois \u00e0 venir du fait du taux d'immunit\u00e9 baisse de la population. En particulier, d'apr\u00e8s leur mod\u00e8le, une lev\u00e9e du confinement serait possible \u00e0 condition de garder les \u00e9coles ferm\u00e9es, les personnes \u00e2g\u00e9es isol\u00e9es et de tester largement pour tracer et isoler tous les cas.", "objectives": "Tr\u00e8s belle \u00e9tude de mod\u00e9lisation SEIR, avec un mod\u00e8le tr\u00e8s compliqu\u00e9. N\u00e9anmoins, des hypoth\u00e8ses fortes restent n\u00e9cessaires pour l'adaptation des matrices de contact en fonction des mesures de distanciation.", "methods": "Evaluer la situation \u00e9pid\u00e9mique en Ile de France au 12 avril, \u00e9valuer l'impact attendu du confinement mis en place le 17 mars et estimer l'efficacit\u00e9 des strat\u00e9gies de sortie possibles.", "topics": ["Mod\u00e9lisation", "Confinement/D\u00e9confinement", "Transversale"], "author_list": [{"id": 353, "name": "Di Domenico L"}], "publication_date": "2020-04-18"}, {"id": 546, "slug": "lupus-anticoagulant-and-abnormal-coagulation-tests-in-patients-with-covid-19", "title": "Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9tude des troubles de la coagulation et de l'anticoagulant lupique chez les patients atteints du COVID-19.", "verbose_date": "07.05.2020", "authors": "Bowles L", "specialties": [{"id": 15, "name": "H\u00e9matologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMc2013656?articleTools=true", "findings": "", "take_away": "", "relevance_level": "La quasi-totalit\u00e9 (91%) des patients avec un TCA augment\u00e9 avait des anticoagulants lupiques et une baisse du taux de facteur XII. Ces anomalies biologiques n'\u00e9taient pas associ\u00e9es \u00e0 une majoration des saignements, mais pr\u00e9sence d'au moins au \u00e9v\u00e8nement thrombotique prouv\u00e9.\r\nLes auteurs conseillent de ne pas s'emp\u00eacher d'instaurer un anticoagulant aux patients infect\u00e9s devant un TCA allong\u00e9 du fait du risque thrombotique plus probable.", "objectives": "\u00c9tude de CohorteR\u00e9trospectiveFaible nombre de patients avec allongement TCA (35)", "methods": "\u00c9tude des troubles de la coagulation et de l'anticoagulant lupique chez les patients atteints du COVID-19.", "pubmed_id": "32369280\n32073213\n32291094\n32320517\n32367170", "doi": "10.1056/NEJMc2013656", "abstract": null, "topics": ["Th\u00e9rapeutique", "H\u00e9matologie", "Infectiologie"], "author_list": [{"id": 511, "name": "Bowles L"}], "publication_date": "2020-05-07"}, {"id": 611, "slug": "susceptible-supply-limits-the-role-of-climate-in-the-early-sars-cov-2-pandemic", "title": "Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer la sensibilit\u00e9 de la transmission du virus SARS-CoV-2 au climat et mod\u00e9liser l\u2019impact de ce dernier sur la propagation de l\u2019\u00e9pid\u00e9mie.", "verbose_date": "25.05.2020", "authors": "Baker RE", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 66, "name": "Science"}, "link": "https://science.sciencemag.org/content/early/2020/05/15/science.abc2535/tab-pdf", "findings": "", "take_away": "", "relevance_level": "Sans mesure de contr\u00f4le efficace, une augmentation du nombre d\u2019infections est \u00e0 pr\u00e9voir lorsque le climat devient froid et humide.\u00a0\nPour autant, les conditions m\u00e9t\u00e9orologiques estivales ne limiteront pas la croissance pand\u00e9mique de fa\u00e7on tr\u00e8s significative.", "objectives": "Bien que l\u2019\u00e9tude soit bas\u00e9e en partie sur les donn\u00e9es d\u2019autres virus, et sur un mod\u00e8le de propagation SIRS, l\u2019analyse de sensibilit\u00e9 r\u00e9alis\u00e9e par les auteurs sugg\u00e8re des r\u00e9sultats robustes. Cependant, l\u2019\u00e9tude ne tient pas compte de certains param\u00e8tres comme la densit\u00e9 de population ou les types de d\u00e9placements associ\u00e9s \u00e0 chaque localisation, comme c\u2019\u00e9tait le cas pour les taux d\u2019humidit\u00e9 au cours de l\u2019ann\u00e9e.", "methods": "D\u00e9terminer la sensibilit\u00e9 de la transmission du virus SARS-CoV-2 au climat et mod\u00e9liser l\u2019impact de ce dernier sur la propagation de l\u2019\u00e9pid\u00e9mie.", "pubmed_id": "32423996", "doi": "10.1126/science.abc2535", "abstract": "Preliminary evidence suggests that climate may modulate the transmission of SARS-CoV-2. Yet it remains unclear whether seasonal and geographic variations in climate can substantially alter the pandemic trajectory, given high susceptibility is a core driver. Here, we use a climate-dependent epidemic model to simulate the SARS-CoV-2 pandemic probing different scenarios based on known coronavirus biology. We find that while variations in weather may be important for endemic infections, during the pandemic stage of an emerging pathogen the climate drives only modest changes to pandemic size. A preliminary analysis of non-pharmaceutical control measures indicates that they may moderate the pandemic-climate interaction via susceptible depletion. Our findings suggest, without effective control measures, strong outbreaks are likely in more humid climates and summer weather will not substantially limit pandemic growth.", "topics": ["Mod\u00e9lisation", "Transversale", "Infectiologie"], "author_list": [{"id": 574, "name": "Baker RE"}], "publication_date": "2020-05-25"}, {"id": 190, "slug": "clinical-analysis-of-10-neonates-born-to-mothers-with-2019-ncov-pneumonia", "title": "Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Description clinique de l'infection \u00e0 SARS-CoV-2 chez les nouveaux n\u00e9s et les m\u00e8res", "verbose_date": "30.03.2020", "authors": "Zhu H ", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 97, "name": "Transl Pediatr"}, "link": "https://www.dropbox.com/s/fo3oh76heyikacf/tp-09-01-51.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Sympt\u00f4mes chez la femme enceinte similaire \u00e0 ceux des adultes : toux fi\u00e8vre, peu de signes d'infection respiratoire haute. Signes digestifs possible.\r\n- Pas de preuve de transmission verticale\r\n- D\u00e9tresse foetale intra ut\u00e9rine fr\u00e9quente (par le biais de l'hypox\u00e9mie maternelle probablement). Pas de preuve de lien avec l'infection.\r\n- Par pr\u00e9caution, pr\u00e9voir la possibilit\u00e9 d'une r\u00e9animation\r\n- Principaux Sympt\u00f4mes chez les nouveaux n\u00e9s : d\u00e9tresse respiratoire, Sympt\u00f4mes gastro-intestinaux.\r\n- Thrombocytop\u00e9nie et fonction h\u00e9patique alt\u00e9r\u00e9e pour deux patients. L'un d'eux \u00e0 pr\u00e9sent\u00e9 comme complication une CVID, un choc r\u00e9fractaire, et une d\u00e9faillance d'organes multiples provoquant le d\u00e9c\u00e8s.", "objectives": "- \u00c9tude r\u00e9trospective- Tr\u00e8s faible effectif (10 nouveaux n\u00e9s, 9 m\u00e8res)\"", "methods": "Description clinique de l'infection \u00e0 SARS-CoV-2 chez les nouveaux n\u00e9s et les m\u00e8res", "pubmed_id": "32154135\n18373106\n30126042\n15218286\n15503406\n26936356\n32051071\n31987001\n15030710\n31978945", "doi": "10.21037/tp.2020.02.06", "abstract": "The newly identified 2019-nCoV, which appears to have originated in Wuhan, the capital city of Hubei province in central China, is spreading rapidly nationwide. A number of cases of neonates born to mothers with 2019-nCoV pneumonia have been recorded. However, the clinical features of these cases have not been reported, and there is no sufficient evidence for the proper prevention and control of 2019-nCoV infections in neonates.\nThe clinical features and outcomes of 10 neonates (including 2 twins) born to 9 mothers with confirmed 2019-nCoV infection in 5 hospitals from January 20 to February 5, 2020 were retrospectively analyzed.\nAmong these 9 pregnant women with confirmed 2019-nCoV infection, onset of clinical symptoms occurred before delivery in 4 cases, on the day of delivery in 2 cases, and after delivery in 3 cases. In most cases, fever and a cough were the first symptoms experienced, and 1 patient also had diarrhea. Of the newborns born to these mothers, 8 were male and 2 were female; 4 were full-term infants and 6 were born premature; 2 were small-for-gestational-age (SGA) infants and 1 was a large-for-gestational-age (LGA) infant; there were 8 singletons and 2 twins. Of the neonates, 6 had a Pediatric Critical Illness Score (PCIS) score of less than 90. Clinically, the first symptom in the neonates was shortness of breath (n=6), but other initial symptoms such as fever (n=2), thrombocytopenia accompanied by abnormal liver function (n=2), rapid heart rate (n=1), vomiting (n=1), and pneumothorax (n=1) were observed. Up to now, 5 neonates have been cured and discharged, 1 has died, and 4 neonates remain in hospital in a stable condition. Pharyngeal swab specimens were collected from 9 of the 10 neonates 1 to 9 days after birth for nucleic acid amplification tests for 2019-nCoV, all of which showed negative results.\nPerinatal 2019-nCoV infection may have adverse effects on newborns, causing problems such as fetal distress, premature labor, respiratory distress, thrombocytopenia accompanied by abnormal liver function, and even death. However, vertical transmission of 2019-nCoV is yet to be confirmed.", "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 183, "name": "Zhu H "}], "publication_date": "2020-03-30"}, {"id": 420, "slug": "to-mask-or-not-to-mask-modeling-the-potential-for-face-mask-use-by-the-general-p", "title": "To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Analyser l'impact du port du masque par la population g\u00e9n\u00e9rale sur les facteurs \u00e9pid\u00e9miologiques (hospitalisations et d\u00e9c\u00e8s)", "verbose_date": "23.04.2020", "authors": "Eikenberry S", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 176, "name": "Infect Dis Modelling"}, "link": "https://reader.elsevier.com/reader/sd/pii/S2468042720300117?token=D1C7C757F080F1F5CEF9C0053A56636A6C4C3EC4C996F51BCC34110E46A475BC3B65047B1C5D81CF74FB6C7B0655985A", "findings": "", "take_away": "", "relevance_level": "Le port de masque grand public (50% de filtration) en population g\u00e9n\u00e9rale aurait un effet tr\u00e8s important pour r\u00e9duire la transmission dans la population et la mortalit\u00e9 (baisse de 17% \u00e0 58%). Les b\u00e9n\u00e9fices en population sont encore plus important quand d'autres mesures de protections sont respect\u00e9es (distanciation sociale) et quand l'adoption est quasi-universelle.", "objectives": "- Mod\u00e8le compartimental type SIR \u00e9tendu- Nombreux param\u00e8tres introduits avec des hypoth\u00e8ses raisonnables- Calibrage sur donn\u00e9es de d\u00e9but d'\u00e9pid\u00e9mie aux Etats Unis- Plusieurs sc\u00e9narios test\u00e9s- Mod\u00e8le th\u00e9orique ne pouvant pas forc\u00e9ment retranscrire les comportements r\u00e9els et les efficacit\u00e9s des diff\u00e9rents masques", "methods": "Analyser l'impact du port du masque par la population g\u00e9n\u00e9rale sur les facteurs \u00e9pid\u00e9miologiques (hospitalisations et d\u00e9c\u00e8s)", "pubmed_id": "32355904\n32232402\n32150748\n30028634\n32099934\n21103330\n32129925\n28799710\n19193267\n32014114\n32215590\n20497389\n15200846\n12387915\n21937487\n32182409\n25903751\n26426786\n32129805\n24229526\n32171076\n29140516\n32214086\n2117040\n20161764\n32179701\n32125371\n18612429\n26225807\n32171059\n32240634\n32289100\n19652172\n15030685\n22323300", "doi": "10.1016/j.idm.2020.04.001", "abstract": "Face mask use by the general public for limiting the spread of the COVID-19 pandemic is controversial, though increasingly recommended, and the potential of this intervention is not well understood. We develop a compartmental model for assessing the community-wide impact of mask use by the general, asymptomatic public, a portion of which may be asymptomatically infectious. Model simulations, using data relevant to COVID-19 dynamics in the US states of New York and Washington, suggest that broad adoption of even relatively ineffective face masks may meaningfully reduce community transmission of COVID-19 and decrease peak hospitalizations and deaths. Moreover, mask use decreases the effective transmission rate in nearly linear proportion to the product of mask effectiveness (as a fraction of potentially infectious contacts blocked) and coverage rate (as a fraction of the general population), while the impact on epidemiologic outcomes (death, hospitalizations) is highly nonlinear, indicating masks could synergize with other non-pharmaceutical measures. Notably, masks are found to be useful with respect to both preventing illness in healthy persons ", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 400, "name": "Eikenberry S"}], "publication_date": "2020-04-23"}, {"id": 430, "slug": "ct-imaging-features-of-4121-patients-with-covid-19-a-meta-analysis", "title": "CT imaging features of 4,121 patients with COVID-19: a meta-analysis", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "R\u00e9sumer les caract\u00e9ristiques de l'imagerie CT de COVID-19, afin de fournir une r\u00e9f\u00e9rence pour la pratique clinique future.", "verbose_date": "23.04.2020", "authors": "Zhu J", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25910", "findings": "", "take_away": "", "relevance_level": "En r\u00e9sum\u00e9, la plupart des patients pr\u00e9sentaient une atteinte pulmonaire bilat\u00e9rale ou multilobaire. Les changements les plus fr\u00e9quents \u00e9tant les \u00ab ground-glass opacities \u00bb et le signe du bronchogramme a\u00e9rien. Les autres changements les plus fr\u00e9quents \u00e9taient des t\u00e2ches, le signe de la toile d'araign\u00e9e, etc. La lymphad\u00e9nopathie et l'\u00e9panchement pleural \u00e9taient rares. Mais en raison de la qualit\u00e9 et de la quantit\u00e9 des \u00e9tudes incluses, les conclusions ci-dessus doivent \u00eatre confirm\u00e9es par d'autres \u00e9tudes de haute qualit\u00e9.", "objectives": "-\tUn \u00e9chantillon de grande taille et une haute qualit\u00e9 des \u00e9tudes incluses.-\tLa plupart des \u00e9tudes incluses sont monocentriques ; la plupart des \u00e9tudes incluses n'ont pas pr\u00e9cis\u00e9 les crit\u00e8res d'inclusion ou d'exclusion, l'\u00e9volution et la gravit\u00e9 de la maladie n'\u00e9taient pas les m\u00eames ; toutes les \u00e9tudes incluses sont des \u00e9tudes r\u00e9trospectives ; cette m\u00e9ta-analyse a r\u00e9v\u00e9l\u00e9 une h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 importante entre les \u00e9tudes.-\tL'analyse de sous-groupe ne parvient pas \u00e0 \u00e9liminer toutes les sources d'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9, ce qui peut affecter la pr\u00e9cision des r\u00e9sultats de la m\u00e9ta-analyse.", "methods": "R\u00e9sumer les caract\u00e9ristiques de l'imagerie CT de COVID-19, afin de fournir une r\u00e9f\u00e9rence pour la pratique clinique future.", "topics": ["Epid\u00e9miologique", "Radiologie"], "author_list": [{"id": 350, "name": "Zhu J"}], "publication_date": "2020-04-23"}, {"id": 342, "slug": "an-effect-assessment-of-airborne-particulate-matter-pollution-on-covid-19-a-mult", "title": "An effect assessment of Airborne particulate matter pollution on COVID-19: A multi-city Study in China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier l'association entre niveau de pollution aux particules en suspension (PM 2.5 et PM10) et nombre de cas de COVID-19", "verbose_date": "15.04.2020", "authors": "Wang B", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.09.20060137v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "On peut suspecter une association positive entre niveau atmosph\u00e9rique des particules en suspension, PM2.5 et PM10, et nombre de cas confirm\u00e9s de COVID-19 (risque relatif significativement sup\u00e9rieur \u00e0 1) mais ces r\u00e9sultats doivent \u00eatre confirm\u00e9s dans des \u00e9tudes avec notamment de plus grands effectifs et plus de facteurs d'ajustement.", "objectives": "- pre-print- non prise en compte d'autres potentiels facteurs de confusion (mesures barri\u00e8res notamment)- certains effectifs par ville et par jour probablement assez faibles- modification de la d\u00e9finition des cas de COVID-19 en Chine sur la p\u00e9riode \u00e9tudi\u00e9e- doute concernant l'authenticit\u00e9 des donn\u00e9es \u00e9pid\u00e9miologiques chinoises", "methods": "Etudier l'association entre niveau de pollution aux particules en suspension (PM 2.5 et PM10) et nombre de cas de COVID-19", "topics": ["Epid\u00e9miologique", "Transversale", "Pneumologie"], "author_list": [{"id": 328, "name": "Wang B"}], "publication_date": "2020-04-15"}, {"id": 215, "slug": "expanded-umbilical-cord-mesenchymal-stem-cells-uc-mscs-as-a-therapeutic-strategy", "title": "Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as \u00e0 Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la possibilit\u00e9 de traitement de la r\u00e9action inflammatoire dans le COVID-9 par les cellules souches m\u00e9senchymateuses du cordon ombilical (UC-MSC) ", "verbose_date": "31.03.2020", "authors": "Atluri S ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 104, "name": "Pain Physician"}, "link": "https://www.dropbox.com/s/5hv7wk0vcwuu1s3/2020%3B23%3BE71-E83.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les donn\u00e9es cliniques pr\u00e9cliniques et pr\u00e9liminaires sugg\u00e8rent que les cellules souches de cordon ombilical inject\u00e9es gr\u00e2ce \u00e0 ses actions anti-inflammatoires et immunomodulatrices, pourrait gu\u00e9rir les tissus am\u00e9liorant ainsi la r\u00e9cup\u00e9ration. De plus, ce traitement semble \u00e9galement \u00eatre antimicrobien. \u00c9tant donn\u00e9 que la majorit\u00e9 des cellules sont pi\u00e9g\u00e9es dans le poumon, cela semblerait \u00e9galement b\u00e9n\u00e9fique, car le poumon est le principal organe affect\u00e9 par le coronavirus. Cette th\u00e9rapie est relativement peu co\u00fbteuse et non invasive.", "objectives": "- Revue narrative de la litt\u00e9rature- Peu de donn\u00e9es cliniques sur l'effet dans le COVID\"", "methods": "Etudier la possibilit\u00e9 de traitement de la r\u00e9action inflammatoire dans le COVID-9 par les cellules souches m\u00e9senchymateuses du cordon ombilical (UC-MSC)", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 206, "name": "Atluri S "}], "publication_date": "2020-03-31"}, {"id": 317, "slug": "cluster-of-coronavirus-disease-2019-covid-19-in-the-french-alps-2020", "title": "Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Identifier les cas secondaires et interrompre la transmission dans le cadre d'un cluster issu d'un cas infect\u00e9 de Singapore ayant s\u00e9journ\u00e9 dans un chalet dans les Alpes ", "verbose_date": "13.04.2020", "authors": "Danis K", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 24, "name": "Clin Infect Dis"}, "link": "https://www.dropbox.com/s/ud005afwjibr793/ciaa424.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Cet article sugg\u00e8re la transmission potentielle du virus par des patients asymptomatiques pouvant avoir une charge virale aussi \u00e9lev\u00e9e que les patients symptomatiques. Dans ce cluster, il est possible que le R0, tr\u00e8s \u00e9lev\u00e9 soit en lien avec un ph\u00e9nom\u00e8ne de \"super spreading\". Les \"super spreadeurs\" semblent avoir une charge virale plus importante, plus longtemps. La dynamique de transmission semble diff\u00e9rente chez les enfants, il est possible qu'une interf\u00e9rence virale chez l'h\u00f4te puisse impacter la susceptibilit\u00e9 individuelle \u00e0 une autre infection respiratoire virale. Une surveillance rapproch\u00e9e de l'\u00e9volution clinique semble primordiale chez les patients suspects notamment devant la dissociation entre les r\u00e9sultats des pr\u00e9l\u00e8vements respiratoires (pr\u00e9l\u00e8vements profonds vs pr\u00e9l\u00e8vements des voies a\u00e9riennes sup\u00e9rieures). Enfin, un syst\u00e8me d'alerte et d'intervention et une approche multidisciplinaire et collaborative sont des \u00e9l\u00e9ments essentiels pour la gestion efficace et la r\u00e9ponse rapide aux maladies infectieuses \u00e9mergentes.", "objectives": "- \u00e9tude observationnelle descriptive tir\u00e9 d'un cluster au d\u00e9but de l'\u00e9pid\u00e9mie en France", "methods": "Identifier les cas secondaires et interrompre la transmission dans le cadre d'un cluster issu d'un cas infect\u00e9 de Singapore ayant s\u00e9journ\u00e9 dans un chalet dans les Alpes", "pubmed_id": "32277759", "doi": "10.1093/cid/ciaa424", "abstract": "On 07/02/2020, French Health authorities were informed of a confirmed case of SARS-CoV-2 coronavirus in an Englishman infected in Singapore who had recently stayed in a chalet in the French Alps. We conducted an investigation to identify secondary cases and interrupt transmission.\nWe defined as a confirmed case a person linked to the chalet with a positive RT-PCR sample for SARS-CoV-2.\nThe index case stayed 4 days in the chalet with 10 English tourists and a family of 5 French residents; SARS-CoV-2 was detected in 5 individuals in France, 6 in England (including the index case), and 1 in Spain (overall attack rate in the chalet: 75%). One pediatric case, with picornavirus and influenza A coinfection, visited 3 different schools while symptomatic. One case was asymptomatic, with similar viral load as that of a symptomatic case. Seven days after the first cases were diagnosed, one tertiary case was detected in a symptomatic patient with a positive endotracheal aspirate; all previous and concurrent nasopharyngeal specimens were negative. Additionally, 172 contacts were monitored, including 73 tested negative for SARS-CoV-2.\nThe occurrence in this cluster of one asymptomatic case with similar viral load as a symptomatic patient, suggests transmission potential of asymptomatic individuals. The fact that an infected child did not transmit the disease despite close interactions within schools suggests potential different transmission dynamics in children. Finally, the dissociation between upper and lower respiratory tract results underscores the need for close monitoring of the clinical evolution of suspect Covid-19 cases.", "topics": ["Epid\u00e9miologique", "Infectiologie", "Pneumologie"], "author_list": [{"id": 304, "name": "Danis K"}], "publication_date": "2020-04-13"}, {"id": 234, "slug": "estimates-of-the-severity-of-coronavirus-disease-2019-a-model-based-analysis", "title": "Estimates of the Severity of Coronavirus Disease 2019: A Model-Based Analysis", "has_other_authors": false, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Estimer les CFR et IFR en Chine et hors de Chine pour le Covid en population g\u00e9n\u00e9rale et stratifi\u00e9e sur l'\u00e2ge, en tenant compte du sous report des cas.", "verbose_date": "02.04.2020", "authors": "Verity R", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 74, "name": "Lancet Infect Dis"}, "link": "https://www.dropbox.com/s/18r495jrv91bc26/PIIS1473309920302437.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Case Fatality Ratio (proportion de d\u00e9c\u00e8s parmi les cas) en Chine et hors de Chine estim\u00e9 \u00e0 1.4%, en tenant compte de la sous-estimation du nombre de cas. Infectious fatality ratio \u00e0 0.66%. CFR comme IFR sont bien plus importants sur les cat\u00e9gories de patients \u00e2g\u00e9s.", "objectives": "M\u00e9thodologie solide, avec des donn\u00e9es \u00e0 la fois en Chine et en dehors. Mais l'appr\u00e9ciation de la sous-estimation des cas garde une incertitude forte.", "methods": "Estimer les CFR et IFR en Chine et hors de Chine pour le Covid en population g\u00e9n\u00e9rale et stratifi\u00e9e sur l'\u00e2ge, en tenant compte du sous report des cas.", "pubmed_id": "32240634", "doi": "10.1016/S1473-3099(20)30243-7", "abstract": "In the face of rapidly changing data, a range of case fatality ratio estimates for coronavirus disease 2019 (COVID-19) have been produced that differ substantially in magnitude. We aimed to provide robust estimates, accounting for censoring and ascertainment biases.\nWe collected individual-case data for patients who died from COVID-19 in Hubei, mainland China (reported by national and provincial health commissions to Feb 8, 2020), and for cases outside of mainland China (from government or ministry of health websites and media reports for 37 countries, as well as Hong Kong and Macau, until Feb 25, 2020). These individual-case data were used to estimate the time between onset of symptoms and outcome (death or discharge from hospital). We next obtained age-stratified estimates of the case fatality ratio by relating the aggregate distribution of cases to the observed cumulative deaths in China, assuming a constant attack rate by age and adjusting for demography and age-based and location-based under-ascertainment. We also estimated the case fatality ratio from individual line-list data on 1334 cases identified outside of mainland China. Using data on the prevalence of PCR-confirmed cases in international residents repatriated from China, we obtained age-stratified estimates of the infection fatality ratio. Furthermore, data on age-stratified severity in a subset of 3665 cases from China were used to estimate the proportion of infected individuals who are likely to require hospitalisation.\nUsing data on 24 deaths that occurred in mainland China and 165 recoveries outside of China, we estimated the mean duration from onset of symptoms to death to be 17\u00b78 days (95% credible interval [CrI] 16\u00b79-19\u00b72) and to hospital discharge to be 24\u00b77 days (22\u00b79-28\u00b71). In all laboratory confirmed and clinically diagnosed cases from mainland China (n=70\u2008117), we estimated a crude case fatality ratio (adjusted for censoring) of 3\u00b767% (95% CrI 3\u00b756-3\u00b780). However, after further adjusting for demography and under-ascertainment, we obtained a best estimate of the case fatality ratio in China of 1\u00b738% (1\u00b723-1\u00b753), with substantially higher ratios in older age groups (0\u00b732% [0\u00b727-0\u00b738] in those aged <60 years vs 6\u00b74% [5\u00b77-7\u00b72] in those aged \u226560 years), up to 13\u00b74% (11\u00b72-15\u00b79) in those aged 80 years or older. Estimates of case fatality ratio from international cases stratified by age were consistent with those from China (parametric estimate 1\u00b74% [0\u00b74-3\u00b75] in those aged <60 years [n=360] and 4\u00b75% [1\u00b78-11\u00b71] in those aged \u226560 years [n=151]). Our estimated overall infection fatality ratio for China was 0\u00b766% (0\u00b739-1\u00b733), with an increasing profile with age. Similarly, estimates of the proportion of infected individuals likely to be hospitalised increased with age up to a maximum of 18\u00b74% (11\u00b70-37\u00b76) in those aged 80 years or older.\nThese early estimates give an indication of the fatality ratio across the spectrum of COVID-19 disease and show a strong age gradient in risk of death.\nUK Medical Research Council.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 224, "name": "Verity R"}], "publication_date": "2020-04-02"}, {"id": 140, "slug": "factors-associated-with-mental-health-outcomes-among-health-care-workers-exposed", "title": "Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "\u00c9valuer les r\u00e9sultats en mati\u00e8re de sant\u00e9 mentale chez les professionnels de la sant\u00e9 traitant des patients atteints de COVID-19 en quantifiant l'ampleur des sympt\u00f4mes de d\u00e9pression, d'anxi\u00e9t\u00e9, d'insomnie et de d\u00e9tresse et en analysant les facteurs de risque potentiels associ\u00e9s \u00e0 ces sympt\u00f4mes.", "verbose_date": "25.03.2020", "authors": "Lai J ", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 7, "name": "JAMA Netw Open"}, "link": "https://www.dropbox.com/s/e2perw7ohgd1fpb/lai_2020_oi_200192.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Une partie consid\u00e9rable des participants (n tot=1257) a montr\u00e9 des signes de d\u00e9pression (50.4%), anxi\u00e9t\u00e9 (44.6%), insomnie (34.0%), stress (71.5%).\n\r\n1)femmes, infirmiers\u00a0avec\u00a0un titre technique moyenne\u00a0ont montr\u00e9 signes plus graves de d\u00e9pression, anxi\u00e9t\u00e9 et stress\u00a0\r\n-d\u00e9pression grave m\u00e9decins vs infirmiers: 4.9% vs 7.1%, p=0.01\r\n-anxi\u00e9t\u00e9 grave hommes vs femmes:3.4% vs 5.8%, p=0.001\r\nop\u00e9rateurs de premi\u00e8re ligne et soignants de Wuhan ont mont\u00e9s de signes plus graves:\r\n- 71.5% de tous les infirmiers n'avaient que quelques ann\u00e9es d'exp\u00e9rience professionnelle\n\r\n2)\u00eatre un\u00a0op\u00e9rateur du terrain\u00a0dans le diagnostic et les soins des patients COVID-19 est un facteur de risque ind\u00e9pendant pour tous les sympt\u00f4mes cliniques:\r\n-insomnie grave op\u00e9rateurs I ligne vs op\u00e9rateurs II ligne: 1.7% vs 0.4%, p<0.001\n\r\n3)les professionnels de sant\u00e9 de\u00a0Wuhan (\u00e9picentre de la crise)\u00a0ont montr\u00e9 des sympt\u00f4mes de d\u00e9pression, d'anxi\u00e9t\u00e9, d'insomnie et de stress plus graves que ceux des autres r\u00e9gions:\r\n-stress grave Wuhan vs province de Hubei vs dehors province de Hubei: 12.6% vs 7.2% vs 7.2%, p<0.001", "objectives": "1) \u00e9tude transversale multicentriqueLimites:- 81.2% des participants \u00e9tait de la province de Hubei ( limite de g\u00e9n\u00e9ralisation aux autres provinces mois concern\u00e9es par l'\u00e9pid\u00e9mie.- \u00e9tude men\u00e9e pendant 6 jours, manque le suivi longitudinal des participants.- incapacit\u00e9 de distinguer l'association des sympt\u00f4mes avec le fait d'\u00eatre un clinicien de la r\u00e9gion par rapport au simple fait de vivre dans la r\u00e9gion (pas groupe de comparaison) et incapacit\u00e9 de distinguer les sympt\u00f4mes pr\u00e9existants par rapport aux nouveaux.- possible biais des non-r\u00e9pondants (soit trop stress\u00e9s pour r\u00e9pondre, soit pas int\u00e9ress\u00e9s)", "methods": "\u00c9valuer les r\u00e9sultats en mati\u00e8re de sant\u00e9 mentale chez les professionnels de la sant\u00e9 traitant des patients atteints de COVID-19 en quantifiant l'ampleur des sympt\u00f4mes de d\u00e9pression, d'anxi\u00e9t\u00e9, d'insomnie et de d\u00e9tresse et en analysant les facteurs de risque potentiels associ\u00e9s \u00e0 ces sympt\u00f4mes.", "pubmed_id": "32202646\n15702757\n15283534\n14645305\n14608214\n15985093\n24123859\n17996803\n31994742\n20722803\n31995857\n12743065\n15345768\n12563552\n15674079\n14562486\n26709880\n32003551\n17500304", "doi": "10.1001/jamanetworkopen.2020.3976", "abstract": "Health care workers exposed to coronavirus disease 2019 (COVID-19) could be psychologically stressed.\nTo assess the magnitude of mental health outcomes and associated factors among health care workers treating patients exposed to COVID-19 in China.\nThis cross-sectional, survey-based, region-stratified study collected demographic data and mental health measurements from 1257 health care workers in 34 hospitals from January 29, 2020, to February 3, 2020, in China. Health care workers in hospitals equipped with fever clinics or wards for patients with COVID-19 were eligible.\nThe degree of symptoms of depression, anxiety, insomnia, and distress was assessed by the Chinese versions of the 9-item Patient Health Questionnaire, the 7-item Generalized Anxiety Disorder scale, the 7-item Insomnia Severity Index, and the 22-item Impact of Event Scale-Revised, respectively. Multivariable logistic regression analysis was performed to identify factors associated with mental health outcomes.\nA total of 1257 of 1830 contacted individuals completed the survey, with a participation rate of 68.7%. A total of 813 (64.7%) were aged 26 to 40 years, and 964 (76.7%) were women. Of all participants, 764 (60.8%) were nurses, and 493 (39.2%) were physicians; 760 (60.5%) worked in hospitals in Wuhan, and 522 (41.5%) were frontline health care workers. A considerable proportion of participants reported symptoms of depression (634 [50.4%]), anxiety (560 [44.6%]), insomnia (427 [34.0%]), and distress (899 [71.5%]). Nurses, women, frontline health care workers, and those working in Wuhan, China, reported more severe degrees of all measurements of mental health symptoms than other health care workers (eg, median [IQR] Patient Health Questionnaire scores among physicians vs nurses: 4.0 [1.0-7.0] vs 5.0 [2.0-8.0]; P\u2009=\u2009.007; median [interquartile range {IQR}] Generalized Anxiety Disorder scale scores among men vs women: 2.0 [0-6.0] vs 4.0 [1.0-7.0]; P\u2009<\u2009.001; median [IQR] Insomnia Severity Index scores among frontline vs second-line workers: 6.0 [2.0-11.0] vs 4.0 [1.0-8.0]; P\u2009<\u2009.001; median [IQR] Impact of Event Scale-Revised scores among those in Wuhan vs those in Hubei outside Wuhan and those outside Hubei: 21.0 [8.5-34.5] vs 18.0 [6.0-28.0] in Hubei outside Wuhan and 15.0 [4.0-26.0] outside Hubei; P\u2009<\u2009.001). Multivariable logistic regression analysis showed participants from outside Hubei province were associated with lower risk of experiencing symptoms of distress compared with those in Wuhan (odds ratio [OR], 0.62; 95% CI, 0.43-0.88; P\u2009=\u2009.008). Frontline health care workers engaged in direct diagnosis, treatment, and care of patients with COVID-19 were associated with a higher risk of symptoms of depression (OR, 1.52; 95% CI, 1.11-2.09; P\u2009=\u2009.01), anxiety (OR, 1.57; 95% CI, 1.22-2.02; P\u2009<\u2009.001), insomnia (OR, 2.97; 95% CI, 1.92-4.60; P\u2009<\u2009.001), and distress (OR, 1.60; 95% CI, 1.25-2.04; P\u2009<\u2009.001).\nIn this survey of heath care workers in hospitals equipped with fever clinics or wards for patients with COVID-19 in Wuhan and other regions in China, participants reported experiencing psychological burden, especially nurses, women, those in Wuhan, and frontline health care workers directly engaged in the diagnosis, treatment, and care for patients with COVID-19.", "topics": ["Epid\u00e9miologique", "Psychiatrie"], "author_list": [{"id": 137, "name": "Lai J "}], "publication_date": "2020-03-25"}, {"id": 193, "slug": "efficacy-of-hydroxychloroquine-in-patients-with-covid-19-results-of-a-randomized", "title": "Efficacy of hydroxychloroquine in patients with COVID-19: results of \u00e0 randomized clinical trial", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer l'efficacit\u00e9 de l'hydroxychloroquine pour le traitement des patient COVID-19 non s\u00e9v\u00e8re.\r\n ", "verbose_date": "31.03.2020", "authors": "Chen Z ", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/icrpcnj1e3bmbvd/2020.03.22.20040758v2.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Cette \u00e9tude sugg\u00e8re que chez des patients pr\u00e9sentant des sympt\u00f4mes mod\u00e9r\u00e9s, un traitement par hydroxychloroquine pourrait r\u00e9duire de mani\u00e8re modeste la dur\u00e9e de la fi\u00e8vre et de la toux (en moyenne environ une journ\u00e9e).\r\n- Ce traitement pourrait s'av\u00e9r\u00e9 utile pour la pr\u00e9vention de l'\u00e9volution vers des formes s\u00e9v\u00e8res. Plus d'\u00e9tude serait n\u00e9cessaire cependant pour pouvoir le recommander.\r\n- Semblerait favoriser l'am\u00e9lioration des l\u00e9sions pulmonaires visibles au scanner (images non publi\u00e9es, sans mention d'une lecture en aveugle)", "objectives": "- Pre-print- \u00e0 priori pas d'aveugle, pas de placebo- Changement de design et de crit\u00e8re par rapport \u00e0 ce qui \u00e9tait initialement pr\u00e9vu (non mentionn\u00e9 dans l'article) cf http://webcache.googleusercontent.com/search?q=cache:-SdEu1yXCaAJ:www.chictr.org.cn/showprojen.aspx%3Fproj%3D48880+&cd=1&hl=fr&ct=clnk&gl=fr- Petite taille- Description du traitement standart succinte", "methods": "\u00c9valuer l'efficacit\u00e9 de l'hydroxychloroquine pour le traitement des patient COVID-19 non s\u00e9v\u00e8re.", "topics": ["Th\u00e9rapeutique", "Infectiologie"], "author_list": [{"id": 186, "name": "Chen Z "}], "publication_date": "2020-03-31"}, {"id": 416, "slug": "comparing-rapid-scoring-systems-in-mortality-prediction-of-critical-ill-patients", "title": "Comparing rapid scoring systems in mortality prediction of critical ill patients with novel coronavirus disease", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparer deux scores pronostiques d'urgence chez les patients s\u00e9v\u00e8res atteints de Covid-19, le score MEWS (Modified Early Warning Score) qui int\u00e8gre fr\u00e9quence cardiaque, pression art\u00e9rielle systolique, fr\u00e9quence respiratoire, temp\u00e9rature corporelle et conscience et le score REMS (Rapid Emergency Medicine Score) bas\u00e9 sur la fr\u00e9quence cardiaque, la pression art\u00e9rielle, la fr\u00e9quence respiratoire, le score de Glasgow, la saturation et l\u2019\u00e2ge ", "verbose_date": "22.04.2020", "authors": "Hu H", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 174, "name": "Acad Emerg Med"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/acem.13992", "findings": "", "take_away": "", "relevance_level": "Le score REMS semble plus performant pour stratifier le risque de mortalit\u00e9, notamment pour les patients jeunes. Il pourrait \u00eatre utile surtout pour l'orientation des patients en phases initiale de la prise en charge (bonne VPN).", "objectives": "R\u00e9trospectif, faible effectif, monocentrique", "methods": "Comparer deux scores pronostiques d'urgence chez les patients s\u00e9v\u00e8res atteints de Covid-19, le score MEWS (Modified Early Warning Score) qui int\u00e8gre fr\u00e9quence cardiaque, pression art\u00e9rielle systolique, fr\u00e9quence respiratoire, temp\u00e9rature corporelle et conscience et le score REMS (Rapid Emergency Medicine Score) bas\u00e9 sur la fr\u00e9quence cardiaque, la pression art\u00e9rielle, la fr\u00e9quence respiratoire, le score de Glasgow, la saturation et l\u2019\u00e2ge", "topics": ["Pronostique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie"], "author_list": [{"id": 91, "name": "Hu H"}], "publication_date": "2020-04-22"}, {"id": 276, "slug": "transplantation-of-ace2-mesenchymal-stem-cells-improves-the-outcome-of-patients-", "title": "Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluation de l'efficacit\u00e9 et de la toxicit\u00e9 de la transplantation de cellules souches m\u00e9senchymateuses pour le traitement des infection \u00e0 SARS-CoV-2.", "verbose_date": "08.04.2020", "authors": "Leng Z", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 131, "name": "Aging Dis"}, "link": "https://www.dropbox.com/s/1oaijwo97sofwal/Transplantation%20of%20ACE2-%20Mesenchymal%20Stem%20Cells%20Improves%20the%20Outcome.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L'injection de cellules souches m\u00e9senchymateuse pourrait limiter la r\u00e9ponse inflammatoire d\u00fb \u00e0 l'infection par SARS-CoV-2 et limiter ainsi les d\u00e9g\u00e2ts caus\u00e9s aux organes.\r\nDiminution du taux de TNF-\u03b1, augmentation de l'IL-10. El\u00e9vation moins importante des lymphocytes T r\u00e9gulateurs et des cellules dendritiques.", "objectives": "- Petit effectif (10 patients, 3 dans le groupe contr\u00f4le)- Crit\u00e8re d'efficacit\u00e9 primaire \u00e9valu\u00e9 sur le seul patient grave.\"", "methods": "Evaluation de l'efficacit\u00e9 et de la toxicit\u00e9 de la transplantation de cellules souches m\u00e9senchymateuses pour le traitement des infection \u00e0 SARS-CoV-2.", "topics": ["Th\u00e9rapeutique", "Infectiologie", "Pneumologie"], "author_list": [{"id": 265, "name": "Leng Z"}], "publication_date": "2020-04-08"}, {"id": 287, "slug": "practice-of-novel-method-of-bedside-postpyloric-tube-placement-in-patients-with-", "title": "Practice of novel method of bedside postpyloric tube placement in patients with coronavirus disease 2019", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'exp\u00e9rience d'une nouvelle pratique de pose de sonde d'alimentation post-pylorique au chevet de patients COVID-19", "verbose_date": "09.04.2020", "authors": "Yuan ST", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 59, "name": "Crit Care"}, "link": "https://ccforum.biomedcentral.com/track/pdf/10.1186/s13054-020-02863-0", "findings": "", "take_away": "", "relevance_level": "Cette technique de pose de sonde d'alimentation post-pylorique peut \u00eatre int\u00e9ressante pour les patients atteints d'un COVID-19 s\u00e9v\u00e8re. Dans cette s\u00e9rie de cas, 3 patients en ont b\u00e9n\u00e9fici\u00e9, pose r\u00e9ussie au premier essai sans complication, dur\u00e9e de pose m\u00e9diane de 19 min. Sonde droite avec guide utilis\u00e9e ici co\u00fbtant le 1/3 du prix d'une sonde spiral\u00e9e.", "objectives": "1) Lettre \u00e0 l'\u00e9diteur2) Revue d'exp\u00e9rience sur 3 patients\"", "methods": "D\u00e9crire l'exp\u00e9rience d'une nouvelle pratique de pose de sonde d'alimentation post-pylorique au chevet de patients COVID-19", "pubmed_id": "32264974\n29519252\n30348463\n31978945", "doi": "10.1186/s13054-020-02863-0", "abstract": null, "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 275, "name": "Yuan ST"}], "publication_date": "2020-04-09"}, {"id": 262, "slug": "baseline-characteristics-and-outcomes-of-1591-patients-infected-with-sars-cov-2-", "title": "Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Caract\u00e9riser les patients COVID-19 ayant n\u00e9cessit\u00e9 des soins intensifs en Lombardie", "verbose_date": "07.04.2020", "authors": "Grasselli G", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://www.dropbox.com/s/fdkw646oemxuuhy/10.1001%40jama.2020.5394.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Dans cette s\u00e9rie de cas de patients admis en soins intensifs en Lombardie, la majorit\u00e9 des patients \u00e9tait des hommes \u00e2g\u00e9s. 88% des patients avec ventilation m\u00e9canique avec des niveaux \u00e9lev\u00e9s de PEP. 11% de ventilation non-invasive. La mortalit\u00e9 en soins intensifs \u00e9tait de 26%.", "objectives": "1) Large s\u00e9rie de cas confirm\u00e9s par RT-PCR n=1 591 dans 72 h\u00f4pitaux de Lombardie2) Etude r\u00e9trospective, recueil des donn\u00e9es par t\u00e9l\u00e9phone3) Suivi pouvant \u00eatre court (minimum 7 jours - maximum 35 jours)4) Donn\u00e9es manquantes pour 44% des patients inclus sur les comorbidit\u00e9s, 18% manquants sur les donn\u00e9es ventilatoires\"", "methods": "Caract\u00e9riser les patients COVID-19 ayant n\u00e9cessit\u00e9 des soins intensifs en Lombardie", "pubmed_id": "32250385\n22777516\n32167538\n32109013\n32171076\n32031570\n31986264\n32191259\n32105632", "doi": "10.1001/jama.2020.5394", "abstract": "In December 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) emerged in China and has spread globally, creating a pandemic. Information about the clinical characteristics of infected patients who require intensive care is limited.\nTo characterize patients with coronavirus disease 2019 (COVID-19) requiring treatment in an intensive care unit (ICU) in the Lombardy region of Italy.\nRetrospective case series of 1591 consecutive patients with laboratory-confirmed COVID-19 referred for ICU admission to the coordinator center (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy) of the COVID-19 Lombardy ICU Network and treated at one of the ICUs of the 72 hospitals in this network between February 20 and March 18, 2020. Date of final follow-up was March 25, 2020.\nSARS-CoV-2 infection confirmed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swabs.\nDemographic and clinical data were collected, including data on clinical management, respiratory failure, and patient mortality. Data were recorded by the coordinator center on an electronic worksheet during telephone calls by the staff of the COVID-19 Lombardy ICU Network.\nOf the 1591 patients included in the study, the median (IQR) age was 63 (56-70) years and 1304 (82%) were male. Of the 1043 patients with available data, 709 (68%) had at least 1 comorbidity and 509 (49%) had hypertension. Among 1300 patients with available respiratory support data, 1287 (99% [95% CI, 98%-99%]) needed respiratory support, including 1150 (88% [95% CI, 87%-90%]) who received mechanical ventilation and 137 (11% [95% CI, 9%-12%]) who received noninvasive ventilation. The median positive end-expiratory pressure (PEEP) was 14 (IQR, 12-16) cm H2O, and Fio2 was greater than 50% in 89% of patients. The median Pao2/Fio2 was 160 (IQR, 114-220). The median PEEP level was not different between younger patients (n\u2009=\u2009503 aged \u226463 years) and older patients (n\u2009=\u2009514 aged \u226564 years) (14 [IQR, 12-15] vs 14 [IQR, 12-16] cm H2O, respectively; median difference, 0 [95% CI, 0-0]; P\u2009=\u2009.94). Median Fio2 was lower in younger patients: 60% (IQR, 50%-80%) vs 70% (IQR, 50%-80%) (median difference, -10% [95% CI, -14% to 6%]; P\u2009=\u2009.006), and median Pao2/Fio2 was higher in younger patients: 163.5 (IQR, 120-230) vs 156 (IQR, 110-205) (median difference, 7 [95% CI, -8 to 22]; P\u2009=\u2009.02). Patients with hypertension (n\u2009=\u2009509) were older than those without hypertension (n\u2009=\u2009526) (median [IQR] age, 66 years [60-72] vs 62 years [54-68]; P\u2009<\u2009.001) and had lower Pao2/Fio2 (median [IQR], 146 [105-214] vs 173 [120-222]; median difference, -27 [95% CI, -42 to -12]; P\u2009=\u2009.005). Among the 1581 patients with ICU disposition data available as of March 25, 2020, 920 patients (58% [95% CI, 56%-61%]) were still in the ICU, 256 (16% [95% CI, 14%-18%]) were discharged from the ICU, and 405 (26% [95% CI, 23%-28%]) had died in the ICU. Older patients (n\u2009=\u2009786; age \u226564 years) had higher mortality than younger patients (n\u2009=\u2009795; age \u226463 years) (36% vs 15%; difference, 21% [95% CI, 17%-26%]; P\u2009<\u2009.001).\nIn this case series of critically ill patients with laboratory-confirmed COVID-19 admitted to ICUs in Lombardy, Italy, the majority were older men, a large proportion required mechanical ventilation and high levels of PEEP, and ICU mortality was 26%.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 251, "name": "Grasselli G"}], "publication_date": "2020-04-07"}, {"id": 40, "slug": "sars-cov2-should-inhibitors-of-the-reninangiotensin-system-be-withdrawn-in-patie", "title": "SARS-CoV2: should inhibitors of the renin\u2013angiotensin system be withdrawn in patients with COVID-19?", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'impact de l'utilisation d'inhibiteurs du syst\u00e8me r\u00e9nine angiotensine sur la charge virale du SARS-CoV-2", "verbose_date": "20.03.2020", "authors": "Kuster GM", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 34, "name": "Eur Heart J"}, "link": "https://www.dropbox.com/s/fpytfq73gau1ebz/ehaa235.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "S'en tenir \u00e0 ce que l'on sait. L'effet b\u00e9n\u00e9fique des inhibiteurs du syst\u00e8me r\u00e9nine angiotensine sur certaines pathologies cardiovasculaires est bien connu. Il n'est pas recommand\u00e9 d'y renoncer devant une suspicion d'effet d\u00e9let\u00e8re en cas d'infection par SARS-CoV-2.", "objectives": "Faible :- bas\u00e9 sur une petite revue de la litt\u00e9rature- Donn\u00e9e issue d'exp\u00e9rience in vitro ou sur des souris", "methods": "Evaluer l'impact de l'utilisation d'inhibiteurs du syst\u00e8me r\u00e9nine angiotensine sur la charge virale du SARS-CoV-2", "pubmed_id": "32196087", "doi": "10.1093/eurheartj/ehaa235", "abstract": null, "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 50, "name": "Kuster GM"}], "publication_date": "2020-03-20"}, {"id": 191, "slug": "controversial-treatments-an-updated-understanding-of-the-coronavirus-disease-201", "title": "Controversial treatments: an updated understanding of the Coronavirus Disease 2019", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Revue des avantages et des complications des traitements propos\u00e9s jusqu'\u00e0 pr\u00e9sent dans la litt\u00e9rature pour la COVID-19", "verbose_date": "30.03.2020", "authors": "Zhang C ", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://www.dropbox.com/s/l53epmihp7jh4jm/10.1002%40jmv.25788.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Parmi les traitements propos\u00e9s dans la litt\u00e9rature pour COVID-19 :\n\r\n1) Remdesivir\r\n- il a un large spectre d'action contre les coronavirus SRAS et MERS\r\n- clinical trial chinois en phase III: remdesivir( 100mg sauf 200mg le premier jour) vs placebo. N.b. les effets secondaires sont inconnus \u00e0 ces doses dans diff\u00e9rentes ethnies\n\r\n2) Ribavirin\r\n- m\u00e9dicament antiviral \u00e0 large spectre\r\n- effets secondaires importants (an\u00e9mie h\u00e9molytique)\r\n- US Food and Drug Administration ne l'a approuv\u00e9 que pour le virus respiratoire syncytial\n\r\n3) Chloroquine\r\n- \u00e9tudes exclusivement sur des cellules ou des mod\u00e8les animaux\r\n- effets secondaires importants: cardiotoxicit\u00e9, r\u00e9tinopathie irr\u00e9versible, excr\u00e9t\u00e9 par le foie avec une longue demi-vie de 2,5 \u00e0 10 jours (m\u00e9canisme d'accumulation chez les patients souffrant d'insuffisance h\u00e9patique)\r\n- dose l\u00e9tale de 2 \u00e0 4 g\n\r\n4) Corticost\u00e9ro\u00efdes\r\n- effet antiviral non prouv\u00e9\r\n- OMS d\u00e9conseille l'utilisation des corticost\u00e9ro\u00efdes pour la COVID-19 \u00e0 moins qu'il n'existe des conditions sous-jacentes (nombreuses \u00e9tudes indiquent que les patients pr\u00e9sentant un \u0153d\u00e8me pulmonaire et une formation de membrane hyaline ont besoin d'un traitement corticost\u00e9ro\u00efde)\r\n- Nombreux effets secondaires (n\u00e9crose avasculaire, psychose, diab\u00e8te)\n\r\n5) Remplacement artificiel du foie\r\n- trois types : non biologique, biologique et hybride\r\n- le repos temporaire du foie permet la r\u00e9g\u00e9n\u00e9ration des cellules mais des facteurs secondaires importants doivent \u00eatre pris en compte (saignement, CIVD, hypotension, infections secondaires, r\u00e9action allergique, d\u00e9s\u00e9quilibre hydro-\u00e9lectrique)\n\r\n6) ECMO\r\n- l'ECMO soutient temporairement la respiration en \u00e9vitant les l\u00e9sions pulmonaires dues aux volumes et pressions \u00e9lev\u00e9s ( efficacit\u00e9 prouv\u00e9e dans les \u00e9tudes pour la pand\u00e9mie H1N1 et l'infection par H7N9)\n\r\nSelon cette revue, la th\u00e9rapie antivirale est la plus efficace pour r\u00e9duire la mortalit\u00e9 chez les patients pr\u00e9sentant des sympt\u00f4mes mod\u00e9r\u00e9s et le soutien des fonctions vitales (organes artificiels) chez les patients pr\u00e9sentant des sympt\u00f4mes graves", "objectives": "- aucune indication n'est donn\u00e9e sur la mani\u00e8re dont les articles sont s\u00e9lectionn\u00e9s (crit\u00e8res d'inclusion et d'exclusion, base de donn\u00e9es)- Donn\u00e9es de la litt\u00e9rature encore parcellaires", "methods": "Revue des avantages et des complications des traitements propos\u00e9s jusqu'\u00e0 pr\u00e9sent dans la litt\u00e9rature pour la COVID-19", "pubmed_id": "32219882\n12734147\n15115870\n32020029\n15486852\n23697469\n21462172\n32127666\n29511076\n31774950\n31502247\n15351731\n16640347\n19822628\n32164085\n15494274\n28659436\n10490733\n16968120\n14523782\n25363618\n14985565\n15059370\n32004427\n16115318\n26934220\n31924756\n15607755\n23594967\n15200845\n31986264\n30243584\n15387943\n12814717\n29310581\n15031783\n21910577\n14592603\n16439323\n15288617", "doi": "10.1002/jmv.25788", "abstract": "An outbreak of severe acute respiratory syndrome-related coronavirus 2 infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among coronavirus disease 2019 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, and chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system, and extracorporeal membrane oxygenation based on available evidence. As a result, we suggest that antiviral therapy and organ function support are vital to reduce mortality for mild patients and critical patients, respectively.", "topics": ["Th\u00e9rapeutique", "Transversale", "Virologie"], "author_list": [{"id": 184, "name": "Zhang C "}], "publication_date": "2020-03-30"}, {"id": 497, "slug": "long-term-coexistence-of-sars-cov-2-with-antibody-response-in-covid-19-patients", "title": "Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la g\u00e9n\u00e9ration d'anticorps et la clairance virale chez des patients COVID-19.", "verbose_date": "30.04.2020", "authors": "Wang B", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25946", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude, coexistence \u00e0 long terme des IgG avec le SRAS-CoV-2 pour 4 patients, ce qui soul\u00e8ve la question de la r\u00e9infection malgr\u00e9 la pr\u00e9sence d'anticorps. Tester seulement les anticorps sp\u00e9cifiques n'est peut \u00eatre donc pas un bon standard pour d\u00e9terminer le statut de l'infection. L'association avec une recherche d'ARN viral pourrait am\u00e9liorer la pr\u00e9cision de la d\u00e9tection du SARS-CoV-2.\nA travers un cas avec clairance virale avant production d'IgG, l'immunit\u00e9 inn\u00e9e pourrait donc \u00eatre suffisamment puissante pour \u00e9liminer le SARS-CoV-2.", "objectives": "1) Pre-proof2) Tr\u00e8s peu d'informations sur la s\u00e9lection ou non des patients \u00e9tudi\u00e9s3) Probablement analyse r\u00e9trospective car analyses des anticorps et des \u00e9chantillons avec recherche d'ARN viral tr\u00e8s disparates selon les patients4) Analyses des anticorps et de l'ARN viral qualitatives", "methods": "Etudier la g\u00e9n\u00e9ration d'anticorps et la clairance virale chez des patients COVID-19.", "pubmed_id": "32343415\n32171076\n32148172\n31502247\n32179860\n32007143\n30606502\n32284614\n31978945\n31986264\n23202451", "doi": "10.1002/jmv.25946", "abstract": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing coronavirus disease 2019 (COVID-19) has spread worldwide. Whether antibodies are important for the adaptive immune responses against SARS-CoV-2 infection needs to be determined. Here, 26 cases of COVID-19 in Jinan, China, were examined and shown to be mild or with common clinical symptoms, and no case of severe symptoms was found among these patients. Strikingly, a subset of these patients had SARS-CoV-2 and virus-specific IgG coexist for an unexpectedly long time, with two cases for up to 50 days. One COVID-19 patient who did not produce any SARS-CoV-2-bound IgG successfully cleared SARS-CoV-2 after 46 days of illness, revealing that without antibody-mediated adaptive immunity, innate immunity alone may still be powerful enough to eliminate SARS-CoV-2. This report may provide a basis for further analysis of both innate and adaptive immunity in SARS-CoV-2 clearance, especially in nonsevere cases.", "topics": ["Pronostique", "Virologie", "Infectiologie"], "author_list": [{"id": 328, "name": "Wang B"}], "publication_date": "2020-04-30"}, {"id": 551, "slug": "tocilizumab-for-the-treatment-of-severe-coronavirus-disease-2019", "title": "Tocilizumab for the treatment of severe coronavirus disease 2019", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'efficacit\u00e9 du Tocilizumab chez des patients atteints de COVID-19 en r\u00e9animation ", "verbose_date": "07.05.2020", "authors": "Allatar R", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25964", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude avec de nombreux biais,36% des patients sont sortis vivants de r\u00e9animation \u00e0 J14 avec de bons r\u00e9sultats au niveau du sevrage respiratoire et de l'hyperthermie, des signes radiologiques de la maladie et de la diminution du taux de CRP. Cette piste th\u00e9rapeutique n\u00e9cessite des \u00e9tudes avec un meilleur niveau de preuve.", "objectives": "R\u00e9trospectif, faible effectif, absence de bras contr\u00f4le, biais de confusion", "methods": "D\u00e9crire l'efficacit\u00e9 du Tocilizumab chez des patients atteints de COVID-19 en r\u00e9animation", "pubmed_id": "32369191\n31978945\n32284951\n29094311\n31502247\n32123347\n31986264\n32198088\n32192578\n32114094\n32214079\n32290839\n32243501", "doi": "10.1002/jmv.25964", "abstract": "Tocilizumab, an interleukin-6 inhibitor, may ameliorate the inflammatory manifestations associated with severe coronavirus disease 2019 (COVID-19) and thus improve clinical outcomes. This was a retrospective review of patients with laboratory-confirmed severe COVID-19 who received tocilizumab and completed 14 days of follow up. Twenty-five patients were included, median age was 58 years (interquartile range, 50-63) and the majority were males (92%). Co-morbidities included diabetes mellitus (48%), chronic kidney disease (16%), and cardiovascular disease (12%). Fever (92%), cough (84%), and dyspnea (72%) were the commonest presenting symptoms. All patients received at least two concomitant investigational antiviral agents. Median oral temperature was on day 1,\u00a03, and 7 was 38.0\u00b0C, 37.3\u00b0C (P\u2009=\u2009.043), and 37.0\u00b0C (P\u2009=\u2009.064), respectively. Corresponding median C-reactive protein\u00a0was 193\u00a0and\u00a07.9\u2009mg/L (P\u2009<\u2009.0001) and <6\u2009mg/L (P\u2009=\u2009.0001). Radiological improvement was noted in 44% of patients by day\u00a07% and 68% by day 14. Nine patients (36%) were discharged alive from intensive care unit and three (12%) died. The proportion of patients on invasive ventilation declined from (84%) at the time of tocilizumab initiation to 60% on day 7 (P\u2009=\u2009.031) and 28% on day 14 (P\u2009=\u2009.001). The majority (92%) of patients experienced at least one adverse event. However, it is not possible to ascertain which adverse events were directly related to tocilizumab therapy. In patients with severe COVID-19, tocilizumab was associated with dramatic decline in inflammatory markers, radiological improvement and reduced ventilatory support requirements. Given the study's limitations, the results require assessment in adequately powered randomized controlled trials.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 517, "name": "Allatar R"}], "publication_date": "2020-05-07"}, {"id": 464, "slug": "direct-oral-anticoagulant-plasma-levels-striking-increase-in-severe-covid19-resp", "title": "Direct oral anticoagulant plasma levels striking increase in severe COVID\u201019 respiratory syndrome patients treated with antiviral agents. The Cremona experience", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer la variation des dosages plasmatiques d\u2019anticoagulants oraux chez des patients hospitalis\u00e9s pour une infection au SARS-CoV-2 et sous antiviraux", "verbose_date": "27.04.2020", "authors": "Testa S", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 96, "name": "J Thromb Haemostasis"}, "link": "https://www.dropbox.com/s/49kksfyf0oa0nz3/10.1111%40jth.14871.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "On remarque une importante augmentation des taux plasmatiques d\u2019anticoagulants oraux chez tous ces patients sous antiviraux, par le biais de modifications pharmacocin\u00e9tiques (cytochrome P450, glycoprot\u00e9ine P) par interaction avec les antiviraux. On ne peut cependant exclure l'impact des traitements concomitants et des dysfonctions d\u2019organes.\r\nCe constat conduit \u00e0 une augmentation du risque h\u00e9morragique et il n'existe pas \u00e0 ce jour de conduite \u00e0 tenir consensuelle vis \u00e0 vis des anticoagulants oraux dans ce cas de figure. Les auteurs conseillent dans ce contexte le remplacement provisoire des anticoagulants oraux par d\u2019autres alternatives.", "objectives": "Tr\u00e8s petit effectif, \u00e9tude descriptive (cependant bonne validit\u00e9 externe et effet important)", "methods": "D\u00e9terminer la variation des dosages plasmatiques d\u2019anticoagulants oraux chez des patients hospitalis\u00e9s pour une infection au SARS-CoV-2 et sous antiviraux", "pubmed_id": "32329231\n29532628\n32081636\n29433148\n24076487\n26672898\n32127666\n23305158\n23790595\n22315269\n29562325\n31013383\n29106357\n22315259", "doi": "10.1111/jth.14871", "abstract": "Antiviral drugs are administered in patients with severe COVID-19 respiratory syndrome, including those treated with direct oral anticoagulants (DOACs). Concomitant administration of antiviral agents has the potential to increase their plasma concentration. A series of patients managed in the Cremona Thrombosis Center were admitted at Cremona Hospital for SARS-CoV-2 and started antiviral drugs without stopping DOAC therapy. DOAC plasma levels were measured in hospital and results compared with those recorded before hospitalization.\nAll consecutive patients on DOACs were candidates for administration of antiviral agents (lopinavir, ritonavir, or darunavir). Plasma samples for DOAC measurement were collected 2to 4\u00a0days after starting antiviral treatment, at 12\u00a0hours from the last dose intake in patients on dabigatran and apixaban, and at 24\u00a0hours in those on rivaroxaban and edoxaban. For each patient, C-trough DOAC level, expressed as ng/mL, was compared with the one measured before hospitalization.\nOf the 1039 patients hospitalized between February 22 and March 15, 2020 with COVID-19 pneumonia\u00a0and candidates for antiviral therapy, 32 were on treatment with a DOAC. DOAC was stopped in 20 and continued in the remaining 12. On average, C-trough levels were 6.14 times higher during hospitalization than in the pre-hospitalization period.\nDOAC patients treated with antiviral drugs show an alarming increase in DOAC plasma levels. In order to prevent bleeding complications, we believe that physicians should consider withholding DOACs from patients with SARS-CoV-2 and replacing them with alternative parenteral antithrombotic strategies for as long as antiviral agents are deemed necessary and until discharge.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 436, "name": "Testa S"}], "publication_date": "2020-04-27"}, {"id": 136, "slug": "treatment-for-severe-acute-respiratory-distress-syndrome-from-covid-19", "title": "Treatment for severe acute respiratory distress syndrome from COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Apporter des solutions \u00e0 mettre en place avant l'oxyg\u00e9nation membranaire extra-corporelle.", "verbose_date": "25.03.2020", "authors": "Matthay MA ", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 87, "name": "Lancet Respir Med"}, "link": "https://www.dropbox.com/s/6x2999jjuscfed1/PIIS2213260020301272.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Voir r\u00e9sultats principaux", "objectives": "Commentaire sur un articleBas\u00e9 sur les recommandations de prise en charge de SDRA notamment d\u00fb \u00e0 des infection virales.", "methods": "Apporter des solutions \u00e0 mettre en place avant l'oxyg\u00e9nation membranaire extra-corporelle.", "pubmed_id": "32203709\n16714767\n29791822\n32203711\n30776290\n31573637\n25981908\n30247273\n30917856\n28973075\n31986264", "doi": "10.1016/S2213-2600(20)30127-2", "abstract": null, "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie"], "author_list": [{"id": 133, "name": "Matthay MA "}], "publication_date": "2020-03-25"}, {"id": 16, "slug": "the-psychological-impact-of-quarantine-and-how-to-reduce-it-rapid-review-of-the-", "title": "The psychological impact of quarantine and how to reduce it: rapid review of the evidence", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Rechercher les cons\u00e9quences sur la sant\u00e9 mentale et le bien \u00eatre psychologique d'une quarantaine\r\nTenter de r\u00e9duire les complications de la quarantaine", "verbose_date": "24.03.2020", "authors": "Brooks SK", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://www.dropbox.com/s/6nmdy8od7ys3hdz/PIIS0140673620304608.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L'information est la cl\u00e9, les personnes en quarantaine doivent comprendre la situation\r\nUne communication rapide et efficace est essentielle\r\nDes provisions m\u00e9dicales et g\u00e9n\u00e9rales doivent \u00eatre fournies\r\nLa p\u00e9riode de quarantaine doit \u00eatre courte et sa dur\u00e9e ne doit pas \u00eatre chang\u00e9e sauf circonstances extr\u00eames\r\nLa plupart des effets viennent d'une restriction des libert\u00e9s. Une quarantaine volontaire est associ\u00e9e \u00e0 moins d'angoisses et moins de complications \u00e0 long terme\r\nLes autorit\u00e9s de sant\u00e9 publique devraient souligner le choix altruiste de s'auto isoler", "objectives": "", "methods": "Rechercher les cons\u00e9quences sur la sant\u00e9 mentale et le bien \u00eatre psychologique d'une quarantaine\r\nTenter de r\u00e9duire les complications de la quarantaine", "pubmed_id": "32112714\n12743065\n16618485\n21353131\n19210022\n22611587\n16229732\n21489421\n15650436\n24618142\n23587175\n17664192\n19497162\n15759346\n21394854\n28748776\n15283537\n28192745\n26650630\n16126821\n28196409\n29252922\n15913861\n25797363\n15030713\n15034821\n21073672\n18831770\n15345768\n18790829\n29439682\n27863536\n15324539\n25856593\n16281248\n29359634\n27504141\n31992552\n17662167", "doi": "10.1016/S0140-6736(20)30460-8", "abstract": "The December, 2019 coronavirus disease outbreak has seen many countries ask people who have potentially come into contact with the infection to isolate themselves at home or in a dedicated quarantine facility. Decisions on how to apply quarantine should be based on the best available evidence. We did a Review of the psychological impact of quarantine using three electronic databases. Of 3166 papers found, 24 are included in this Review. Most reviewed studies reported negative psychological effects including post-traumatic stress symptoms, confusion, and anger. Stressors included longer quarantine duration, infection fears, frustration, boredom, inadequate supplies, inadequate information, financial loss, and stigma. Some researchers have suggested long-lasting effects. In situations where quarantine is deemed necessary, officials should quarantine individuals for no longer than required, provide clear rationale for quarantine and information about protocols, and ensure sufficient supplies are provided. Appeals to altruism by reminding the public about the benefits of quarantine to wider society can be favourable.", "topics": ["Th\u00e9rapeutique", "Psychiatrie"], "author_list": [{"id": 26, "name": "Brooks SK"}], "publication_date": "2020-03-24"}, {"id": 135, "slug": "findings-of-lung-ultrasonography-of-novel-coronavirus-pneumonia-during-the-20192", "title": "\"Findings of lung ultrasonography of novel coronavirus pneumonia during the 2019\u20132020 epidemic\"", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00e9sum\u00e9 de l'exp\u00e9rience des m\u00e9decin chinois sur l'utilisation d'\u00e9chographie pulmonaire pour le diagnostic pr\u00e9coce de l'infection \u00e0 SRAS-CoV-2.", "verbose_date": "25.03.2020", "authors": "Peng QY ", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 2, "name": "Intensive Care Med"}, "link": "https://www.dropbox.com/s/uwrb3m0u2mv5dvr/Chinese%20Critical%20Care%20Ultrasound.%20-%202020%20-%20Fin....pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Devant la surcharge de certains services du \u00e0 l'\u00e9pid\u00e9mie, l'\u00e9chographie pourrait \u00eatre effectu\u00e9e en premi\u00e8re intention et avoir recours au scanner si l'\u00e9chographie ne permet pas de r\u00e9pondre \u00e0 la question clinique pos\u00e9e.", "objectives": "Lettre \u00e0 l'\u00e9diteur", "methods": "R\u00e9sum\u00e9 de l'exp\u00e9rience des m\u00e9decin chinois sur l'utilisation d'\u00e9chographie pulmonaire pour le diagnostic pr\u00e9coce de l'infection \u00e0 SRAS-CoV-2.", "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 132, "name": "Peng QY "}], "publication_date": "2020-03-25"}, {"id": 469, "slug": "aerosol-filtration-efficiency-of-common-fabrics-used-in-respiratory-cloth-masks", "title": "Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluation de l\u2019efficacit\u00e9 de la filtration de particules a\u00e9rosols offerte par diff\u00e9rentes combinaisons de couches de tissus afin de proposer des lignes directrices pour la confection de masques en tissu artisanaux.", "verbose_date": "28.04.2020", "authors": "Konda A", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 190, "name": "ACS Nano"}, "link": "https://pubs.acs.org/doi/pdf/10.1021/acsnano.0c03252", "findings": "", "take_away": "", "relevance_level": "Pour la confection artisanale de masques, les mat\u00e9riaux \u00e0 faible porosit\u00e9 et finement tress\u00e9s sont \u00e0 privil\u00e9gier. Le coton 600TPI apporte une protection satisfaisante pour les particules >300 nm par filtrage m\u00e9canique.\nLa soie naturelle, la flanelle et la mousseline de coton offrent une meilleure protection vis \u00e0 vis des particules tr\u00e8s fines par filtrage \u00e9lectrostatique. 4 couches de soie apportent une protection satisfaisante pour ce type de particule.\nLa combinaison de ces deux approches par superposition de ces deux type de mat\u00e9riaux semblent fournir de bons r\u00e9sultats. Les auteurs recommandent une couche de coton \u00e0 forte densit\u00e9 de fibre accol\u00e9e \u00e0 2 couches de soie naturelle ou de mousseline par exemple.\nLa bonne adaptation du masque au visage est un param\u00e8tre d\u00e9terminant, un \u00e9cart peut diminuer de l\u2019ordre de 60\u00a0% le niveau de protection offert par le masque. Il est donc crucial de porter une importance particuli\u00e8re \u00e0 la qualit\u00e9 d\u2019adaptation du masque au visage lors de sa conception et son port.", "objectives": "Etude exp\u00e9rimentale de bonne qualit\u00e9. Le protocole de test de filtration est un standard pour la qualification de respirateurs faciaux  (NIOSH 42 CFR Part84). Chaque test est r\u00e9p\u00e9t\u00e9 7 fois (conform\u00e9ment au protocole) et la dispersion des mesures est assez faible. Pour autant on pourra tout de m\u00eame noter que le mat\u00e9riel utilis\u00e9 ne permet pas d\u2019\u00e9valuer l\u2019efficacit\u00e9 de la filtration des particules de tailles comprises entre 178 et 300 nm. Les tissus utilis\u00e9s ne sont identifi\u00e9s que par leurs appellation courante et aucun test  n\u2019est r\u00e9alis\u00e9 pour les caract\u00e9riser sp\u00e9cifiquement (porosit\u00e9, \u00e9lectrostaticit\u00e9, etc.). Par ailleurs, l\u2019\u00e9tude ne pr\u00e9cise pas la concentration en particules dans l\u2019air filtr\u00e9 par les \u00e9chantillons de tissu (graph fournis en \u00ab\u00a0unit\u00e9 arbitraire). Cela pose la question de la validit\u00e9 des r\u00e9sultats et donc du maintien de la qualit\u00e9 de filtration pour des concentrations en gouttelettes dans l\u2019environnement diff\u00e9rentes. Une plus forte concentration en particules que celle test\u00e9e pourrait saturer les sites de captures (m\u00e9caniques ou \u00e9lectrostatiques). Cette question de la saturation des sites et donc de la perte d\u2019efficacit\u00e9 des masques, peut \u00e9galement se poser dans le temps, compte tenu du fait que l\u2019auteur ne pr\u00e9cise pas apr\u00e8s combien de temps de filtration les mesures sont effectu\u00e9es.", "methods": "Evaluation de l\u2019efficacit\u00e9 de la filtration de particules a\u00e9rosols offerte par diff\u00e9rentes combinaisons de couches de tissus afin de proposer des lignes directrices pour la confection de masques en tissu artisanaux.", "pubmed_id": "32329337", "doi": "10.1021/acsnano.0c03252", "abstract": "The emergence of a pandemic affecting the respiratory system can result in a significant demand for face masks. This includes the use of cloth masks by large sections of the public, as can be seen during the current global spread of COVID-19. However, there is limited knowledge available on the performance of various commonly available fabrics used in cloth masks. Importantly, there is a need to evaluate filtration efficiencies as a function of aerosol particulate sizes in the 10 nm to 10 \u03bcm range, which is particularly relevant for respiratory virus transmission. We have carried out these studies for several common fabrics including cotton, silk, chiffon, flannel, various synthetics, and their combinations. Although the filtration efficiencies for various fabrics when a single layer was used ranged from 5 to 80% and\u00a05 to 95% for particle sizes of <300 nm and >300 nm, respectively, the efficiencies improved when multiple layers were used and when using a specific combination of different fabrics. Filtration efficiencies of the hybrids (such as cotton-silk, cotton-chiffon, cotton-flannel) was >80% (for particles <300 nm) and >90% (for particles >300 nm). We speculate that the enhanced performance of the hybrids is likely due to the combined effect of mechanical and electrostatic-based filtration. Cotton, the most widely used material for cloth masks performs better at higher weave densities (", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 437, "name": "Konda A"}], "publication_date": "2020-04-28"}, {"id": 463, "slug": "fibrinolytic-abnormalities-in-acute-respiratory-distress-syndrome-ards-and-versa", "title": "Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Sugg\u00e9rer la recherche sur l'administration de drogue fibrinolytique inhal\u00e9e dans le SDRA pour action locale fibrinolytique (en plus de l'action syst\u00e9mique anticoagulante des H\u00e9parines).", "verbose_date": "27.04.2020", "authors": "Whyte CS", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 96, "name": "J Thromb Haemostasis"}, "link": "https://www.dropbox.com/s/c7bkjki6x0znk6x/10.1111%40jth.14872.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Dans le SDRA, d\u00e9p\u00f4ts de fibrine dans le parenchyme pulmonaire secondaire \u00e0 un d\u00e9s\u00e9quilibre coagulation/fibrinolyse. Les patients COVID ont des D-dim\u00e8res et un fibrinog\u00e8ne \u00e9lev\u00e9s. Le facteur tissulaire est exprim\u00e9 \u00e0 la surface des cellules endoth\u00e9liales alv\u00e9olaires stimulant la fibrinoformation. Alors que PAI-1 est retrouv\u00e9 \u00e0 des niveaux \u00e9lev\u00e9s dans l'\u00e9pith\u00e9lium pulmonaire et l'endoth\u00e9lium cr\u00e9ant un \u00e9tat d'hypofibrinolyse. La pr\u00e9vention thromboembolique par HBPM est importante mais stimuler la fibrinolyse locale semble aussi int\u00e9ressant (tPA). Cette revue discute l'utilisation du tPA inhal\u00e9 pour am\u00e9liorer l'oxyg\u00e9nation des patients.", "objectives": "Revue narrative de la litt\u00e9rature, fibrinolytiques inhal\u00e9s actuellement en tests phase 2. Postulat physiopathologique tr\u00e8s int\u00e9ressant. Tr\u00e8s peu de donn\u00e9es chez l'humain.", "methods": "Sugg\u00e9rer la recherche sur l'administration de drogue fibrinolytique inhal\u00e9e dans le SDRA pour action locale fibrinolytique (en plus de l'action syst\u00e9mique anticoagulante des H\u00e9parines).", "pubmed_id": "32329246", "doi": "10.1111/jth.14872", "abstract": "The global pandemic of coronavirus disease 2019 (COVID-19) is associated with the development of acute respiratory distress syndrome (ARDS), which requires ventilation in critically ill patients. The pathophysiology of ARDS results from acute inflammation within the alveolar space and prevention of normal gas exchange. The increase in proinflammatory cytokines within the lung leads to recruitment of leukocytes, further propagating the local inflammatory response. A consistent finding in ARDS is the deposition of fibrin in the air spaces and lung parenchyma. COVID-19 patients show elevated D-dimers and fibrinogen. Fibrin deposits are found in the lungs of patients due to the dysregulation of the coagulation and fibrinolytic systems. Tissue factor (TF) is exposed on damaged alveolar endothelial cells and on the surface of leukocytes promoting fibrin deposition, while significantly elevated levels of plasminogen activator inhibitor 1 (PAI-1) from lung epithelium and endothelial cells create a hypofibrinolytic state. Prophylaxis treatment of COVID-19 patients with low molecular weight heparin (LMWH) is important to limit coagulopathy. However, to degrade pre-existing fibrin in the lung it is essential to promote local fibrinolysis. In this review, we discuss the repurposing of fibrinolytic drugs, namely tissue-type plasminogen activator (tPA), to treat COVID-19 associated ARDS. tPA is an approved intravenous thrombolytic treatment, and the nebulizer form has been shown to be effective in plastic bronchitis and is currently in Phase II clinical trial. Nebulizer plasminogen activators may provide a targeted approach in COVID-19 patients to degrade fibrin and improving oxygenation in critically ill patients.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 435, "name": "Whyte CS"}], "publication_date": "2020-04-27"}, {"id": 41, "slug": "the-clinical-characteristics-of-pneumonia-patients-coinfected-with-2019-novel-co", "title": "The clinical characteristics of pneumonia patients co\u2010infected with 2019 novel coronavirus and influenza virus in Wuhan, China", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Description clinique des patient ayant une coinfection SARS-CoV-2, grippe.", "verbose_date": "20.03.2020", "authors": "Ding Q", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://www.dropbox.com/s/o74j57obek6k7qc/jmv.25781.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Effectif trop faible pour pouvoir tirer des conclusions- Pas d'aggravation due \u00e0 la coinfection- Pr\u00e9sentation clinique similaire \u00e0 celle du COVID19. Pr\u00e9sence possible de symptomes inhabituels pour une infection \u00e0 COVID19 comme l'obstruction nasale et les douleurs pharyng\u00e9es.", "objectives": "Faible :- Etude descriptive- Tr\u00e8s faible effectif (5 patients)", "methods": "Description clinique des patient ayant une coinfection SARS-CoV-2, grippe.", "topics": ["Epid\u00e9miologique", "Infectiologie"], "author_list": [{"id": 51, "name": "Ding Q"}], "publication_date": "2020-03-20"}, {"id": 199, "slug": "stability-issues-of-rt-pcr-testing-of-sars-cov-2-for-hospitalized-patients-clini", "title": "Stability Issues of RT-PCR Testing of SARS-CoV-2 for Hospitalized Patients Clinically Diagnosed with COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluation de la sensibilit\u00e9 du test RT-PCR sur l'\u00e9chantillon nasopharyng\u00e9 \u00e0 diff\u00e9rents moments du diagnostic et de la th\u00e9rapie des patients COVID-19", "verbose_date": "31.03.2020", "authors": "Li Y ", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25786", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude \u00e0 r\u00e9v\u00e9l\u00e9 une instabilit\u00e9 potentielle des r\u00e9sultats de la RT-PCR (real time PCR) sur des pr\u00e9l\u00e8vements nasopharyng\u00e9s de patients atteints de COVID-19 :\r\n* sur 384 patients n\u00e9gatifs au premier test, 48 ont eu un r\u00e9sultat positif lors du deuxi\u00e8me test RT-PCR et 12 lors des tests suivants\r\n* sur 168 patients ayant obtenu un r\u00e9sultat positif au premier test, 17 \u00e9taient n\u00e9gatifs au deuxi\u00e8me test (apr\u00e8s traitement), mais \u00e0 nouveau positifs au troisi\u00e8me test (apr\u00e8s am\u00e9lioration des sympt\u00f4mes)\n\r\nSur la base de ces donn\u00e9es, les chercheurs:\r\n1) d\u00e9conseillent d'utiliser le r\u00e9sultat du test comme seul crit\u00e8re pour le diagnostic, le traitement, l'isolement et la sortie de ces patients.\r\n2) l'isolement du patient doit durer quelques jours apr\u00e8s sa sortie de l'h\u00f4pital afin de r\u00e9duire le risque de transmission (8 patients \u00e9taient positifs pour la RT-PCR apr\u00e8s deux r\u00e9sultats n\u00e9gatifs cons\u00e9cutifs)\r\n3) en cas de pathologie critique (insuffisance respiratoire, choc, d\u00e9faillance de plusieurs organes), les patients doivent \u00eatre transf\u00e9r\u00e9s aux soins intensifs malgr\u00e9 un r\u00e9sultat n\u00e9gatif de la RT-PCR", "objectives": "1) \u00e9tude observationnelle r\u00e9trospective2) \u00e9chatillon de 610 patients chinois3) manque d'informations d\u00e9taill\u00e9es sur les patients en raison de la surcharge de travail des professionnels de la sant\u00e9 qui ont pris soin des patients", "methods": "Evaluation de la sensibilit\u00e9 du test RT-PCR sur l'\u00e9chantillon nasopharyng\u00e9 \u00e0 diff\u00e9rents moments du diagnostic et de la th\u00e9rapie des patients COVID-19", "pubmed_id": "32219885", "doi": "10.1002/jmv.25786", "abstract": "In this study, we collected a total of 610 hospitalized patients from Wuhan between February 2, 2020, and February 17, 2020. We reported a potentially high false negative rate of real-time reverse-transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 in the 610 hospitalized patients clinically diagnosed with COVID-19 during the 2019 outbreak. We also found that the RT-PCR results from several tests at different points were variable from the same patients during the course of diagnosis and treatment of these patients. Our results indicate that in addition to the emphasis on RT-PCR testing, clinical indicators such as computed tomography images should also be used not only for diagnosis and treatment but also for isolation, recovery/discharge, and transferring for hospitalized patients clinically diagnosed with COVID-19 during the current epidemic. These results suggested the urgent needs for the standard of procedures of sampling from different anatomic sites, sample transportation, optimization of RT-PCR, serology diagnosis/screening for SARS-CoV-2 infection, and distinct diagnosis from other respiratory diseases such as fluenza infections as well.", "topics": ["Diagnostique", "Virologie"], "author_list": [{"id": 192, "name": "Li Y "}], "publication_date": "2020-03-31"}, {"id": 201, "slug": "potential-effects-of-coronaviruses-on-the-cardiovascular-a-system-review", "title": "Potential Effects of Coronaviruses on the Cardiovascular. A System Review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Revue des choses apprises sur MERS , SARS et grippe saisonni\u00e8re pour obtenir des pistes sur les effets du coronavirus sur le syst\u00e8me cardiovasculaire ", "verbose_date": "31.03.2020", "authors": "Madjid M ", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}, {"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 99, "name": "JAMA Cardiol"}, "link": "https://www.dropbox.com/s/257mgczg9qqgm5v/jamacardiology_madjid_2020_rv_200002.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Des l\u00e9sions cardiaques aigu\u00ebs (troponines \u00e9lev\u00e9es) sont observ\u00e9es dans les formes s\u00e9v\u00e8res et sont associ\u00e9es \u00e0 une mortalit\u00e9 accrue.\r\nLes SDRA sont aussi associ\u00e9s \u00e0 une plus forte mortalit\u00e9.\r\nLe coronavirus est associ\u00e9 \u00e0 un \u00e9tat inflammatoire pouvant entra\u00eener inflammation vasculaire, myocardite, et arythmies cardiaques.", "objectives": "- revue de biblio existante sur le sujet (surtout sur le MERS)- pas de m\u00e9thode sur la recherche des articles", "methods": "Revue des choses apprises sur MERS , SARS et grippe saisonni\u00e8re pour obtenir des pistes sur les effets du coronavirus sur le syst\u00e8me cardiovasculaire", "topics": ["Epid\u00e9miologique", "Cardiologie et maladies m\u00e9taboliques", "Transversale"], "author_list": [{"id": 194, "name": "Madjid M "}], "publication_date": "2020-03-31"}, {"id": 667, "slug": "clinical-efficacy-of-chloroquine-derivatives-in-covid-19-infection-comparative-m", "title": "Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Fournir une analyse critique des donn\u00e9es disponibles sur les d\u00e9riv\u00e9s de la chloroquine.\r\n\r\n ", "verbose_date": "09.06.2020", "authors": "Million M", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 250, "name": "New Microbes and New Infections"}, "link": "https://www.sciencedirect.com/science/article/pii/S2052297520300615?via%3Dihub", "findings": "", "take_away": "", "relevance_level": "Les \u00e9tudes\u00a0observationnelles de big data ont \u00e9t\u00e9 associ\u00e9es \u00e0 des conflits d'int\u00e9r\u00eats, \u00e0 un manque d'information sur posologie / dur\u00e9e de traitement et \u00e0 une absence de r\u00e9sultat favorable. Les \u00e9tudes cliniques ont \u00e9t\u00e9 associ\u00e9es \u00e0 r\u00e9sultats favorables et \u00e0 des d\u00e9tails sur le traitement.", "objectives": "- Pre-proof- Risque de conflit d'int\u00e9r\u00eat important alors que la d\u00e9claration ne le mentionne pas car l'\u00e9diteur en chef du journal fait partie du m\u00eame institut que plusieurs auteurs et est le subordonn\u00e9 du dernier auteur- Inclusion d'\u00e9tudes en pre-print- Inclusion syst\u00e9matique de toutes les publications de l'\u00e9quipe et attribution du code couleur vert (conflit d'int\u00e9r\u00eat)- M\u00e9thodes tr\u00e8s peu d\u00e9taill\u00e9es, pas de pr\u00e9cision sur les crit\u00e8res d'inclusion des \u00e9tudes, exclusion (pas de flow chart)- Crit\u00e8re de tri des \u00e9tudes peu habituels- Pas de suivi de recommandations type PRISMA- Nombreux crit\u00e8res \u00e9tudi\u00e9s- Forest plot comptant parfois en double et certains crit\u00e8res de jugement sont compt\u00e9s s\u00e9par\u00e9ment- Objectif de l'\u00e9tude pas vraiment clair...", "methods": "Fournir une analyse critique des donn\u00e9es disponibles sur les d\u00e9riv\u00e9s de la chloroquine.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 295, "name": "Million M"}], "publication_date": "2020-06-09"}, {"id": 141, "slug": "time-kinetics-of-viral-clearance-and-resolution-of-symptoms-in-novel-coronavirus", "title": "Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la clairance virale apr\u00e8s disparition des sympt\u00f4mes", "verbose_date": "25.03.2020", "authors": "Chang D ", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 3, "name": "Am J Respir Crit Care Med"}, "link": "https://www.dropbox.com/s/avhndbtgrd27dcl/rccm.202003-0524le.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- la moiti\u00e9es des patients continuent d'\u00eatre positif au virus meme apres la r\u00e9solution des sympt\u00f4mes et ce jusqu'\u00e0 8 jours\r\n- des r\u00e9sultats similaires avaient \u00e9t\u00e9 publi\u00e9s : 12 jours de clairance (aucun patient d\u00e9c\u00e9d\u00e9)\r\n- Dans d'autres \u00e9tudes, le virus peut rester 20 jours (mortalit\u00e9>40%)", "objectives": "- petits effectifs 16- jeunes, majoritairement des Hm- que des formes l\u00e9g\u00e8res- il faudrait regarder ce d\u00e9lai chez les plus vuln\u00e9rables", "methods": "Etudier la clairance virale apr\u00e8s disparition des sympt\u00f4mes", "pubmed_id": "32200654", "doi": "10.1164/rccm.202003-0524LE", "abstract": null, "topics": ["Pronostique", "Transversale", "Virologie"], "author_list": [{"id": 138, "name": "Chang D "}], "publication_date": "2020-03-25"}, {"id": 244, "slug": "a-first-case-of-meningitisencephalitis-associated-with-sars-coronavirus-2", "title": "A first Case of Meningitis/Encephalitis associated with SARS-Coronavirus-2", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9cire un possible cas de m\u00e9ningite \u00e0 SARS-CoV-2", "verbose_date": "04.04.2020", "authors": "Moriguchi T", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.ijidonline.com/action/showPdf?pii=S1201-9712%2820%2930195-8", "findings": "", "take_away": "", "relevance_level": "Un homme de 24 ans a pr\u00e9sent\u00e9 ce qui semble \u00eatre une m\u00e9ningite \u00e0 SARS-CoV-2 avec d\u00e9tection de l'ARN viral dans le LCR (pas au niveau naso-pharyng\u00e9). Les sympt\u00f4mes ont commenc\u00e9 par de l'asth\u00e9nie et de la fi\u00e8vre \u00e0 J1 puis, \u00e0 J9, le patient a \u00e9t\u00e9 retrouv\u00e9 inconscient. Il a alors d\u00e9velopp\u00e9 des crises g\u00e9n\u00e9ralis\u00e9es transitoires avec une raideur de nuque et des signes IRM en faveur d'une m\u00e9ningite.\r\nAttention en cas de sympt\u00f4mes neurologiques \u00e0 une possible atteinte m\u00e9ning\u00e9e du COVID.", "objectives": "- Un unique case-report japonais", "methods": "D\u00e9cire un possible cas de m\u00e9ningite \u00e0 SARS-CoV-2", "pubmed_id": "32251791", "doi": "10.1016/j.ijid.2020.03.062", "abstract": "Novel coronavirus (SARS-Coronavirus-2:SARS-CoV-2) which emerged in Wuhan, China, has spread to multiple countries rapidly. We report the first case of meningitis associated with SARS-CoV-2 who was brought in by ambulance due to a convulsion accompanied by unconsciousness. He had never been to any foreign countries. He felt generalized fatigue and fever (day 1). He saw doctors nearby twice (day 2 and 5) and was prescribed Laninamivir and antipyretic agents, His family visited his home and found that he was unconsciousness and lying on the floor in his vomit. He was immediately transported to this hospital by ambulance (day 9). Under emergency transport, he had transient generalized seizures that lasted about a minute. He had obvious neck stiffness. The specific SARS-CoV-2 RNA was not detected in the nasopharyngeal swab but was detected in a CSF. Anti- HSV 1 and varicella-zoster IgM antibodies were not detected in serum samples. A brain MRI showed hyperintensity along the wall of right lateral ventricle and hyperintense signal changes in the right mesial temporal lobe and hippocampus, suggesting the possibility of SARS-CoV-2 meningitis. This case warns the physicians of patients who have CNS symptoms.", "topics": ["Epid\u00e9miologique", "Infectiologie"], "author_list": [{"id": 234, "name": "Moriguchi T"}], "publication_date": "2020-04-04"}, {"id": 353, "slug": "inhibitors-of-the-renin-angiotensin-system-the-potential-role-in-the-pathogenesi", "title": "Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire le r\u00f4le des diff\u00e9rentes voies du syst\u00e8me r\u00e9nine-angiotensine dans la physiopathologie du COVID-19", "verbose_date": "16.04.2020", "authors": "Huang Z", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 151, "name": "Cardiol J"}, "link": "https://www.dropbox.com/s/u28uxiu6qwnjy2a/68220-207254-2-PB.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Un d\u00e9s\u00e9quilibre entre deux voies impliqu\u00e9es dans le syst\u00e8me r\u00e9nine-angiotensine par le biais d'une inhibition virale de la voie enzyme de conversion de l'angiotensine II/ l'angiotensine 1-7/ r\u00e9cepteur Mas participerait \u00e0 l\u2019emballement immunitaire multi-syst\u00e9mique d\u00e9crit dans la physiopathologie du COVID-19.\u00a0\r\nIl pourrait \u00eatre pertinent d\u2019\u00e9valuer l\u2019efficacit\u00e9 de certains bloqueurs du SRA dans le traitement du COVID-19.", "objectives": "Revue narrative de la litt\u00e9rature avec peu de r\u00e9f\u00e9rences", "methods": "D\u00e9crire le r\u00f4le des diff\u00e9rentes voies du syst\u00e8me r\u00e9nine-angiotensine dans la physiopathologie du COVID-19", "pubmed_id": "32286678", "doi": "10.5603/CJ.a2020.0056", "abstract": "Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians.", "topics": ["Autres", "Transversale", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 340, "name": "Huang Z"}], "publication_date": "2020-04-16"}, {"id": 83, "slug": "adoption-of-covid-19-triage-strategies-for-low-income-settings", "title": "Adoption of COVID-19 triage strategies for low-income settings", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Trouver algorithme de triage des patients dans les payes \u00e0 faibles ressources", "verbose_date": "16.03.2020", "authors": "Ayebare RR", "specialties": [{"id": 8, "name": "Pneumologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 1, "name": "Lancet Repir Med"}, "link": "https://www.dropbox.com/s/iqhdl94hmnes3k6/10.1016%40S2213-26002030114-4.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Recherche de temp\u00e9rature >37.3\u00b0C OU toux,  - si non : faible risque de COVID - si oui : Recherche exposition \u00e0 un cas COVID positif ou voyage dans une zone infect\u00e9e - si non : faible risque de COVID  - si oui : 1 : isolement,  2 : suppl\u00e9mentation en oxyg\u00e8ne si tachypn\u00e9e FR>20 ou hypox\u00e9mie sat <93% 3 : test COVID", "objectives": "Faible : 1) lettre \u00e0 l'\u00e9diteur", "methods": "Trouver algorithme de triage des patients dans les payes \u00e0 faibles ressources", "pubmed_id": "32171063\n28490619\n28845357\n32007143\n32061335", "doi": "10.1016/S2213-2600(20)30114-4", "abstract": null, "topics": ["Diagnostique", "Pneumologie"], "author_list": [{"id": 93, "name": "Ayebare RR"}], "publication_date": "2020-03-16"}, {"id": 559, "slug": "impact-of-corticosteroid-therapy-on-outcomes-of-persons-with-sars-cov-2-sars-cov", "title": "Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer l'efficacit\u00e9 des cortico\u00efdes chez des patients atteints de SARS-CoV, MERS-CoV et COVID-19", "verbose_date": "09.05.2020", "authors": "Li H", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 220, "name": "Leukemia"}, "link": "https://www.nature.com/articles/s41375-020-0848-3.pdf", "findings": "", "take_away": "", "relevance_level": "L'utilisation des cortico\u00efdes n'\u00e9tait pas associ\u00e9e \u00e0 une diff\u00e9rence statistiquement significative de la mortalit\u00e9 chez les patients atteints de\u00a0SARS-CoV, MERS-CoV et COVID-19. En ce qui concerne l'impact sur la clairance virale et la dur\u00e9e d'hospitalisation, les \u00e9tudes portant sur le COVID-19 n'ont pas \u00e9t\u00e9 analys\u00e9es.\u00a0\r\nAucune interpr\u00e9tation possible en ce qui concerne la corticoth\u00e9rapie et\u00a0l'usage de la ventilation m\u00e9canique.", "objectives": "M\u00e9ta-analyse avec un bon effectif mais un seul essai clinique randomis\u00e9, biais de publication, de nombreux crit\u00e8res n'\u00e9taient \u00e9valu\u00e9s que pour 2 des 3 pathologies \u00e9tudi\u00e9es, inclusion de patients s\u00e9v\u00e8res et non s\u00e9v\u00e8res alors que l'utilisation des cortico\u00efdes se discute surtout pour les patients graves", "methods": "Evaluer l'efficacit\u00e9 des cortico\u00efdes chez des patients atteints de SARS-CoV, MERS-CoV et COVID-19", "pubmed_id": "32372026", "doi": "10.1038/s41375-020-0848-3", "abstract": "We performed a meta-analysis to determine safety and efficacy of corticosteroids in SARS-CoV-2, SARS-CoV, and MERS-CoV infections. We searched PubMed, Web of Science, Medline, WanFang Chinese database, and ZhiWang Chinese database using Boolean operators and search terms covering SARS-CoV-2, SARS-CoV, OR MERS-CoV AND corticosteroids to find appropriate studies. Review Manager 5.3 was used to analyze results of meta-analysis. Observational studies were analyzed for quality using the modified Newcastle-Ottawa scale and randomized clinical trials, using the Jadad scale. Subjects were divided into those with severe-only and other (severe and not severe) cohorts based on published criteria. Efficacy endpoints studied included mortality, hospitalization duration, rates of intensive care unit (ICU) admission, use of mechanical ventilation, and a composite endpoint (death, ICU admission, or mechanical ventilation). We included 11 reports including 10 cohort studies and 1 randomized clinical trial involving 5249 subjects (2003-2020). Two discussed the association of corticosteroids and virus clearing and 10 explored how corticosteroids\u00a0impacted mortality, hospitalization duration, use of mechanical ventilation, and a composite endpoint. Corticosteroid use was associated with delayed virus clearing with a mean difference (MD)\u2009=\u20093.78 days (95% confidence Interval [CI]\u2009=\u20091.16, 6.41 days; I", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 393, "name": "Li H"}], "publication_date": "2020-05-09"}, {"id": 602, "slug": "risk-factors-for-sars-cov-2-among-patients-in-the-oxford-royal-college-of-genera", "title": "Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Identifier les facteurs de risque d\u00e9mographiques et cliniques pour la positivit\u00e9 d'un test pour le SARS-CoV-2 au sein du r\u00e9seau de soins primaires du Centre de recherche et de surveillance du Coll\u00e8ge Royal d'Oxford.", "verbose_date": "18.05.2020", "authors": "Lusignan S", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 74, "name": "Lancet Infect Dis"}, "link": "https://www.thelancet.com/action/showPdf?pii=S1473-3099%2820%2930371-6", "findings": "", "take_away": "", "relevance_level": "Facteurs de risque de r\u00e9sultat positif :\u00a0similaires \u00e0 ceux observ\u00e9s pour les issues graves du COVID-19 en milieu hospitalier (notamment la privation, la densit\u00e9 de population, l'origine ethnique et la maladie r\u00e9nale chronique), \u00e0 l'exception du tabagisme.", "objectives": "Etude de cohorte, n=3 802 personnes test\u00e9es, \u00e9chelle locale.Exclusion d'environ 2,2% de la population du r\u00e9seau ne souhaitant pas partager leurs donn\u00e9es m\u00e9dicales.Imputation multiple des donn\u00e9es manquantes (plus de 10% de donn\u00e9es manquantes pour l'IMC, le statut tabagique, l'origine ethnique).Changement dans les pratiques au 14 mars : auto-pr\u00e9l\u00e8vement depuis.", "methods": "Identifier les facteurs de risque d\u00e9mographiques et cliniques pour la positivit\u00e9 d'un test pour le SARS-CoV-2 au sein du r\u00e9seau de soins primaires du Centre de recherche et de surveillance du Coll\u00e8ge Royal d'Oxford.", "pubmed_id": "32422204\n30879056\n32074416\n19758977\n32171076\n25641062\n21502561\n32248812\n32173574\n28346128\n31685296\n32226295\n22251996\n32227760\n32240123\n19926667\n21116339\n30088946\n28963401\n32052492\n10402742\n29020390\n32206052\n31211103", "doi": "10.1016/S1473-3099(20)30371-6", "abstract": "There are few primary care studies of the COVID-19 pandemic. We aimed to identify demographic and clinical risk factors for testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the Oxford Royal College of General Practitioners (RCGP) Research and Surveillance Centre primary care network.\nWe analysed routinely collected, pseudonymised data for patients in the RCGP Research and Surveillance Centre primary care sentinel network who were tested for SARS-CoV-2 between Jan 28 and April 4, 2020. We used multivariable logistic regression models with multiple imputation to identify risk factors for positive SARS-CoV-2 tests within this surveillance network.\nWe identified 3802 SARS-CoV-2 test results, of which 587 were positive. In multivariable analysis, male sex was independently associated with testing positive for SARS-CoV-2 (296 [18\u00b74%] of 1612 men vs 291 [13\u00b73%] of 2190 women; adjusted odds ratio [OR] 1\u00b755, 95% CI 1\u00b727-1\u00b789). Adults were at increased risk of testing positive for SARS-CoV-2 compared with children, and people aged 40-64 years were at greatest risk in the multivariable model (243 [18\u00b75%] of 1316 adults aged 40-64 years vs 23 [4\u00b76%] of 499 children; adjusted OR 5\u00b736, 95% CI 3\u00b728-8\u00b776). Compared with white people, the adjusted odds of a positive test were greater in black people (388 [15\u00b75%] of 2497 white people vs 36 [62\u00b71%] of 58 black people; adjusted OR 4\u00b775, 95% CI 2\u00b765-8\u00b751). People living in urban areas versus rural areas (476 [26\u00b72%] of 1816 in urban areas vs 111 [5\u00b76%] of 1986 in rural areas; adjusted OR 4\u00b759, 95% CI 3\u00b757-5\u00b790) and in more deprived areas (197 [29\u00b75%] of 668 in most deprived vs 143 [7\u00b77%] of 1855 in least deprived; adjusted OR 2\u00b703, 95% CI 1\u00b751-2\u00b771) were more likely to test positive. People with chronic kidney disease were more likely to test positive in the adjusted analysis (68 [32\u00b79%] of 207 with chronic kidney disease vs 519 [14\u00b74%] of 3595 without; adjusted OR 1\u00b791, 95% CI 1\u00b731-2\u00b778), but there was no significant association with other chronic conditions in that analysis. We found increased odds of a positive test among people who are obese (142 [20\u00b79%] of 680 people with obesity vs 171 [13\u00b72%] of 1296 normal-weight people; adjusted OR 1\u00b741, 95% CI 1\u00b704-1\u00b791). Notably, active smoking was linked with decreased odds of a positive test result (47 [11\u00b74%] of 413 active smokers vs 201 [17\u00b79%] of 1125 non-smokers; adjusted OR 0\u00b749, 95% CI 0\u00b734-0\u00b771).\nA positive SARS-CoV-2 test result in this primary care cohort was associated with similar risk factors as observed for severe outcomes of COVID-19 in hospital settings, except for smoking. We provide evidence of potential sociodemographic factors associated with a positive test, including deprivation, population density, ethnicity, and chronic kidney disease.\nWellcome Trust.", "topics": ["Pronostique", "Transversale", "Infectiologie"], "author_list": [{"id": 565, "name": "Lusignan S"}], "publication_date": "2020-05-18"}, {"id": 277, "slug": "locally-informed-simulation-to-predict-hospital-capacity-needs-during-the-covid-", "title": "Locally Informed Simulation to Predict Hospital Capacity Needs During the COVID-19 Pandemic", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Estimer les moments critiques de demandes de soins hospitaliers li\u00e9es au COVID-19 et les diff\u00e9rents sc\u00e9narios locaux de pression sur la capacit\u00e9 hospitali\u00e8re", "verbose_date": "08.04.2020", "authors": "Weissman GE", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 41, "name": "Ann Intern Med"}, "link": "https://annals.org/aim/fullarticle/2764423/locally-informed-simulation-predict-hospital-capacity-needs-during-covid-19", "findings": "", "take_away": "", "relevance_level": "Accessible au public sur https://penn-chime.phl.io/ (donn\u00e9es sur l'h\u00f4pital \u00e0 rentrer ainsi que donn\u00e9es sur la transmission et la s\u00e9v\u00e9rit\u00e9) et con\u00e7u pour la gestion des h\u00f4pitaux, cette mod\u00e9lisation peut \u00eatre utile pour pr\u00e9voir l'augmentation des capacit\u00e9s lors de cette pand\u00e9mie.", "objectives": "1) Mod\u00e8le SIR simplifi\u00e92) Donn\u00e9es du mod\u00e8le bas\u00e9es principalement sur des donn\u00e9es chinoises et une \u00e9tude italienne.3) CHIME n'inclut pas davantage de donn\u00e9es pour mod\u00e9liser la gravit\u00e9 de l'infection, les contacts sociaux pour mod\u00e9liser la dynamique de transmission ou les donn\u00e9es g\u00e9ographiques pour tenir compte des mod\u00e8les spatiaux d'interaction humaine.\"", "methods": "Estimer les moments critiques de demandes de soins hospitaliers li\u00e9es au COVID-19 et les diff\u00e9rents sc\u00e9narios locaux de pression sur la capacit\u00e9 hospitali\u00e8re", "pubmed_id": "32259197", "doi": "10.7326/M20-1260", "abstract": "The coronavirus disease 2019 (COVID-19) pandemic challenges hospital leaders to make time-sensitive, critical decisions about clinical operations and resource allocations.\nTo estimate the timing of surges in clinical demand and the best- and worst-case scenarios of local COVID-19-induced strain on hospital capacity, and thus inform clinical operations and staffing demands and identify when hospital capacity would be saturated.\nMonte Carlo simulation instantiation of a susceptible, infected, removed (SIR) model with a 1-day cycle.\n3 hospitals in an academic health system.\nAll people living in the greater Philadelphia region.\nThe COVID-19 Hospital Impact Model (CHIME) (http://penn-chime.phl.io) SIR model was used to estimate the time from 23 March 2020 until hospital capacity would probably be exceeded, and the intensity of the surge, including for intensive care unit (ICU) beds and ventilators.\nUsing patients with COVID-19 alone, CHIME estimated that it would be 31 to 53 days before demand exceeds existing hospital capacity. In best- and worst-case scenarios of surges in the number of patients with COVID-19, the needed total capacity for hospital beds would reach 3131 to 12\u00a0650 across the 3 hospitals, including 338 to 1608 ICU beds and 118 to 599 ventilators.\nModel parameters were taken directly or derived from published data across heterogeneous populations and practice environments and from the health system's historical data. CHIME does not incorporate more transition states to model infection severity, social networks to model transmission dynamics, or geographic information to account for spatial patterns of human interaction.\nPublicly available and designed for hospital operations leaders, this modeling tool can inform preparations for capacity strain during the early days of a pandemic.\nUniversity of Pennsylvania Health System and the Palliative and Advanced Illness Research Center.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 266, "name": "Weissman GE"}], "publication_date": "2020-04-08"}, {"id": 158, "slug": "covid-19-and-smoking-a-systematic-review-of-the-evidence", "title": "COVID-19 and smoking: A systematic review of the evidence", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer la corr\u00e9lation entre le statut tabagique (actuel ou ancien) et les cons\u00e9quences possibles de la COVID-19 (gravit\u00e9 de la pathologie, n\u00e9cessit\u00e9 de ventilation m\u00e9canique, acc\u00e8s \u00e0 l'unit\u00e9 de soins intensifs, d\u00e9c\u00e8s).", "verbose_date": "26.03.2020", "authors": "Vardavas CI ", "specialties": [{"id": 8, "name": "Pneumologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 83, "name": "Tob Induc Dis"}, "link": "https://www.dropbox.com/s/adz6efj6bsctnv9/COVID-19%20and%20smoking_%20A.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Parmi les \u00e9tudes analys\u00e9es, la plus grande (Guan et al, n=1099) fait \u00e9tat d'un pourcentage statistiquement significatif de fumeurs actuels ou anciens parmi les patients n\u00e9cessitant une ventilation m\u00e9canique, des soins intensifs ou d\u00e9c\u00e9d\u00e9s.\n\r\nEn utilisant les donn\u00e9es de l'\u00e9tude, les auteurs de l'article ont calcul\u00e9 que les fumeurs sont 1,4 fois plus susceptibles d'avoir des sympt\u00f4mes graves (RR=1.4, 95%, IC: 0.98-2.00)et 2,4 fois plus susceptibles d'avoir une ventilation m\u00e9canique, des soins intensifs et la mort (RR=2.4, 95%, IC:1.43-4.04)", "objectives": "1) \u00c9ditorial2) 5 \u00e9tudes chinoises (r\u00e9trospectives et prospectives) : 4 en Wuhan, 1 en province chinoise3) \u00c9chantillon limit\u00e9 avec une taille comprise entre 41 et 1099 patients par \u00e9tude et couvrant uniquement les mois de d\u00e9cembre 2019 et janvier 2020)", "methods": "\u00c9valuer la corr\u00e9lation entre le statut tabagique (actuel ou ancien) et les cons\u00e9quences possibles de la COVID-19 (gravit\u00e9 de la pathologie, n\u00e9cessit\u00e9 de ventilation m\u00e9canique, acc\u00e8s \u00e0 l'unit\u00e9 de soins intensifs, d\u00e9c\u00e8s).", "pubmed_id": "32206052\n32109013\n32077115\n32014114\n15534156\n31768164\n31986264\n32118640\n27891067\n31995857\n32138488\n29716568\n32171076", "doi": "10.18332/tid/119324", "abstract": null, "topics": ["Autres", "Pneumologie"], "author_list": [{"id": 154, "name": "Vardavas CI "}], "publication_date": "2020-03-26"}, {"id": 410, "slug": "airborne-transmission-of-severe-acute-respiratory-syndrome-coronavirus-2-to-heal", "title": "Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare workers: a narrative review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Revue sur la transmission a\u00e9rienne du SARS-CoV-2 aux soignants.", "verbose_date": "22.04.2020", "authors": "Wilson N", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 129, "name": "Anaesthesia"}, "link": "https://onlinelibrary.wiley.com/doi/abs/10.1111/anae.15093", "findings": "", "take_away": "", "relevance_level": "Hypoth\u00e8se que le temps \u00e0 proximit\u00e9 d'un malade est plus important que la proc\u00e9dure en soi. Un patient en d\u00e9tresse respiratoire aigu\u00eb nous para\u00eet plus a\u00e9rosolisant que certaines proc\u00e9dures. Actuellement pr\u00e9cautions gouttelettes pour tous et a\u00e9riennes pour proc\u00e9dures a\u00e9rosolisantes. Pas assez de donn\u00e9es pour pr\u00e9ciser la transmission a\u00e9rienne de ce virus (ou gouttelettes seules?), il manque des informations sur le timing et la cause de la transmission pendant les proc\u00e9dures. Les pr\u00e9cautions a\u00e9riennes devraient donc peut-\u00eatre \u00eatre \u00e0 tout moment. Mais les contraintes mat\u00e9rielles rendent importante la rationalisation l'utilisation des EPI au risque local de transmission.", "objectives": "Revue de la litt\u00e9rature mais peu de donn\u00e9es physiques sur l'actuel virus, analogies avec SARS COV 1.", "methods": "Revue sur la transmission a\u00e9rienne du SARS-CoV-2 aux soignants.", "pubmed_id": "32311771\n17283614\n15030699\n29878137\n24789791\n30705129\n20475760\n15102999\n15141377\n15583121\n15030698\n23418548\n12651864\n22156667\n14990393\n32094336\n32232685\n3745978\n15030692\n28373015\n17542834\n19133798\n5773092\n5918954\n31815775\n27590694\n25523206\n23505369\n15364765\n25578684\n15030686\n10168531\n15030696\n22563403\n20056850\n22651099\n21094184\n30634967\n15809906", "doi": "10.1111/anae.15093", "abstract": "Healthcare workers are at risk of infection during the severe acute respiratory syndrome coronavirus-2 pandemic. International guidance suggests direct droplet transmission is likely and airborne transmission occurs only with aerosol-generating procedures. Recommendations determining infection control measures to ensure healthcare worker safety follow these presumptions. Three mechanisms have been described for the production of smaller sized respiratory particles ('aerosols') that, if inhaled, can deposit in the distal airways. These include: laryngeal activity such as talking and coughing; high velocity gas flow; and cyclical opening and closure of terminal airways. Sneezing and coughing are effective aerosol generators, but all forms of expiration produce particles across a range of sizes. The 5-\u03bcm diameter threshold used to differentiate droplet from airborne is an over-simplification of multiple complex, poorly understood biological and physical variables. The evidence defining aerosol-generating procedures comes largely from low-quality case and cohort studies where the exact mode of transmission is unknown as aerosol production was never quantified. We propose that transmission is associated with time in proximity to severe acute respiratory syndrome coronavirus-1 patients with respiratory symptoms, rather than the procedures per se. There is no proven relation between any aerosol-generating procedure with airborne viral content with the exception of bronchoscopy and suctioning. The mechanism for severe acute respiratory syndrome coronavirus-2 transmission is unknown but the evidence suggestive of airborne spread is growing. We speculate that infected patients who cough, have high work of breathing, increased closing capacity and altered respiratory tract lining fluid will be significant producers of pathogenic aerosols. We suggest several aerosol-generating procedures may in fact result in less pathogen aerosolisation than a dyspnoeic and coughing patient. Healthcare workers should appraise the current evidence regarding transmission and apply this to the local infection prevalence. Measures to mitigate airborne transmission should be employed at times of risk. However, the mechanisms and risk factors for transmission are largely unconfirmed. Whilst awaiting robust evidence, a precautionary approach should be considered to assure healthcare worker safety.", "topics": ["Autres", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Hygi\u00e8ne"], "author_list": [{"id": 391, "name": "Wilson N"}], "publication_date": "2020-04-22"}, {"id": 227, "slug": "covid-19-outbreak-associated-with-air-conditioning-in-restaurant-guangzhou-china", "title": "COVID-19 Outbreak Associated With Air Conditioning in Restaurant, Guangzhou, China, 2020", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les effets de l'air conditionn\u00e9 dans un restaurant", "verbose_date": "02.04.2020", "authors": "Lu J", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 28, "name": "Emerg Infect Dis"}, "link": "https://wwwnc.cdc.gov/eid/article/26/7/20-0764_article", "findings": "", "take_away": "", "relevance_level": "Les goutelettes sont transmises par les ventilation par air conditionn\u00e9. Le facteur cl\u00e9 est la direction du flux d'air.\r\nPour limiter la transmission du virus dans un restaurant :\u00a0\r\n- renforcer la surveillance des temp\u00e9ratures\r\n- augmenter les distances entre tables\r\n- am\u00e9liorer la ventilation", "objectives": "- lettre a l'editeur- rapport de cas (3 familles)- les clients asymptomatiques n'ont pas \u00e9t\u00e9 test\u00e9s\"", "methods": "D\u00e9crire les effets de l'air conditionn\u00e9 dans un restaurant", "pubmed_id": "32240078", "doi": "10.3201/eid2607.200764", "abstract": "During January 26-February 10, 2020, an outbreak of 2019 novel coronavirus disease in an air-conditioned restaurant in Guangzhou, China, involved 3 family clusters. The airflow direction was consistent with droplet transmission. To prevent the spread of the virus in restaurants, we recommend increasing the distance between tables and improving ventilation.", "topics": ["Epid\u00e9miologique", "Hygi\u00e8ne"], "author_list": [{"id": 217, "name": "Lu J"}], "publication_date": "2020-04-02"}, {"id": 168, "slug": "antibodies-in-infants-born-to-mothers-with-covid-19-pneumonia", "title": "Antibodies in Infants Born to Mothers With COVID-19 Pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer la pr\u00e9sence d'anticorps chez les nouveaux n\u00e9s de m\u00e8res infect\u00e9es", "verbose_date": "27.03.2020", "authors": "Zeng H ", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://www.dropbox.com/s/ae0s7qpbj796d9w/10.1001%40jama.2020.4861.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Parmi les 6 mere infect\u00e9es au SARS-CoV-2, aucun de leur nouveau n\u00e9 n'a pr\u00e9sent\u00e9 de virus dans les echantillons de gorge ou dans le sang.\r\nLes IgG \u00e9taient \u00e9lev\u00e9s chez 5 enfants. Ils sont passivement transf\u00e9r\u00e9s par le placenta a la fin du deuxieme trimestre et sont retrouv\u00e9s a de fortes concentration a la naissance.\r\nLes IgM sont detect\u00e9s chez 2 enfants, ils ne sont pas habituellement transf\u00e9r\u00e9 par la mere au foetus car cette mol\u00e9cule est plus grosse.", "objectives": "- lettre \u00e0 l'\u00e9diteur- 6 patientes- pas d'analyse du sang de cordon, liquide amniotique, lait maternel- outcome incomplet chez les enfants, d\u00e9claration de la maladie apres la sortie ?", "methods": "Evaluer la pr\u00e9sence d'anticorps chez les nouveaux n\u00e9s de m\u00e8res infect\u00e9es", "pubmed_id": "32215589\n16753741\n32151335\n5950290", "doi": "10.1001/jama.2020.4861", "abstract": null, "topics": ["Diagnostique", "P\u00e9diatrie"], "author_list": [{"id": 163, "name": "Zeng H "}], "publication_date": "2020-03-27"}, {"id": 213, "slug": "tilorone-a-broad-spectrum-antiviral-invented-in-the-usa-and-commercialized-in-ru", "title": "Tilorone: \u00e0 Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Pr\u00e9senter la Tilorone comme \u00e9ventuel traitement pour le COVID-19", "verbose_date": "31.03.2020", "authors": "Ekins S ", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 103, "name": "Pharm Res"}, "link": "https://www.dropbox.com/s/xhio5dlqslpc3ec/11095_2020_Article_2799.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Tilorone doit \u00eatre envisag\u00e9e dans l'arsenal th\u00e9rapeutique contre le SARS-Cov-2\r\nUtilis\u00e9e depuis de nombreuses ann\u00e9es dans les pays de l'Est", "objectives": "\"Faible : 1) Editorial\"", "methods": "Pr\u00e9senter la Tilorone comme \u00e9ventuel traitement pour le COVID-19", "topics": ["Th\u00e9rapeutique", "Infectiologie"], "author_list": [{"id": 204, "name": "Ekins S "}], "publication_date": "2020-03-31"}, {"id": 371, "slug": "description-and-proposed-management-of-the-acute-covid-19-cardiovascular-syndrom", "title": "Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9crire et proposer une strat\u00e9gie de prise en charge du Syndrome Cardiovasculaire Aigu li\u00e9 au COVID-19 (ACovCS) \u00e0 partir de donn\u00e9es de la litt\u00e9rature", "verbose_date": "18.04.2020", "authors": "Hendren NS", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 9, "name": "Circulation"}, "link": "https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.047349", "findings": "", "take_away": "", "relevance_level": "Le Syndrome Cardiovasculaire Aigu li\u00e9 au COVID-19 comprend les l\u00e9sions myocardiques, les troubles du rythme ainsi que les cardiomyopathies. On peut les expliquer par des ph\u00e9nom\u00e8nes de myocardite, d\u2019orage cytokinique, de dysfonction microvasculaire, des ph\u00e9nom\u00e8nes de microthrombose ou m\u00eame une cardiomyopathie de stress. Les patients stables dont la troponine est augment\u00e9e ne rel\u00e8vent pas d'examens compl\u00e9mentaires particuliers, sauf si une \u00e9chographie cardiaque au lit du patient est disponible facilement. Les patients h\u00e9modynamiquement instables n\u00e9cessitent plus d\u2019investigations ainsi qu'une prise en charge multi-disciplinaire. Diff\u00e9rents traitement modulant la r\u00e9plication virale et l'immunit\u00e9 sont en cours d'\u00e9tude sans r\u00e9el consensus et n\u00e9cessitent une \u00e9valuation au cas par cas. (cf algorithme de prise en charge \u00e0 la fin du document)", "objectives": "Revue de la litt\u00e9rature d'\u00e9tudes avec niveau de preuve tr\u00e8s variables mais nombreuses \u00e9tudes", "methods": "D\u00e9crire et proposer une strat\u00e9gie de prise en charge du Syndrome Cardiovasculaire Aigu li\u00e9 au COVID-19 (ACovCS) \u00e0 partir de donn\u00e9es de la litt\u00e9rature", "pubmed_id": "32297796", "doi": "10.1161/CIRCULATIONAHA.120.047349", "abstract": "Coronavirus disease 2019 (COVID-19) is a rapidly expanding global pandemic caused by severe acute respiratory syndrome coronavirus 2, resulting in significant morbidity and mortality. A substantial minority of patients hospitalized develop an acute COVID-19 cardiovascular syndrome, which can manifest with a variety of clinical presentations but often presents as an acute cardiac injury with cardiomyopathy, ventricular arrhythmias, and hemodynamic instability in the absence of obstructive coronary artery disease. The cause of this injury is uncertain but is suspected to be related to myocarditis, microvascular injury, systemic cytokine-mediated injury, or stress-related cardiomyopathy. Although histologically unproven, severe acute respiratory syndrome coronavirus 2 has the potential to directly replicate within cardiomyocytes and pericytes, leading to viral myocarditis. Systemically elevated cytokines are also known to be cardiotoxic and have the potential to result in profound myocardial injury. Prior experience with severe acute respiratory syndrome coronavirus 1 has helped expedite the evaluation of several promising therapies, including antiviral agents, interleukin-6 inhibitors, and convalescent serum. Management of acute COVID-19 cardiovascular syndrome should involve a multidisciplinary team including intensive care specialists, infectious disease specialists, and cardiologists. Priorities for managing acute COVID-19 cardiovascular syndrome include balancing the goals of minimizing healthcare staff exposure for testing that will not change clinical management with early recognition of the syndrome at a time point at which intervention may be most effective. This article aims to review the best available data on acute COVID-19 cardiovascular syndrome epidemiology, pathogenesis, diagnosis, and treatment. From these data, we propose a surveillance, diagnostic, and management strategy that balances potential patient risks and healthcare staff exposure with improvement in meaningful clinical outcomes.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 358, "name": "Hendren NS"}], "publication_date": "2020-04-18"}, {"id": 610, "slug": "corticosteroids-but-not-tnf-antagonists-are-associated-with-adverse-covid-19-out", "title": "Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Caract\u00e9riser le parcours clinique du Covid-19 chez les patients avec une maladie inflammatoire chronique de l'intestin et \u00e9valuer les facteurs de risque de la s\u00e9v\u00e9rit\u00e9 de la maladie.", "verbose_date": "20.05.2020", "authors": "Brenner EJ", "specialties": [{"id": 19, "name": "H\u00e9pato-gastro-ent\u00e9rologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 21, "name": "Gastroenterology"}, "link": "https://www.gastrojournal.org/article/S0016-5085(20)30655-7/pdf", "findings": "", "take_away": "", "relevance_level": "L'\u00e2ge, les comorbidit\u00e9s et les corticost\u00e9ro\u00efdes sont associ\u00e9s \u00e0 la s\u00e9v\u00e9rit\u00e9 du Covid-19 chez les patients avec une Maladie Inflammatoire Chronique Intestinale. Les antagonistes TNF ne le sont pas.", "objectives": "- Base de donn\u00e9es importante, mondiale, comportant tous les \u00e2ges- Biais de d\u00e9claration possible (sur la base de la volont\u00e9 des m\u00e9decins) : d\u00e9claration des cas les plus graves- Biais de s\u00e9lection aussi possible dans l'autre sens : les cas les plus graves d\u00e9c\u00e9d\u00e9s en dehors de l\u2019h\u00f4pital ne sont pas enregistr\u00e9s.- Possibilit\u00e9 de facteurs de confusion non mesur\u00e9s", "methods": "Caract\u00e9riser le parcours clinique du Covid-19 chez les patients avec une maladie inflammatoire chronique de l'intestin et \u00e9valuer les facteurs de risque de la s\u00e9v\u00e9rit\u00e9 de la maladie.", "topics": ["Pronostique", "H\u00e9pato-gastro-ent\u00e9rologie"], "author_list": [{"id": 573, "name": "Brenner EJ"}], "publication_date": "2020-05-20"}, {"id": 260, "slug": "diagnostic-value-and-dynamic-variance-of-serum-antibody-in-coronavirus-disease-2", "title": "Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la valeur diagnostique des tests s\u00e9rologiques et l'\u00e9volution des anticorps s\u00e9riques dans la COVID-19", "verbose_date": "07.04.2020", "authors": "Jin Y", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.ijidonline.com/article/S1201-9712(20)30198-3/pdf", "findings": "", "take_away": "", "relevance_level": "Les tests s\u00e9rologiques dans l'infection par le SARS-CoV-2 semblent pr\u00e9senter de bons param\u00e8tres diagnostiques en particulier pour les IgG (sensibilit\u00e9 entre 89% et 94% selon le moment de pr\u00e9l\u00e8vement, paraissant durable dans le temps, sp\u00e9cificit\u00e9 autour de 91%) mais les donn\u00e9es de cette \u00e9tude ne permettent pas de conclure du fait d'un trop faible effectif et d'une m\u00e9thodologie de qualit\u00e9 insuffisante.", "objectives": "- faibles effectifs- pas de patients s\u00e9v\u00e8res inclus- pas de protocole pour le rythme de r\u00e9alisation des tests s\u00e9rologiques (\u00e9tude r\u00e9trospective)- gold-standard (RT-PCR) discutable pour classer les sujets, notamment pour les patients contr\u00f4les pour lesquels on dispose de peu de donn\u00e9es de suivi", "methods": "Etudier la valeur diagnostique des tests s\u00e9rologiques et l'\u00e9volution des anticorps s\u00e9riques dans la COVID-19", "pubmed_id": "32251798\n31978945\n32109013\n23075143\n32075786\n27106390\n14585636\n31986264\n32110875\n32065057\n32032682", "doi": "10.1016/j.ijid.2020.03.065", "abstract": "To investigate the diagnostic value of serological testing and dynamic variance of serum antibody in coronavirus disease 2019 (COVID-19).\nThis study retrospectively included 43 patients with a laboratory-confirmed infection and 33 patients with a suspected infection, in whom the disease was eventually excluded. The IgM/IgG titer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was measured by chemiluminescence immunoassay analysis.\nCompared to molecular detection, the sensitivities of serum IgM and IgG antibodies to diagnose COVID-19 were 48.1% and 88.9%, and the specificities were 100% and 90.9%, respectively.In the COVID-19 group, the IgM-positive rate increased slightly at first and then decreased over time; in contrast, the IgG-positive rate increased to 100% and was higher than IgM at all times. The IgM-positive rate and titer were not significantly different before and after conversion to virus-negative. The IgG-positive rate was up to 90% and not significantly different before and after conversion to virus-negative. However, the median IgG titer after conversion to virus-negative was double that before, and the difference was significant.\nViral serological testing is an effective means of diagnosis for SARS-CoV-2 infection. The positive rate and titer variance of IgG are higher than those of IgM in COVID-19.", "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 249, "name": "Jin Y"}], "publication_date": "2020-04-07"}, {"id": 397, "slug": "efficacy-and-safety-of-lopinavirritonavir-or-arbidol-in-adult-patients-with-mild", "title": "Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer de mani\u00e8re exploratoire l'efficacit\u00e9 et la s\u00e9curit\u00e9 de deux traitements antiviraux, l'association LOPINAVIR/RITONAVIR et l'UMIFENOVIR, dans le traitement de la COVID-19 l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e", "verbose_date": "21.04.2020", "authors": "Li Y", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://marlin-prod.literatumonline.com/pb-assets/products/coronavirus/MEDJ1.pdf", "findings": "", "take_away": "", "relevance_level": "D'apr\u00e8s cette \u00e9tude de faible niveau de preuve, il n'y a pas d'argument en faveur d'une efficacit\u00e9 d'un traitement par LOPINAVIR/RITONAVIR ou par UMIFENOVIR sur l'\u00e9limination du SARS-CoV-2, l'am\u00e9lioration de certains sympt\u00f4mes comme la fi\u00e8vre ou la toux, l'\u00e9volution de la maladie vers un \u00e9tat s\u00e9v\u00e8re ou encore la disparition des anomalies sur le scanner thoracique. Par ailleurs ces traitements pr\u00e9sentent des effets secondaires, notamment la diarrh\u00e9e,avec des cons\u00e9quences potentielles non n\u00e9gligeables.", "objectives": "- \u00e9tude monocentrique- faible effectif- pas de placebo administr\u00e9 dans le groupe contr\u00f4le- pas d'aveugle strict", "methods": "\u00c9valuer de mani\u00e8re exploratoire l'efficacit\u00e9 et la s\u00e9curit\u00e9 de deux traitements antiviraux, l'association LOPINAVIR/RITONAVIR et l'UMIFENOVIR, dans le traitement de la COVID-19 l\u00e9g\u00e8re \u00e0 mod\u00e9r\u00e9e", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie", "Pneumologie"], "author_list": [{"id": 79, "name": "Li Y"}], "publication_date": "2020-04-21"}, {"id": 411, "slug": "cerebrovascular-disease-is-associated-with-an-increased-disease-severity-in-pati", "title": "Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "\u00c9valuer l'association entre les maladies c\u00e9r\u00e9bro-vasculaires et l\u2019augmentation de la s\u00e9v\u00e9rit\u00e9 du Covid-19.", "verbose_date": "22.04.2020", "authors": "Aggarwal G", "specialties": [{"id": 18, "name": "Neurologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 172, "name": "Int J Stroke"}, "link": "https://journals.sagepub.com/doi/pdf/10.1177/1747493020921664", "findings": "", "take_away": "", "relevance_level": "Les maladies c\u00e9r\u00e9bro-vasculaires ont \u00e9t\u00e9 associ\u00e9es \u00e0 une augmentation de 2,5 fois la gravit\u00e9 de la maladie chez les patients atteints de COVID-19. Cependant, des \u00e9tudes plus importantes sont n\u00e9cessaires pour confirmer ces r\u00e9sultats.", "objectives": "Bonne m\u00e9thodologie de revues mais faible nombre des \u00e9tudes avec \u00e9chantillons de petite taille.", "methods": "\u00c9valuer l'association entre les maladies c\u00e9r\u00e9bro-vasculaires et l\u2019augmentation de la s\u00e9v\u00e9rit\u00e9 du Covid-19.", "pubmed_id": "32310015", "doi": "10.1177/1747493020921664", "abstract": "There is an urgent need to identify patients at high risk during the ongoing coronavirus disease (COVID-19) pandemic. Whether a history of stroke is associated with increased severity of disease or mortality is unknown.\nWe pooled studies from published literature to assess the association of a history of stroke with outcomes in patients with COVID-19.\nA pooled analysis of 4 studies showed a \u223c2.5-fold increase in odds of severe COVID-19. While a trend was observed, there was no statistically significant association of stroke with mortality in patients with COVID-19 infection.\nOur findings are limited by a small number of studies and sample size.\nThere is a \u223c2.5-fold increase in odds of severe COVID-19 illness with a history of cerebrovascular disease.", "topics": ["Epid\u00e9miologique", "Neurologie"], "author_list": [{"id": 392, "name": "Aggarwal G"}], "publication_date": "2020-04-22"}, {"id": 243, "slug": "the-fda-approved-drug-ivermectin-inhibits-the-replication-of-sars-cov-2-in-vitro", "title": "The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etude in vitro de l'effet de l'ivermectine sur le SARS-CoV-2", "verbose_date": "04.04.2020", "authors": "Caly L", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 114, "name": "Antiviral Res"}, "link": "https://www.dropbox.com/s/17tx7k57xam5a72/1-s2.0-S0166354220302011-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "In vitro, l'ivermectine semble \u00eatre une piste th\u00e9rapeutique int\u00e9ressante, celle-ci ayant entra\u00een\u00e9e la disparition de la charge virale en 48 h.\u00a0\r\nN\u00e9cessit\u00e9 d'\u00e9tudes compl\u00e9mentaires in vivo pour garantier la s\u00e9curit\u00e9 et l'efficacit\u00e9 du traitement.", "objectives": "- Etude exp\u00e9rimentale IN VITRO\"", "methods": "Etude in vitro de l'effet de l'ivermectine sur le SARS-CoV-2", "pubmed_id": "32251768\n31097261\n32147628\n11287589\n32020029\n18446504\n22535622\n32119961\n32094225\n21297106\n26351913\n11533198\n26988202\n11119619\n30826604\n23769930\n22417684\n31839144\n16103202\n31960060\n32127666\n26082769\n24161512\n30266338\n22750233\n31558376\n15992957\n17596301\n32135219", "doi": "10.1016/j.antiviral.2020.104787", "abstract": "Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2\u00a0h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48\u00a0h. Ivermectin therefore warrants further investigation for possible benefits in humans.", "topics": ["Th\u00e9rapeutique", "Virologie"], "author_list": [{"id": 233, "name": "Caly L"}], "publication_date": "2020-04-04"}, {"id": 402, "slug": "risk-factors-associated-with-disease-severity-and-length-of-hospital-stay-in-cov", "title": "Risk Factors Associated with Disease Severity and Length of Hospital Stay in COVID-19 Patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Identifier les facteurs de risque de s\u00e9v\u00e9rit\u00e9 et d\u2019hospitalisation prolong\u00e9e pour les cas pneumopathies \u00e0 COVID-19 hospitalis\u00e9s.", "verbose_date": "21.04.2020", "authors": "Liu X", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.journalofinfection.com/article/S0163-4453(20)30216-4/pdf", "findings": "", "take_away": "", "relevance_level": "- dur\u00e9e m\u00e9diane d\u2019hospitalisation de 22 jours (min. 9, max. 46) pour les pneumopathies non-s\u00e9v\u00e8res contre 25 jours pour les pneumopathies s\u00e9v\u00e8res (min. 14, max. 44).\r\n- une lymphop\u00e9nie et une \u00e9l\u00e9vation de la CRP semblent \u00eatre associ\u00e9es de mani\u00e8re ind\u00e9pendante \u00e0 la s\u00e9v\u00e9rit\u00e9 de la pneumopathie par COVID-19.\r\n- tend \u00e0 confirmer une association ind\u00e9pendante entre HTA et s\u00e9v\u00e9rit\u00e9 de la pneumopathie \u00e0 COVID-19.\r\n- la lymphop\u00e9nie (lymphocytes < 1.1G/L) et l\u2019administration de glucocortico\u00efdes [voie(s) d\u2019administration, posologie(s) non pr\u00e9cis\u00e9e(s)] semblent ind\u00e9pendamment corr\u00e9l\u00e9es \u00e0 une hospitalisation prolong\u00e9e.", "objectives": "- Lettre \u00e0 l\u2019\u00e9diteur, pre-proof- \u00c9tude observationnelle r\u00e9trospective descriptive- Faible effectif (n=99), seulement 38 pneumopathies s\u00e9v\u00e8res (dont seules 34 ont fait l\u2019objet d\u2019une analyse multivari\u00e9e)- Probables biais de s\u00e9lection (seuls les patients avec donn\u00e9es m\u00e9dicales \u00ab\u00a0cl\u00e9s\u00a0\u00bb renseign\u00e9es dans le dossier ont \u00e9t\u00e9 inclus),  de classement (pas de d\u00e9finition des crit\u00e8res classant en pneumonie s\u00e9v\u00e8re ou non-s\u00e9v\u00e8re) et d\u2019information (certains examens biologiques n\u2019\u00e9taient pas renseign\u00e9s pour l\u2019ensemble des patients inclus)", "methods": "Identifier les facteurs de risque de s\u00e9v\u00e9rit\u00e9 et d\u2019hospitalisation prolong\u00e9e pour les cas pneumopathies \u00e0 COVID-19 hospitalis\u00e9s.", "pubmed_id": "32305490", "doi": "10.1016/j.jinf.2020.04.008", "abstract": null, "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 15, "name": "Liu X"}], "publication_date": "2020-04-21"}, {"id": 278, "slug": "risk-of-nosocomial-transmission-of-coronavirus-disease-2019-an-experience-in-a-g", "title": "Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'investigation d'un cas de COVID-19 hospitalis\u00e9 dans un espace ouvert avant le diagnostic.", "verbose_date": "08.04.2020", "authors": "Wong SC", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 6, "name": "J Hosp Infect"}, "link": "https://www.journalofhospitalinfection.com/article/S0195-6701(20)30174-2/pdf", "findings": "", "take_away": "", "relevance_level": "Les auteurs sugg\u00e8rent que l'infection n'est pas a\u00e9roport\u00e9e avec l'investigation de ce cas. Les mesures d'hygi\u00e8ne basiques avec hygi\u00e8ne des mains, masque chirurgical et hygi\u00e8ne de l'environnement ont \u00e9t\u00e9 appliqu\u00e9es avant le diagnostic de COVID-19 pour le cas index et absence de contacts infect\u00e9s.", "objectives": "1) Pre-proof2) Revue d'exp\u00e9rience d'un cas index et de l'investigation des contacts3) Tests uniquement des personnes symptomatiques\"", "methods": "D\u00e9crire l'investigation d'un cas de COVID-19 hospitalis\u00e9 dans un espace ouvert avant le diagnostic.", "topics": ["Epid\u00e9miologique", "Hygi\u00e8ne"], "author_list": [{"id": 267, "name": "Wong SC"}], "publication_date": "2020-04-08"}, {"id": 655, "slug": "neurologic-manifestations-in-hospitalized-patients-with-covid-19-the-albacovid-r", "title": "Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer les manifestations neurologiques communes chez les patients hospitalis\u00e9s atteints du Covid-19 et description de leurs principales caract\u00e9ristiques.", "verbose_date": "04.06.2020", "authors": "Romero-Sanchez CM", "specialties": [{"id": 18, "name": "Neurologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 171, "name": "Neurology"}, "link": "https://n.neurology.org/content/neurology/early/2020/06/01/WNL.0000000000009937.full.pdf", "findings": "", "take_away": "", "relevance_level": "Plus de la moiti\u00e9 des patients atteints de COVID-19 (57,4%) ont d\u00e9velopp\u00e9 au moins un sympt\u00f4me neurologique, une proportion significativement plus \u00e9lev\u00e9e que les 36,4% rapport\u00e9s dans les \u00e9tudes pr\u00e9c\u00e9dentes.\nUne grande vari\u00e9t\u00e9 de sympt\u00f4mes neurologiques peut appara\u00eetre lors d'une infection par le COVID-19 et peut \u00eatre li\u00e9e\u00a0soit \u00e0 des dommages directs aux tissus neurologiques, soit indirectement \u00e0 la lib\u00e9ration de cytokines, \u00e0 une insuffisance respiratoire, \u00e0 une maladie grave et aux effets secondaires du traitement pharmacologique.", "objectives": "- Etude r\u00e9trospective observationnelle- Biais de s\u00e9lection avec certaines informations manquantes. - \u00c9valuation neurologique non compl\u00e8te dans la plupart des cas et si les probl\u00e8mes neurologiques \u00e9taient caus\u00e9s par l'infection par le SRAS-CoV-2 ou par d'autres facteurs tels que l'immunit\u00e9 crois\u00e9e, la r\u00e9action inflammatoire ou les effets secondaires des traitements.", "methods": "D\u00e9terminer les manifestations neurologiques communes chez les patients hospitalis\u00e9s atteints du Covid-19 et description de leurs principales caract\u00e9ristiques.", "pubmed_id": "32482845", "doi": "10.1212/WNL.0000000000009937", "abstract": "The coronavirus disease 2019 (COVID-19) has spread worldwide since December 2019. Neurological symptoms have been reported as part of the clinical spectrum of the disease. We aim to determine whether neurological manifestations are common in hospitalized COVID-19 patients and to describe their main characteristics.\nWe systematically review all patients diagnosed with COVID-19 admitted to hospital in a Spanish population during March 2020. Demographic characteristics, systemic and neurological clinical manifestations, and complementary tests were analyzed.\nOf 841 patients hospitalized with COVID-19 (mean age 66.4 years, 56.2% men) 57.4% developed some form of neurological symptom. Nonspecific symptoms such as myalgias (17.2%), headache (14.1%), and dizziness (6.1%) were present mostly in the early stages of infection. Anosmia (4.9%) and dysgeusia (6.2%) tended to occur early (60% as the first clinical manifestation) and were more frequent in less severe cases. Disorders of consciousness occurred commonly (19.6%), mostly in older patients and in severe and advanced COVID-19 stages. Myopathy (3.1%), dysautonomia (2.5%), cerebrovascular diseases (1.7%), seizures (0.7%), movement disorders (0.7%), encephalitis (n=1), Guillain-Barr\u00e9 syndrome (n=1), and optic neuritis (n=1) were also reported, but less frequent. Neurological complications were the main cause of death in 4.1% of all deceased study subjects.\nNeurological manifestations are common in hospitalized COVID-19 patients. In our series, more than half of patients presented some form of neurological symptom. Clinicians need to maintain close neurological surveillance for prompt recognition of these complications. The investigation of the mechanisms and emerging consequences of SARS-CoV-2 neurological involvement require further studies.", "topics": ["Epid\u00e9miologique", "Neurologie"], "author_list": [{"id": 616, "name": "Romero-Sanchez CM"}], "publication_date": "2020-06-04"}, {"id": 17, "slug": "clinical-characteristics-of-novel-coronavirus-disease-2019-covid-19-in-newborns-", "title": "Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Descrire les formes p\u00e9diatriques", "verbose_date": "24.03.2020", "authors": "Hong H", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 13, "name": "Pediatr Neonatol"}, "link": "https://www.dropbox.com/s/oao6kzm1cl7sk6s/PIIS1875957220300267.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les formes p\u00e9diatriques existent, formes diverses : asymptomatique, fievre, toux seche, fatigue, quelques symptomes respiratoires hauts (congestion nasale, ecoulement nasal), signes gastrointestinaux (inconfort abdominal, naus\u00e9, vomissements, douleur abdo, diarh\u00e9e). La plupart ont des formes legeres et sont de bon prognostic. Ils guerissent en 1\u00e02 semaine. L'infection respi est rare. Les cas severe evoluent vers un SDRA, choc septique, acidose m\u00e9tabolique refractaires, troubels de coag, mais c'est rare.1 cas s\u00e9v\u00e8re decrit chez un garcon de 1 an.Diag infection neonatale SARS-CoV-2 necessite tous ces criteres : au moins 1 symptom + rx pulm patho + membre de la famille infect\u00e9 + contact etroit avec une personne infect\u00e9e ou ayant une pneumopathie ou ayant des animaux sauvages ou du march\u00e9. Si un nouveau n\u00e9 est infect\u00e9 il faut le mettre en USI, si syndromes de detresse respi : surfactant, inhalation d'oxyde nitrique, et une ventilation oscillatoire \u00e0 haute fr\u00e9quence doivent etre consid\u00e9r\u00e9. Dans les formes critiques : glucocorticoide IV ou immunoglobulines, remplacement rein, ECMO doivent etre consid\u00e9r\u00e9", "objectives": "Faible : - lettre a l'editeur- se base sur faibles echantillons", "methods": "Descrire les formes p\u00e9diatriques", "pubmed_id": "32199864\n31986261\n31995857\n32043976\n32151335\n32087114\n31953166\n32045966\n31978293\n32058570\n32154135", "doi": "10.1016/j.pedneo.2020.03.001", "abstract": null, "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 27, "name": "Hong H"}], "publication_date": "2020-03-24"}, {"id": 114, "slug": "detection-of-sars-cov-2-in-different-typesof-clinical-specimens", "title": "Detection of SARS-CoV-2 in Different Typesof Clinical Specimens", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer la transmission et les sites de pr\u00e9l\u00e8vement possible du virus", "verbose_date": "11.03.2020", "authors": "Wang", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://www.dropbox.com/s/57lqy1qm9irw37r/10.1001%40jama.2020.3786.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les sites de pr\u00e9l\u00e8vements les plus fiables sont :- le liquide bronchio-alv\u00e9olaire- les expectorations - puis seulement l'\u00e9couvillonage nasal (63% de d\u00e9tection)", "objectives": "Faible : 1) Lettre \u00e0 l'\u00e9diteur sans processus de blind reviewing2) Uniquement bas\u00e9 sur la bibliographie pr\u00e9c\u00e9dente et les hypoth\u00e8ses de l'auteur3) Pas de m\u00e9thodologie exp\u00e9rimentale permettant de confirmer ces propos", "methods": "Evaluer la transmission et les sites de pr\u00e9l\u00e8vement possible du virus", "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 120, "name": "Wang"}], "publication_date": "2020-03-11"}, {"id": 216, "slug": "performance-of-vivadiagtm-covid-19-igmigg-rapid-test-is-inadequate-for-diagnosis", "title": "Performance of VivaDiagTM COVID-19 IgM/IgG Rapid Test Is Inadequate for Diagnosis of COVID-19 in Acute Patients Referring to Emergency Room Department", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Valider l'utilisation du test rapide VivaDiagTM COVID-19 IgM/IgG Rapid Test lateral flow immunoassay (LFIA) pour le diagnostic rapide de COVID-19 dans le service des urgences", "verbose_date": "01.04.2020", "authors": "Cassaniti I ", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25800", "findings": "", "take_away": "", "relevance_level": "Selon cette \u00e9tude in vivo, la sensibilit\u00e9 du test rapide VivaDiagTM COVID-19 IgM/IgG est de 18,4 %.\r\nUne sensibilit\u00e9 aussi faible conduit au non-diagnostic de la plupart des patients, c'est pourquoi les auteurs\u00a0ne recommandent pas l'utilisation du test rapide VivaDiagTM COVID-19 IgM/IgG pour le triage des patients suspects de COVID-19\u00a0aux urgences.", "objectives": "1) lettre \u00e0 l'\u00e9diteur2) \u00e9tude in vivo sur 110 patients de l'h\u00f4pital Fondazione IRCCS Policlinico San Matteo (Pavia, Italie)\"", "methods": "Valider l'utilisation du test rapide VivaDiagTM COVID-19 IgM/IgG Rapid Test lateral flow immunoassay (LFIA) pour le diagnostic rapide de COVID-19 dans le service des urgences", "topics": ["Diagnostique", "Virologie"], "author_list": [{"id": 207, "name": "Cassaniti I "}], "publication_date": "2020-04-01"}, {"id": 320, "slug": "the-possible-of-immunotherapy-for-covid-19-a-systematic-review", "title": "The possible of immunotherapy for COVID-19: A systematic review", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Examiner les tentatives d'immunoth\u00e9rapie contre le COVID-19 et \u00e9num\u00e9rer les strat\u00e9gies immunoth\u00e9rapeutiques exp\u00e9rimentales actuelles pour le COVID-19", "verbose_date": "12.04.2020", "authors": "AminJafari A", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 144, "name": "Int Immunopharmacol"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1567576920309127?token=48E25965D10F9184E873C7380CBF3E3E9D82CB499B21D7DC8D9C9FE219599ECE4B169310DFDD108FD2FF7C210AA751E0", "findings": "", "take_away": "", "relevance_level": "- Parmi les approches d'immunoth\u00e9rapie pour bloquer l'attachement ou l'entr\u00e9e du virus, les anticorps monoclonaux sont pr\u00e9f\u00e9r\u00e9s en raison de leur sp\u00e9cificit\u00e9, de leur puret\u00e9, de leur faible risque de contamination par des agents pathog\u00e8nes transmissibles par le sang et de leur s\u00e9curit\u00e9 par rapport \u00e0 la s\u00e9roth\u00e9rapie et aux pr\u00e9parations d'immunoglobulines intraveineuses.\r\n- Les r\u00e9sultats prometteurs dans le SRAS-CoV et le MERS-CoV des anticorps monoclonaux sont encourageant pour le SARS-CoV-2\r\n- Du fait du r\u00f4le de l'inflammation dans la gravit\u00e9 de la maladie, une cible int\u00e9ressante pour l'immunoth\u00e9rapie pourrait \u00eatre les cytokine ; plus particuli\u00e8rement l'IL-6.", "objectives": "- Pas de traitement par immunoth\u00e9rapie test\u00e9 dans le cas du COVID-19, seulement des extrapolations depuis des r\u00e9sultats obtenus sur le SARS et le MERS- Faible nombre d'articles retenus\"", "methods": "Examiner les tentatives d'immunoth\u00e9rapie contre le COVID-19 et \u00e9num\u00e9rer les strat\u00e9gies immunoth\u00e9rapeutiques exp\u00e9rimentales actuelles pour le COVID-19", "pubmed_id": "32272396\n32065055\n32134278\n32117569\n32106567\n19622512\n32036774\n31428074\n32110875\n32022276\n32108352\n32203189\n32098302", "doi": "10.1016/j.intimp.2020.106455", "abstract": "The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.", "topics": ["Th\u00e9rapeutique", "Immunit\u00e9", "Transversale"], "author_list": [{"id": 307, "name": "AminJafari A"}], "publication_date": "2020-04-12"}, {"id": 449, "slug": "incidence-of-adverse-drug-reactions-in-covid-19-patients-in-china-an-active-moni", "title": "Incidence of Adverse Drug Reactions in COVID-19 patients in China: an active monitoring study by Hospital Pharmacovigilance System", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer l'incidence, les types et les facteurs de risques associ\u00e9s aux \u00e9v\u00e9nements ind\u00e9sirables m\u00e9dicamenteux (EIM) parmi les patients COVID-19 hospitalis\u00e9s dans un h\u00f4pital Chinois.", "verbose_date": "25.04.2020", "authors": "Sun J", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 116, "name": "Clin Pharmacol Ther"}, "link": "https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.1866", "findings": "", "take_away": "", "relevance_level": "Plus d'1/3 des patients hospitalis\u00e9s pour COVID-19 pr\u00e9sentaient des effets ind\u00e9sirables m\u00e9dicamenteux, notamment gastro-ent\u00e9rologiques et h\u00e9patiques.\r\nLa dur\u00e9e de s\u00e9jour, le nombre de m\u00e9dicaments et la pr\u00e9sence de comorbidit\u00e9s \u00e9taient associ\u00e9s \u00e0 l'incidence d'EIM.", "objectives": "- Bas\u00e9 sur syst\u00e8me de pharmacovigilance- Mais \u00e9tude r\u00e9trospective monocentrique- Ne concerne que les patients hospitalis\u00e9s- Difficult\u00e9 \u00e0 s\u00e9parer l'effet du m\u00e9dicament et l'effet du Covid-19- Pas de prise en compte des EIM apr\u00e8s la sortie\"", "methods": "\u00c9valuer l'incidence, les types et les facteurs de risques associ\u00e9s aux \u00e9v\u00e9nements ind\u00e9sirables m\u00e9dicamenteux (EIM) parmi les patients COVID-19 hospitalis\u00e9s dans un h\u00f4pital Chinois.", "pubmed_id": "32324898\n19209283\n24312892\n29678344\n31996494\n20672994\n30635818\n24362489\n29637279\n15878262\n22391553\n31859772\n32074550\n31950516\n12671061\n32004427\n30051231\n31829506", "doi": "10.1002/cpt.1866", "abstract": "To evaluate the incidence, type, and risk factors associated with adverse drug reactions (ADRs) among patients with coronavirus disease 2019 (COVID-19) by Hospital Pharmacovigilance System (CHPS). A retrospective analysis was performed on 217 patients with COVID-19 admitted to the First Hospital of Changsha in China, from January 17, 2020, to February 29, 2020. The active monitoring model in CHPS was used to detect ADR signals of the hospital information system. The risk factors for the ADRs were classified using the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) system. Univariate and multivariate logistic regressions were carried out to analyze the risk factors of ADRs. Our results showed that the prevalence of ADRs was 37.8% in the patients, which was predominated by drug-induced gastrointestinal disorders and liver system disorders (23.0% vs. 13.8%). The ADR could be explained by the use of lopinavir/ ritonavir and umifenovir by 63.8% and 18.1%, respectively. There were 96.8% of ADRs that occurred within 14\u00a0days of hospitalization. Multivariable analysis showed that length of stay (odds ratio (OR): 2.02; 95% confidence interval (CI) 1.03-3.96; P\u00a0=\u00a00.04), number of drugs used in the hospital (OR: 3.17; 95% CI 1.60-6.27; P\u00a0=\u00a00.001) and underlying basic diseases (OR: 2.07; 95% CI 1.02-4.23; P\u00a0=\u00a00.04) were independent risk factor for ADRs in the patients. Together, the incidence of ADRs was significantly high during the treatment period. Moreover, the active monitoring of the CHPS system reflected ADRs during COVID-19 treatment in the real world, which provided reference for safe medication in the clinic.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 423, "name": "Sun J"}], "publication_date": "2020-04-25"}, {"id": 293, "slug": "prediction-for-progression-risk-in-patients-with-covid-19-pneumonia-the-call-sco", "title": "Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Clarifier les facteurs de risque d'aggavation avec une analyse multivari\u00e9e et d'\u00e9tablir une pr\u00e9diction de la progression de COVID-19.", "verbose_date": "10.04.2020", "authors": "Ji D", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 24, "name": "Clin Infect Dis"}, "link": "https://www.dropbox.com/s/oieyykp3gzf4qis/ciaa414.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La pr\u00e9sence de comorbidit\u00e9s sous-jacentes, l'\u00e2ge avanc\u00e9, l'\u00e9l\u00e9vation des LDH et une lymphop\u00e9nie \u00e9taient des facteurs de risque ind\u00e9pendants de s\u00e9v\u00e9rit\u00e9 de COVID-19.\u00a0\r\nLe CALL-score (pour comorbidit\u00e9, \u00e2ge, lymphocyte, LDH est utilis\u00e9 dans cette \u00e9tude pour pr\u00e9dire la progression de la maladie avec une sensibilit\u00e9 \u00e0 95%.\r\nCURB 65 n'a pas sembl\u00e9 efficace pour \u00e9valuer la progression de la maladie.", "objectives": "1) Etude r\u00e9trospective dans 2 centres hospitaliers chinois, n=2082) Suivi minimum de 24 jours3) Cohorte jeune \u00e2ge moyen de 44 ans, repr\u00e9sentative des patients hospitalis\u00e9s pour COVID-19?4) Crit\u00e8re de jugement int\u00e9grant l'aggravation radiologique5) Exclusion des patients avec co-infection\"", "methods": "Clarifier les facteurs de risque d'aggavation avec une analyse multivari\u00e9e et d'\u00e9tablir une pr\u00e9diction de la progression de COVID-19.", "pubmed_id": "32271369", "doi": "10.1093/cid/ciaa414", "abstract": "We aimed to clarify the high-risk factors with multivariate analysis and establish a prediction of disease progression, so as to help clinicians to better choose therapeutic strategy.\nAll the consecutive patients with COVID-19 admitted to Fuyang second people's hospital or the fifth medical center of Chinese PLA general hospital between January 20 and February 22, 2020, were enrolled and their clinical data were retrospectively collected. Multivariate COX regression was used to identify the risk factors associated with progression, and then were incorporated into the nomogram to establish a novel prediction scoring model. ROC was used to assess the performance of the novel model.\nOverall, 208 patients were divided into stable group (n=168, 80.8%) and progressive group (n=40,19.2%) based on whether their conditions worsened during the hospitalization Univariate and multivariate analysis showed that comorbidity, older age, lower lymphocyte and higher lactate dehydrogenase at presentation were independent high-risk factors for COVID-19 progression. Incorporating these 4 factors, the nomogram achieved good concordance indexes of 0.86 (95%CI 0.81 - 0.91), and had well-fitted calibration curves. A novel scoring model, named as CALL, was established, and its area under ROC was 0.91 (95% CI 0.86 to 0.94). Using a cutoff value of 6 points, the positive and negative predictive values were 50.7% (38.9% - 62.4%) and 98.5% (94.7% - 99.8%), respectively.\nUsing the CALL score model, clinicians can improve the therapeutic effect and reduce the mortality of COVID-19 with more accurate and reasonable resolutions on medical resources.", "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 282, "name": "Ji D"}], "publication_date": "2020-04-10"}, {"id": 392, "slug": "sars-cov-2-rna-detection-of-hospital-isolation-wards-hygiene-monitoring-during-t", "title": "SARS-CoV-2 RNA detection of hospital isolation wards hygiene monitoring during the Coronavirus Disease 2019 outbreak in a Chinese hospital", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Surveiller la pr\u00e9sence de SARS-CoV-2 sur les surfaces, les \u00e9quipements de protection individuelle et les eaux us\u00e9es dans les services d'isolement prenant en charge des patients COVID-19", "verbose_date": "20.04.2020", "authors": "Wang J", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://reader.elsevier.com/reader/sd/pii/S120197122030237X?token=289BB90321DEBAB0681D2B5D9A3E1E8520944E8AC9AF884617EFF093651A58CF418976825912546E32CD485DE3AA2A0A", "findings": "", "take_away": "", "relevance_level": "Pas de d\u00e9tection de SARS-CoV-2 sur les surfaces des objets dans les salles d'isolement, y compris la zone propre, la zone semi-contamin\u00e9e et la zone contamin\u00e9e. Pas de d\u00e9tection non plus sur les \u00e9quipements de protection individuelle. Aucun des \u00e9chantillons respiratoires du personnel des unit\u00e9s d'isolement n'\u00e9tait positif. Pas de virus d\u00e9tectable dans les eaux us\u00e9es apr\u00e8s traitement de l'eau.", "objectives": "1) Pre-proof 2) Monocentrique, uniquement 33 \u00e9chantillons de surface et 9 sur les \u00e9quipements de protection individuelle3) Pas d'\u00e9chantillonnage sur les toilettes\"", "methods": "Surveiller la pr\u00e9sence de SARS-CoV-2 sur les surfaces, les \u00e9quipements de protection individuelle et les eaux us\u00e9es dans les services d'isolement prenant en charge des patients COVID-19", "topics": ["Autres", "Infectiologie", "Hygi\u00e8ne"], "author_list": [{"id": 239, "name": "Wang J"}], "publication_date": "2020-04-20"}, {"id": 335, "slug": "protecting-labor-and-delivery-personnel-from-covid-19-during-the-second-stage-of", "title": "Protecting Labor and Delivery Personnel from COVID-19 during the Second Stage of Labor", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer l'int\u00e9r\u00eat de l'utilisation d'\u00e9quipements de protection individuelle appropri\u00e9s pour le personnel de sant\u00e9 pendant l'accouchement.", "verbose_date": "15.04.2020", "authors": "Palatnik A", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}, {"id": 2, "name": "Hygi\u00e8ne"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 135, "name": "AM J Perinatol"}, "link": "https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0040-1709689.pdf", "findings": "", "take_away": "", "relevance_level": "La deuxi\u00e8me phase de l'accouchement (du moment de la dilatation compl\u00e8te du col de l'ut\u00e9rus \u00e0 la d\u00e9livrance du nouveau-n\u00e9) doit \u00eatre consid\u00e9r\u00e9e comme une proc\u00e9dure g\u00e9n\u00e9rateur d'a\u00e9rosols et le personnel de sant\u00e9 concern\u00e9 doit porter tous les \u00e9quipements de s\u00e9curit\u00e9 personnelle (gants, blouse, lunettes de protection) et un masque de type N95 (FFP2) selon les auteurs.\r\nLes recommandations actuelles recommandent l'utilisation de masques chirurgicaux aux travailleurs de la sant\u00e9 pendant l'accouchement.\r\nN.b. Il a \u00e9t\u00e9 d\u00e9montr\u00e9 que les masques N95 filtrent 95% des gouttelettes <0,3\u00b5m contre 75% pour les masques chirurgicaux.", "objectives": "1) Lettre \u00e0 l'\u00e9diteur2) Peu de donn\u00e9es dans la litt\u00e9rature actuellement", "methods": "D\u00e9terminer l'int\u00e9r\u00eat de l'utilisation d'\u00e9quipements de protection individuelle appropri\u00e9s pour le personnel de sant\u00e9 pendant l'accouchement.", "pubmed_id": "32276282", "doi": "10.1055/s-0040-1709689", "abstract": "\u00b7 Second stage of labor exposes providers to aerosol.. \u00b7 COVID-19 risk during second stage of labor is high.. \u00b7 N95 should be used during second stage of labor.. The novel coronavirus disease 2019 (COVID-19) is spreading fast and is affecting the clinical workers at much higher risk than the general population. Little is known about COVID-19 effect on pregnant women; however, the emerging evidence suggests they may be at high risk of asymptomatic disease. In light of projected shortage of personal protective equipment (PPE), there is an aggressive attempt at conservation. In obstetrics, the guidelines on PPE use are controversial and differ among hospitals, globally, as well as nationally. The centers for disease control and prevention (CDC) recommend using N95 respirators, which are respirators that offer a higher level of protection instead of a facemask for when performing or present for an aerosol-generating procedures (AGP). However, the second stage of labor is not considered an AGP. The second stage of labor can last up to 4\u2009hours. During that time, labor and delivery personnel is in close contact to patients, who are exerting extreme effort during and frequently blow out their breath, cough, shout, and vomit, all of which put the health care team at risk, considering that COVID-19 transmission occurs through aerosol generated by coughing and sneezing. The CDC and the American College of Obstetricians and Gynecologists (ACOG) do not provide clarification on the use of N95 during the second stage. We recommend that labor and delivery personnel have the utmost caution and be granted the protection they need to protect themselves and other patients. This includes providing labor and delivery personnel full PPE including N95 for the second stage of labor. This is critical to ensure the adequate protection for health care workers and to prevent spread to other health care workers and patients.", "topics": ["Autres", "Gyn\u00e9cologie Obst\u00e9trique", "Hygi\u00e8ne", "P\u00e9diatrie"], "author_list": [{"id": 322, "name": "Palatnik A"}], "publication_date": "2020-04-15"}, {"id": 54, "slug": "coronavirus-disease-covid-19-in-a-paucisymptomatic-patient-epidemiological-and-c", "title": "Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la transmission du SARS-CoV-2 par les patients paucisymptomatiques", "verbose_date": "19.03.2020", "authors": "Nicastri E", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 46, "name": "Eurosurveillance"}, "link": "https://www.dropbox.com/s/jxkpjot8x8meni6/eurosurv-25-11-3.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Dans les zones o\u00f9 la transmission du SARS-CoV-2 reste limit\u00e9e, il faut rester vigilant sur le r\u00f4le des sujets infect\u00e9s et paucisymptomatiques. Selon l'ECDC, l'isolement peut \u00eatre lev\u00e9 apr\u00e8s 2 RT-PCR sur \u00e9couvillon des voies respiratoires sup\u00e9rieures n\u00e9gatives \u00e0 24h d'intervalle. Les r\u00e9sultats de cette \u00e9tude, sugg\u00e8rent que multiplier les pr\u00e9l\u00e8vements biologiques sur sites divers pourrait renforcer la suret\u00e9 de suppression de l'isolement. Toutefois il faudrait mieux \u00e9tudier le potentiel infectant du virus dans ces diff\u00e9rents sites biologiques avant de conclure.", "objectives": "Faible:1) Revue d'un cas2) L'\u00e9volution naturelle de la maladie et l'excr\u00e9tion du SARS-CoV-2 dans les diff\u00e9rents compartiments biologiques ont pu \u00eatre modifi\u00e9es par le traitement antivirial mis-en place 2j apr\u00e8s le diagnostic, limitant l'extrapolation des r\u00e9sultats3) Les tests r\u00e9alis\u00e9s dans les diff\u00e9rents pr\u00e9l\u00e8vements permettent d'identifier des mol\u00e9cules du virus mais ne signifient pas que le virus y \u00e9tait pr\u00e9sent sous forme infectante.", "methods": "Etudier la transmission du SARS-CoV-2 par les patients paucisymptomatiques", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 64, "name": "Nicastri E"}], "publication_date": "2020-03-19"}, {"id": 322, "slug": "plausibility-of-therapeutic-effects-of-rho-kinase-inhibitors-against-severe-acut", "title": "Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'int\u00e9r\u00eat d'un traitement par inhibiteurs de Rho kinase dans le cadre de l'infection \u00e0 SARS-CoV-2", "verbose_date": "14.04.2020", "authors": "Abedi F", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 82, "name": "Pharmacol Res"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1043661820311166?token=DBC6F86EB24A4A5A569CCA9EDC39AA06313A774E96685DEF2E00D63BD89EF002A3498E55F2F3637DE870BEFEA99166EF", "findings": "", "take_away": "", "relevance_level": "Le traitement par inhibiteur de Rho kinase pourrait \u00eatre int\u00e9ressant \u00e0 explorer pour l'infection COVID-19 puisque ce m\u00e9dicament permet de cibler pr\u00e9f\u00e9rentiellement le poumon en r\u00e9duisant la r\u00e9ponse immunitaire et inflammatoire. Il pourrait aussi agir via le r\u00e9cepteur ACE2. Mais r\u00e9sultats obtenus sur les autres coronavirus.\r\nBesoin d'\u00e9tude sp\u00e9cifique sur l'effet de ce traitement in vivo sur le SARS-CoV-2.", "objectives": "- Revue narrative sur tr\u00e8s peu de r\u00e9f\u00e9rences bibliographiques- Bas\u00e9 sur les autres coronavirus (pas de donn\u00e9es sur le SARS-CoV-2)- Bas\u00e9 sur des exp\u00e9rimentations parfois animales\"", "methods": "Evaluer l'int\u00e9r\u00eat d'un traitement par inhibiteurs de Rho kinase dans le cadre de l'infection \u00e0 SARS-CoV-2", "pubmed_id": "32283223\n32135249\n32133153\n32081636\n32125455\n30784777\n15661082", "doi": "10.1016/j.phrs.2020.104808", "abstract": null, "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie", "Pneumologie"], "author_list": [{"id": 309, "name": "Abedi F"}], "publication_date": "2020-04-14"}, {"id": 368, "slug": "mental-health-problems-and-social-media-exposure-during-covid-19-outbreak", "title": "Mental health problems and social media exposure during COVID-19 outbreak", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer la pr\u00e9valence des probl\u00e8mes de sant\u00e9 mentale et examiner leur association avec l'exposition aux m\u00e9dias sociaux.", "verbose_date": "18.04.2020", "authors": "Gao J", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 158, "name": "PLoS One"}, "link": "https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0231924&type=printable", "findings": "", "take_away": "", "relevance_level": "Pr\u00e9valence de l'anxi\u00e9t\u00e9 22,6% , pr\u00e9valence de sympt\u00f4mes d\u00e9pressifs 48,3% sur les deux derni\u00e8res semaines dans cette \u00e9tude transversale sur la population chinoise.\r\nAssociations significatives entre exposition fr\u00e9quente aux m\u00e9dias sociaux et anxi\u00e9t\u00e9 OR=1,72 et exposition fr\u00e9quente et la combinaison anxi\u00e9t\u00e9 d\u00e9pression OR=1,92.", "objectives": "1) Etude transversale, n= 4 8722) \u00c9chelle s\u00e9lectionn\u00e9e pour la d\u00e9pression critiquable3) \u00c9chelle qualitative d'exposition aux m\u00e9dias sociaux: jamais, de temps en temps, parfois, souvent, tr\u00e8s souvent (pas de notion de dur\u00e9e ou de fr\u00e9quence m\u00eame d\u00e9clarative)\"", "methods": "Evaluer la pr\u00e9valence des probl\u00e8mes de sant\u00e9 mentale et examiner leur association avec l'exposition aux m\u00e9dias sociaux.", "pubmed_id": "32298385\n16717171\n19555791\n32043982\n21903818\n28061463\n24889601\n28084103\n32034840\n30792114\n31141094\n32035030\n25532102", "doi": "10.1371/journal.pone.0231924", "abstract": "Huge citizens expose to social media during a novel coronavirus disease (COVID-19) outbroke in Wuhan, China. We assess the prevalence of mental health problems and examine their association with social media exposure. A cross-sectional study among Chinese citizens aged\u226518 years old was conducted during Jan 31 to Feb 2, 2020. Online survey was used to do rapid assessment. Total of 4872 participants from 31 provinces and autonomous regions were involved in the current study. Besides demographics and social media exposure (SME), depression was assessed by The Chinese version of WHO-Five Well-Being Index (WHO-5) and anxiety was assessed by Chinese version of generalized anxiety disorder scale (GAD-7). multivariable logistic regressions were used to identify associations between social media exposure with mental health problems after controlling for covariates. The prevalence of depression, anxiety and combination of depression and anxiety (CDA) was 48.3% (95%CI: 46.9%-49.7%), 22.6% (95%CI: 21.4%-23.8%) and 19.4% (95%CI: 18.3%-20.6%) during COVID-19 outbroke in Wuhan, China. More than 80% (95%CI:80.9%-83.1%) of participants reported frequently exposed to social media. After controlling for covariates, frequently SME was positively associated with high odds of anxiety (OR = 1.72, 95%CI: 1.31-2.26) and CDA (OR = 1.91, 95%CI: 1.52-2.41) compared with less SME. Our findings show there are high prevalence of mental health problems, which positively associated with frequently SME during the COVID-19 outbreak. These findings implicated the government need pay more attention to mental health problems, especially depression and anxiety among general population and combating with \"infodemic\" while combating during public health emergency.", "topics": ["Epid\u00e9miologique", "Psychiatrie"], "author_list": [{"id": 355, "name": "Gao J"}], "publication_date": "2020-04-18"}, {"id": 275, "slug": "effectiveness-of-convalescent-plasma-therapy-in-severe-covid-19-patients", "title": "Effectiveness of convalescent plasma therapy in severe COVID-19 patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier l'efficacit\u00e9 des transfusions de plasma pour les patients s\u00e9v\u00e8res", "verbose_date": "08.04.2020", "authors": "Duan K", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 36, "name": "Proc Natl Acad Sci USA"}, "link": "https://www.pnas.org/content/pnas/early/2020/04/02/2004168117.full.pdf", "findings": "", "take_away": "", "relevance_level": "Cette \u00e9tude a montr\u00e9 que la th\u00e9rapie CP \u00e9tait bien tol\u00e9r\u00e9e et pourrait potentiellement am\u00e9liorer la clinique par neutralisation de la vir\u00e9mie dans les cas grave de COVID 19. La dose optimale et le moment d'administration doivent \u00eatre d\u00e9termin\u00e9 par des essais contr\u00f4l\u00e9s de grande envergure.", "objectives": "\"petit nombre de cas (10) les patients ont re\u00e7u d'autres traitements diff\u00e9rents pas d'harmonisation dans le timing de l'administration : administration \u00e0 des dur\u00e9es diff\u00e9rentes depuis l'apparition des sympt\u00f4mes la dynamique des cytokine n'a pas \u00e9t\u00e9 mesur\u00e9e\"", "methods": "Etudier l'efficacit\u00e9 des transfusions de plasma pour les patients s\u00e9v\u00e8res", "pubmed_id": "32253318\n32015507\n21248066\n15616839\n32020029\n32122468\n17148811\n16183666\n25073113\n32004427\n29732571\n27532807\n31986264\n17914053\n25030060\n31996494\n32035811\n17855683\n12777656\n32113510\n28466096\n26735992\n29923831\n32043983\n26041403\n26104444\n19663827\n26674811\n32007143", "doi": "10.1073/pnas.2004168117", "abstract": "Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 \u00d7 10", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 264, "name": "Duan K"}], "publication_date": "2020-04-08"}, {"id": 428, "slug": "multicenter-initial-guidance-on-use-of-antivirals-for-children-with-covid-19sars", "title": "Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Suggestion d'approche th\u00e9rapeutique par des experts USA Canada", "verbose_date": "23.04.2020", "authors": "Chiotos K", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 7, "name": "Recommandations", "icon": "icon-reco"}, "journal": {"id": 179, "name": "J Pediatr Infect Dis"}, "link": "https://www.dropbox.com/s/6rlmdl37ohwyara/piaa045.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Peu de besoin de traitement sp\u00e9cifique car pr\u00e9sentation habituelle l\u00e9g\u00e8re. Mais antiviraux peuvent \u00eatre int\u00e9ressant pour les plus graves, avec comorbidit\u00e9s.", "objectives": "Avis d'expert sans revue exhaustive de la litt\u00e9rature.", "methods": "Suggestion d'approche th\u00e9rapeutique par des experts USA Canada", "pubmed_id": "32318706", "doi": "10.1093/jpids/piaa045", "abstract": "Although Coronavirus Disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develops severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics.\nA panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion.\nGiven the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that weighs risks and benefits based on disease severity as indicated by respiratory support needs, with consideration on a case-by-case basis of potential pediatric risk factors for disease progression. If an antiviral is used, the panel suggests remdesivir as the preferred agent. Hydroxychloroquine could be considered for patients who are not candidates for remdesivir or when remdesivir is not available. Antivirals should preferably be used as part of a clinical trial if available.\nAntiviral therapy for COVID-19 is not necessary for the great majority of pediatric patients. For those rare children who develop severe or critical disease, this guidance offer an approach for decision-making regarding antivirals, informed by available data. As evidence continues to evolve rapidly, the need for updates to the guidance is anticipated.", "topics": ["Recommandations", "Infectiologie", "P\u00e9diatrie"], "author_list": [{"id": 407, "name": "Chiotos K"}], "publication_date": "2020-04-23"}, {"id": 58, "slug": "natural-small-molecules-as-inhibitors-of-coronavirus-lipid-dependent-attachment-", "title": "Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Investiguer une voie possible de d\u00e9veloppement d'une mol\u00e9cule antivirale : r\u00f4le du cholesterol et des radeaux lipidiques dans l'endocytose du virus dans la cellule h\u00f4te", "verbose_date": "19.03.2020", "authors": "Baglivo M", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 49, "name": "Acta Biomed"}, "link": "https://www.dropbox.com/s/xsq5udyp8bjkskd/9402-Article%20Text-45534-3-10-20200319.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le m\u00e9canisme d'endocytose des virus dans les cellules h\u00f4tes via des int\u00e9eactions avec les lipides membranaires pourrait constituer une strat\u00e9gie de d\u00e9veloppement de m\u00e9dicaments anti-viraux, mais n\u00e9cessitent des \u00e9tudes suppl\u00e9mentaires. Des mol\u00e9cules comme les phytost\u00e9rols pourraient alors \u00eatre des candidats.", "objectives": "Faible :Revue de la litt\u00e9rature bas\u00e9e essentiellement sur des \u00e9tudes in-vitro", "methods": "Investiguer une voie possible de d\u00e9veloppement d'une mol\u00e9cule antivirale : r\u00f4le du cholesterol et des radeaux lipidiques dans l'endocytose du virus dans la cellule h\u00f4te", "pubmed_id": "32191676", "doi": "10.23750/abm.v91i1.9402", "abstract": "Viral infectivity depends on interactions between components of the host cell plasma membrane and the virus envelope. Here we review strategies that could help stem the advance of the SARS-COV-2 epidemic.\nWe focus on the role of lipid structures, such as lipid rafts and cholesterol, involved in the process, mediated by endocytosis, by which viruses attach to and infect cells. Previous studies have shown that many naturally derived substances, such as cyclodextrin and sterols, could reduce the infectivity of many types of viruses, including the coronavirus family, through interference with lipid-dependent attachment to human host cells.\nCertain molecules prove able to reduce the infectivity of some coronaviruses, possibly by inhibiting viral lipid-dependent attachment to host cells. More research into these molecules and methods would be worthwhile as it could provide insights the mechanism of transmission of SARS-COV-2 and, into how they could become a basis for new antiviral strategies.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 68, "name": "Baglivo M"}], "publication_date": "2020-03-19"}, {"id": 490, "slug": "remdesivir-in-adults-with-severe-covid-19-a-randomised-double-blind-placebo-cont", "title": "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial", "has_other_authors": true, "impact_factor": {"id": 5, "name": "Fort", "posts_count": 5, "color": "green", "order": 1}, "goals_plain": "Evaluer l'efficacit\u00e9 et la s\u00e9curit\u00e9 du traitement par remdesivir chez des patients COVID-19 s\u00e9v\u00e8res", "verbose_date": "30.04.2020", "authors": "Wang Y", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}, {"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://www.dropbox.com/s/tv2qpn7rjo0rabl/remdesivir.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le traitement par remdesivir des patients COVID-19 s\u00e9v\u00e8res n'est pas associ\u00e9 de mani\u00e8re significative \u00e0\u00a0une r\u00e9duction du d\u00e9lai d'am\u00e9lioration clinique (HR=1,23), ni de la mortalit\u00e9 \u00e0 28 jours. 66% des patients sous remdesivir ont par ailleurs pr\u00e9sent\u00e9 des effets ind\u00e9sirables et 12% ont du arr\u00eater le traitement pr\u00e9cocemment.\nBien qu'une l\u00e9g\u00e8re am\u00e9lioration de l'\u00e9tat clinique semble \u00eatre pr\u00e9sente sous remdesivir, cette \u00e9tude de fort niveau de preuve ne permet pas de conclure \u00e0 l'int\u00e9r\u00eat de ce traitement pour les patients s\u00e9v\u00e8res.", "objectives": "- Essai contr\u00f4l\u00e9 randomis\u00e9 contre placebo en double-aveugle avec peu de biais majeurs- Possible d\u00e9faut de puissance (calcul d'effectif r\u00e9alis\u00e9 en unilat\u00e9ral avec hypoth\u00e8ses revues en cours d'essai)- Exclusion de certaines comorbidit\u00e9s repr\u00e9sentant une part importante des patients s\u00e9v\u00e8res (insuffisants r\u00e9naux notamment)- Certains patients avec co-traitements antiviral pouvant fausser- Repr\u00e9sentativit\u00e9 de l'\u00e9chantillon n'est pas tout \u00e0 fait assur\u00e9e par rapport \u00e0 la population fran\u00e7aise (moins de comorbidit\u00e9s notamment)", "methods": "Evaluer l'efficacit\u00e9 et la s\u00e9curit\u00e9 du traitement par remdesivir chez des patients COVID-19 s\u00e9v\u00e8res", "pubmed_id": "32423584", "doi": "10.1016/S0140-6736(20)31022-9", "abstract": "No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models.\nWe did a randomised, double-blind, placebo-controlled, multicentre trial at ten hospitals in Hubei, China. Eligible patients were adults (aged \u226518 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection, with an interval from symptom onset to enrolment of 12 days or less, oxygen saturation of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and radiologically confirmed pneumonia. Patients were randomly assigned in a 2:1 ratio to intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions) or the same volume of placebo infusions for 10 days. Patients were permitted concomitant use of lopinavir-ritonavir, interferons, and corticosteroids. The primary endpoint was time to clinical improvement up to day 28, defined as the time (in days) from randomisation to the point of a decline of two levels on a six-point ordinal scale of clinical status (from 1=discharged to 6=death) or discharged alive from hospital, whichever came first. Primary analysis was done in the intention-to-treat (ITT) population and safety analysis was done in all patients who started their assigned treatment. This trial is registered with ClinicalTrials.gov, NCT04257656.\nBetween Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population. Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1\u00b723 [95% CI 0\u00b787-1\u00b775]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1\u00b752 [0\u00b795-2\u00b743]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early.\nIn this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.\nChinese Academy of Medical Sciences Emergency Project of COVID-19, National Key Research and Development Program of China, the Beijing Science and Technology Project.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie", "Transversale", "Infectiologie"], "author_list": [{"id": 458, "name": "Wang Y"}], "publication_date": "2020-04-30"}, {"id": 23, "slug": "prolonged-presence-of-sars-cov-2-viral-rna-in-faecal-samples", "title": "Prolonged presence of SARS-CoV-2 viral RNA in faecal samples", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la persistance d'ARN viral dans les selles chez les patients COVID-19", "verbose_date": "24.03.2020", "authors": "Wu Y", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 19, "name": "Lancet Gastroenrol Hepatol"}, "link": "https://www.dropbox.com/s/ax3ljz0ikw5fenm/PIIS2468125320300832.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Possibilit\u00e9 d'une excr\u00e9tion virale prolong\u00e9e dans les selles jusqu'\u00e0 5 semaines (moyenne 11.2 jours) apr\u00e8s que les \u00e9chantillons respiratoires soient n\u00e9gatifs (potentielle transmission f\u00e9cale-orale)Surveillance d'\u00e9chantillons f\u00e9caux conseill\u00e9e apr\u00e8s la n\u00e9gativit\u00e9 des tests pharyng\u00e9s", "objectives": "Faible :1) Lettre \u00e0 l'\u00e9diteur2) monocentrique, 41 patients \u00e9tudi\u00e9s", "methods": "Etudier la persistance d'ARN viral dans les selles chez les patients COVID-19", "pubmed_id": "32199469", "doi": "10.1016/S2468-1253(20)30083-2", "abstract": null, "topics": ["Diagnostique", "Virologie"], "author_list": [{"id": 33, "name": "Wu Y"}], "publication_date": "2020-03-24"}, {"id": 66, "slug": "pregnancy-and-perinatal-outcomes-of-women-with-coronavirus-disease-covid-19-pneu", "title": "Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les manifestations cliniques et scanographiques de la pneumopathie \u00e0 COVID-19 chez les femmes enceintes et leur \u00e9volution apr\u00e8s l'accouchement.", "verbose_date": "18.03.2020", "authors": "Liu D", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}, {"id": 3, "name": "Radiologie"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 53, "name": "AJR Am J Roentgenol"}, "link": "https://www.dropbox.com/s/bphahp2cju6l1sw/ajr.20.23072.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La pr\u00e9sentation clinique de la pneumopathie mod\u00e9r\u00e9e \u00e0 SARS-Covid-2 chez ces femmes enceintes sans comoribidit\u00e9 majeure semble similaire \u00e0 celle de femmes en \u00e2ge de procr\u00e9er et non enceintes avec comme premiers sympt\u00f4mes fi\u00e8vre et toux. Bonne sant\u00e9 des nouveaux-n\u00e9. De m\u00eame, les signes scanographiques semblent suivre la m\u00eame \u00e9volution que celle observ\u00e9e par Pan et al. : opacit\u00e9s en verre d\u00e9poli surtout dans les bases, puis petites plages en mosa\u00efque, consolidation et enfin absorption progressive.", "objectives": "Faible:1) Design de l'\u00e9tude: absence de groupe contr\u00f4le de femmes non enceintes2) Petit effectif (n=15)3) Seulement des femmes avec atteinte pulmonaire l\u00e9g\u00e8re4) T2 et T3 surtout (12 \u00e0 32 semaines d'am\u00e9norrh\u00e9e, moyenne 21SA)5) D\u00e9finition large de la fi\u00e8vre : \u00e0 partir de 37.6\u00b0C6) 5 femmes avec 1 scan seulement (2 pour les autres)7) 13 femmes encores hospitalis\u00e9es \u00e0 la fin de l'\u00e9tude: absence d'information sur leur \u00e9tat \u00e0 la toute fin de la maladie", "methods": "D\u00e9crire les manifestations cliniques et scanographiques de la pneumopathie \u00e0 COVID-19 chez les femmes enceintes et leur \u00e9volution apr\u00e8s l'accouchement.", "pubmed_id": "32186894", "doi": "10.2214/AJR.20.23072", "abstract": "", "topics": ["Autres", "Gyn\u00e9cologie Obst\u00e9trique", "Radiologie", "P\u00e9diatrie"], "author_list": [{"id": 76, "name": "Liu D"}], "publication_date": "2020-03-18"}, {"id": 639, "slug": "neurologic-manifestations-of-hospitalized-patients-with-coronavirus-disease-2019", "title": "Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier les manifestations neurologiques des patients atteints du Covid-19.\r\n\r\n ", "verbose_date": "28.05.2020", "authors": "Mao L", "specialties": [{"id": 18, "name": "Neurologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 247, "name": "JAMA Neurol"}, "link": "https://jamanetwork.com/journals/jamaneurology/fullarticle/2764549", "findings": "", "take_away": "", "relevance_level": "Le SARS-Cov-2 peut infecter le syst\u00e8me nerveux central et les muscles squelettiques aussi bien que le syst\u00e8me respiratoire.\nChez les personnes atteintes d'une infection s\u00e9v\u00e8re, l'atteinte neurologique est plus fr\u00e9quente,\u00a0comprenant les maladies c\u00e9r\u00e9brovasculaires aigu\u00ebs, les troubles de la conscience et les l\u00e9sions\u00a0musculaires\u00a0squelettiques.\nIl est particuli\u00e8rement significatif d'apprendre que pour ceux qui ont une infection COVID-19 s\u00e9v\u00e8re, une d\u00e9t\u00e9rioration ou une aggravation clinique rapide pourrait \u00eatre associ\u00e9e \u00e0 un \u00e9v\u00e9nement neurologique tel qu'un accident vasculaire c\u00e9r\u00e9bral, ce qui contribuerait \u00e0 augmenter\u00a0le taux de mortalit\u00e9.", "objectives": "- Etude r\u00e9trospective observationnelle bas\u00e9e sur des dossiers m\u00e9dicaux/infirmiers, r\u00e9sultats de laboratoire et d'imagerie.- 214 patients, risque de biais dans l'observation clinique- Les donn\u00e9es ont \u00e9t\u00e9 extraites via des rapports m\u00e9dicaux \u00e9lectroniques, les patients avec des sympt\u00f4mes neurologiques l\u00e9gers pourraient \u00eatre omis.- Les r\u00e9sultats cliniques de la plupart des patients hospitalis\u00e9s n'\u00e9taient pas disponibles au moment de l'analyse, il \u00e9tait difficile d'\u00e9valuer l'effet des manifestations neurologiques sur leur issue.- Un certain nombre d'examens n\u00e9cessaires pour \u00e9tayer les diagnostics neurologiques n'ont pas \u00e9t\u00e9 r\u00e9alis\u00e9s (ponction lombaire, \u00e9lectromyographie/vitesse de conduction, IRM) compte tenu du contexte de la pand\u00e9mie. En effet, la plupart des sympt\u00f4mes \u00e9taient des descriptions subjectives des patients.Dans ce cas, il est difficile de distinguer si les manifestations neurologiques sont caus\u00e9es directement par le virus ou indirectement par la maladie pulmonaire ou d'autres l\u00e9sions d'organes.", "methods": "Etudier les manifestations neurologiques des patients atteints du\u00a0Covid-19.", "pubmed_id": "32275288\n32015507\n32109013\n31978945\n15141376\n31573350\n15141377\n28177862\n27012512\n25764065\n31986264", "doi": "10.1001/jamaneurol.2020.1127", "abstract": "The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, is serious and has the potential to become an epidemic worldwide. Several studies have described typical clinical manifestations including fever, cough, diarrhea, and fatigue. However, to our knowledge, it has not been reported that patients with COVID-19 had any neurologic manifestations.\nTo study the neurologic manifestations of patients with COVID-19.\nThis is a retrospective, observational case series. Data were collected from January 16, 2020, to February 19, 2020, at 3 designated special care centers for COVID-19 (Main District, West Branch, and Tumor Center) of the Union Hospital of Huazhong University of Science and Technology in Wuhan, China. The study included 214 consecutive hospitalized patients with laboratory-confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 infection.\nClinical data were extracted from electronic medical records, and data of all neurologic symptoms were checked by 2 trained neurologists. Neurologic manifestations fell into 3 categories: central nervous system manifestations (dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and seizure), peripheral nervous system manifestations (taste impairment, smell impairment, vision impairment, and nerve pain), and skeletal muscular injury manifestations.\nOf 214 patients (mean [SD] age, 52.7 [15.5] years; 87 men [40.7%]) with COVID-19, 126 patients (58.9%) had nonsevere infection and 88 patients (41.1%) had severe infection according to their respiratory status. Overall, 78 patients (36.4%) had neurologic manifestations. Compared with patients with nonsevere infection, patients with severe infection were older, had more underlying disorders, especially hypertension, and showed fewer typical symptoms of COVID-19, such as fever and cough. Patients with more severe infection had neurologic manifestations, such as acute cerebrovascular diseases (5 [5.7%] vs 1 [0.8%]), impaired consciousness (13 [14.8%] vs 3 [2.4%]), and skeletal muscle injury (17 [19.3%] vs 6 [4.8%]).\nPatients with COVID-19 commonly have neurologic manifestations. During the epidemic period of COVID-19, when seeing patients with neurologic manifestations, clinicians should suspect severe acute respiratory syndrome coronavirus 2 infection as a differential diagnosis to avoid delayed diagnosis or misdiagnosis and lose the chance to treat and prevent further transmission.", "topics": ["Epid\u00e9miologique", "Neurologie"], "author_list": [{"id": 601, "name": "Mao L"}], "publication_date": "2020-05-28"}, {"id": 223, "slug": "headaches-associated-with-personal-protective-equipment-a-crosssectional-study-a", "title": "Headaches Associated with Personal Protective Equipment \u2013 A Cross\u2010sectional Study Amongst Frontline Healthcare Workers During COVID\u201019 (HAPPE Study)", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Identifier les facteurs associ\u00e9s \u00e0 l'apparition de c\u00e9phal\u00e9es dues au port de masques N95 et/ou lunettes de protection en p\u00e9riode d'\u00e9pid\u00e9mie de COVID-19 chez les soignants ainsi que leur r\u00e9tentissement sur leur \u00e9tat de sant\u00e9 et capacit\u00e9s de travail", "verbose_date": "01.04.2020", "authors": "Hong JY", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 107, "name": "Headache"}, "link": "https://headachejournal.onlinelibrary.wiley.com/doi/epdf/10.1111/head.13811", "findings": "", "take_away": "", "relevance_level": "L'utilisation des masques respiratoires type N95 et de masques de protection oculaire semble favoriser l'apparition de c\u00e9phal\u00e9es par compression externe chez les soignants, en particulier ceux ayant un ant\u00e9c\u00e9dent de migraines ou de c\u00e9phal\u00e9es de tension et lors du port combin\u00e9 des deux \u00e9quipements durant plus de 4h par jour.\r\nElles seraient le plus souvent l\u00e9g\u00e8res mais pourraient affecter leur efficacit\u00e9 et engendrer quelques arr\u00eats de travail. On peut s'attendre \u00e0 une augmentation de ce trouble si l'\u00e9pid\u00e9mie devait persister et il semble important de r\u00e9fl\u00e9chir \u00e0 des solutions pour limiter le port de ces \u00e9quipements ou am\u00e9liorer l'ergonomie/confort de l'\u00e9quipement.", "objectives": "1) Questionnaire auto-administr\u00e9 (-)2) Effectif (-)3) Analyse multivari\u00e9e pour identifier les facteurs de risque de c\u00e9phal\u00e9es (+) mais sans prise en compte de facteurs psychologiques ou du manque de sommeil (-)4) Possible soumission cibl\u00e9e des questionnaires (-)\"", "methods": "Identifier les facteurs associ\u00e9s \u00e0 l'apparition de c\u00e9phal\u00e9es dues au port de masques N95 et/ou lunettes de protection en p\u00e9riode d'\u00e9pid\u00e9mie de COVID-19 chez les soignants ainsi que leur r\u00e9tentissement sur leur \u00e9tat de sant\u00e9 et capacit\u00e9s de travail", "topics": ["Autres", "Transversale"], "author_list": [{"id": 214, "name": "Hong JY"}], "publication_date": "2020-04-01"}, {"id": 442, "slug": "extracorporeal-membrane-oxygenation-in-the-treatment-of-severe-pulmonary-and-car", "title": "Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'utilisation de l'ECMO chez les patients atteints de forme s\u00e9v\u00e8re de COVID-19", "verbose_date": "24.04.2020", "authors": "Jacobs J", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 168, "name": "ASAIO Journal"}, "link": "https://www.dropbox.com/s/6v16eys193j65lr/Extracorporeal_Membrane_Oxygenation_in_the.98533.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "68% (22/32) des patients \u00e9taient vivant \u00e0 la fin de l'\u00e9tude mais dont 17/32 encore sous ECMO, avec seulement 33,3% (5/15) de patients sevr\u00e9s de l\u2019ECMO et vivants \u00e0 la fin de l\u2019\u00e9tude. \u2028Il est impossible de mettre en \u00e9vidence des diff\u00e9rences entre les survivants et les non survivants devant un nombre de sujet tr\u00e8s faible.\u2028La place de l\u2019ECMO dans les formes s\u00e9v\u00e8res de COVID-19 sera pr\u00e9cis\u00e9e dans des \u00e9tudes \u00e0 venir.", "objectives": "N = 32 ( et n = 5 dans le groupe sevr\u00e9 de l\u2019ECMO), \u00e9tude observationnelle", "methods": "D\u00e9crire l'utilisation de l'ECMO chez les patients atteints de forme s\u00e9v\u00e8re de COVID-19", "pubmed_id": "32317557\n16822469\n32203709\n32328170\n32125452\n8676720\n32358232\n32219363\n30220265\n17698689\n19822628\n32178774\n31509822\n32243267\n30642778\n28555385\n32200663\n19029268\n19762075\n32192578\n32007143\n32105632\n32304395", "doi": "10.1097/MAT.0000000000001185", "abstract": "As COVID-19 cases surge worldwide, an urgent need exists to enhance our understanding of the role of extracorporeal membrane oxygenation (ECMO) in the management of severely ill patients with COVID-19 who develop acute respiratory and cardiac compromise refractory to conventional therapy. The purpose of this manuscript is to review our initial clinical experience in 32 patients with confirmed COVID-19 treated with ECMO.A multi-institutional registry and database was created and utilized to assess all patients who were supported with ECMO provided by SpecialtyCare. Data captured included patient characteristics, pre-COVID-19 risk factors and comorbidities, confirmation of COVID-19 diagnosis, features of ECMO support, specific medications utilized to treat COVID-19, and short-term outcomes through hospital discharge. This analysis includes all of our patients with COVID-19 supported with ECMO, with an analytic window starting March 17, 2020 when our first COVID-19 patient was placed on ECMO, and ending April 9, 2020.During the 24 days of this study, 32 consecutive patients with COVID-19 were placed on ECMO at 9 different hospitals. As of the time of analysis, 17 remain on ECMO, 10 died prior to or shortly after decannulation, and 5 are alive and extubated after removal from ECMO, with one of these 5 discharged from the hospital. Adjunctive medication in the surviving patients while on ECMO was as follows: 4 of 5 survivors received intravenous steroids, 3 of 5 survivors received antiviral medications (Remdesivir), 2 of 5 survivors were treated with anti-interleukin-6-receptor monoclonal antibodies (Tocilizumab or Sarilumab), and 1 of 5 survivors received hydroxychloroquine.An analysis of 32 COVID-19 patients with severe pulmonary compromise supported with ECMO suggests that ECMO may play a useful role in salvaging select critically ill patients with COVID-19. Additional patient experience and associated clinical and laboratory data must be obtained to further define the optimal role of ECMO in patients with COVID-19 and ARDS. These initial data may provide useful information to help define the best strategies to care for these challenging patients, and may also provide a framework for much-needed future research about the use of ECMO to treat patients with COVID-19.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 418, "name": "Jacobs J"}], "publication_date": "2020-04-24"}, {"id": 491, "slug": "objective-evaluation-of-anosmia-and-ageusia-in-covid-19-patients-a-single-center", "title": "Objective evaluation of anosmia and ageusia in COVID-19 patients: a single-center experience on 72 cases", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Objectiver l'atteinte olfactive et l'atteinte gustative par l'usage de tests psycho-physiologiques objectifs chez les patients atteints du COVID-19 de l'h\u00f4pital universitaire de Sassari. ", "verbose_date": "02.05.2020", "authors": "Vaira L", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 199, "name": "Head & Neck"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/hed.26204", "findings": "", "take_away": "", "relevance_level": "Sur 72 patients atteints du COVID-19 confirm\u00e9s par \u00e9couvillonage naso-pharyng\u00e9s :\n- 53 patients (73,6%) rapportent des troubles de l'olfaction et/ou du go\u00fbt au cours de l'infection,\n- 44 patients (61,1%) rapportent avoir ou avoir eu une alt\u00e9ration de l'olfaction au cours de l'infection dont 34 rapportent un anosmie\n- 39 patients rapportent avoir ou avoir eu une alt\u00e9ration du go\u00fbt au cours de l'infection, dont 28 une agueusie\nAu moment de l'\u00e9valuation (r\u00e9alis\u00e9e en moyenne \u00e0 19,3 jours du d\u00e9but des sympt\u00f4mes) :\n- 56 hyposmies tous stades confondus, 2 anosmies. A noter que 28 patients rapportant une r\u00e9cup\u00e9ration ad integrum de leur olfaction pr\u00e9sentaient objectivement une hyposmie au moment du test.\n- 34 hypogueusies tous stades confondus et une agueusie.", "objectives": "\u00c9tude observationnelle descriptive transverse.\u00c9valuation r\u00e9alis\u00e9e apr\u00e8s un intervalle variable,  en moyenne 19,3 jours apr\u00e8s le d\u00e9but des sympt\u00f4mes.", "methods": "Objectiver l'atteinte olfactive et l'atteinte gustative par l'usage de tests psycho-physiologiques objectifs chez les patients atteints du COVID-19 de l'h\u00f4pital universitaire de\u00a0Sassari.", "topics": ["Diagnostique", "Infectiologie"], "author_list": [{"id": 459, "name": "Vaira L"}], "publication_date": "2020-05-02"}, {"id": 516, "slug": "confirmation-of-the-high-cumulative-incidence-of-thrombotic-complications-in-cri", "title": "Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Confirmation de la haute incidence des complications thrombo-emboliques art\u00e9rielles et veineuses chez les patients graves atteints de covid-19. Mise \u00e0 jour.\r\nSuite du suivi d'une cohorte de patients sur le m\u00eame sujet.", "verbose_date": "04.05.2020", "authors": "Klok FA", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 204, "name": "Thromb Res"}, "link": "https://www.dropbox.com/s/ngq3ligzppg6n91/1-s2.0-S0049384820301572-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Tr\u00e8s haute incidence des complications TE chez les patients atteints de pneumonie COVID-19 s\u00e9v\u00e8re. La prophylaxie anti-thrombotique chez tous ces patients en r\u00e9animation reste capitale. Participation \u00e0 la discussion sur la dose optimale d'HBPM \u00e0 vis\u00e9e prophylactique.", "objectives": "Etude observationnelle.Int\u00e9ressant de compl\u00e9ter les donn\u00e9es de l'\u00e9tude pr\u00e9c\u00e9dente.", "methods": "Confirmation de la haute incidence des complications thrombo-emboliques art\u00e9rielles et veineuses chez les patients graves atteints de covid-19. Mise \u00e0 jour.\r\nSuite du suivi d'une cohorte de patients sur le m\u00eame sujet.", "pubmed_id": "32381264\n32085846\n32473124\n29770793\n32320517\n32302453\n32361513\n32291094\n32367170\n32369666\n32402996\n32353746", "doi": "10.1016/j.thromres.2020.04.041", "abstract": "We recently reported a high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 admitted to the intensive care units (ICUs) of three Dutch hospitals. In answering questions raised regarding our study, we updated our database and repeated all analyses.\nWe re-evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction and/or systemic arterial embolism in all COVID-19 patients admitted to the ICUs of 2 Dutch university hospitals and 1 Dutch teaching hospital from ICU admission to death, ICU discharge or April 22nd 2020, whichever came first.\nWe studied the same 184 ICU patients as reported on previously, of whom a total of 41 died (22%) and 78 were discharged alive (43%). The median follow-up duration increased from 7 to 14\u00a0days. All patients received pharmacological thromboprophylaxis. The cumulative incidence of the composite outcome, adjusted for competing risk of death, was 49% (95% confidence interval [CI] 41-57%). The majority of thrombotic events were PE (65/75; 87%). In the competing risk model, chronic anticoagulation therapy at admission was associated with a lower risk of the composite outcome (Hazard Ratio [HR] 0.29, 95%CI 0.091-0.92). Patients diagnosed with thrombotic complications were at higher risk of all-cause death (HR 5.4; 95%CI 2.4-12). Use of therapeutic anticoagulation was not associated with all-cause death (HR 0.79, 95%CI 0.35-1.8).\nIn this updated analysis, we confirm the very high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 pneumonia.", "topics": ["Epid\u00e9miologique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 484, "name": "Klok FA"}], "publication_date": "2020-05-04"}, {"id": 288, "slug": "screening-and-severity-of-coronavirus-disease-2019-covid-19-in-children-in-madri", "title": "Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la proportion de cas confirm\u00e9s / cas test\u00e9s et la gravit\u00e9 du COVID-19 chez les enfants.", "verbose_date": "09.04.2020", "authors": "Tagarro A", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 95, "name": "JAMA Pediatrics"}, "link": "https://www.dropbox.com/s/f79dzr7azxhtjux/10.1001%40jamapediatrics.2020.1346.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "11% environ des enfants test\u00e9s \u00e9taient positifs au COVID-19.\r\nSur le 41 cas confirm\u00e9s, 61% ont \u00e9t\u00e9 hospitalis\u00e9s et 9,8% ont \u00e9t\u00e9 hospitalis\u00e9s en soins intensifs. Pas de d\u00e9c\u00e8s.", "objectives": "1) Lettre \u00e0 l'\u00e9diteur2) Changement des recommandations de test le 9 mars : les patients hospitalis\u00e9s et les patients avec des comorbidit\u00e9s \u00e0 risque 3) n=41 pour l'\u00e9tude du taux d'hospitalisation et des de la gravit\u00e9\"", "methods": "Etudier la proportion de cas confirm\u00e9s / cas test\u00e9s et la gravit\u00e9 du COVID-19 chez les enfants.", "pubmed_id": "32267485\n31992387\n32163697\n32058570\n32159775\n32179660", "doi": "10.1001/jamapediatrics.2020.1346", "abstract": null, "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 276, "name": "Tagarro A"}], "publication_date": "2020-04-09"}, {"id": 361, "slug": "clinical-features-and-outcomes-of-pregnant-women-suspected-of-coronavirus-diseas", "title": "Clinical Features and Outcomes of Pregnant Women Suspected of Coronavirus Disease 2019", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluations des caract\u00e9ristiques cliniques et des r\u00e9sultats chez les patientes COVID-19 enceintes.", "verbose_date": "17.04.2020", "authors": "Yang H", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.journalofinfection.com/article/S0163-4453(20)30212-7/pdf", "findings": "", "take_away": "", "relevance_level": "Les auteurs de l'\u00e9tude recommandent d'utiliser des scanners thoraciques et des r\u00e9sultats de laboratoire tels que la num\u00e9ration des globules blancs et le rapport neutrophiles/lymphocytes pour diagnostiquer les patientes enceintes COVID-19 paucisymptomatiques ou asymptomatiques \u00e0 l'accouchement si l'on n'a pas le temps de proc\u00e9der \u00e0 un d\u00e9pistage par pr\u00e9l\u00e8vement oral.\r\nIl est important de noter que l'\u00e9tude n'a pas trouv\u00e9 de diff\u00e9rences statistiquement significatives dans les images CT et les r\u00e9sultats de laboratoire entre le groupe d'\u00e9tude et le groupe de contr\u00f4le.", "objectives": "1) \u00e9tude observationnelle 2) petit \u00e9chantillon (55 patientes au total: groupe d'\u00e9tude= 13 patientes, groupe de contr\u00f4le= 44 patientes)3) \u00e9tude men\u00e9e dans un h\u00f4pital non d\u00e9sign\u00e9 comme h\u00f4pital COVID-19 : les patientes impliqu\u00e9es dans l'\u00e9tude \u00e9taient asymptomatiques ou paucisymptomatiques (les patientes pr\u00e9sentant des sympt\u00f4mes plus graves ont \u00e9t\u00e9 transf\u00e9r\u00e9s dans des h\u00f4pitaux d\u00e9sign\u00e9s COVID-19)4) les \u00e9chantillons orals et les tests RT-PCR ont \u00e9t\u00e9 effectu\u00e9s sur 20 nouveau-n\u00e9s seulement (57 nourrissons au total impliqu\u00e9s dans l'\u00e9tude). N.b.: l'\u00e9tude des nouveau-n\u00e9s n'est pas sp\u00e9cifi\u00e9e comme objectif primaire ou secondaire de l'\u00e9tude et dans la m\u00e9thodologie appliqu\u00e9e. Aucune conclusion \u00e0 cet \u00e9gard dans l'\u00e9tude.5) aucun test pour d\u00e9terminer la pr\u00e9sence du SRAS-CoV-2 sur des \u00e9chantillons tels que le placenta, le liquide amniotique et le sang de cordon ombilical\"", "methods": "Evaluations des caract\u00e9ristiques cliniques et des r\u00e9sultats chez les patientes COVID-19 enceintes.", "pubmed_id": "32294503", "doi": "10.1016/j.jinf.2020.04.003", "abstract": "2019 novel coronavirus disease (COVID-19) has become a worldwide pandemic. Under such circumstance pregnant women are also affected significantly.\nThis study aims to observe the clinical features and outcomes of pregnant women who have been confirmed with COVID-19.\nThe research objects were 55 cases of suspected COVID-19 pregnant women who gave a birth from Jan 20th 2020 to Mar 5th 2020 in our hospital-a big birth center delivering about 30,000 babies in the last 3 years. These cases were subjected to pulmonary CT scan and routine blood test, manifested symptoms of fever, cough, chest tightness or gastrointestinal symptoms. They were admitted to an isolated suite, with clinical features and newborn babies being carefully observed. Among the 55 cases, 13 patients were assigned into the confirmed COVID-19 group for being tested positive sever acute respiratory syndrome coronavirus 2(SARS-CoV-2) via maternal throat swab test, and the other 42 patients were assigned into the control group for being ruled out COVID-19 pneumonia based on new coronavirus pneumonia prevention and control program(the 7th edition).\nThere were 2 fever patients during the prenatal period and 8 fever patients during the postpartum period in the confirmed COVID-19 group. In contrast, there were 11 prenatal fever patients and 20 postpartum fever patients in the control group (p>0.05). Among 55 cases, only 2 case had cough in the confirmed group. The imaging of pulmonary CT scan showed ground- glass opacity (46.2%, 6/13), patch-like shadows(38.5%, 5/13), fiber shadow(23.1%, 3/13), pleural effusion (38.5%, 5/13)and pleural thickening(7.7%, 1/13), and there was no statistical difference between the confirmed COVID-19 group and the control group (p>0.05). During the prenatal and postpartum period, there was no difference in the count of WBC, Neutrophils and Lymphocyte, the radio of Neutrophils and Lymphocyte and the level of CRP between the confirmed COVID-19 group and the control group(p<0.05). 20 babies (from confirmed mother and from normal mother) were subjected to SARS-CoV-2 examination by throat swab samples in 24\u00a0h after birth and no case was tested positive.\nThe clinical symptoms and laboratory indicators are not obvious for asymptomatic and mild COVID-19 pregnant women. Pulmonary CT scan plus blood routine examination are more suitable for finding pregnancy women with asymptomatic or mild COVID-19 infection, and can be used screening COVID-19 pregnant women in the outbreak area of COVID-19 infection.", "topics": ["Epid\u00e9miologique", "Infectiologie", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 348, "name": "Yang H"}], "publication_date": "2020-04-17"}, {"id": 448, "slug": "unexpected-blood-pressure-sensitivity-to-angiotensin-ii-in-a-covid-19-patient-wi", "title": "Unexpected Blood Pressure Sensitivity to Angiotensin II in a COVID-19 Patient with ARDS and Septic Shock", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Case report sugg\u00e9rant une utilit\u00e9 du traitement par angiotensine 2 dans le choc septique lors d'une infection \u00e0 SARS-COV 2", "verbose_date": "25.04.2020", "authors": "Wang H", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 185, "name": "Chest"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0012369220307479?token=1F9692BEBAB056631C0A784E46C30AF893A439DB903CDFDF63ACB546DAC334BEEF8141F65799BCC84486424D6D518743", "findings": "", "take_away": "", "relevance_level": "88 ans, avec comorbidit\u00e9s, sous IEC, choc septique et SDRA, tr\u00e8s sensible \u00e0 l'administration d'angiotensine 2 permettant un sevrage rapide des vasopresseurs. Ils suspectent que cette sensibilit\u00e9 \u00e0 l'angiotensine 2 soit un effet biologique de l'infection \u00e0 SARS-COV 2. Proposition de poursuivre la recherche sur l'Ang-2 pour les patients COVID-19 en choc septique (mesures biologiques des patients trait\u00e9s par Ang2 \u00e0 consigner).", "objectives": "Case report, dose maximum d'ADH semble atteinte, faibles doses de noradr\u00e9naline utilis\u00e9es au moment de la mise sous Ang-2, gravit\u00e9 tr\u00e8s mod\u00e9r\u00e9e aux vues des donn\u00e9es biologiques et th\u00e9rapeutiques. Donn\u00e9es d\u00e9j\u00e0 connues dans un contexte non-COVID. Facteurs confondants (cortico\u00efdes)", "methods": "Case report sugg\u00e9rant une utilit\u00e9 du traitement par angiotensine 2 dans le choc septique lors d'une infection \u00e0 SARS-COV 2", "topics": ["Pronostique", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie"], "author_list": [{"id": 84, "name": "Wang H"}], "publication_date": "2020-04-25"}, {"id": 63, "slug": "severe-outcomes-among-patients-with-coronavirus-disease-2019-covid-19", "title": "Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19)", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la survenue d'hospitalisation, admission en soins intensifs, d\u00e9c\u00e8s", "verbose_date": "18.03.2020", "authors": "CDC COVID-19 Response Team", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 52, "name": "MMWR Morb Mortal Wkly Rep"}, "link": "https://www.dropbox.com/s/5msc7m7hqe3nsdp/mm6912e2-H.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Pas d'admission en soins intensifs ou de d\u00e9c\u00e8s pour des personnes \u00e2g\u00e9es de moins de 19 ans Taux d'hospitalisation croissant avec l'\u00e2ge, ainsi que d\u00e9c\u00e8s. Admission en soins intensifs croissant avec l'\u00e2ge (sauf > 85 ans)", "objectives": "Faible1) n= 4 226 mais nombreuses donn\u00e9es manquantes: statut hospitalisation manquant pour 35,8% / 53,3% manquant pour le statut soins intensifs / 47,3% manquant pour les d\u00e9c\u00e8s / 9,1% pour l'\u00e2ge2) 49 \u00e9tats inclus et cas rapatri\u00e9s de Chine, du Japon, des navires de croisi\u00e8re exclus", "methods": "Etudier la survenue d'hospitalisation, admission en soins intensifs, d\u00e9c\u00e8s", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 73, "name": "CDC COVID-19 Response Team"}], "publication_date": "2020-03-18"}, {"id": 119, "slug": "detection-of-novel-coronavirus-by-rt-pcr-in-stool-specimen-from-asymptomatic-chi", "title": "Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire un cas asymptomatique positif chez l'enfant", "verbose_date": "09.03.2020", "authors": "Tang", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 80, "name": "Emerge Inf Dis"}, "link": "https://wwwnc.cdc.gov/eid/article/26/6/20-0301_article", "findings": "", "take_away": "", "relevance_level": "Int\u00e9r\u00eat du d\u00e9pistage des cas asymptomatiques chez les enfantsPossibilit\u00e9 de pr\u00e9l\u00e8vements respiratoires n\u00e9gatifs donc pr\u00e9lever aussi les selles", "objectives": "Faible : 1) Lettre \u00e0 l'\u00e9diteur sans processus de blind reviewing2) Bas\u00e9 sur un seul cas !", "methods": "D\u00e9crire un cas asymptomatique positif chez l'enfant", "pubmed_id": "32150527\n31978945\n32030925\n32004427\n32047895\n32035997\n15964082\n32031570\n32022836\n32007143\n32032543", "doi": "10.3201/eid2606.200301", "abstract": "We report an asymptomatic child who was positive for a coronavirus by reverse transcription PCR in a stool specimen 17 days after the last virus exposure. The child was virus positive in stool specimens for at least an additional 9 days. Respiratory tract specimens were negative by reverse transcription PCR.", "topics": ["Diagnostique", "P\u00e9diatrie"], "author_list": [{"id": 125, "name": "Tang"}], "publication_date": "2020-03-09"}, {"id": 398, "slug": "d-dimer-levels-on-admission-to-predict-in-hospital-mortality-in-patients-with-co", "title": "D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire comment le taux de D-dim\u00e8res pourrait \u00eatre un marqueur pr\u00e9dictif de mortalit\u00e9 chez les patients atteints de Covid-19", "verbose_date": "21.04.2020", "authors": "Zhang L", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 96, "name": "J Thromb Haemostasis"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.14859", "findings": "", "take_away": "", "relevance_level": "Un taux de D-dim\u00e8res \u2265 \u00e0 2.0 \u00b5g/ml est associ\u00e9 \u00e0 une augmentation de la mortalit\u00e9 chez les patients atteints de Covid-19", "objectives": "R\u00e9trospective, monocentrique biais de s\u00e9lection, biais de confusion, exclusion de patients, n = 343Cependant bonne coh\u00e9rence externe (\u00e9tudes ant\u00e9rieure, physiopathologie inflammatoire et hypoxique)\"", "methods": "D\u00e9crire comment le taux de D-dim\u00e8res pourrait \u00eatre un marqueur pr\u00e9dictif de mortalit\u00e9 chez les patients atteints de Covid-19", "pubmed_id": "32306492", "doi": "10.1111/jth.14859", "abstract": "The outbreak of the coronavirus disease 2019 (Covid-19) has shown a global spreading trend.\u00a0Early and effective predictors of clinical outcomes are urgently needed to improve management of Covid-19 patients.\nThe aim of the present study was to evaluate whether elevated D-dimer levels could predict mortality in patients with Covid-19.\nPatients with laboratory confirmed Covid-19 were retrospective enrolled in Wuhan Asia General Hospital from January 12, 2020, to March 15, 2020. D-dimer levels on admission and death events were collected to calculate the optimum cutoff using receiver operating characteristic\u00a0curves. According to the cutoff, the subjects were divided into two groups. Then the in-hospital mortality between two groups were compared to assess the predictive value of D-dimer level.\nA total of 343 eligible patients were enrolled in the study. The optimum cutoff value of D-dimer to predict in-hospital mortality was 2.0\u00a0\u00b5g/mL with a sensitivity of 92.3% and a specificity of 83.3%. There were 67 patients with D-dimer \u22652.0\u00a0\u00b5g/mL, and 267 patients with D-dimer <2.0\u00a0\u00b5g/mL on admission. 13 deaths occurred during hospitalization. Patients with D-dimer levels \u22652.0\u00a0\u00b5g/mL had a higher incidence of mortality when comparing with those who with D-dimer levels <2.0\u00a0\u00b5g/mL (12/67 vs 1/267, P\u00a0<\u00a0.001; hazard ratio, 51.5; 95% confidence interval, 12.9-206.7).\nD-dimer on admission greater than 2.0 \u00b5g/mL (fourfold increase) could effectively predict in-hospital mortality in patients with Covid-19, which indicated D-dimer could be an early and helpful marker to improve management of Covid-19 patients. (Chinese Clinical Trial Registry: ChiCTR2000031428).", "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 381, "name": "Zhang L"}], "publication_date": "2020-04-21"}, {"id": 447, "slug": "neutralization-of-sars-cov-2-spike-pseudotyped-virus-by-recombinant-ace2-ig", "title": "Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluation de l'effet neutralisant de l'enzyme de conversion de l'angiotensine 2 recombin\u00e9e ciblant la prot\u00e9ine S du SARS-COVID-2", "verbose_date": "25.04.2020", "authors": "Lei C", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 184, "name": "Nature Comm"}, "link": "https://www.nature.com/articles/s41467-020-16048-4.pdf", "findings": "", "take_away": "", "relevance_level": "Etude pr\u00e9-clinique (in vitro et in vivo sur mod\u00e8le murin) qui r\u00e9v\u00e8le le possible potentiel th\u00e9rapeutique d'une strat\u00e9gie tourn\u00e9e vers l\u2019enzyme de conversion de l'angiotensine 2 et d'un blocage de celle-ci (qui est la porte d'entr\u00e9e du virus dans l'organisme).\u00a0\r\nPotentiel usage pour le diagnostic, pour traitements ou pour un vaccin contre le SARS-COV-2", "objectives": "Etude pr\u00e9-clinique M\u00e9thodologie bonne Hypoth\u00e8se scientifique bas\u00e9e sur des faits scientifiques prouv\u00e9s par des pr\u00e9c\u00e9dentes \u00e9tudes En attente phase 1", "methods": "Evaluation de l'effet neutralisant de l'enzyme de conversion de l'angiotensine 2 recombin\u00e9e ciblant la prot\u00e9ine S du SARS-COVID-2", "pubmed_id": "32332765\n24800825\n15749124\n27927599\n14651994\n15642942\n21189404\n25666495\n17620608\n23943614\n26813885\n27018342\n29691064\n17000927\n27311929\n23681967\n32015507\n32075877\n19948988\n23930915\n14670965\n14647384\n16585421\n16001071\n31986264\n32132184\n16007097\n16049057\n15814718\n31005675", "doi": "10.1038/s41467-020-16048-4", "abstract": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, at the end of 2019, and there are currently no specific antiviral treatments or vaccines available. SARS-CoV-2 has been shown to use the same cell entry receptor as SARS-CoV,\u00a0angiotensin-converting enzyme 2 (ACE2). In this report, we generate a recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. A fusion protein containing an ACE2 mutant with low catalytic activity is also used in this study. The fusion proteins are then characterized. Both fusion proteins have a high binding affinity for the receptor-binding domains of SARS-CoV and SARS-CoV-2 and exhibit desirable pharmacological properties in mice. Moreover, the fusion proteins neutralize virus pseudotyped with SARS-CoV or SARS-CoV-2 spike proteins in vitro. As these fusion proteins exhibit cross-reactivity against coronaviruses, they have potential applications in the diagnosis, prophylaxis, and treatment of SARS-CoV-2.", "topics": ["Th\u00e9rapeutique", "Virologie", "Infectiologie"], "author_list": [{"id": 422, "name": "Lei C"}], "publication_date": "2020-04-25"}, {"id": 237, "slug": "detection-of-air-and-surface-contamination-by-severe-acute-respiratory-syndrome-", "title": "Detection of Air and Surface Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Hospital Rooms of Infected Patients", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9tecter la contamination des surfaces et de l'air par SARS-CoV-2 et \u00e9tudier les niveaux de risque chez les patients", "verbose_date": "03.04.2020", "authors": "Chia PY", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.03.29.20046557v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Une contamination environnementale a \u00e9t\u00e9 d\u00e9tect\u00e9e dans les chambres \u00e0 pression n\u00e9gative avec des patients COVID 19 \u00e0 des stades pr\u00e9coces de la maladie, mais \u00e9tait signifcativement moindre apr\u00e8s 7 jours de maladie. Dans ces chambres, des particules de SRAS-CoV-2 de taille entre 1 - 4 \u00b5m et > 4 \u00b5m de diam\u00e8tre ont \u00e9t\u00e9 retrouv\u00e9es.", "objectives": "- Preprint - Les cultures virales n'\u00e9taient pas disponibles pour \u00e9tudier la viabilit\u00e9 du virus contaminant les surfaces et donc son potentiel infectieux - Faible nombre de patients - Les pr\u00e9l\u00e8vement d'air ne sont pas repr\u00e9sentatifs - Les pr\u00e9l\u00e8vements ont \u00e9t\u00e9 r\u00e9alis\u00e9s une seule fois dans les chambres, pas de suivi durant l'hospitalisation. - les r\u00e9sultats cliniques ayant \u00e9t\u00e9 obtenus dans les 72 heures suivant les tests environnementaux, il est plausible que pendant la journ\u00e9e des tests, la charge virale \u00e9tait en fait faible ou n\u00e9gligeable, limitant ainsi la contamination environnementale.\"", "methods": "D\u00e9tecter la contamination des surfaces et de l'air par SARS-CoV-2 et \u00e9tudier les niveaux de risque chez les patients", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 227, "name": "Chia PY"}], "publication_date": "2020-04-03"}, {"id": 133, "slug": "cancer-patients-in-sras-cov-2-infection-a-nationwide-analysis-in-china", "title": "Cancer patients in SRAS-CoV-2 infection: a nationwide analysis in China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les cas de COVID-19 chez des patients avec un ant\u00e9c\u00e9dent de cancer et analyser si cet ant\u00e9c\u00e9dent est associ\u00e9 \u00e0 une plus mauvaise \u00e9volution de la maladie.", "verbose_date": "25.03.2020", "authors": "Liang W ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 86, "name": "Lancet Oncol"}, "link": "https://www.dropbox.com/s/kkluy9kgs7bwjca/COVID_Cancer.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les patients avec ant\u00e9c\u00e9dent de cancer pourraient \u00eatre plus susceptibles de d\u00e9velopper la COVID-19 avec une moins bonne \u00e9volution de la maladie. N\u00e9anmoins cette \u00e9tude porte sur un trop faible effectif pour conclure. Les auteurs \u00e9mettent toutefois 3 recommandations pour les patients COVID-19 avec ant\u00e9c\u00e9dent de cancer :\r\n1) dans les zones end\u00e9miques, repousser si possible les chimioth\u00e9rapies adjuvantes et les chirurgies non urgentes chez les patients stables\r\n2) faire plus de provisions d'\u00e9quipements de protection personnelles\r\n3) augmenter la surveillance et le traitement de ces patients, surtout les plus vieux et ceux pr\u00e9sentant des comorbidit\u00e9s", "objectives": "1) Faible effectif de patients avec ant\u00e9c\u00e9dent de cancer2) Exclusion de 417 cas sur les 2007 initiaux en raison de donn\u00e9es manquantes concernant les ant\u00e9c\u00e9dents m\u00e9dicaux\"", "methods": "D\u00e9crire les cas de COVID-19 chez des patients avec un ant\u00e9c\u00e9dent de cancer et analyser si cet ant\u00e9c\u00e9dent est associ\u00e9 \u00e0 une plus mauvaise \u00e9volution de la maladie.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 130, "name": "Liang W "}], "publication_date": "2020-03-25"}, {"id": 261, "slug": "a-comparative-descriptive-analysis-of-clinical-characteristics-in-2019-coronavir", "title": "A comparative-descriptive analysis of clinical characteristics in 2019- Coronavirus-infected children and adults", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparer les caract\u00e9ristiques cliniques de COVID-19 chez les enfants et les adultes et explorer les causes possibles des diff\u00e9rences constat\u00e9es", "verbose_date": "07.04.2020", "authors": "Han YN", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25835", "findings": "", "take_away": "", "relevance_level": "Clinique diff\u00e9rente entre les cas p\u00e9diatriques et cas adultes (diarrh\u00e9es et/ou vomissement relativement fr\u00e9quents chez les enfants). Quelques particularit\u00e9s \u00e9galement au niveau biologique constat\u00e9es dans cette \u00e9tude : plut\u00f4t leucop\u00e9nie chez les adultes et leucocytose chez les enfants.", "objectives": "1) Pre-proof2) Etude descriptive r\u00e9trospective sur 32 cas, dont 7 p\u00e9diatriques3) Pas de calcul du nombre de sujets n\u00e9cessaires4) Comparaison difficiles entre les cas p\u00e9diatriques avec moyenne d'\u00e2ge \u00e0 1,3 ans et des cas adultes sur des sympt\u00f4mes subjectifs comme les myalgies et l'asth\u00e9nie...\"", "methods": "Comparer les caract\u00e9ristiques cliniques de COVID-19 chez les enfants et les adultes et explorer les causes possibles des diff\u00e9rences constat\u00e9es", "pubmed_id": "32249943", "doi": "10.1002/jmv.25835", "abstract": "Acute respiratory disease caused by 2019 novel coronavirus (2019-nCoV) has rapidly spread throughout China. Children and adults show a different clinical course. The purpose of the current study is to comparatively analyze the clinical characteristics of 2019-nCoV infection in children and adults and to explore the possible causes for the discrepancies present. The medical records of 25 adults and 7 children confirmed cases of 2019-2019-nCoV acute respiratory diseases were reviewed retrospectively. All children were family clusters. The total adult patients were differentiated into the local residents of Wuhan, a history of travel to Wuhan and direct contact with people from Wuhan. The numbers were 14 (56%), 10 (40%), and 1 (4%), respectively. The median incubation period of children and adults was 5 days (ranged, 3-12 days) and 4 days (ranged, 2-12 days), respectively. Diarrhoea and/or vomiting (57.1%) were demic by World Health Organiza more common in children, whereas for adults it was myalgia or fatigue (52%). On admission, the percentage of children having pneumonia (5%, 71.4%) was roughly the same as adults (20%, 80%). A total of 20% of adults had leucopoenia, but leukocytosis was more frequently in children (28.6%, P=.014). A higher number of children had elevated creatine kinase isoenzyme (57.1% vs 4%, P=.004). Antiviral therapy was given to all adult patients but to none of the children. In summary, knowledge of these differences between children and adults will not only be helpful for the clinical diagnosis of\u00a02019-nCoV disease, but also for a future discussion on age-specific coronavirus infection.", "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 250, "name": "Han YN"}], "publication_date": "2020-04-07"}, {"id": 115, "slug": "clinical-characteristics-of-severe-acute-respiratory-syndrome-coronavirus-2-reac", "title": "Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation.", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Trouver des crit\u00e8res pr\u00e9dictifs de r\u00e9activation de SARS-CoV-2 : analyse des donn\u00e9es cliniques, des r\u00e9sultats de laboratoire, des scanners pulmonaires et des th\u00e9rapies administr\u00e9es.", "verbose_date": "11.03.2020", "authors": "Ye G", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.dropbox.com/s/e386obn76crbpzn/10.1016%40j.jinf.2020.03.001.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Pas de marqueurs fiables pour pr\u00e9dire le risque de r\u00e9activation. Pas de tests valables pour d\u00e9terminer les liens entre l'utilisation de certains traitements et la r\u00e9activation du virus.", "objectives": "Faible", "methods": "Trouver des crit\u00e8res pr\u00e9dictifs de r\u00e9activation de SARS-CoV-2 : analyse des donn\u00e9es cliniques, des r\u00e9sultats de laboratoire, des scanners pulmonaires et des th\u00e9rapies administr\u00e9es.", "pubmed_id": "32171867", "doi": "10.1016/j.jinf.2020.03.001", "abstract": "Previous studies on the pneumonia outbreak caused by the 2019 novel coronavirus disease (COVID-19) were based on information from the general population. However, limited data was available for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reactivation. This study aimed to evaluate the clinical characteristics of the SARS-CoV-2 reactivation.\nClinical records, laboratory results, and chest CT scans were retrospectively reviewed for 55 patients with laboratory-confirmed COVID-19 pneumonia (i.e., with throat swab samples that were positive for SARS-CoV-2) who were admitted to Zhongnan Hospital of Wuhan University, Wuhan, China, from Jan. 8 to Feb. 10, 2020.\nAll 55 patients had a history of epidemiological exposure to COVID-19, and 5 (9%) patients who discharged from hospital presented with SARS-CoV-2 reactivation. Among the 5 reactivated patients, other symptoms were also observed, including fever, cough, sore throat, and fatigue. One of the 5 patients had progressive lymphopenia (from 1.3 to 0.56\u202f\u00d7\u202f10\nFindings from this small group of cases suggested that there was currently evidence for reactivation of SARS-CoV-2 and there might be no specific clinical characteristics to distinguish them.", "topics": ["Pronostique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 121, "name": "Ye G"}], "publication_date": "2020-03-11"}, {"id": 360, "slug": "ct-features-of-sars-cov-2-pneumonia-according-to-clinical-presentation-a-retrosp", "title": "CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Caract\u00e9riser l'imagerie en scanner thoracique et l'\u00e9volution clinique des cas asymptomatiques de COVID-19 avec pneumonie ", "verbose_date": "15.04.2020", "authors": "Zhang R", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 155, "name": "Eur Radiol"}, "link": "https://www.dropbox.com/s/gonpxwf87oiaus6/Zhang2020_Article_CTFeaturesOfSARS-CoV-2Pneumoni.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Des caract\u00e9ristiques particuli\u00e8res sont retrouv\u00e9es en imagerie thoracique chez les patients asymptomatiques avec une pneumonie : opacit\u00e9s en verre d\u00e9poli, distribution p\u00e9riph\u00e9rique, atteinte unilat\u00e9rale, impliquant principalement un ou deux lobes . Certains patients ont d\u00e9velopp\u00e9 dans les suites des sympt\u00f4mes.\u00a0\r\nL'imagerie thoracique pourrait \u00eatre utilis\u00e9e pour les patients hautement suspects mais asymptomatiques avec RT-PCR n\u00e9gative.", "objectives": "1) Pre-proof2) Etude r\u00e9trospective descriptive, n=58\"", "methods": "Caract\u00e9riser l'imagerie en scanner thoracique et l'\u00e9volution clinique des cas asymptomatiques de COVID-19 avec pneumonie", "pubmed_id": "32279115\n15026600\n21697307\n23891402\n29757717\n12759474", "doi": "10.1007/s00330-020-06854-1", "abstract": "To characterize the chest computed tomography (CT) findings of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) according to clinical severity. We compared the CT features of common cases and severe cases, symptomatic patients and asymptomatic patients, and febrile and afebrile patients.\nThis was a retrospective analysis of the clinical and thoracic CT features of 120 consecutive patients with confirmed SARS-CoV-2 pneumonia admitted to a tertiary university hospital between January 10 and February 10, 2020, in Wuhan city, China.\nOn admission, the patients generally complained of fever, cough, shortness of breath, and myalgia or fatigue, with diarrhea often present in severe cases. Severe patients were 20\u00a0years older on average and had comorbidities and an elevated lactate dehydrogenase (LDH) level. There were no differences in the CT findings between asymptomatic and symptomatic common type patients or between afebrile and febrile patients, defined according to Chinese National Health Commission guidelines.\nThe clinical and CT features at admission may enable clinicians to promptly evaluate the prognosis of patients with SARS-CoV-2 pneumonia. Clinicians should be aware that clinically silent cases may present with CT features similar to those of symptomatic common patients.\n\u2022 The clinical features and predominant patterns of abnormalities on CT for asymptomatic, typic common, and severe cases were summarized. These findings may help clinicians to identify severe patients quickly at admission. \u2022 Clinicians should be cautious that CT findings of afebrile/asymptomatic patients are not better than the findings of other types of patients. These patients should also be quarantined. \u2022 The use of chest CT as the main screening method in epidemic areas is recommended.", "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 347, "name": "Zhang R"}], "publication_date": "2020-04-15"}, {"id": 156, "slug": "how-to-perform-lung-ultrasound-in-pregnant-women-with-suspected-covid-19-infecti", "title": "How to perform lung ultrasound in pregnant women with suspected COVID-19 infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Expliquer l'approche pratique de l'\u00e9chographie pulmonaire pour explorer une potentielle infection pulmonaire chez la femme enceinte", "verbose_date": "26.03.2020", "authors": "Moro F ", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 75, "name": "Ultrasound Obstet Gynecol"}, "link": "https://www.dropbox.com/s/rrvv19dovy9bey6/uog.22028.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Pour les femmes enceintes :\r\n- Description de la s\u00e9miologie d'une infection pulmonaire \u00e0 l'\u00e9chographie\u00a0\r\n- Description des\u00a0aspects pratiques de l'\u00e9chographie pulmonaire", "objectives": "- \u00c9tude essentiellement descriptive- Proc\u00e9dure technique int\u00e9ressante", "methods": "Expliquer l'approche pratique de l'\u00e9chographie pulmonaire pour explorer une potentielle infection pulmonaire chez la femme enceinte", "topics": ["Diagnostique", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 152, "name": "Moro F "}], "publication_date": "2020-03-26"}, {"id": 208, "slug": "coronavirus-disease-19-infection-does-not-result-in-acute-kidney-injury-an-analy", "title": "Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients From Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluation du d\u00e9veloppement de l'insuffisance r\u00e9nale aigu\u00eb chez les patients sans insuffisance r\u00e9nale chronique et du d\u00e9veloppement de l'insuffisance r\u00e9nale aigu\u00eb ou de l'aggravation de l'insuffisance r\u00e9nale chronique chez les patients dialys\u00e9s", "verbose_date": "01.04.2020", "authors": "Wang L ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 102, "name": "Am J Nephrol"}, "link": "https://www.dropbox.com/s/udn064gf7nsz9ht/507471.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "1) Sur 116 patients recrut\u00e9s (111 sans maladie r\u00e9nale ant\u00e9rieure et 5 patients dialys\u00e9s en insuffisance r\u00e9nale chronique) aucun n'a d\u00e9velopp\u00e9 d'insuffisance r\u00e9nale aigu\u00eb.\n\r\n2) Les 5 patients en IRC n'ont eu aucune modification de leur traitement de dialyse (3 s\u00e9ances par semaine) et n'ont eu aucune modification des marqueurs de la fonction r\u00e9nale.\n\r\n3) \u00e9tude conclut que l'IRA et l'exacerbation de l'IRC ne sont pas des \u00e9v\u00e9nements communs au cours d'une infection par le SRAS-CoV-2.\n\r\n4) Dans tous les cas, la fonction r\u00e9nale des patients COVID-19 doit \u00eatre \u00e9troitement surveill\u00e9e, en particulier pour les patients pr\u00e9sentant un taux de cr\u00e9atinine s\u00e9rique \u00e9lev\u00e9. En cas de signes d'IRA, des mesures de protection (telles que la dialyse) doivent \u00eatre prises le plus t\u00f4t possible.", "objectives": "1) \u00e9tude observationnelle2) \u00e9chantillon petit:116 patients3) patients souffrant d'insuffisance r\u00e9nale chronique avant dialyse non pris en compte dans l'\u00e9tude", "methods": "Evaluation du d\u00e9veloppement de l'insuffisance r\u00e9nale aigu\u00eb chez les patients sans insuffisance r\u00e9nale chronique et du d\u00e9veloppement de l'insuffisance r\u00e9nale aigu\u00eb ou de l'aggravation de l'insuffisance r\u00e9nale chronique chez les patients dialys\u00e9s", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 200, "name": "Wang L "}], "publication_date": "2020-04-01"}, {"id": 568, "slug": "off-label-use-of-hydroxychloroquine-azithromycin-lopinavir-ritonavir-and-chloroq", "title": "\u201cOff-label\u201d use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Caract\u00e9riser toutes les r\u00e9actions cardiaques ind\u00e9sirables associ\u00e9es \u00e0 l'utilisation d'hydroxychloroquine (HCQ), de chloroquine (CQ), d'azithromycine (AZI) et de lopinavir-ritonavir (LOPI) chez les patients COVID-19.", "verbose_date": "11.05.2020", "authors": "G\u00e9rard A", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 226, "name": "Therapies"}, "link": "https://doi.org/10.1016/j.therap.2020.05.002", "findings": "", "take_away": "", "relevance_level": "\u00c0 la date de r\u00e9daction de l'article, le 27 avril 2020, aucun traitement \u00e9tudi\u00e9 n'a montr\u00e9 une r\u00e9elle efficacit\u00e9 contre le SRAS-CoV-2.\nParmi les traitements \u00e9tudi\u00e9s (HCQ, CQ, AZI et LOPI), l'hydroxychloroquine \u00e9tait corr\u00e9l\u00e9e \u00e0 80% des effets secondaires cardiaques signal\u00e9s, avec une fr\u00e9quence\u00a0entre 0,77% et 1,54%(sur 10000 et 5000 respectivement), sans tenir compte de la sous-d\u00e9claration due \u00e0 la\u00a0charge de travail des m\u00e9decins hospitaliers pendant la p\u00e9riode d'\u00e9tude consid\u00e9r\u00e9e.\nIl est donc clair que le profil de s\u00e9curit\u00e9 de ces traitements ne doit pas \u00eatre n\u00e9glig\u00e9 lors d'une utilisation off-label\u00a0pour les patients\u00a0COVID-19.", "objectives": "Interm\u00e9diaire:1) Etude de pharmacovigilance2) Article pre-proof", "methods": "Caract\u00e9riser toutes les r\u00e9actions cardiaques ind\u00e9sirables associ\u00e9es \u00e0 l'utilisation d'hydroxychloroquine (HCQ), de chloroquine (CQ), d'azithromycine (AZI) et de lopinavir-ritonavir (LOPI) chez les patients COVID-19.", "pubmed_id": "32418730", "doi": "10.1016/j.therap.2020.05.002", "abstract": "COVID-19 is an unprecedented challenge for physicians and scientists. Several publicized drugs are being used with not much evidence of their efficacy such as hydroxychloroquine, azithromycin or lopinavir-ritonavir. Yet, the cardiac safety of these drugs in COVID-19 deserves scrutiny as they are known to foster cardiac adverse ADRs, notably QTc interval prolongation on the electrocardiogram and its arrhythmogenic consequences.\nSince March 27th, 2020, the French Pharmacovigilance Network directed all cardiac adverse drug reactions associated with \"off-label\" use of hydroxychloroquine, azithromycin and lopinavir-ritonavir in COVID-19 to the Nice Regional Center of Pharmacovigilance. Each Regional Center of Pharmacovigilance first assessed causality of drugs. We performed a specific analysis of these cardiac adverse drug reactions amidst an array of risk factors, reassessed the electrocardiograms and estimated their incidence in coronavirus disease 2019.\nIn one month, 120 reports of cardiac adverse drug reactions have been notified, 103 of which associated with hydroxychloroquine alone (86%), or associated with azithromycin (60%). Their estimated incidence is 0.77% to 1.54% of all patients, notwithstanding strong underreporting. Lopinavir-ritonavir came third with 17 reports (14%) and chloroquine fourth with 3 reports (2.5%). There were 8 sudden, unexplained or aborted deaths (7%), 8 ventricular arrhythmias (7%), 90 reports of prolonged QTc (75%) most of them \"serious\" (64%), 48 of which proved \u2265 500ms, 20 reports of severe conduction disorders (17%) and 5 reports of other cardiac causes (4%). Six reports derived from automedication.\n\"Off-label\" use of treatments in COVID-19 increases the risk of cardiac ADRs, some of them avoidable. Even if these drugs are perceived as familiar, they are used in patients with added risk factors caused by infection. Precautions should be taken to mitigate the risk, even if they will be proven efficacious.", "topics": ["Th\u00e9rapeutique", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 533, "name": "G\u00e9rard A"}], "publication_date": "2020-05-11"}, {"id": 219, "slug": "analysis-of-heart-injury-laboratory-parameters-in-273-covid19-patients-in-one-ho", "title": "Analysis of heart injury laboratory parameters in 273 COVID\u201019 patients in one hospital in Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyser les marqueurs biologiques cardiaques de patients COVID-19 pour \u00e9valuer la corr\u00e9lation entre l'atteinte cardiaque et la gravit\u00e9 de la maladie.", "verbose_date": "01.04.2020", "authors": "Han H ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25809", "findings": "", "take_away": "", "relevance_level": "Des taux plus \u00e9lev\u00e9s de CK-MB de MYO, d'ultra-TnI et NT-proBNP \u00e9taient associ\u00e9s \u00e0 la gravit\u00e9 et \u00e0 la l\u00e9talit\u00e9.\r\nLes auteurs recommandent une surveillance attentive des profils enzymatiques myocardiques pour r\u00e9duire les complications et la mortalit\u00e9 chez les patients COVID-19.", "objectives": "1) Pre-proof2) Etude de cohorte r\u00e9trospective monocentrique au d\u00e9but de l'\u00e9pid\u00e9mie en Chine\"", "methods": "Analyser les marqueurs biologiques cardiaques de patients COVID-19 pour \u00e9valuer la corr\u00e9lation entre l'atteinte cardiaque et la gravit\u00e9 de la maladie.", "pubmed_id": "32232979", "doi": "10.1002/jmv.25809", "abstract": "An outbreak of severe acute respiratory syndrome novel coronavirus (SARS-CoV-2) epidemic spreads rapidly worldwide. SARS-CoV-2 infection caused mildly to seriously and fatally respiratory, enteric, cardiovascular, and neurological diseases. In this study, we detected and analyzed the main laboratory indicators related to heart injury, creatine kinase isoenzyme-MB (CK-MB), myohemoglobin (MYO), cardiac troponin I (ultra-TnI), and N-terminal pro-brain natriuretic peptide (NT-proBNP), in 273 patients with COVID-19 and investigated the correlation between heart injury and severity of the disease. It was found that higher concentration in venous blood of CK-MB, MYO, ultra-TnI, and NT-proBNP were associated with the severity and case fatality rate of COVID-19. Careful monitoring of the myocardiac enzyme profiles is of great importance in reducing the complications and mortality in patients with COVID-19.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 210, "name": "Han H "}], "publication_date": "2020-04-01"}, {"id": 195, "slug": "high-resolution-computed-tomography-manifestations-of-covid-19-infections-in-pat", "title": "High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Descriptions des l\u00e9sions pulmonaires visibles au scanner du COVID-19.", "verbose_date": "31.03.2020", "authors": "Chen Z ", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 26, "name": "Eur J Radiol"}, "link": "https://www.dropbox.com/s/61oc9tc6gd31odh/PIIS0720048X20301613.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Les patients plus jeunes pr\u00e9sentent moins de l\u00e9sions quelque soit le lobe.\r\n- L\u00e9sions principalement situ\u00e9es dans le lobe inf\u00e9rieur droit\r\n- Principalement des opacit\u00e9s en verre d\u00e9poli avec un aspect en crazy paving ou un \u00e9paississement du septum interlobulaire\r\n- L\u00e9sions principalement dans la zone p\u00e9riph\u00e9rique\r\n- L\u00e9sions majoritairement entre 1 et 3 cm\r\n- Chez les patients plus \u00e2g\u00e9s (>45 ans), on voit appara\u00eetre plus fr\u00e9quemment des l\u00e9sions de 5 \u00e0 10cm voir > 10cm.\r\n- L\u00e9sions pulmonaires plus diffuses et plus s\u00e9v\u00e8res chez les patients \u00e2g\u00e9s. Pr\u00e9sence plus fr\u00e9quente de bronchogramme a\u00e9rien", "objectives": "- \u00c9tude r\u00e9trospective- Multiplicit\u00e9 des tests statistiques avec inflation du risque alpha- Effectif faible", "methods": "Descriptions des l\u00e9sions pulmonaires visibles au scanner du COVID-19.", "pubmed_id": "32240913", "doi": "10.1016/j.ejrad.2020.108972", "abstract": "We aimed to compare chest HRCT lung signs identified in scans of differently aged patients with COVID-19 infections.\nCase data of patients diagnosed with COVID-19 infection in Hangzhou City, Zhejiang Province in China were collected, and chest HRCT signs of infected patients in four age groups (<18 years, 18-44 years, 45-59 years, \u226560 years) were compared.\nSmall patchy, ground-glass opacity (GGO), and consolidations were the main HRCT signs in 98 patients with confirmed COVID-19 infections. Patients aged 45-59 years and aged \u226560 years had more bilateral lung, lung lobe, and lung field involvement, and greater lesion numbers than patients <18 years. GGO accompanied with the interlobular septa thickening or a crazy-paving pattern, consolidation, and air bronchogram sign were more common in patients aged 45-59 years, and \u226560 years, than in those aged <18 years, and aged 18-44 years.\nChest HRCT manifestations in patients with COVID-19 are related to patient's age, and HRCT signs may be milder in younger patients.", "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 186, "name": "Chen Z "}], "publication_date": "2020-03-31"}, {"id": 422, "slug": "psychological-stress-of-medical-staffs-during-outbreak-of-covid-19-and-adjustmen", "title": "Psychological stress of medical staffs during outbreak of COVID-19 and adjustment strategy", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9tudier l'\u00e9tat de stress psychologique des personnels m\u00e9dicaux en Chine durant l'\u00e9pid\u00e9mie de COVID-19.", "verbose_date": "23.04.2020", "authors": "Wu W", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25914", "findings": "", "take_away": "", "relevance_level": "- les personnels m\u00e9dicaux chinois et plus particuli\u00e8rement ceux de Wuhan ont un un niveau de stress psychologique plus \u00e9lev\u00e9 que celui des \u00e9tudiants universitaires chinois, ce qui correspond \u00e0 un \u00ab effet d\u2019exposition \u00bb.\r\n- \u00e0 noter que si le personnel m\u00e9dical de Wuhan pr\u00e9sentait des moyennes significativement plus \u00e9lev\u00e9es sur 6 items du questionnaire de stress psychologique par rapport au personnel m\u00e9dical hors Wuhan, il semblait plus confiant en la victoire m\u00e9dicale sur cette \u00e9pid\u00e9mie.", "objectives": "- \u00e9tude observationnelle transversale- biais de s\u00e9lection (sur repr\u00e9sentation personnels m\u00e9dicaux et \u00e9tudiants de Wuhan malgr\u00e9 \u00e9chantillonnage al\u00e9atoire sur l'ensemble du territoire annonc\u00e9 ; exclusion des questionnaires remplis en < 3 minutes), probable biais de d\u00e9sirabilit\u00e9 sociale", "methods": "\u00c9tudier l'\u00e9tat de stress psychologique des personnels m\u00e9dicaux en Chine durant l'\u00e9pid\u00e9mie de COVID-19.", "pubmed_id": "32314806", "doi": "10.1002/jmv.25914", "abstract": "COVID-19 has a significant impact on public health and poses a challenge to medical staffs, especially to front-line medical staffs who are exposed to direct contact with patients. To understand the psychological stress status of medical staffs during the outbreak of COVID-19. Random sample questionnaire survey was conducted among 2110 medical staffs and 2158 college students in all provinces of china through a questionnaire which was compiled and completed through the Questionnaire Star platform relying on Wechat, QQ and other social software. The differences in psychological stress status of different groups were compared through the analysis of the questionnaire. Results revealed that in all provinces of china, medical staffs scored significantly higher on all items of psychological stress than college students(P<0.001). In Wuhan, medical staff scored significantly higher than college students in all items of psychological stress(P<0.001). While for medical staff, the group in Wuhan area scored significantly higher than the group outside Wuhan on \"Thought of being in danger\", \"The possibility of self-illness\", \"Worrying about family infection\"(P<0.05), \"Poor sleep quality\", \"Needing psychological guidance\" and \"Worrying about being infected\"(P<0.01) items in the psychological stress questionnaire, and in the item of \"Confidence in the victory of the epidemic\", the group in Wuhan area scored significantly lower than the group in the area outside Wuhan(P<0.05). The emotion, cognition, physical and mental response of front-line medical staff showed obvious \"exposure effect\", and psychological crisis intervention strategy can be helpful. This article is protected by copyright. All rights reserved.", "topics": ["Epid\u00e9miologique", "Psychiatrie"], "author_list": [{"id": 402, "name": "Wu W"}], "publication_date": "2020-04-23"}, {"id": 292, "slug": "trials-of-anti-tumour-necrosis-factor-therapy-for-covid-19-are-urgently-needed", "title": "Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer le potentiel d'un traitement par anticorps anti-TNF dans l'infection COVID-19", "verbose_date": "10.04.2020", "authors": "Feldmann M", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2930858-8", "findings": "", "take_away": "", "relevance_level": "Les auteurs \u00e9voquent une piste th\u00e9rapeutique potentielle pour \u00e9viter l'aggravation des patients atteints par le COVID-19 gr\u00e2ce \u00e0 l'utilisation d'anticorps anti-TNF. Ce traitement pourrait agir sur l'exc\u00e8s d'inflammation dans le cadre de l'infection et ainsi \u00e9viter le d\u00e9veloppement de forme s\u00e9v\u00e8re, avec des risques limit\u00e9s (bon profil de s\u00e9curit\u00e9 de l'infliximab et de l'adalimumab utilis\u00e9 dans certains pathologies inflammatoires chroniques).", "objectives": "- Correspondance- Revue narrative de la litt\u00e9rature- Aucune \u00e9tude concernant ce traitement dans le COVID pour le moment\"", "methods": "Evaluer le potentiel d'un traitement par anticorps anti-TNF dans l'infection COVID-19", "pubmed_id": "32278362", "doi": "10.1016/S0140-6736(20)30858-8", "abstract": null, "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 281, "name": "Feldmann M"}], "publication_date": "2020-04-10"}, {"id": 311, "slug": "covid-xpert-an-ai-powered-population-screening-of-covid-19-cases-using-chest-rad", "title": "COVID-Xpert: An AI Powered Population Screening of COVID-19 Cases Using Chest Radiography Images", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer une m\u00e9thode diagnostique via la radiographie thoracique et l'intelligence artificielle", "verbose_date": "13.04.2020", "authors": "Li x", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://arxiv.org/pdf/2004.03042.pdf", "findings": "", "take_away": "", "relevance_level": "Pr\u00e9sentation d'un mod\u00e8le d'intelligence artificielle permettant le diagnostic de cas COVID bas\u00e9 sur la radiographie thoracique avec une bonne efficacit\u00e9 diagnostique : aire sous la courbe de 97,3 pour diff\u00e9rencier une pneumopathie \u00e0 COVID d'une pneumopathie classique ou d'un patient sain.\r\nMais n\u00e9cessit\u00e9 de test sur un plus large \u00e9chantillon pour valider ce mod\u00e8le.", "objectives": "- Pre-prints- Echantillon pour apprentissage et validation assez restreint dans le contexte de deep learning- Algorithme non test\u00e9 sur un nouvel \u00e9chantillon prospectif", "methods": "Evaluer une m\u00e9thode diagnostique via la radiographie thoracique et l'intelligence artificielle", "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 298, "name": "Li x"}], "publication_date": "2020-04-13"}, {"id": 319, "slug": "comparative-replication-and-immune-activation-profiles-of-sars-cov-2-and-sars-co", "title": "Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparaison de la r\u00e9plication et de l'activation du syst\u00e8me pour le SARS-CoV et le SARS-CoV-2", "verbose_date": "11.04.2020", "authors": "Chu H", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 24, "name": "Clin Infect Dis"}, "link": "https://www.dropbox.com/s/1yvh6lc50b47hpu/ciaa410.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- La capacit\u00e9 d'infection et de r\u00e9plication pulmonaire du SARS-CoV-2 est plus importante que celle du SARS-CoV (production de 3.20 fois plus de particules virales en 48 heures). Cela pourrait expliquer les fortes concentration de virus dans les s\u00e9cr\u00e9tions respiratoire et ainsi la forte capacit\u00e9 de transmission de personne \u00e0 personne.\r\n- Le SARS-CoV-2 provoque une r\u00e9action inflammatoire moins importante, pouvant \u00eatre la raison de la forte proportion des patients \u00e0 ne pr\u00e9senter que des sympt\u00f4mes l\u00e9ger, voir asymptomatique.\r\n-La r\u00e9ponse immunitaire inn\u00e9e activ\u00e9e de mani\u00e8re sous-optimale permettrait au SRAS-CoV-2 de se r\u00e9pliquer \u00e0 des niveaux \u00e9lev\u00e9s dans les voies respiratoires d\u00e8s le d\u00e9but et pourrait contribuer \u00e0 sa transmission efficace de personne \u00e0 personne via des gouttelettes ou au contact de s\u00e9cr\u00e9tions respiratoires contamin\u00e9es contenant des charges virales \u00e9lev\u00e9es.", "objectives": "- Faible effectif : 6 donneurs- Dur\u00e9e de vie des tissus pulmonaires courte : seul d\u00e8s dur\u00e9e d'infection limit\u00e9 ont \u00e9t\u00e9 \u00e9tudi\u00e9 (48 heures).- La m\u00e9thodologie semble appropri\u00e9e\"", "methods": "Comparaison de la r\u00e9plication et de l'activation du syst\u00e8me pour le SARS-CoV et le SARS-CoV-2", "pubmed_id": "32270184", "doi": "10.1093/cid/ciaa410", "abstract": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging coronavirus that has resulted in nearly 1,000,000 laboratory-confirmed cases including over 50,000 deaths. Although SARS-CoV-2 and SARS-CoV share a number of common clinical manifestations, SARS-CoV-2 appears to be highly efficient in person-to-person transmission and frequently cause asymptomatic infections. However, the underlying mechanism that confers these viral characteristics on high transmissibility and asymptomatic infection remain incompletely understood.\nWe comprehensively investigated the replication, cell tropism, and immune activation profile of SARS-CoV-2 infection in human lung tissues with SARS-CoV included as a comparison.\nSARS-CoV-2 infected and replicated in human lung tissues more efficiently than that of SARS-CoV. Within the 48-hour interval, SARS-CoV-2 generated 3.20 folds more infectious virus particles than that of SARS-CoV from the infected lung tissues (P<0.024). SARS-CoV-2 and SARS-CoV were similar in cell tropism, with both targeting types I and II pneumocytes, and alveolar macrophages. Importantly, despite the more efficient virus replication, SARS-CoV-2 did not significantly induce types I, II, or III interferons in the infected human lung tissues. In addition, while SARS-CoV infection upregulated the expression of 11 out of 13 (84.62%) representative pro-inflammatory cytokines/chemokines, SARS-CoV-2 infection only upregulated 5 of these 13 (38.46%) key inflammatory mediators despite replicating more efficiently.\nOur study provided the first quantitative data on the comparative replication capacity and immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung tissues. Our results provided important insights on the pathogenesis, high transmissibility, and asymptomatic infection of SARS-CoV-2.", "topics": ["Autres", "Immunit\u00e9", "Virologie", "Infectiologie", "Pneumologie"], "author_list": [{"id": 306, "name": "Chu H"}], "publication_date": "2020-04-11"}, {"id": 444, "slug": "effect-of-high-vs-low-doses-of-chloroquine-diphosphate-as-adjunctive-therapy-for", "title": "Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. A Randomized Clinical Trial", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer l'efficacit\u00e9 et la s\u00e9curit\u00e9 de la chloroquine \u00e0 faible ou forte dose dans le traitement du syndrome de d\u00e9tresse respiratoire aigu\u00eb chez des patients COVID-19", "verbose_date": "25.04.2020", "authors": "Borba MGS", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 183, "name": "JAMA Network Open"}, "link": "https://www.dropbox.com/s/wjsptdsm0sd3qgz/borba_2020_oi_200372.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le traitement par chloroquine ne doit pas \u00eatre administr\u00e9 \u00e0 des patients s\u00e9v\u00e8res pr\u00e9sentant une d\u00e9tresse respiratoire dans le cadre d'une suspicion d'infection \u00e0 COVID-19, en particulier au dosage le plus \u00e9lev\u00e9 car augmente de plus de 3 fois le risque de d\u00e9c\u00e8s. Ce sur-risque a provoqu\u00e9 l'arr\u00eat pr\u00e9matur\u00e9 de l'\u00e9tude.\r\nDes troubles du rythme cardiaque s\u00e9v\u00e8res sont plus souvent observ\u00e9s avec les fortes doses de chloroquine et peuvent conduire au d\u00e9c\u00e8s apr\u00e8s tachycardie ventriculaire.\u00a0\n\nLe traitement par forte dose de chloroquine n'est donc pas recommand\u00e9 chez les patients s\u00e9v\u00e8res et le traitement par faible dose n'a pas fait preuve d'une baisse de la mortalit\u00e9, sous r\u00e9serve des biais pr\u00e9sents dans l'\u00e9tude.", "objectives": "Essai clinique randomis\u00e9 mais nombreux biais :- Inclusion et randomisation de patients suspects d'infection \u00e0 COVID-19 mais finalement n\u00e9gatifs pour un quart d'entre eux et pas d'analyse dans ce sous-groupes de patients confirm\u00e9s COVID-19- Hypoth\u00e8se discutable pour le calcul d'effectif (estimation d'une baisse de la mortalit\u00e9 de 50%)- Choix des posologies test\u00e9es discutable en l'absence de guidelines- On ne sait pas sur quelles variables le mod\u00e8le de r\u00e9gression logistique est ajust\u00e9- Repr\u00e9sentativit\u00e9 de l'\u00e9chantillon discutable car plut\u00f4t jeune et avec moins de comorbidit\u00e9s- Fluctuations d'\u00e9chantillonnage importante car patients plus \u00e2g\u00e9s et avec plus de probl\u00e8mes cardiaques dans le bras \u00e0 forte dose - Absence de groupe contr\u00f4le (placebo)", "methods": "Evaluer l'efficacit\u00e9 et la s\u00e9curit\u00e9 de la chloroquine \u00e0 faible ou forte dose dans le traitement du syndrome de d\u00e9tresse respiratoire aigu\u00eb chez des patients COVID-19", "pubmed_id": "32339248", "doi": "10.1001/jamanetworkopen.2020.8857", "abstract": "There is no specific antiviral therapy recommended for coronavirus disease 2019 (COVID-19). In vitro studies indicate that the antiviral effect of chloroquine diphosphate (CQ) requires a high concentration of the drug.\nTo evaluate the safety and efficacy of 2 CQ dosages in patients with severe COVID-19.\nThis parallel, double-masked, randomized, phase IIb clinical trial with 81 adult patients who were hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was conducted from March 23 to April 5, 2020, at a tertiary care facility in Manaus, Brazilian Amazon.\nPatients were allocated to receive high-dosage CQ (ie, 600 mg CQ twice daily for 10 days) or low-dosage CQ (ie, 450 mg twice daily on day 1 and once daily for 4 days).\nPrimary outcome was reduction in lethality by at least 50% in the high-dosage group compared with the low-dosage group. Data presented here refer primarily to safety and lethality outcomes during treatment on day 13. Secondary end points included participant clinical status, laboratory examinations, and electrocardiogram results. Outcomes will be presented to day 28. Viral respiratory secretion RNA detection was performed on days 0 and 4.\nOut of a predefined sample size of 440 patients, 81 were enrolled (41 [50.6%] to high-dosage group and 40 [49.4%] to low-dosage group). Enrolled patients had a mean (SD) age of 51.1 (13.9) years, and most (60 [75.3%]) were men. Older age (mean [SD] age, 54.7 [13.7] years vs 47.4 [13.3] years) and more heart disease (5 of 28 [17.9%] vs 0) were seen in the high-dose group. Viral RNA was detected in 31 of 40 (77.5%) and 31 of 41 (75.6%) patients in the low-dosage and high-dosage groups, respectively. Lethality until day 13 was 39.0% in the high-dosage group (16 of 41) and 15.0% in the low-dosage group (6 of 40). The high-dosage group presented more instance of QTc interval greater than 500 milliseconds (7 of 37 [18.9%]) compared with the low-dosage group (4 of 36 [11.1%]). Respiratory secretion at day 4 was negative in only 6 of 27 patients (22.2%).\nThe preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir. These findings cannot be extrapolated to patients with nonsevere COVID-19.\nClinicalTrials.gov Identifier: NCT04323527.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 419, "name": "Borba MGS"}], "publication_date": "2020-04-25"}, {"id": 22, "slug": "sars-cov-2-turned-positive-in-a-discharged-patient-with-covid-19-arouses-concern", "title": "SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire le cas d'un patient redevenu positif apr\u00e8s sa sortie d'hospitalisation", "verbose_date": "24.03.2020", "authors": "Zhang JF", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.dropbox.com/s/ty4ooev964yrxpy/PIIS1201971220301260.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Crit\u00e8res de sortie des patients COVID-19 \u00e0 \u00e9tudierN\u00e9cessit\u00e9 de surveillance suppl\u00e9mentaire apr\u00e8s la sortie d'hospitalisation avec contr\u00f4le des pr\u00e9levementsCas d'un patient de nouveau positif et donc potentiellement infectant apr\u00e8s sa sortie d'hospitalisation (avait \u00e9t\u00e9 transf\u00e9r\u00e9 en unit\u00e9 de surveillance et de quarantaine pour encore 14 jours)", "objectives": "Faible1) Case-report d'un patient", "methods": "D\u00e9crire le cas d'un patient redevenu positif apr\u00e8s sa sortie d'hospitalisation", "topics": ["Autres", "Transversale"], "author_list": [{"id": 32, "name": "Zhang JF"}], "publication_date": "2020-03-24"}, {"id": 179, "slug": "self-reported-olfactory-and-taste-disorders-in-sars-cov-2-patients-a-cross-secti", "title": "Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Mettre en \u00e9vidence la pr\u00e9sence de sympt\u00f4mes mineurs dans les premiers stades de l'infection COVID-19, tels que des troubles de l'odorat et du go\u00fbt", "verbose_date": "31.03.2020", "authors": "Giacomelli A ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 24, "name": "Clin Infect Dis"}, "link": "https://www.dropbox.com/s/0apf3oqyruu0s0c/ciaa330.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les troubles du go\u00fbt et de l'odorat sont connus pour \u00eatre li\u00e9s \u00e0 certaines infections virales\r\nSelon cette enqu\u00eate transversale les troubles du go\u00fbt et de l'odorat li\u00e9s \u00e0 l'infection par SRAS-CoV-2:\r\n1)\u00a0plus fr\u00e9quents avant l'hospitalisation:\u00a0\r\n20 patients (20.3%) ayant des sympt\u00f4mes avant l'hospitalisation et 8 (13.5%) ayant des sympt\u00f4mes pendant l'hospitalisation\r\n2)\u00a0alt\u00e9ration du go\u00fbt la plus fr\u00e9quente avant l'hospitalisation\u00a0(91%), aucune diff\u00e9rence entre l'alt\u00e9ration du go\u00fbt et de l'olfaction pendant l'hospitalisation\r\n3)\u00a0plus fr\u00e9quents chez les femmes:\u00a0\r\n10/19 (52.6%) femmes vs 10/40 (25%) hommes\r\n4)\u00a0les jeunes patients les plus touch\u00e9s:\r\nles patients pr\u00e9sentant des sympt\u00f4mes avaient un \u00e2ge moyen inf\u00e9rieur \u00e0 celui des patients ne pr\u00e9sentant pas de sympt\u00f4mes: 56 ans(IQR 47-60) vs 66 ans (IQR 52-77), p=0.035", "objectives": "1) Lettre \u00e0 l'\u00e9diteur2) Enqu\u00eate transversale sur 59 patients", "methods": "Mettre en \u00e9vidence la pr\u00e9sence de sympt\u00f4mes mineurs dans les premiers stades de l'infection COVID-19, tels que des troubles de l'odorat et du go\u00fbt", "pubmed_id": "32215618\n6463130\n32176772\n32064853\n18495771\n25294743\n31986264\n32094336\n22558054", "doi": "10.1093/cid/ciaa330", "abstract": null, "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 173, "name": "Giacomelli A "}], "publication_date": "2020-03-31"}, {"id": 30, "slug": "ct-manifestations-of-coronavirus-disease-2019-a-retrospective-analysis-of-73-cas", "title": "CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer les signes radiologiques en fonction de la s\u00e9v\u00e9rit\u00e9 des patients atteints du COVID-19", "verbose_date": "21.03.2020", "authors": "Liu KC", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 26, "name": "Eur J Radiol"}, "link": "https://www.dropbox.com/s/rj9q12psbqk1vsg/PIIS0720048X20301303.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Forme commune : opacit\u00e9s en verre d\u00e9poli p\u00e9riph\u00e9riques\nForme s\u00e9v\u00e8re : extension des opacit\u00e9s et possible \u00e9paississement septal\nForme critique : poumon blanc\nPhase r\u00e9solutive : r\u00e9solution compl\u00e8te g\u00e9n\u00e9ralement", "objectives": "Interm\u00e9diaire : 1) Etude r\u00e9trospective2) Patients suspects inclus", "methods": "Evaluer les signes radiologiques en fonction de la s\u00e9v\u00e9rit\u00e9 des patients atteints du COVID-19", "pubmed_id": "32193037", "doi": "10.1016/j.ejrad.2020.108941", "abstract": "To report CT features of coronavirus disease-2019 (COVID-19) in patients with various disease severity.\nThe CT manifestations and clinical data of 73 patients with COVID-19 were retrospectively collected in 6 hospitals from Jan 21 to Feb 3, 2020. We analyzed the initial and follow-up CT features of patients with disease severity, according to the Guidelines for the Diagnosis and Treatment of New Coronavirus Pneumonia.\nSix patients (8%) were diagnosed as mild type pneumonia; these patients had no obvious abnormal CT findings or manifested mild changes of lung infection. All 43 patients (59 %) with common type presented unique or multiple ground-glass opacities (GGO) in the periphery of the lungs, with or without interlobular septal thickening. In the 21 patients (29 %) with severe type, extensive GGO and pulmonary consolidation were found in 16 cases (16/21, 76 %) and 5 cases (24 %), respectively. An extensive \"white lung\", with atelectasis and pleural effusion were found in critical type patients (3, 4%). On the resolutive phase of the disease, CT abnormalities showed complete resolution, or demonstrated residual linear opacities.\nDifferent CT features are seen according to disease severity, which can help COVID-19 stratification.", "topics": ["Epid\u00e9miologique", "Radiologie"], "author_list": [{"id": 40, "name": "Liu KC"}], "publication_date": "2020-03-21"}, {"id": 578, "slug": "triple-combination-of-interferon-beta-1b-lopinavirritonavir-and-ribavirin-in-the", "title": "Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluation de l'efficacit\u00e9 antivirale de l'interferon beta-1b associ\u00e9 au lopinavir-ritonavir et \u00e0 la ribavirine chez des patients COVID-19 (essai de phase II)", "verbose_date": "13.05.2020", "authors": "Hung I", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://doi.org/10.1016/S0140-6736(20)31042-4", "findings": "", "take_away": "", "relevance_level": "Efficacit\u00e9 de la combinaison th\u00e9rapeutique test\u00e9e (interferon beta-1b, lopinavir-ritonavir, ribavirine) sur la r\u00e9duction du d\u00e9lai de n\u00e9gativation virologique (r\u00e9duction de 5 jours) par rapport au groupe contr\u00f4le (lopinavir-ritonavir)\nPossible diminution du d\u00e9lai d'am\u00e9lioration clinique, de la charge virale et du niveau d'inflammation sous la combinaison test\u00e9e, mais pas de preuve sur la mortalit\u00e9 ou l'intubation\nBonne s\u00e9curit\u00e9 du traitement, car pas de diff\u00e9rences en termes d'effets ind\u00e9sirables\u00a0retrouv\u00e9s\nN\u00e9cessit\u00e9 d'un essai de phase III pour conclure", "objectives": "- Pas d'aveugle- Calcul d'effectif bas\u00e9 sur des hypoth\u00e8ses d'efficacit\u00e9 du lopinavir-ritonavir pour le SARS-CoV-1 ce qui n'est ni le traitement \u00e9tudi\u00e9, ni le le virus \u00e9tudi\u00e9- Echantillon dont la repr\u00e9sentativit\u00e9 n'est pas parfaite (moins de comorbidit\u00e9s et plus jeune) mais bonne comparabilit\u00e9 des 2 bras- Pr\u00e9sentation clinique diff\u00e9rente de celle en Europe (tr\u00e8s peu d'anosmie par exemple) et aucun d\u00e9c\u00e8s (patients peu s\u00e9v\u00e8res)- Pas de conclusion possible sur les crit\u00e8res de jugement secondaires (inflation du risque alpha)", "methods": "Evaluation de l'efficacit\u00e9 antivirale de l'interferon beta-1b associ\u00e9 au lopinavir-ritonavir et \u00e0 la ribavirine chez des patients COVID-19 (essai de phase II)", "pubmed_id": "32401715\n31986261\n32147628\n32172546\n32020029\n26198719\n32205204\n31925415\n24841269\n32213337\n30184455\n21810214\n15288617\n25213733\n32187464\n25030060\n32270184\n15474623\n14985565\n30974127\n27884765\n32127666\n29511076\n27095301\n32215622\n32171872\n24096239\n31924756\n15200845\n32178711", "doi": "10.1016/S0140-6736(20)31042-4", "abstract": "Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19.\nThis was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group). The primary endpoint was the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR, and was done in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT04276688.\nBetween Feb 10 and March 20, 2020, 127 patients were recruited; 86 were randomly assigned to the combination group and 41 were assigned to the control group. The median number of days from symptom onset to start of study treatment was 5 days (IQR 3-7). The combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days [IQR 5-11]) than the control group (12 days [8-15]; hazard ratio 4\u00b737 [95% CI 1\u00b786-10\u00b724], p=0\u00b70010). Adverse events included self-limited nausea and diarrhoea with no difference between the two groups. One patient in the control group discontinued lopinavir-ritonavir because of biochemical hepatitis. No patients died during the study.\nEarly triple antiviral therapy was safe and superior to lopinavir-ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19. Future clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted.\nThe Shaw-Foundation, Richard and Carol Yu, May Tam Mak Mei Yin, and Sanming Project of Medicine.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 542, "name": "Hung I"}], "publication_date": "2020-05-13"}, {"id": 362, "slug": "the-impact-of-copd-and-smoking-history-on-the-severity-of-covid-19-a-systemic-re", "title": "The impact of COPD and smoking history on the severity of Covid-19: A systemic review and meta-analysis", "has_other_authors": false, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Explorer le risque de Covid-19 s\u00e9v\u00e8re chez les patients BPCO et fumeurs actifs", "verbose_date": "17.04.2020", "authors": "Zhao Q", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25889", "findings": "", "take_away": "", "relevance_level": "Le risque d'avoir une pr\u00e9sentation s\u00e9v\u00e8re du Covid-19 chez les patients BPCO est multipli\u00e9 par 4.\u00a0\r\nL'effet du tabagisme sur la s\u00e9v\u00e9rit\u00e9 du Covid-19 est contrevers\u00e9.", "objectives": "-Revue syst\u00e9matique de la litt\u00e9rature de plusieurs databases en anglais et chinois-2 reviewers ind\u00e9pendants, un 3eme si d\u00e9saccord-H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 mod\u00e9r\u00e9e-Exploration de cette h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 via analyses de sensibilit\u00e9 et analyses en sous-groupes-Biais de publication \u00e9valu\u00e9 et non significatif-Mais nombre d'articles faibles (n=11) -Articles d\u00e9crivant des cas uniquement en Chine, biais de s\u00e9lection possible-Certaines \u00e9tudes qui ne d\u00e9crivait qu'une des variables explicatives (BPCO ou tabagisme)-M\u00e9ta-analyse sur \u00e9tudes de cas, biais de confusion possible-Qualit\u00e9 m\u00e9thodologique de ces \u00e9tudes mod\u00e9r\u00e9e-Crit\u00e8re de s\u00e9v\u00e9rit\u00e9 du COVID-19 composite-Dans certaines \u00e9tudes pas de diff\u00e9renciation entre tabagisme actif et ant\u00e9c\u00e9dant de tabagisme-Pour la m\u00e9ta-analyse, pas de de description de la m\u00e9thode statistique employ\u00e9e pour obtenir les OR pool\u00e9s.\"", "methods": "Explorer le risque de Covid-19 s\u00e9v\u00e8re chez les patients BPCO et fumeurs actifs", "pubmed_id": "32293753\n32171076\n31502247\n31986264\n32048163\n11067570\n11371392", "doi": "10.1002/jmv.25889", "abstract": "Comorbidities are associated with the severity of coronavirus disease 2019 (COVID-19). This meta-analysis aimed to explore the risk of severe COVID-19 in patients with pre-existing chronic obstructive pulmonary disease (COPD) and ongoing smoking history. A comprehensive systematic literature search was carried out to find studies published from December 2019 to 22 March 2020 from five databases. The languages of literature included English and Chinese. The point prevalence of severe COVID-19 in patients with pre-existing COPD and those with ongoing smoking was evaluated with this meta-analysis. Overall 11 case series, published either in Chinese or English language with a total of 2002 cases, were included in this study. The pooled OR of COPD and the development of severe COVID-19 was 4.38 (fixed-effects model; 95% CI: 2.34-8.20), while the OR of ongoing smoking was 1.98 (fixed-effects model; 95% CI: 1.29-3.05). There was no publication bias as examined by the funnel plot and Egger's test (P\u2009=\u2009not significant). The heterogeneity of included studies was moderate for both COPD and ongoing smoking history on the severity of COVID-19. COPD and ongoing smoking history attribute to the worse progression and outcome of COVID-19.", "topics": ["Epid\u00e9miologique", "Infectiologie", "Pneumologie"], "author_list": [{"id": 349, "name": "Zhao Q"}], "publication_date": "2020-04-17"}, {"id": 365, "slug": "the-imperfect-cytokine-storm-severe-covid-19-with-ards-in-patient-on-durable-lva", "title": "The Imperfect Cytokine Storm: Severe COVID-19 with ARDS in Patient on Durable LVAD Support", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9velopper les r\u00e9flexions et l'approche syst\u00e9matique utilis\u00e9e pour l'infection \u00e0 COVID grave chez le patient avec assistance circulatoire permanente.", "verbose_date": "17.04.2020", "authors": "Chau VQ", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 157, "name": "JACC Case Rep"}, "link": "https://reader.elsevier.com/reader/sd/pii/S2666084920303314?token=A1AB009C80FCD3073829AB5E64C3E57F47B73375E5F76DAEBC6C48D6089843A504403B22885F8F8D2BCA28EBC2891642", "findings": "", "take_away": "", "relevance_level": "Sans surprise r\u00e9animation complexe. Ils proposent un tableau d'aide \u00e0 la prise en charge des patients sous assistance ventriculaire atteints de COVID. Pas de DV du fait de la machine.", "objectives": "Case report.", "methods": "D\u00e9velopper les r\u00e9flexions et l'approche syst\u00e9matique utilis\u00e9e pour l'infection \u00e0 COVID grave chez le patient avec assistance circulatoire permanente.", "pubmed_id": "32292915\n30498496\n10793162\n28267435\n28459724\n22390970\n29495891", "doi": "10.1016/j.jaccas.2020.04.001", "abstract": "As health systems worldwide grapple with the COVID-19 pandemic, patients on durable LVAD support represent a unique population at risk for the disease. We outline such a patient who developed COVID-19 complicated by \"cytokine storm\" with severe ARDS and myocardial injury; and describe the challenges that arose during management.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 352, "name": "Chau VQ"}], "publication_date": "2020-04-17"}, {"id": 494, "slug": "estimating-the-burden-of-united-states-workers-exposed-to-infection-or-disease-a", "title": "Estimating the burden of United States workers exposed to infection or disease: A key factor in containing risk of COVID-19 infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Recenser le nombre de personnes aux Etats-Unis expos\u00e9es plus d'une fois par mois \u00e0 un risque infectieux dans le cadre de leur travail.", "verbose_date": "30.04.2020", "authors": "Baker M", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 48, "name": "PLOS One"}, "link": "https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0232452&type=printable", "findings": "", "take_away": "", "relevance_level": "Une part importante des travailleurs aux Etats-Unis semble concern\u00e9e par une exposition professionnelle aux infections. Ces personnes devraient faire l'objet de mesures sp\u00e9cifiques de pr\u00e9vention de la transmission de l'infection en particulier : la mise \u00e0 disposition d'\u00e9quipement de protection individuelle et des actions de pr\u00e9vention de la pr\u00e9sence de personnes malades sur leur lieu de travail en favorisant les arr\u00eats de travail indemnis\u00e9s ou encore le remplacement des professionnels occupant des postes essentiels.", "objectives": "- \u00e9tude r\u00e9trospective- donn\u00e9es issues d'enqu\u00eates avec questionnaires auto-administr\u00e9s soumis \u00e0 plusieurs biais (de rappel, de classification notamment)- non prise en compte de certains m\u00e9tiers : militaires, ind\u00e9pendants entre autres- non prise en compte d'\u00e9ventuelles mesures de pr\u00e9vention de la transmission mises en place sur les lieux de travail- questions de l'enqu\u00eate relative \u00e0 l'exposition professionnelle \u00e0 des maladies et infections soumises \u00e0 diff\u00e9rentes interpr\u00e9tations", "methods": "Recenser le nombre de personnes aux Etats-Unis expos\u00e9es plus d'une fois par mois \u00e0 un risque infectieux dans le cadre de leur travail.", "pubmed_id": "32343747\n11105178\n19448572\n20698022\n32154831\n30649219\n32091533\n28189802\n31226966\n28850081\n27060594\n23606055\n32107548\n19081162\n24523425\n30567547\n23763426\n30548877\n30655228", "doi": "10.1371/journal.pone.0232452", "abstract": "With the global spread of COVID-19, there is a compelling public health interest in quantifying who is at increased risk of contracting disease. Occupational characteristics, such as interfacing with the public and being in close quarters with other workers, not only put workers at high risk for disease, but also make them a nexus of disease transmission to the community. This can further be exacerbated through presenteeism, the term used to describe the act of coming to work despite being symptomatic for disease. Quantifying the number of workers who are frequently exposed to infection and disease in the workplace, and understanding which occupational groups they represent, can help to prompt public health risk response and management for COVID-19 in the workplace, and subsequent infectious disease outbreaks.\nTo estimate the number of United States workers frequently exposed to infection and disease in the workplace, national employment data (by Standard Occupational Classification) maintained by the Bureau of Labor Statistics (BLS) was merged with a BLS O*NET survey measure reporting how frequently workers in each occupation are exposed to infection or disease at work. This allowed us to estimate the number of United States workers, across all occupations, exposed to disease or infection at work more than once a month.\nBased on our analyses, approximately 10% (14.4 M) of United States workers are employed in occupations where exposure to disease or infection occurs at least once per week. Approximately 18.4% (26.7 M) of all United States workers are employed in occupations where exposure to disease or infection occurs at least once per month. While the majority of exposed workers are employed in healthcare sectors, other occupational sectors also have high proportions of exposed workers. These include protective service occupations (e.g. police officers, correctional officers, firefighters), office and administrative support occupations (e.g. couriers and messengers, patient service representatives), education occupations (e.g. preschool and daycare teachers), community and social services occupations (community health workers, social workers, counselors), and even construction and extraction occupations (e.g. plumbers, septic tank installers, elevator repair).\nThe large number of persons employed in occupations with frequent exposure to infection and disease underscore the importance of all workplaces developing risk response plans for COVID-19. Given the proportion of the United States workforce exposed to disease or infection at work, this analysis also serves as an important reminder that the workplace is a key locus for public health interventions, which could protect both workers and the communities they serve.", "topics": ["Epid\u00e9miologique", "Infectiologie", "Hygi\u00e8ne"], "author_list": [{"id": 463, "name": "Baker M"}], "publication_date": "2020-04-30"}, {"id": 271, "slug": "atazanavir-inhibits-sars-cov-2-replication-and-pro-inflammatory-cytokine-product", "title": "Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'effet in vitro de l'atazanavir sur l'infection \u00e0 SARS-CoV-2", "verbose_date": "09.04.2020", "authors": "Fintelman-Rodrigues N", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.biorxiv.org/content/10.1101/2020.04.04.020925v2.full.pdf", "findings": "", "take_away": "", "relevance_level": "IN VITRO, l'atazanavir a une efficacit\u00e9 sur la r\u00e9duction de l'activit\u00e9 enzymatique du SARS-CoV-2 en particulier au niveau pulmonaire et sur la r\u00e9duction de la r\u00e9action inflammatoire.\r\nIl pourrait donc \u00eatre un traitement int\u00e9ressant \u00e0 \u00e9tudier in vivo seul ou en association avec le ritonavir, car ce traitement pourrait avoir moins d'effets ind\u00e9sirables que le lopinavir.", "objectives": "- Pre-prints- Etude in vitro- Pas de comparateur pour l'\u00e9valuation de l'activit\u00e9 enzymatique\"", "methods": "Evaluer l'effet in vitro de l'atazanavir sur l'infection \u00e0 SARS-CoV-2", "topics": ["Th\u00e9rapeutique", "Virologie", "Infectiologie"], "author_list": [{"id": 260, "name": "Fintelman-Rodrigues N"}], "publication_date": "2020-04-09"}, {"id": 328, "slug": "covid-19-in-children-in-the-united-states-intensive-care-admissions-estimated-to", "title": "COVID-19 in Children in the United States: Intensive Care Admissions, Estimated Total Infected, and Projected Numbers of Severe Pediatric Cases in 2020", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9nombrer et estimer le nombre d'enfants infect\u00e9s par le SARS-CoV-2 aux USA au 6 avril et \u00e0 la fin de l'ann\u00e9e 2020, notamment les cas s\u00e9v\u00e8res et critiques, afin de mettre en place des mesures adapt\u00e9es", "verbose_date": "14.04.2020", "authors": "Pathak EB", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 147, "name": "J Public Health Manag Prac"}, "link": "https://www.dropbox.com/s/wjawhzgzcf9v9ao/COVID_19_in_Children_in_the_United_States_.99293.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les sc\u00e9narios interm\u00e9diaires de proportion d'enfants atteints estiment \u00e0 plusieurs millions le nombres d'enfants infect\u00e9s par le SARS-CoV-2 fin 2020 et \u00e0 plusieurs milliers le nombres de cas p\u00e9diatriques s\u00e9v\u00e8res. Environ 11% des enfants hospitalis\u00e9s pour COVID-19 n\u00e9cessiteraient des soins intensifs et les Etats-Unis disposent \u00e0 ce jour de 5100 lits de soins intensifs p\u00e9diatriques. Il appara\u00eet donc important de pr\u00e9voir d'augmenter les capacit\u00e9s d'accueil, le mat\u00e9riel \u00e0 disposition et de r\u00e9organiser les services concern\u00e9s, de communiquer largement aux familles les mesures barri\u00e8res \u00e0 appliquer et de d\u00e9tecter, traiter et isoler pr\u00e9coc\u00e9ment les cas.", "objectives": "- estimation du nombre d'enfants admis en soins intensifs pour COVID-19 au 6/04 ne prenant pas en compte tous les \u00e9tablissements concern\u00e9s sur le territoire des Etats-Unis- se base notamment sur des donn\u00e9es chinoises dont on ignore l'authenticit\u00e9- r\u00e9sultats bas\u00e9s sur plusieurs hypoth\u00e8ses non v\u00e9rifi\u00e9es- estimation du taux d'enfants hospitalis\u00e9s n\u00e9cessitant des soins intensifs concordant avec le taux publi\u00e9s par les CDC\"", "methods": "D\u00e9nombrer et estimer le nombre d'enfants infect\u00e9s par le SARS-CoV-2 aux USA au 6 avril et \u00e0 la fin de l'ann\u00e9e 2020, notamment les cas s\u00e9v\u00e8res et critiques, afin de mettre en place des mesures adapt\u00e9es", "pubmed_id": "32282440", "doi": "10.1097/PHH.0000000000001190", "abstract": "A surge in severe cases of COVID-19 (coronavirus disease 2019) in children would present unique challenges for hospitals and public health preparedness efforts in the United States.\nTo provide evidence-based estimates of children infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) and projected cumulative numbers of severely ill pediatric COVID-19 cases requiring hospitalization during the US 2020 pandemic.\nEmpirical case projection study.\nAdjusted pediatric severity proportions and adjusted pediatric criticality proportions were derived from clinical and spatiotemporal modeling studies of the COVID-19 epidemic in China for the period January-February 2020. Estimates of total children infected with SARS-CoV-2 in the United States through April 6, 2020, were calculated using US pediatric intensive care unit (PICU) cases and the adjusted pediatric criticality proportion. Projected numbers of severely and critically ill children with COVID-19 were derived by applying the adjusted severity and criticality proportions to US population data, under several scenarios of cumulative pediatric infection proportion (CPIP).\nBy April 6, 2020, there were 74 children who had been reported admitted to PICUs in 19 states, reflecting an estimated 176 190 children nationwide infected with SARS-CoV-2 (52 381 infants and toddlers younger than 2 years, 42 857 children aged 2-11 years, and 80 952 children aged 12-17 years). Under a CPIP scenario of 5%, there would be 3.7 million children infected with SARS-CoV-2, 9907 severely ill children requiring hospitalization, and 1086 critically ill children requiring PICU admission. Under a CPIP scenario of 50%, 10 865 children would require PICU admission, 99 073 would require hospitalization for severe pneumonia, and 37.0 million would be infected with SARS-CoV-2.\nBecause there are 74.0 million children 0 to 17 years old in the United States, the projected numbers of severe cases could overextend available pediatric hospital care resources under several moderate CPIP scenarios for 2020 despite lower severity of COVID-19 in children than in adults.", "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 315, "name": "Pathak EB"}], "publication_date": "2020-04-14"}, {"id": 644, "slug": "mortality-and-pulmonary-complications-in-patients-undergoing-surgery-with-periop", "title": "Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer la mortalit\u00e9 \u00e0 30 jours ainsi que les complications pulmonaires en post-op\u00e9ratoire pour les patients infect\u00e9s par le SARS-CoV-2 lors d'une chirurgie", "verbose_date": "02.06.2020", "authors": "Nepogodiev D", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931182-X", "findings": "", "take_away": "", "relevance_level": "Chez des patients infect\u00e9s par le SARS-CoV-2 en p\u00e9ri-op\u00e9ratoire, des complications pulmonaires post-op\u00e9ratoires surviennent dans la moiti\u00e9 des cas avec une mortalit\u00e9 \u00e0 7 jours de 5% et une mortalit\u00e9 \u00e0 30 jours de 24%\nLes patients les plus \u00e0 risques sont les hommes de plus de 70 ans op\u00e9r\u00e9s pour un cancer\u00a0avec un score ASA sup\u00e9rieur ou \u00e9gal \u00e0 3 et dont l'infection est survenue en pr\u00e9-op\u00e9ratoire", "objectives": "- Grande \u00e9tude observationnelle de cohorte bien men\u00e9e- Pourcentage de donn\u00e9es manquantes non n\u00e9gligeable et absence de m\u00e9thodologie de prise en compte- Recueil des donn\u00e9es parfois r\u00e9trospectif sur dossier (on ne conna\u00eet pas la part de ces donn\u00e9es)", "methods": "Evaluer la mortalit\u00e9 \u00e0 30 jours ainsi que les complications pulmonaires en post-op\u00e9ratoire pour les patients infect\u00e9s par le SARS-CoV-2 lors d'une chirurgie", "pubmed_id": "32479829\n27763576\n27829093\n18064739\n29916860\n27145169\n32057212\n32264898\n31986264\n29661384\n26903335\n29076260\n29306587\n32171076\n30224322\n32246185", "doi": "10.1016/S0140-6736(20)31182-X", "abstract": "The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection.\nThis international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation.\nThis analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74\u00b70%) had emergency surgery and 280 (24\u00b78%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26\u00b71%) patients. 30-day mortality was 23\u00b78% (268 of 1128). Pulmonary complications occurred in 577 (51\u00b72%) of 1128 patients; 30-day mortality in these patients was 38\u00b70% (219 of 577), accounting for 82\u00b76% (219 of 265) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1\u00b775 [95% CI 1\u00b728-2\u00b740], p<0\u00b70001), age 70 years or older versus younger than 70 years (2\u00b730 [1\u00b765-3\u00b722], p<0\u00b70001), American Society of Anesthesiologists grades 3-5 versus grades 1-2 (2\u00b735 [1\u00b757-3\u00b753], p<0\u00b70001), malignant versus benign or obstetric diagnosis (1\u00b755 [1\u00b701-2\u00b739], p=0\u00b7046), emergency versus elective surgery (1\u00b767 [1\u00b706-2\u00b763], p=0\u00b7026), and major versus minor surgery (1\u00b752 [1\u00b701-2\u00b731], p=0\u00b7047).\nPostoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery.\nNational Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research.", "topics": ["Pronostique", "Transversale", "Pneumologie"], "author_list": [{"id": 606, "name": "Nepogodiev D"}], "publication_date": "2020-06-02"}, {"id": 45, "slug": "recommendations-for-the-prevention-mitigation-and-containment-of-the-emerging-sa", "title": "Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "recommandations de EUDIAL pour la pr\u00e9vention, l'att\u00e9nuation et l'endiguement dans les centres d'h\u00e9modialyse de l'\u00e9pid\u00e9mie COVID19", "verbose_date": "20.03.2020", "authors": "Basile C", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 7, "name": "Recommandations", "icon": "icon-reco"}, "journal": {"id": 39, "name": "Nephrol Dial Transplant"}, "link": "https://www.dropbox.com/s/p6nxx7unpvsgpvm/gfaa069.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Resum\u00e9 des recommandations, pas tout mis voir article pour les d\u00e9tails et le reste des reco :L'\u00e9quipe soignante doit \u00eatre entra\u00een\u00e9e et pr\u00e9par\u00e9e \u00e0 l'\u00e9pid\u00e9mie (conna\u00eetre le virus, les gestes et \u00e9quipements de pr\u00e9vention et leur utilisation etc...)Les m\u00e9decins doivent \u00eatre tenus au courant des derni\u00e8res avanc\u00e9es de l'\u00e9pid\u00e9mie et des recommandations.L'\u00e9quipe doit surveiller ses propres sympt\u00f4mes et en informer le team leader en cas de signe personnel ou dans sa famille. Les symptomatiques doivent rester chez eux.Les infirmi\u00e8res doivent s'entra\u00eener aux tests de d\u00e9pistage (\u00e9quipement protection complet, geste). Informer et \u00e9duquer les patients et leur famille sur les gestes barri\u00e8res. Mettre GHA \u00e0 disposition. Laisser les patients attendre \u00e0 l'ext\u00e9rieur dans leur voiture ou le cas \u00e9ch\u00e9ant dans une salle \u00e0 deux m\u00e8tres les uns des autres.Les zones de traitements doivent avoir l'air conditionn\u00e9 et une ventilation efficace.Prise de temp\u00e9rature chez les patients avant et apr\u00e8s la dialyse.Reconna\u00eetre rapidement les patients symptomatiques pour les isoler et les tester.La dialyse d'un patient symptomatique doit se faire dans une pi\u00e8ce isol\u00e9e avec syst\u00e8me de pression n\u00e9gative et porte ferm\u00e9e. Sinon il faut les faire attendre dans une pi\u00e8ce isol\u00e9e et les faire passer \u00e0 la fin du programme. Il doit porter un masque filtrant 95% de particules <2.5\u00b5m.Les patients COVID19 doivent avoir leur dialyse dans une pi\u00e8ce isol\u00e9e et pas dans unn centre de dialyse ambulatoire sauf si une chambre d'isolement des infections a\u00e9roport\u00e9es est dispobinle. Le personnel doit prendre les protections maximales.Ne pas m\u00e9langer les cas suspects et confirm\u00e9s mais regrouper les patients suspects et confirm\u00e9s \u00e0 une \u00e9quipe soignante d\u00e9di\u00e9e chacun.Tester tous les patients avec chirurgie d'acc\u00e8s vasculaire....", "objectives": "Interm\u00e9diaire/fort ?- groupe de travail qui se base sur les reco de The Chinese Society of Nephrology, the Taiwan Societyof Nephrology and the Centers for Disease Control and Prevention ainsi que sur les reco WHO pour les \u00e9quipements de protection", "methods": "recommandations de EUDIAL pour la pr\u00e9vention, l'att\u00e9nuation et l'endiguement dans les centres d'h\u00e9modialyse de l'\u00e9pid\u00e9mie COVID19", "pubmed_id": "32196116", "doi": "10.1093/ndt/gfaa069", "abstract": "COVID-19, a disease caused by a novel coronavirus, is a major global human threat that has turned into a pandemic. This novel coronavirus has specifically high morbidity in the elderly and in comorbid populations. Uraemic patients on dialysis combine an intrinsic fragility and a very frequent burden of comorbidities with a specific setting in which many patients are repeatedly treated in the same area (haemodialysis centres). Moreover, if infected, the intensity of dialysis requiring specialized resources and staff is further complicated by requirements for isolation, control and prevention, putting healthcare systems under exceptional additional strain. Therefore, all measures to slow if not to eradicate the pandemic and to control unmanageably high incidence rates must be taken very seriously. The aim of the present review of the European Dialysis (EUDIAL) Working Group of ERA-EDTA is to provide recommendations for the prevention, mitigation and containment in haemodialysis centres of the emerging COVID-19 pandemic. The management of patients on dialysis affected by COVID-19 must be carried out according to strict protocols to minimize the risk for other patients and personnel taking care of these patients. Measures of prevention, protection, screening, isolation and distribution have been shown to be efficient in similar settings. They are essential in the management of the pandemic and should be taken in the early stages of the disease.", "topics": ["Recommandations", "Transversale"], "author_list": [{"id": 55, "name": "Basile C"}], "publication_date": "2020-03-20"}, {"id": 145, "slug": "predicting-the-angiotensin-converting-enzyme-2-ace-2-utilizing-capability-as-the", "title": "Predicting the angiotensin converting enzyme 2 (ACE 2) utilizing capability as the receptor of SRAS-CoV-2", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Pr\u00e9dire les esp\u00e8ces animales qui poss\u00e8dent des r\u00e9cepteurs ACE 2 (Enzyme de Conversion de l'Angiotensine 2) auxquels le SRAS-CoV-19 est capable de se lier.\r\nCette pr\u00e9diction peut aider \u00e0 s\u00e9lectionner les h\u00f4tes interm\u00e9diaires du SRAS-CoV-19.\r\n ", "verbose_date": "24.03.2020", "authors": "Qiu Y ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 17, "name": "Microb Infect"}, "link": "https://www.dropbox.com/s/i7houmen11kkwh7/1-s2.0-S1286457920300496-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Il a \u00e9t\u00e9 d\u00e9montr\u00e9 que le SRAS-CoV-2 utilise le r\u00e9cepteur ACE 2 comme r\u00e9cepteur cellulaire mais n'est pas capable de se lier au r\u00e9cepteur de toutes les esp\u00e8ces.\u00a0\r\nPour identifier d'\u00e9ventuels h\u00f4tes interm\u00e9diaires du virus, les s\u00e9quences d'acides amin\u00e9s du r\u00e9cepteur ACE 2 ont \u00e9t\u00e9 analys\u00e9es pour 250 esp\u00e8ces, identifiant 9 polymorphismes aa qui r\u00e9duisent ou inhibent la liaison.\r\nUne valeur (entre 0 et 100) a \u00e9t\u00e9 attribu\u00e9e \u00e0 chaque esp\u00e8ce pour la force de liaison entre le r\u00e9cepteur ACE 2 et SRAS-CoV-2 en fonction des polymorphismes.\u00a0\r\nLes esp\u00e8ces ayant une force de liaison r\u00e9cepteur-virus >50 sont consid\u00e9r\u00e9es comme des esp\u00e8ces susceptibles d'\u00eatre des h\u00f4tes interm\u00e9diaires du virus: le pangolin, le chat, la vache, le buffle, la ch\u00e8vre et le mouton (mammif\u00e8res avec score=100) et pigeons (oiseaux, score=70).", "objectives": "", "methods": "Pr\u00e9dire les esp\u00e8ces animales qui poss\u00e8dent des r\u00e9cepteurs ACE 2 (Enzyme de Conversion de l'Angiotensine 2) auxquels le SRAS-CoV-19 est capable de se lier.\r\nCette pr\u00e9diction peut aider \u00e0 s\u00e9lectionner les h\u00f4tes interm\u00e9diaires du SRAS-CoV-19.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 142, "name": "Qiu Y "}], "publication_date": "2020-03-24"}, {"id": 515, "slug": "hydroxychloroquine-application-is-associated-with-a-decreased-mortality-in-criti", "title": "Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer si le traitement par hydroxychloroquine peut \u00eatre associ\u00e9 \u00e0 une diminution du risque de d\u00e9c\u00e8s chez les patients COVID-19 gravement malades", "verbose_date": "03.05.2020", "authors": "Bo Y", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.27.20073379v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Etude avec nombreux biais ne permettant pas de conclure \u00e0 une r\u00e9duction de la mortalit\u00e9 chez des patients s\u00e9v\u00e8res trait\u00e9s par hydroxychloroquine pourtant montr\u00e9e par les auteurs (24,7%). Par ailleurs, la dur\u00e9e d'hospitalisation n'est pas modifi\u00e9e avec ce traitement.\nToutefois, il existe une possible action anti-inflammatoire de l'hydroxychloroquine par diminution des cytokines pro-inflammatoires. L'ensemble de ces r\u00e9sultats sont \u00e0 confirmer dans une \u00e9tude plus robuste m\u00e9thodologiquement.", "objectives": "- Design de l'\u00e9tude ne permet pas de r\u00e9pondre \u00e0 la question pos\u00e9e : sur quels crit\u00e8res s'est fait le choix de l'hydroxychloroquine ? Seule la randomisation peut lever cette ambigu\u00eft\u00e9- Etude chinoise r\u00e9trospective dont on ne conna\u00eet pas les h\u00f4pitaux concern\u00e9s et qui n'a pas encore \u00e9t\u00e9 relue (pre-prints)- Mauvaise comparabilit\u00e9 des 2 groupes : seul le faible effectif du groupe hydroxychloroquine fait qu'il n'y a pas de diff\u00e9rence significative sur des caract\u00e9ristiques pourtant majeures et d\u00e9s\u00e9quilibr\u00e9es comme les coronaropathie et la BPCO (sur-risque de d\u00e9c\u00e8s sup\u00e9rieur \u00e0 2,5 fois)- Peu d'information sur les traitements pris par le groupe \"contr\u00f4le\" et pas de ma\u00eetrise des co-prescriptions qui peuvent \u00eatre tr\u00e8s diff\u00e9rentes d'un patient \u00e0 l'autre- Pas de calcul de nombre de sujets n\u00e9cessaire et ici tr\u00e8s faible nombre de patients trait\u00e9s par hydroxychloroquine compar\u00e9s aux autres (fluctuations majeures)- Etude peu d\u00e9taill\u00e9e et tr\u00e8s mal r\u00e9dig\u00e9e", "methods": "D\u00e9terminer si le traitement par hydroxychloroquine peut \u00eatre associ\u00e9 \u00e0 une diminution du risque de d\u00e9c\u00e8s chez les patients COVID-19 gravement malades", "topics": ["Th\u00e9rapeutique", "Transversale", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie"], "author_list": [{"id": 483, "name": "Bo Y"}], "publication_date": "2020-05-03"}, {"id": 614, "slug": "covid-19-related-neuroimaging-findings-a-signal-of-thromboembolic-complications-", "title": "COVID-19 related neuroimaging findings: A signal of thromboembolic complications and a strong prognostic marker of poor patient outcome", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Investiguer l'incidence et le spectre des r\u00e9sultats de neuro-imagerie et leur r\u00f4le pronostique chez les patients Covid-19 hospitalis\u00e9s dans la ville de New York.", "verbose_date": "22.05.2020", "authors": "Jain R", "specialties": [{"id": 18, "name": "Neurologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 167, "name": "J Neurol Sci"}, "link": "https://www.sciencedirect.com/science/article/pii/S0022510X20302604", "findings": "", "take_away": "", "relevance_level": "L'incidence d'AVC aigu\u00eb parmi les patients Covid-19 hospitalis\u00e9s \u00e9tait de 1.1%. Cette derni\u00e8re telle que d\u00e9termin\u00e9e par les r\u00e9sultats de la neuroimagerie est inf\u00e9rieure \u00e0 2,8% d'incidence trouv\u00e9e chez les patients admis aux Urgences.\nLa d\u00e9couverte d'un accident vasculaire c\u00e9r\u00e9bral aigu par neuroimagerie est un marqueur pronostique fort de mauvais r\u00e9sultats.\nPar ailleurs, il est important de signaler qu'il existe une utilisation restreinte de la neuroimagerie chez les patients COVID-19 en raison de multiples contraintes logistiques, y compris la gravit\u00e9 de leur maladie et le souci de propagation de l'infection.", "objectives": "- Etude r\u00e9trospective- Grand \u00e9chantillon de d\u00e9part mais petit nombre (n=38 soit 8.4%) de patients ayant une imagerie en faveur d'une atteinte neurologique.- Biais de s\u00e9lection clair  > certaines manifestations neurologiques peuvent s'accompagner d'une absence d'anomalie \u00e0 l'imagerie. > certaines pr\u00e9cautions de contact et des mesures strictes de contr\u00f4le des infections peuvent limiter la capacit\u00e9 d'effectuer des examens et obtenir la neuroimagerie en particulier l'IRM. > les patients intub\u00e9s donc difficiles \u00e0 transporter et \u00e0 explorer par imagerie et peuvent donc avoir \u00e9t\u00e9 sous-diagnostiqu\u00e9s.", "methods": "Investiguer l'incidence et le spectre des r\u00e9sultats de neuro-imagerie et leur r\u00f4le pronostique chez les patients Covid-19 hospitalis\u00e9s dans la ville de New York.", "topics": ["Pronostique", "Neurologie"], "author_list": [{"id": 577, "name": "Jain R"}], "publication_date": "2020-05-22"}, {"id": 367, "slug": "sequential-analysis-of-viral-load-in-a-neonate-and-her-mother-infected-with-sars", "title": "Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Case report sur l'analyse de la charge virale chez un nouveau-n\u00e9 et sa m\u00e8re, tous les 2 symptomatiques avec infection SARS-COV 2", "verbose_date": "18.04.2020", "authors": "Han MS", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}, {"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 24, "name": "Clin Infect Dis"}, "link": "https://www.dropbox.com/s/ap2qkl7n0i1yifz/ciaa447.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Nouveau-n\u00e9 symptomatique, RNA positive dans nasopharynx, oropharynx, selles, salive, plasma, urines. Diminution progressive dans le Nasopharynx alors que reste \u00e9lev\u00e9e dans les selles. Evolution favorable m\u00e8re et nouveau-n\u00e9 sans traitement sp\u00e9cifique. Infection syst\u00e9mique chez le nouveau-n\u00e9 (tous pr\u00e9l\u00e8vements positifs)? Hygi\u00e8ne capitale car charge virale positive longtemps dans les selles.", "objectives": "Case report", "methods": "Case report sur l'analyse de la charge virale chez un nouveau-n\u00e9 et sa m\u00e8re, tous les 2 symptomatiques avec infection SARS-COV 2", "topics": ["Pronostique", "Virologie", "Infectiologie", "Gyn\u00e9cologie Obst\u00e9trique", "P\u00e9diatrie"], "author_list": [{"id": 354, "name": "Han MS"}], "publication_date": "2020-04-18"}, {"id": 505, "slug": "epidemiological-and-clinical-features-of-asymptomatic-patients-with-sars-cov-2-i", "title": "Epidemiological and clinical features of asymptomatic patients with SARS-CoV-2 infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier les caract\u00e9ristiques \u00e9pid\u00e9miologiques et cliniques des patients infect\u00e9s par le SARS-CoV-2 sans aucun sympt\u00f4me tout du long de l'infection.", "verbose_date": "02.05.2020", "authors": "Xu T", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25944", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude, 15 patients asymptomatiques (sur 342 patients avec infection \u00e0 SARS-CoV-2 confirm\u00e9e), 10 ont pr\u00e9sent\u00e9 des anomalies biologiques, 8 des anomalies radiologiques.\nLes patients ne pr\u00e9sentant aucun sympt\u00f4me mais expos\u00e9s devraient \u00eatre test\u00e9s pour le SARS-CoV-2 par des pr\u00e9l\u00e8vements en naso-pharyng\u00e9 mais \u00e9galement en rectal.\nLes patients asymptomatiques infect\u00e9s par le SRAS-CoV-2 avaient dans cette \u00e9tude des issues favorables.", "objectives": "1) Pre-proof2) Etude uniquement descriptive, r\u00e9trospective3) 15 patients \u00e9tudi\u00e9s, asymptomatiques tout du long de l'infection4) Examen des dossiers m\u00e9dicaux par au moins deux personnes. Donn\u00e9es recoup\u00e9es et si incoh\u00e9rence, contact des m\u00e9decins responsables des patients5) Multicentrique", "methods": "Etudier les caract\u00e9ristiques \u00e9pid\u00e9miologiques et cliniques des patients infect\u00e9s par le SARS-CoV-2 sans aucun sympt\u00f4me tout du long de l'infection.", "pubmed_id": "32346873\n31978945\n32109013\n32145766\n31502247\n32134800\n32087116\n32003551\n31986264\n32112886", "doi": "10.1002/jmv.25944", "abstract": "Few studies reported the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients with completely asymptomatic throughout the disease course. We investigated the epidemiological and clinical features of patients infected by SARS-CoV-2 without any symptoms. Patients with confirmed SARS-CoV-2 infection were retrospectively recruited. The demographic characteristics, clinical data, treatment, and outcomes of SARS-CoV-2 infected patients without any symptoms were analyzed. Fifteen (4.4%) of 342 SARS-CoV-2 infected patients did not develop any symptom during the course of the disease. The median time from exposure to diagnosis was 7.0 days (interquartile range [IQR]: 1.0-15.0 days). Of the 15 patients, 14 patients were diagnosed by tested positive for SARS-CoV-2 in throat swabs, while one patient was only tested positive for SARS-CoV-2 in anal swabs. During hospitalization, only 1 (6.7%) patient developed lymphopenia. Abnormalities of chest computed tomography examinations were detected in 8 (53.4%) patients on admission. As of 8 March 2020, all patients have been discharged. The median time of SARS-CoV-2 tested negative from admission was 7.0 days (IQR: 4.0-9.0 days). Patients without any symptoms but with SARS-CoV-2 exposure should be closely monitored and tested for SARS-CoV-2 both in anal and throat swabs to excluded the infection. Asymptomatic patients infected by SARS-CoV-2 have favorable outcomes.", "topics": ["Epid\u00e9miologique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 473, "name": "Xu T"}], "publication_date": "2020-05-02"}, {"id": 588, "slug": "manifestations-and-prognosis-of-gastrointestinal-and-liver-involvement-in-patien", "title": "Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la pr\u00e9valence des sympt\u00f4mes gastrointestinaux et h\u00e9patiques chez les patients avec le Covid-19.", "verbose_date": "14.05.2020", "authors": "Mao R", "specialties": [{"id": 19, "name": "H\u00e9pato-gastro-ent\u00e9rologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 235, "name": "Lancet Gastro Enterol"}, "link": "https://www.thelancet.com/action/showPdf?pii=S2468-1253%2820%2930126-6", "findings": "", "take_away": "", "relevance_level": "Les sympt\u00f4mes digestifs et h\u00e9patiques ne sont pas marginaux chez les patients COVID-19 et semblent \u00eatre li\u00e9s \u00e0 la s\u00e9v\u00e9rit\u00e9 de la maladie.", "objectives": "-M\u00e9ta-Analyse conduite dans les r\u00e8gles, mais-Toutes les \u00e9tudes incluses de mauvaises qualit\u00e9-Pas de possibilit\u00e9 de prise en compte du sexe, de l'\u00e2ge, et des comorbidit\u00e9s-Crit\u00e8re pour la s\u00e9v\u00e9rit\u00e9 du Covid-19 pouvant varier selon les \u00e9tudes-H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 tr\u00e8s significative selon les sympt\u00f4mes analys\u00e9s, \u00e9tudi\u00e9e via des analyses en sous-groupe-Biais de publication retrouv\u00e9", "methods": "Etudier la pr\u00e9valence des sympt\u00f4mes gastrointestinaux et h\u00e9patiques chez les patients avec le Covid-19.", "pubmed_id": "32405603\n32085846\n32037389\n32171076\n32112884\n32105637\n9310563\n32178768\n31986264\n32048163\n32182409\n32284613\n31986261\n32145190\n32199469\n32107577\n32087098\n31995857\n32075786\n32105638\n32187458\n32004427\n32007143\n32027573", "doi": "10.1016/S2468-1253(20)30126-6", "abstract": "The prevalence and prognosis of digestive system involvement, including gastrointestinal symptoms and liver injury, in patients with COVID-19 remains largely unknown. We aimed to quantify the effects of COVID-19 on the digestive system.\nIn this systematic review and meta-analysis, we systematically searched PubMed, Embase, and Web of Science for studies published between Jan 1, 2020, and April 4, 2020. The websites of WHO, CDC, and major journals were also searched. We included studies that reported the epidemiological and clinical features of COVID-19 and the prevalence of gastrointestinal findings in infected patients, and excluded preprints, duplicate publications, reviews, editorials, single case reports, studies pertaining to other coronavirus-related illnesses, and small case series (<10 cases). Extracted data included author; date; study design; country; patient demographics; number of participants in severe and non-severe disease groups; prevalence of clinical gastrointestinal symptoms such as vomiting, nausea, diarrhoea, loss of appetite, abdominal pain, and belching; and digestive system comorbidities including liver disease and gastrointestinal diseases. Raw data from studies were pooled to determine effect estimates.\nWe analysed findings from 35 studies, including 6686 patients with COVID-19, that met inclusion criteria. 29 studies (n=6064) reported gastrointestinal symptoms in patients with COVID-19 at diagnosis, and the pooled prevalence of digestive system comorbidities was 4% (95% CI 2-5; range 0-15; \nOur study showed that digestive symptoms and liver injury are not uncommon in patients with COVID-19. Increased attention should be paid to the care of this unique group of patients.\nNone.", "topics": ["Epid\u00e9miologique", "H\u00e9pato-gastro-ent\u00e9rologie"], "author_list": [{"id": 552, "name": "Mao R"}], "publication_date": "2020-05-14"}, {"id": 465, "slug": "prognostic-value-of-interleukin-6-c-reactive-protein-and-procalcitonin-in-patien", "title": "Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer si l\u2019IL-6, CRP et PCT sont des indicateurs s\u00e9rologiques pouvant \u00eatre utilis\u00e9s pour le diagnostic et l'orientation des d\u00e9cisions de traitement.", "verbose_date": "27.04.2020", "authors": "Liu F", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 143, "name": "J Clin Virol"}, "link": "https://www.dropbox.com/s/n2f1kmoypi5zvqm/10.1016%40j.jcv.2020.104370.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les taux s\u00e9riques d'IL-6 et de CRP ont une corr\u00e9lation significative avec la gravit\u00e9 de COVID-19.\r\nLes taux s\u00e9riques d'IL-6 et de CRP peuvent \u00eatre utilis\u00e9s comme facteurs ind\u00e9pendants pour pr\u00e9dire le risque de maladie.\r\nLa validit\u00e9 de la PCT n\u00e9cessite d'autres \u00e9tudes pour confirmer son caract\u00e8re pr\u00e9dictif de s\u00e9v\u00e9rit\u00e9", "objectives": "Etude pr\u00e9-proofMonocentrique, r\u00e9trospective, petit effectif Biais de manque de donn\u00e9es cliniques d\u00e9clar\u00e9esMAIS plusieurs \u00e9tudes retrouvent les m\u00eame r\u00e9sultats pour IL6 et CRP", "methods": "\u00c9valuer si l\u2019IL-6, CRP et PCT sont des indicateurs s\u00e9rologiques pouvant \u00eatre utilis\u00e9s pour le diagnostic et l'orientation des d\u00e9cisions de traitement.", "pubmed_id": "32344321\n26560024\n32031570\n23844114\n31986264\n24552665\n32035018\n29148856\n12813013\n21281676\n28277917\n29433841", "doi": "10.1016/j.jcv.2020.104370", "abstract": "The inflammatory response plays a critical role in coronavirus disease 2019 (COVID-19), and inflammatory cytokine storm increases the severity of COVID-19.\nTo investigate the ability of interleukin-6 (IL-6), C-reactive protein (CRP), and procalcitonin (PCT) to predict mild and severe cases of COVID-19.\nThis retrospective cohort study included 140 patients diagnosed with COVID-19 from January 18, 2020, to March 12, 2020. The study population was divided into two groups according to disease severity: a mild group (MG) (n\u2009=\u2009107) and a severe group (SG) (n\u2009=\u200933). Data on demographic characteristics, baseline clinical characteristics, and the levels of IL-6, CRP, and PCT on admission were collected.\nAmong the 140 patients, the levels of IL-6, CRP, and PCT increased in 95 (67.9 %), 91 (65.0 %), and 8 (5.7 %) patients on admission, respectively. The proportion of patients with increased IL-6, CRP, and PCT levels was significantly higher in the SG than in the MG. Cox proportional hazard model showed that IL-6 and CRP could be used as independent factors to predict the severity of COVID-19. Furthermore, patients with IL-6\u2009>\u200932.1\u2009pg/mL or CRP\u2009>\u200941.8\u2009mg/L were more likely to have severe complications.\nThe serum levels of IL-6 and CRP can effectively assess disease severity and predict outcome in patients with COVID-19.", "topics": ["Pronostique", "Infectiologie"], "author_list": [{"id": 115, "name": "Liu F"}], "publication_date": "2020-04-27"}, {"id": 64, "slug": "sars-cov-2-infection-in-children", "title": "SARS-CoV-2 Infection in Children", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques \u00e9pid\u00e9miologiques, cliniques et radiologiques en p\u00e9diatrie", "verbose_date": "18.03.2020", "authors": "Lu X", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.dropbox.com/s/1dpxkgdcaxsngtp/nejmc2005073.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La plupart des enfants ont une forme simple, 16% de formes asymptomatiques, rares admissions en soins intensifs et d\u00e9c\u00e8s (enfants avec ant\u00e9c\u00e9dents)Signes cliniques les plus souvent pr\u00e9sents: toux, \u00e9ryth\u00e8me pharyng\u00e9, fi\u00e8vre, tachycardieSignes radiologiques: opacit\u00e9s en verre d\u00e9poli dans 1/3 des cas", "objectives": "Faible 1) Lettre \u00e0 l'\u00e9diteur2) n=171 & monocentrique mais seul centre d\u00e9sign\u00e9 pour traiter les moins de 16 ans \u00e0 Wuhan", "methods": "D\u00e9crire les caract\u00e9ristiques \u00e9pid\u00e9miologiques, cliniques et radiologiques en p\u00e9diatrie", "pubmed_id": "32187458", "doi": "10.1056/NEJMc2005073", "abstract": null, "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 74, "name": "Lu X"}], "publication_date": "2020-03-18"}, {"id": 429, "slug": "diagnostic-performance-between-ct-and-initial-real-time-rt-pcr-for-clinically-su", "title": "Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Comparaison des performances diagnostiques du TC scan thoracique et du test RT-PCR pour le diagnostic de COVID-19 dans les r\u00e9gions situ\u00e9es en dehors de la zone end\u00e9mique, en utilisant des tests RT-PCR r\u00e9p\u00e9t\u00e9s comme norme de r\u00e9f\u00e9rence.", "verbose_date": "23.04.2020", "authors": "He JL", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 180, "name": "Respir Med"}, "link": "https://www.resmedjournal.com/article/S0954-6111(20)30120-7/pdf", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude montre que la RT-PCR sur l'\u00e9chantillonnage des voies a\u00e9riennes et la TC scan ont une capacit\u00e9 bonne et similaire\u00a0\u00e0 diagnostiquer les patients COVID-19 dans les premiers stades (sensibilit\u00e9 de 79% et 77% respectivement) en dehors des zones end\u00e9miques.\r\nLes auteurs recommandent, \u00e9tant donn\u00e9 la forte possibilit\u00e9 de faux n\u00e9gatifs dans les deux m\u00e9thodes, d'utiliser la TC scan pour les patients suspects de COVID-19 avec une RT-PCR initiale n\u00e9gative (l'utilisation simultan\u00e9e des deux m\u00e9thodes a une sensibilit\u00e9 de 94% vs sensibilit\u00e9 de 79% pour RT-PCR seul).", "objectives": "1) \u00e9tude de cohorte r\u00e9trospective monocentrique2) petit \u00e9chantillon (n=82, COVID+ 34, COVID- 48)3) les scanners sont \u00e9valu\u00e9s par des radiologues form\u00e9s \u00e0 la lecture des imageries COVID-19 sp\u00e9cifiques mais travaillant en dehors de la zone d'\u00e9pid\u00e9mie (possible biais d\u00fb \u00e0 l'exp\u00e9rience)4) les kits RT-PCR utilis\u00e9s pour le diagnostic ont \u00e9t\u00e9 d\u00e9velopp\u00e9s en urgence et n'ont peut-\u00eatre pas \u00e9t\u00e9 test\u00e9s de mani\u00e8re ad\u00e9quate (n\u00e9cessit\u00e9 d'utiliser un meilleur standard)\"", "methods": "Comparaison des performances diagnostiques du TC scan thoracique et du test RT-PCR pour le diagnostic de COVID-19 dans les r\u00e9gions situ\u00e9es en dehors de la zone end\u00e9mique, en utilisant des tests RT-PCR r\u00e9p\u00e9t\u00e9s comme norme de r\u00e9f\u00e9rence.", "pubmed_id": "32364959", "doi": "10.1016/j.rmed.2020.105980", "abstract": "Chest CT is thought to be sensitive but less specific in diagnosing the 2019 coronavirus disease (COVID-19). The diagnostic value of CT is unclear. We aimed to compare the performance of CT and initial RT-PCR for clinically suspected COVID-19 patients outside the epicentre-Wuhan, China.\nPatients clinically suspected of COVID-19 infection who underwent initial RT-PCR and chest CT at the same time were retrospectively enrolled. Two radiologists with specific training reviewed the CT images independently and final diagnoses of the presence or absence of COVID-19 was reached by consensus. With serial RT-PCR as reference standard, the performance of initial RT-PCR and chest CT was analysed. A strategy of combining initial RT-PCR and chest CT was analysed to study the additional benefit.\n82 patients admitted to hospital between Jan 10, 2020 to Feb 28, 2020 were enrolled. 34 COVID-19 and 48 non-COVID-19 patients were identified by serial RT-PCR. The sensitivity, specificity was 79% (27/34) and 100% (48/48) for initial RT-PCR and 77% (26/34) and 96% (46/48) for chest CT. The image readers had a good interobserver agreement with Cohen's kappa of 0.69. No statistical difference was found in the diagnostic performance between initial RT-PCR and chest CT. The comprehensive strategy had a higher sensitivity of 94% (32/34).\nInitial RT-PCR and chest CT had comparable diagnostic performance in identification of suspected COVID-19 patients outside the epidemic center. To compensate potential risk of false-negative PCR, chest CT should be applied for clinically suspected patients with negative initial RT-PCR.", "topics": ["Diagnostique", "Virologie", "Radiologie"], "author_list": [{"id": 408, "name": "He JL"}], "publication_date": "2020-04-23"}, {"id": 218, "slug": "the-experience-of-high-flow-nasal-cannula-in-hospitalized-patients-with-2019-nov", "title": "The Experience of High-Flow Nasal Cannula in Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Two Hospitals of Chongqing, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Rapporter l'exp\u00e9rience de HFNC (canule nasale \u00e0 haut d\u00e9bit)", "verbose_date": "01.04.2020", "authors": "Wang K ", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 58, "name": "Ann Intensive Care"}, "link": "https://www.dropbox.com/s/fz6162fm011udpf/s13613-020-00653-z.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "HFNC \u00e9tait le mode de ventilation le plus utilis\u00e9 chez les patients ayant une pneumopathie.\r\nLes patients ayant un rapport PaO2/FiO2 faibles sont plus susceptible de pr\u00e9senter un \u00e9chec de l'HFNC.\r\nLe taux d'intubation \u00e9tait de 15% chez les patients pr\u00e9sentant une pneumopathie avec SDRA.", "objectives": "- Pas de d\u00e9finition pr\u00e9alable sur l'utilisation de HFNC- Transition vers VNI/Intubation d\u00e9cid\u00e9e par les cliniciens (opinions et mode d'exercice diff\u00e9rents)- Faible nombre de patients : 27\"", "methods": "Rapporter l'exp\u00e9rience de HFNC (canule nasale \u00e0 haut d\u00e9bit)", "pubmed_id": "32232685\n32070465\n32061312\n31167660\n32064853\n32030925\n26647455\n30705129\n32004427\n28701227\n32031570\n25981908\n32057211\n28807988\n31986261\n32015507\n31995857\n31744865\n32007143\n32067043", "doi": "10.1186/s13613-020-00653-z", "abstract": "The outbreak of a novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) is currently ongoing in China. Most of the critically ill patients received high-flow nasal cannula (HFNC) oxygen therapy. However, the experience of HFNC in this population is lacking.\nWe retrospectively screened 318 confirmed patients with NCIP in two hospitals of Chongqing, China, from January 1st to March 4th, 2020. Among them, 27 (8.4%) patients experienced severe acute respiratory failure including 17 patients (63%) treated with HFNC as first-line therapy, 9 patients (33%) treated with noninvasive ventilation (NIV) and one patient (4%) treated with invasive ventilation. HFNC failure was defined by the need of NIV or intubation as rescue therapy.\nOf the 17 HFNC patients, 7 (41%) experienced HFNC failure. The HFNC failure rate was 0% (0/6) in patients with PaO\nOur study indicated that HFNC was the most common ventilation support for patients with NCIP. Patients with lower PaO", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 209, "name": "Wang K "}], "publication_date": "2020-04-01"}, {"id": 120, "slug": "the-effect-of-travel-restrictions-on-the-spread-of-the-2019novel-coronavirus-cov", "title": "The effect of travel restrictions on the spread of the 2019novel coronavirus (COVID-19) outbreak.", "has_other_authors": true, "impact_factor": {"id": 5, "name": "Fort", "posts_count": 5, "color": "green", "order": 1}, "goals_plain": "Mod\u00e9liser l'effet des restrictions de circulation sur la transmission du virus", "verbose_date": "06.03.2020", "authors": "Chinazzi e", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 66, "name": "Science"}, "link": "https://www.dropbox.com/s/zvuj4h7mo22muuo/science.aba9757.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Int\u00e9r\u00eat des restrictions de circulation surtout pour la transmission internationale\r\nRalentit le pic \u00e9pid\u00e9mique de 3 \u00e0 5 jours\r\nImportance des restrictions de d\u00e9placement intra-communautaires pour une efficacit\u00e9 des mesures", "objectives": "Forte : 1) Mod\u00e9lisation robuste bas\u00e9e sur l'ensemble des donn\u00e9es disponibles en Chine2) M\u00e9thodologie satisfaisante3) Mais se base uniquement sur les donn\u00e9es officielles chinoises...", "methods": "Mod\u00e9liser l'effet des restrictions de circulation sur la transmission du virus", "pubmed_id": "32144116\n12766206\n32309796\n23341757\n32014114\n32019669\n32007643\n32053479\n17183647\n31986264\n19744314\n32144116\n28442561\n32046819\n20018697\n12766207\n31995857\n32234804\n25642360\n21415939", "doi": "10.1126/science.aba9757", "abstract": "Motivated by the rapid spread of coronavirus disease 2019 (COVID-19) in mainland China, we use a global metapopulation disease transmission model to project the impact of travel limitations on the national and international spread of the epidemic. The model is calibrated on the basis of internationally reported cases and shows that, at the start of the travel ban from Wuhan on 23 January 2020, most Chinese cities had already received many infected travelers. The travel quarantine of Wuhan delayed the overall epidemic progression by only 3 to 5 days in mainland China but had a more marked effect on the international scale, where case importations were reduced by nearly 80% until mid-February. Modeling results also indicate that sustained 90% travel restrictions to and from mainland China only modestly affect the epidemic trajectory unless combined with a 50% or higher reduction of transmission in the community.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 126, "name": "Chinazzi e"}], "publication_date": "2020-03-06"}, {"id": 394, "slug": "sars-cov-2-isolation-from-ocular-secretions-of-a-patient-with-covid-19-in-italy-", "title": "SARS-CoV-2 Isolation From Ocular Secretions of a Patient With COVID-19 in Italy With Prolonged Viral RNA Detection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Pr\u00e9senter un cas de d\u00e9tection pr\u00e9coce du SARS-CoV-2 dans les s\u00e9cr\u00e9tions oculaires chez un patient italien COVID-19", "verbose_date": "20.04.2020", "authors": "Colavita F", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 41, "name": "Ann Intern Med"}, "link": "https://annals.org/aim/fullarticle/2764963/sars-cov-2-isolation-from-ocular-secretions-patient-covid-19", "findings": "", "take_away": "", "relevance_level": "Description d'un case report avec conjonctivite dans le cadre d'une infection \u00e0 COVID-19. L'ARN viral a \u00e9t\u00e9 d\u00e9tect\u00e9 dans les pr\u00e9l\u00e8vements oculaires avec une concentration importante jusqu'\u00e0 pr\u00e8s d'un mois apr\u00e8s le d\u00e9but des sympt\u00f4mes et alors que les pr\u00e9l\u00e8vements naso-pharyng\u00e9s s'\u00e9taient n\u00e9gativ\u00e9s.", "objectives": "Case report", "methods": "Pr\u00e9senter un cas de d\u00e9tection pr\u00e9coce du SARS-CoV-2 dans les s\u00e9cr\u00e9tions oculaires chez un patient italien COVID-19", "pubmed_id": "32302380", "doi": "10.7326/M20-1176", "abstract": null, "topics": ["Diagnostique", "Transversale", "Virologie", "Infectiologie"], "author_list": [{"id": 378, "name": "Colavita F"}], "publication_date": "2020-04-20"}, {"id": 337, "slug": "covid-19-in-a-patient-with-long-term-use-of-glucocorticoids-a-study-of-a-familia", "title": "COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les particularit\u00e9s de l\u2019\u00e9volution naturelle de l\u2019infection \u00e0 Covid-19 chez une patiente trait\u00e9e par corticoth\u00e9rapie au long cours et la transmission virale \u00e0 ses proches ", "verbose_date": "15.04.2020", "authors": "Han YN", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 90, "name": "Clin Immunol"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1521661620302059?token=94AD7EBF5785B7F7A8EE7DBB67164DFF4DB3990DEF1FC69B9EF9E509BEA3D55C6687F3EEAD97DB3F8658B77E9AA3B0DC", "findings": "", "take_away": "", "relevance_level": "P\u00e9riode d\u2019incubation extr\u00eamement longue pour le cas index (28 jours alors que m\u00e9diane de 4-5,2 jours) et sympt\u00f4mes atypiques (rhinorrh\u00e9e, discr\u00e8te toux) dans le cadre d\u2019une immunod\u00e9pression aux cortico\u00efdes. De plus les anomalies biologiques et scannographiques semblent prolong\u00e9es.\u00a0\r\nLes auteurs recommandent donc une quarantaine stricte pour tout cas expos\u00e9 malgr\u00e9 l\u2019absence de sympt\u00f4me et sup\u00e9rieure \u00e0 14 jours si notion de traitement au long cours par cortico\u00efdes.", "objectives": "Etude de cas, pas d\u2019explication physio-pathologique dans l\u2019\u00e9tude pour appuyer les arguments avanc\u00e9s", "methods": "D\u00e9crire les particularit\u00e9s de l\u2019\u00e9volution naturelle de l\u2019infection \u00e0 Covid-19 chez une patiente trait\u00e9e par corticoth\u00e9rapie au long cours et la transmission virale \u00e0 ses proches", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 250, "name": "Han YN"}], "publication_date": "2020-04-15"}, {"id": 284, "slug": "excess-cases-of-influenza-like-illnesses-synchronous-with-coronavirus-disease-co", "title": "Excess cases of influenza-like illnesses synchronous with coronavirus disease (COVID-19) epidemic, France, March 2020", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Etudier la propagation de l'\u00e9pid\u00e9mie de COVID-19 en France (par r\u00e9gions) via les r\u00e9seaux sentinelles", "verbose_date": "09.04.2020", "authors": "Bo\u00eblle PY", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 46, "name": "Eurosurveillance"}, "link": "https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/25/14/eurosurv-25-14-4.pdf?expires=1586506300&id=id&accname=guest&checksum=E264476B6191525D8E21CFD01A4B4A13", "findings": "", "take_away": "", "relevance_level": "Exc\u00e8s de consultation pour syndrome grippal ou maladie respiratoire aigu\u00eb retrouv\u00e9 en France \u00e0 partir de d\u00e9but mars (semaine 9 et 19) avec une croissance rapide dans plusieurs r\u00e9gions fran\u00e7aises simultan\u00e9ment, plus de 15 jours apr\u00e8s le pic \u00e9pid\u00e9mique de la grippe saisonni\u00e8re.\r\nLes r\u00e9gions les plus touch\u00e9es par cet exc\u00e8s de consultation \u00e9tait dans l'ordre : Hauts-de-France, Centre-Val-de-Loire, Auvergne-Rh\u00f4ne-Alpes, puis Grand-Est et Ile-de-France.", "objectives": "- R\u00e9seau Sentinelles fiable en France- Couvre l'ensemble du territoire- Mauvaise corr\u00e9lation entre les consultations et les cas confirm\u00e9s\"", "methods": "Etudier la propagation de l'\u00e9pid\u00e9mie de COVID-19 en France (par r\u00e9gions) via les r\u00e9seaux sentinelles", "pubmed_id": "32290901\n32070465\n30703528\n28830105\n18401408\n30428158\n21909366\n1983924", "doi": "10.2807/1560-7917.ES.2020.25.14.2000326", "abstract": "Several French regions where coronavirus disease (COVID-19) has been reported currently show a renewed increase in ILI cases in the general practice-based ", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 272, "name": "Bo\u00eblle PY"}], "publication_date": "2020-04-09"}, {"id": 181, "slug": "prevalence-and-impact-of-diabetes-among-people-infected-with-sars-cov-2", "title": "Prevalence and Impact of Diabetes Among People Infected With SARS-CoV-2", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Faire le point sur la pr\u00e9valence du diab\u00e8te et son impact chez les sujets infect\u00e9s par le SARS-CoV-2 \u00e0 l'aide des donn\u00e9es disponibles le 19/03/2020", "verbose_date": "28.03.2020", "authors": "Fadini GP ", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}, {"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 92, "name": "J Endocrinol Invest"}, "link": "https://www.dropbox.com/s/b999dbaauwxpuc3/Fadini2020_Article_PrevalenceAndImpactOfDiabetesA.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "D'apr\u00e8s cet article les sujets diab\u00e9tiques n'auraient pas de sur-risque d'infection par le SARS-CoV-2, par contre, une fois infect\u00e9s, ils semblent pr\u00e9senter des \u00e9volutions plus p\u00e9joratives que les non-diab\u00e9tiques. Ces observations sont \u00e0 confirmer sur des donn\u00e9es portant \u00e9galement sur des sujets non-hospitalis\u00e9s.", "objectives": "1) Repr\u00e9sentativit\u00e9 : patients hospitalis\u00e9s essentiellement (dont l'\u00e9tude sur 1099 patients): quelle influence des patients diab\u00e9tiques peu graves en quarantaine \u00e0 domicile sur ces r\u00e9sultats? (-)2) Tous les patients avaient une confirmation du diagnostic par RT-PCR (+)3) Effectif total cons\u00e9quent (+)", "methods": "Faire le point sur la pr\u00e9valence du diab\u00e8te et son impact chez les sujets infect\u00e9s par le SARS-CoV-2 \u00e0 l'aide des donn\u00e9es disponibles le 19/03/2020", "pubmed_id": "32222956", "doi": "10.1007/s40618-020-01236-2", "abstract": null, "topics": ["Epid\u00e9miologique", "Cardiologie et maladies m\u00e9taboliques", "Transversale"], "author_list": [{"id": 175, "name": "Fadini GP "}], "publication_date": "2020-03-28"}, {"id": 562, "slug": "association-of-treatment-dose-anticoagulation-with-in-hospital-survival-among-ho", "title": "Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'effet d'une anticoagulation syst\u00e9mique [pr\u00e9ventive ou curative?] (par voie orale, sous-cutan\u00e9e ou intraveineuse) sur la mortalit\u00e9 intra-hospitali\u00e8re de patients COVID-19.", "verbose_date": "11.05.2020", "authors": "Paranjpe I", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 222, "name": "JACC"}, "link": "https://doi.org/10.1016/j.jacc.2020.05.001", "findings": "", "take_away": "", "relevance_level": "Sous r\u00e9serve d'un article pre-proof portant sur une \u00e9tude semblant de faible qualit\u00e9 m\u00e9thodologique :\n- La mise en place d'une anticoagulation chez les patients COVID-19 hospitalis\u00e9s semble \u00eatre associ\u00e9e avec un allongement de la dur\u00e9e m\u00e9diane de survie.\n- La dur\u00e9e de l'anticoagulation semble associ\u00e9e \u00e0 la mortalit\u00e9 intra-hospitali\u00e8re avec HR=0,86 (p<0,001).\n- Il ne semble pas y avoir dans cette \u00e9tude de diff\u00e9rence statistiquement significative en termes d'\u00e9v\u00e8nements h\u00e9morragiques graves entre les patients anticoagul\u00e9s et ceux qui ne l'\u00e9taient pas.", "objectives": "- \u00c9tude observationnelle descriptive- Pre-proof et pas de description d\u00e9taill\u00e9e des m\u00e9thodes - Tr\u00e8s probables biais de confusion (dont biais d'indication)", "methods": "Evaluer l'effet d'une anticoagulation syst\u00e9mique [pr\u00e9ventive ou curative?] (par voie orale, sous-cutan\u00e9e ou intraveineuse) sur la mortalit\u00e9 intra-hospitali\u00e8re de patients COVID-19.", "pubmed_id": "32387623", "doi": "10.1016/j.jacc.2020.05.001", "abstract": null, "topics": ["Th\u00e9rapeutique", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 527, "name": "Paranjpe I"}], "publication_date": "2020-05-11"}, {"id": 182, "slug": "clinical-characteristics-of-54-medical-staff-with-covid-19-a-retrospective-study", "title": "Clinical Characteristics of 54 Medical Staff With COVID-19: A Retrospective Study in a Single Center in Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire la COVID-19 chez les soignants infect\u00e9s ainsi que leurs caract\u00e9ristiques socio-d\u00e9mographiques", "verbose_date": "29.03.2020", "authors": "Chu J ", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25793", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude 80% des soignants atteints par le COVID-19 pr\u00e9sentaient une forme s\u00e9v\u00e8re ou critique. La plupart des soignants travaillaient dans des services cliniques hors-urgences dans lesquels le niveau d'alerte vis-\u00e0-vis du risque de transmission \u00e9tait s\u00fbrement moindre. Il faudrait donc sensibiliser davantage ces soignants et \u00eatre en mesure de leur fournir suffisamment d'\u00e9quipement de protection personnelle.", "objectives": "1) Diagnostic d'infection parfois seulement clinique2) Faible effectif3) Tests multiples sans correction de l'inflation du risque alpha", "methods": "D\u00e9crire la COVID-19 chez les soignants infect\u00e9s ainsi que leurs caract\u00e9ristiques socio-d\u00e9mographiques", "topics": ["Epid\u00e9miologique", "Transversale", "Virologie"], "author_list": [{"id": 176, "name": "Chu J "}], "publication_date": "2020-03-29"}, {"id": 619, "slug": "safety-tolerability-and-immunogenicity-of-a-recombinant-adenovirus-type-5-vector", "title": "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'innocuit\u00e9, la tol\u00e9rabilit\u00e9 et l'immunog\u00e9nicit\u00e9 d'un vaccin recombinant \u00e0 ad\u00e9novirus de type 5 exprimant la glycoprot\u00e9ine de pointe d'une souche de SARS-CoV-2.", "verbose_date": "23.05.2020", "authors": "Zhu FC", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931208-3", "findings": "", "take_away": "", "relevance_level": "Le vaccin COVID-19 vectoris\u00e9 par ad\u00e9novirus de type 5 est tol\u00e9rable et immunog\u00e8ne \u00e0 J28 apr\u00e8s la vaccination. Les r\u00e9ponses humorales contre le SARS-CoV-2 ont culmin\u00e9 \u00e0 J28 apr\u00e8s la vaccination chez des adultes en bonne sant\u00e9, et des r\u00e9ponses rapides sp\u00e9cifiques aux cellules T ont \u00e9t\u00e9 not\u00e9es \u00e0 partir de J14.\nLe vaccin \u00e0 forte dose avait tendance \u00e0 \u00eatre plus immunog\u00e8ne que les vaccins \u00e0 dose moyenne et \u00e0 faible dose, il \u00e9tait \u00e9galement associ\u00e9 \u00e0 une r\u00e9actog\u00e9nicit\u00e9 plus \u00e9lev\u00e9e. Une fi\u00e8vre s\u00e9v\u00e8re, de la fatigue, une dyspn\u00e9e, des douleurs musculaires et des douleurs articulaires ont \u00e9t\u00e9 signal\u00e9es chez certains des receveurs du groupe \u00e0 forte dose.", "objectives": "Etude de phase 1, monocentrique, non randomis\u00e9e, en ouvert, analyse en intention de traiter, n=108Etude pr\u00e9liminaire, avec suivi des 28 premiers joursR\u00e9alisation de l'\u00e9tude dans un \"centre de r\u00e9adaptation\" ?Autod\u00e9claration des effets ind\u00e9sirables dans les 28 jours, avec v\u00e9rification par les enqu\u00eateurs au cours des 14 premiers joursEnviron la moiti\u00e9 des participants dans les 3 groupes avaient un titre pr\u00e9existant d'anticorps neutralisant Ad5 \u00e9lev\u00e9 ( > 1: 200).Aucun participant n'avait plus de 60 ans et seulement 17 participants avaient plus de 50 ans (16%)Quatorzaine des participants apr\u00e8s la vaccination, vu la circulation active du virus \u00e0 Wuhan", "methods": "Evaluer l'innocuit\u00e9, la tol\u00e9rabilit\u00e9 et l'immunog\u00e9nicit\u00e9 d'un vaccin recombinant \u00e0 ad\u00e9novirus de type 5 exprimant la glycoprot\u00e9ine de pointe d'une souche de SARS-CoV-2.", "pubmed_id": "32450106", "doi": "10.1016/S0140-6736(20)31208-3", "abstract": "A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain.\nWe did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrolled and allocated to one of three dose groups (5\u2008\u00d7\u200810\nBetween March 16 and March 27, 2020, we screened 195 individuals for eligibility. Of them, 108 participants (51% male, 49% female; mean age 36\u00b73 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. All enrolled participants were included in the analysis. At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83%) participants in the low dose group, 30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination.\nThe Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation.\nNational Key R&D Program of China, National Science and Technology Major Project, and CanSino Biologics.", "topics": ["Th\u00e9rapeutique", "Immunit\u00e9", "Transversale"], "author_list": [{"id": 582, "name": "Zhu FC"}], "publication_date": "2020-05-23"}, {"id": 434, "slug": "safety-and-immunogenicity-of-a-candidate-middle-east-respiratory-syndrome-corona", "title": "Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluation de la s\u00e9curit\u00e9 et de l'immunog\u00e9nicit\u00e9 du vaccin ChAdOx1 pour MERS dans l'esp\u00e8ce humaine.", "verbose_date": "22.04.2020", "authors": "Folegatti PM", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 74, "name": "Lancet Infect Dis"}, "link": "https://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(20)30160-2.pdf", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude, le vaccin ChAdOx1 s'est av\u00e9r\u00e9 s\u00fbr et bien tol\u00e9r\u00e9 \u00e0 toutes les doses test\u00e9es (la plupart des effets secondaires d\u00e9tect\u00e9s sont l\u00e9gers ou mod\u00e9r\u00e9s, et se r\u00e9solvent d'eux-m\u00eames dans tous les cas).\u00a0\r\nUne seule dose de vaccin \u00e9tait suffisante pour stimuler la r\u00e9ponse humorale et cellulaire contre MERS-CoV pour au moins un an.\r\nLes r\u00e9sultats obtenus soutiennent l'exp\u00e9rimentation du vaccin dans les essais cliniques de phase 1b et 2.", "objectives": "1) essai clinique ouvert, non randomis\u00e9, non contr\u00f4l\u00e9, de phase 1a2) petit \u00e9chantillon (n=24)3) suivi des patients pendant seulement 12 mois apr\u00e8s la vaccination4) donn\u00e9es limit\u00e9es concernant l'immunit\u00e9 pr\u00e9existante et la r\u00e9activit\u00e9 crois\u00e9e pour d'autres coronavirus\"", "methods": "Evaluation de la s\u00e9curit\u00e9 et de l'immunog\u00e9nicit\u00e9 du vaccin ChAdOx1 pour MERS dans l'esp\u00e8ce humaine.", "pubmed_id": "32325038\n8876144\n22275401\n30938227\n28579232\n25863564\n27269431\n31351922\n25456101\n30236531\n23831647\n23986586\n23075143\n27578435\n15507655\n27486736\n26692185\n29263883\n23785207\n26355094\n29519670\n18495857\n25629663", "doi": "10.1016/S1473-3099(20)30160-2", "abstract": "Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absence of currently available effective countermeasures. We aimed to assess the safety and immunogenicity of the candidate simian adenovirus-vectored vaccine expressing the full-length spike surface glycoprotein, ChAdOx1 MERS, in humans.\nThis dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial was done at the Centre for Clinical Vaccinology and Tropical Medicine (Oxford, UK) and included healthy people aged 18-50 years with negative pre-vaccination tests for HIV antibodies, hepatitis B surface antigen, and hepatitis C antibodies (and a negative urinary pregnancy test for women). Participants received a single intramuscular injection of ChAdOx1 MERS at three different doses: the low-dose group received 5\u2008\u00d7\u200810\nBetween March 14 and Aug 15, 2018, 24 participants were enrolled: six were assigned to the low-dose group, nine to the intermediate-dose group, and nine to the high-dose group. All participants were available for follow-up at 6 months, but five (one in the low-dose group, one in the intermediate-dose group, and three in the high-dose group) were lost to follow-up at 12 months. A single dose of ChAdOx1 MERS was safe at doses up to 5\u2008\u00d7\u200810\nChAdOx1 MERS was safe and well tolerated at all tested doses. A single dose was able to elicit both humoral and cellular responses against MERS-CoV. The results of this first-in-human clinical trial support clinical development progression into field phase 1b and 2 trials.\nUK Department of Health and Social Care, using UK Aid funding, managed by the UK National Institute for Health Research.", "topics": ["Th\u00e9rapeutique", "Immunit\u00e9", "Virologie", "Infectiologie"], "author_list": [{"id": 411, "name": "Folegatti PM"}], "publication_date": "2020-04-22"}, {"id": 399, "slug": "first-successful-treatment-of-covid-19-induced-refractory-cardiogenic-plus-vasop", "title": "First successful treatment of COVID-19 induced refractory cardiogenic plus vasoplegic shock by combination of pVAD and ECMO - a case report", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Case report: stabilisation apr\u00e8s SDRA et choc cardiog\u00e9nique/vasopl\u00e9gique suite \u00e0 l'implantation d'un pVAD (Impella) et ECMO", "verbose_date": "21.04.2020", "authors": "Bemtgen X", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 168, "name": "ASAIO Journal"}, "link": "https://www.dropbox.com/s/2dy6yw8u68gfkk0/First_successful_treatment_of_COVID_19_induced.98535.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Association d'une assistance cardiaque type Impella et ECMO veino-art\u00e9rielle puis veino-veineuse. Permettant un sevrage de l'assistance cardiaque. m\u00e9thode int\u00e9ressante hors afflux massif de malades pour des gens jeunes gravement atteints. mais le pronostic reste sur l'\u00e9volution du SDRA.", "objectives": "Case report", "methods": "Case report: stabilisation apr\u00e8s SDRA et choc cardiog\u00e9nique/vasopl\u00e9gique suite \u00e0 l'implantation d'un pVAD (Impella) et ECMO", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 382, "name": "Bemtgen X"}], "publication_date": "2020-04-21"}, {"id": 228, "slug": "our-italian-experience-using-lung-ultrasound-for-identification-grading-and-seri", "title": "Our Italian Experience Using Lung Ultrasound for Identification, Grading and Serial Follow-up of Severity of Lung Involvement for Management of Patients With COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Utilisation de l'\u00e9chographie pour identifier le degr\u00e9 d'atteinte pulmonaire chez les patients COVID-19 (diagnostic de la maladie pulmonaire, identification du degr\u00e9 de gravit\u00e9 et suivi de la maladie)", "verbose_date": "02.04.2020", "authors": "Vertrugno L", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 110, "name": "Echocardiography"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/echo.14664", "findings": "", "take_away": "", "relevance_level": "1) L'\u00e9chographie thoracique permet de diagnostiquer l'atteinte pulmonaire et la gravit\u00e9 de la maladie en attribuant un score \u00e0 chacun des 6 secteurs pulmonaires :\r\n- 0 point: poumon en bonne sant\u00e9\u00a0\r\n- 1 point: syndrome interstitiel\u00a0\r\n- 2 points: ventilation pulmonaire tr\u00e8s faible\r\n- 3 points: condensation pulmonaire\r\nLe score total peut varier de 0 point = poumon sain \u00e0 36 points = pire situation possible.\n\r\n2) L'\u00e9chographie thoracique est une technique de diagnostic s\u00fbre et rapide (un \u00e9chographiste exp\u00e9riment\u00e9 peut l'effectuer en 5 minutes) qui permet d'analyser le patient dans sa chambre d'h\u00f4pital.\n\r\n3) L'utilisation de l'\u00e9chographie thoracique permet de r\u00e9duire le nombre de radiographies et de scanners effectu\u00e9s sur le patient (N.b. la capacit\u00e9 \u00e0 distinguer la pneumonie bact\u00e9rienne de la pneumonie non bact\u00e9rienne est de 60% pour la radiographie pulmonaire et de 80% pour l'\u00e9chographie, comme l'ont d\u00e9montr\u00e9 des \u00e9tudes ant\u00e9rieures, mais il n'y a pas beaucoup d'\u00e9tudes men\u00e9es sur la pneumonie virale).\n\r\n4) Aucune image ultrasonore pathognomonique de COVID-19 n'a \u00e9t\u00e9 identifi\u00e9e.", "objectives": "1) Partage d'exp\u00e9rience2) Le nombre de patients sur lesquels l'examen a \u00e9t\u00e9 effectu\u00e9 n'est pas connu 3) Le r\u00e9sultat de l'\u00e9chographie n'est pas compar\u00e9 au r\u00e9sultat du scanner ou des images radiographiques sur le m\u00eame patient", "methods": "Utilisation de l'\u00e9chographie pour identifier le degr\u00e9 d'atteinte pulmonaire chez les patients COVID-19 (diagnostic de la maladie pulmonaire, identification du degr\u00e9 de gravit\u00e9 et suivi de la maladie)", "pubmed_id": "32239532\n26298866\n25501898\n31977519\n31784642\n31405211\n22340202\n24158410\n28903756\n2656052", "doi": "10.1111/echo.14664", "abstract": "Lung ultrasound (LU) has rapidly become a tool for assessment of patients stricken by the novel coronavirus 2019 (COVID-19). Over the past two and a half months (January, February, and first half of March 2020) we have used this modality for identification of lung involvement along with pulmonary severity in patients with suspected or documented COVID-19 infection. Use of LU has helped us in clinical decision making and reduced the use of both chest x-rays and computed tomography (CT).", "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 218, "name": "Vertrugno L"}], "publication_date": "2020-04-02"}, {"id": 38, "slug": "transmission-of-covid-19-in-the-terminal-stage-of-incubation-period-a-familial-c", "title": "Transmission of COVID-19 in the terminal stage of incubation period: a familial cluster", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Eclairer le risque de transmission du SARS-CoV-2 durant la p\u00e9riode d'incubation \u00e0 l'aide d'un cas de cluster familial", "verbose_date": "20.03.2020", "authors": "Li P", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.dropbox.com/s/yg0sjlr5btwgid0/PIIS1201971220301466.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Transmission du SARS-CoV-2 probablement possible au moins d\u00e8s la fin de la p\u00e9riode d'incubation", "objectives": "Faible :1) Bas\u00e9 sur un unique cluster familial2) mais histoire \u00e9pid\u00e9miologique rigoureuse", "methods": "Eclairer le risque de transmission du SARS-CoV-2 durant la p\u00e9riode d'incubation \u00e0 l'aide d'un cas de cluster familial", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 48, "name": "Li P"}], "publication_date": "2020-03-20"}, {"id": 620, "slug": "remdesivir-for-the-treatment-of-covid-19-preliminary-report", "title": "Remdesivir for the Treatment of Covid-19 \u2014 Preliminary Report", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer l'efficacit\u00e9 et la s\u00e9curit\u00e9 du remdesivir dans le traitement de l'infection COVID-19", "verbose_date": "23.05.2020", "authors": "Beigel JH", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2007764?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Les r\u00e9sultats pr\u00e9liminaires de cet essai contr\u00f4l\u00e9 randomis\u00e9 en double aveugle permettent de mettre en \u00e9vidence une efficacit\u00e9 significative du remdesivir compar\u00e9 \u00e0 un placebo sur le d\u00e9lai de r\u00e9cup\u00e9ration et l'am\u00e9lioration clinique, en particulier sur des patients avec une forme mod\u00e9r\u00e9e du COVID-19.\u00a0L'effet sur la mortalit\u00e9 reste \u00e0 d\u00e9montrer et l'ensemble des r\u00e9sultats doit encore \u00eatre\u00a0confirm\u00e9 par l'analyse de l'ensemble des donn\u00e9es de cette \u00e9tude et par d'autres essais bien conduits.", "objectives": "Etude randomis\u00e9e contr\u00f4l\u00e9e en double aveugle de bon niveau mais :- R\u00e9sultats pr\u00e9liminaires avec peu de d\u00e9tails dans la m\u00e9thodologie de l'\u00e9tude concernant les crit\u00e8res d'inclusion des patients ou le calcul du nombre de sujet n\u00e9cessaire par exemple- Changement du crit\u00e8re de jugement principal en cours d'\u00e9tude sans explication sur l'incidence en termes de puissance notamment- Pas d'information sur la r\u00e9alisation d'une analyse en intention de traiter- Pas d'information sur les caract\u00e9ristiques des patients effectivement analys\u00e9s dans cette \u00e9tude pr\u00e9liminaire (analyse de l'ensemble des inclusions)", "methods": "Evaluer l'efficacit\u00e9 et la s\u00e9curit\u00e9 du remdesivir dans le traitement de l'infection COVID-19", "pubmed_id": "32445440\n24062443\n32187464\n32020029\n28659436\n31233808\n32423584\n32330277\n31924756\n32344679\n31037242\n29511076\n32054787", "doi": "10.1056/NEJMoa2007764", "abstract": "Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious.\nWe conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only.\nA total of 1063 patients underwent randomization. The data and safety monitoring board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who underwent randomization (27.0%).\nRemdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 ClinicalTrials.gov number, NCT04280705.).", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 583, "name": "Beigel JH"}], "publication_date": "2020-05-23"}, {"id": 514, "slug": "cardiovascular-disease-drug-therapy-and-mortality-in-covid-19", "title": "Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etude pronostique de la relation entre les maladies cardiovasculaires ainsi que leur traitement (IEC/ARA2/statines/\u00df-bloquants) avec la mortalit\u00e9 chez des patients COVID-19", "verbose_date": "03.05.2020", "authors": "Mandeep RM", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}, {"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2007621?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Attention : certains auteurs de cette \u00e9tude se sont r\u00e9tract\u00e9s entra\u00eenant le retrait de la publication du fait de l'impossibilit\u00e9 de v\u00e9rifier la fiabilit\u00e9 des donn\u00e9es sources issues de Surgisphere\nSur une large cohorte de patients hospitalis\u00e9s, les auteurs ont montr\u00e9 un taux de mortalit\u00e9 de 5,8% (4% en conventionnel et 24,7% en r\u00e9animation)\nLes facteurs protecteurs du d\u00e9c\u00e8s semblent \u00eatre la prise d'inhibiteurs de l'enzyme de conversion (IEC) et de statines avec des Odds Ratio inf\u00e9rieurs \u00e0 0,35\nLes facteurs augmentant le risque de d\u00e9c\u00e8s semblent \u00eatre les ant\u00e9c\u00e9dents cardiaques (coronaropathie, arythmie, insuffisance cardiaque) avec un risque multipli\u00e9 par plus de 2 et les pathologies pulmonaires avec la BPCO (risque multipli\u00e9 par 3) et le tabagisme actif (risque multipli\u00e9 par 2)\nL'\u00e2ge sup\u00e9rieur \u00e0 65 ans et le fait d'\u00eatre un homme sont \u00e9galement des facteurs de risque de d\u00e9c\u00e8s", "objectives": "- La plus grande cohorte actuellement \u00e9tudi\u00e9e avec m\u00e9thodologie robuste- Mais donn\u00e9es issues de registres dont la fiabilit\u00e9 n'est pas compl\u00e8tement \u00e9tablie \u00e0 ce jour, entra\u00eenant le retrait de cette publication- Pas de calcul de la puissance de l'\u00e9tude", "methods": "Etude pronostique de la relation entre les maladies cardiovasculaires ainsi que leur traitement (IEC/ARA2/statines/\u00df-bloquants) avec la mortalit\u00e9 chez des patients COVID-19", "pubmed_id": "32356626\n28619367\n32125452\n27546235\n27438105\n15283675\n32362390\n32142651\n32213097\n32219356\n28373583\n32155444\n32211816\n32360242\n15897343\n32293672\n14742282\n32191259\n32171062\n32208485", "doi": "10.1056/NEJMoa2007621", "abstract": "Coronavirus disease 2019 (Covid-19) may disproportionately affect people with cardiovascular disease. Concern has been aroused regarding a potential harmful effect of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) in this clinical context.\nUsing an observational database from 169 hospitals in Asia, Europe, and North America, we evaluated the relationship of cardiovascular disease and drug therapy with in-hospital death among hospitalized patients with Covid-19 who were admitted between December 20, 2019, and March 15, 2020, and were recorded in the Surgical Outcomes Collaborative registry as having either died in the hospital or survived to discharge as of March 28, 2020.\nOf the 8910 patients with Covid-19 for whom discharge status was available at the time of the analysis, a total of 515 died in the hospital (5.8%) and 8395 survived to discharge. The factors we found to be independently associated with an increased risk of in-hospital death were an age greater than 65 years (mortality of 10.0%, vs. 4.9% among those \u226465 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41), coronary artery disease (10.2%, vs. 5.2% among those without disease; odds ratio, 2.70; 95% CI, 2.08 to 3.51), heart failure (15.3%, vs. 5.6% among those without heart failure; odds ratio, 2.48; 95% CI, 1.62 to 3.79), cardiac arrhythmia (11.5%, vs. 5.6% among those without arrhythmia; odds ratio, 1.95; 95% CI, 1.33 to 2.86), chronic obstructive pulmonary disease (14.2%, vs. 5.6% among those without disease; odds ratio, 2.96; 95% CI, 2.00 to 4.40), and current smoking (9.4%, vs. 5.6% among former smokers or nonsmokers; odds ratio, 1.79; 95% CI, 1.29 to 2.47). No increased risk of in-hospital death was found to be associated with the use of ACE inhibitors (2.1% vs. 6.1%; odds ratio, 0.33; 95% CI, 0.20 to 0.54) or the use of ARBs (6.8% vs. 5.7%; odds ratio, 1.23; 95% CI, 0.87 to 1.74).\nOur study confirmed previous observations suggesting that underlying cardiovascular disease is associated with an increased risk of in-hospital death among patients hospitalized with Covid-19. Our results did not confirm previous concerns regarding a potential harmful association of ACE inhibitors or ARBs with in-hospital death in this clinical context. (Funded by the William Harvey Distinguished Chair in Advanced Cardiovascular Medicine at Brigham and Women's Hospital.).", "topics": ["Pronostique", "Cardiologie et maladies m\u00e9taboliques", "Transversale"], "author_list": [{"id": 482, "name": "Mandeep RM"}], "publication_date": "2020-05-03"}, {"id": 499, "slug": "elevated-interleukin-6-and-severe-covid-19-a-meta-analysis", "title": "Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "M\u00e9ta-analyse et revue syst\u00e9matique d\u00e9montrant l'association entre un taux d'IL-6 \u00e9lev\u00e9 et des formes s\u00e9v\u00e8res de COVID 19", "verbose_date": "30.04.2020", "authors": "Aziz M", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25948", "findings": "", "take_away": "", "relevance_level": "Les patients pr\u00e9sentant des formes s\u00e9v\u00e8res de COVID ont une IL-6 plus \u00e9lev\u00e9e que les autres (p<0,001). Une moyenne \u00e9lev\u00e9e d'IL-6 \u00e9tait aussi associ\u00e9e \u00e0 une surmortalit\u00e9 (p =0,03). Ce marqueur pourrait \u00eatre utilis\u00e9 pour d\u00e9pister les formes graves, dans le cadre d'un score de gravit\u00e9. Les anticorps anti-IL6 (tocilizumab) doivent \u00eatre explor\u00e9s dans cette indication.", "objectives": "9 \u00e9tudes observationnelles, pas d'information sur les comorbidit\u00e9s associ\u00e9es.", "methods": "M\u00e9ta-analyse et revue syst\u00e9matique d\u00e9montrant l'association entre un taux d'IL-6 \u00e9lev\u00e9 et des formes s\u00e9v\u00e8res de COVID 19", "pubmed_id": "32343429\n32217835\n32217556\n19368420\n29622697\n25190079", "doi": "10.1002/jmv.25948", "abstract": null, "topics": ["Pronostique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie"], "author_list": [{"id": 467, "name": "Aziz M"}], "publication_date": "2020-04-30"}, {"id": 326, "slug": "the-effect-of-corticosteroid-treatment-on-patients-with-coronavirus-infection-a-", "title": "The Effect of Corticosteroid Treatment on Patients With Coronavirus Infection: A Systematic Review and Meta-Analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Identifier le r\u00f4le de l\u2019utilisation de cortico\u00efdes chez patients atteints de pneumopathie \u00e0 coronavirus ainsi que leurs effets secondaires ", "verbose_date": "14.04.2020", "authors": "Yang Z", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.journalofinfection.com/article/S0163-4453(20)30191-2/pdf", "findings": "", "take_away": "", "relevance_level": "Les patients s\u00e9v\u00e8res seraient plus susceptibles de n\u00e9cessiter un traitement par cortico\u00efdes, ce qui est concordant avec l'utilisation possible des cortico\u00efdes en soins critiques en phase subaigu\u00eb fibro-prolif\u00e9rative d'un SDRA dans le cadre d'une r\u00e9ponse inflammatoire excessive.\r\nAugmentation de la mortalit\u00e9 et de la dur\u00e9e de s\u00e9jour qui serait associ\u00e9e \u00e0 l'utilisation de cortico\u00efdes, \u00e0 nuancer puisqu\u2019utilis\u00e9s chez les patients plus graves.\r\nEffets secondaires connus des cortico\u00efdes (infections bact\u00e9riennes, hypokali\u00e9mie).", "objectives": "Peu d\u2019articles (n=15), bas\u00e9 sur des \u00e9tudes de cohortes r\u00e9trospectives, biais de publication, aucun contr\u00f4le des autres traitements", "methods": "Identifier le r\u00f4le de l\u2019utilisation de cortico\u00efdes chez patients atteints de pneumopathie \u00e0 coronavirus ainsi que leurs effets secondaires", "pubmed_id": "32283144", "doi": "10.1016/j.jinf.2020.03.062", "abstract": "An outbreak of novel coronavirus in 2019 threatens the health of people, and there is no proven pharmacological treatment. Although corticosteroids were widely used during outbreaks of severe acute respiratory syndrome and Middle East respiratory syndrome, their efficacy remainedhighly controversial. We aimed to further evaluate the influence of corticosteroids on patients with coronavirus infection.\nWe conducted a comprehensive search of literature published in PubMed, Embase, Cochrane library, and China National Knowledge Infrastructure (CNKI) from January 1, 2002 to March 15, 2020. All statistical analyses in this study were performed on stata14.0.\nA total of 5270 patients from 15 studies were included in this meta-analysis. The result indicated that critical patients were more likely to require corticosteroids therapy (risk ratio [RR]\u202f=\u202f1.56, 95% confidence interval [CI]\u202f=\u202f1.28-1.90, P<0.001). However, corticosteroid treatment was associated with higher mortality (RR\u202f=\u202f2.11, 95%CI\u202f=\u202f1.13-3.94, P\u202f=\u202f0.019), longer length of stay (weighted mean difference [WMD]\u202f=\u202f6.31, 95%CI\u202f=\u202f5.26-7.37, P<0.001), a higher rate of bacterial infection (RR\u202f=\u202f2.08, 95%CI\u202f=\u202f1.54-2.81, P<0.001), and hypokalemia (RR\u202f=\u202f2.21, 95%CI\u202f=\u202f1.07-4.55, P\u202f=\u202f0.032) but not hyperglycemia (RR\u202f=\u202f1.37, 95%CI=0.68-2.76, P\u00a0=\u00a00.376) or hypocalcemia (RR\u202f=\u202f1.35, 95%CI\u202f=\u202f0.77-2.37, P\u202f=\u202f0.302).\nPatients with severe conditions are more likely to require corticosteroids. Corticosteroid use is associated with increased mortality in patients with coronavirus pneumonia.", "topics": ["Th\u00e9rapeutique", "Infectiologie", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie"], "author_list": [{"id": 313, "name": "Yang Z"}], "publication_date": "2020-04-14"}, {"id": 53, "slug": "aerosol-and-surface-stability-of-sars-cov-2-as-compared-with-sars-cov-1", "title": "Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la dur\u00e9e de survie du virus SARS-CoV-2 sur les surfaces", "verbose_date": "19.03.2020", "authors": "van Doremalen", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.dropbox.com/s/dqok2jq6zacev1i/nejmc2004973.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Demi-vie de plusieurs heures sur les surfacesVirus d\u00e9tectable encore 72h apr\u00e8s sur le m\u00e9tal ou le plastique", "objectives": "Faible : 1) Correspondance sans processus de blind reviewing2) Conditions exp\u00e9rimentales sur 5 surfaces3) Faible nombre d'exp\u00e9riences (n=10)", "methods": "Etudier la dur\u00e9e de survie du virus SARS-CoV-2 sur les surfaces", "pubmed_id": "32182409", "doi": "10.1056/NEJMc2004973", "abstract": null, "topics": ["Autres", "Transversale"], "author_list": [{"id": 63, "name": "van Doremalen"}], "publication_date": "2020-03-19"}, {"id": 558, "slug": "modeling-shield-immunity-to-reduce-covid-19-epidemic-spread", "title": "Modeling shield immunity to reduce COVID-19 epidemic spread", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Mod\u00e9liser les effets \u00e9pid\u00e9miologiques d\u2019une strat\u00e9gie de barri\u00e8re immunologique consistant en une substitution des contacts de fa\u00e7on pr\u00e9f\u00e9rentielle vers des personnes s\u00e9ropositives.", "verbose_date": "08.05.2020", "authors": "Weitz J", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 115, "name": "Nature Med"}, "link": "https://www.nature.com/articles/s41591-020-0895-3.pdf", "findings": "", "take_away": "", "relevance_level": "La barri\u00e8re immunologique ne devra pas \u00eatre vue comme une strat\u00e9gie unique mais un outil suppl\u00e9mentaire pour enrayer la pand\u00e9mie.\nCombin\u00e9e avec les distanciations sociales, cette barri\u00e8re pourrait r\u00e9duire l\u2019impact n\u00e9gatif des politiques de distanciation sur la suppression (et donc le retardement dans le temps de l\u2019atteinte d\u2019une immunit\u00e9 collective).\nDes tests s\u00e9rologiques \u00e0 l\u2019\u00e9chelle des populations sont n\u00e9cessaires \u00e0 la gestion de la crise et \u00e0 la mise en place de strat\u00e9gies adapt\u00e9es telles que la barri\u00e8re immunologique.", "objectives": "Les conclusions des auteurs se basent sur des hypoth\u00e8ses tr\u00e8s fortes et non d\u00e9montr\u00e9es \u00e0 ce jour. En particulier, le d\u00e9veloppement de d\u00e9fenses immunisantes permanentes pour les individus ayant r\u00e9cup\u00e9r\u00e9 de leur maladie est loin d\u2019\u00eatre d\u00e9montr\u00e9 \u00e0 ce jour.", "methods": "Mod\u00e9liser les effets \u00e9pid\u00e9miologiques d\u2019une strat\u00e9gie de barri\u00e8re immunologique consistant en une substitution des contacts de fa\u00e7on pr\u00e9f\u00e9rentielle vers des personnes s\u00e9ropositives.", "pubmed_id": "32382154", "doi": "10.1038/s41591-020-0895-3", "abstract": "The COVID-19 pandemic has precipitated a global crisis, with more than 1,430,000 confirmed cases and more than 85,000 confirmed deaths globally as of 9 April 2020", "topics": ["Mod\u00e9lisation", "Immunit\u00e9", "Virologie", "Infectiologie"], "author_list": [{"id": 524, "name": "Weitz J"}], "publication_date": "2020-05-08"}, {"id": 57, "slug": "association-of-radiologic-findings-with-mortality-of-patients-infected-with-2019", "title": "Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyser l'association entre constats radiologiques et mortalit\u00e9 dans l'infection par le SARS-CoV-2", "verbose_date": "19.03.2020", "authors": "Yuan M", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 48, "name": "PLOS One"}, "link": "https://www.dropbox.com/s/hp4qgzkrixhz4ho/journal.pone.0230548.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le score d'atteinte pulmonaire \u00e9tudi\u00e9 dans cet article et obtenu \u00e0 partir d'un scanner thoracique non inject\u00e9 para\u00eet utile pour pr\u00e9dire la survie des patients atteints du covid 19. N\u00e9anmoins, on pourrait probablement am\u00e9liorer sa sensibilit\u00e9 (85.6%) et sp\u00e9cificit\u00e9 (84.5%) en y ajoutant d'autres crit\u00e8res associ\u00e9s \u00e0 la gu\u00e9rison ou au d\u00e9c\u00e8s.", "objectives": "Faible:1) Petits effectifs (-)2) Seulement des cas hospitalis\u00e9s (-)3) Cas cons\u00e9cutifs (+)4) Pas le m\u00eame protocole de traitement \u00e0 vis\u00e9e curative pour tous les patients (-)5) Score final obtenu par consensus entre 2 pneumologues, sans calcul de l'accord inter-observateur6) Multiples tests (-)", "methods": "Analyser l'association entre constats radiologiques et mortalit\u00e9 dans l'infection par le SARS-CoV-2", "pubmed_id": "32191764\n29052924\n25033169\n12759474\n23821754\n31995857\n31986264\n32031481\n31994742\n24918624\n21035974\n32031570\n14990845\n32032497\n32007143\n32027573\n12853655\n24705783", "doi": "10.1371/journal.pone.0230548", "abstract": "Radiologic characteristics of 2019 novel coronavirus (2019-nCoV) infected pneumonia (NCIP) which had not been fully understood are especially important for diagnosing and predicting prognosis. We retrospective studied 27 consecutive patients who were confirmed NCIP, the clinical characteristics and CT image findings were collected, and the association of radiologic findings with mortality of patients was evaluated. 27 patients included 12 men and 15 women, with median age of 60 years (IQR 47-69). 17 patients discharged in recovered condition and 10 patients died in hospital. The median age of mortality group was higher compared to survival group (68 (IQR 63-73) vs 55 (IQR 35-60), P = 0.003). The comorbidity rate in mortality group was significantly higher than in survival group (80% vs 29%, P = 0.018). The predominant CT characteristics consisted of ground glass opacity (67%), bilateral sides involved (86%), both peripheral and central distribution (74%), and lower zone involvement (96%). The median CT score of mortality group was higher compared to survival group (30 (IQR 7-13) vs 12 (IQR 11-43), P = 0.021), with more frequency of consolidation (40% vs 6%, P = 0.047) and air bronchogram (60% vs 12%, P = 0.025). An optimal cutoff value of a CT score of 24.5 had a sensitivity of 85.6% and a specificity of 84.5% for the prediction of mortality. 2019-nCoV was more likely to infect elderly people with chronic comorbidities. CT findings of NCIP were featured by predominant ground glass opacities mixed with consolidations, mainly peripheral or combined peripheral and central distributions, bilateral and lower lung zones being mostly involved. A simple CT scoring method was capable to predict mortality.", "topics": ["Pronostique", "Radiologie"], "author_list": [{"id": 67, "name": "Yuan M"}], "publication_date": "2020-03-19"}, {"id": 340, "slug": "hydroxychloroquine-in-patients-with-mainly-mild-to-moderate-coronavirus-disease-", "title": "Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'efficacit\u00e9 et la s\u00e9curit\u00e9 d'un traitement du COVID-19 par sulfate d'hydroxychloroquine", "verbose_date": "06.05.2020", "authors": "Tang W", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 57, "name": "BMJ"}, "link": "https://www.bmj.com/content/bmj/369/bmj.m1849.full.pdf", "findings": "", "take_away": "", "relevance_level": "Cette \u00e9tude n'a pas montr\u00e9 de r\u00e9ponse virologique suppl\u00e9mentaire en ajoutant de l'hydroxychloroquine \u00e0 la prise en charge habituelle. Il n'y avait pas de diff\u00e9rence significative par rapport \u00e0 la strat\u00e9gie contr\u00f4le et les effets ind\u00e9sirables ont \u00e9t\u00e9 bien plus important dans le groupe hydroxychloroquine.", "objectives": "1) Etude en ouvert, randomisation non centralis\u00e9e avec un syst\u00e8me d'enveloppe sujette \u00e0 des biais, analyse en intention de traiter pour l'efficacit\u00e9 et per protocole pour la s\u00e9curit\u00e92) Nombre de sujets n\u00e9cessaires calcul\u00e9 \u00e0 360 patients avec analyse interm\u00e9diaire pr\u00e9vue \u00e0 7 jours avec 150 patients. Au total ici 150 patients3) Crit\u00e8res de jugement principalement sur la biologie4) D\u00e9lai moyen entre d\u00e9but des sympt\u00f4mes et randomisation de 16,6 jours.5) Uniquement 2 patients s\u00e9v\u00e8res \u00e0 l'inclusion6) Pas de prise en compte de l'inflation du risque alpha avec de multiples analyses post-hoc7) Antiviraux dans la prise en charge de base\"", "methods": "Evaluer l'efficacit\u00e9 et la s\u00e9curit\u00e9 d'un traitement du COVID-19 par sulfate d'hydroxychloroquine", "pubmed_id": "32409561\n32187464\n17109296\n32020029\n19808132\n12115175\n32034323\n19281331\n32217556\n15356306\n32187463\n26189086\n32159775\n32317267\n32074550\n29143192\n32150618\n26246395", "doi": "10.1136/bmj.m1849", "abstract": "To assess the efficacy and safety of hydroxychloroquine plus standard of care compared with standard of care alone in adults with coronavirus disease 2019 (covid-19).\nMulticentre, open label, randomised controlled trial.\n16 government designated covid-19 treatment centres in China, 11 to 29 February 2020.\n150 patients admitted to hospital with laboratory confirmed covid-19 were included in the intention to treat analysis (75 patients assigned to hydroxychloroquine plus standard of care, 75 to standard of care alone).\nHydroxychloroquine administrated at a loading dose of 1200 mg daily for three days followed by a maintenance dose of 800 mg daily (total treatment duration: two or three weeks for patients with mild to moderate or severe disease, respectively).\nNegative conversion of severe acute respiratory syndrome coronavirus 2 by 28 days, analysed according to the intention to treat principle. Adverse events were analysed in the safety population in which hydroxychloroquine recipients were participants who received at least one dose of hydroxychloroquine and hydroxychloroquine non-recipients were those managed with standard of care alone.\nOf 150 patients, 148 had mild to moderate disease and two had severe disease. The mean duration from symptom onset to randomisation was 16.6 (SD 10.5; range 3-41) days. A total of 109 (73%) patients (56 standard of care; 53 standard of care plus hydroxychloroquine) had negative conversion well before 28 days, and the remaining 41 (27%) patients (19 standard of care; 22 standard of care plus hydroxychloroquine) were censored as they did not reach negative conversion of virus. The probability of negative conversion by 28 days in the standard of care plus hydroxychloroquine group was 85.4% (95% confidence interval 73.8% to 93.8%), similar to that in the standard of care group (81.3%, 71.2% to 89.6%). The difference between groups was 4.1% (95% confidence interval -10.3% to 18.5%). In the safety population, adverse events were recorded in 7/80 (9%) hydroxychloroquine non-recipients and in 21/70 (30%) hydroxychloroquine recipients. The most common adverse event in the hydroxychloroquine recipients was diarrhoea, reported in 7/70 (10%) patients. Two hydroxychloroquine recipients reported serious adverse events.\nAdministration of hydroxychloroquine did not result in a significantly higher probability of negative conversion than standard of care alone in patients admitted to hospital with mainly persistent mild to moderate covid-19. Adverse events were higher in hydroxychloroquine recipients than in non-recipients.\nChiCTR2000029868.", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 326, "name": "Tang W"}], "publication_date": "2020-05-06"}, {"id": 26, "slug": "the-toughest-triage-allocating-ventilators-in-a-pandemic", "title": "The Toughest Triage \u2014 Allocating Ventilators in a Pandemic", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Expliquer la difficile gestion de la s\u00e9lection des patients pouvant b\u00e9n\u00e9ficier de ventilation m\u00e9canique", "verbose_date": "23.03.2020", "authors": "Truog RD", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.dropbox.com/s/fftvz4gv7wm0wgv/nejmp2005689.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Proposition d'un comit\u00e9 ind\u00e9pendant pour prendre les d\u00e9cisions d'attribution (ou de retrait) d'un respirateur en essayant d'anticiper le plus possible le moment o\u00f9 la ventilation est n\u00e9cessaire par discussion avec le patient et sa famille. Respect de crit\u00e8res objectifs : - risque de mortalit\u00e9 (score de SOFA)- r\u00e9-\u00e9valuation r\u00e9guli\u00e8re sous ventilation pour discuter un possible retrait", "objectives": "Faible1) Lettre \u00e0 l'\u00e9diteur2) Proposition sans s'appuyer r\u00e9ellement sur la litt\u00e9rature (contexte in\u00e9dit)", "methods": "Expliquer la difficile gestion de la s\u00e9lection des patients pouvant b\u00e9n\u00e9ficier de ventilation m\u00e9canique", "pubmed_id": "32202721", "doi": "10.1056/NEJMp2005689", "abstract": null, "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 36, "name": "Truog RD"}], "publication_date": "2020-03-23"}, {"id": 268, "slug": "vascular-changes-detected-with-thoracic-ct-in-coronavirus-disease-covid-19-might", "title": "Vascular Changes Detected With Thoracic CT in Coronavirus Disease (COVID-19) Might Be Significant Determinants for Accurate Diagnosis and Optimal Patient Management", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Discuter de l'int\u00e9r\u00eat des anomalies vasculaires pour le diagnostic du COVID au scanner thoracique ", "verbose_date": "08.04.2020", "authors": "Qanadli SD", "specialties": [{"id": 3, "name": "Radiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 53, "name": "AJR Am J Roentgenol"}, "link": "https://www.ajronline.org/doi/pdf/10.2214/AJR.20.23185", "findings": "", "take_away": "", "relevance_level": "Les changements vasculaires doivent faire partie de l'analyse du scanner thoracique dans le cadre d'une infection \u00e0 COVID avec commes signes cardinaux (relativement sp\u00e9cifiques) :\r\n1) Epaississement vasculaire ou \u00e9largissement des vaisseaux\u00a0\r\n2) Pr\u00e9sence d'embole dans les petites branches lobaires", "objectives": "- Lettre \u00e0 l'\u00e9diteur sans exp\u00e9rimentations et bas\u00e9e sur tr\u00e8s peu de r\u00e9f\u00e9rences bibliographiques\"", "methods": "Discuter de l'int\u00e9r\u00eat des anomalies vasculaires pour le diagnostic du COVID au scanner thoracique", "pubmed_id": "32255684", "doi": "10.2214/AJR.20.23185", "abstract": null, "topics": ["Diagnostique", "Radiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 257, "name": "Qanadli SD"}], "publication_date": "2020-04-08"}, {"id": 39, "slug": "drive-through-screening-center-for-covid-19-a-safe-and-efficient-screening-syste", "title": "Drive-Through Screening Center for COVID-19: a Safe and Efficient Screening System against Massive Community Outbreak", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Partager l'exp\u00e9rience de \"drives\" de d\u00e9pistage du COVID-19 impl\u00e9ment\u00e9s dans 68 centres en Cor\u00e9e du Sud", "verbose_date": "20.03.2020", "authors": "Kwon KT", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 33, "name": "J Korean Med Sci"}, "link": "https://www.dropbox.com/s/g9cizq34lcn1r52/jkms-35-e123.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les drives de d\u00e9pistage du COVID-19, m\u00eame s'ils pr\u00e9sentent certaines limites, sont int\u00e9ressants \u00e0 mettre en place \u00e0 conditions d'avoir les moyens suffisants notamment kits de test et \u00e9quipements de protection personnelle. Ils permettent de limiter le risque de transmission entre les sujets test\u00e9s qui restent alors dans leur voiture.", "objectives": "Interm\u00e9diaire :1) Retour d'exp\u00e9rience sur un nombre significatifs de drives : 682) n\u00e9cessite une bonne adh\u00e9sion aux r\u00e8gles de s\u00e9curit\u00e9 par les sujets test\u00e9s", "methods": "Partager l'exp\u00e9rience de \"drives\" de d\u00e9pistage du COVID-19 impl\u00e9ment\u00e9s dans 68 centres en Cor\u00e9e du Sud", "pubmed_id": "32193904\n21612365\n12836624\n20079956\n19126810\n32174069", "doi": "10.3346/jkms.2020.35.e123", "abstract": "As the coronavirus disease 2019 (COVID-19) outbreak is ongoing, the number of individuals to be tested for COVID-19 is rapidly increasing. For safe and efficient screening for COVID-19, drive-through (DT) screening centers have been designed and implemented in Korea. Herein, we present the overall concept, advantages, and limitations of the COVID-19 DT screening centers. The steps of the DT centers include registration, examination, specimen collection, and instructions. The entire service takes about 10 minutes for one testee without leaving his or her cars. Increased testing capacity over 100 tests per day and prevention of cross-infection between testees in the waiting space are the major advantages, while protection of staff from the outdoor atmosphere is challenging. It could be implemented in other countries to cope with the global COVID-19 outbreak and transformed according to their own situations.", "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 49, "name": "Kwon KT"}], "publication_date": "2020-03-20"}, {"id": 636, "slug": "hospitalization-and-mortality-among-black-patients-and-white-patients-with-covid", "title": "Hospitalization and Mortality among Black Patients and White Patients with Covid-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparer les caract\u00e9ristiques cliniques et la dur\u00e9e d'hospitalisation de sujets caucasiens et afro-am\u00e9ricains atteints du COVID-19.", "verbose_date": "28.05.2020", "authors": "Price-Haywood EG", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMsa2011686?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude, les patients atteints du COVID-19 afro-am\u00e9ricains sont plus nombreux que les patients COVID-19 caucasiens \u00e0 consulter dans un groupe d'h\u00f4pitaux en Louisiane. Le fait d'\u00eatre afro-am\u00e9ricain semble associ\u00e9 \u00e0 un sur-risque d'hospitalisation mais pas de d\u00e9c\u00e8s hospitalier. Ces r\u00e9sultats restent \u00e0 confirmer dans des \u00e9tudes plus robustes et \u00e0 confronter a d'autres donn\u00e9es socio-\u00e9conomiques, clliniques et \u00e9ventuellement biologiques.", "objectives": "- \u00e9tude r\u00e9trospective- \u00e9tude limit\u00e9e \u00e0 un groupe d'h\u00f4pitaux ne refl\u00e9tant pas forc\u00e9ment l'ensemble de la patient\u00e8le de la r\u00e9gion- nombreuses donn\u00e9es manquantes imput\u00e9es- suivi incomplet pour des sujets qui restaient hospitalis\u00e9s en fin d'\u00e9tude", "methods": "Comparer les caract\u00e9ristiques cliniques et la dur\u00e9e d'hospitalisation de sujets caucasiens et afro-am\u00e9ricains atteints du COVID-19.", "pubmed_id": "32459916\n12725876\n27768889\n32298250\n32250385\n32286245\n17621469\n3558716\n32335169\n32320003\n31025305\n31986264\n32227758\n32214079\n32240123\n32091533\n32379729\n32191259\n19153585", "doi": "10.1056/NEJMsa2011686", "abstract": "Many reports on coronavirus disease 2019 (Covid-19) have highlighted age- and sex-related differences in health outcomes. More information is needed about racial and ethnic differences in outcomes from Covid-19.\nIn this retrospective cohort study, we analyzed data from patients seen within an integrated-delivery health system (Ochsner Health) in Louisiana between March 1 and April 11, 2020, who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, the virus that causes Covid-19) on qualitative polymerase-chain-reaction assay. The Ochsner Health population is 31% black non-Hispanic and 65% white non-Hispanic. The primary outcomes were hospitalization and in-hospital death.\nA total of 3626 patients tested positive, of whom 145 were excluded (84 had missing data on race or ethnic group, 9 were Hispanic, and 52 were Asian or of another race or ethnic group). Of the 3481 Covid-19-positive patients included in our analyses, 60.0% were female, 70.4% were black non-Hispanic, and 29.6% were white non-Hispanic. Black patients had higher prevalences of obesity, diabetes, hypertension, and chronic kidney disease than white patients. A total of 39.7% of Covid-19-positive patients (1382 patients) were hospitalized, 76.9% of whom were black. In multivariable analyses, black race, increasing age, a higher score on the Charlson Comorbidity Index (indicating a greater burden of illness), public insurance (Medicare or Medicaid), residence in a low-income area, and obesity were associated with increased odds of hospital admission. Among the 326 patients who died from Covid-19, 70.6% were black. In adjusted time-to-event analyses, variables that were associated with higher in-hospital mortality were increasing age and presentation with an elevated respiratory rate; elevated levels of venous lactate, creatinine, or procalcitonin; or low platelet or lymphocyte counts. However, black race was not independently associated with higher mortality (hazard ratio for death vs. white race, 0.89; 95% confidence interval, 0.68 to 1.17).\nIn a large cohort in Louisiana, 76.9% of the patients who were hospitalized with Covid-19 and 70.6% of those who died were black, whereas blacks comprise only 31% of the Ochsner Health population. Black race was not associated with higher in-hospital mortality than white race, after adjustment for differences in sociodemographic and clinical characteristics on admission.", "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 598, "name": "Price-Haywood EG"}], "publication_date": "2020-05-28"}, {"id": 385, "slug": "safety-signals-for-qt-prolongation-or-torsades-de-pointes-associated-with-azithr", "title": "Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyse de pharmacovigilance du QT long, Torsade de Pointe, d\u00e9c\u00e8s avec chloroquine/azithromycine/les 2.", "verbose_date": "20.04.2020", "authors": "Sarayani A", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 163, "name": "Res Soc Admin Pharm"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1551741120303910?token=ACF3396D89B49FAC7914336E2A0B57A542819DAC5C475675F8C208149780A16BAC5FE4F95404E7A3DA326D59E9C9265C", "findings": "", "take_away": "", "relevance_level": "Pas de signal d'alerte sur CQ/HCQ seul mais azithromycine seul significatif associ\u00e9e \u00e0 des allongements QT et Torsade de Pointe. Non significatif sur l'association de mol\u00e9cules. Concordant avec la litt\u00e9rature mais \u00e9tudes non r\u00e9alis\u00e9es sur patients COVID. Remarque: aucune information sur les doses moyennes utilis\u00e9es.", "objectives": "Analyse de pharmacovigilance r\u00e9trospective o\u00f9 il manque des donn\u00e9es pour l'appliquer au patient grave et pas dans un contexte COVID.", "methods": "Analyse de pharmacovigilance du QT long, Torsade de Pointe, d\u00e9c\u00e8s avec chloroquine/azithromycine/les 2.", "pubmed_id": "32327397\n27183377\n16615675\n27622822\n14594906\n31341415\n32145363\n24243665\n14592603\n16640347\n32171740\n32205204\n24643967\n11998548", "doi": "10.1016/j.sapharm.2020.04.016", "abstract": "Combinations of hydroxychloroquine (HCQ) and azithromycin have been promoted as treatments for COVID-19 based on small, uncontrolled clinical trials that have not assessed potential risks. Risks of treatment include QT segment prolongation, Torsades de Pointes (TdP), and death. This comparative pharmacovigilance analysis evaluated the risk of these events.\nData from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) (>13 million total reports) were used. Queries extracted reports based on exposures of HCQ/chloroquine (CQ) alone, azithromycin alone, HCQ/CQ\u00a0+\u00a0azithromycin, amoxicillin alone, HCQ/CQ\u00a0+\u00a0amoxicillin alone. Amoxicillin served as a control. Events of interest included death and TdP/QT prolongation as well as accidents/injuries and depression as control events. Proportional Reporting Ratios (PRR) and 95% confidence intervals (CI) were calculated where a lower limit of the of 95% CI (Lower95CI) value of \u22652.0 is interpreted as a potential safety signal.\nLower95CIs for HCQ/CQ alone showed no potential safety signals for TdP/QT prolongation, death, or any of the control events included. The PRRs and 95% CIs for TdP/QT prolongation was 1.43 (1.29-2.59) with HCQ/CQ use alone and 4.10 (3.80-4.42) for azithromycin alone. For the combined HCQ/CQ\u00a0+\u00a0azithromycin group, the PRR and 95% CI was 3.77 (1.80-7.87). For the control of amoxicillin, there were no safety signals when used alone or in combination with HCQ/CQ.\nHCQ/CQ use was not associated with a safety signal in this analysis of FAERS data. However, azithromycin used alone was associated with TdP/QT prolongation events and should be used with caution.", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie", "Pneumologie"], "author_list": [{"id": 371, "name": "Sarayani A"}], "publication_date": "2020-04-20"}, {"id": 533, "slug": "neonatal-late-onset-infection-with-severe-acute-respiratory-syndrome-coronavirus", "title": "Neonatal Late Onset Infection with Severe Acute Respiratory Syndrome Coronavirus 2", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluation apr\u00e8s retour \u00e0 domicile des nouveau-n\u00e9s de m\u00e8re COVID+ pendant la grossesse, test\u00e9s n\u00e9gatifs \u00e0 la naissance.\r\n ", "verbose_date": "05.05.2020", "authors": "Buonsenso D", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 210, "name": "Am J Perinatology"}, "link": "https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0040-1710541.pdf", "findings": "", "take_away": "", "relevance_level": "Il est important de suivre les nouveau-n\u00e9s de m\u00e8res COVID+ pendant la grossesse puisqu'ils peuvent s'infecter au d\u00e9but de leur vie avec des cons\u00e9quences au long terme inconnues \u00e0 ce jour. Besoin de recommandations sur le sujet. Les soins p\u00e9rinataux optimaux n'\u00e9tant pas connus, le rapport b\u00e9n\u00e9fices-risques doit \u00eatre discut\u00e9 avec la famille. Ce protocole comprend un suivi \u00e0 long terme jusqu'\u00e0 12 mois de vie.", "objectives": "Etude observationnelle. Faible effectif, r\u00e9sultats interm\u00e9diaires.", "methods": "Evaluation apr\u00e8s retour \u00e0 domicile des nouveau-n\u00e9s de m\u00e8re COVID+ pendant la grossesse, test\u00e9s n\u00e9gatifs \u00e0 la naissance.", "pubmed_id": "32359227", "doi": "10.1055/s-0040-1710541", "abstract": "\u2003To date, no information on late-onset infection in newborns to mother with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contracted in pregnancy are available. This study aimed to evaluate postdischarge SARS-CoV-2 status of newborns to mothers with COVID-19 in pregnancy that, at birth, were negative to SARS-CoV-2.\n\u2003This is an observational study of neonates born to mothers with coronavirus disease 2019 (COVID-19).\n\u2003Seven pregnant women with documented SARS-CoV-2 infection have been evaluated in our institution. One woman had a spontaneous abortion at 8 weeks of gestational age, four women recovered and are still in follow-up, and two women delivered. Two newborns were enrolled in the study. At birth and 3 days of life, newborns were negative to SARS-CoV-2. At 2-week follow-up, one newborn tested positive although asymptomatic.\n\u2003Our findings highlight the importance of follow-up of newborns to mothers with COVID-19 in pregnancy, since they remain at risk of contracting the infection in the early period of life and long-term consequences are still unknown.\n\u00b7 Newborns to mothers with coronavirus disease 2019 (COVID-19) in pregnancy can acquire the infection later after birth.. \u00b7 Newborns to mothers with COVID-19 in pregnancy need a long-term follow-up, even if they tested negative at birth.. \u00b7 Specific guidelines for the long-term follow-up of newborns to mothers with COVID-19 in pregnancy are needed..", "topics": ["Pronostique", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 499, "name": "Buonsenso D"}], "publication_date": "2020-05-05"}, {"id": 417, "slug": "covid19-during-pregnancy-a-systematic-review-of-reported-cases", "title": "COVID19 during pregnancy: a systematic review of reported cases", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Recueillir et examiner les informations disponibles sur l'impact du COVID 19 sur la m\u00e8re et le f\u0153tus et se concentrer sur le moment et le mode d'accouchement.", "verbose_date": "22.04.2020", "authors": "Della Gatta AN", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 175, "name": "Am J Obstet Gynecol"}, "link": "https://www.ajog.org/article/S0002-9378(20)30438-5/pdf", "findings": "", "take_away": "", "relevance_level": "Les donn\u00e9es disponibles sur la maladie COVID-19 chez les patientes enceintes ne permettent pas de tirer une conclusion claire sur les implications cliniques pour la m\u00e8re et le f\u0153tus. Bien que la transmission verticale du SARS-Cov2 ait \u00e9t\u00e9 exclue jusqu'\u00e0 pr\u00e9sent et que le r\u00e9sultat pour les m\u00e8res et les f\u0153tus ait \u00e9t\u00e9 g\u00e9n\u00e9ralement bon, le taux \u00e9lev\u00e9 de c\u00e9sariennes pr\u00e9matur\u00e9es est un motif de pr\u00e9occupation. Le r\u00e9sultat d\u00e9crit jusqu'\u00e0 pr\u00e9sent est favorable, mais les risques pour le f\u0153tus et la m\u00e8re doivent \u00eatre sous-estim\u00e9s. Bien que les accouchements pr\u00e9matur\u00e9s aient \u00e9t\u00e9 principalement la cons\u00e9quence d'interventions \u00e9lectives, une tendance \u00e0 la pr\u00e9maturit\u00e9 spontan\u00e9e est pr\u00e9sente. Il est essentiel que les \u00e9tudes futures fournissent des informations plus d\u00e9taill\u00e9es sur les conditions de la m\u00e8re et du f\u0153tus, ainsi que sur la justification des interventions obst\u00e9tricales. L'exp\u00e9rience, jusqu'\u00e0 pr\u00e9sent, se limite aux patientes qui ont d\u00e9velopp\u00e9 la maladie en fin de gestation et qui ont accouch\u00e9 peu apr\u00e8s le diagnostic. Les cons\u00e9quences pour le f\u0153tus des infections de longue dur\u00e9e survenant au d\u00e9but de la gestation sont inconnues.", "objectives": "-\tPre-proof-\t6 \u00e9tudes dont 51 femmes \u00e9taient \u00e9ligibles pour la revue syst\u00e9matique : la litt\u00e9rature disponible sur les implications obst\u00e9tricales du COVD-19 est limit\u00e9e, tant en nombre qu'en qualit\u00e9", "methods": "Recueillir et examiner les informations disponibles sur l'impact du COVID 19 sur la m\u00e8re et le f\u0153tus et se concentrer sur le moment et le mode d'accouchement.", "topics": ["Epid\u00e9miologique", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 397, "name": "Della Gatta AN"}], "publication_date": "2020-04-22"}, {"id": 189, "slug": "coronavirus-disease-2019-covid-19-during-pregnancy-a-case-series", "title": "Coronavirus disease 2019 (COVID-19) during pregnancy: A case series.", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Description clinique d'une infection \u00e0 SARS-CoV-2 chez des femmes enceintes et des nouveaux n\u00e9s.", "verbose_date": "30.03.2020", "authors": "Liu W ", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/nozfwwlzlsa8h1s/preprints202002.0373.v1.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Pas d'arguments pour une transmission verticale du SARS-CoV-2\r\n- Compte tenu des donn\u00e9es de la litt\u00e9rature, l'infection par SARS-CoV-2 au cours de la grossesse semble \u00e0 risque", "objectives": "-  pre-prints- \u00c9tude de cas (n=3)", "methods": "Description clinique d'une infection \u00e0 SARS-CoV-2 chez des femmes enceintes et des nouveaux n\u00e9s.", "topics": ["Epid\u00e9miologique", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 182, "name": "Liu W "}], "publication_date": "2020-03-30"}, {"id": 144, "slug": "infection-par-le-sras-cov-2-chez-les-femmes-enceintes-etat-des-connaissances-et-", "title": "Infection par le SRAS-CoV-2 chez les femmes enceintes. \u00c9tat des connaissances et proposition de prise en charge", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Informer les professionnels de sant\u00e9 sur le SRAS-Cov Id-2, ses sympt\u00f4mes, la connaissance actuelle sur la transmission inter individuelle et pendant la grossesse et de proposer un protocole de prise en charge pour les femmes enceintes en France", "verbose_date": "24.03.2020", "authors": "Peyronnet V ", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 7, "name": "Recommandations", "icon": "icon-reco"}, "journal": {"id": 88, "name": "Gyn\u00e9co Obst Fert Senol"}, "link": "https://www.dropbox.com/s/ayy9o6z246ilpg6/1-s2.0-S2468718920301100-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Proposition tenant compte d'avis d'experts et revue de la litt\u00e9rature:\n\r\nFemmes enceintes:\r\n- memes symtomes de la population g\u00e9n\u00e9rale\r\n- plus \u00e0 risque de rupture pr\u00e9matur\u00e9e des membranes, d'accouchements pr\u00e9matur\u00e9s, de mort foetales in utero, retard de croissance, d\u00e9c\u00e8s n\u00e9onatals\n\r\nFoetus et nouveau-n\u00e9:\r\n- l'infection materno-foetale n'est pas prouv\u00e9e\r\n- transmission par voie a\u00e9rienne en per-partum a \u00e9t\u00e9 rapport\u00e9e\r\n- l'infection maternelle p\u00e9rinatale peut avoir des cons\u00e9quences n\u00e9fastes sur les issues obst\u00e9tricales et sur les nouveaux n\u00e9s entra\u00eenant notamment des\r\nd\u00e9tresses respiratoires, des anomalies biologiques des accouchements pr\u00e9matur\u00e9s et m\u00eame un d\u00e9c\u00e8s", "objectives": "1) Avis d'experts2) Revue de la litt\u00e9rature actuelle tr\u00e8s limit\u00e9e sur femmes enceintes COVID-19", "methods": "Informer les professionnels de sant\u00e9 sur le SRAS-Cov Id-2, ses sympt\u00f4mes, la connaissance actuelle sur la transmission inter individuelle et pendant la grossesse et de proposer un protocole de prise en charge pour les femmes enceintes en France", "topics": ["Recommandations", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 141, "name": "Peyronnet V "}], "publication_date": "2020-03-24"}, {"id": 298, "slug": "clinical-efficacy-of-lopinavirritonavir-in-the-treatment-of-coronavirus-disease-", "title": "Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "\u00c9valuer les effets du traitement par lopinavir/ritonavir en association avec d'autres m\u00e9dicaments adjuvants sur les patients atteints de COVID-19.", "verbose_date": "10.04.2020", "authors": "Ye XT", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 138, "name": "Eur Rev Med Pharmacol"}, "link": "https://www.europeanreview.org/wp/wp-content/uploads/3390-3396.pdf", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude montre que le traitement au lopinavir/ritonavir associ\u00e9 \u00e0 un traitement adjuvant par rapport au traitement adjuvant seul permet un retour \u00e0 la temp\u00e9rature de base en moins de temps, r\u00e9duit les anomalies des globules blancs, des lymphocytes et des prot\u00e9ines C-r\u00e9actives apr\u00e8s trois traitements, et permet un d\u00e9pistage n\u00e9gatif en moins de temps.", "objectives": "1) \u00e9tude exp\u00e9rimentale2) petit \u00e9chantillon: 42 patients (groupe d'\u00e9tude) vs 5 patients (groupe t\u00e9moin)3) manque de donn\u00e9es : absence de mesure de la temp\u00e9rature corporelle pour certains patients (pas mesur\u00e9e tous les 10 jours de l'\u00e9tude)\"", "methods": "\u00c9valuer les effets du traitement par lopinavir/ritonavir en association avec d'autres m\u00e9dicaments adjuvants sur les patients atteints de COVID-19.", "pubmed_id": "32271456", "doi": "10.26355/eurrev_202003_20706", "abstract": "The Coronavirus disease 2019 (COVID-19) which outbroke in December 2019 is highly contagious with a low cure rate. In view of this, there is an urgent need to find a more appropriate therapeutic scheme against COVID-19. The study aimed to investigate whether lopinavir/ritonavir (LPV/r) in combination with other pneumonia-associated adjuvant drugs has a better therapeutic effect on COVID-19.\nTotally 47 patients with COVID-19 infection who were admitted to Rui'an People's Hospital between January 22 and January 29, 2020 were collected. The patients were divided into the test group and the control group according to whether they had been treated with LPV/r or not during hospitalization. Patients in the test group were treated with LPV/r combined with adjuvant medicine, while those in the control group were just treated with adjuvant medicine. The changes of body temperature, blood routine and blood biochemistry between the two groups were observed and compared.\nBoth groups achieved good therapeutic effect with the body temperature of patients decreased gradually from admission to the 10th day of treatment. But the body temperature of patients in the test group decreased faster than that of the control group. Blood routine indexes showed that compared with the control group, the abnormal proportion of white blood cells, lymphocytes and C-reactive protein of the test group could be reduced to some extent. Blood biochemical indexes exhibited that the proportion of patients with abnormal alanine aminotransferase and aspartate aminotransferase in the test group were lower than the control group. The number of days for nCoV-RNA turning negative after treatment was significantly decreased in the test group than that in the control group.\nCompared with the treatment of pneumonia-associated adjuvant drugs alone, the combination treatment with LPV/r and adjuvant drugs has a more evident therapeutic effect in lowering the body temperature and restoring normal physiological mechanisms with no evident toxic and side effects. In view of these conclusions, we suggested that the use of LPV/r combined with pneumonia-associated adjuvant drugs in the clinical treatment for patients with COVID-19 should be promoted.", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie", "Pneumologie"], "author_list": [{"id": 286, "name": "Ye XT"}], "publication_date": "2020-04-10"}, {"id": 377, "slug": "relationships-among-lymphocyte-subsets-cytokines-and-the-pulmonary-inflammation-", "title": "Relationships among Lymphocyte Subsets, Cytokines, and the Pulmonary Inflammation Index in Coronavirus (COVID-19) Infected Patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Explorer les relations entre les sous-ensembles de lymphocytes, les cytokines, l'indice d'inflammation pulmonaire et l'\u00e9volution de la maladie chez les patients atteints de COVID-19", "verbose_date": "18.04.2020", "authors": "Wan S", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 68, "name": "Br J Haematol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.16659", "findings": "", "take_away": "", "relevance_level": "Les taux de CD4, CD8, IL-6 et IL-10 et l'index d'inflammation pulmonaire pourraient \u00eatre utilis\u00e9s comme indicateurs de l'\u00e9volution de la maladie. L'index d'inflammation pulmonaire pourrait \u00eatre utilis\u00e9 comme indicateur ind\u00e9pendant de l'\u00e9volution de la maladie.", "objectives": "1) Pre-proof2) Etude de cohorte monocentrique, n=123 avec 4 d\u00e9c\u00e8s repertori\u00e93) Dur\u00e9e de suivi maximale de 20 jours4) Patients divis\u00e9s en 2 formes cliniques (formes dites mod\u00e9r\u00e9es et formes s\u00e9v\u00e8res) 5) Pas de donn\u00e9es sur le d\u00e9lai entre la date de pr\u00e9levement et de r\u00e9alisation du scanner par rapport au d\u00e9but des sympt\u00f4mes\"", "methods": "Explorer les relations entre les sous-ensembles de lymphocytes, les cytokines, l'indice d'inflammation pulmonaire et l'\u00e9volution de la maladie chez les patients atteints de COVID-19", "pubmed_id": "32297671\n32037389\n32122468\n32067043\n32031570\n31986264\n32361250\n32007143\n31505937\n32030925\n31991079", "doi": "10.1111/bjh.16659", "abstract": "We explored the relationships between lymphocyte subsets, cytokines, pulmonary inflammation index (PII) and disease evolution in patients with (corona virus disease 2019) COVID-19. A total of 123 patients with COVID-19 were divided into mild and severe groups. Lymphocyte subsets and cytokines were detected on the first day of hospital admission and lung computed tomography results were quantified by PII. Difference analysis and correlation analysis were performed on the two groups. A total of 102 mild and 21 severe patients were included in the analysis. There were significant differences in cluster of differentiation 4 (CD4", "topics": ["Pronostique", "Transversale", "Infectiologie"], "author_list": [{"id": 364, "name": "Wan S"}], "publication_date": "2020-04-18"}, {"id": 472, "slug": "covid19-coagulopathy-in-caucasian-patients", "title": "COVID\u201019 Coagulopathy in Caucasian patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Description de la coagulopathie chez les patients caucasiens.", "verbose_date": "28.04.2020", "authors": "Fogarty H", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 68, "name": "Br J Haematol"}, "link": "https://www.dropbox.com/s/wcl7e1dnvdytuoi/10.1111%40bjh.16749.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L'origine ethnique est importante quant au risque thrombotique, moindre chez les chinois (x3-4) et plus \u00e9lev\u00e9e chez les afro-am\u00e9ricains. Les formes graves de COVID chez les caucasiens sont associ\u00e9es \u00e0 une coagulopathie. Malgr\u00e9 des D-dim\u00e8res \u00e9lev\u00e9s, l'\u00e9volution vers la CIVD des patients caucasiens sous HBPM est rare. Les donn\u00e9es sugg\u00e8rent l'association d'une inflammation pulmonaire bilat\u00e9rale et d'une vasculopathie sp\u00e9cifique du poumon appel\u00e9e dans cet article Coagulopathie intra-vasculaire pulmonaire. Peut-\u00eatre \u00e0 l'origine de l'explication de la diff\u00e9rence de mortalit\u00e9 inter-ethnique?", "objectives": "Etude observationnelle avec un petit effectif. Les calculs des r\u00e9sultats sont faits sur toute la cohorte. Comment comparent-ils les diff\u00e9rences interethniques qui n'apparaissent pas dans les r\u00e9sultats? Le titre traite de la coagulopathie chez les caucasiens et les r\u00e9sultats montrent que plus il y a de troubles de coagulation plus le pronostic est engag\u00e9 mais sur toute la cohorte! Quid de la comparaison interethnique?", "methods": "Description de la coagulopathie chez les patients caucasiens.", "topics": ["Epid\u00e9miologique", "Infectiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 440, "name": "Fogarty H"}], "publication_date": "2020-04-28"}, {"id": 172, "slug": "clinical-characteristics-of-113-deceased-patients-with-coronavirus-disease-2019-", "title": "Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyse des charact\u00e9ristiques cliniques des patients d\u00e9c\u00e9d\u00e9s d'une infection \u00e0 SRAS-CoV-2", "verbose_date": "27.03.2020", "authors": "Chen T ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 57, "name": "BMJ"}, "link": "https://www.dropbox.com/s/4h7zipqxh1e3dry/bmj.m1091.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Les patients les plus s\u00e9v\u00e8rement touch\u00e9s sont principalement des hommes, ag\u00e9s, avec de l'hypertension et/ou des comorbidit\u00e9s cardio-vasculaires.\r\n- hypox\u00e9mie, inflammation syst\u00e9mique et d\u00e9faillance d'organe plus fr\u00e9quent dans le groupe de patient d\u00e9c\u00e9d\u00e9.\r\n- Situation plus critique \u00e0 l'admission pour les patients d\u00e9c\u00e9d\u00e9 (dyspn\u00e9e, tachycardie, oppression thoracique, trouble de la conscience)\r\n- Leucocytose et lymphop\u00e9nie fr\u00e9quente dans les formes les plus grave.\r\n- Procalcitone rarement \u00e9lev\u00e9 dans le groupe de patients gu\u00e9ri indiquant qu'une infection bact\u00e9rienne secondaire pourrait \u00eatre pr\u00e9sente pour une forte proportion des patients d\u00e9c\u00e9d\u00e9s.\r\n- Dans le groupe de patients d\u00e9c\u00e9d\u00e9 on observe fr\u00e9quemment un sydrome inflammatoire, des disfonctions cardiques, r\u00e9nales, h\u00e9patique, un bilan de coagulation pertub\u00e9. Des taux de cytokine \u00e9lev\u00e9 sont aussi observ\u00e9 dans ce groupe.\r\n- Les complications les plus fr\u00e9quente sont : SDRA, insuffisance respiratoire de type I, sepsis, l\u00e9sion cardiaque aigue, arr\u00eat cardiaque, l\u00e9sion r\u00e9nale aigue, enc\u00e9phalopathie hypoxique, choc, acidose ou alkalose, et plus rarement CIVD et l\u00e9sion h\u00e9patique aigue.", "objectives": "- Etude restrospective- Descriptive- Multiplicit\u00e9 des analyses", "methods": "Analyse des charact\u00e9ristiques cliniques des patients d\u00e9c\u00e9d\u00e9s d'une infection \u00e0 SRAS-CoV-2", "pubmed_id": "32217556\n31995857\n32085846\n31978945\n32064853\n23075143\n12690091\n31991541\n22890468\n32091533\n32031570\n16293638\n15302738\n31986264\n32007143\n31986261\n32015507\n32075786\n32145768", "doi": "10.1136/bmj.m1091", "abstract": "To delineate the clinical characteristics of patients with coronavirus disease 2019 (covid-19) who died.\nRetrospective case series.\nTongji Hospital in Wuhan, China.\nAmong a cohort of 799 patients, 113 who died and 161 who recovered with a diagnosis of covid-19 were analysed. Data were collected until 28 February 2020.\nClinical characteristics and laboratory findings were obtained from electronic medical records with data collection forms.\nThe median age of deceased patients (68 years) was significantly older than recovered patients (51 years). Male sex was more predominant in deceased patients (83; 73%) than in recovered patients (88; 55%). Chronic hypertension and other cardiovascular comorbidities were more frequent among deceased patients (54 (48%) and 16 (14%)) than recovered patients (39 (24%) and 7 (4%)). Dyspnoea, chest tightness, and disorder of consciousness were more common in deceased patients (70 (62%), 55 (49%), and 25 (22%)) than in recovered patients (50 (31%), 48 (30%), and 1 (1%)). The median time from disease onset to death in deceased patients was 16 (interquartile range 12.0-20.0) days. Leukocytosis was present in 56 (50%) patients who died and 6 (4%) who recovered, and lymphopenia was present in 103 (91%) and 76 (47%) respectively. Concentrations of alanine aminotransferase, aspartate aminotransferase, creatinine, creatine kinase, lactate dehydrogenase, cardiac troponin I, N-terminal pro-brain natriuretic peptide, and D-dimer were markedly higher in deceased patients than in recovered patients. Common complications observed more frequently in deceased patients included acute respiratory distress syndrome (113; 100%), type I respiratory failure (18/35; 51%), sepsis (113; 100%), acute cardiac injury (72/94; 77%), heart failure (41/83; 49%), alkalosis (14/35; 40%), hyperkalaemia (42; 37%), acute kidney injury (28; 25%), and hypoxic encephalopathy (23; 20%). Patients with cardiovascular comorbidity were more likely to develop cardiac complications. Regardless of history of cardiovascular disease, acute cardiac injury and heart failure were more common in deceased patients.\nSevere acute respiratory syndrome coronavirus 2 infection can cause both pulmonary and systemic inflammation, leading to multi-organ dysfunction in patients at high risk. Acute respiratory distress syndrome and respiratory failure, sepsis, acute cardiac injury, and heart failure were the most common critical complications during exacerbation of covid-19.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 167, "name": "Chen T "}], "publication_date": "2020-03-27"}, {"id": 427, "slug": "the-sensitivity-and-specificity-analyses-of-ambient-temperature-and-population-s", "title": "The sensitivity and specificity analyses of ambient temperature and population size on the transmission rate of the novel coronavirus (COVID-19) in different provinces of Iran", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer la sensibilit\u00e9 de la temp\u00e9rature annuelle moyenne et du nombre d'habitants dans diff\u00e9rentes provinces d'Iran pour y pr\u00e9dire le taux de transmission de la COVID-19", "verbose_date": "23.04.2020", "authors": "Jahangiri M", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 166, "name": "Science of The Total Environment"}, "link": "https://www.dropbox.com/s/9kc716gkqen6rba/10.1016%40j.scitotenv.2020.138872.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "D'apr\u00e8s cette \u00e9tude, dans chaque province iranienne, la taille de la population semble \u00eatre un pr\u00e9dicteur de l'importance du taux de cas de COVID-19 contrairement au param\u00e8tre climatique. Cependant, le choix d'utiliser la temp\u00e9rature annuelle moyenne plut\u00f4t que la temp\u00e9rature effective sur la m\u00eame p\u00e9riode que celle de l'\u00e9pid\u00e9mie pourrait \u00eatre \u00e0 l'origine de l'absence de lien observ\u00e9. Dans les villes et provinces fortement peupl\u00e9es, les mesures de contr\u00f4le de l'\u00e9pid\u00e9mie sont particuli\u00e8rement importantes.", "objectives": "- m\u00e9thodes peu d\u00e9taill\u00e9es- utilisation de la temp\u00e9rature annuelle moyenne de chaque province, pas forc\u00e9ment repr\u00e9sentative de la temp\u00e9rature au moment de l'\u00e9pid\u00e9mie de COVID-19- pas d'ajustement sur des facteurs de confusion", "methods": "D\u00e9terminer la sensibilit\u00e9 de la temp\u00e9rature annuelle moyenne et du nombre d'habitants dans diff\u00e9rentes provinces d'Iran pour y pr\u00e9dire le taux de transmission de la COVID-19", "pubmed_id": "32335407", "doi": "10.1016/j.scitotenv.2020.138872", "abstract": "On 10 April 2020, Iran reported 68,192 COVID-19 cumulative cases including 4232 death and 35,465 recovery cases. Numerous factors could influence the transmission rate and survival of coronavirus. On this basis and according to the latest epidemiological researches, both ambient temperature (AT) and population size (PS) can be considered as significant transmissibility factors for coronavirus. The analysis of receiver operating characteristics (ROC) allows measuring the performance of a classification model using the confusion matrix. This study intends to investigate the sensitivity of AT and PS on the transmission rate of the novel coronavirus in different provinces of Iran. For this purpose, the information of each province of Iran including the annual average of AT and the number of healthy and diseased cases are categorized. Subsequently, the sensitivity and specificity analyses of both AT and PS factors are performed. The obtained results confirm that AT and PS have low sensibility and high sensitivity, respectively. Thus, there is no scientific reason to confirm that the number of COVID-19 cases in warmer climates is less than that of moderate or cold climates. Therefore, it is recommended that the cities/provinces with a population of over 1.7 million people have stricter inspections and more precise controls as their management policy.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 406, "name": "Jahangiri M"}], "publication_date": "2020-04-23"}, {"id": 25, "slug": "effect-of-gastrointestinal-symptoms-on-patients-infected-with-covid-19", "title": "Effect of gastrointestinal symptoms on patients infected with COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Caract\u00e9riser l'impact des sympt\u00f4mes gastro-intestinaux d'une infection \u00e0 SRAS-CoV-2 sur la pr\u00e9sentation clinique, les complications, la prise en charge, et l'issue.", "verbose_date": "24.03.2020", "authors": "Zhou Z", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 21, "name": "Gastroenterology"}, "link": "https://www.dropbox.com/s/xgc0635a3p3hwg1/PIIS0016508520303620.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Sympt\u00f4mes gastro intestinaux fr\u00e9quence dans la pr\u00e9sentation clinique d'une infection \u00e0 SRAS-CoV-2\r\n- Ne semble pas avoir d'impact sur la survenue de complication ou l'issue de l'infection", "objectives": "- Multiplicit\u00e9 des tests statistiques- Incoh\u00e9rence des r\u00e9sultats entre les groupes personnel m\u00e9dical et non personnel m\u00e9dical- Majorit\u00e9 des patients (192/254) toujours hospitalis\u00e9, donc r\u00e9sultats sur les complications pr\u00e9matur\u00e9.- Groupes personnel m\u00e9dical et non personnel m\u00e9dical non comparable (\u00e2ge, comorbidit\u00e9)   * ces diff\u00e9rences pourraient expliquer les diff\u00e9rences de symptomatologies chez les patients ayant des sympt\u00f4mes GI dans le groupe non personnel m\u00e9dical - Patient diagnostiqu\u00e9 COVID 19 + cliniquement (faux positif)", "methods": "Caract\u00e9riser l'impact des sympt\u00f4mes gastro-intestinaux d'une infection \u00e0 SRAS-CoV-2 sur la pr\u00e9sentation clinique, les complications, la prise en charge, et l'issue.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 35, "name": "Zhou Z"}], "publication_date": "2020-03-24"}, {"id": 106, "slug": "real-estimates-of-mortality-following-covid-19-infection", "title": "Real estimates of mortality following COVID-19 infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00e9-estimer les taux de mortalit\u00e9 en tenant compte du temps d'incubation", "verbose_date": "12.03.2020", "authors": "Baud", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 70, "name": "The Lancet"}, "link": "https://www.dropbox.com/s/pe00vfuxa69aoj8/PIIS147330992030195X.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Possible sous estimation du risque de mortalit\u00e9 chez les patients symptomatiques :Taux plus \u00e9lev\u00e9 en dehors de Chine avec une moyenne autour de 5,7%", "objectives": "Faible : 1) Correspondance sans processus de blind reviewing2) Uniquement bas\u00e9 sur la bibliographie pr\u00e9c\u00e9dente et les hypoth\u00e8ses de l'auteur3) Pas de m\u00e9thodologie exp\u00e9rimentale permettant de confirmer ces propos", "methods": "R\u00e9-estimer les taux de mortalit\u00e9 en tenant compte du temps d'incubation", "pubmed_id": "32171390\n31986264", "doi": "10.1016/S1473-3099(20)30195-X", "abstract": null, "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 112, "name": "Baud"}], "publication_date": "2020-03-12"}, {"id": 543, "slug": "hydroxychloroquine-in-the-treatment-and-prophylaxis-of-sars-cov-2-infection-in-n", "title": "Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non- human primates", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Tester, chez des macaques infect\u00e9s par le SARS-CoV-2, diff\u00e9rentes strat\u00e9gies de traitement avec l\u2019hydroxychloroquine, seule ou en combinaison avec l'azithromycine, avant ou apr\u00e8s le pic de r\u00e9plication virale.", "verbose_date": "07.05.2020", "authors": "Maisonnasse P", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/cpg7cqcoyt0gv2e/v1.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Cette \u00e9tude n'a montr\u00e9 ni activit\u00e9 antivirale ni efficacit\u00e9 clinique du traitement \u00e0 l'hydroxychloroquine, quel que soit le moment o\u00f9 le traitement a \u00e9t\u00e9 instaur\u00e9, que ce soit avant l'infection, t\u00f4t apr\u00e8s l'infection (avant le pic de charge virale) ou tard apr\u00e8s l'infection (apr\u00e8s le pic de charge virale). Ceci en d\u00e9pit d'une concentration \u00e9lev\u00e9e de m\u00e9dicament dans le sang et d'une exposition des poumons et du plasma similaire \u00e0 celle observ\u00e9e chez les patients COVID trait\u00e9s \u00e0 l'hydroxychloroquine. Il est donc peu probable que le traitement par l\u2019hydroxychloroquine ait une activit\u00e9 antivirale dans les compartiments respiratoires chez l'homme.\nEn conclusion, l\u2019\u00e9valuation des r\u00e9sultats de l'hydroxychloroquine dans un mod\u00e8le de COVID-19 chez un primate non humain ne soutient pas son utilisation comme agent antiviral pour le traitement de COVID-19 chez l'homme.", "objectives": "-\tPreprint-\tEssai randomis\u00e9 chez les macaques-\t\u00c9chantillon limit\u00e9", "methods": "Tester, chez des macaques infect\u00e9s par le SARS-CoV-2, diff\u00e9rentes strat\u00e9gies de traitement avec l\u2019hydroxychloroquine, seule ou en combinaison avec l'azithromycine, avant ou apr\u00e8s le pic de r\u00e9plication virale.", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 508, "name": "Maisonnasse P"}], "publication_date": "2020-05-07"}, {"id": 355, "slug": "epidemiological-characteristics-of-covid-19-cases-in-italy-and-estimates-of-the-", "title": "Epidemiological characteristics of COVID-19 cases in Italy and estimates of the reproductive numbers one month into the epidemic", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00e9sumer les donn\u00e9es \u00e9pid\u00e9miologiques nationales italiennes des 60 000 premiers cas confirm\u00e9s de COVID-19 ainsi que les ph\u00e9nom\u00e8nes de transmission observ\u00e9s dans les diff\u00e9rentes r\u00e9gions du pays", "verbose_date": "16.04.2020", "authors": "Riccardo F", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.08.20056861v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Le retard de d\u00e9tection de la transmission locale du SARS-CoV-2 a probablement jou\u00e9 un r\u00f4le important dans l'ampleur de l'\u00e9pid\u00e9mie en Italie. La situation est tr\u00e8s variable selon les r\u00e9gions avec une majorit\u00e9 de cas dans le nord du pays. C'est aussi au nord qu'il semblerait que le taux de reproduction net ait commenc\u00e9 \u00e0 diminuer le plus t\u00f4t mais ces taux ont \u00e9t\u00e9 estim\u00e9s dans seulement 6 r\u00e9gions est le recul est insuffisant sur ces donn\u00e9es. Le taux de l\u00e9talit\u00e9 est \u00e9lev\u00e9 dans cette \u00e9tude mais certainement surestim\u00e9 puisque seuls les cas confirm\u00e9s par RT-PCR sont inclus. N\u00e9anmoins l'\u00e2ge et le sexe masculin paraissent \u00eatre des facteurs de mauvais pronostic. Il y a un grand nombre de cas parmi les soignants.", "objectives": "- pre-print- seulement les cas confirm\u00e9s par RT-PCR sont inclus pouvant expliquer le taux \u00e9lev\u00e9 de l\u00e9talit\u00e9 report\u00e9- d\u00e9finition large du statut de soignant : toute personne ayant d\u00e9j\u00e0 exerc\u00e9 dans le secteur de la sant\u00e9- estimation des taux de reproduction sur les donn\u00e9es de seulement 6 r\u00e9gions\"", "methods": "R\u00e9sumer les donn\u00e9es \u00e9pid\u00e9miologiques nationales italiennes des 60 000 premiers cas confirm\u00e9s de COVID-19 ainsi que les ph\u00e9nom\u00e8nes de transmission observ\u00e9s dans les diff\u00e9rentes r\u00e9gions du pays", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 342, "name": "Riccardo F"}], "publication_date": "2020-04-16"}, {"id": 573, "slug": "perinatal-depressive-and-anxiety-symptoms-of-pregnant-women-along-with-covid-19-", "title": "Perinatal depressive and anxiety symptoms of pregnant women along with COVID-19 outbreak in China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la pr\u00e9valence de la d\u00e9pression et de l'anxi\u00e9t\u00e9 parmi les femmes au 3e trimestre de grossesse apr\u00e8s la d\u00e9claration de l'\u00e9pid\u00e9mie de COVID-19, ainsi que les facteurs de risque associ\u00e9s.", "verbose_date": "12.05.2020", "authors": "Wu Y", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 175, "name": "Am J Obstet Gynecol"}, "link": "https://www.ajog.org/article/S0002-9378(20)30534-2/pdf", "findings": "", "take_away": "", "relevance_level": "- Augmentation de la pr\u00e9valence des sympt\u00f4mes d\u00e9pressifs et anxieux chez des femmes au 3e trimestre de grossesse apr\u00e8s l'annonce de la contagiosit\u00e9 inter-humaine du SARS-CoV-2.\n- Augmentation de la pr\u00e9valence de pens\u00e9es auto-agressives dans la p\u00e9riode \u00e9pid\u00e9mique.\n- Dans le cadre de l'\u00e9pid\u00e9mie COVID-19, les femmes enceintes primipares, de moins de 35 ans, avec une surface habitable/personne de plus (sic) de 20m2 et avec un IMC pr\u00e9-gestationnel \u226418.5 semblent plus \u00e0 risque de d\u00e9velopper des sympt\u00f4mes d\u00e9pressifs.", "objectives": "- Etude observationnelle transversale  - Pre-proof", "methods": "Etudier la pr\u00e9valence de la d\u00e9pression et de l'anxi\u00e9t\u00e9 parmi les femmes au 3e trimestre de grossesse apr\u00e8s la d\u00e9claration de l'\u00e9pid\u00e9mie de COVID-19, ainsi que les facteurs de risque associ\u00e9s.", "pubmed_id": "32437665", "doi": "10.1016/j.ajog.2020.05.009", "abstract": "On January 20, 2020, a new coronavirus epidemic with \"human-to-human\" transmission was officially announced by the Chinese government, which caused significant public panic in China. Pregnant women may be particularly vulnerable and in special need for preventative mental health strategies. Thus far, no reports exist to investigate the mental health response of pregnant women to the COVID-19 outbreak.\nThe aim of the present study is to examine the impact of COVID-19 outbreak on the prevalence of depressive and anxiety symptoms and the corresponding risk factors among pregnant women across China.\nA multi-center cross-sectional study was initiated in early December 2019 to identify mental health concerns in pregnancy using the Edinburgh Postnatal Depression Scale (EPDS). This study provided a unique opportunity to compare the mental status of pregnant women before and after the announcement of the COVID-19 epidemic. A total of 4124 pregnant women during their third trimester from 25 hospitals in 10 provinces across China were examined in this cross-sectional study from January 1 to February 9, 2020. Of these women, 1285 were assessed after January 20, 2020 when the coronavirus epidemic was publically announced and 2839 were assessed before this pivotal time point. The internationally recommended EPDS was used to assess maternal depression and anxiety symptoms. Prevalence rates and risk factors were compared between the pre and post study groups.\nPregnant women assessed after the declaration of COVID-19 epidemic had significantly higher rates of depressive symptoms (26.0% vs 29.6%, P=0.02) than women assess pre-epidemic announcement. These women were also more likely to endorse thoughts of self-harm (P=0.005). The depressive rates were positively associated with the number of newly-confirmed COVID-19 cases (P=0.003), suspected infections (P=0.004), and death cases per day (P=0.001). Pregnant women who were underweight pre-pregnancy, primiparous, < 35 years old, employed full-time, middle income, and had appropriate living space were at increased risk to develop depressive and anxiety symptoms during the outbreak.\nMajor life-threatening public health events such as the COVID-19 outbreak may increase the risk for mental illness among pregnant women including thoughts of self-harm. Strategies targeting maternal stress and isolation such as effective risk communication and the provision of psychological first aid may be particularly useful to prevent negative outcomes for women and their fetuses.", "topics": ["Epid\u00e9miologique", "Psychiatrie"], "author_list": [{"id": 33, "name": "Wu Y"}], "publication_date": "2020-05-12"}, {"id": 281, "slug": "evidence-that-vitamin-d-supplementation-could-reduce-risk-of-influenza-and-covid", "title": "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID- 19 Infections and Deaths", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Faire le point sur le r\u00f4le de la vitamine D dans la pr\u00e9vention des infections des voies respiratoires et l'int\u00e9r\u00eat de la suppl\u00e9mentation en vitamine D dans le COVID-19", "verbose_date": "08.04.2020", "authors": "Grant WB", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 132, "name": "Nutrients"}, "link": "https://www.dropbox.com/s/u4bvclh5g3a6mpx/nutrients-12-00988-v2.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Des \u00e9tudes solides sont n\u00e9cessaires pour statuer sur l'efficacit\u00e9 d'une suppl\u00e9mentation en vitamine D pour pr\u00e9venir la survenue de l'infection \u00e0 COVID-19 sp\u00e9cifiquement.", "objectives": "- revue narrative- \u00e9tudes cit\u00e9es de qualit\u00e9s in\u00e9gales- pas d'\u00e9tude sp\u00e9cifique sur le sujet dans le cadre de la COVID-19\"", "methods": "Faire le point sur le r\u00f4le de la vitamine D dans la pr\u00e9vention des infections des voies respiratoires et l'int\u00e9r\u00eat de la suppl\u00e9mentation en vitamine D dans le COVID-19", "pubmed_id": "32252338\n31071595\n29080638\n29853961\n31324202\n29480918\n17352842\n20186267\n30218062\n30382350\n29102433\n26690210\n28358827\n20592793\n31755707\n30328294\n21118827\n30048734\n28457494\n31506273\n31185932\n31173679\n28390010\n30601999\n31978945\n24330136\n27799758\n7462597\n26035247\n31567995\n19523595\n31439177\n25946368\n20515520\n30352414\n26151742\n25903964\n31699030\n21646368\n32171076\n31611877\n19918922\n31963293\n25496239\n29414327\n31615079\n26287796\n28216084\n28259644\n28760906\n24023689\n3156926\n20824663\n19843932\n10602348\n20429698\n29052924\n29409825\n28842142\n28350929\n12499343\n20559424\n30065699\n28903788\n22115013\n30115864\n29496507\n19299728\n29505145\n29949167\n31996793\n26557038\n27419080\n26113982\n26404359\n30092343\n25088394\n17634462\n21242105\n31673337\n25648729\n26458289\n30666233\n28877159\n19307527\n21803724\n32147032\n30312110\n25372709\n31883660\n31274211\n16959053\n32054544\n31662885\n32031570\n27380386\n32084305\n31005969\n25912039\n31075507\n24284777\n14585636\n31776371\n18101618\n2997282\n31852327\n32064853\n21995874\n16129616\n28114957\n31986264\n30646565\n28892933\n30076864\n30611908\n25738588\n22928073\n23782161\n28078341\n19204283\n31892611\n31959942\n27293435\n19556586\n22933544\n22928072\n30935437\n28686645\n20139241\n17727333\n29315160\n32214325\n31197611\n12803194\n7879731\n28539181\n16497887\n23003113\n28464004\n17953482\n32131740\n18298852\n22908115\n31330869\n29739069\n31484329\n28202713\n27489574\n31758375\n15030519\n32036122\n30415629\n22031815\n28477055\n20219962\n28856667", "doi": "10.3390/nu12040988", "abstract": "The world is in the grip of the COVID-19 pandemic. Public health measures that can reduce the risk of infection and death in addition to quarantines are desperately needed. This article reviews the roles of vitamin D in reducing the risk of respiratory tract infections, knowledge about the epidemiology of influenza and COVID-19, and how vitamin D supplementation might be a useful measure to reduce risk. Through several mechanisms, vitamin D can reduce risk of infections. Those mechanisms include inducing cathelicidins and defensins that can lower viral replication rates and reducing concentrations of pro-inflammatory cytokines that produce the inflammation that injures the lining of the lungs, leading to pneumonia, as well as increasing concentrations of anti-inflammatory cytokines. Several observational studies and clinical trials reported that vitamin D supplementation reduced the risk of influenza, whereas others did not. Evidence supporting the role of vitamin D in reducing risk of COVID-19 includes that the outbreak occurred in winter, a time when 25-hydroxyvitamin D (25(OH)D) concentrations are lowest; that the number of cases in the Southern Hemisphere near the end of summer are low; that vitamin D deficiency has been found to contribute to acute respiratory distress syndrome; and that case-fatality rates increase with age and with chronic disease comorbidity, both of which are associated with lower 25(OH)D concentration. To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/d of vitamin D", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 270, "name": "Grant WB"}], "publication_date": "2020-04-08"}, {"id": 10, "slug": "lung-recruitability-in-sars-cov-2-associated-acute-respiratory-distress-syndrome", "title": "Lung Recruitability in SARS-CoV-2 Associated Acute Respiratory Distress Syndrome: A Single-center, Observational Study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "developper une m\u00e9thode de mesure du recrutement pulmonaire", "verbose_date": "25.03.2020", "authors": "Pan C", "specialties": [{"id": 8, "name": "Pneumologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 3, "name": "Am J Respir Crit Care Med"}, "link": "https://www.dropbox.com/s/fti9qb5ki6alv53/rccm.202003-0527le.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "12 patients inclus- aucun n'avaient une fermeture complete des voies aerienne ni une auto PEEP- la pression motrice \u00e9tait \u00e9lev\u00e9e et la compliance faible- la majorit\u00e9 des patients \u00e9taient peu recrutables avec des PEEP hautes mais la recrutabilit\u00e9 semble changer quand on alterne avec du DV- l'alternance de DV/DD est suivie d'une augmentation du recrutement (\u00e0 confirmer)- l'am\u00e9lioration de l'oxyg\u00e9nation en DV n'est pas stat significative mais semble cliniquement parlante.- une fois que le Ratio \u00e9tait calcul\u00e9, la PEEP \u00e9tait mise entre 5-10 cmH2O si le recrutement \u00e9tait faible. Chez les patients a fort recrutement une PEEP plus haute \u00e9tait utilis\u00e9, aussi longtemps que le plateau de pression \u00e9tait tol\u00e9rable.\nLe recrutment pulmonaire peut etre mesur\u00e9 facilement au lit du patient", "objectives": "Faible :- petits effectifs (12) et not random- patients severes avec 22cmH2O de pression motrice malgr\u00e9 l'utilisation d'un volume courant de 6 ml/kg.- pas de gold standard pour comparer le ratio|- les patients ont eu des moyens de ventilations diff\u00e9rents avant d'arriver en r\u00e9a, il aurait fallu faire les mesures d\u00e8s qu'ils \u00e9taient intub\u00e9s.- 3 patients ont eu ECMO qui peu jouer sur le recrutment- la PEEP \u00e9tait r\u00e9gl\u00e9e chez chaque patient \u00e0 la discretion de chaque medecin", "methods": "developper une m\u00e9thode de mesure du recrutement pulmonaire", "topics": ["Autres", "Pneumologie"], "author_list": [{"id": 21, "name": "Pan C"}], "publication_date": "2020-03-25"}, {"id": 654, "slug": "covid-19-mortality-in-patients-with-cancer-on-chemotherapy-or-other-anticancer-t", "title": "COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les issues de l'infection COVID-19 chez des patients symptomatiques porteurs d'un cancer, \u00e9valuer l'impact d'une pathologie canc\u00e9reuse et des chimioth\u00e9rapires cytotoxiques sur le ph\u00e9notype de l'infection COVID-19.\r\n\r\n ", "verbose_date": "04.06.2020", "authors": "Lee LYW", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931173-9", "findings": "", "take_away": "", "relevance_level": "Mortalit\u00e9 globale de 28%.\nLes patients porteurs d'un cancer actif et pr\u00e9sentant une COVID-19 symptomatique semblent plus \u00e0 risque de d\u00e9c\u00e8s si ils sont \u00e2g\u00e9s, de sexe masculin, pr\u00e9sentant une HTA ou une maladie cardio-vasculaire.\nParmi les patients ayant re\u00e7u une chimioth\u00e9rapie au cours des 4 semaines pr\u00e9c\u00e9dant l'infection, il ne semble pas y avoir de surmortalit\u00e9. M\u00eame observation pour les immunoth\u00e9rapies, hormonoth\u00e9rapies, radioth\u00e9rapies et th\u00e9rapies cibl\u00e9es.", "objectives": "- \u00c9tude observationnelle prospective, descriptive.- Biais de s\u00e9lection probable : biais de recrutement (faux n\u00e9gatifs de RT-PCR) et d'\u00e9chantillonnage (malades symptomatiques uniquement)- Biais de confusion majeur non pris en compte : le stade du cancer (entre autre l'absence de diff\u00e9rence de mortalit\u00e9 entre les sous-groupes \"chimioth\u00e9rapie dans les 4 semaines\" et \"pas de chimioth\u00e9rapie\" peut \u00eatre due \u00e0 une surrepr\u00e9sentation de malades \u00e0 un stade avanc\u00e9e de la maladie dans le sous-groupe \"pas de chimioth\u00e9rapie\")", "methods": "D\u00e9crire les issues de l'infection COVID-19 chez des patients\u00a0symptomatiques porteurs d'un cancer, \u00e9valuer l'impact d'une pathologie canc\u00e9reuse et des chimioth\u00e9rapires cytotoxiques sur le ph\u00e9notype de l'infection COVID-19.", "pubmed_id": "32473682\n32304634\n32405058\n32240603\n32066541\n18929686\n22777516", "doi": "10.1016/S0140-6736(20)31173-9", "abstract": "Individuals with cancer, particularly those who are receiving systemic anticancer treatments, have been postulated to be at increased risk of mortality from COVID-19. This conjecture has considerable effect on the treatment of patients with cancer and data from large, multicentre studies to support this assumption are scarce because of the contingencies of the pandemic. We aimed to describe the clinical and demographic characteristics and COVID-19 outcomes in patients with cancer.\nIn this prospective observational study, all patients with active cancer and presenting to our network of cancer centres were eligible for enrolment into the UK Coronavirus Cancer Monitoring Project (UKCCMP). The UKCCMP is the first COVID-19 clinical registry that enables near real-time reports to frontline doctors about the effects of COVID-19 on patients with cancer. Eligible patients tested positive for severe acute respiratory syndrome coronavirus 2 on RT-PCR assay from a nose or throat swab. We excluded patients with a radiological or clinical diagnosis of COVID-19, without a positive RT-PCR test. The primary endpoint was all-cause mortality, or discharge from hospital, as assessed by the reporting sites during the patient hospital admission.\nFrom March 18, to April 26, 2020, we analysed 800 patients with a diagnosis of cancer and symptomatic COVID-19. 412 (52%) patients had a mild COVID-19 disease course. 226 (28%) patients died and risk of death was significantly associated with advancing patient age (odds ratio 9\u00b742 [95% CI 6\u00b756-10\u00b702]; p<0\u00b70001), being male (1\u00b767 [1\u00b719-2\u00b734]; p=0\u00b7003), and the presence of other comorbidities such as hypertension (1\u00b795 [1\u00b736-2\u00b780]; p<0\u00b7001) and cardiovascular disease (2\u00b732 [1\u00b747-3\u00b764]). 281 (35%) patients had received cytotoxic chemotherapy within 4 weeks before testing positive for COVID-19. After adjusting for age, gender, and comorbidities, chemotherapy in the past 4 weeks had no significant effect on mortality from COVID-19 disease, when compared with patients with cancer who had not received recent chemotherapy (1\u00b718 [0\u00b781-1\u00b772]; p=0\u00b7380). We found no significant effect on mortality for patients with immunotherapy, hormonal therapy, targeted therapy, radiotherapy use within the past 4 weeks.\nMortality from COVID-19 in cancer patients appears to be principally driven by age, gender, and comorbidities. We are not able to identify evidence that cancer patients on cytotoxic chemotherapy or other anticancer treatment are at an increased risk of mortality from COVID-19 disease compared with those not on active treatment.\nUniversity of Birmingham, University of Oxford.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 615, "name": "Lee LYW"}], "publication_date": "2020-06-04"}, {"id": 645, "slug": "early-transmission-dynamics-in-wuhan-china-of-novel-coronavirus-infected-pneumon", "title": "Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques \u00e9pid\u00e9miologiques et la dynamique de transmission des premiers cas de COVID-19.", "verbose_date": "02.06.2020", "authors": "Li Q", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001316?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Sur la base de ces informations, il existe des preuves qu'une transmission interhumaine a eu lieu parmi des contacts \u00e9troits depuis la mi-d\u00e9cembre 2019.", "objectives": "n=425 cas de WuhanEstimation de la p\u00e9riode d'incubation sur 10 casD\u00e9finition des cas pr\u00e9sum\u00e9s assez s\u00e9v\u00e8re et excluant les pr\u00e9sentations atypiquesPCR disponible \u00e0 partir du 11 janvierModifications des crit\u00e8res des cas pr\u00e9sum\u00e9s au 18 janvierFinanc\u00e9 entre autres par le Minist\u00e8re des Sciences et Technologies de Chine", "methods": "D\u00e9crire les caract\u00e9ristiques \u00e9pid\u00e9miologiques et la dynamique de transmission des premiers cas de COVID-19.", "pubmed_id": "31995857\n31986261\n12766207\n31978945\n26468744\n24206646\n31978944\n31992388\n16222170\n19679345\n27344959\n31978293\n24896817\n31971553", "doi": "10.1056/NEJMoa2001316", "abstract": "The initial cases of novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) occurred in Wuhan, Hubei Province, China, in December 2019 and January 2020. We analyzed data on the first 425 confirmed cases in Wuhan to determine the epidemiologic characteristics of NCIP.\nWe collected information on demographic characteristics, exposure history, and illness timelines of laboratory-confirmed cases of NCIP that had been reported by January 22, 2020. We described characteristics of the cases and estimated the key epidemiologic time-delay distributions. In the early period of exponential growth, we estimated the epidemic doubling time and the basic reproductive number.\nAmong the first 425 patients with confirmed NCIP, the median age was 59 years and 56% were male. The majority of cases (55%) with onset before January 1, 2020, were linked to the Huanan Seafood Wholesale Market, as compared with 8.6% of the subsequent cases. The mean incubation period was 5.2 days (95% confidence interval [CI], 4.1 to 7.0), with the 95th percentile of the distribution at 12.5 days. In its early stages, the epidemic doubled in size every 7.4 days. With a mean serial interval of 7.5 days (95% CI, 5.3 to 19), the basic reproductive number was estimated to be 2.2 (95% CI, 1.4 to 3.9).\nOn the basis of this information, there is evidence that human-to-human transmission has occurred among close contacts since the middle of December 2019. Considerable efforts to reduce transmission will be required to control outbreaks if similar dynamics apply elsewhere. Measures to prevent or reduce transmission should be implemented in populations at risk. (Funded by the Ministry of Science and Technology of China and others.).", "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 498, "name": "Li Q"}], "publication_date": "2020-06-02"}, {"id": 197, "slug": "development-and-validation-of-a-rapid-single-step-reverse-transcriptase-loop-med", "title": "Development and validation of a rapid single-step reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) system potentially to be used for reliable and high-throughput screening of COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9velopper et valider un RT-LAMP : reverse transcriptase loop-mediated isothermal amplification technique pour une identification rapide du SARS Cov-2", "verbose_date": "31.03.2020", "authors": "Jiang M ", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/blvnkrhnb1kkbrv/2020.03.15.20036376v2.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "RT-LAMP plus rapide que RT-PCR avec bonne sensibilit\u00e9 et sp\u00e9cificit\u00e9 dans cette \u00e9tude\r\nStock possible \u00e0 temp\u00e9rature ambiante\r\n\u00e0 confirmer par d'autres \u00e9tudes", "objectives": "1) Pre-proof2) Pas de notion d'aveugle, modalit\u00e9 de s\u00e9lection des patients tr\u00e8s mal d\u00e9crite3) Deux centres4) Gold-standard ici 2 tests de RT-PCR quantitative le jour de la RT-LAMP\"", "methods": "D\u00e9velopper et valider un RT-LAMP : reverse transcriptase loop-mediated isothermal amplification technique pour une identification rapide du SARS Cov-2", "topics": ["Diagnostique", "Virologie"], "author_list": [{"id": 189, "name": "Jiang M "}], "publication_date": "2020-03-31"}, {"id": 102, "slug": "clinical-laboratory-and-imaging-features-of-covid-19-a-systematic-review-and-met", "title": "Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "R\u00e9sumer les caract\u00e9ristiques cliniques, biologiques et radiologiques du COVID-19 Examiner l'issue des cas de COVID-19, en incluant les facteurs de risque, les patients n\u00e9cessitant des soins intensifs et les d\u00e9c\u00e8s\u00c9valuer la pr\u00e9valence des comorbidit\u00e9s parmi les cas confirm\u00e9s de COVID-19.", "verbose_date": "13.03.2020", "authors": "Rodriguez-Morales AJ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 69, "name": "Travel Med Infect Dis"}, "link": "https://www.dropbox.com/s/pkhnymwxs4kgp2d/1-s2.0-S1477893920300910-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Signes principaux fi\u00e8vre et toux chez l'adulte, moins fr\u00e9quent ches les enfantsBiologie : hypoalbumin\u00e9mie fr\u00e9quenteRadiologie : atteinte bilat\u00e9rale aspect de verre d\u00e9poli20% des patients hospitalis\u00e9s n\u00e9cessitent des soins intensifs, d\u00e9c\u00e8s chez 13,9% des patients hospitalis\u00e9sAtteinte respiratoire, cardiaque et r\u00e9nale", "objectives": "Interm\u00e9diaire1) M\u00e9thodologie globalement bonne mais grande h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e92) 19 \u00e9tudes dans la m\u00e9ta-analyse (dont 18 \u00e9tudes chinoises et 1 australienne ) : au total 2 874 patients / souvent moins d'une dizaine d'\u00e9tudes pour une variable...3) 39 \u00e9tudes de cas: au total 126 patients", "methods": "R\u00e9sumer les caract\u00e9ristiques cliniques, biologiques et radiologiques du COVID-19 Examiner l'issue des cas de COVID-19, en incluant les facteurs de risque, les patients n\u00e9cessitant des soins intensifs et les d\u00e9c\u00e8s\u00c9valuer la pr\u00e9valence des comorbidit\u00e9s parmi les cas confirm\u00e9s de COVID-19.", "pubmed_id": "32179124", "doi": "10.1016/j.tmaid.2020.101623", "abstract": "An epidemic of Coronavirus Disease 2019 (COVID-19) began in December 2019 in China leading to a Public Health Emergency of International Concern (PHEIC). Clinical, laboratory, and imaging features have been partially characterized in some observational studies. No systematic reviews on COVID-19 have been published to date.\nWe performed a systematic literature review with meta-analysis, using three databases to assess clinical, laboratory, imaging features, and outcomes of COVID-19 confirmed cases. Observational studies and also case reports, were included, and analyzed separately. We performed a random-effects model meta-analysis to calculate pooled prevalences and 95% confidence intervals (95%CI).\n660 articles were retrieved for the time frame (1/1/2020-2/23/2020). After screening, 27 articles were selected for full-text assessment, 19 being finally included for qualitative and quantitative analyses. Additionally, 39 case report articles were included and analyzed separately. For 656 patients, fever (88.7%, 95%CI 84.5-92.9%), cough (57.6%, 95%CI 40.8-74.4%) and dyspnea (45.6%, 95%CI 10.9-80.4%) were the most prevalent manifestations. Among the patients, 20.3% (95%CI 10.0-30.6%) required intensive care unit (ICU), 32.8% presented with acute respiratory distress syndrome (ARDS) (95%CI 13.7-51.8), 6.2% (95%CI 3.1-9.3) with shock. Some 13.9% (95%CI 6.2-21.5%) of hospitalized patients had fatal outcomes (case fatality rate, CFR).\nCOVID-19 brings a huge burden to healthcare facilities, especially in patients with comorbidities. ICU was required for approximately 20% of polymorbid, COVID-19 infected patients and hospitalization was associated with a CFR of >13%. As this virus spreads globally, countries need to urgently prepare human resources, infrastructure and facilities to treat severe COVID-19.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 108, "name": "Rodriguez-Morales AJ"}], "publication_date": "2020-03-13"}, {"id": 622, "slug": "features-of-20-133-uk-patients-in-hospital-with-covid-19-using-the-isaric-who-cl", "title": "Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques cliniques des patients admis \u00e0 l'h\u00f4pital avec la maladie \u00e0 coronavirus 2019 (covid-19) au Royaume-Uni pendant la phase de croissance de la premi\u00e8re vague de cette \u00e9pid\u00e9mie, qui ont \u00e9t\u00e9 recrut\u00e9s dans l'\u00e9tude de l\u2019International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK), et explorer les facteurs de risque associ\u00e9s \u00e0 la mortalit\u00e9 \u00e0 l'h\u00f4pital.\r\n\r\n ", "verbose_date": "30.05.2020", "authors": "Docherty AB", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 57, "name": "BMJ"}, "link": "https://www.bmj.com/content/bmj/369/bmj.m1985.full.pdf", "findings": "", "take_away": "", "relevance_level": "ISARIC WHO CCP-UK est une vaste \u00e9tude de cohorte prospective sur des patients hospitalis\u00e9s atteints de covid-19. L'\u00e9tude est toujours en cours au moment de la r\u00e9daction de ce rapport.\nLa plupart des patients atteints de covid-19 pr\u00e9sentent une maladie b\u00e9nigne. Cependant, dans cette cohorte, parmi ceux qui ont \u00e9t\u00e9 admis \u00e0 l'h\u00f4pital deux semaines avant l'extraction des donn\u00e9es, moins de la moiti\u00e9 \u00e9taient sortis et un quart \u00e9taient d\u00e9c\u00e9d\u00e9s. Les autres patients ont continu\u00e9 de\u00a0recevoir des soins \u00e0 la date du rapport. 17%\u00a0des patients admis \u00e0 l'h\u00f4pital ont eu besoin de soins\u00a0critiques. Les facteurs associ\u00e9s \u00e0 la mortalit\u00e9 \u00e0 l'h\u00f4pital \u00e9taient l'\u00e2ge croissant, le sexe masculin, l'ob\u00e9sit\u00e9 et les comorbidit\u00e9s majeures.\nCette vaste \u00e9tude men\u00e9e rapidement sur des patients hospitalis\u00e9s en Angleterre, au Pays de Galles et en \u00c9cosse a montr\u00e9 l'importance de la pr\u00e9paration \u00e0 une pand\u00e9mie et la n\u00e9cessit\u00e9 de rester pr\u00eat \u00e0 lancer des \u00e9tudes de recherche en r\u00e9ponse aux \u00e9pid\u00e9mies.", "objectives": "- \u00c9tude de cohorte observationnelle prospective avec collecte rapide de donn\u00e9es et analyse en temps quasi r\u00e9el.- N = 20 133 patients hospitalis\u00e9s atteints du covid-19.- 208 h\u00f4pitaux en Angleterre, au Pays de Galles et en \u00c9cosse", "methods": "D\u00e9crire les caract\u00e9ristiques cliniques des patients admis \u00e0 l'h\u00f4pital avec la maladie \u00e0 coronavirus 2019 (covid-19) au Royaume-Uni pendant la phase de croissance de la premi\u00e8re vague de cette \u00e9pid\u00e9mie, qui ont \u00e9t\u00e9 recrut\u00e9s dans l'\u00e9tude de l\u2019International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK), et explorer les facteurs de risque associ\u00e9s \u00e0 la mortalit\u00e9 \u00e0 l'h\u00f4pital.", "pubmed_id": "32444460\n22407890\n32178769\n32203977\n32109013\n32250385\n32240634\n31006605\n26692185\n32320003\n31986264\n29403115\n32007143\n31488196\n20627925\n32330939", "doi": "10.1136/bmj.m1985", "abstract": "To characterise the clinical features of patients admitted to hospital with coronavirus disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave of this outbreak who were enrolled in the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) study, and to explore risk factors associated with mortality in hospital.\nProspective observational cohort study with rapid data gathering and near real time analysis.\n208 acute care hospitals in England, Wales, and Scotland between 6 February and 19 April 2020. A case report form developed by ISARIC and WHO was used to collect clinical data. A minimal follow-up time of two weeks (to 3 May 2020) allowed most patients to complete their hospital admission.\n20\u2009133 hospital inpatients with covid-19.\nAdmission to critical care (high dependency unit or intensive care unit) and mortality in hospital.\nThe median age of patients admitted to hospital with covid-19, or with a diagnosis of covid-19 made in hospital, was 73 years (interquartile range 58-82, range 0-104). More men were admitted than women (men 60%, n=12\u2009068; women 40%, n=8065). The median duration of symptoms before admission was 4 days (interquartile range 1-8). The commonest comorbidities were chronic cardiac disease (31%, 5469/17\u2009702), uncomplicated diabetes (21%, 3650/17\u2009599), non-asthmatic chronic pulmonary disease (18%, 3128/17\u2009634), and chronic kidney disease (16%, 2830/17\u2009506); 23% (4161/18\u2009525) had no reported major comorbidity. Overall, 41% (8199/20\u2009133) of patients were discharged alive, 26% (5165/20\u2009133) died, and 34% (6769/20\u2009133) continued to receive care at the reporting date. 17% (3001/18\u2009183) required admission to high dependency or intensive care units; of these, 28% (826/3001) were discharged alive, 32% (958/3001) died, and 41% (1217/3001) continued to receive care at the reporting date. Of those receiving mechanical ventilation, 17% (276/1658) were discharged alive, 37% (618/1658) died, and 46% (764/1658) remained in hospital. Increasing age, male sex, and comorbidities including chronic cardiac disease, non-asthmatic chronic pulmonary disease, chronic kidney disease, liver disease and obesity were associated with higher mortality in hospital.\nISARIC WHO CCP-UK is a large prospective cohort study of patients in hospital with covid-19. The study continues to enrol at the time of this report. In study participants, mortality was high, independent risk factors were increasing age, male sex, and chronic comorbidity, including obesity. This study has shown the importance of pandemic preparedness and the need to maintain readiness to launch research studies in response to outbreaks.\nISRCTN66726260.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 585, "name": "Docherty AB"}], "publication_date": "2020-05-30"}, {"id": 621, "slug": "individual-quarantine-versus-active-monitoring-of-contacts-for-the-mitigation-of", "title": "Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparer l'efficacit\u00e9 de la quarantaine individuelle et du monitoring actif des contacts dans diff\u00e9rents sc\u00e9narios sur le contr\u00f4le de l'\u00e9pidemie de Covid-19.", "verbose_date": "25.05.2020", "authors": "Peak CM", "specialties": [{"id": 21, "name": "Confinement/D\u00e9confinement"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 74, "name": "Lancet Infect Dis"}, "link": "https://www.thelancet.com/action/showPdf?pii=S1473-3099%2820%2930361-3", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude de mod\u00e9lisation, les r\u00e9sultats sur l'efficacit\u00e9 de la quarantaine individuelle ou du monitoring actif d\u00e9pendent fortement des param\u00e8tres entr\u00e9s, et notamment du temps d'intervalle s\u00e9riel et de la transmission pr\u00e9symptomatique.\r\nLe d\u00e9but de l'infectiosit\u00e9 par rapport au d\u00e9but des sympt\u00f4mes varie de -0.8 \u00e0 +0.5 jours.\r\nQuarantaine individuelle et monitoring actif participent \u00e0 la limitation de l'\u00e9pid\u00e9mie.\r\nD'autres \u00e9tudes sont n\u00e9cessaires pour affiner les param\u00e8tres utilis\u00e9s dans le mod\u00e8le.", "objectives": "- Etude de mod\u00e9lisation avec un mod\u00e8le SEIR- Utilisant diff\u00e9rents sc\u00e9narios avec des hypoth\u00e8ses sens\u00e9es- Mais param\u00e8tres entr\u00e9s \u00e0 partir d'autres \u00e9tudes et contenant une forte approximation (d\u00e9finis dans les premiers stades de l\u2019\u00e9pid\u00e9mie)- Pas de prise en compte de la d\u00e9pl\u00e9tion des susceptibles dans le mod\u00e8le- Hypoth\u00e8se forte de R0 constant selon les sc\u00e9narios", "methods": "Comparer l'efficacit\u00e9 de la quarantaine individuelle et du monitoring actif des contacts dans diff\u00e9rents sc\u00e9narios sur le contr\u00f4le de l'\u00e9pidemie de Covid-19.", "pubmed_id": "32445710\n29138130\n29947788\n32119825\n15071187\n28351976\n32003551\n32191691\n31995857\n14693876\n15752447", "doi": "10.1016/S1473-3099(20)30361-3", "abstract": "Voluntary individual quarantine and voluntary active monitoring of contacts are core disease control strategies for emerging infectious diseases such as COVID-19. Given the impact of quarantine on resources and individual liberty, it is vital to assess under what conditions individual quarantine can more effectively control COVID-19 than active monitoring. As an epidemic grows, it is also important to consider when these interventions are no longer feasible and broader mitigation measures must be implemented.\nTo estimate the comparative efficacy of individual quarantine and active monitoring of contacts to control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we fit a stochastic branching model to reported parameters for the dynamics of the disease. Specifically, we fit a model to the incubation period distribution (mean 5\u00b72 days) and to two estimates of the serial interval distribution: a shorter one with a mean serial interval of 4\u00b78 days and a longer one with a mean of 7\u00b75 days. To assess variable resource settings, we considered two feasibility settings: a high-feasibility setting with 90% of contacts traced, a half-day average delay in tracing and symptom recognition, and 90% effective isolation; and a low-feasibility setting with 50% of contacts traced, a 2-day average delay, and 50% effective isolation.\nModel fitting by sequential Monte Carlo resulted in a mean time of infectiousness onset before symptom onset of 0\u00b777 days (95% CI -1\u00b798 to 0\u00b729) for the shorter serial interval, and for the longer serial interval it resulted in a mean time of infectiousness onset after symptom onset of 0\u00b751 days (95% CI -0\u00b777 to 1\u00b750). Individual quarantine in high-feasibility settings, where at least 75% of infected contacts are individually quarantined, contains an outbreak of SARS-CoV-2 with a short serial interval (4\u00b78 days) 84% of the time. However, in settings where the outbreak continues to grow (eg, low-feasibility settings), so too will the burden of the number of contacts traced for active monitoring or quarantine, particularly uninfected contacts (who never develop symptoms). When resources are prioritised for scalable interventions such as physical distancing, we show active monitoring or individual quarantine of high-risk contacts can contribute synergistically to mitigation efforts. Even under the shorter serial interval, if physical distancing reduces the reproductive number to 1\u00b725, active monitoring of 50% of contacts can result in overall outbreak control (ie, effective reproductive number <1).\nOur model highlights the urgent need for more data on the serial interval and the extent of presymptomatic transmission to make data-driven policy decisions regarding the cost-benefit comparisons of individual quarantine versus active monitoring of contacts. To the extent that these interventions can be implemented, they can help mitigate the spread of SARS-CoV-2.\nNational Institute of General Medical Sciences, National Institutes of Health.", "topics": ["Mod\u00e9lisation", "Confinement/D\u00e9confinement", "Infectiologie"], "author_list": [{"id": 584, "name": "Peak CM"}], "publication_date": "2020-05-25"}, {"id": 388, "slug": "laboratory-data-analysis-of-novel-coronavirus-covid-19-screening-in-2510-patient", "title": "Laboratory data analysis of novel coronavirus (COVID-19) screening in 2510 patients", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques de la biologie sanguine des patients COVID-19 et la comparer \u00e0 celle des patients non COVID-19", "verbose_date": "20.04.2020", "authors": "Yun H", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 164, "name": "Clinica Chimica Acta"}, "link": "https://reader.elsevier.com/reader/sd/pii/S000989812030173X?token=2355EA4E29D0224CF9AC311DF1D529C1C355195CA12C4DCA7A583F05A73A2F43F643D61A3B93E7E4531261D4ACC35D06", "findings": "", "take_away": "", "relevance_level": "- tend \u00e0 la confirmation d'une diminution de la num\u00e9ration et du ratio des lymphocytes et des \u00e9osinophiles pr\u00e9c\u00e9demment d\u00e9crites chez les patients positifs au COVID-19 par rapports aux patients indemnes\r\n- tend \u00e0 la confirmation d\u2019une \u00e9l\u00e9vation de la prot\u00e9in\u00e9mie, de l'albumin\u00e9mie et d\u2019une diminution de l\u2019ur\u00e9mie chez les patients positifs au COVID-19 par rapport aux patients indemnes\r\n- d\u00e9tection d'ARN COVID-19 dans les selles de 8 patients sur 43 : pourrait avoir un int\u00e9r\u00eat en alternative \u00e0 l'\u00e9couvillonnage naso-pharyng\u00e9 si contre-indication ou en couplage pour augmenter la sensibilit\u00e9 du d\u00e9pistage", "objectives": "- \u00e9tude observationnelle descriptive r\u00e9trospective monocentrique- seulement 32 cas de COVID-19 inclus- pas de description des normes biologiques utilis\u00e9es- pre-proof", "methods": "D\u00e9crire les caract\u00e9ristiques de la biologie sanguine des patients COVID-19 et la comparer \u00e0 celle des patients non COVID-19", "pubmed_id": "32315614\n32077115\n32075786\n32102928\n31986259\n31986264\n32048163\n32003551\n32044814\n31986261\n32015507\n32114074\n32007145", "doi": "10.1016/j.cca.2020.04.018", "abstract": "Novel coronavirus (COVID-19) is highly infectious and requires early detection, isolation, and treatment. We tried to find some useful information by analyzing the covid-19 screening data, so as to provide help for clinical practice.\nWe collected nucleic acid and hematology data from 2510 patients for COVID-19 infection for retrospective analysis.\nCOVID-19 and influenza A and B infection rates were 1.3%, 3%, and 3%, respectively. COVID-19 nucleic acid was detected in stool but not in tear samples from 8 positive patients. Among the 32 patients with COVID-19, 15 (47%) and 16 (50%) patients showed decreased lymphocyte count and lymphocyte ratio, 21(66%) and 24(75%) patients showed decreased eosinophil count and eosinophil ratio, and 18 (56%) patients showed increased C-reactive protein. Ten hematological indicators significantly differed in the blood of patients with COVID-19 and those with influenza A and B (P\u00a0<\u00a00.05). Eighteen hematological indicators significantly differed between patients with COVID-19 and negative patients (P\u00a0<\u00a00.05).\nThe positive rate of influenza A and B infection was higher than that of COVID-19. When pharyngeal swab collection may cause infection, fecal samples can be examined. Evaluation of pharyngeal swab and fecal samples can improve the positive rate of nucleic acid detection. The COVID-19 can cause some hematological indices changes.", "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 374, "name": "Yun H"}], "publication_date": "2020-04-20"}, {"id": 233, "slug": "liver-impairment-in-covid-19-patients-a-retrospective-analysis-of-115-cases-from", "title": "Liver Impairment in COVID-19 Patients: A Retrospective Analysis of 115 Cases From a Single Center in Wuhan City, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyser la signification clinique des perturbations h\u00e9patiques durant la COVID-19 et sa relation avec la progression de la maladie", "verbose_date": "02.04.2020", "authors": "Zhang Y", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 63, "name": "Liver Int"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.14455", "findings": "", "take_away": "", "relevance_level": "Il semble que le foie n'est pas une cible majeure du SARS-CoV-2. Cela pourrait s'expliquer par la faible expression de l'ACE 2 dans le tissu h\u00e9patique. Les quelques anomalies observ\u00e9es restaient l\u00e9g\u00e8res.", "objectives": "1) Exclusions : 4 mineurs (< 14 ans) et 2 patients atteints d'h\u00e9patique B chronique2) Faibles effectifs pour l'analyse de l'\u00e9volution chez les patients critiques3) Pas de correction de l'inflation du risque alpha4) Choix de comparaison \u00e0 un groupe contr\u00f4le de patients avec pneumopathie communautaire discutable\"", "methods": "Analyser la signification clinique des perturbations h\u00e9patiques durant la COVID-19 et sa relation avec la progression de la maladie", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 223, "name": "Zhang Y"}], "publication_date": "2020-04-02"}, {"id": 51, "slug": "covid-19-what-should-anesthetists-and-intensivists-know-about-it", "title": "COVID-19 \u2013 what should anesthetists and intensivists know about it?", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "R\u00e9pertorier les derni\u00e8res informations sur le COVID-19 pour sa prise en charge par les anesth\u00e9sistes et r\u00e9animateurs", "verbose_date": "20.03.2020", "authors": "Magdalena A", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 45, "name": "Anaesth Intensive Ther"}, "link": "https://www.dropbox.com/s/g5kurc2f1v8zcmm/10.5114%40ait.2020.93756.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Article tr\u00e8s dense avec nombreux d\u00e9tails techniques difficiles \u00e0 r\u00e9sumer ici. Avant tout et dans l'attente d'un traitement anti-infectieux d'efficacit\u00e9 prouv\u00e9e, les r\u00e8gles d'hygi\u00e8ne et de protection personelle sont essentielles et particuli\u00e8rement dans les services de soins intentifs et r\u00e9animation o\u00f9 les personnels sont tr\u00e8s expos\u00e9s notamment \u00e0 cause d'a\u00e9rosols infectieux et lors d'\u00e9v\u00e8nements aigus o\u00f9 l'\u00e9quipement personnel des soignants est moins bon (RCP++).", "objectives": "Interm\u00e9diaire : 1) Bas\u00e9 sur la bibliographie existante (revue)2) Encore peu d'\u00e9tudes en r\u00e9animation sur le COVID-19", "methods": "R\u00e9pertorier les derni\u00e8res informations sur le COVID-19 pour sa prise en charge par les anesth\u00e9sistes et r\u00e9animateurs", "topics": ["Autres", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 61, "name": "Magdalena A"}], "publication_date": "2020-03-20"}, {"id": 572, "slug": "prevalence-and-duration-of-acute-loss-of-smell-or-taste-in-covid-19-patients", "title": "Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9terminer la pr\u00e9valence de la perte aigu\u00eb d'odeur ou de go\u00fbt chez les patients COVID-19", "verbose_date": "12.05.2020", "authors": "Lee Y", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 33, "name": "J Korean Med Sci"}, "link": "https://doi.org/10.3346/jkms.2020.35.e174", "findings": "", "take_away": "", "relevance_level": "L'anosmie et l'agueusie semblent faire partie des sympt\u00f4mes importants et des indices pour le diagnostic du Covid-19 particuli\u00e8rement dans les stades pr\u00e9coces de la maladie.\nLes sympt\u00f4mes peuvent regresser en\u00a03 semaines.", "objectives": "- Etude prospective- Echantillon de grande taille- Syst\u00e8me de score de la s\u00e9v\u00e9rit\u00e9 par t\u00e9l\u00e9phone constitue une limitation quant \u00e0 l'\u00e9valuation exacte des patients", "methods": "D\u00e9terminer la pr\u00e9valence de la perte aigu\u00eb d'odeur ou de go\u00fbt chez les patients COVID-19", "pubmed_id": "32383370\n32242348\n32109013\n18495771\n32356867\n25294743\n32267483\n32253535\n32307026\n32215618\n32064853\n31986264\n32007143\n32105632\n22558054\n32094336\n32301298", "doi": "10.3346/jkms.2020.35.e174", "abstract": "Initially, acute loss of smell (anosmia) and taste (ageusia) was not considered important symptoms for coronavirus disease 2019 (COVID-19). To determine the prevalence of these symptoms and to evaluate their diagnostic significance, we (approximately 150 physicians of the Daegu Medical Association) prospectively collected data of cases of anosmia and ageusia from March 8, 2020, via telephone interview among 3,191 patients in Daegu, Korea. Acute anosmia or ageusia was observed in 15.3% (488/3,191) patients in the early stage of COVID-19 and in 15.7% (367/2,342) patients with asymptomatic-to-mild disease severity. Their prevalence was significantly more common among females and younger individuals (", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 537, "name": "Lee Y"}], "publication_date": "2020-05-12"}, {"id": 306, "slug": "severe-acute-respiratory-syndrome-coronavirus-specific-antibody-responses-in-cor", "title": "Severe Acute Respiratory Syndrome Coronavirus. Specific Antibody Responses in Coronavirus Disease 2019 Patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9veloppement de tests s\u00e9rologiques pour la d\u00e9tection des anticorps neutralisants du SARS-CoV-2, des prot\u00e9ines sp\u00e9cifiques aux spikes et des Ac sp\u00e9cifiques des nucl\u00e9ocapsides.", "verbose_date": "09.04.2020", "authors": "Nisreen MAO", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 28, "name": "Emerg Infect Dis"}, "link": "https://wwwnc.cdc.gov/eid/article/26/7/20-0841_article", "findings": "", "take_away": "", "relevance_level": "La pluparts des patients SARS-CoV 2 confirm\u00e9s ont eu une s\u00e9roconversion dans les 2 semaines apr\u00e8s le d\u00e9but de la maladie.\r\nLa s\u00e9roconversion IgG peut \u00eatre confirm\u00e9e de mani\u00e8re fiable dans la deuxi\u00e8me semaine apr\u00e8s le d\u00e9but de la maladie. Cependant, en raison du nombre limit\u00e9 d'\u00e9chantillons de s\u00e9rum de patients COVID-19 test\u00e9s par les tests internes, il \u00e9tait difficile d'\u00e9valuer avec pr\u00e9cision le temps de s\u00e9roconversion.\r\nLes test commerciaux S1 IgG ou IgA ELISA ont une faible sp\u00e9cificit\u00e9 et la sensibilit\u00e9 varie entre les 2 tests, Le IgA ELISA montre une forte sensitivit\u00e9.\n\r\nDans l'ensemble, les tests d\u00e9velopp\u00e9s et valid\u00e9s dans cette \u00e9tude pourraient \u00eatre d\u00e9terminants pour la d\u00e9tection d'anticorps sp\u00e9cifiques au SARS-CoV-2 pour le suivi des patients contacts, les \u00e9tudes de s\u00e9rosurveillance et les \u00e9tudes d'\u00e9valuation des vaccins. Cependant, \u00e9tant donn\u00e9 que diverses \u00e9tudes seront men\u00e9es dans diff\u00e9rents laboratoires, il est crucial d'\u00e9talonner et de standardiser les tests d\u00e9velopp\u00e9s en utilisant des r\u00e9f\u00e9rences standard bien d\u00e9finies dans le cadre de la validation des tests de diagnostic. Cette standardisation est non seulement n\u00e9cessaire pour r\u00e9duire la variabilit\u00e9 inter-essais, mais aussi pour corr\u00e9ler les r\u00e9sultats obtenus de diff\u00e9rents laboratoires qui utilisent diff\u00e9rents dosages. Cette corr\u00e9lation est cruciale pour une meilleure comparaison et interpr\u00e9tation des r\u00e9sultats de diff\u00e9rentes \u00e9tudes; \u00e9valuer les essais de vaccins; permettre une \u00e9valuation uniforme de l'immunog\u00e9nicit\u00e9 et de l'efficacit\u00e9; et une meilleure compr\u00e9hension des corr\u00e9lats de la protection immunitaire. Ainsi, la mise en place de panels de r\u00e9f\u00e9rence est un \u00e9l\u00e9ment essentiel de nos approches de pr\u00e9paration aux virus \u00e9mergents.", "objectives": "- faible nombre de patients (3)", "methods": "D\u00e9veloppement de tests s\u00e9rologiques pour la d\u00e9tection des anticorps neutralisants du SARS-CoV-2, des prot\u00e9ines sp\u00e9cifiques aux spikes et des Ac sp\u00e9cifiques des nucl\u00e9ocapsides.", "pubmed_id": "32267220", "doi": "10.3201/eid2607.200841", "abstract": "A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.", "topics": ["Pronostique", "Transversale", "Virologie", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie"], "author_list": [{"id": 293, "name": "Nisreen MAO"}], "publication_date": "2020-04-09"}, {"id": 312, "slug": "disinfection-of-n95-respirators-by-ionized-hydrogen-peroxide-in-pandemic-coronav", "title": "Disinfection of N95 respirators by ionized hydrogen peroxide in pandemic coronavirus disease 2019 (COVID-19) due to SARS-CoV-2", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'efficacit\u00e9 d'une m\u00e9thode de s\u00e9rilisation des masques apr\u00e8s usage via le p\u00e9roxyde d'hydrog\u00e8ne", "verbose_date": "13.04.2020", "authors": "Cheng VCC", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 6, "name": "J Hosp Infect"}, "link": "https://www.journalofhospitalinfection.com/article/S0195-6701(20)30178-X/pdf", "findings": "", "take_away": "", "relevance_level": "D\u00e9veloppement d'une m\u00e9thode de st\u00e9rilisation des masques FFP2 qui pourrait \u00eatre efficace via le p\u00e9roxyde d'hydrog\u00e8ne en gaz.\u00a0\r\nToutefois, pas de test sp\u00e9cifique avec le virus SARS-CoV-2 et propri\u00e9t\u00e9 de filtration du masque post-st\u00e9rilisation \u00e0 \u00e9valuer.", "objectives": "- Lettre \u00e0 l'\u00e9diteur- Bas\u00e9e sur un faible nombre d'exp\u00e9riences- Le virus utilis\u00e9 n'est pas le SARS-CoV-2 mais diff\u00e9rents sous-types du virus de la grippe H1N1- Performance  du masque en terme de protection non \u00e9valu\u00e9 apr\u00e8s la proc\u00e9dure de st\u00e9rilisation\"", "methods": "Evaluer l'efficacit\u00e9 d'une m\u00e9thode de s\u00e9rilisation des masques apr\u00e8s usage via le p\u00e9roxyde d'hydrog\u00e8ne", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 299, "name": "Cheng VCC"}], "publication_date": "2020-04-13"}, {"id": 585, "slug": "longitudinal-hematologic-and-immunologic-variations-associated-with-the-progress", "title": "Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Cette \u00e9tude r\u00e9trospective vise \u00e0 aborder les changements dynamiques des biomarqueurs h\u00e9matologiques et immunologiques et leurs associations avec la gravit\u00e9 et l\u2019issue de la maladie.", "verbose_date": "13.05.2020", "authors": "Chen R", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 15, "name": "H\u00e9matologie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 233, "name": "J Allergy Clin Immunol"}, "link": "https://www.dropbox.com/s/dl1bf73ik3q5uka/1-s2.0-S0091674920306382-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les d\u00e9ficiences h\u00e9matologiques et immunologiques ont montr\u00e9 un profil significativement diff\u00e9rent entre les survivants et les non-survivants chez les patients atteints de COVID-19 avec une gravit\u00e9 diff\u00e9rente. Depuis le stade pr\u00e9coce de la maladie, non seulement les lymphocytes et les sous-ensembles de cellules T, mais aussi les \u00e9osinophiles pr\u00e9sentent une diminution marqu\u00e9e, associ\u00e9e \u00e0 la gravit\u00e9 de la maladie et \u00e0 l'issue clinique. L'alt\u00e9ration des interactions immunologiques entre les sous-ensembles de cellules T et les indices h\u00e9matologiques sugg\u00e8re une alt\u00e9ration de la r\u00e9ponse immunitaire depuis le d\u00e9but de la maladie. Les changements dynamiques des indices h\u00e9matologiques et immunologiques ont vari\u00e9 chez les survivants et les non-survivants, et pourraient servir de pr\u00e9dicteurs du r\u00e9tablissement ou de l'issue fatale du COVID-19.", "objectives": "-\tPre-proof-\tEtude r\u00e9trospective-\tPuisqu'il s'agit d'une \u00e9tude r\u00e9trospective, certains indices n'ont pas \u00e9t\u00e9 d\u00e9tect\u00e9s chez tous les patients, comme les donn\u00e9es de suivi des sous-ensembles de cellules T.-\tA l'exception de l\u2019IL-6 et de certains indices d'infection clinique, d'autres cytokines pro-inflammatoires ou chimiokines associ\u00e9es aux lymphocytes n'ont pas \u00e9t\u00e9 d\u00e9tect\u00e9es : d'autres \u00e9tudes sont n\u00e9cessaires pour caract\u00e9riser le r\u00f4le de la r\u00e9ponse immunitaire des cellules T dans le COVID-19. -\tLes donn\u00e9es sur le profil d'excr\u00e9tion du virus ou de vir\u00e9mie ne sont pas disponibles : des \u00e9tudes suppl\u00e9mentaires sont n\u00e9cessaires pour d\u00e9crire l'association entre la cin\u00e9tique de charge du virus et les r\u00e9ponses immunitaires dynamiques.", "methods": "Cette \u00e9tude r\u00e9trospective vise \u00e0 aborder les changements dynamiques des biomarqueurs h\u00e9matologiques et immunologiques et leurs associations avec la gravit\u00e9 et l\u2019issue de la maladie.", "pubmed_id": "32407836\n32109013\n32171076\n26857507\n27287409\n32203188\n31986264\n32048163\n12955652\n28541437\n12816821\n24845462\n15657466\n32187464\n24912383\n26867177\n32085846\n12890367\n32178975\n31978945\n15105985\n15200814\n16019455\n17374415\n32173576\n12837163\n27671972\n15364884\n8810592\n32217834\n16095942\n28466096\n28787295\n27573114\n29846635\n26203058\n16618789\n27087246\n16174304\n22809390\n12899763\n32007143\n17031779\n30584196", "doi": "10.1016/j.jaci.2020.05.003", "abstract": "Crucial roles of hematologic and immunologic responses in progression of coronavirus disease 2019 (COVID-19) remain largely unclear.\nWe sought to address the dynamic changes in hematologic and immunologic biomarkers and their associations with severity and outcomes of COVID-19.\nA retrospective study including 548 patients with COVID-19 with clarified outcome (discharged or deceased) from a national cohort in China was performed. Cross-sectional and longitudinal variations were compared and the associations with different severity and outcomes were analyzed.\nOn admission, the counts of lymphocytes, T-cell subsets, eosinophils, and platelets decreased markedly, especially in severe/critical and fatal patients. Increased neutrophil count and neutrophils-to-lymphocytes ratio were predominant in severe/critical cases or nonsurvivors. During hospitalization, eosinophils, lymphocytes, and platelets showed an increasing trend in survivors, but maintained lower levels or dropped significantly afterwards in nonsurvivors. Nonsurvivors kept a high level or showed an upward trend for neutrophils, IL-6, procalcitonin, D-dimer, amyloid A protein, and C-reactive protein, which were kept stable or showed a downward trend in survivors. Positive correlation between CD8\nHematologic and immunologic impairment showed a significantly different profile between survivors and nonsurvivors in patients with COVID-19 with different severity. The longitudinal variations in these biomarkers could serve to predict recovery or fatal outcome.", "topics": ["Pronostique", "Immunit\u00e9", "H\u00e9matologie", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 122, "name": "Chen R"}], "publication_date": "2020-05-13"}, {"id": 331, "slug": "diagnostic-testing-for-severe-acute-respiratory-syndrome-related-coronavirus-2-a", "title": "Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Pr\u00e9senter l'ensemble des tests disponibles pour le SARS-CoV-2, les disparit\u00e9s en terme de capacit\u00e9 diagnostique et proposer des solutions potentielles", "verbose_date": "14.04.2020", "authors": "Chen MP", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 41, "name": "Ann Intern Med"}, "link": "https://annals.org/aim/fullarticle/2764737/diagnostic-testing-severe-acute-respiratory-syndrome-related-coronavirus-2-narrative", "findings": "", "take_away": "", "relevance_level": "Il faut faciliter au maximum l'extension du nombre de tests r\u00e9alis\u00e9s pour pouvoir les \u00e9tendre aux sujets asymptomatiques et mieux \u00e0 la fois comprendre et contr\u00f4ler la transmission du SARS-CoV-2. Cela passe notamment par un all\u00e8gement des proc\u00e9dures r\u00e9glementaires et le d\u00e9veloppement de tests simples et rapides qui auront un r\u00f4le cl\u00e9s dans les pays \u00e0 moindre ressource de sant\u00e9.", "objectives": "- revue narrative de la litt\u00e9rature", "methods": "Pr\u00e9senter l'ensemble des tests disponibles pour le SARS-CoV-2, les disparit\u00e9s en terme de capacit\u00e9 diagnostique et proposer des solutions potentielles", "pubmed_id": "32282894", "doi": "10.7326/M20-1301", "abstract": "Diagnostic testing to identify persons infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-19 that began in late 2019. In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies. In contrast, the United States, hampered by limited testing capacity, has prioritized testing for specific groups of persons. Real-time reverse transcriptase polymerase chain reaction-based assays performed in a laboratory on respiratory specimens are the reference standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging. Although excellent tools exist for the diagnosis of symptomatic patients in well-equipped laboratories, important gaps remain in screening asymptomatic persons in the incubation phase, as well as in the accurate determination of live viral shedding during convalescence to inform decisions to end isolation. Many affluent countries have encountered challenges in test delivery and specimen collection that have inhibited rapid increases in testing capacity. These challenges may be even greater in low-resource settings. Urgent clinical and public health needs currently drive an unprecedented global effort to increase testing capacity for SARS-CoV-2 infection. Here, the authors review the current array of tests for SARS-CoV-2, highlight gaps in current diagnostic capacity, and propose potential solutions.", "topics": ["Diagnostique", "Transversale", "Virologie", "Infectiologie"], "author_list": [{"id": 318, "name": "Chen MP"}], "publication_date": "2020-04-14"}, {"id": 660, "slug": "kawasaki-like-multisystem-inflammatory-syndrome-in-children-during-the-covid-19-", "title": "Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques d\u00e9mographiques et cliniques d'enfants affect\u00e9s par un syndrome inflammatoire multisyst\u00e9mique proche de la maladie de Kawasaki et \u00e9valuer son association temporelle avec une potentielle infection par le SARS-CoV-2.", "verbose_date": "05.06.2020", "authors": "Toubiana J", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 57, "name": "BMJ"}, "link": "https://www.bmj.com/content/bmj/369/bmj.m2094.full.pdf", "findings": "", "take_away": "", "relevance_level": "Le lien de causalit\u00e9 entre infection par le SARS-CoV-2 et l'\u00e9mergence d'un syndrome type maladie de Kawasaki chez les enfants ne peut \u00eatre prouv\u00e9 par cette \u00e9tude mais on peut noter que l'association temporelle entre ces deux atteintes est coh\u00e9rente.\r\nPar ailleurs, dans cette s\u00e9rie de cas de syndrome type Kawasaki, les sympt\u00f4mes digestifs sont syst\u00e9matiques ce qui n'est habituellement pas le cas. De la m\u00eame mani\u00e8re, l'instabilit\u00e9 h\u00e9modynamique et la myocardite sont plus importantes.\r\nEnfin, il est \u00e0 noter qu'une grande partie des enfants ont un parent d'origine Africaine ou des Cara\u00efbes ce qui pose la question du lien avec la susceptibilit\u00e9 de contracter la COVID-19.", "objectives": "- faible effectif- biais de rappel probable vis-\u00e0-vis de sympt\u00f4mes viraux r\u00e9cents ou d'un contact avec un sujet symptomatique- suivi trop court pour diagnostiquer l'ensemble des complications coronaires qui peuvent appara\u00eetre \u00e0 distance- biais de s\u00e9lection : l'h\u00f4pital Necker est un centre de r\u00e9f\u00e9rence et concentre les cas- pas de test du SARS-CoV-2 syst\u00e9matique des proches- risque de faux positifs de la s\u00e9rologie li\u00e9 \u00e0 une r\u00e9activit\u00e9 crois\u00e9e", "methods": "D\u00e9crire les caract\u00e9ristiques d\u00e9mographiques et cliniques d'enfants affect\u00e9s par un syndrome inflammatoire multisyst\u00e9mique proche de la maladie de Kawasaki et \u00e9valuer son association temporelle avec une potentielle infection par le SARS-CoV-2.", "pubmed_id": "32493739", "doi": "10.1136/bmj.m2094", "abstract": "To describe the characteristics of children and adolescents affected by an outbreak of Kawasaki-like multisystem inflammatory syndrome and to evaluate a potential temporal association with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\nProspective observational study.\nGeneral paediatric department of a university hospital in Paris, France.\n21 children and adolescents (aged \u226418 years) with features of Kawasaki disease who were admitted to hospital between 27 April and 11 May 2020 and followed up until discharge by 15 May 2020.\nThe primary outcomes were clinical and biological data, imaging and echocardiographic findings, treatment, and outcomes. Nasopharyngeal swabs were prospectively tested for SARS-CoV-2 using reverse transcription-polymerase chain reaction (RT-PCR) and blood samples were tested for IgG antibodies to the virus.\n21 children and adolescents (median age 7.9 (range 3.7-16.6) years) were admitted with features of Kawasaki disease over a 15 day period, with 12 (57%) of African ancestry. 12 (57%) presented with Kawasaki disease shock syndrome and 16 (76%) with myocarditis. 17 (81%) required intensive care support. All 21 patients had noticeable gastrointestinal symptoms during the early stage of illness and high levels of inflammatory markers. 19 (90%) had evidence of recent SARS-CoV-2 infection (positive RT-PCR result in 8/21, positive IgG antibody detection in 19/21). All 21 patients received intravenous immunoglobulin and 10 (48%) also received corticosteroids. The clinical outcome was favourable in all patients. Moderate coronary artery dilations were detected in 5 (24%) of the patients during hospital stay. By 15 May 2020, after 8 (5-17) days of hospital stay, all patients were discharged home.\nThe ongoing outbreak of Kawasaki-like multisystem inflammatory syndrome among children and adolescents in the Paris area might be related to SARS-CoV-2. In this study an unusually high proportion of the affected children and adolescents had gastrointestinal symptoms, Kawasaki disease shock syndrome, and were of African ancestry.", "topics": ["Epid\u00e9miologique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "P\u00e9diatrie"], "author_list": [{"id": 620, "name": "Toubiana J"}], "publication_date": "2020-06-05"}, {"id": 354, "slug": "keratoconjunctivitis-as-the-initial-medical-presentation-of-the-novel-coronaviru", "title": "Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19)", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'\u00e9volution de la prise en charge diagnostique d'un cas de COVID-19 se manifestant principalement par une k\u00e9rato conjonctivite", "verbose_date": "16.04.2020", "authors": "Cheema M", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 152, "name": "Can J Ophthalmol"}, "link": "https://www.canadianjournalofophthalmology.ca/article/S0008-4182(20)30305-7/pdf", "findings": "", "take_away": "", "relevance_level": "Le cas de COVID-19 de cette patiente s'est initialement manifest\u00e9 par des sympt\u00f4mes oculaires de k\u00e9ratoconjonctivite (bien que des sympt\u00f4mes respiratoires l\u00e9gers \u00e9taient aussi pr\u00e9sents). C'est la premi\u00e8re fois qu'une keratoconjonctivite a \u00e9t\u00e9 d\u00e9crite comme symptome initial de Covid-19 (des conjonctivites initiales avaient d\u00e9j\u00e0 \u00e9t\u00e9 d\u00e9crites).\r\nLes sympt\u00f4mes oculaires peuvent varier au cours du temps.\u00a0\r\nLes professionnels de la sant\u00e9 des yeux doivent rester vigilants et garder \u00e0 l'esprit cette possible pr\u00e9sentation du COVID-19.", "objectives": "-Etude de cas-n=1-Premi\u00e8re occurence de cette pr\u00e9sentation dans la litt\u00e9rature (validit\u00e9 externe faible) \"", "methods": "D\u00e9crire l'\u00e9volution de la prise en charge diagnostique d'un cas de COVID-19 se manifestant principalement par une k\u00e9rato conjonctivite", "pubmed_id": "32284146\n31986264\n32035510\n32086236", "doi": "10.1016/j.jcjo.2020.03.003", "abstract": "We present a case of coronavirus disease 2019 (COVID-19) with an initial medical presentation of keratoconjunctivitis, the first such reported case in North America. The patient's primary symptom was a red eye with watery discharge, though she did have mild respiratory symptoms, without fever. She was diagnosed with keratoconjunctivitis; evolving corneal findings were characterized through repeat visits to ophthalmology. A conjunctival swab of the affected eye was positive for the SAR-CoV-2 virus. This case emphasizes the importance of ensuring that first-line health care providers, including ophthalmologists, optometrists, emergency physicians, and family physicians, consider COVID-19 on the differential for any patient with recent travel who presents with acute conjunctivitis. Having a high index of suspicion with this presentation would allow for appropriate precautions to be taken to prevent further spread of COVID-19.", "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 341, "name": "Cheema M"}], "publication_date": "2020-04-16"}, {"id": 19, "slug": "should-biologics-for-psoriasis-be-interrupted-in-the-era-of-covid-19", "title": "Should biologics for psoriasis be interrupted in the era of COVID-19?", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Discuter les indications de traitement par bioth\u00e9rapie chez les patients atteints de psoriasis dans le contexte de pand\u00e9mie \u00e0 COVID-19", "verbose_date": "24.03.2020", "authors": "Lebwohl M", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 10, "name": "Dermatologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 15, "name": "J Am Ac Dermatol"}, "link": "https://www.dropbox.com/s/yxgb81oi2uaccis/PIIS019096222030445X.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Possible l\u00e9ger sur-risque d'infection respiratoire pour les patients sous bioth\u00e9rapies pour un psoriasis mais ne prend pas en compte les sp\u00e9cificit\u00e9s du SARS-CoV-2 et notamment le possible r\u00f4le d\u00e9l\u00e9t\u00e8re de la r\u00e9ponse inflammatoire dans les formes graves. Par ailleurs risque de perdre la r\u00e9ponse au traitement si une pause est r\u00e9alis\u00e9e.", "objectives": "Faible :1) Bas\u00e9 sur le bibliographie2) Etudes de faible niveau de preuve (faibles effectifs d'infection, courtes p\u00e9riodes de contr\u00f4le par placebo, risque de sous-d\u00e9claration des infections respiratoires mineures)3) Etudes ne portant ni sur le SARS-CoV-2, le SARS-CoV ou le MERS-CoV", "methods": "Discuter les indications de traitement par bioth\u00e9rapie chez les patients atteints de psoriasis dans le contexte de pand\u00e9mie \u00e0 COVID-19", "pubmed_id": "32199889", "doi": "10.1016/j.jaad.2020.03.031", "abstract": null, "topics": ["Th\u00e9rapeutique", "Transversale", "Dermatologie"], "author_list": [{"id": 29, "name": "Lebwohl M"}], "publication_date": "2020-03-24"}, {"id": 192, "slug": "potential-rapid-diagnostics-vaccine-and-therapeutics-for-2019-novel-coronavirus-", "title": "Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Revue syst\u00e9matique des formes possibles de diagnostic rapide, de vaccins et de th\u00e9rapies pour le SRAS-CoV-2, le MERS-CoV et le SRAS-CoV afin d'orienter les axes de recherche et de d\u00e9veloppement", "verbose_date": "30.03.2020", "authors": "Pang J ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 98, "name": "J Clin Med"}, "link": "https://www.dropbox.com/s/fjk8klwqal4dfkr/jcm-09-00623-v2.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Diagnostic\r\n1)le diagnostic de laboratoire peut \u00eatre effectu\u00e9 \u00e0 l'aide de 4 techniques :\u00a0\r\n*recherche du mat\u00e9riel g\u00e9n\u00e9tique du virus (limites : possibilit\u00e9 de r\u00e9action crois\u00e9e avec des r\u00e9gions g\u00e9n\u00e9tiques non sp\u00e9cifiques et intervalle de temps limit\u00e9 au d\u00e9but de l'infection)\r\n*recherche d'anticorps sp\u00e9cifiques,\u00a0\r\n*tests s\u00e9rologiques (limites : deux \u00e9chantillons doivent \u00eatre pr\u00e9lev\u00e9s dans la phase aigu\u00eb et pendant la r\u00e9mission des sympt\u00f4mes pour exclure toute r\u00e9action crois\u00e9e),\u00a0\r\n*culture et isolement de particules virales (limites : longue dur\u00e9e de vie et comp\u00e9tences techniques \u00e9lev\u00e9es)\r\n2) Pour le SRAS et le MERS, les \u00e9chantillons provenant de voies respiratoires basses pr\u00e9sentaient des taux d'ARN viral plus \u00e9lev\u00e9s et plus prolong\u00e9s que les \u00e9chantillons de voies respiratoires hautes\n\r\nVaccins\r\n1) il n'existe actuellement aucun vaccin en cours de d\u00e9veloppement ou test\u00e9 pour SRAS-CoV-2\n\r\nTh\u00e9rapie\r\n1) Plusieurs essais cliniques ont d\u00e9but\u00e9 en Chine sur la base des th\u00e9rapies propos\u00e9es pour les SRAS et les MERS:\r\n-\u00a0Interf\u00e9ron\u00a0: l'interf\u00e9ron b\u00eata semble plus actif que l'interf\u00e9ron alpha. L'utilisation d'interf\u00e9ron + corticost\u00e9ro\u00efdes semble am\u00e9liorer l'oxyg\u00e9nation et r\u00e9duire les anomalies de la radiographie thoracique. Le timing de la th\u00e9rapie semble avoir une grande importance sur l'efficacit\u00e9.\r\n-\u00a0Ribavirin: m\u00e9dicament le plus utilis\u00e9 selon la litt\u00e9rature, utilis\u00e9 \u00e0 des doses th\u00e9rapeutiques ou en prophylaxie chez les professionnels de sant\u00e9 expos\u00e9s\r\n-\u00a0Lopinavir/ritonavir: premi\u00e8re combinaison propos\u00e9e d'inhibiteurs de prot\u00e9ase, efficacit\u00e9 signal\u00e9e dans de nombreuses \u00e9tudes, peu d'effets secondaires (moins que ribavirin seul)\r\n-\u00a0Plasma des convalescents\u00a0\u00e0 diff\u00e9rentes doses : les \u00e9tudes font \u00e9tat d'une r\u00e9duction significative de la mortalit\u00e9 par rapport au placebo mais les \u00e9tudes ont un faible niveau de preuve car elles portent sur de petits \u00e9chantillons\r\n-\u00a0Chloroquine\u00a0: r\u00e9duit la production et la lib\u00e9ration de facteurs qui m\u00e9dient l'inflammation et agit sur le r\u00e9cepteur ACE2 et le pH endosomal\r\n-\u00a0Niclosamide: inhibe la synth\u00e8se virale\r\n-\u00a0Glycyrrhizine:\u00a0inhibe la p\u00e9n\u00e9tration pendant les premiers stades de la r\u00e9plication virale", "objectives": "1) revue syst\u00e9matique de 27 \u00e9tudes (publi\u00e9s en PubMed, Embase et Cochrane library) et 19 \u00e9tudes (Google)2)\u00a0publication bias:\u00a0certains progr\u00e8s peuvent avoir \u00e9t\u00e9 publi\u00e9s et d'autres peuvent encore \u00eatre des donn\u00e9es confidentielles3)\u00a0reporting bias: peut \u00eatre due \u00e0 la n\u00e9cessit\u00e9 de publier rapidement les r\u00e9sultats\u00a04) pas de m\u00e9ta-analyse des donn\u00e9es: en raison du nombre limit\u00e9 de donn\u00e9es fournies et de la mani\u00e8re h\u00e9t\u00e9rog\u00e8ne de pr\u00e9senter les r\u00e9sultats dans les diff\u00e9rentes \u00e9tudes", "methods": "Revue syst\u00e9matique des formes possibles de diagnostic rapide, de vaccins et de th\u00e9rapies pour le SRAS-CoV-2, le MERS-CoV et le SRAS-CoV afin d'orienter les axes de recherche et de d\u00e9veloppement", "pubmed_id": "32110875\n15872279\n16022791\n15497005\n18018769\n25030060\n18565970\n12867568\n27106390\n27344959\n30815285\n15351731\n32007143\n32032682\n14522060\n15494274\n32015507\n29329957\n32007145\n15131160\n15030702\n31992387\n31978945\n23075143\n28191331\n27374710\n14985565\n17163583\n32014114\n25103205\n17163582\n14699465\n31428074\n23993766\n15215127\n28807812\n15070991\n14652014\n14585636\n15242944\n30531947\n31986264\n15013997\n31351922\n26828465\n12814717\n31944312\n32031583\n31252170\n15288617\n18824060", "doi": "10.3390/jcm9030623", "abstract": "Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence.", "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 185, "name": "Pang J "}], "publication_date": "2020-03-30"}, {"id": 42, "slug": "coronavirus-endoribonuclease-targets-viral-polyuridine-sequences-to-evade-activa", "title": "Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etude d'un des m\u00e9canismes par lesquels les CoV r\u00e9duisent la r\u00e9ponse interf\u00e9ron de type I : l'endoribunuclease EndoU", "verbose_date": "20.03.2020", "authors": "Hackbart M", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 36, "name": "Proc Natl Acad Sci USA"}, "link": "https://www.dropbox.com/s/1vx9jclludz3yho/1921485117.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Des \u00e9tudes suppl\u00e9mentaires sont n\u00e9cessaires afin de mieux comprendre les m\u00e9canismes utilis\u00e9s par les CoV pour alt\u00e9rer et traiter l'ARN viral\r\n- Nouveau m\u00e9canisme viral utilis\u00e9 pour d\u00e9grader des PAMP viral\r\n- L'endoribonuclease EndoU n'est pas n\u00e9cessaire pour le cycle de reproduction viral et son absence limite la virulence des CoV : piste possible pour le d\u00e9veloppement de vaccins att\u00e9nu\u00e9s\r\n- L'activit\u00e9 enzymatique de l'EndoU pourrait \u00eatre cibl\u00e9e afin de d\u00e9velopper des th\u00e9rapeutiques anti CoV", "objectives": "", "methods": "Etude d'un des m\u00e9canismes par lesquels les CoV r\u00e9duisent la r\u00e9ponse interf\u00e9ron de type I : l'endoribunuclease EndoU", "pubmed_id": "32198201\n16882730\n29870915\n19297500\n16877062\n30914508\n15507608\n30393776\n26958916\n791748\n32015507\n15304651\n17480233\n25878098\n26867177\n19041350\n28484023\n20071574\n22912574\n12927536\n24336571\n24846384\n12368349\n27760233\n22704621\n29307596\n21262835\n18798692\n27025250\n16216269\n17481902\n31138817\n11907209\n27712625\n31355779\n20357099\n16873248\n1920635\n18045871\n28143984\n30728254\n17898055\n1985203\n14970378\n10364348\n31986264\n27783669\n31978293\n30918070\n18667505\n2057357\n10074205\n16828802\n17409150\n11805321\n16625202\n19656871\n19109397\n26863439\n28158275\n30658390", "doi": "10.1073/pnas.1921485117", "abstract": "Coronaviruses (CoVs) are positive-sense RNA viruses that can emerge from endemic reservoirs and infect zoonotically, causing significant morbidity and mortality. CoVs encode an endoribonuclease designated EndoU that facilitates evasion of host pattern recognition receptor MDA5, but the target of EndoU activity was not known. Here, we report that EndoU cleaves the 5'-polyuridines from negative-sense viral RNA, termed PUN RNA, which is the product of polyA-templated RNA synthesis. Using a virus containing an EndoU catalytic-inactive mutation, we detected a higher abundance of PUN RNA in the cytoplasm compared to wild-type-infected cells. Furthermore, we found that transfecting PUN RNA into cells stimulates a robust, MDA5-dependent interferon response, and that removal of the polyuridine extension on the RNA dampens the response. Overall, the results of this study reveal the PUN RNA to be a CoV MDA5-dependent pathogen-associated molecular pattern (PAMP). We also establish a mechanism for EndoU activity to cleave and limit the accumulation of this PAMP. Since EndoU activity is highly conserved in all CoVs, inhibiting this activity may serve as an approach for therapeutic interventions against existing and emerging CoV infections.", "topics": ["Th\u00e9rapeutique", "Virologie"], "author_list": [{"id": 52, "name": "Hackbart M"}], "publication_date": "2020-03-20"}, {"id": 482, "slug": "effects-of-temperature-and-humidity-on-the-daily-new-cases-and-new-deaths-of-cov", "title": "Effects of temperature and humidity on the daily new cases and new deaths of COVID-19 in 166 countries", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Examiner les effets de la temp\u00e9rature et de l'humidit\u00e9 relative sur les nouveaux cas quotidiens et les nouveaux d\u00e9c\u00e8s quotidiens de COVID-19.", "verbose_date": "29.04.2020", "authors": "WU Y", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 166, "name": "Science of The Total Environment"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0048969720325687?token=ED80AF1E8858ABFDBBA4CFBC44DE951067303C67577FFA4213C66A3251B35D3E0CD1B1FD8B3247A264318DA88911D3C4", "findings": "", "take_away": "", "relevance_level": "Ces r\u00e9sultats fournissent des preuves pr\u00e9liminaires que la pand\u00e9mie de COVID-19 pourrait \u00eatre partiellement supprim\u00e9e avec l'augmentation de la temp\u00e9rature et de l'humidit\u00e9.", "objectives": "-\tPre-proof-\tLes donn\u00e9es ont \u00e9t\u00e9 recueillies pour 166 pays (\u00e0 l'exception de la Chine) au 27 mars 2020.-\tCette \u00e9tude \u00e9tait une analyse de s\u00e9ries chronologiques.-\tCette \u00e9tude comprenait des variables qui refl\u00e9taient le niveau \u00e9conomique, les conditions m\u00e9dicales, le vieillissement de la population et la densit\u00e9 de la population afin de r\u00e9duire les biais confondants.-\tOn a utilis\u00e9 les dates des rapports de situation quotidiens COVID-19 de l'OMS au lieu de la date d'apparition, ce qui peut engendrer un biais car l'intervalle de temps varie en fonction des conditions m\u00e9dicales, de la formulation des politiques et des crit\u00e8res de diagnostic de chaque pays.-\tLe nombre de cas confirm\u00e9s a in\u00e9vitablement \u00e9t\u00e9 sous-estim\u00e9, en particulier dans les r\u00e9gions \u00e0 faible revenu, en raison de la faible couverture de d\u00e9tection de COVID-19. -\tLes effets des politiques et des mesures sur la transmission de COVID-19 n'ont pas \u00e9t\u00e9 \u00e9valu\u00e9s dans cette \u00e9tude ; cependant, certaines mesures, comme la quarantaine, peuvent affecter la pr\u00e9valence des maladies infectieuses. -\tDes erreurs \u00e9cologiques peuvent avoir \u00e9t\u00e9 commises en utilisant la temp\u00e9rature et l'humidit\u00e9 des capitales pour refl\u00e9ter la temp\u00e9rature et l'humidit\u00e9 moyennes nationales, et en utilisant l'exposition ext\u00e9rieure comme indicateur de l'exposition personnelle.", "methods": "Examiner les effets de la temp\u00e9rature et de l'humidit\u00e9 relative sur les nouveaux cas quotidiens et les nouveaux d\u00e9c\u00e8s quotidiens de COVID-19.", "pubmed_id": "32361460", "doi": "10.1016/j.scitotenv.2020.139051", "abstract": "The coronavirus disease 2019 (COVID-19) pandemic is the defining global health crisis of our time and the greatest challenge facing the world. Meteorological parameters are reportedly crucial factors affecting respiratory infectious disease epidemics; however, the effect of meteorological parameters on COVID-19 remains controversial. This study investigated the effects of temperature and relative humidity on daily new cases and daily new deaths of COVID-19, which has useful implications for policymakers and the public. Daily data on meteorological conditions, new cases and new deaths of COVID-19 were collected for 166 countries (excluding China) as of March 27, 2020. Log-linear generalized additive model was used to analyze the effects of temperature and relative humidity on daily new cases and daily new deaths of COVID-19, with potential confounders controlled for, including wind speed, median age of the national population, Global Health Security Index, Human Development Index and population density. Our findings revealed that temperature and relative humidity were both negatively related to daily new cases and deaths. A 1\u00a0\u00b0C increase in temperature was associated with a 3.08% (95% CI: 1.53%, 4.63%) reduction in daily new cases and a 1.19% (95% CI: 0.44%, 1.95%) reduction in daily new deaths, whereas a 1% increase in relative humidity was associated with a 0.85% (95% CI: 0.51%, 1.19%) reduction in daily new cases and a 0.51% (95% CI: 0.34%, 0.67%) reduction in daily new deaths. The results remained robust when different lag structures and the sensitivity analysis were used. These findings provide preliminary evidence that the COVID-19 pandemic may be partially suppressed with temperature and humidity increases. However, active measures must be taken to control the source of infection, block transmission and prevent further spread of COVID-19.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 450, "name": "WU Y"}], "publication_date": "2020-04-29"}, {"id": 375, "slug": "case-fatality-rate-analysis-of-italian-covid-19-outbreak", "title": "Case fatality rate analysis of Italian COVID-19 outbreak", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyse du taux de mortalit\u00e9 en Italie li\u00e9 au COVID-19 en comparaison aux autres pays europ\u00e9ens", "verbose_date": "18.04.2020", "authors": "Giangreco G", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25894", "findings": "", "take_away": "", "relevance_level": "Le taux de mortalit\u00e9 italien (12%) ou espagnol (9%) sont pr\u00e8s de 7 \u00e0 8 fois plus \u00e9lev\u00e9 que celui de la Cor\u00e9e du Sud et de l'Allemagne. La France et le Royaume-Uni sont \u00e0 un niveau interm\u00e9diaire (7%).\r\nCes chiffres ne rep\u00e9sentent toutefois pas le taux de mortalit\u00e9 r\u00e9el (cas positifs non test\u00e9s) et les comparaisons entre pays sont difficiles (du fait des diff\u00e9rences de strat\u00e9gie de d\u00e9pistage).", "objectives": "- Bas\u00e9 sur le nombre de personnes infect\u00e9es officiellement, hors on sait que suivant les pays et leur strat\u00e9gie de tests, ce nombre de cas est fortement biais\u00e9, sans compter que pr\u00e8s de la moiti\u00e9 des sujets sont asymptomatiques\"", "methods": "Analyse du taux de mortalit\u00e9 en Italie li\u00e9 au COVID-19 en comparaison aux autres pays europ\u00e9ens", "pubmed_id": "32297983", "doi": "10.1002/jmv.25894", "abstract": "The Italian outbreak of COVID-19 cases is a public health emergency and there is a worldwide tremendous interest in the evaluation of the Italian epidemic evolution. Indeed, from February 2020, Italy is facing an explosion of COVID-19 cases. In particular, the Italian observed case fatality rate (CFR) is much higher than the other countries. Recently, it has been hypothesized that the extensive number of intergenerational contacts-typical of Italian culture-could contribute to explain the high number of deaths observed in Italy. However, through an analysis performed for all the Italian regions, here it is shown that the deaths are localized in specific regions and that the CFRs of different Italian regions are overlapping with the rates of European countries. Moreover, through correlation analyses between CFRs and different social habits, it is shown that no positive correlation is observed between social behaviors and CFRs. In conclusion, this analysis clearly rejects the possibility that social habits and intergenerational contacts can contribute to explaining such a profound effect on the number of deaths observed in Italy during the COVID-19 outbreak and more effort should be addressed to evaluate the real amount of positive cases.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 362, "name": "Giangreco G"}], "publication_date": "2020-04-18"}, {"id": 203, "slug": "a-nationwide-survey-of-psychological-distress-among-chinese-people-in-the-covid-", "title": "A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Mesurer la pr\u00e9valence et la s\u00e9v\u00e9rit\u00e9 de la d\u00e9tresse psychologique g\u00e9n\u00e9r\u00e9e par l'\u00e9pid\u00e9mie de COVID-19 et des mesures de quarantaine en Chine, ainsi que le poids des pathologies mentales sur la soci\u00e9t\u00e9 afin d'adapter efficacement les politiques relatives \u00e0 la sant\u00e9 mentale \u00e0 venir", "verbose_date": "31.03.2020", "authors": "Oiu J ", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 100, "name": "Gen Psychiatr"}, "link": "https://www.dropbox.com/s/iyt0b8ndzhi2b43/e100213.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Il faudrait porter une attention plus particuli\u00e8re \u00e0 la sant\u00e9 mentale des groupes \u00e0 risque : femmes, sujets entre 18-30 ans et > 60 ans, travailleurs immigr\u00e9s. Am\u00e9liorer l'accessibilit\u00e9 aux structures de soin et de sant\u00e9 publique pourrait avoir un effet b\u00e9n\u00e9fique sur la d\u00e9tresse psychologique de la population. Il semble important d'organiser une strat\u00e9gie nationale de mise en place et de coordination de soins psychologiques primaires en cas de crise \u00e9pid\u00e9mique, via la t\u00e9l\u00e9m\u00e9decine notamment.", "objectives": "1) Questionnaire auto-administr\u00e9 (-)2) Effectif cons\u00e9quent (+ mais valeur clinique des r\u00e9sultats statistiquement significatifs \u00e0 bien explorer)3) Probable sous-repr\u00e9sentation des sujets les plus \u00e2g\u00e9s du fait de l'acc\u00e8s \u00e0 l'enqu\u00eate via un code QR, l'\u00e2ge moyen/median des enqu\u00eat\u00e9s n'est d'ailleurs pas indiqu\u00e9", "methods": "Mesurer la pr\u00e9valence et la s\u00e9v\u00e9rit\u00e9 de la d\u00e9tresse psychologique g\u00e9n\u00e9r\u00e9e par l'\u00e9pid\u00e9mie de COVID-19 et des mesures de quarantaine en Chine, ainsi que le poids des pathologies mentales sur la soci\u00e9t\u00e9 afin d'adapter efficacement les politiques relatives \u00e0 la sant\u00e9 mentale \u00e0 venir", "pubmed_id": "32215365\n25962178\n23408506\n25137105\n30134869\n22883254", "doi": "10.1136/gpsych-2020-100213", "abstract": "The Coronavirus Disease 2019 (COVID-19) epidemic emerged in Wuhan, China, spread nationwide and then onto half a dozen other countries between December 2019 and early 2020. The implementation of unprecedented strict quarantine measures in China has kept a large number of people in isolation and affected many aspects of people's lives. It has also triggered a wide variety of psychological problems, such as panic disorder, anxiety and depression. This study is the first nationwide large-scale survey of psychological distress in the general population of China during the COVID-19 epidemic.", "topics": ["Epid\u00e9miologique", "Psychiatrie"], "author_list": [{"id": 195, "name": "Oiu J "}], "publication_date": "2020-03-31"}, {"id": 624, "slug": "clinical-characteristics-and-outcomes-of-inpatients-with-neurologic-disease-and-", "title": "Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Caract\u00e9ristiques cliniques et biologiques, ainsi que le traitement et les r\u00e9sultats cliniques des patients admis pour des maladies neurologiques avec et sans COVID-19.", "verbose_date": "26.05.2020", "authors": "Benussi A", "specialties": [{"id": 18, "name": "Neurologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 171, "name": "Neurology"}, "link": "https://n.neurology.org/content/neurology/early/2020/05/22/WNL.0000000000009848.full.pdf", "findings": "", "take_away": "", "relevance_level": "Les auteurs ont observ\u00e9 une augmentation significative des taux d'accidents vasculaires c\u00e9r\u00e9braux chez les patients atteints de COVID-19, avec de moins bons r\u00e9sultats par rapport au groupe non-COVID-19, y compris des scores mRS plus \u00e9lev\u00e9s \u00e0 la sortie et un nombre significativement plus faible de patients avec un bon r\u00e9sultat.\nLes patients COVID-19 admis pour une maladie neurologique, y compris un AVC, ont une mortalit\u00e9 hospitali\u00e8re, un risque de d\u00e9lirium et une invalidit\u00e9 significativement plus \u00e9lev\u00e9s que les patients sans COVID-19..\nGrande \u00e9tude de cohorte r\u00e9trospective parmi des patients atteints de troubles neurologiques et de COVID-19, avec un r\u00e9sultat d\u00e9finitif.", "objectives": "- Grande \u00e9tude de cohorte retrospective. - Vu le caract\u00e8re r\u00e9trospectif, tous les tests de laboratoire n'ont pas \u00e9t\u00e9 effectu\u00e9s chez tous les patients.- Plusieurs facteurs n'ont pas \u00e9t\u00e9 tenus en compte en raison de la conception r\u00e9trospective (les sous-types d'AVC, le volume d'infarctus et les taux de recanalisation).- Biais de s\u00e9lection en raison de la r\u00e9ticence des patients pr\u00e9sentant des sympt\u00f4mes ou une infection li\u00e9s aux COVID \u00e0 venir pour une \u00e9valuation neurologique \u00e0 l'h\u00f4pital, sauf si cela est extr\u00eamement n\u00e9cessaire, comme dans le cas d'un accident vasculaire c\u00e9r\u00e9bral, d'une \u00e9pilepsie ou d'autres troubles neurologiques majeurs.", "methods": "Caract\u00e9ristiques cliniques et biologiques, ainsi que le traitement et les r\u00e9sultats cliniques des patients admis pour des maladies neurologiques avec et sans COVID-19.", "pubmed_id": "32444493", "doi": "10.1212/WNL.0000000000009848", "abstract": "To report clinical and laboratory characteristics, as well as treatment and clinical outcomes of patients admitted for neurologic diseases with and without COVID-19.\nIn this retrospective, single center cohort study, we included all adult inpatients with confirmed COVID-19, admitted to a Neuro-COVID Unit from February 21, 2020, who had been discharged or died by April 5, 2020. Demographic, clinical, treatment, and laboratory data were extracted from medical records and compared (FDR-corrected) to those of neurologic patients without COVID-19 admitted in the same period.\nOne hundred seventy-three patients were included in this study, of whom 56 were positive for COVID-19 while 117 were negative for COVID-19. Patients with COVID-19 were older (77.0, IQR 67.0-83.8 vs 70.1, IQR 52.9-78.6, \nCOVID-19 patients admitted with neurologic disease, including stroke, have a significantly higher in-hospital mortality, incident delirium and higher disability than patients without COVID-19.", "topics": ["Epid\u00e9miologique", "Neurologie"], "author_list": [{"id": 587, "name": "Benussi A"}], "publication_date": "2020-05-26"}, {"id": 76, "slug": "covid-19-and-community-mitigation-strategies-in-a-pandemic", "title": "Covid-19 and community mitigation strategies in a pandemic", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Lister des mesures possibles pour contenir l'\u00e9pid\u00e9mie.", "verbose_date": "17.03.2020", "authors": "Shahul H Ebrahim", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 57, "name": "BMJ"}, "link": "https://www.dropbox.com/s/xgi4q62lwbqmyiv/bmj.m1066.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les mesures pr\u00e9sent\u00e9es sont d\u00e9j\u00e0 effectives. Pas d'apport concernant la prise en charge hospitali\u00e8re.", "objectives": "Faible :1) Recommandation bas\u00e9e sur les recommandation du CDC pour limiter l'\u00e9pid\u00e9mie de grippe, et les analyses r\u00e9trospectives des mesures mise en place lors de l'\u00e9pid\u00e9mie d'\u00e9bola et de grippe espagnole", "methods": "Lister des mesures possibles pour contenir l'\u00e9pid\u00e9mie.", "pubmed_id": "32184233", "doi": "10.1136/bmj.m1066", "abstract": null, "topics": ["Autres", "Transversale"], "author_list": [{"id": 86, "name": "Shahul H Ebrahim"}], "publication_date": "2020-03-17"}, {"id": 79, "slug": "coronavirus-disease-2019-covid-19-a-systematic-review-of-imaging-findings-in-919", "title": "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer les caract\u00e9ristiques radiologiques des patients COVID", "verbose_date": "17.03.2020", "authors": "Salehi S", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 61, "name": "Am J Radiol"}, "link": "https://www.dropbox.com/s/xngxfdm8xf03boi/ajr.20.23034.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Caract\u00e9ristiques initiales :- Verre d\u00e9poli de distribution p\u00e9riph\u00e9rique, surtout dans les lobes inf\u00e9rieurs- Parfois : opacit\u00e9s superpos\u00e9es, surtout en population \u00e2g\u00e9e- Plus rare : \u00e9paississement septal, bronchectasie, \u00e9paississement pleural- Forme s\u00e9v\u00e8re : augmentation et progression vers le crazy paving", "objectives": "Interm\u00e9diaire : 1) Revue syst\u00e9matique de la litt\u00e9rature portant sur 30 publications dont 11 case reports soit 919 patients chinois au total 2) Grande h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 des publications int\u00e9gr\u00e9es dont beaucoup de faible niveau de preuve", "methods": "Evaluer les caract\u00e9ristiques radiologiques des patients COVID", "pubmed_id": "32174129", "doi": "10.2214/AJR.20.23034", "abstract": "", "topics": ["Epid\u00e9miologique", "Radiologie"], "author_list": [{"id": 89, "name": "Salehi S"}], "publication_date": "2020-03-17"}, {"id": 241, "slug": "severe-acute-respiratory-syndrome-coronavirus-2-rna-detected-in-blood-donations", "title": "Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer la pr\u00e9sence d'ARN viral du SARS-CoV-2 dans les pr\u00e9l\u00e8vements des donneurs de sang en situation \u00e9pid\u00e9mique", "verbose_date": "04.04.2020", "authors": "Le C", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 28, "name": "Emerg Infect Dis"}, "link": "https://wwwnc.cdc.gov/eid/article/26/7/20-0839_article", "findings": "", "take_away": "", "relevance_level": "Sur plus de 7000 \u00e9chantillons de sang provenant de donateurs chinois asymptomatiques, 4 cas de pr\u00e9sence d'ARN viral ont \u00e9t\u00e9 d\u00e9tect\u00e9s, cet ARN semblant stable dans le plasma.\r\nLes auteurs encouragent \u00e0 \u00eatre vigilant et \u00e0 tester les poches de sang, m\u00eame si l'infectiosit\u00e9 en cas de transfusion n'est pas av\u00e9r\u00e9e, n\u00e9cessitant des \u00e9tudes compl\u00e9mentaires.", "objectives": "- Etude de cohorte r\u00e9tro-prospective sur des milliers d'\u00e9chantillons sanguins- Caract\u00e9ritiques des donateurs peu connus- Pas de preuve de l'infectiosit\u00e9 de ces poches\"", "methods": "Evaluer la pr\u00e9sence d'ARN viral du SARS-CoV-2 dans les pr\u00e9l\u00e8vements des donneurs de sang en situation \u00e9pid\u00e9mique", "pubmed_id": "32243255", "doi": "10.3201/eid2607.200839", "abstract": "Because of high rates of 2019 novel coronavirus disease in Wuhan, China, Wuhan Blood Center began screening for severe acute respiratory syndrome coronavirus 2 RNA on January 25, 2020. We screened donations in real-time and retrospectively and found plasma samples positive for viral RNA from 4 asymptomatic donors.", "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 231, "name": "Le C"}], "publication_date": "2020-04-04"}, {"id": 55, "slug": "influenza-associated-pneumonia-as-reference-to-assess-seriousness-of-coronavirus", "title": "Influenza-associated pneumonia as reference to assess seriousness of coronavirus disease (COVID-19)", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer la s\u00e9v\u00e9rit\u00e9 de la maladie : survenue de SDRA, recours \u00e0 la ventilation, hospitalisation en soins intensifs, et d\u00e9c\u00e8s.", "verbose_date": "19.03.2020", "authors": "Kinross P", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 47, "name": "Euro Surveill"}, "link": "https://www.dropbox.com/s/vamji43mlayrxja/eurosurv-25-11-2.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Taux de recours \u00e0 la ventilation plus important que dans les pneumonies.- S\u00e9v\u00e9rit\u00e9 de l'infection chez les patients jeunes plus importante", "objectives": "Faible :- non comparabilit\u00e9 des deux groupes du fait des diff\u00e9rences de la population et des syst\u00e8mes de sant\u00e9- R\u00e9sultats pr\u00e9liminaires concernant le COVID-19 (plus de la moti\u00e9 des cas sont encore hospitilis\u00e9s)- possible sous/sur diagnostique des comorbidit\u00e9s dans les diff\u00e9rents groupes", "methods": "Evaluer la s\u00e9v\u00e9rit\u00e9 de la maladie : survenue de SDRA, recours \u00e0 la ventilation, hospitalisation en soins intensifs, et d\u00e9c\u00e8s.", "pubmed_id": "32186278", "doi": "10.2807/1560-7917.ES.2020.25.11.2000258", "abstract": "Information on severity of coronavirus disease (COVID-19) (transmissibility, disease seriousness, impact) is crucial for preparation of healthcare sectors. We present a simple approach to assess disease seriousness, creating a reference cohort of pneumonia patients from sentinel hospitals. First comparisons exposed a higher rate of COVID-19 patients requiring ventilation. There were more case fatalities among COVID-19 patients without comorbidities than in the reference cohort. Hospitals should prepare for high utilisation of ventilation and intensive care resources.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 65, "name": "Kinross P"}], "publication_date": "2020-03-19"}, {"id": 638, "slug": "are-chilblain-like-acral-skin-lesions-really-indicative-of-covid-19-a-prospectiv", "title": "Are chilblain-like acral skin lesions really indicative of COVID-19? A prospective study and literature review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "- Etablir la pr\u00e9valence d'infection COVID-19 parmi les patients pr\u00e9sentant des l\u00e9sions dermatologiques acrales semblable \u00e0 des engelures.", "verbose_date": "28.05.2020", "authors": "Docampo-Simon A", "specialties": [{"id": 10, "name": "Dermatologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 246, "name": "J Eur Acad Dermatol Venerol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.16665", "findings": "", "take_away": "", "relevance_level": "Il n'existe pas actuellement d'\u00e9l\u00e9ment faisant suspecter une association entre l\u00e9sions dermatologiques acrales \u00e0 type d'engelure et infection \u00e0 SARS-CoV-2.", "objectives": "- Lettre \u00e0 l'\u00e9diteur- \u00c9tude observationnelle transversale coupl\u00e9e \u00e0 une revue de la litt\u00e9rature semblant syst\u00e9matique mais aucun d\u00e9tail m\u00e9thodologique n'est donn\u00e9.", "methods": "- Etablir la pr\u00e9valence d'infection COVID-19 parmi les patients pr\u00e9sentant des l\u00e9sions dermatologiques acrales semblable \u00e0 des engelures.", "pubmed_id": "32452545", "doi": "10.1111/jdv.16665", "abstract": "Recently, young COVID-19 patients have presented with erythematous and purpuric acral lesions similar to chilblains", "topics": ["Epid\u00e9miologique", "Dermatologie"], "author_list": [{"id": 600, "name": "Docampo-Simon A"}], "publication_date": "2020-05-28"}, {"id": 461, "slug": "prediction-of-the-covid-19-spread-in-african-countries-and-implications-for-prev", "title": "Prediction of the COVID-19 spread in African countries and implications for prevention and controls: A case study in South Africa, Egypt, Algeria, Nigeria, Senegal and Kenyascien", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Simuler et pr\u00e9dire la propagation \u00e9pid\u00e9mique du Covid-19 dans 6 pays africains selon diff\u00e9rents sc\u00e9narios d'intervention.", "verbose_date": "27.04.2020", "authors": "Zhao Z", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 166, "name": "Science of The Total Environment"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0048969720324761?token=F6F78580900823DEE61EFE9C2CA85F552F1B20ACD16F8191B3E770B2A5D1ABEA51B74D22B77A81FD137BB037BE178E50", "findings": "", "take_away": "", "relevance_level": "Des mesures fortes d'intervention pour la suppression de la transmission du virus r\u00e9sulterait en un contr\u00f4le fin Avril de l'\u00e9pid\u00e9mie dans les pays africains. Un manque de contr\u00f4le important risquerait de tripler le nombre de personnes infect\u00e9es et de retarder le contr\u00f4le de l'\u00e9pid\u00e9mie d'un mois.", "objectives": "- Mod\u00e8le compartimental type SEIR \u00e9tendu- M\u00e9thode d'optimisation du param\u00e8tre de Hastings pour estimer les param\u00e8tres \u00e9pid\u00e9miologiques selon les pays- Calibrage du mod\u00e8le sur donn\u00e9es issues de l'Universit\u00e9 de John Hopkins- Plusieurs sc\u00e9narios test\u00e9s\"", "methods": "Simuler et pr\u00e9dire la propagation \u00e9pid\u00e9mique du Covid-19 dans 6 pays africains selon diff\u00e9rents sc\u00e9narios d'intervention.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 433, "name": "Zhao Z"}], "publication_date": "2020-04-27"}, {"id": 217, "slug": "prevalence-of-underlying-diseases-in-hospitalized-patients-with-covid-19-a-syste", "title": "Prevalence of Underlying Diseases in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Estimer la pr\u00e9valence des maladies sous jacentes chez les COVID 19 hospitalis\u00e9s ", "verbose_date": "01.04.2020", "authors": "Emami A ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 105, "name": "Arch Acad Emerg Med"}, "link": "https://www.dropbox.com/s/gujnrujioqbj4z3/aaem-8-e35.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La pr\u00e9valence group\u00e9e chez les patients infect\u00e9s par SARS-CoV-2 de :\r\n- hypertension = 16.37% (IC 9510.15%-23.65%)\r\n- maladies cardiovasculaires = 12.11% (95%CI 4.40%-22.75%),\r\n- fumeurs = 7.63% (95%CI 3.83%-12.43%)\r\n- diab\u00e8te = 7.87% (95%CI 6.57%-9.28%)\n\r\nHTA, MCV, diab\u00e8te, tabac, BPCO, tumeur (et notamment les cancers pulmonaires), insuffisance r\u00e9nale chronique sont parmis les comorbidit\u00e9s les plus fr\u00e9quentes chez les patients COVID19 hospitalis\u00e9s\n\r\nLes MCV sont les comorbidit\u00e9s les plus pr\u00e9valentes.", "objectives": "- beaucoup d'articles chinois, seuls les abstracts ont \u00e9t\u00e9 lus- inclut des \u00e9tudes non randomis\u00e9es- lecture par 2 auteurs, ind\u00e9pendante- petit nombre d'articles (10)- S\u00e9lections de \"vieux\" articles: phase pr\u00e9coce de l'\u00e9pid\u00e9mie- Majorit\u00e9 des articles sont chinois", "methods": "Estimer la pr\u00e9valence des maladies sous jacentes chez les COVID 19 hospitalis\u00e9s", "pubmed_id": "32232218\n32044814\n32083985\n32077115\n32081636\n32075786\n32109279\n32031570\n32127124\n32027631\n31986257\n32050635\n32088678\n32077665\n32044389\n25336990\n27352628\n32066541\n32052846\n31986264\n32029004\n32004066\n32052373\n32142622\n32048163\n29020176\n32007143\n31971553\n32035511\n32139904", "doi": null, "abstract": "In the beginning of 2020, an unexpected outbreak due to a new corona virus made the headlines all over the world. Exponential growth in the number of those affected makes this virus such a threat. The current meta-analysis aimed to estimate the prevalence of underlying disorders in hospitalized COVID-19 patients.\nA comprehensive systematic search was performed on PubMed, Scopus, Web of science, and Google scholar, to find articles published until 15 February 2020. All relevant articles that reported clinical characteristics and epidemiological information of hospitalized COVID-19 patients were included in the analysis.\nThe data of 76993 patients presented in 10 articles were included in this study. According to the meta-analysis, the pooled prevalence of hypertension, cardiovascular disease, smoking history and diabetes in people infected with SARS-CoV-2 were estimated as 16.37% (95%CI: 10.15%-23.65%), 12.11% (95%CI 4.40%-22.75%), 7.63% (95%CI 3.83%-12.43%) and 7.87% (95%CI 6.57%-9.28%), respectively.\nAccording to the findings of the present study, hypertension, cardiovascular diseases, diabetes mellitus, smoking, chronic obstructive pulmonary disease (COPD), malignancy, and chronic kidney disease were among the most prevalent underlying diseases among hospitalized COVID-19 patients, respectively.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 208, "name": "Emami A "}], "publication_date": "2020-04-01"}, {"id": 548, "slug": "clinical-course-imaging-features-and-outcomes-of-covid-19-in-kidney-transplant-r", "title": "Clinical Course, Imaging Features, and Outcomes of COVID-19 in Kidney Transplant Recipients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer les sp\u00e9cificit\u00e9s en termes d\u2019\u00e9volution clinique, de caract\u00e9ristiques d\u2019imagerie et de pronostic, des patients transplant\u00e9s r\u00e9naux, sous r\u00e9gime immunosuppressif, atteints du COVID-19.", "verbose_date": "07.05.2020", "authors": "Abrishami A", "specialties": [{"id": 20, "name": "N\u00e9phrologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 215, "name": "Eur Urology"}, "link": "https://www.sciencedirect.com/science/article/pii/S0302283820303328", "findings": "", "take_away": "", "relevance_level": "Toutes les images TDM prises \u00e0 l\u2019admission de patients COVID-19 et receveurs de greffe du rein \u00e9taient compatibles avec une fonction immunitaire normale \u00e0 l'exception d'une atteinte unilat\u00e9rale et sur la condensation, qui \u00e9taient l\u00e9g\u00e8rement plus fr\u00e9quentes dans notre s\u00e9rie que dans une \u00e9tude multicentrique pr\u00e9c\u00e9dente sur 101 patients immunocomp\u00e9tents atteints de COVID-19.\r\nLa plupart des patients receveurs de greffe a pr\u00e9sent\u00e9 \u00e0 des stades ult\u00e9rieurs une atteinte sous-pleurale beaucoup moins typique.\r\nA mesure que la maladie progresse, d'autres r\u00e9sultats inhabituels apparaissent, tels que des \u00e9panchements pleuraux ou p\u00e9ricardiques, des lymphad\u00e9nopathies, cavitations, signes de halo ou pneumothorax.\r\nLes caract\u00e9ristiques d'imagerie les plus courantes ont \u00e9t\u00e9 l\u2019atteinte bilat\u00e9rale multilobaire et la condensation sous-segmentaire.\r\nL'\u00e9paississement septal interlobulaire, les atteintes multilobaires, la condensation, l\u2019\u00e9panchement pleural ou p\u00e9ricardique et un score \u00e9lev\u00e9 pour l'atteinte pulmonaire semblent plus fr\u00e9quents chez les patients avec une \u00e9volution d\u00e9favorable et des cas compliqu\u00e9s de SDRA.", "objectives": "S\u00e9rie de 12 \u00e9tudes de cas cliniques. Les patients re\u00e7oivent de nombreux traitements, beaucoup de facteurs de confusion possibles, toute comparaison avec d\u2019autres cohortes s\u2019av\u00e9rerait p\u00e9rilleuse .", "methods": "D\u00e9terminer les sp\u00e9cificit\u00e9s en termes d\u2019\u00e9volution clinique, de caract\u00e9ristiques d\u2019imagerie et de pronostic, des patients transplant\u00e9s r\u00e9naux, sous r\u00e9gime immunosuppressif, atteints du COVID-19.", "pubmed_id": "32409114\n31986264\n32007143\n21792558\n32125873\n32259130", "doi": "10.1016/j.eururo.2020.04.064", "abstract": "Coronavirus disease 2019 (COVID-19) is a novel and highly contagious disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Older adults and patients with comorbidities and immunosuppressive conditions may experience severe signs and symptoms that can lead to death. This case series assesses the clinical course, imaging features, and outcomes for 12 patients with COVID-19 and a history of kidney transplantation. Patients were evaluated for symptoms, laboratory data, imaging findings, and outcomes from February 2020 to April 2020. Fever, cough, and dyspnea were the most common clinical symptoms, noted in 75% (nine/12), 75% (nine/12), and 41.7% (five/12) of the patients, respectively. Most of the patients had a normal white blood cell count, while 33.3% (four/12) had leukopenia and 8.3% (one/12) had leukocytosis. A combination of consolidation and ground glass opacity was the most predominant (75%) pattern of lung involvement on computed tomography (CT). Eight patients died of severe COVID-19 pneumonia and acute respiratory distress syndrome and four were discharged. All recovered cases had a unilateral peripheral pattern of involvement limited to only one zone on initial chest CT. It seems that CT imaging has an important role in predicting COVID-19 outcomes for solid organ transplant recipients. Future studies with long-term follow up and more cases are needed to elucidate COVID-19 diagnosis, outcome, and management strategies for these patients.", "topics": ["Pronostique", "N\u00e9phrologie"], "author_list": [{"id": 513, "name": "Abrishami A"}], "publication_date": "2020-05-07"}, {"id": 308, "slug": "early-treatment-of-1061-covid-19-patients-with-hydroxychloroquine-and-azithromyc", "title": "Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin, Marseille, France", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'efficacit\u00e9 du traitement par hydrxychloroquine et azythromycine en combinaison chez des patients non s\u00e9v\u00e8res infect\u00e9s par le COVID-19", "verbose_date": "12.04.2020", "authors": "Million M", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Abstract_Raoult_EarlyTrtCovid19_09042020_vD1v.pdf", "findings": "", "take_away": "", "relevance_level": "Analyse pr\u00e9liminaire sur l'ABSTRACT : potentielle efficacit\u00e9 clinique et virologique de l'association hydroxychloroquine et azythromycine avec une relative s\u00e9curit\u00e9 du traitement sur cette cohorte.\u00a0\r\nCependant, la repr\u00e9sentativit\u00e9 de l'\u00e9chantillon et l'absence de contr\u00f4le satisfaisant ne permet pas de conclure sur la base de cette seule \u00e9tude, le niveau de preuve restant clairement faible.", "objectives": "- Pas de publication compl\u00e8te disponible pour le moment = uniquement Abstract (\u00e9tude non publi\u00e9e)- Etude de cohorte sans groupe contr\u00f4le- Mauvaise repr\u00e9sentativit\u00e9 de la population : en majorit\u00e9 des femmes, moyenne d'\u00e2ge jeune, comorbidit\u00e9s et ob\u00e9sit\u00e9 peu repr\u00e9sent\u00e9s par rapport \u00e0 la population g\u00e9n\u00e9rale infect\u00e9e par le COVID\"", "methods": "Evaluer l'efficacit\u00e9 du traitement par hydrxychloroquine et azythromycine en combinaison chez des patients non s\u00e9v\u00e8res infect\u00e9s par le COVID-19", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie", "Pneumologie"], "author_list": [{"id": 295, "name": "Million M"}], "publication_date": "2020-04-12"}, {"id": 104, "slug": "estimation-of-the-asymptomatic-ratio-of-novel-coronavirus-infections-covid-19", "title": "Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Estimer le pourcentage de patients COVID-19 asymptomatiques", "verbose_date": "13.03.2020", "authors": "Nishiura H", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.dropbox.com/s/phxnvtzvnpa5jcs/PIIS1201971220301399.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude d\u00e9termine que dans moins de la moiti\u00e9 des cas les patients COVID-19 sont asymptomatiques (\u00e9tude men\u00e9e sur un petit \u00e9chantillon non randomis\u00e9)", "objectives": "Faible:1) Lettre \u00e0 l'editeur2) Petit \u00e9chantillon (N=565)3) Age-d\u00e9pendance et autres aspects de l'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 de l'\u00e9chantillon inconnus", "methods": "Estimer le pourcentage de patients COVID-19 asymptomatiques", "pubmed_id": "32179137\n31995857\n24520993\n31991628\n32079150\n18230677\n32033064", "doi": "10.1016/j.ijid.2020.03.020", "abstract": null, "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 110, "name": "Nishiura H"}], "publication_date": "2020-03-13"}, {"id": 506, "slug": "elevations-of-serum-cancer-biomarkers-correlate-with-severity-of-covid-19", "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Comparer les dosages de biomarqueurs tumoraux chez des patients atteints de SARS-CoV-2 selon 3 stades de s\u00e9v\u00e9rit\u00e9 \u00e0 ceux r\u00e9alis\u00e9s chez des patients non atteints de SARS-CoV-2 (qui pr\u00e9sentaient des dosages consid\u00e9r\u00e9s comme normaux)", "verbose_date": "01.05.2020", "authors": "Wei X", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25957", "findings": "", "take_away": "", "relevance_level": "Augmentation significative de certains biomarqueurs tumoraux HE4, CYFRA21-1, CEA, CA 125 et CA 153\u00a0dans le COVID-19, proportionnellement \u00e0 la CRP et \u00e0 la s\u00e9v\u00e9rit\u00e9, chez des patients a priori indemnes de pathologie tumorale. Cette augmentation est coh\u00e9rente avec des \u00e9tudes pr\u00e9c\u00e9dentes qui sugg\u00e8rent une augmentation de certains de ces marqueurs dans les \u00e9tats inflammatoires pulmonaires. Ces r\u00e9sultats n\u00e9cessiteraient des investigations suppl\u00e9mentaires pour voir en quoi ces marqueurs pourraient refl\u00e9ter les l\u00e9sions pulmonaires associ\u00e9es au COVID-19 et une aide \u00e0 l'\u00e9valuation pronostique des patients.", "objectives": "Etude r\u00e9trospective, monocentrique, biais de genre pour l'HE4 o\u00f9 tous les patients contr\u00f4les sont des femmes, pas de suivi au long cours des patients, pas de nouveau dosage pour voir une \u00e9ventuelle corr\u00e9lation avec la r\u00e9ponse th\u00e9rapeutique", "methods": "Comparer les dosages de biomarqueurs tumoraux chez des patients atteints de SARS-CoV-2 selon 3 stades de s\u00e9v\u00e9rit\u00e9 \u00e0 ceux r\u00e9alis\u00e9s chez des patients non atteints de SARS-CoV-2 (qui pr\u00e9sentaient des dosages consid\u00e9r\u00e9s comme normaux)", "pubmed_id": "32347972", "doi": "10.1002/jmv.25957", "abstract": "In this retrospective study, we evaluated the levels of a series of serum biomarkers in coronavirus disease 2019 (COVID-19) patients (mild: 131; severe: 98; critical: 23). We found that there were significant increases in levels of human epididymis protein 4 (HE4) (73.6\u2009\u00b1\u200938.3 vs 46.5\u2009\u00b1\u200914.7 pmol/L; P\u2009<\u2009.001), cytokeratin-19 fragment (CYFRA21-1) (2.2\u2009\u00b1\u20090.9 vs 1.9\u2009\u00b1\u20090.8 \u03bcg/L; P\u2009<\u2009.001), carcinoembryonic antigen (CEA) (3.4\u2009\u00b1\u20092.2 vs 2.1\u2009\u00b1\u20091.2 \u03bcg/L; P\u2009<\u2009.001), carbohydrate antigens (CA) 125 (18.1\u2009\u00b1\u200913.5 vs 10.5\u2009\u00b1\u20094.6 \u03bcg/L; P\u2009<\u2009.001), and 153 (14.4\u2009\u00b1\u20098.9 vs 10.1\u2009\u00b1\u20094.4 \u03bcg/L; P\u2009<\u2009.001) in COVID-19 mild cases as compared to normal control subjects; their levels showed continuous and significant increases in severe and critical cases (HE4, CYFRA21-1, and CA125: P\u2009<\u2009.001; CEA and CA153: P\u2009<\u2009.01). Squamous cell carcinoma antigen (SCC) and CA199 increased significantly only in critical cases of COVID-19 as compared with mild and severe cases and normal controls (P\u2009<\u2009.01). There were positive associations between levels of C-reactive protein and levels of HE4 (R\u2009=\u2009.631; P\u2009<\u2009.001), CYFRA21-1 (R\u2009=\u2009.431; P\u2009<\u2009.001), CEA (R\u2009=\u2009.316; P\u2009<\u2009.001), SCC (R\u2009=\u2009.351; P\u2009<\u2009.001), CA153 (R\u2009=\u2009.359; P\u2009<\u2009.001) and CA125 (R\u2009=\u2009.223; P\u2009=\u2009.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19.", "topics": ["Pronostique", "Transversale", "Virologie"], "author_list": [{"id": 474, "name": "Wei X"}], "publication_date": "2020-05-01"}, {"id": 279, "slug": "intensive-care-management-of-coronavirus-disease-2019-covid-19-challenges-and-re", "title": "Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Recommandations pour l'organisation des services de soins intensifs, pour la gestion du personnel de sant\u00e9 et pour la prise en charge des patients COVID-19 dans ces services.", "verbose_date": "08.04.2020", "authors": "Phua J", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 7, "name": "Recommandations", "icon": "icon-reco"}, "journal": {"id": 1, "name": "Lancet Repir Med"}, "link": "https://www.thelancet.com/action/showPdf?pii=S2213-2600%2820%2930161-2", "findings": "", "take_away": "", "relevance_level": "Compte tenu du nombre \u00e9lev\u00e9 de patients COVID-19 n\u00e9cessitant un acc\u00e8s aux soins intensifs et consid\u00e9rant la difficult\u00e9 de distinguer les patients atteints de COVID-19 des autres formes de pneumonie communautaire, des strat\u00e9gies hospitali\u00e8res nationales et locales doivent \u00eatre appliqu\u00e9es pour augmenter la capacit\u00e9 d'accueil de ces services.\n\r\nCes strat\u00e9gies devraient viser \u00e0:\r\n1) augmenter le nombre de lits de soins intensifs (augmentation des lits dans les services existants et cr\u00e9ation de nouveaux services temporaires).\r\n2) garantir l'\u00e9quipement appropri\u00e9 des services tels que les ventilateurs, les m\u00e9dicaments et les dispositifs de s\u00e9curit\u00e9 individuels.\r\n3) assurer le bien-\u00eatre psycho-physique des travailleurs de la sant\u00e9 (une surcharge de travail est corr\u00e9l\u00e9e \u00e0 une augmentation de la mortalit\u00e9).", "objectives": "1) revue de la litt\u00e9rature mais pas syst\u00e9matique2) peu d'\u00e9tudes disponibles\"", "methods": "Recommandations pour l'organisation des services de soins intensifs, pour la gestion du personnel de sant\u00e9 et pour la prise en charge des patients COVID-19 dans ces services.", "pubmed_id": "32272080", "doi": "10.1016/S2213-2600(20)30161-2", "abstract": "As coronavirus disease 2019 (COVID-19) spreads across the world, the intensive care unit (ICU) community must prepare for the challenges associated with this pandemic. Streamlining of workflows for rapid diagnosis and isolation, clinical management, and infection prevention will matter not only to patients with COVID-19, but also to health-care workers and other patients who are at risk from nosocomial transmission. Management of acute respiratory failure and haemodynamics is key. ICU practitioners, hospital administrators, governments, and policy makers must prepare for a substantial increase in critical care bed capacity, with a focus not just on infrastructure and supplies, but also on staff management. Critical care triage to allow the rationing of scarce ICU resources might be needed. Researchers must address unanswered questions, including the role of repurposed and experimental therapies. Collaboration at the local, regional, national, and international level offers the best chance of survival for the critically ill.", "topics": ["Recommandations", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 268, "name": "Phua J"}], "publication_date": "2020-04-08"}, {"id": 264, "slug": "high-sensitivity-cardiac-troponin-can-be-an-ally-in-the-fight-against-covid-19", "title": "High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Utiliser la troponine cardiaque hypersensibles comme outil de diagnostic et de pronostic pr\u00e9coce des patients COVID-19 : pour stratifier les patients \u00e0 haut risque, reconna\u00eetre les patients dont les chances de survie sont d\u00e9tourn\u00e9es et allouer les ressources disponibles.", "verbose_date": "07.04.2020", "authors": "Chapman AR", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 9, "name": "Circulation"}, "link": "https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.047008", "findings": "", "take_away": "", "relevance_level": "1) La troponine cardiaque hypersensible n'est pas un marqueur d'infarctus du myocarde.\r\nLa troponine cardiaque est le marqueur le plus pr\u00e9coce et le plus sensible pour d\u00e9tecter les l\u00e9sions hypoxiques et la r\u00e9duction de la perfusion tissulaire, qui, dans le cas de patients graves, est \u00e9tendue \u00e0 plusieurs organes.\n\r\n2) Compte tenu de l'\u00e9l\u00e9vation de la troponine hypersensible, l'\u00e9lectrocardiogramme et l'\u00e9tat clinique du patient peuvent aider au diagnostic et au pronostic pr\u00e9coces des patients atteints de COVID-19, en identifiant ceux qui pr\u00e9sentent un risque plus \u00e9lev\u00e9, et faciliter le triage pour les soins intensifs.", "objectives": "1) Revue narrative2) 2 \u00e9tudes prises en compte, dont aucune \u00e9tude exp\u00e9rimentale3) petits \u00e9chantillons : 191 patients pour la premi\u00e8re \u00e9tude et 416 patients pour la seconde \"", "methods": "Utiliser la troponine cardiaque hypersensibles comme outil de diagnostic et de pronostic pr\u00e9coce des patients COVID-19 : pour stratifier les patients \u00e0 haut risque, reconna\u00eetre les patients dont les chances de survie sont d\u00e9tourn\u00e9es et allouer les ressources disponibles.", "pubmed_id": "32251612", "doi": "10.1161/CIRCULATIONAHA.120.047008", "abstract": null, "topics": ["Pronostique", "Transversale", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 253, "name": "Chapman AR"}], "publication_date": "2020-04-07"}, {"id": 633, "slug": "an-interpretable-mortality-prediction-model-for-covid-19-patients", "title": "An interpretable mortality prediction model for COVID-19 patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "L'article d\u00e9crit une m\u00e9thode de classification de l'outcome de survie (oui/non) chez les patients atteints du Covid-19 \u00e0 partir de biomarqueurs.", "verbose_date": "26.05.2020", "authors": "Yan L", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 244, "name": "Nature Machine Intelligence"}, "link": "https://www.nature.com/articles/s42256-020-0180-7.pdf", "findings": "", "take_away": "", "relevance_level": "Un algorithme de classification XGBoost entrain\u00e9 sur 375 patients Covid-19 hospitalis\u00e9s \u00e0 Wuhan semble pr\u00e9dire la survie avec une tr\u00e8s bonne performance. Les variables cliniques les plus informatives sont le LDH, le hs-CRP, et les lymphocytes.", "objectives": "Deux points faibles:- La base de donn\u00e9es a \u00e9t\u00e9 collect\u00e9e dans l'h\u00f4pital prenant en charge les cas les plus graves \u00e0 Wuhan. Cela pourrait \u00eatre \u00e0 l'origine d'un biais de s\u00e9lection qui est difficile \u00e0 appr\u00e9cier sans analyser des donn\u00e9es d'autres h\u00f4pitaux.- Pour la plupart des patients, les variables ont \u00e9t\u00e9 mesur\u00e9es \u00e0 des temps diff\u00e9rents. Malgr\u00e9 une section sp\u00e9cifique dans l'article, il n'est pas tr\u00e8s clair comment cela a \u00e9t\u00e9 pris en compte.", "methods": "L'article d\u00e9crit une m\u00e9thode de classification de l'outcome de survie (oui/non) chez les patients atteints du Covid-19 \u00e0 partir de biomarqueurs.", "topics": ["Mod\u00e9lisation", "Transversale"], "author_list": [{"id": 596, "name": "Yan L"}], "publication_date": "2020-05-26"}, {"id": 252, "slug": "a-systematic-review-of-covid-19-epidemiology-based-on-current-evidence", "title": "A Systematic Review of COVID-19 Epidemiology Based on Current Evidence", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la transmission du virus", "verbose_date": "06.04.2020", "authors": "Park M", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 98, "name": "J Clin Med"}, "link": "https://www.dropbox.com/s/1hlqumiltn09h1i/jcm-09-00967.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La taille de l'\u00e9pid\u00e9mie est bien plus grande que ce qui est rapport\u00e9.\r\n1 personne contamin\u00e9e peut contaminer 2 \u00e0 3 autres personnes en moyenne.\r\nL'\u00e9pid\u00e9mie double de taille tous les 3 \u00e0 7 jours.\r\nIncubation de 3 \u00e0 6 jours, 5j en moyenne.\r\nIntervalle de s\u00e9rie de 4 \u00e0 8j.\r\nLe taux de mortalit\u00e9 para\u00eet plus faible que pour les autres coronavirus, autour de 4.8% dans le monde pour SARS-CoV-2.\r\nLa fermeture des \u00e9coles est moins efficace que l'\u00e9loignement du lieu de travail ou la mise en quarantaine des individus expos\u00e9s, une strat\u00e9gie combin\u00e9e qui met en \u0153uvre les trois mesures\r\nensemble s'est av\u00e9r\u00e9e la plus efficace pour r\u00e9duire la propagation.", "objectives": "- revue de litt\u00e9rature incluant des preprint - la plupart des \u00e9tudes sont sur des donn\u00e9es de Chine, \u00e0 un stade pr\u00e9coce de l'\u00e9pid\u00e9mie - certaines \u00e9tudes avec tr\u00e8s peu de cas\"", "methods": "Etudier la transmission du virus", "pubmed_id": "32244365\n32046819\n12766207\n24239323\n32109013\n26132767\n32026148\n32151335\n32046814\n32014114\n32007643\n31986264\n32154135\n32083643\n32007143\n32046816\n20205928\n32035431\n31995857\n32213332\n12766206\n32019669\n32056235\n32191173\n32091533\n32053479\n32079150\n32024089\n23782161\n32033064\n32075152\n32144116\n32046137\n32183930", "doi": "10.3390/jcm9040967", "abstract": "As the novel coronavirus (SARS-CoV-2) continues to spread rapidly across the globe, we aimed to identify and summarize the existing evidence on epidemiological characteristics of SARS-CoV-2 and the effectiveness of control measures to inform policymakers and leaders in formulating management guidelines, and to provide directions for future research. We conducted a systematic review of the published literature and preprints on the coronavirus disease (COVID-19) outbreak following predefined eligibility criteria. Of 317 research articles generated from our initial search on PubMed and preprint archives on 21 February 2020, 41 met our inclusion criteria and were included in the review. Current evidence suggests that it takes about 3-7 days for the epidemic to double in size. Of 21 estimates for the basic reproduction number ranging from 1.9 to 6.5, 13 were between 2.0 and 3.0. The incubation period was estimated to be 4-6 days, whereas the serial interval was estimated to be 4-8 days. Though the true case fatality risk is yet unknown, current model-based estimates ranged from 0.3% to 1.4% for outside China. There is an urgent need for rigorous research focusing on the mitigation efforts to minimize the impact on society.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 242, "name": "Park M"}], "publication_date": "2020-04-06"}, {"id": 547, "slug": "sars-cov-2-detection-in-formalin-fixed-paraffin-embedded-tissue-specimens-from-s", "title": "SARS-CoV-2 detection in formalin-fixed paraffin-embedded tissue specimens from surgical resection of tongue squamous cell carcinoma", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer la pr\u00e9sence du virus SARS-CoV-2 dans des \u00e9chantillons anatomiques fix\u00e9s au formol et le risque que cela peut repr\u00e9senter pour les anatomo-pathologistes", "verbose_date": "07.05.2020", "authors": "Guerini-Rocco E", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 29, "name": "J Clin Pathol"}, "link": "https://jcp.bmj.com/content/jclinpath/early/2020/05/04/jclinpath-2020-206635.full.pdf", "findings": "", "take_away": "", "relevance_level": "D\u00e9tection possible du virus SARS-CoV-2 sur des \u00e9chantillons fix\u00e9s au formol \u00e0 la concentration de 10% pendant 24 heures\nIl convient de prendre des pr\u00e9cautions pour toutes les pi\u00e8ces anatomiques, m\u00eame apr\u00e8s fixation au formol et m\u00eame si le patient \u00e9tait asymptomatique, bien que la d\u00e9tection du virus n'implique pas forc\u00e9ment un risque infectieux", "objectives": "- Unique case report mais pi\u00e8ces op\u00e9ratoires rarement test\u00e9es dans la litt\u00e9rature jusqu'\u00e0 pr\u00e9sent- Premier cas d\u00e9crit de positivit\u00e9 sur \u00e9chantillon en anatomopathologie- Test diagnostique PCR fiable- Possibilit\u00e9 de contamination a posteriori de l'\u00e9chantillon non exclue mais peu probable", "methods": "Evaluer la pr\u00e9sence du virus SARS-CoV-2 dans des \u00e9chantillons anatomiques fix\u00e9s au formol et le risque que cela peut repr\u00e9senter pour les anatomo-pathologistes", "pubmed_id": "32366599", "doi": "10.1136/jclinpath-2020-206635", "abstract": "In the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, pathologists can be exposed to infection handling surgical specimens. Guidelines related to safety procedures in the laboratory have been released. However, there is a lack of studies performed on biopsy and surgical resection specimens. Here we report the detection of SARS-CoV-2 in formalin-fixed paraffin-embedded samples from surgical resection of tongue squamous cell carcinoma of a patient who developed COVID-19 postsurgery. RNA of SARS-CoV-2 strain was detected in the tumour and the normal submandibular gland samples using real-time PCR-based assay. No viral RNA was found in metastatic and reactive lymph nodes. We demonstrated that SARS-CoV-2 RNA can be detected in routine histopathological samples even before COVID-19 disease development. These findings may give important information on the possible sites of infection or virus reservoir, and highlight the necessity of proper handling and fixation before sample processing.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 512, "name": "Guerini-Rocco E"}], "publication_date": "2020-05-07"}, {"id": 544, "slug": "occurrence-prevention-and-management-of-the-psychological-effects-of-emerging-vi", "title": "Occurrence, prevention, and management of the psychological effects of emerging virus outbreaks on healthcare workers: rapid review and meta-analysis", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Identifier via une revue de la litt\u00e9rature rapide les r\u00e9percussions psychologiques des \u00e9pid\u00e9mies sur les soignants qui y sont expos\u00e9s et les mesures appropri\u00e9es pour contr\u00f4ler ces effets.", "verbose_date": "07.05.2020", "authors": "Kisely S", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 57, "name": "BMJ"}, "link": "https://www.bmj.com/content/bmj/369/bmj.m1642.full.pdf", "findings": "", "take_away": "", "relevance_level": "-M\u00e9ta-analyse sur 25 \u00e9tudes : le personnel expos\u00e9 pr\u00e9sentait des niveaux de stress aigu, de stress post-traumatique et de d\u00e9tresse psychologique sup\u00e9rieurs au non-expos\u00e9s.\u00a0\n- Facteurs de risques professionnels : exp\u00e9rience moindre, travail \u00e0 temps partiel, contact augment\u00e9 avec les patients affect\u00e9s, infirmi\u00e8r.e.s (par rapport au m\u00e9decins)\n- Facteurs protecteurs professionnels : pauses courtes et fr\u00e9quentes sur les gardes, temps de travail adapt\u00e9, impression d'\u00eatre correctement form\u00e9, environnement de travail favorable, communication claire, acc\u00e8s \u00e0 un soutien psychologique, d\u00e9veloppement de protocoles de soutien du personnel.", "objectives": "Revue de la litt\u00e9rature \"rapide\" mais ayant une approche similaire \u00e0 une revue de la litt\u00e9rature syst\u00e9matique, m\u00e9ta-analyse sur les \u00e9tudes s'y pr\u00eatant, contr\u00f4le des biais de publication et d'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9.\nCependant, la grande majorit\u00e9 des \u00e9tudes incluses dans cette revue sont des \u00e9tudes observationnelles transversales donc intrins\u00e8quement de faible niveau de preuve.", "methods": "Identifier via une revue de la litt\u00e9rature rapide les r\u00e9percussions psychologiques des \u00e9pid\u00e9mies sur les soignants qui y sont expos\u00e9s et les mesures appropri\u00e9es pour contr\u00f4ler ces effets.", "pubmed_id": "32371466\n15564361\n18182545\n15283534\n16460760\n32139372\n22624741\n32143502\n30343247\n17326946\n15927185\n29413067\n32202646\n19497162\n21062471\n15697046\n15283537\n17230391\n15608831\n15970782\n15133143\n32131151\n27580330\n28991605\n15286063\n16618485\n17053338\n26409446\n19423869\n22587960\n15323599\n26423938\n18222131\n17183035\n28057317\n21527961\n29252922\n14966227\n15345768\n31406720\n19247834\n21489421\n21288353\n12974482\n30544131\n15805323\n16145182\n15674079\n15796643\n15958885\n17500305\n28690117\n26262565\n16168796\n15479961\n15324539\n26847480\n14993174\n32085839\n17086611\n29851209\n15637196", "doi": "10.1136/bmj.m1642", "abstract": "To examine the psychological effects on clinicians of working to manage novel viral outbreaks, and successful measures to manage stress and psychological distress.\nRapid review and meta-analysis.\nCochrane Central Register of Controlled Trials, PubMed/Medline, PsycInfo, Scopus, Web of Science, Embase, and Google Scholar, searched up to late March 2020.\nAny study that described the psychological reactions of healthcare staff working with patients in an outbreak of any emerging virus in any clinical setting, irrespective of any comparison with other clinicians or the general population.\n59 papers met the inclusion criteria: 37 were of severe acute respiratory syndrome (SARS), eight of coronavirus disease 2019 (covid-19), seven of Middle East respiratory syndrome (MERS), three each of Ebola virus disease and influenza A virus subtype H1N1, and one of influenza A virus subtype H7N9. Of the 38 studies that compared psychological outcomes of healthcare workers in direct contact with affected patients, 25 contained data that could be combined in a pairwise meta-analysis comparing healthcare workers at high and low risk of exposure. Compared with lower risk controls, staff in contact with affected patients had greater levels of both acute or post-traumatic stress (odds ratio 1.71, 95% confidence interval 1.28 to 2.29) and psychological distress (1.74, 1.50 to 2.03), with similar results for continuous outcomes. These findings were the same as in the other studies not included in the meta-analysis. Risk factors for psychological distress included being younger, being more junior, being the parents of dependent children, or having an infected family member. Longer quarantine, lack of practical support, and stigma also contributed. Clear communication, access to adequate personal protection, adequate rest, and both practical and psychological support were associated with reduced morbidity.\nEffective interventions are available to help mitigate the psychological distress experienced by staff caring for patients in an emerging disease outbreak. These interventions were similar despite the wide range of settings and types of outbreaks covered in this review, and thus could be applicable to the current covid-19 outbreak.", "topics": ["Epid\u00e9miologique", "Psychiatrie"], "author_list": [{"id": 509, "name": "Kisely S"}], "publication_date": "2020-05-07"}, {"id": 92, "slug": "substantial-undocumented-infection-facilitates-the-rapid-dissemination-of-novel-", "title": "Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Mod\u00e9liser les infections non document\u00e9es et leurs impacts sur la transmission et la propagation du virus.", "verbose_date": "16.03.2020", "authors": "Li R", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 66, "name": "Science"}, "link": "https://www.dropbox.com/s/xwl15cxdoni1s0k/science.abb3221.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Importante proportion de cas non document\u00e9s (a- ou paucisymptomatiques) avant la mise en place d'une surveillance \u00e9tendue (86%), qui ont un r\u00f4le important dans dans la transmission du virus -> n\u00e9cessit\u00e9 de tester et d'\u00e9tendre les mesures restrictives aux personnes ne pr\u00e9sentant pas de sympt\u00f4mes.\r\n- Avant les contr\u00f4les renforc\u00e9s, p\u00e9riode de latence entre le d\u00e9but des sympt\u00f4mes et le diagnostic\r\n- Importance des mesures de restrictions de d\u00e9placements, et du d\u00e9pistage large dans le controle de l'\u00e9pid\u00e9mie, et la pr\u00e9vision de la lev\u00e9e des mesures restrictives\r\n- Le mod\u00e8le ne permet pas de pr\u00e9voir si rebond aura lieu \u00e0 la lev\u00e9e des mesures de restriction\r\n- Extrapolation difficile des r\u00e9sultats \u00e0 d'autre pays", "objectives": "Cet aticle traite d'une mod\u00e9lisation \u00e9pid\u00e9miologique assez avanc\u00e9e. Je n'ai pas les comp\u00e9tences pour \u00e9valuer sa validit\u00e9.Cependant, il semble que le mod\u00e8le donne des r\u00e9sultats concordant avec les observations.----------------Ajout Sol\u00e8ne :Niveau de preuve interm\u00e9diaire:Article tr\u00e8s solide (publi\u00e9 dans Science, m\u00e9thodologie bien d\u00e9crite et coh\u00e9rente, analyses de sensibilit\u00e9) mais : 1. \u00e7a reste de la mod\u00e9lisation 2. les r\u00e9sultats quantitatifs ne sont pas g\u00e9n\u00e9ralisables \u00e0 d'autres populations que la Chine (en particulier tr\u00e8s mesures-d\u00e9pendants)", "methods": "Mod\u00e9liser les infections non document\u00e9es et leurs impacts sur la transmission et la propagation du virus.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 98, "name": "Li R"}], "publication_date": "2020-03-16"}, {"id": 532, "slug": "eosinopenia-and-elevated-c-reactive-protein-facilitate-triage-of-covid-19-patien", "title": "Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Identifier des biomarqueurs simples et facilement disponibles pour faciliter le tri efficace des patients suspects de COVID-19.", "verbose_date": "05.05.2020", "authors": "Li Q", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 209, "name": "EClinicalMedicine"}, "link": "https://www.dropbox.com/s/l11u8k8ydp3zr6a/1-s2.0-S258953702030119X-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Utiliser l'\u00e9osinop\u00e9nie et l'\u00e9l\u00e9vation de la CRP comme crit\u00e8re de tri des patients suspects Covid-19 peut \u00eatre utile.", "objectives": "Faible :-Etude r\u00e9trospective-Nombre de sujets restreint-Pas de validation externe-Biais de s\u00e9lection : cas hospitaliers-Biais de classement (Faux n\u00e9gatifs de la PCR)", "methods": "Identifier des biomarqueurs simples et facilement disponibles pour faciliter le tri efficace des patients suspects de COVID-19.", "pubmed_id": "32368728\n32085846\n32098875\n7410543\n32061335\n16161804\n7502322\n31986264\n21435708\n3203132\n32109013\n17569110\n32007143\n26049252\n21204120\n32061284", "doi": "10.1016/j.eclinm.2020.100375", "abstract": "Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently a pandemic affecting over 200 countries. Many cities have established designated fever clinics to triage suspected COVID-19 patients from other patients with similar symptoms. However, given the limited availability of the nucleic acid test as well as long waiting time for both the test and radiographic examination, the quarantine or therapeutic decisions for a large number of mixed patients were often not made in time. We aimed to identify simple and quickly available laboratory biomarkers to facilitate effective triage at the fever clinics for sorting suspected COVID-19 patients from those with COVID-19-like symptoms.\nWe collected clinical, etiological, and laboratory data of 989 patients who visited the Fever Clinic at Wuhan Union Hospital, Wuhan, China, from Jan 31 to Feb 21. Based on polymerase chain reaction (PCR) nucleic acid testing for SARS-CoV-2 infection, they were divided into two groups: SARS-CoV-2-positive patients as cases and SARS-CoV-2-negative patients as controls. We compared the clinical features and laboratory findings of the two groups, and analyzed the diagnostic performance of several laboratory parameters in predicting SARS-CoV-2 infection and made relevant comparisons to the China diagnosis guideline of having a normal or decreased number of leukocytes (\u22649\u20225 10\nNormal or decreased number of leukocytes (\u22649\u20225 10\nThe combination of eosinopenia and elevated hs-CRP can effectively triage suspected COVID-19 patients from other patients attending the fever clinic with COVID-19-like initial symptoms. This finding would be particularly useful for designing triage strategies in an epidemic region having a large number of patients with COVID-19 and other respiratory diseases while limited medical resources for nucleic acid tests and radiographic examination.\nThis work was supported by the National Natural Science Foundation of China (NSFC) and the Major Scientific and Technological Innovation Projects of Hubei Province (MSTIP).", "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 498, "name": "Li Q"}], "publication_date": "2020-05-05"}, {"id": 534, "slug": "longitudinal-association-between-markers-of-liver-injury-and-mortality-in-covid-", "title": "Longitudinal association between markers of liver injury and mortality in COVID-19 in China", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Etudier les modifications des marqueurs h\u00e9patiques chez des patients atteints de COVID-19 et d\u00e9terminer en quoi certaines peuvent \u00eatre des facteurs de risque de mortalit\u00e9.", "verbose_date": "05.05.2020", "authors": "Lei FL", "specialties": [{"id": 19, "name": "H\u00e9pato-gastro-ent\u00e9rologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 211, "name": "Hepatology"}, "link": "https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.31301", "findings": "", "take_away": "", "relevance_level": "L'augmentation des taux de transaminases, des PAL et de la bilirubine est associ\u00e9e \u00e0 une augmentation de la mortalit\u00e9 chez les patients atteints de COVID-19 avec une association forte pour les ASAT. Cependant il existe de nombreux facteurs de confusion notamment l'h\u00e9patotoxicit\u00e9 iatrog\u00e8ne.\u00a0\r\nUne hypoth\u00e8se selon laquelle les cholangiocytes (exprimant beaucoup plus l'ACE2 que les h\u00e9patocytes) seraient une cible virale privil\u00e9gi\u00e9e a \u00e9t\u00e9 \u00e9tudi\u00e9e mais n'est pas tout \u00e0 fait coh\u00e9rente avec cette \u00e9tude (augmentation surtout des transaminases) ni avec des \u00e9tudes histologiques pr\u00e9c\u00e9dentes.\u00a0\r\nDans tous les cas il est important de monitorer la fonction h\u00e9patique r\u00e9guli\u00e8rement chez les patients atteints de COVID-19 devant l'atteinte possible fr\u00e9quente et multi-factorielle.", "objectives": "Etude de cohorte r\u00e9trospective avec des facteurs de confusion pas tous corrig\u00e9s, mais multicentrique avec un effectif important.", "methods": "Etudier les\u00a0modifications\u00a0des marqueurs h\u00e9patiques chez des patients atteints de COVID-19 et d\u00e9terminer en quoi certaines peuvent \u00eatre des facteurs de risque de mortalit\u00e9.", "pubmed_id": "32359177", "doi": "10.1002/hep.31301", "abstract": "Coronavirus disease 2019 (COVID-19) is a new infectious disease. To reveal the hepatic injury related to this disease and its clinical significance, we conducted a multicenter retrospective cohort study that included 5,771 adult patients with COVID-19 pneumonia in Hubei Province. We reported the distributional and temporal patterns of liver injury indicators in these patients and determined their associated factors and death risk. Longitudinal liver function tests were retrospectively analyzed and correlated with the risk factors and death. Liver injury dynamic patterns differed in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBIL). AST elevated first, followed by ALT, in severe patients. ALP modestly increased during hospitalization and largely remained in the normal range. The fluctuation in TBIL levels was mild in the non-severe and the severe group. AST abnormality was associated with the highest mortality risk compared to other indicators of liver injury during hospitalization. Common factors associated with elevated liver injury indicators were lymphocyte count decrease, neutrophil count increase, and male gender. CONCLUSION: The dynamic patterns of liver injury indicators and their potential risk factors may provide an important explanation for the COVID-19-associated liver injury. Because elevated liver injury indicators, particularly AST, are strongly associated with the mortality risk, our study indicates that these parameters should be monitored during hospitalization.", "topics": ["Pronostique", "H\u00e9pato-gastro-ent\u00e9rologie"], "author_list": [{"id": 500, "name": "Lei FL"}], "publication_date": "2020-05-05"}, {"id": 601, "slug": "use-of-prone-positioning-in-nonintubated-patients-with-covid-19-and-hypoxemic-ac", "title": "Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer la faisabilit\u00e9, l'efficacit\u00e9 et la tol\u00e9rance du d\u00e9cubitus ventral chez les patients COVID-19 \u00e9veill\u00e9s hors r\u00e9animation", "verbose_date": "18.05.2020", "authors": "Elharrar X", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://jamanetwork.com/journals/jama/fullarticle/2766292", "findings": "", "take_away": "", "relevance_level": "Le d\u00e9cubitus ventral chez des patients COVID-19 non-intub\u00e9s est plut\u00f4t bien tol\u00e9r\u00e9 (63% des cas)\nL'oxyg\u00e9nation n'a augment\u00e9 que dans 25% des cas et n'a pas \u00e9t\u00e9 maintenue apr\u00e8s le d\u00e9cubitus ventral dans la majorit\u00e9 des cas\nLe d\u00e9cubitus ventral semble donc am\u00e9liorer temporairement la situation respiratoire mais n\u00e9cessite de plus amples \u00e9tudes pour confirmer et quantifier l'effet", "objectives": "- Etude pseudo-exp\u00e9rimentale avant-apr\u00e8s sur petit \u00e9chantillon- Un seul \u00e9pisode de d\u00e9cubitus ventral dont la dur\u00e9e n'est pas connue- Pas d'\u00e9valuation de l'am\u00e9lioration de la symptomatologie clinique hors respiratoire, ni des signes biologiques ou radiologiques- Pas de calcul de nombre de sujets n\u00e9cessaires r\u00e9alis\u00e9 a priori et puissance visiblement trop faible pour les crit\u00e8res de jugement secondaire- Pas de prise en compte de la p\u00e9riode comme facteur al\u00e9atoire d'ajustement et pas d'ajustement sur de potentiels facteurs de confusion- Choix du crit\u00e8re de jugement principal et du seuil de 20% non justifi\u00e9", "methods": "Evaluer la faisabilit\u00e9, l'efficacit\u00e9 et la tol\u00e9rance du d\u00e9cubitus ventral chez les patients COVID-19 \u00e9veill\u00e9s hors r\u00e9animation", "pubmed_id": "32412581\n23688302\n29068269\n32250385\n26271685\n32000806\n32189136", "doi": "10.1001/jama.2020.8255", "abstract": null, "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie"], "author_list": [{"id": 564, "name": "Elharrar X"}], "publication_date": "2020-05-18"}, {"id": 72, "slug": "diagnostic-utility-of-clinical-laboratory-data-determinations-for-patients-with-", "title": "Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques h\u00e9matologiques des patients COVID19, d\u00e9terminer la corr\u00e9lation entre la bio et la s\u00e9v\u00e9rit\u00e9 de la maladie,d\u00e9terminer la valeur pr\u00e9dictive des param\u00e8tres biologiques pour la s\u00e9verit\u00e9 de la maladie", "verbose_date": "18.03.2020", "authors": "Gao Y", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://www.dropbox.com/s/e88scswi6sy0rb9/jmv.25770.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Il6 et Ddimere pourraient \u00eatre utilis\u00e9s pour estimer la s\u00e9v\u00e9rit\u00e9 du COVID19, ils devraient \u00eatre mesur\u00e9s pour aider au diagnostic de s\u00e9v\u00e9rit\u00e9", "objectives": "Interm\u00e9diaire :- faible nombre de cas : 2 groupes de 28 et 15 personnes- pas de suivi continu des taux sanguins et periode de mesure diff\u00e9rente dans les 2 groupes- pas de groupe controle sain- pas de validation interne ni externe du modele de regression, peu d'indicateurs de performance (seulement accuracy)", "methods": "D\u00e9crire les caract\u00e9ristiques h\u00e9matologiques des patients COVID19, d\u00e9terminer la corr\u00e9lation entre la bio et la s\u00e9v\u00e9rit\u00e9 de la maladie,d\u00e9terminer la valeur pr\u00e9dictive des param\u00e8tres biologiques pour la s\u00e9verit\u00e9 de la maladie", "pubmed_id": "32181911", "doi": "10.1002/jmv.25770", "abstract": "The role of clinical laboratory data in the differential diagnosis of the severe forms of COVID-19 has not been definitely established. The aim of this study was to look for the warning index in severe COVID-19 patients. We investigated 43 adult patients with COVID-19. The patients were classified into mild group (28 patients) and severe group (15 patients). A comparison of the hematological parameters between the mild and severe groups showed significant differences in interleukin-6 (IL-6), d-dimer (d-D), glucose, thrombin time, fibrinogen, and C-reactive protein (P\u2009<\u2009.05). The optimal threshold and area under the receiver operator characteristic curve (ROC) of IL-6 were 24.3 and 0.795\u2009\u00b5g/L, respectively, while those of d-D were 0.28 and 0.750\u2009\u00b5g/L, respectively. The area under the ROC curve of IL-6 combined with d-D was 0.840. The specificity of predicting the severity of COVID-19 during IL-6 and d-D tandem testing was up to 93.3%, while the sensitivity of IL-6 and d-D by parallel test in the severe COVID-19 was 96.4%. IL-6 and d-D were closely related to the occurrence of severe COVID-19 in the adult patients, and their combined detection had the highest specificity and sensitivity for early prediction of the severity of COVID-19 patients, which has important clinical value.", "topics": ["Pronostique", "Virologie"], "author_list": [{"id": 82, "name": "Gao Y"}], "publication_date": "2020-03-18"}, {"id": 31, "slug": "the-potential-added-value-of-fdg-petct-for-covid-19-pneumonia", "title": "The potential added value of FDG PET/CT for COVID-19 pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Proposer une m\u00e9thode diagnostique par TEP/FDG", "verbose_date": "21.03.2020", "authors": "Deng Y", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 27, "name": "Eur j Nucl Med Mol Imaging"}, "link": "https://link.springer.com/article/10.1007%2Fs00259-020-04767-1", "findings": "", "take_away": "", "relevance_level": "Utilit\u00e9 possible de la TEP FDG pour le diagnostic, le suivi et la recherche de complications dans le cadre d'une infection au COVID-19.N\u00e9cessite une \u00e9tude clinique pour le d\u00e9montrer !", "objectives": "Faible :1) lettre \u00e0 l'\u00e9diteur sans processus de blind reviewing2) bas\u00e9 sur une dizaine de r\u00e9f\u00e9rences de niveau de preuve assez faible", "methods": "Proposer une m\u00e9thode diagnostique par TEP/FDG", "pubmed_id": "32198615", "doi": "10.1007/s00259-020-04767-1", "abstract": null, "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 41, "name": "Deng Y"}], "publication_date": "2020-03-21"}, {"id": 582, "slug": "characteristics-and-clinical-significance-of-myocardial-injury-in-patients-with-", "title": "Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9terminer, dans le contexte de COVID-19, la valeur pr\u00e9dictive de d\u00e9c\u00e8s hospitaliers des marqueurs de souffrance myocardique et \u00e9valuer les caract\u00e9ristiques et causes potentielles de cette atteinte dans les cas s\u00e9v\u00e8res.", "verbose_date": "13.05.2020", "authors": "Shi S", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 34, "name": "Eur Heart J"}, "link": "https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa408/5835730", "findings": "", "take_away": "", "relevance_level": "La souffrance myocardique semble fr\u00e9quente dans les formes s\u00e9v\u00e8res/critiques de COVID-19 et en particulier chez les patients d\u00e9c\u00e9d\u00e9s.\r\nDeux biomarqueurs d'atteinte cardiaque semblent associ\u00e9s \u00e0 la survenue d'un d\u00e9c\u00e8s hospitalier : la cr\u00e9atine phospho-kinase myocardiaque (CPK-MB) et la troponine I cardiaque.\r\nLes facteurs associ\u00e9s \u00e0 la survenue de cette atteinte cardiaque seraient eux l'\u00e2ge \u00e9lev\u00e9, le niveau de r\u00e9ponse inflammatoire refl\u00e9t\u00e9 par la CRP et des ant\u00e9c\u00e9dents comme l'HTA, la coronaropathie, l'insuffisance r\u00e9nale chronique ou encore la BPCO.\r\nDes \u00e9tudes de meilleur niveau de preuve sont n\u00e9cessaires pour confirmer ces r\u00e9sultats.", "objectives": "- \u00e9tude r\u00e9trospective monocentrique (-)- le suivi d'une grande partie des patients \u00e9tait toujours en cours \u00e0 la fin de l'\u00e9tude (-)- pas de correction de l'inflation du risque alpha (-)- ajustement des mod\u00e8les multivari\u00e9s sur des facteurs de confusion pertinents (+) mais certains ajustements manquent peut \u00eatre (type de traitement antiviral utilis\u00e9 par exemple) (-)- plusieurs types de relation ont \u00e9t\u00e9 envisag\u00e9s (lin\u00e9aire et non lin\u00e9aire) (+) mais sans tests pr\u00e9sent\u00e9s pour statuer (-)- effectifs d\u00e9s\u00e9quilibr\u00e9s entre d\u00e9c\u00e9d\u00e9s et non d\u00e9c\u00e9d\u00e9s (-)", "methods": "D\u00e9terminer, dans le contexte de COVID-19, la valeur pr\u00e9dictive de d\u00e9c\u00e8s hospitaliers des marqueurs de souffrance myocardique et \u00e9valuer les caract\u00e9ristiques et causes potentielles de cette atteinte dans les cas s\u00e9v\u00e8res.", "pubmed_id": "32391877", "doi": "10.1093/eurheartj/ehaa408", "abstract": "To investigate the characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019 (COVID-19).\nWe enrolled 671 eligible hospitalized patients with severe COVID-19 from 1 January to 23 February 2020, with a median age of 63 years. Clinical, laboratory, and treatment data were collected and compared between patients who died and survivors. Risk factors of death and myocardial injury were analysed using multivariable regression models. A total of 62 patients (9.2%) died, who more often had myocardial injury (75.8% vs. 9.7%; P < 0.001) than survivors. The area under the receiver operating characteristic curve of initial cardiac troponin I (cTnI) for predicting in-hospital mortality was 0.92 [95% confidence interval (CI), 0.87-0.96; sensitivity, 0.86; specificity, 0.86; P < 0.001]. The single cut-off point and high level of cTnI predicted risk of in-hospital death, hazard ratio (HR) was 4.56 (95% CI, 1.28-16.28; P = 0.019) and 1.25 (95% CI, 1.07-1.46; P = 0.004), respectively. In multivariable logistic regression, senior age, comorbidities (e.g. hypertension, coronary heart disease, chronic renal failure, and chronic obstructive pulmonary disease), and high level of C-reactive protein were predictors of myocardial injury.\nThe risk of in-hospital death among patients with severe COVID-19 can be predicted by markers of myocardial injury, and was significantly associated with senior age, inflammatory response, and cardiovascular comorbidities.", "topics": ["Epid\u00e9miologique", "Anesth\u00e9sie-R\u00e9animation", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 547, "name": "Shi S"}], "publication_date": "2020-05-13"}, {"id": 352, "slug": "hematologic-biochemical-and-immune-biomarker-abnormalities-associated-with-sever", "title": "Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Identifier les marqueurs h\u00e9matologiques, biochimiques et immunologiques associ\u00e9s \u00e0 la s\u00e9v\u00e9rit\u00e9 et la mortalit\u00e9 de la maladie chez les patients atteints de Covid-19", "verbose_date": "16.04.2020", "authors": "Henry BM", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 7, "name": "Transversale"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 150, "name": "Clin Chem Lab Med"}, "link": "https://www.dropbox.com/s/bycpnvjasq0ydv9/article-10.1515-cclm-2020-0369.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "\u00c9ventuels marqueurs de mauvais pronostique : an\u00e9mie (s\u00e9v\u00e9rit\u00e9), hyperbilirubin\u00e9mie totale, augmentation des CPK, de l'IL-6 et hyperferritin\u00e9mie (mortalit\u00e9), leucocytose (s\u00e9v\u00e9rit\u00e9 et de la mortalit\u00e9)", "objectives": "Exclusion des \u00e9tudes \u00e0 tr\u00e8s faible niveau de preuve, 2 relecteurs ind\u00e9pendants, n = 3377Beaucoup d'\u00e9tudes exclues, peu de renseignements sur les m\u00e9thodes statistiques dans les \u00e9tudes, crit\u00e8re de s\u00e9v\u00e9rit\u00e9 composite, faible effectif pour la cohorte de mortalit\u00e9 \"", "methods": "Identifier les marqueurs h\u00e9matologiques, biochimiques et immunologiques associ\u00e9s \u00e0 la s\u00e9v\u00e9rit\u00e9 et la mortalit\u00e9 de la maladie chez les patients atteints de Covid-19", "pubmed_id": "32286245", "doi": "10.1515/cclm-2020-0369", "abstract": "Background As coronavirus disease 2019 (COVID-19) pandemic rages on, there is urgent need for identification of clinical and laboratory predictors for progression towards severe and fatal forms of this illness. In this study we aimed to evaluate the discriminative ability of hematologic, biochemical and immunologic biomarkers in patients with and without the severe or fatal forms of COVID-19. Methods An electronic search in Medline (PubMed interface), Scopus, Web of Science and China National Knowledge Infrastructure (CNKI) was performed, to identify studies reporting on laboratory abnormalities in patients with COVID-19. Studies were divided into two separate cohorts for analysis: severity (severe vs. non-severe and mortality, i.e. non-survivors vs. survivors). Data was pooled into a meta-analysis to estimate weighted mean difference (WMD) with 95% confidence interval (95% CI) for each laboratory parameter. Results A total number of 21 studies was included, totaling 3377 patients and 33 laboratory parameters. While 18 studies (n\u2009=\u20092984) compared laboratory findings between patients with severe and non-severe COVID-19, the other three (n\u2009=\u2009393) compared survivors and non-survivors of the disease and were thus analyzed separately. Patients with severe and fatal disease had significantly increased white blood cell (WBC) count, and decreased lymphocyte and platelet counts compared to non-severe disease and survivors. Biomarkers of inflammation, cardiac and muscle injury, liver and kidney function and coagulation measures were also significantly elevated in patients with both severe and fatal COVID-19. Interleukins 6 (IL-6) and 10 (IL-10) and serum ferritin were strong discriminators for severe disease. Conclusions Several biomarkers which may potentially aid in risk stratification models for predicting severe and fatal COVID-19 were identified. In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness.", "topics": ["Pronostique", "Immunit\u00e9", "Transversale", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 106, "name": "Henry BM"}], "publication_date": "2020-04-16"}, {"id": 356, "slug": "clinical-characteristics-of-19-neonates-born-to-mothers-with-covid-19", "title": "Clinical characteristics of 19 neonates born to mothers with COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier les caract\u00e9ristiques cliniques des nouveau-n\u00e9s n\u00e9s de m\u00e8res infect\u00e9es par le SARS-CoV-2. ", "verbose_date": "16.04.2020", "authors": "Liu W", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 153, "name": "Front Med"}, "link": "https://link.springer.com/content/pdf/10.1007/s11684-020-0772-y.pdf", "findings": "", "take_away": "", "relevance_level": "Les strat\u00e9gies les plus importantes pour pr\u00e9venir l'infection n\u00e9onatale par le SARS-CoV-2 consistent \u00e0 pr\u00e9venir l'infection maternelle et \u00e0 r\u00e9duire la possibilit\u00e9 d'exposition n\u00e9onatale au virus. L'accouchement doit avoir lieu en isolement et les nouveau-n\u00e9s doivent \u00eatre s\u00e9par\u00e9s des m\u00e8res et des personnes infect\u00e9es qui s'occupent d'eux.", "objectives": "-\t\u00c9tude observationnelle prospective-\t19 nouveau-n\u00e9s inclus dans la recherche-\tAbsence de tests d'anticorps au moment de l'\u00e9tude", "methods": "Etudier les caract\u00e9ristiques cliniques des nouveau-n\u00e9s n\u00e9s de m\u00e8res infect\u00e9es par le SARS-CoV-2.", "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 343, "name": "Liu W"}], "publication_date": "2020-04-16"}, {"id": 418, "slug": "outcomes-of-hydroxychloroquine-usage-in-united-states-veterans-hospitalized-with", "title": "Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer l'efficacit\u00e9 de l'hydroxychloroquine seule ou en association avec l'azithromycine sur une cohorte de v\u00e9t\u00e9rans am\u00e9ricains infect\u00e9s par le COVID-19", "verbose_date": "23.04.2020", "authors": "Magagnoli J", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Cette \u00e9tude de cohorte r\u00e9trospective avec utilisation de score de propension n'a pas permis de montrer \u00e0 une efficacit\u00e9 du traitement par hydroxychloroquine (HC) ou hydroxychloroquine+azithromycine (HC+AZ) compar\u00e9 \u00e0 un traitement m\u00e9dical standard.\u00a0\r\nL'\u00e9tude montre m\u00eame une augmentation significative de 2,6 fois de la mortalit\u00e9 avec le traitement par HC et une possible augmentation du recours \u00e0 la ventilation m\u00e9canique. En association avec l'AZ, le traitement pourrait \u00eatre plus efficace mais pas de diff\u00e9rence significative mise en \u00e9vidence.\r\nAinsi, toujours pas de preuve que l'utilisation de l'HC ou de l'HC+AZ peut avoir un b\u00e9n\u00e9fice, il semblerait m\u00eame que l'utilisation de l'HC seule soit \u00e0 d\u00e9conseiller du fait de la sur-mortalit\u00e9. A confirmer dans une \u00e9tude de plus haut niveau de preuve.", "objectives": "- Ajustement via score de propension contenant de nombreuses variables cliniques, d\u00e9mographiques, comorbidit\u00e9s permettant une bonne prise en compte des facteurs de confusion potentiels et permettant de se rapprocher d'un essai contr\u00f4l\u00e9- Pas d'information sur la dur\u00e9e ou la posologie du traitement par hydroxychloroquine et azithromycine- Repr\u00e9sentativit\u00e9 de l'\u00e9chantillon mauvais car uniquement des hommes avec une sur-repr\u00e9sentation des afro-am\u00e9ricains- Comparabilit\u00e9 de l'\u00e9chantillon discutable car s\u00e9v\u00e9rit\u00e9 des patients potentiellement inf\u00e9rieure dans le groupe non trait\u00e9", "methods": "Evaluer l'efficacit\u00e9 de l'hydroxychloroquine seule ou en association avec l'azithromycine sur une cohorte de v\u00e9t\u00e9rans am\u00e9ricains infect\u00e9s par le COVID-19", "pubmed_id": "32511622\n4608161\n32171076\n28913837\n32205204\n32194981\n32240719\n18254131\n2757893\n32282022\n32298251\n32109013\n32289216\n31502924", "doi": "10.1101/2020.04.16.20065920", "abstract": "Despite limited and conflicting data on the use of hydroxychloroquine in patients with Covid-19, the U.S. Food and Drug Administration has authorized the emergency use of this drug when clinical trials are unavailable or infeasible. Hydroxychloroquine, alone or in combination with azithromycin, is being widely used in Covid-19 therapy based on anecdotal and limited observational evidence.\nWe performed a retrospective analysis of data from patients hospitalized with confirmed SARS-CoV-2 infection in all United States Veterans Health Administration medical centers until April 11, 2020. Patients were categorized based on their exposure to hydroxychloroquine alone (HC) or with azithromycin (HC+AZ) as treatments in addition to standard supportive management for Covid-19. The two primary outcomes were death and the need for mechanical ventilation. We determined the association between treatment and the primary outcomes using competing risk hazard regression adjusting for clinical characteristics via propensity scores. Discharge and death were taken into account as competing risks and subdistribution hazard ratios are presented.\nA total of 368 patients were evaluated (HC, n=97; HC+AZ, n=113; no HC, n=158). Rates of death in the HC, HC+AZ, and no HC groups were 27.8%, 22.1%, 11.4%, respectively. Rates of ventilation in the HC, HC+AZ, and no HC groups were 13.3%, 6.9%, 14.1%, respectively. Compared to the no HC group, the risk of death from any cause was higher in the HC group (adjusted hazard ratio, 2.61; 95% CI, 1.10 to 6.17; P=0.03) but not in the HC+AZ group (adjusted hazard ratio, 1.14; 95% CI, 0.56 to 2.32; P=0.72). The risk of ventilation was similar in the HC group (adjusted hazard ratio, 1.43; 95% CI, 0.53 to 3.79; P=0.48) and in the HC+AZ group (adjusted hazard ratio, 0.43; 95% CI, 0.16 to 1.12; P=0.09), compared to the no HC group.\nIn this study, we found no evidence that use of hydroxychloroquine, either with or without azithromycin, reduced the risk of mechanical ventilation in patients hospitalized with Covid-19. An association of increased overall mortality was identified in patients treated with hydroxychloroquine alone. These findings highlight the importance of awaiting the results of ongoing prospective, randomized, controlled studies before widespread adoption of these drugs.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 398, "name": "Magagnoli J"}], "publication_date": "2020-04-23"}, {"id": 318, "slug": "severity-of-coronavirus-respiratory-tract-infections-in-adults-admitted-to-acute", "title": "Severity of coronavirus respiratory tract infections in adults admitted to acute care in Toronto, Ontario", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer la proportion et d\u00e9crire l'\u00e9pid\u00e9miologie des infections \u00e0 coronavirus chez des patients admis en soins aigus dans un centre hospitalier de Toronto, sur une p\u00e9riode de 6 ans de 2010 \u00e0 2016, et identifier les facteurs de mauvais pronostic", "verbose_date": "13.04.2020", "authors": "Kozak R", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 143, "name": "J Clin Virol"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1386653220300809?token=C99B259727B268573A7B87FCC81DD481E16C2CAA3508F4B31B98541B3AF8B1635320F9D3F215C395628C7CE831E7779C", "findings": "", "take_away": "", "relevance_level": "Proportion importante des infections \u00e0 coronavirus parmis les infections respiratoires virales en soins aigus (3\u00e8me ordre de fr\u00e9quence)\r\nTaux d'hospitalisation en soins continus et de mortalit\u00e9 (respectivement 17% et 7%) comparables \u00e0 ceux des virus influenza et VRS\r\nSexe f\u00e9minin (non concordant avec \u00e9tudes pr\u00e9c\u00e9dentes) et tabagisme seraient associ\u00e9s dans cette \u00e9tude \u00e0 des facteurs de s\u00e9v\u00e9rit\u00e9 (hospitalisation en soins intensifs et mortalit\u00e9)", "objectives": "Etude \u00e9pid\u00e9miologique descriptive transversale, monocentrique, n = 226", "methods": "D\u00e9terminer la proportion et d\u00e9crire l'\u00e9pid\u00e9miologie des infections \u00e0 coronavirus chez des patients admis en soins aigus dans un centre hospitalier de Toronto, sur une p\u00e9riode de 6 ans de 2010 \u00e0 2016, et identifier les facteurs de mauvais pronostic", "pubmed_id": "32278299\n30452608\n24915939\n16757599\n6262450\n21849456\n29350887\n28689664\n9431390\n16267760\n28893197\n29170370\n27899100\n31158256\n29427907\n9043091\n29716568\n26668769\n16829999\n31861926\n25863564\n28616442\n18821175\n20554810\n28838146\n28050020\n18689592\n6043624\n28457597\n28329354\n29214503\n15810082", "doi": "10.1016/j.jcv.2020.104338", "abstract": "The World Health Organization has highlighted the need for improved surveillance and understanding of the health burden imposed by non-influenza RNA respiratory viruses. Human coronaviruses (CoVs) are a major cause of respiratory and gastrointestinal tract infections with associated morbidity and mortality.\nThe objective of our study was to characterize the epidemiology of CoVs in our tertiary care centre, and identify clinical correlates of disease severity.\nA cross-sectional study was performed of 226 patients admitted with confirmed CoV respiratory tract infection between 2010 and 2016. Variables consistent with a severe disease burden were evaluated including symptoms, length of stay, intensive care unit (ICU) admission and mortality.\nCoVs represented 11.3% of all positive respiratory virus samples and OC43 was the most commonly identified CoV. The majority of infections were community-associated while 21.6% were considered nosocomial. The average length of stay was 11.8 days with 17.3% of patients requiring ICU admission and an all-cause mortality of 7%. In a multivariate model, female gender and smoking were associated with increased likelihood of admission to ICU or death.\nThis study highlights the significant burden of CoVs and justifies the need for surveillance in the acute care setting.", "topics": ["Epid\u00e9miologique", "Virologie", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie"], "author_list": [{"id": 305, "name": "Kozak R"}], "publication_date": "2020-04-13"}, {"id": 90, "slug": "epidemiological-characteristics-of-2143-pediatric-patients-with-2019-coronavirus", "title": "Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques \u00e9pid\u00e9miologiques et le mod\u00e8le de\r\ntransmission du COVID-19 chez les patients de moins de 18 ans en Chine.", "verbose_date": "16.03.2020", "authors": "Dong Y", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 65, "name": "Pediatrics"}, "link": "https://www.dropbox.com/s/hh89woz8cy4vy14/peds.2020-0702.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Proportion de cas s\u00e9v\u00e8res chez les enfants moins importante que chez l'adulte.\r\nTransmission de personne \u00e0 personne\r\nEfficacit\u00e9 des mesures de restriction de mobilit\u00e9", "objectives": "1) Revue syst\u00e9matique2) Relativement peu de cas chez l'enfant3) La plupart des \u00e9tudes des cas p\u00e9diatriques portent sur les enfants chinois4) Recoupement des cas entre \u00e9tudes5) Des articles chinois non traduits en anglais pour le moment6) Recommandations chinoises pour les enfants non adapt\u00e9es aux formes l\u00e9g\u00e8res (balance b\u00e9n\u00e9fice-risque du scanner thoracique dans ce cas?)7) Des cas non confirm\u00e9s par test du SRAS-CoV-2", "methods": "D\u00e9crire les caract\u00e9ristiques \u00e9pid\u00e9miologiques et le mod\u00e8le de\r\ntransmission du COVID-19 chez les patients de moins de 18 ans en Chine.", "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 96, "name": "Dong Y"}], "publication_date": "2020-03-16"}, {"id": 36, "slug": "laboratory-diagnosis-of-emerging-human-coronavirus-infections-the-state-of-the-a", "title": "Laboratory Diagnosis of Emerging Human Coronavirus Infections \u2014 The State of the Art", "has_other_authors": false, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Faire le point sur les m\u00e9thodes d'analyse en laboratoire disponibles pour le diagnostic du COVID-19", "verbose_date": "20.03.2020", "authors": "Loeffelholz MJ", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 32, "name": "Emerg Microbes Infect"}, "link": "https://www.dropbox.com/s/uq1o8yokn2eizdv/Laboratory%20Diagnosis%20of%20Emerging%20Human%20Coronavirus%20Infections.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Ecouvillonnage naso-pharyng\u00e9 \u00e0 favoriser. Id\u00e9alement r\u00e9p\u00e9ter les tests car les faux n\u00e9gatifs sont fr\u00e9quents au stade pr\u00e9coce de l'infection. Il y a des perspectives pour am\u00e9liorer la sensibilit\u00e9 des tests (notamment pour les tests rapides de d\u00e9tection d'antig\u00e8nes), de nombreux appareils de RT-PCR sont en d\u00e9veloppement avec certains protocoles disponibles sur le site de l'OMS.", "objectives": "Interm\u00e9diaire :1) Revue de la litt\u00e9rature sur 70 publications", "methods": "Faire le point sur les m\u00e9thodes d'analyse en laboratoire disponibles pour le diagnostic du COVID-19", "pubmed_id": "32196430\n16258152\n23891402\n24781747\n29263204\n28539345\n22518855\n21084464\n32105632\n32015507\n23782859\n19342289\n32007145\n12690092\n15789222\n15872279\n31995857\n15243033\n31987001\n31992387\n31978945\n27144915\n32160148\n29688086\n26468744\n30882305\n29872531\n32156607\n32034659\n31950516\n23075143\n20554810\n25073585\n31929382\n9694322\n22692748\n17922396\n19892228\n27122378\n30405553\n32004427\n32004165\n32020836\n27012512\n15158632\n26019210\n31304835\n23053517\n4912236\n24989611\n32123347\n15034574\n15613317\n31994742\n30541871\n29304039\n21858753\n17889596\n32065057\n32159775\n32003551\n12711465\n14288084\n17130280\n32015508\n29212701", "doi": "10.1080/22221751.2020.1745095", "abstract": "The three unprecedented outbreaks of emerging human coronavirus (HCoV) infections at the beginning of the twenty-first century have highlighted the necessity for readily available, accurate and fast diagnostic testing methods. The laboratory diagnostic methods for human coronavirus infections have evolved substantially, with the development of novel assays as well as the availability of updated tests for emerging ones. Newer laboratory methods are fast, highly sensitive and specific, and are gradually replacing the conventional gold standards. This presentation reviews the current laboratory methods available for testing coronaviruses by focusing on the coronavirus disease 2019 (COVID-19) outbreak going on in Wuhan. Viral pneumonias typically do not result in the production of purulent sputum. Thus, a nasopharyngeal swab is usually the collection method used to obtain a specimen for testing. Nasopharyngeal specimens may miss some infections; a deeper specimen may need to be obtained by bronchoscopy. Alternatively, repeated testing can be used because over time, the likelihood of the SARS-CoV-2 being present in the nasopharynx increases. Several integrated, random-access, point-of-care molecular devices are currently under development for fast and accurate diagnosis of SARS-CoV-2 infections. These assays are simple, fast and safe and can be used in the local hospitals and clinics bearing the burden of identifying and treating patients.", "topics": ["Diagnostique", "Virologie"], "author_list": [{"id": 46, "name": "Loeffelholz MJ"}], "publication_date": "2020-03-20"}, {"id": 647, "slug": "ethnic-and-socioeconomic-differences-in-sars-cov-2-infection-prospective-cohort-", "title": "Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer le r\u00f4le de l'ethnicit\u00e9 et de la position socio-\u00e9conomique dans le risque de d\u00e9velopper une infection par le SRAS-CoV-2.", "verbose_date": "02.06.2020", "authors": "Niedwiedz C", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 249, "name": "BMC Medicine"}, "link": "https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/s12916-020-01640-8", "findings": "", "take_away": "", "relevance_level": "La pauvret\u00e9 et l'absence de qualifications semblent syst\u00e9matiquement associ\u00e9es \u00e0 un risque plus \u00e9lev\u00e9 d'infection.\nCertaines minorit\u00e9s ethniques semblent pr\u00e9senter un risque plus \u00e9lev\u00e9 d'infection par le SRAS-CoV-2 au Royaume-Uni, selon les donn\u00e9es de la Biobank.\nCe dernier point semble\u00a0persister lorsqu\u2019on s\u2019affranchit, par des m\u00e9thodes statistiques, des diff\u00e9rences de conditions socio-\u00e9conomiques, des facteurs de risque de sant\u00e9 auto-d\u00e9clar\u00e9s ou des facteurs de risque comportementaux.", "objectives": "Etude r\u00e9trospective, bas\u00e9e sur la mise en relation de deux banques de donn\u00e9es d\u2019\u00e9tudes distinctes\u00a0: Public\u00a0Health England pour les r\u00e9sultats des tests et UK BioBank pour les autres facteurs. Un fort biais de repr\u00e9sentatitivit\u00e9 est \u00e0 attendre puisque\u00a0:- la population ayant choisi de participer \u00e0 l\u2019\u00e9tude UK Biobank est plus ais\u00e9e que la population g\u00e9n\u00e9rale et est sur-repr\u00e9sent\u00e9e- les populations issues de classes plus populaires et de minorit\u00e9s \u00e9thniques ont moins particip\u00e9 \u00e0 l\u2019\u00e9tude et sont sous-repr\u00e9sent\u00e9es\nDe plus, les deux bases on \u00e9t\u00e9 remplies avec plus de 10 ans d\u2019\u00e9cart (Public Health England en 2020 et UK BioBank entre 2006 et 2010)\nEnfin, les auteurs expliquent qu\u2019en raison de donn\u00e9es incompl\u00e8tes, ils n\u2019ont pu explorer le r\u00f4le de pathologies sp\u00e9cifiques telles que l'asthme, le diab\u00e8te et l'hypertension art\u00e9rielle, qui se sont av\u00e9r\u00e9es \u00eatre associ\u00e9es \u00e0 un risque plus \u00e9lev\u00e9 d\u2019\u00e9volution grave pour le COVID-19, et sont plus r\u00e9pandues parmi les les groupes socio-\u00e9conomiquement d\u00e9favoris\u00e9s ainsi que certains groupes et minorit\u00e9s ethniques.", "methods": "\u00c9valuer le r\u00f4le de l'ethnicit\u00e9 et de la position socio-\u00e9conomique dans le risque de d\u00e9velopper une infection par le SRAS-CoV-2.", "pubmed_id": "32466757\n32051121\n17274224\n16286485\n29130073\n32120203\n32300018\n32167524\n30528486\n17881624\n29494587\n15033648\n32405103\n19797739\n32320270\n32171076\n32341002\n29685729\n30967141\n28835246\n25826379\n32312785\n29040562\n28572633\n17564486\n29137869", "doi": "10.1186/s12916-020-01640-8", "abstract": "Understanding of the role of ethnicity and socioeconomic position in the risk of developing SARS-CoV-2 infection is limited. We investigated this in the UK Biobank study.\nThe UK Biobank study recruited 40-70-year-olds in 2006-2010 from the general population, collecting information about self-defined ethnicity and socioeconomic variables (including area-level socioeconomic deprivation and educational attainment). SARS-CoV-2 test results from Public Health England were linked to baseline UK Biobank data. Poisson regression with robust standard errors was used to assess risk ratios (RRs) between the exposures and dichotomous variables for being tested, having a positive test and testing positive in hospital. We also investigated whether ethnicity and socioeconomic position were associated with having a positive test amongst those tested. We adjusted for covariates including age, sex, social variables (including healthcare work and household size), behavioural risk factors and baseline health.\nAmongst 392,116 participants in England, 2658 had been tested for SARS-CoV-2 and 948 tested positive (726 in hospital) between 16 March and 3 May 2020. Black and south Asian groups were more likely to test positive (RR 3.35 (95% CI 2.48-4.53) and RR 2.42 (95% CI 1.75-3.36) respectively), with Pakistani ethnicity at highest risk within the south Asian group (RR 3.24 (95% CI 1.73-6.07)). These ethnic groups were more likely to be hospital cases compared to the white British. Adjustment for baseline health and behavioural risk factors led to little change, with only modest attenuation when accounting for socioeconomic variables. Socioeconomic deprivation and having no qualifications were consistently associated with a higher risk of confirmed infection (RR 2.19 for most deprived quartile vs least (95% CI 1.80-2.66) and RR 2.00 for no qualifications vs degree (95% CI 1.66-2.42)).\nSome minority ethnic groups have a higher risk of confirmed SARS-CoV-2 infection in the UK Biobank study, which was not accounted for by differences in socioeconomic conditions, baseline self-reported health or behavioural risk factors. An urgent response to addressing these elevated risks is required.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 608, "name": "Niedwiedz C"}], "publication_date": "2020-06-02"}, {"id": 549, "slug": "association-of-use-of-angiotensin-converting-enzyme-inhibitors-and-angiotensin-i", "title": "Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier l'association entre l'utilisation des inhibiteurs de l'enzyme de conversion (IEC) et/ou antagonistes des r\u00e9cepteurs de l'angiotensine (ARA) et la probabilit\u00e9 d'\u00eatre test\u00e9 positif pour le COVID-19.\r\n\r\nEtudier les issues s\u00e9v\u00e8res (hospitalisation, admission en unit\u00e9 de soins intensifs et ventilation m\u00e9canique) chez les patients COVID-19 prenant des IEC / ARA.", "verbose_date": "07.05.2020", "authors": "Mehta N", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 99, "name": "JAMA Cardiol"}, "link": "https://jamanetwork.com/journals/jamacardiology/fullarticle/2765695", "findings": "", "take_away": "", "relevance_level": "Pas d'association entre la prise d'IEC ou d'ARA et la positivit\u00e9 des tests COVID-19 : soutien des directives actuelles de ne pas interrompre les traitements par IEC ou ARA dans le contexte de la pand\u00e9mie de COVID-19.\nUne \u00e9tude plus approfondie sur un plus grand nombre de patients hospitalis\u00e9s recevant un traitement ACEI et ARB est n\u00e9cessaire pour d\u00e9terminer l'association de la prise d'IEC/ARA avec les issues graves du COVID-19.", "objectives": "Etude de cohorte r\u00e9trospective, faible nombre d'\u00e9venements Modification de l'indication de test COVID-19 pendant l'\u00e9tude, pa.s de conduite \u00e0 tenir en cas de test n\u00e9gatif (faux n\u00e9gatifs possibles).Pas la variable IMC dans le score de propension car donn\u00e9es manquantes pour 1/3 des patients.Seuls ceux n\u00e9gatifs pour la grippe et le virus respiratoire syncytial ont ensuite \u00e9t\u00e9 test\u00e9s pour le SRAS-CoV-2 (mais co-infections retrouv\u00e9es dans des \u00e9tudes).Crit\u00e8re de jugement secondaire composite associant hospitalisation (?), admission en soins intensifs et ventilation m\u00e9canique.Possibilit\u00e9 que certains patients positifs aient \u00e9t\u00e9 admis dans un h\u00f4pital en dehors du syst\u00e8me de sant\u00e9 \u00e9tudi\u00e9 et aient ainsi \u00e9t\u00e9 non inclus dans les patients hospitalis\u00e9s.", "methods": "Etudier l'association entre l'utilisation des inhibiteurs de l'enzyme de conversion (IEC) et/ou antagonistes des r\u00e9cepteurs de l'angiotensine (ARA) et la probabilit\u00e9 d'\u00eatre test\u00e9 positif pour le COVID-19.\nEtudier les issues s\u00e9v\u00e8res (hospitalisation, admission en unit\u00e9 de soins intensifs et ventilation m\u00e9canique) chez les patients COVID-19 prenant des IEC / ARA.", "pubmed_id": "32369097\n18929686\n32219356\n31978945\n14647384\n32242890\n15007027\n17938396\n32091533\n32087114\n29610734\n30189042\n15897343\n31078660\n16007097\n32171062\n32129518\n32227760", "doi": "10.1001/jamacardio.2020.1855", "abstract": "The role of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in the setting of the coronavirus disease 2019 (COVID-19) pandemic is hotly debated. There have been recommendations to discontinue these medications, which are essential in the treatment of several chronic disease conditions, while, in the absence of clinical evidence, professional societies have advocated their continued use.\nTo study the association between use of ACEIs/ARBs with the likelihood of testing positive for COVID-19 and to study outcome data in subsets of patients taking ACEIs/ARBs who tested positive with severity of clinical outcomes of COVID-19 (eg, hospitalization, intensive care unit admission, and requirement for mechanical ventilation).\nRetrospective cohort study with overlap propensity score weighting was conducted at the Cleveland Clinic Health System in Ohio and Florida. All patients tested for COVID-19 between March 8 and April 12, 2020, were included.\nHistory of taking ACEIs or ARBs at the time of COVID-19 testing.\nResults of COVID-19 testing in the entire cohort, number of patients requiring hospitalizations, intensive care unit admissions, and mechanical ventilation among those who tested positive.\nA total of 18\u202f472 patients tested for COVID-19. The mean (SD) age was 49\u2009(21) years, 7384 (40%) were male, and 12\u202f725 (69%) were white. Of 18\u202f472 patients who underwent COVID-19 testing, 2285 (12.4%) were taking either ACEIs or ARBs. A positive COVID-19 test result was observed in 1735 of 18\u202f472 patients (9.4%). Among patients who tested positive, 421 (24.3%) were admitted to the hospital, 161 (9.3%) were admitted to an intensive care unit, and 111 (6.4%) required mechanical ventilation. Overlap propensity score weighting showed no significant association of ACEI and/or ARB use with COVID-19 test positivity (overlap propensity score-weighted odds ratio, 0.97; 95% CI, 0.81-1.15).\nThis study found no association between ACEI or ARB use and COVID-19 test positivity. These clinical data support current professional society guidelines to not discontinue ACEIs or ARBs in the setting of the COVID-19 pandemic. However, further study in larger numbers of hospitalized patients receiving ACEI and ARB therapy is needed to determine the association with clinical measures of COVID-19 severity.", "topics": ["Epid\u00e9miologique", "Infectiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 514, "name": "Mehta N"}], "publication_date": "2020-05-07"}, {"id": 310, "slug": "exploring-possible-mechanisms-for-covid-19-induced-thrombocytopenia-unanswered-q", "title": "Exploring possible mechanisms for COVID-19 induced thrombocytopenia: Unanswered Questions", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Explorer les m\u00e9canismes possibles induisant la thrombocytop\u00e9nie dans les cas de COVID-19", "verbose_date": "13.04.2020", "authors": "Amgalan A", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 96, "name": "J Thromb Haemostasis"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.14832", "findings": "", "take_away": "", "relevance_level": "Le COVID-19 est connu pour provoquer des troubles de la coagulation (71% de pr\u00e9sence chez les patients d\u00e9c\u00e9d\u00e9s) avec des CIVD notamment. Ainsi, les D-Dim\u00e8res \u00e9lev\u00e9s ou une thrombop\u00e9nie sont des marqueurs biologiques pronostiques de l'\u00e9volution vers une forme s\u00e9v\u00e8re de l'infection.\r\nLe m\u00e9canisme induisant la thrombop\u00e9nie n'est pas encore suffisament \u00e9tudi\u00e9, mais il pourrait \u00eatre li\u00e9 \u00e0 une interaction directe entre le virus et les plaquettes via le r\u00e9cepteur de reconnaissance des pathog\u00e8nes, entra\u00eenant l'activation des plaquettes.", "objectives": "- Lettre \u00e0 l'\u00e9diteur- Bas\u00e9e principalement sur 2 \u00e9tudes concernant le COVID- Hypoth\u00e8se physiopathologique des auteurs sans exp\u00e9rimentations ou litt\u00e9rature d\u00e9di\u00e9e au COVID sur le sujet", "methods": "Explorer les m\u00e9canismes possibles induisant la thrombocytop\u00e9nie dans les cas de COVID-19", "pubmed_id": "32278338", "doi": "10.1111/jth.14832", "abstract": null, "topics": ["Pronostique", "Transversale", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 297, "name": "Amgalan A"}], "publication_date": "2020-04-13"}, {"id": 270, "slug": "adverse-skin-reactions-among-healthcare-workers-during-the-coronavirus-disease-2", "title": "Adverse Skin Reactions Among Healthcare Workers During the Coronavirus Disease 2019 Outbreak: A Survey in Wuhan and Its Surrounding Regions", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer les effets cutan\u00e9s du port des \u00e9quipements de protections individuels sur le personnel soignant ", "verbose_date": "08.04.2020", "authors": "Lin P", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 128, "name": "Br J Dermatol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjd.19089", "findings": "", "take_away": "", "relevance_level": "Le port prolong\u00e9 des \u00e9quipements de protection individuel (>6h) en particulier chez les soignants f\u00e9minins provoque des l\u00e9sions cutan\u00e9es dans 74,5% des cas avec une s\u00e9cheresse, de l'\u00e9ryth\u00e8me ou de la mac\u00e9ration, touchant surtout les mains puis les joues et le nez.", "objectives": "- Lettre \u00e0 l'\u00e9diteur- Bas\u00e9 sur un auto-questionnaire d\u00e9claratif- Pas de suivi des l\u00e9sions- Pas de v\u00e9rification du port des \u00e9quipements et de la fa\u00e7on dont ils sont port\u00e9s\"", "methods": "Evaluer les effets cutan\u00e9s du port des \u00e9quipements de protections individuels sur le personnel soignant", "pubmed_id": "32255197\n10524977\n29708265\n30134982\n21831480\n17026695\n30764759", "doi": "10.1111/bjd.19089", "abstract": null, "topics": ["Autres", "Transversale", "Hygi\u00e8ne"], "author_list": [{"id": 259, "name": "Lin P"}], "publication_date": "2020-04-08"}, {"id": 476, "slug": "serial-ct-features-in-discharged-covid-19-patients-with-positive-rt-pcr-re-test", "title": "Serial CT features in discharged COVID-19 patients with positive RT-PCR re-test", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'\u00e9volution des images scannographiques de deux patients COVID-19 ayant pr\u00e9sent\u00e9 une nouvelle positivation de tests pour le SARS-CoV-2 lors de leur suivi apr\u00e8s retour \u00e0 domicile", "verbose_date": "28.04.2020", "authors": "Dou P", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 26, "name": "Eur J Radiol"}, "link": "http://ejradiology.com/retrieve/pii/S0720048X20301996", "findings": "", "take_away": "", "relevance_level": "Quelques cas clairsem\u00e9s de COVID-19 montrent une r\u00e9cidive de positivit\u00e9 des tests RT-PCR du SARS-CoV-2. Ceux-ci pourraient \u00eatre li\u00e9s \u00e0 de pr\u00e9c\u00e9dents faux n\u00e9gatifs ou \u00e0 une r\u00e9-infection des sujets. Leur contagiosit\u00e9 et la n\u00e9cessit\u00e9 de r\u00e9introduction d'un traitement sont inconnues mais posent la question des crit\u00e8res de sortie d'hospitalisation \u00e0 utiliser. En Chine, la mise \u00e0 jour des recommandations a appuy\u00e9 l'importance de l'examen des images scannographiques pour autoriser la sortie des patients avec n\u00e9cessit\u00e9 d'une diminution significative des l\u00e9sions pulmonaires exsudatives. Le suivi avec des examens r\u00e9p\u00e9t\u00e9s pourrait \u00eatre int\u00e9ressant de ce point de vue l\u00e0.", "objectives": "- \u00e9tude r\u00e9trospective- seulement 2 cas analys\u00e9s, issus d'un m\u00eame cluster- les r\u00e9sultats pr\u00e9sent\u00e9s entre les deux patients ne sont pas strictement comparables- date de confirmation diagnostique par RT-PCR non indiqu\u00e9e- types d'\u00e9couvillonages initiaux non sp\u00e9cifi\u00e9s- pas d'information sur l'\u00e9tat clinique des deux sujets au moment de la r\u00e9cidive de positivit\u00e9 des tests\"", "methods": "D\u00e9crire l'\u00e9volution des images scannographiques de deux patients COVID-19 ayant pr\u00e9sent\u00e9 une nouvelle positivation de tests pour le SARS-CoV-2 lors de leur suivi apr\u00e8s retour \u00e0 domicile", "pubmed_id": "32334369", "doi": "10.1016/j.ejrad.2020.109010", "abstract": null, "topics": ["Autres", "Radiologie"], "author_list": [{"id": 444, "name": "Dou P"}], "publication_date": "2020-04-28"}, {"id": 273, "slug": "personal-protective-equipment-during-the-covid-19-pandemic-a-narrative-review", "title": "Personal protective equipment during the COVID-19 pandemic - a narrative review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Clarifier les m\u00e9canismes de transmission du SRAS-CoV-2 et d\u00e9terminer quel dispositif de s\u00e9curit\u00e9 individuel est mieux utiliser selon les proc\u00e9dures effectu\u00e9es (revue adapt\u00e9e au Royaume-Uni)", "verbose_date": "06.04.2020", "authors": "Cook TM", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 129, "name": "Anaesthesia"}, "link": "https://onlinelibrary.wiley.com/doi/abs/10.1111/anae.15071", "findings": "", "take_away": "", "relevance_level": "1) \u00c9quipement de protection individuelle contact\u00a0: pour le personnel de sant\u00e9 dans la m\u00eame pi\u00e8ce que les patients COVID-19 mais \u00e0 au moins deux m\u00e8tres de distance, sans utiliser de proc\u00e9dures g\u00e9n\u00e9rant des a\u00e9rosols.\n\n2) Equipement de protection individuelle pour les gouttelettes\u00a0: pendant les soins au patient ou \u00e0 moins de deux m\u00e8tres du patient. Utilisez \u00e9galement des lunettes de protection et faites porter au patient un masque chirurgical.\n\n3) Equipement de protection individuelle pour pour les petites particules en suspension dans l'air :\u00a0seulement pendant les proc\u00e9dures qui peuvent produire des a\u00e9rosols et ensuite jusqu'\u00e0 ce que l'a\u00e9ration de l'environnement ait suffisamment r\u00e9duit la charge virale.\n\r\nLes dispositifs de protection doivent \u00eatre faciles \u00e0 retirer et des protocoles doivent \u00eatre mis en place pour porter et retirer les dispositifs en toute s\u00e9curit\u00e9 (listes de contr\u00f4le \u00e0 suivre).\n\r\nLes patients doivent \u00eatre trait\u00e9s dans une chambre \u00e0 pression n\u00e9gative, mais un renouvellement rapide et ad\u00e9quat de l'air dans la chambre est l'outil le plus efficace et le plus pratique \u00e0 appliquer.", "objectives": "Simple revue narrative de la litt\u00e9rature", "methods": "Clarifier les m\u00e9canismes de transmission du SRAS-CoV-2 et d\u00e9terminer quel dispositif de s\u00e9curit\u00e9 individuel est mieux utiliser selon les proc\u00e9dures effectu\u00e9es (revue adapt\u00e9e au Royaume-Uni)", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 262, "name": "Cook TM"}], "publication_date": "2020-04-06"}, {"id": 383, "slug": "neurologic-features-in-severe-sars-cov-2-infection", "title": "Neurologic Features in Severe SARS-CoV-2 Infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer l'atteinte neurologique chez des patients pr\u00e9sentant une infection s\u00e9v\u00e8re \u00e0 SARS-Cov-2.", "verbose_date": "19.04.2020", "authors": "Helms J", "specialties": [{"id": 18, "name": "Neurologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMc2008597?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Manque de donn\u00e9es actuellement qui permettent de d\u00e9terminer lesquelles de ces caract\u00e9ristiques cliniques observ\u00e9es sont sp\u00e9cifiques de l'infection SARS-Cov-2 ou d'une enc\u00e9phalopathie li\u00e9e \u00e0 une maladie grave ou \u00e0 l'effet versus retrait des m\u00e9dicaments.", "objectives": "Etude observationnelle, manque de donn\u00e9es", "methods": "\u00c9valuer l'atteinte neurologique chez des patients pr\u00e9sentant une infection s\u00e9v\u00e8re \u00e0 SARS-Cov-2.", "pubmed_id": "32294339", "doi": "10.1056/NEJMc2008597", "abstract": null, "topics": ["Epid\u00e9miologique", "Neurologie"], "author_list": [{"id": 369, "name": "Helms J"}], "publication_date": "2020-04-19"}, {"id": 111, "slug": "early-dynamics-of-transmission-and-control-of-covid-19-a-mathematical-modelling-", "title": "Early dynamics of transmission and control of COVID-19: a mathematical modelling study", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer le potentiel de transmission interhumaine si des cas de Covid-19 \u00e9taient introduits dans une r\u00e9gion indemne", "verbose_date": "11.03.2020", "authors": "Kusharski AJ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 76, "name": "The Lancet Infectious Disease"}, "link": "https://www.dropbox.com/s/fwa81epypupykqq/PIIS1473309920301444.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La transmission de COVID-19 diminue \u00e0 partir d'une semaine apr\u00e8s la prise de mesure de restriction des d\u00e9placements co\u00efncidant avec l'introduction de mesures de contr\u00f4le des d\u00e9placements. Le potentiel de transmission du virus est \u00e9lev\u00e9 en l'absence de mesures de contr\u00f4le avec le d\u00e9veloppement de nombreuses cha\u00eenes de transmission dans une population indemne.", "objectives": "Interm\u00e9diaire :1) Mod\u00e8le math\u00e9matique bas\u00e9 en partie sur les donn\u00e9es du SRAS2) Donn\u00e9es \u00e9pid\u00e9miologiques r\u00e9elles dont la fiabilit\u00e9 n'est pas certaine car nombreux cas asymptomatiques potentiels", "methods": "Evaluer le potentiel de transmission interhumaine si des cas de Covid-19 \u00e9taient introduits dans une r\u00e9gion indemne", "pubmed_id": "32171059\n31995857\n25737806\n16292310\n32019669\n28396473\n16640458\n25244186\n24115913\n32019667\n26132768\n25694150\n23292757\n12766206\n28958414\n19718434\n32003551\n31975746", "doi": "10.1016/S1473-3099(20)30144-4", "abstract": "An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to 95\u2008333 confirmed cases as of March 5, 2020. Understanding the early transmission dynamics of the infection and evaluating the effectiveness of control measures is crucial for assessing the potential for sustained transmission to occur in new areas. Combining a mathematical model of severe SARS-CoV-2 transmission with four datasets from within and outside Wuhan, we estimated how transmission in Wuhan varied between December, 2019, and February, 2020. We used these estimates to assess the potential for sustained human-to-human transmission to occur in locations outside Wuhan if cases were introduced.\nWe combined a stochastic transmission model with data on cases of coronavirus disease 2019 (COVID-19) in Wuhan and international cases that originated in Wuhan to estimate how transmission had varied over time during January, 2020, and February, 2020. Based on these estimates, we then calculated the probability that newly introduced cases might generate outbreaks in other areas. To estimate the early dynamics of transmission in Wuhan, we fitted a stochastic transmission dynamic model to multiple publicly available datasets on cases in Wuhan and internationally exported cases from Wuhan. The four datasets we fitted to were: daily number of new internationally exported cases (or lack thereof), by date of onset, as of Jan 26, 2020; daily number of new cases in Wuhan with no market exposure, by date of onset, between Dec 1, 2019, and Jan 1, 2020; daily number of new cases in China, by date of onset, between Dec 29, 2019, and Jan 23, 2020; and proportion of infected passengers on evacuation flights between Jan 29, 2020, and Feb 4, 2020. We used an additional two datasets for comparison with model outputs: daily number of new exported cases from Wuhan (or lack thereof) in countries with high connectivity to Wuhan (ie, top 20 most at-risk countries), by date of confirmation, as of Feb 10, 2020; and data on new confirmed cases reported in Wuhan between Jan 16, 2020, and Feb 11, 2020.\nWe estimated that the median daily reproduction number (R\nOur results show that COVID-19 transmission probably declined in Wuhan during late January, 2020, coinciding with the introduction of travel control measures. As more cases arrive in international locations with similar transmission potential to Wuhan before these control measures, it is likely many chains of transmission will fail to establish initially, but might lead to new outbreaks eventually.\nWellcome Trust, Health Data Research UK, Bill & Melinda Gates Foundation, and National Institute for Health Research.", "topics": ["Mod\u00e9lisation", "Transversale"], "author_list": [{"id": 117, "name": "Kusharski AJ"}], "publication_date": "2020-03-11"}, {"id": 409, "slug": "viral-load-dynamics-and-disease-severity-in-patients-infected-with-sars-cov-2-in", "title": "Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer les charges virales de diff\u00e9rents tissus au cours du COVID-19, dans les 4 premiers mois de l'\u00e9pid\u00e9mie dans la province de Zhejiang en Chine.", "verbose_date": "22.04.2020", "authors": "Zheng S", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 57, "name": "BMJ"}, "link": "https://www.bmj.com/content/bmj/369/bmj.m1443.full.pdf", "findings": "", "take_away": "", "relevance_level": "La pr\u00e9sence du SARS-COV-2 est plus longue dans les selles que dans le s\u00e9rum ou les tissus respiratoires.\u00a0\r\nLe virus se maintient \u00e9galement plus longtemps dans les tissus respiratoires des personnes atteintes de formes graves.", "objectives": "- \u00c9tude de cohorte r\u00e9trospective monocentrique- Nombre de patients peu important (n=96)- Biais de s\u00e9lection en ne prenant que les \u00e9chantillons de patients restant \u00e0 l'h\u00f4pital- Charge virale d\u00e9pendante de la qualit\u00e9 de la collection d'\u00e9chantillons- La PCR ne distingue pas virus viable et non-viable \"", "methods": "Evaluer les charges virales de diff\u00e9rents tissus au cours du COVID-19, dans les 4 premiers mois de l'\u00e9pid\u00e9mie dans la province de Zhejiang en Chine.", "pubmed_id": "32317267\n31995857\n15522678\n32064853\n12781535\n29028950\n32047895\n15860669\n17219094\n15695719\n32048163\n14742282\n32296168\n31986261\n25187734\n20393220\n26044074\n31978945\n28373583\n23075143\n26565003\n14522061\n16043521\n23727167\n14681520\n32091533\n32074444\n14633867\n15158632\n24837403\n14517783\n32187464\n32043983", "doi": "10.1136/bmj.m1443", "abstract": "To evaluate viral loads at different stages of disease progression in patients infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first four months of the epidemic in Zhejiang province, China.\nRetrospective cohort study.\nA designated hospital for patients with covid-19 in Zhejiang province, China.\n96 consecutively admitted patients with laboratory confirmed SARS-CoV-2 infection: 22 with mild disease and 74 with severe disease. Data were collected from 19 January 2020 to 20 March 2020.\nRibonucleic acid (RNA) viral load measured in respiratory, stool, serum, and urine samples. Cycle threshold values, a measure of nucleic acid concentration, were plotted onto the standard curve constructed on the basis of the standard product. Epidemiological, clinical, and laboratory characteristics and treatment and outcomes data were obtained through data collection forms from electronic medical records, and the relation between clinical data and disease severity was analysed.\n3497 respiratory, stool, serum, and urine samples were collected from patients after admission and evaluated for SARS-CoV-2 RNA viral load. Infection was confirmed in all patients by testing sputum and saliva samples. RNA was detected in the stool of 55 (59%) patients and in the serum of 39 (41%) patients. The urine sample from one patient was positive for SARS-CoV-2. The median duration of virus in stool (22 days, interquartile range 17-31 days) was significantly longer than in respiratory (18 days, 13-29 days; P=0.02) and serum samples (16 days, 11-21 days; P<0.001). The median duration of virus in the respiratory samples of patients with severe disease (21 days, 14-30 days) was significantly longer than in patients with mild disease (14 days, 10-21 days; P=0.04). In the mild group, the viral loads peaked in respiratory samples in the second week from disease onset, whereas viral load continued to be high during the third week in the severe group. Virus duration was longer in patients older than 60 years and in male patients.\nThe duration of SARS-CoV-2 is significantly longer in stool samples than in respiratory and serum samples, highlighting the need to strengthen the management of stool samples in the prevention and control of the epidemic, and the virus persists longer with higher load and peaks later in the respiratory tissue of patients with severe disease.", "topics": ["Epid\u00e9miologique", "Virologie", "Infectiologie"], "author_list": [{"id": 390, "name": "Zheng S"}], "publication_date": "2020-04-22"}, {"id": 648, "slug": "spread-and-dynamics-of-the-covid-19-epidemic-in-italy-effects-of-emergency-conta", "title": "Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Le but de l'article est de trouver un contr\u00f4le optimal c*(t) qui minimise une fonction objectif qui prend en compte le nombre des personnes d\u00e9c\u00e9d\u00e9es et un co\u00fbt total associ\u00e9 \u00e0 l'impl\u00e9mentation des mesures d'isolement.", "verbose_date": "30.05.2020", "authors": "Gatto M", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 36, "name": "Proc Natl Acad Sci USA"}, "link": "https://www.pnas.org/content/pnas/117/19/10484.full.pdf", "findings": "", "take_away": "", "relevance_level": "Dans ce papier les auteurs consid\u00e8rent un mod\u00e8le d'\u00e9volution de l'\u00e9pid\u00e9mie bas\u00e9 sur des \u00e9quations diff\u00e9rentielles ordinaires. Ils utilisent la th\u00e9orie du contr\u00f4le optimal afin de trouver la meilleure strat\u00e9gie \u00e0 suivre par les pouvoirs publiques pour le contr\u00f4le de la transmission du virus, en attendant un vaccin.\u00a0Cette strat\u00e9gie optimale consiste en un contr\u00f4le avec une intensit\u00e9 qui augmente fortement au d\u00e9but et qui diminue r\u00e9guli\u00e8rement ensuite. Les auteurs montrent \u00a0la sup\u00e9riorit\u00e9 de cette strat\u00e9gie par rapport \u00e0 des strat\u00e9gies souvent sugg\u00e9r\u00e9es par les \u00e9pid\u00e9miologistes, comme par exemple \u00a0la strat\u00e9gie de contr\u00f4le constante, la strat\u00e9gie dite de \"lock-down\" (confinement)", "objectives": "Le mod\u00e8le distingue pour chacun des  \u00e9tats (E), (A), (I) et (R)  deux degr\u00e9s de s\u00e9v\u00e9rit\u00e9: s\u00e9v\u00e8re (s) et \"pas s\u00e9v\u00e8re\" (ou \"mild\" (m)).  Le but de l'article est de trouver un contr\u00f4le optimal c*(t) qui minimise une fonction co\u00fbt appropri\u00e9e; ce contr\u00f4le optimal est calcul\u00e9 en r\u00e9solvant num\u00e9riquement un syst\u00e8me d'optimalit\u00e9 obtenu en utilisant le principe de maximum de Pontryagin. Cette strat\u00e9gie optimale consiste en un contr\u00f4le avec une intensit\u00e9 qui augmente fortement au d\u00e9but et qui diminue r\u00e9guli\u00e8rement ensuite. Les auteurs montrent  la sup\u00e9riorit\u00e9 de cette strat\u00e9gie par rapport \u00e0 des strat\u00e9gies souvent sugg\u00e9r\u00e9es par les \u00e9pid\u00e9miologistes, comme par exemple  la strat\u00e9gie de contr\u00f4le constante, la strat\u00e9gie dite de \"lock-down\" (confinement), ou aussi des strat\u00e9gies cycliques qui consistent \u00e0 alterner des valeurs minimale et maximale pour la fonction contr\u00f4le. Je pense que les r\u00e9sultats obtenus seront tr\u00e8s utiles pour les \u00e9pid\u00e9miologistes.", "methods": "Le but de l'article est de trouver un contr\u00f4le optimal c*(t) qui minimise une fonction objectif qui prend en compte le nombre des personnes d\u00e9c\u00e9d\u00e9es et un co\u00fbt total associ\u00e9 \u00e0 l'impl\u00e9mentation des mesures d'isolement.", "pubmed_id": "32327608\n25900882\n23150538\n32234805\n32300018\n19892718\n32179701\n21870615\n21415939\n31994742\n32270376\n32046137\n32046819\n29768401\n32133152\n12766207\n32096566\n31995857\n32099934\n32178769\n18051645\n25631563\n28352101\n15539347\n32119825\n29056816\n23933724\n15141212\n22505737\n23908230\n27217564\n32145466\n32014114\n32150748\n23268232\n32191173\n32079150\n32171059\n32074444\n32031570\n31986264\n16642006\n16079797\n32187463\n18704085\n16504214\n32192578\n32234117\n32019667\n32199494\n18366252\n32144116", "doi": "10.1073/pnas.2004978117", "abstract": "The spread of coronavirus disease 2019 (COVID-19) in Italy prompted drastic measures for transmission containment. We examine the effects of these interventions, based on modeling of the unfolding epidemic. We test modeling options of the spatially explicit type, suggested by the wave of infections spreading from the initial foci to the rest of Italy. We estimate parameters of a metacommunity Susceptible-Exposed-Infected-Recovered (SEIR)-like transmission model that includes a network of 107 provinces connected by mobility at high resolution, and the critical contribution of presymptomatic and asymptomatic transmission. We estimate a generalized reproduction number ([Formula: see text] = 3.60 [3.49 to 3.84]), the spectral radius of a suitable next-generation matrix that measures the potential spread in the absence of containment interventions. The model includes the implementation of progressive restrictions after the first case confirmed in Italy (February 21, 2020) and runs until March 25, 2020. We account for uncertainty in epidemiological reporting, and time dependence of human mobility matrices and awareness-dependent exposure probabilities. We draw scenarios of different containment measures and their impact. Results suggest that the sequence of restrictions posed to mobility and human-to-human interactions have reduced transmission by 45% (42 to 49%). Averted hospitalizations are measured by running scenarios obtained by selectively relaxing the imposed restrictions and total about 200,000 individuals (as of March 25, 2020). Although a number of assumptions need to be reexamined, like age structure in social mixing patterns and in the distribution of mobility, hospitalization, and fatality, we conclude that verifiable evidence exists to support the planning of emergency measures.", "topics": ["Mod\u00e9lisation", "Transversale", "Infectiologie"], "author_list": [{"id": 609, "name": "Gatto M"}], "publication_date": "2020-05-30"}, {"id": 98, "slug": "risk-factors-associated-with-acute-respiratory-distress-syndrome-and-death-in-pa", "title": "Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Identifier les caract\u00e9ristiques des patients atteint de Covid-19 et les facteurs de risque de d\u00e9c\u00e8s", "verbose_date": "13.03.2020", "authors": "Wu", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://www.dropbox.com/s/uk1zvfn0f8w7c5h/10.1001%40jamainternmed.2020.0994.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Facteurs de risques de SDRA :\u00e2ge \u00e9lev\u00e9, dysfonction d'organe, coagulopathie, comorbidit\u00e9sMais fi\u00e8vre \u00e9lev\u00e9e n\u00e9gativement associ\u00e9e au risque de d\u00e9c\u00e8sProportion \u00e9lev\u00e9e de lymphocyte T CD3 et CD4 protecteur du SDRA", "objectives": "Interm\u00e9diaire :1) Etude \u00e9pid\u00e9miologique de cohorte bien conduite avec nombreux facteurs \u00e9tudi\u00e9s2) Faible effectif de patients \u00e2g\u00e9s ou avec comorbidit\u00e9s, peu de d\u00e9c\u00e8s 3) Etude monocentrique chinoise", "methods": "Identifier les caract\u00e9ristiques des patients atteint de Covid-19 et les facteurs de risque de d\u00e9c\u00e8s", "pubmed_id": "32167524\n27146253\n14767818\n27709848\n15105985\n25888703\n28466096\n12865379\n31986264\n32007143\n12955652\n12781536\n25554550\n20610717\n32015507\n8995086\n31978945\n16043521\n17891146\n26857507", "doi": "10.1001/jamainternmed.2020.0994", "abstract": "Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. Risk factors for the clinical outcomes of COVID-19 pneumonia have not yet been well delineated.\nTo describe the clinical characteristics and outcomes in patients with COVID-19 pneumonia who developed acute respiratory distress syndrome (ARDS) or died.\nRetrospective cohort study of 201 patients with confirmed COVID-19 pneumonia admitted to Wuhan Jinyintan Hospital in China between December 25, 2019, and January 26, 2020. The final date of follow-up was February 13, 2020.\nConfirmed COVID-19 pneumonia.\nThe development of ARDS and death. Epidemiological, demographic, clinical, laboratory, management, treatment, and outcome data were also collected and analyzed.\nOf 201 patients, the median age was 51 years (interquartile range, 43-60 years), and 128 (63.7%) patients were men. Eighty-four patients (41.8%) developed ARDS, and of those 84 patients, 44 (52.4%) died. In those who developed ARDS, compared with those who did not, more patients presented with dyspnea (50 of 84 [59.5%] patients and 30 of 117 [25.6%] patients, respectively [difference, 33.9%; 95% CI, 19.7%-48.1%]) and had comorbidities such as hypertension (23 of 84 [27.4%] patients and 16 of 117 [13.7%] patients, respectively [difference, 13.7%; 95% CI, 1.3%-26.1%]) and diabetes (16 of 84 [19.0%] patients and 6 of 117 [5.1%] patients, respectively [difference, 13.9%; 95% CI, 3.6%-24.2%]). In bivariate Cox regression analysis, risk factors associated with the development of ARDS and progression from ARDS to death included older age (hazard ratio [HR], 3.26; 95% CI 2.08-5.11; and HR, 6.17; 95% CI, 3.26-11.67, respectively), neutrophilia (HR, 1.14; 95% CI, 1.09-1.19; and HR, 1.08; 95% CI, 1.01-1.17, respectively), and organ and coagulation dysfunction (eg, higher lactate dehydrogenase [HR, 1.61; 95% CI, 1.44-1.79; and HR, 1.30; 95% CI, 1.11-1.52, respectively] and D-dimer [HR, 1.03; 95% CI, 1.01-1.04; and HR, 1.02; 95% CI, 1.01-1.04, respectively]). High fever (\u226539 \u00b0C) was associated with higher likelihood of ARDS development (HR, 1.77; 95% CI, 1.11-2.84) and lower likelihood of death (HR, 0.41; 95% CI, 0.21-0.82). Among patients with ARDS, treatment with methylprednisolone decreased the risk of death (HR, 0.38; 95% CI, 0.20-0.72).\nOlder age was associated with greater risk of development of ARDS and death likely owing to less rigorous immune response. Although high fever was associated with the development of ARDS, it was also associated with better outcomes among patients with ARDS. Moreover, treatment with methylprednisolone may be beneficial for patients who develop ARDS.", "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 104, "name": "Wu"}], "publication_date": "2020-03-13"}, {"id": 387, "slug": "early-ct-features-and-temporal-lung-changes-in-covid-19-pneumonia-in-wuhan-china", "title": "Early CT features and temporal lung changes in COVID-19 pneumonia in Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les premi\u00e8res caract\u00e9ristiques au scanner de la pneumonie COVID-19 \u00e0 partir d'une l\u00e9sion isol\u00e9e sur les premiers scanners. On a proc\u00e9d\u00e9 \u00e0 une \u00e9valuation compl\u00e8te de la l\u00e9sion isol\u00e9e sur le premier scanner positif des patients atteints de pneumonie COVID-19. En outre, on a pr\u00e9sent\u00e9 les changements pulmonaires temporels lors des scanners thoraciques de suivi.", "verbose_date": "20.04.2020", "authors": "Hu Q", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 26, "name": "Eur J Radiol"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0720048X20302060?token=039E9F4EC8383B2CDCEC62D32249126BD348B5A491C6EC3F7C571EE208B19064B5200C8714CC686C1D0944C9E7957D35", "findings": "", "take_away": "", "relevance_level": "Les caract\u00e9ristiques typiques de la pneumonie COVID-19 sont la \u00ab ground-glass opacity \u00bb, la localisation p\u00e9riph\u00e9rique ou sous-pleurale et la dilatation des art\u00e8res pulmonaires. La r\u00e9ticulation \u00e9tait \u00e9vidente apr\u00e8s la 2e semaine et persistait chez la moiti\u00e9 des patients \u00e9valu\u00e9s dans les 4 semaines suivant le d\u00e9but. Un suivi \u00e0 long terme est n\u00e9cessaire pour d\u00e9terminer si la r\u00e9ticulation repr\u00e9sente une fibrose irr\u00e9versible.", "objectives": "-\tPre-proof-\t\u00c9tude observationnelle r\u00e9trospective monocentrique-\tLa gamme compl\u00e8te de l'apparition et de la distribution de la pneumonie COVID-19 n'a peut-\u00eatre pas \u00e9t\u00e9 prise en compte : il est n\u00e9cessaire de disposer d'un \u00e9chantillon plus important -\tUn suivi \u00e0 long terme est n\u00e9cessaire \u00e0 l'avenir pour d\u00e9terminer si la r\u00e9ticulation repr\u00e9sente une fibrose irr\u00e9versible", "methods": "D\u00e9crire les premi\u00e8res caract\u00e9ristiques au scanner de la pneumonie COVID-19 \u00e0 partir d'une l\u00e9sion isol\u00e9e sur les premiers scanners. On a proc\u00e9d\u00e9 \u00e0 une \u00e9valuation compl\u00e8te de la l\u00e9sion isol\u00e9e sur le premier scanner positif des patients atteints de pneumonie COVID-19. En outre, on a pr\u00e9sent\u00e9 les changements pulmonaires temporels lors des scanners thoraciques de suivi.", "pubmed_id": "32387924\n24845462\n31978945\n12805557\n32004066\n32007143\n31986264\n18195376", "doi": "10.1016/j.ejrad.2020.109017", "abstract": "To analyse the high-resolution computed tomography (HRCT) early imaging features and the changing trend of coronavirus disease 2019 (COVID-19) pneumonia.\nForty-six patients with COVID-19 pneumonia who had an isolated lesion on the first positive CT were enrolled in this study. The following parameters were recorded for each lesion: sites, sizes, location (peripheral or central), attenuation (ground-glass opacity or consolidation), and other abnormalities (supply pulmonary artery dilation, air bronchogram, interstitial thickening, etc.). The follow-up CT images were compared with the previous CT scans, and the development of the lesions was evaluated.\nThe lesions tended to be peripheral and subpleural. All the lesions exhibited ground-glass opacity with or without consolidation. A higher proportion of supply pulmonary artery dilation (89.13 % [41/46]) and air bronchogram (69.57 % [32/46]) were found. Other \ufb01ndings included thickening of the intralobular interstitium and a halo sign of ground glass around a solid nodule. Cavitation, calci\ufb01cation or lymphadelopathy were not observed. The reticular patterns were noted from the 14 days after symptoms onset in 7 of 20 patients (45 %). At 22-31 days, the lesions were completely absorbed only in 2 of 7 patients (28.57 %).\nThe typical early CT features of COVID-19 pneumonia are ground-glass opacity, and located peripheral or subpleural location, and with supply pulmonary artery dilation. Reticulation was evident after the 2nd week and persisted in half of patients evaluated in 4 weeks after the onset. Long-term follow-up is required to determine whether the reticulation represents irreversible \ufb01brosis.", "topics": ["Autres", "Radiologie"], "author_list": [{"id": 373, "name": "Hu Q"}], "publication_date": "2020-04-20"}, {"id": 291, "slug": "covid-19-in-long-term-liver-transplant-patients-preliminary-experience-from-an-i", "title": "COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluation du risque li\u00e9 au COVID-19 pour des transplant\u00e9s h\u00e9patiques", "verbose_date": "10.04.2020", "authors": "Bhoori S", "specialties": [{"id": 19, "name": "H\u00e9pato-gastro-ent\u00e9rologie"}, {"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 19, "name": "Lancet Gastroenrol Hepatol"}, "link": "https://www.thelancet.com/action/showPdf?pii=S2468-1253%2820%2930116-3", "findings": "", "take_away": "", "relevance_level": "Les patients greff\u00e9s h\u00e9patiques ne semblent pas pr\u00e9senter une mortalit\u00e9 augment\u00e9e, l'immunosuppression pouvant \u00eatre un facteur protecteur dans le cadre de l'infection \u00e0 COVID-19. Toutefois, le d\u00e9veloppement des comorbidit\u00e9s cardiovasculaires en post-greffe rend ces patients \u00e0 risque de d\u00e9velopper une forme s\u00e9v\u00e8re.", "objectives": "- Correspondance- Revue d'exp\u00e9rience sur 3 patients d\u00e9c\u00e9d\u00e9s\"", "methods": "Evaluation du risque li\u00e9 au COVID-19 pour des transplant\u00e9s h\u00e9patiques", "pubmed_id": "32278366\n32298473\n32224313\n27917074\n30622369\n32109013\n32170806\n32196933", "doi": "10.1016/S2468-1253(20)30116-3", "abstract": null, "topics": ["Pronostique", "H\u00e9pato-gastro-ent\u00e9rologie", "Transversale"], "author_list": [{"id": 279, "name": "Bhoori S"}], "publication_date": "2020-04-10"}, {"id": 248, "slug": "global-interim-guidance-on-coronavirus-disease-2019-covid-19-during-pregnancy-an", "title": "Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals.", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Recommandations pour la prise en charge des patientes enceintes COVID-19 suspect\u00e9es ou confirm\u00e9es lors des visites pr\u00e9natales ambulatoires, du triage obst\u00e9trique, de l'accouchement et de la prise en charge du post-partum.\r\nRecommandations de traitement m\u00e9dical pour les patients confirm\u00e9s COVID-19.", "verbose_date": "06.04.2020", "authors": "Poon LC", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 7, "name": "Recommandations", "icon": "icon-reco"}, "journal": {"id": 44, "name": "Int J Gynaecol Obstet"}, "link": "https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1002/ijgo.13156", "findings": "", "take_away": "", "relevance_level": "1) Diagnostic: tous les cas suspects doivent \u00eatre test\u00e9s \u00e0 l'aide de tests mol\u00e9culaires tels que le qRT-PCR pr\u00e9f\u00e9rant les \u00e9chantillons des voies respiratoires basses.\n\r\n2) Imagerie diagnostique: le scanner thoracique pour les femmes enceintes est consid\u00e9r\u00e9 comme l'un des principaux outils pour diagnostiquer une infection COVID-19 dans les zones end\u00e9miques.\n\r\n3) Traitement m\u00e9dical:\r\n- les patients pr\u00e9sentant des sympt\u00f4mes l\u00e9gers peuvent \u00eatre pris en charge par l'isolement \u00e0 domicile.\r\n- pour les patients hospitalis\u00e9s :\u00a0\r\n*traitement pour maintenir un \u00e9quilibre hydro-\u00e9lectrique correct et traitement symptomatique (les antipyr\u00e9tiques, les anti-diarrh\u00e9iques - il n'y a pas de contre-indications \u00e0 l'ibuprof\u00e8ne).\r\n*surveillance maternelle des signes vitaux et de la saturation pour minimiser l'hypoxie (assurer une SpO2 d'au moins 95%)\r\n*surveillance f\u0153tale avec tocardiographie pour surveiller les battements de c\u0153ur du f\u0153tus apr\u00e8s 23-28 SA\r\n*si sympt\u00f4mes graves : patient plac\u00e9 en isolement en soins intensifs dans une chambre \u00e0 pression n\u00e9gative, \u00e9ventuellement en d\u00e9cubitus lat\u00e9ral gauche\n\r\n4) Examens pr\u00e9nataux ambulatoires:\r\n- le nombre de visites pr\u00e9natales pour les patientes \u00e0 faible risque devrait \u00eatre r\u00e9duit et remplac\u00e9 par des t\u00e9l\u00e9consultations\r\n- pour les patients COVID-19 confirm\u00e9e, un contr\u00f4le \u00e9chographique mensuel est recommand\u00e9 pour \u00e9valuer la croissance f\u0153tale, le liquide amniotique et l'anatomie f\u0153tale, ainsi qu'une \u00e9chographie morphologique \u00e0 18-23 SA\r\n- attention aux patients pr\u00e9sentant des comorbidit\u00e9s telles que l'hyperglyc\u00e9mie et l'hypertension (suivre les protocoles normaux sauf dans le cas de patients pr\u00e9sentant une hyperglyc\u00e9mie n\u00e9cessitant une th\u00e9rapie m\u00e9dicale - pr\u00e9f\u00e9rer l'insulinoth\u00e9rapie)\n\r\n5) Triage obst\u00e9trique:\r\n- toutes les patientes se pr\u00e9sentant pour un triage obst\u00e9trique ou des urgences doivent \u00eatre \u00e9valu\u00e9es pour les sympt\u00f4mes et l'exposition au COVID-19\n\r\n6) Accouchement:\r\n- l'accouchement doit avoir lieu dans des chambres individuelles \u00e0 pression n\u00e9gative et l'acc\u00e8s au partenaire doit \u00eatre interdit\r\n- l'infection par COVID-19 n'est pas une indication d'accouchement et il n'y a pas de contre-indication \u00e0 l'accouchement vaginal\r\n- l'anesth\u00e9sie r\u00e9gionale et l'anesth\u00e9sie g\u00e9n\u00e9rale peuvent toutes deux \u00eatre envisag\u00e9es : l'anesth\u00e9sie r\u00e9gionale est pr\u00e9f\u00e9rable compte tenu du risque de d\u00e9veloppement d'a\u00e9rosols\u00a0\u00a0\r\n- en cas d'accouchement pr\u00e9matur\u00e9, l'utilisation de corticost\u00e9ro\u00efdes pour la maturation des poumons du f\u0153tus pourrait aggraver les conditions cliniques de la m\u00e8re : administrer les corticost\u00e9ro\u00efdes apr\u00e8s la naissance et \u00e9viter la tocolyse afin de ne pas retarder leur administration\r\n- consid\u00e9rer les embryons ou f\u0153tus avort\u00e9s et le placenta comme des tissus infect\u00e9s\n\r\n7) Soins n\u00e9onatals post-partum:\r\n- dans le cas d'un patient pr\u00e9sentant des sympt\u00f4mes graves : s\u00e9paration de la m\u00e8re et du nouveau-n\u00e9 garantissant la production de lait maternel\u00a0\r\n- en cas de m\u00e8re pr\u00e9sentant des sympt\u00f4mes l\u00e9gers, maintenir la m\u00e8re et le nouveau-n\u00e9 dans la m\u00eame pi\u00e8ce et assurer un allaitement au sein s\u00fbr (hygi\u00e8ne des mains et masque chirurgical)", "objectives": "1) Recommandation de l' International Federation of Gynecology and Obstetrics2) Donn\u00e9es cliniques et \u00e9tudes limit\u00e9es sur les femmes enceintes avec COVID-19\"", "methods": "Recommandations pour la prise en charge des patientes enceintes COVID-19 suspect\u00e9es ou confirm\u00e9es lors des visites pr\u00e9natales ambulatoires, du triage obst\u00e9trique, de l'accouchement et de la prise en charge du post-partum.\r\nRecommandations de traitement m\u00e9dical pour les patients confirm\u00e9s COVID-19.", "pubmed_id": "32248521", "doi": "10.1002/ijgo.13156", "abstract": null, "topics": ["Recommandations", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 238, "name": "Poon LC"}], "publication_date": "2020-04-06"}, {"id": 33, "slug": "autopsy-in-suspected-covid-19-cases", "title": "Autopsy in suspected COVID-19 cases", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00e9sumer et interpr\u00e9ter les recommandations du Royal College of Pathologists pour les autopsies des cas suspects de COVID-19", "verbose_date": "20.03.2020", "authors": "Hanley B", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 29, "name": "J Clin Pathol"}, "link": "https://www.dropbox.com/s/71xmaisqrbh55yl/jclinpath-2020-206522.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Si le d\u00e9c\u00e8s est consid\u00e9r\u00e9 comme \u00e9tant d\u00fb \u00e0 une infection confirm\u00e9e au COVID-19, une autopsie ne sera probablement pas n\u00e9cessaireSi n\u00e9cessaire possibilit\u00e9 de proc\u00e9der par \u00e9tapes mais \u00e9galement de r\u00e9aliser une autopsie limit\u00e9e", "objectives": "Faible :1) R\u00e9sum\u00e9 de recommandations nationales anglaises2) Peu de litt\u00e9rature", "methods": "R\u00e9sumer et interpr\u00e9ter les recommandations du Royal College of Pathologists pour les autopsies des cas suspects de COVID-19", "pubmed_id": "32198191", "doi": "10.1136/jclinpath-2020-206522", "abstract": "The severe acute respiratory syndrome (SARS)-coronavirus-2 (CoV-2) outbreak in Wuhan, China has now spread to many countries across the world including the UK with an increasing death toll. This will inevitably lead to an increase in the number of suspected coronavirus disease 2019 (COVID-19)-related deaths at autopsy. The Royal College of Pathologists has responded to this concern with the release of a briefing on autopsy practice relating to COVID-19. The following article is a summary and interpretation of these guidelines. It includes a description of hazard group 3 organisms, the category to which SARS-CoV-2 has been assigned, a brief description of what is currently known about the pathological and autopsy findings in COVID-19, a summary of the recommendations for conducting autopsies in suspected COVID-19 cases and the techniques for making the diagnosis at autopsy. It concludes by considering the clinicopathological correlation and notification of such cases.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 43, "name": "Hanley B"}], "publication_date": "2020-03-20"}, {"id": 675, "slug": "clinical-characteristics-of-58-children-with-a-pediatric-inflammatory-multisyste", "title": "Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques cliniques et de laboratoire des enfants hospitalis\u00e9s qui r\u00e9pondent aux crit\u00e8res du syndrome inflammatoire multisyst\u00e9mique p\u00e9diatrique temporellement associ\u00e9 au SARS-CoV-2 (PIMS-TS) et comparer ces caract\u00e9ristiques avec d'autres troubles inflammatoires p\u00e9diatriques.", "verbose_date": "10.06.2020", "authors": "Whittaker E", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://jamanetwork.com/journals/jama/fullarticle/2767209", "findings": "", "take_away": "", "relevance_level": "Dans cette s\u00e9rie de cas d'enfants hospitalis\u00e9s qui r\u00e9pondaient aux crit\u00e8res du PIMS-TS, il y avait un large spectre de signes et de sympt\u00f4mes et de gravit\u00e9 de la maladie, allant de la fi\u00e8vre et de l'inflammation aux l\u00e9sions myocardiques, au choc et au d\u00e9veloppement d'an\u00e9vrismes des art\u00e8res coronaires. La comparaison avec des patients atteints de maladie de Kawasaki et du syndrome de choc de la maladie de Kawasaki permet de mieux comprendre ce syndrome et sugg\u00e8re que ce trouble diff\u00e8re des autres entit\u00e9s inflammatoires p\u00e9diatriques.", "objectives": "-\tS\u00e9rie de cas de 58 enfants-\tCette \u00e9tude est bas\u00e9e sur une collecte de donn\u00e9es r\u00e9trospectives aupr\u00e8s d'un certain nombre d'h\u00f4pitaux au cours d'une p\u00e9riode ant\u00e9rieure \u00e0 l'\u00e9laboration de la d\u00e9finition de cas et pendant celle-ci. Les enqu\u00eates et la gestion ont \u00e9t\u00e9 individualis\u00e9es par centre et par patient plut\u00f4t que de suivre un protocole standardis\u00e9.-\tPendant cette p\u00e9riode, le test PCR des selles n'a pas \u00e9t\u00e9 effectu\u00e9 de mani\u00e8re syst\u00e9matique ; il n'a donc \u00e9t\u00e9 mesur\u00e9 que dans un petit groupe d'enfants de cette cohorte. -\tLes donn\u00e9es de s\u00e9ropr\u00e9valence chez les enfants au Royaume-Uni ne sont pas disponibles.-\tIl n'existe pas de test de diagnostic pour la maladie de Kawasaki, il n'est donc pas possible d'exclure que la cohorte comprenne des enfants atteints de la maladie de Kawasaki plut\u00f4t que d'une nouvelle maladie \u00e9mergente associ\u00e9e au SARS-CoV-2. -\tIl n'existe pas de registre national de la maladie de Kawasaki ou du syndrome de choc toxique en Angleterre.", "methods": "D\u00e9crire les caract\u00e9ristiques cliniques et de laboratoire des enfants hospitalis\u00e9s qui r\u00e9pondent aux crit\u00e8res du syndrome inflammatoire multisyst\u00e9mique p\u00e9diatrique temporellement associ\u00e9 au SARS-CoV-2 (PIMS-TS) et comparer ces caract\u00e9ristiques avec d'autres troubles inflammatoires p\u00e9diatriques.", "pubmed_id": "32511692", "doi": "10.1001/jama.2020.10369", "abstract": "In communities with high rates of coronavirus disease 2019, reports have emerged of children with an unusual syndrome of fever and inflammation.\nTo describe the clinical and laboratory characteristics of hospitalized children who met criteria for the pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PIMS-TS) and compare these characteristics with other pediatric inflammatory disorders.\nCase series of 58 children from 8 hospitals in England admitted between March 23 and May 16, 2020, with persistent fever and laboratory evidence of inflammation meeting published definitions for PIMS-TS. The final date of follow-up was May 22, 2020. Clinical and laboratory characteristics were abstracted by medical record review, and were compared with clinical characteristics of patients with Kawasaki disease (KD) (n\u2009=\u20091132), KD shock syndrome (n\u2009=\u200945), and toxic shock syndrome (n\u2009=\u200937) who had been admitted to hospitals in Europe and the US from 2002 to 2019.\nSigns and symptoms and laboratory and imaging findings of children who met definitional criteria for PIMS-TS from the UK, the US, and World Health Organization.\nClinical, laboratory, and imaging characteristics of children meeting definitional criteria for PIMS-TS, and comparison with the characteristics of other pediatric inflammatory disorders.\nFifty-eight children (median age, 9 years [interquartile range {IQR}, 5.7-14]; 33 girls [57%]) were identified who met the criteria for PIMS-TS. Results from SARS-CoV-2 polymerase chain reaction tests were positive in 15 of 58 patients (26%) and SARS-CoV-2 IgG test results were positive in 40 of 46 (87%). In total, 45 of 58 patients (78%) had evidence of current or prior SARS-CoV-2 infection. All children presented with fever and nonspecific symptoms, including vomiting (26/58 [45%]), abdominal pain (31/58 [53%]), and diarrhea (30/58 [52%]). Rash was present in 30 of 58 (52%), and conjunctival injection in 26 of 58 (45%) cases. Laboratory evaluation was consistent with marked inflammation, for example, C-reactive protein (229 mg/L [IQR, 156-338], assessed in 58 of 58) and ferritin (610 \u03bcg/L [IQR, 359-1280], assessed in 53 of 58). Of the 58 children, 29 developed shock (with biochemical evidence of myocardial dysfunction) and required inotropic support and fluid resuscitation (including 23/29 [79%] who received mechanical ventilation); 13 met the American Heart Association definition of KD, and 23 had fever and inflammation without features of shock or KD. Eight patients (14%) developed coronary artery dilatation or aneurysm. Comparison of PIMS-TS with KD and with KD shock syndrome showed differences in clinical and laboratory features, including older age (median age, 9 years [IQR, 5.7-14] vs 2.7 years [IQR, 1.4-4.7] and 3.8 years [IQR, 0.2-18], respectively), and greater elevation of inflammatory markers such as C-reactive protein (median, 229 mg/L [IQR 156-338] vs 67 mg/L [IQR, 40-150 mg/L] and 193 mg/L [IQR, 83-237], respectively).\nIn this case series of hospitalized children who met criteria for PIMS-TS, there was a wide spectrum of presenting signs and symptoms and disease severity, ranging from fever and inflammation to myocardial injury, shock, and development of coronary artery aneurysms. The comparison with patients with KD and KD shock syndrome provides insights into this syndrome, and suggests this disorder differs from other pediatric inflammatory entities.", "topics": ["Epid\u00e9miologique", "Anesth\u00e9sie-R\u00e9animation", "P\u00e9diatrie"], "author_list": [{"id": 634, "name": "Whittaker E"}], "publication_date": "2020-06-10"}, {"id": 324, "slug": "neutrophil-to-lymphocyte-ratio-as-an-independent-risk-factor-for-mortality-in-ho", "title": "Neutrophil-to-lymphocyte Ratio as an Independent Risk Factor for Mortality in Hospitalized Patients With COVID-19", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "\u00c9valuer si le rapport neutrophiles/lymphocytes peut \u00eatre utilis\u00e9 comme facteur pr\u00e9dictif de la mortalit\u00e9 intra-hospitali\u00e8re chez les patients COVID-19", "verbose_date": "14.04.2020", "authors": "Liu Y", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.journalofinfection.com/article/S0163-4453(20)30208-5/pdf", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude montre que l'augmentation du ratio neutrophiles/lymphocytes est associ\u00e9e \u00e0 une augmentation de 8% du risque de mortalit\u00e9 dans le mod\u00e8le statistique ajust\u00e9 pour tous les facteurs confondants.\r\nL'augmentation du risque de mortalit\u00e9 est \u00e9galement associ\u00e9 \u00e0 la stratification du rapport neutrophiles/lymphocytes, le tertile 3 est associ\u00e9 \u00e0 un risque plus \u00e9lev\u00e9 que le tertile 1 (OR= 16.04, IC 95%: 1.14-224.95, p= 0.0395).\r\nLe rapport neutrophiles/lymphocytes peut \u00eatre rapidement calcul\u00e9 par des tests h\u00e9matologiques de routine \u00e0 l'admission et peut aider \u00e0 identifier les patients COVID-19 pr\u00e9sentant un risque accru de mortalit\u00e9 \u00e0 un stade pr\u00e9coce.", "objectives": "1) \u00e9tude de cohorte r\u00e9trospective2) utilisation d'ajustements statistiques pour minimiser le biais donn\u00e9 par les facteurs confondants et \u00e9valuation de la robustesse des r\u00e9sultats en r\u00e9p\u00e9tant l'analyse pour les tertiles du rapport neutrophiles/lymphocytes (RNL)3) petit \u00e9chantillon (245 patients au total)4) \u00e9chantillon compos\u00e9 uniquement de patients chinois : incertitude quant \u00e0 l'application des r\u00e9sultats \u00e0 d'autres groupes ethniques\"", "methods": "\u00c9valuer si le rapport neutrophiles/lymphocytes peut \u00eatre utilis\u00e9 comme facteur pr\u00e9dictif de la mortalit\u00e9 intra-hospitali\u00e8re chez les patients COVID-19", "pubmed_id": "32283162", "doi": "10.1016/j.jinf.2020.04.002", "abstract": "Several studies have described the clinical characteristics of patients with novel coronavirus (SARS-CoV-2) infected pneumonia (COVID-19), indicating severe patients tended to have higher neutrophil to lymphocyte ratio (NLR). Whether baseline NLR could be an independent predictor of in-hospital death in Chinese COVID-19 patients remains to be investigated.\nA cohort of patients with COVID-19 admitted to the Zhongnan Hospital of Wuhan University from January 1 to February 29 was retrospectively analyzed. The baseline data of laboratory examinations, including NLR, were collected. Univariate and multivariate logistic regression models were developed to assess the independent relationship between the baseline NLR and in-hospital all-cause death. A sensitivity analysis was performed by converting NLR from a continuous variable to a categorical variable according to tertile. Interaction and stratified analyses were conducted as well.\n245 COVID-19 patients were included in the final analyses, and the in-hospital mortality was 13.47%. Multivariate analysis demonstrated that there was 8% higher risk of in-hospital mortality for each unit increase in NLR (Odds ratio [OR]\u202f=\u202f1.08; 95% confidence interval [95% CI], 1.01 to 1.14; P\u202f=\u202f0.0147). Compared with patients in the lowest tertile, the NLR of patients in the highest tertile had a 15.04-fold higher risk of death (OR\u202f=\u202f16.04; 95% CI, 1.14 to 224.95; P\u202f=\u202f0.0395) after adjustment for potential confounders. Notably, the fully adjusted OR for mortality was 1.10 in males for each unit increase of NLR (OR\u202f=\u202f1.10; 95% CI, 1.02 to 1.19; P\u202f=\u202f0.016).\nNLR is an independent risk factor of the in-hospital mortality for COVID-19 patients especially for male. Assessment of NLR may help identify high risk individuals with COVID-19.", "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 311, "name": "Liu Y"}], "publication_date": "2020-04-14"}, {"id": 184, "slug": "genomic-characterisation-and-phylogenetic-analysis-of-sars-cov-2-in-italy", "title": "GENOMIC CHARACTERISATION AND PHYLOGENETIC ANALYSIS OF SARS-COV-2 IN ITALY", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9crire l'isolement, La caract\u00e9risation mol\u00e9culaire et l'analyse phylog\u00e9nique des 3 premiers g\u00e9nomes SARS-CoV-2 complets isol\u00e9s de 3 patients de Lombardie COVID 19. ", "verbose_date": "29.03.2020", "authors": "Zehender G ", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://www.dropbox.com/s/2wu9mfu5fcyj8qf/2020.03.15.20032870v1.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le SARS-CoV-2 isol\u00e9 qui a infect\u00e9 les patients nord italiens et qui a aussi \u00e9t\u00e9 isol\u00e9 chez des patients europ\u00e9ens et d'Am\u00e9rique latine ayant eu des contacts avec l'Italie, est \u00e9troitement li\u00e9 \u00e0 la m\u00eame souche isol\u00e9e lors de l'un des premiers clusters en Bavi\u00e8re fin janvier 2020.\r\nLes donn\u00e9es \u00e9pid\u00e9miologiques montrent que le premier cas en Allemagne pr\u00e9c\u00e8de les premiers cas d'Italie d'au moins un mois, sugg\u00e8rent que la souche soit entr\u00e9e en Allemagne avant d'arriver en Italie.\r\nL'analyse de seulement 3 souches ne peut pas exclure une introduction multiple.", "objectives": "", "methods": "D\u00e9crire l'isolement, La caract\u00e9risation mol\u00e9culaire et l'analyse phylog\u00e9nique des 3 premiers g\u00e9nomes SARS-CoV-2 complets isol\u00e9s de 3 patients de Lombardie COVID 19.", "topics": ["Epid\u00e9miologique", "Virologie"], "author_list": [{"id": 178, "name": "Zehender G "}], "publication_date": "2020-03-29"}, {"id": 575, "slug": "viral-dynamics-in-asymptomatic-patients-with-covid-19", "title": "Viral dynamics in asymptomatic patients with COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Caract\u00e9riser la charge virale et le risque d'infection pour les patients COVID-19 asymptomatiques.", "verbose_date": "12.05.2020", "authors": "Zhou R", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.ijidonline.com/article/S1201-9712(20)30337-4/pdf", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude fait \u00e9tat d'une plus grande diff\u00e9rence de charge virale chez les patients asymptomatique en phase d'incubation (APIs) que chez les patients asymptomatiques (APs),\u00a0toutefois, aucune diff\u00e9rence significative n'a \u00e9t\u00e9 constat\u00e9e pour la dur\u00e9e de la p\u00e9riode de contagiosit\u00e9 entre les deux \u00e9chantillons.\u00a0\nCela sugg\u00e8re que les patients asymptomatiques peuvent \u00eatre une source importante d'infection et doivent \u00eatre suivis longitudinalement pour d\u00e9tecter la pr\u00e9sence d'acides nucl\u00e9iques viraux.\u00a0Rappelons toutefois les limites de l'\u00e9tude, men\u00e9e sur un tr\u00e8s petit \u00e9chantillon et sans surveillance longitudinale \u00e0 long terme des patients asymptomatiques.", "objectives": "Faible:1) Article pre-proof2) Petit \u00e9chantillon (n=31)3) Manque de suivi longitudinal des patients asymptomatiques", "methods": "Caract\u00e9riser la charge virale et le risque d'infection pour les patients COVID-19 asymptomatiques.", "pubmed_id": "32437933", "doi": "10.1016/j.ijid.2020.05.030", "abstract": "Data are limited on the viral load, viral shedding patterns, and potential infectivity of asymptomatic patients (APs) with coronavirus disease 2019 (COVID-19). This study included 31 adult patients who were virologically confirmed to have COVID-19 but were asymptomatic on admission. Among these 31 patients, 22 presented symptoms after admission and were defined as asymptomatic patients in the incubation period (APIs); the other nine patients remained asymptomatic during hospitalization and were defined as asymptomatic patients (APs). The median cycle threshold (Ct) value of APs (39.0, interquartile range (IQR) 37.5-39.5) was significantly higher than that of APIs (34.5, IQR 32.2-37.0), indicating a lower viral load in APs. However, the duration of viral shedding remained similar in the two groups (7 days, IQR 5-14 days vs. 8 days, IQR 5-16 days). The study findings demonstrated that although APs with COVID-19 have a lower viral load, they still have certain period of viral shedding, which suggests the possibility of transmission during their asymptomatic period. Further longitudinal surveillance of these asymptomatic cases via virus nucleic acid testing are warranted.", "topics": ["Epid\u00e9miologique", "Virologie"], "author_list": [{"id": 539, "name": "Zhou R"}], "publication_date": "2020-05-12"}, {"id": 272, "slug": "face-mask-use-in-the-general-population-and-optimal-resource-allocation-during-t", "title": "Face mask use in the general population and optimal resource allocation during the COVID-19 pandemic", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer par mod\u00e9lisation l'impact du port de masques dans la population pour limiter l'\u00e9pid\u00e9mie \u00e0 SARS-CoV-2 selon plusieurs sc\u00e9narios tenant compte de la p\u00e9nurie d'\u00e9quipements", "verbose_date": "09.04.2020", "authors": "Wordy CJ", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.04.20052696v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "En mod\u00e9lisation, l'effiacit\u00e9 de la distribution de masques \u00e0 la population est \u00e9vident. Plus le port du masque est g\u00e9n\u00e9ralis\u00e9, plus la r\u00e9duction de la mortalit\u00e9 est importante. Plus la mise en place du port de masque est pr\u00e9coce, plus l'efficacit\u00e9 est importante avec un d\u00e9calage du pic \u00e9pid\u00e9mique.\n\r\nCependant, cela varie avec la disponibilit\u00e9 des masques, leur efficacit\u00e9 et l'adoption par la population. Ainsi dans le cas d'une ressource en masque limit\u00e9e, le plus int\u00e9ressant semble la distribution en priorit\u00e9 aux personnes \u00e0 risque, en particulier aux personnes \u00e2g\u00e9es, plut\u00f4t qu'aux personnes infect\u00e9es (trop de personnes asymptomatiques).\n\r\nM\u00eame si les masques ont une efficacit\u00e9 de filtration faible (masques \"maisons\" par exemple), la r\u00e9duction de la mortalit\u00e9 est significative : de 65% \u00e0 30% selon l'efficacit\u00e9 du masque avec une adoption du masque limit\u00e9e dans la population.", "objectives": "- Mod\u00e9lisation bien conduite avec hypoth\u00e8ses raisonnables- Multitudes de sc\u00e9narios test\u00e9s", "methods": "Evaluer par mod\u00e9lisation l'impact du port de masques dans la population pour limiter l'\u00e9pid\u00e9mie \u00e0 SARS-CoV-2 selon plusieurs sc\u00e9narios tenant compte de la p\u00e9nurie d'\u00e9quipements", "pubmed_id": "32511626\n32086236\n19773323\n24664384\n32164834\n20161764\n19193267\n32125371\n32091533\n32389846\n32064853\n19815575\n32083643\n19652172\n32214079\n32179137\n32203710\n32203376\n32371934\n23505369\n32074444\n32241884\n32292898", "doi": "10.1101/2020.04.04.20052696", "abstract": "The ongoing novel coronavirus disease (COVID-19) pandemic has rapidly spread in early 2020, causing tens of thousands of deaths, over a million cases and widespread socioeconomic disruption. With no vaccine available and numerous national healthcare systems reaching or exceeding capacity, interventions to limit transmission are urgently needed. While there is broad agreement that travel restrictions and closure of non-essential businesses and schools are beneficial in limiting local and regional spread, and such measures have been adopted in countries around the world, recommendations around the use of face masks for the general population are less consistent internationally. In this study, we examined the role of face masks in mitigating the spread of COVID-19 in the general population, using epidemic models to estimate the total reduction of infections and deaths under various scenarios. In particular, we examined the optimal deployment of face masks when resources are limited. We found that face masks, even with a limited protective effect, can reduce infections and deaths, and can delay the peak time of the epidemic. We consistently found that a random distribution of masks in the population was a suboptimal strategy when resources were limited. Prioritizing coverage among the elderly was more beneficial, while allocating a proportion of available resources for diagnosed infected cases provided further mitigation under a range of scenarios. In summary, face mask use, particularly for a pathogen with relatively common asymptomatic carriage, can effectively provide some mitigation of transmission, while balancing provision between vulnerable healthy persons and symptomatic persons can optimize mitigation efforts when resources are limited.", "topics": ["Epid\u00e9miologique", "Transversale", "Hygi\u00e8ne"], "author_list": [{"id": 261, "name": "Wordy CJ"}], "publication_date": "2020-04-09"}, {"id": 607, "slug": "posttraumatic-stress-symptoms-of-health-care-workers-during-the-corona-virus-dis", "title": "Posttraumatic Stress Symptoms of Health Care Workers during the Corona Virus Disease 2019 (COVID-19)", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer les sympt\u00f4mes de stress post traumatique (PTSS) et la qualit\u00e9 du sommeil de soignants chinois en premi\u00e8re ligne contre l'\u00e9pid\u00e9mie COVID-19 apr\u00e8s un mois d'exposition.", "verbose_date": "19.05.2020", "authors": "Yin Q", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 240, "name": "Clin Psychol Psychotherapy"}, "link": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpp.2477", "findings": "", "take_away": "", "relevance_level": "A un mois du d\u00e9but de l'\u00e9pid\u00e9mie (fix\u00e9 au 5 janvier d'apr\u00e8s les auteurs), parmi 371 soignants chinois dont 66% n'\u00e9taient plus expos\u00e9s :\n- Pr\u00e9valence de PTSS : 3,8%, les femmes semblant plus \u00e0 risque (HR=2,136).\n- Les soignants les plus expos\u00e9s pr\u00e9sentaient significativement plus de sympt\u00f4mes d'hypervigilance (HR=4,026).\n- Il semble y avoir un lien indirect entre PTSS et niveau d'exposition (coefficient =1.750, 95% CI of Boostroop test=0.543-2.998), \u00e9tant exclusivement m\u00e9di\u00e9 par un lien direct entre qualit\u00e9 de sommeil et PTSS (coefficient =1.700, p<0.001).", "objectives": "- Etude observationnelle descriptive transversale- Faibles effectifs : 371 soignants dont seulement 34% directement expos\u00e9s au COVID-19- Probables biais de d\u00e9claration et de confusion non pris en compte.", "methods": "Evaluer les sympt\u00f4mes de stress post traumatique (PTSS) et la qualit\u00e9 du sommeil de soignants chinois en premi\u00e8re ligne contre l'\u00e9pid\u00e9mie COVID-19 apr\u00e8s un mois d'exposition.", "topics": ["Epid\u00e9miologique", "Psychiatrie"], "author_list": [{"id": 570, "name": "Yin Q"}], "publication_date": "2020-05-19"}, {"id": 379, "slug": "decline-of-acute-coronary-syndrome-admissions-in-austria-since-the-outbreak-of-c", "title": "Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluation de l'impact du COVID-19 sur le diagnostic et le traitement du syndrome coronarien aigu (SCA).", "verbose_date": "19.04.2020", "authors": "Metzler B", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 34, "name": "Eur Heart J"}, "link": "https://www.dropbox.com/s/x10z8efkzlt985w/ehaa314.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude a montr\u00e9 une diminution de 39,4 % des admissions hospitali\u00e8res en Autriche en mars 2020 pour syndrome coronarien aigu (SCA).\r\nLes auteurs estiment que la diminution des admissions a pu conduire \u00e0 la non prise en charge de 275 patients et \u00e0 110 d\u00e9c\u00e8s.", "objectives": "1) \u00e9tude observationnelle r\u00e9trospective multicentrique2) 17 services (sur 19 contact\u00e9s) ont fourni les nombres d'admission pour SCA3) pas de donn\u00e9es sur la mortalit\u00e9 par SCA\"", "methods": "Evaluation de l'impact du COVID-19 sur le diagnostic et le traitement du syndrome coronarien aigu (SCA).", "pubmed_id": "32297932", "doi": "10.1093/eurheartj/ehaa314", "abstract": null, "topics": ["Epid\u00e9miologique", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 366, "name": "Metzler B"}], "publication_date": "2020-04-19"}, {"id": 437, "slug": "high-incidence-of-venous-thromboembolic-events-in-anticoagulated-severe-covid-19", "title": "High incidence of venous thromboembolic events in anticoagulated s\u00e9v\u00e8re COVID-19 patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Caract\u00e9riser la pr\u00e9valence de thrombose veineuse chez les patients COVID-19 s\u00e9v\u00e8res sous anticoagulants.", "verbose_date": "24.04.2020", "authors": "Llitjos JF", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 96, "name": "J Thromb Haemostasis"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.14869", "findings": "", "take_away": "", "relevance_level": "Les patients COVID-19 s\u00e9v\u00e8res ont une pr\u00e9valence \u00e9lev\u00e9e d'\u00e9v\u00e9nements thrombotiques m\u00eame sous anticoagulants.", "objectives": "- Multicentrique- Dupplex Doppler syst\u00e9matique- Mais nombre de patients faible- Design r\u00e9trospectif\"", "methods": "Caract\u00e9riser la pr\u00e9valence de thrombose veineuse chez les patients COVID-19 s\u00e9v\u00e8res sous anticoagulants.", "topics": ["Epid\u00e9miologique", "Infectiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 414, "name": "Llitjos JF"}], "publication_date": "2020-04-24"}, {"id": 159, "slug": "th17-responses-in-cytokine-storm-of-covid-19-an-emerging-target-of-jak2-inhibito", "title": "TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Examen de la r\u00e9ponse des patients COVID-19 ayant un profil immunologique TH17 et test du Fedratinib (inhibiteurs JAK2)", "verbose_date": "26.03.2020", "authors": "Wu D ", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 84, "name": "J Microbiol Immunol Infect"}, "link": "https://www.dropbox.com/s/cjtjln6hhdftm8t/1-s2.0-S1684118220300657-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La revue de la litt\u00e9rature montre que les cytokines produites par les cellules TH17 sont dans la majorit\u00e9 des cas impliqu\u00e9es dans la temp\u00eate de cytokines induite par le SRAS-CoV-2.\r\nLes auteurs ont essay\u00e9 d'inhiber les cellules TH17 en utilisant le m\u00e9dicament Fedratinib, inhibiteur de JAK2 approuv\u00e9 par la FDA pour les n\u00e9oplasmes my\u00e9loprolif\u00e9ratifs.\r\nLe Fedratinib diminuait l'expression de l'IL-17 par les cellules murines TH17 et ce suppresseur est plus profonde lorsque l'IL-23 est ajout\u00e9. Le Fedratinib r\u00e9duit aussi l'IL-22 mais a un effet marginal sur l'expression de l'IL-21", "objectives": "1) Revue de une \u00e9tude (Xu et al.) sur un seul patient.2) Exp\u00e9rimentation du Fedratinib sur les cellules murines TH17", "methods": "Examen de la r\u00e9ponse des patients COVID-19 ayant un profil immunologique TH17 et test du Fedratinib (inhibiteurs JAK2)", "pubmed_id": "32205092", "doi": "10.1016/j.jmii.2020.03.005", "abstract": "COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.", "topics": ["Th\u00e9rapeutique", "Infectiologie"], "author_list": [{"id": 155, "name": "Wu D "}], "publication_date": "2020-03-26"}, {"id": 498, "slug": "understanding-the-renin-angiotensin-aldosterone-sars-cov-axis-a-comprehensive-re", "title": "Understanding the Renin-Angiotensin-Aldosterone-SARS-CoV-Axis: A Comprehensive Review", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9crire, \u00e0 l'aide d'un liste exhaustive de 116 \u00e9tudes, l'implication du SRAA en physiopathologie humaine ainsi que dans l'infection au COVID-19 et les pistes th\u00e9rapeutiques \u00e9ventuelles.", "verbose_date": "30.04.2020", "authors": "Ingraham NE", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 142, "name": "Eur Respir J"}, "link": "https://erj.ersjournals.com/content/erj/early/2020/04/20/13993003.00912-2020.full.pdf", "findings": "", "take_away": "", "relevance_level": "Les donn\u00e9es cliniques sont encore insuffisantes pour recommander un bloqueur du SRAA pour traiter l'infection \u00e0 COVID-19.\u00a0 Des \u00e9tudes sugg\u00e8rents que l'inhibition du SRAA diminuerait les l\u00e9sions pulmonaires et augmenterait la survie tout en diminuant la charge virale chez la souris, pour les infections utilisant l'ACE2 pour entrer dans les cellules (telles que les infections aux coronavirus), par le biais d'une meilleure r\u00e9gulation des voies antagonistes du SRRA m\u00e9diant notamment l'inflammation et la protection pulmonaire. Concernant l'humain, ces hypoth\u00e8ses n\u00e9cessitent plus d'investigations pour \u00e9tablir un lien significatif entre la modulation du SRAA et la physiopathologie pulmonaire dans le cas pr\u00e9cis du COVID-19, ainsi que les pistes th\u00e9rapeutiques qui en d\u00e9coulent.", "objectives": "Revue de la litt\u00e9rature avec bon effectif (116 articles)", "methods": "D\u00e9crire, \u00e0 l'aide d'un liste exhaustive de 116 \u00e9tudes, l'implication du SRAA en physiopathologie humaine ainsi que dans l'infection au COVID-19 et les pistes th\u00e9rapeutiques \u00e9ventuelles.", "pubmed_id": "32341103\n21047406\n32061198\n26813885\n18022664\n15549171\n29563786\n32015507\n32075877\n24800825\n32092483\n27738071\n12352014\n8993851\n16303146\n7596116\n18809792\n25981293\n22182843\n24420847\n12235231\n32171076\n32228222\n17688881\n25225202\n14647384\n31135703\n29206762\n31133031\n17715238\n25007996\n8498975\n25655897\n18041882\n8380358\n9740600\n22718567\n25391767\n17096009\n12075344\n32125455\n17107992\n12734120\n16282461\n25604220\n31723629\n32171067\n16995204\n22536270\n32007643\n16001071\n11073110\n24800963\n26714908\n18490652\n22918991\n22009550\n32269089\n9010643\n27344959\n32005675\n12570788\n29897923\n27919443\n23962453\n15897343\n16908757\n32048163\n29709898\n16007097\n32171062\n32142651\n8471405\n19411314\n18554741\n22158645\n2013151\n15165741\n32052466\n16484896\n16988814\n23957905\n19864379", "doi": "10.1183/13993003.00912-2020", "abstract": "Coronavirus Disease 19 (COVID-19), the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a global pandemic with significant morbidity and mortality since first appearing in Wuhan, China, in late 2019. As many countries are grappling with the onset of their epidemics, pharmacotherapeutics remain lacking. The window of opportunity to mitigate downstream morbidity and mortality is narrow but remains open. The renin-angiotensin-aldosterone system (RAAS) is crucial to the homeostasis of both the cardiovascular and respiratory systems. Importantly, SARS-CoV-2 utilises and interrupts this pathway directly, which could be described as the renin-angiotensin-aldosterone-SARS-CoV-2-axis (RAAS-SCoV-axis). There exists significant controversy and confusion surrounding how anti-hypertensive agents might function along this pathway. This review explores the current state of knowledge regarding the RAAS-SCoV-axis, informed by prior studies of SARS-CoV, how this relates to our currently evolving pandemic, and how these insights might guide our next steps in an evidence-based manner.\nThis review discusses the role of the RAAS-SCoV-axis in acute lung injury and the effects, risks, and benefits of pharmacologic modification of this axis. There may be an opportunity to leverage the different aspects of RAAS inhibitors to mitigate indirect viral-induced lung injury. Concerns have been raised that such modulation might exacerbate the disease. While relevant preclinical, experimental models to date favor a protective effect of RAAS-SCoV-axis inhibition on both lung injury and survival, clinical data related to the role of RAAS modulation in the setting of SARS-CoV-2 remains limited.\nProposed interventions for SARS-CoV-2 predominantly focus on viral microbiology and aim to inhibit viral cellular injury. While these therapies are promising, immediate use may not be feasible, and the time window of their efficacy remains a major unanswered question. An alternative approach is the modulation of the specific downstream pathophysiologic effects caused by virus that lead to morbidity and mortality. We propose a preponderance of evidence that supports clinical equipoise regarding the efficacy of RAAS-based interventions, and the imminent need for a multisite randomised controlled clinical trial to evaluate the inhibition of the RAAS-SCoV-axis on acute lung injury in COVID-19.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 466, "name": "Ingraham NE"}], "publication_date": "2020-04-30"}, {"id": 240, "slug": "coronavirus-disease-2019-in-elderly-patients-characteristics-and-prognostic-fact", "title": "Coronavirus Disease 2019 in Elderly Patients: Characteristics and Prognostic Factors Based on 4-week Follow-Up", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier les caract\u00e9ristiques et les facteurs pronostiques chez les patients \u00e2g\u00e9s avec COVID 19", "verbose_date": "02.04.2020", "authors": "Wang L", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 13, "name": "G\u00e9riatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.dropbox.com/s/n9n69cvuc2qce89/PIIS0163445320301468.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "De forte proportions de formes s\u00e9v\u00e8res et critiques, et un fort taux de mortalit\u00e9 sont observ\u00e9s chez les patients \u00e2g\u00e9s atteints de COVID 19.\r\nUne progression rapide vers le d\u00e9c\u00e8s est constat\u00e9, avec un temps m\u00e9dian de survie de 5 jours apr\u00e8s admission\r\nLa dyspn\u00e9e, lymphocytop\u00e9nie, comorbidit\u00e9s (maladies cardiovasculaires et BPCO), et SDRA sont pr\u00e9dictifs de mortalit\u00e9.\r\nUne surveillance rapproch\u00e9e et un traitement rapide doivent \u00eatre mis en place pour les patients \u00e2g\u00e9s \u00e0 risque.", "objectives": "- pre-proof- monocentrique- chaque dossier patient est \u00e9tudi\u00e9 par 3 cliniciens- centre sp\u00e9cialis\u00e9 dans les formes s\u00e9v\u00e8res de COVID 19- r\u00e9trospectif : certaines donn\u00e9es comme IL 6 sont manquantes\"", "methods": "Etudier les caract\u00e9ristiques et les facteurs pronostiques chez les patients \u00e2g\u00e9s avec COVID 19", "pubmed_id": "32240670", "doi": "10.1016/j.jinf.2020.03.019", "abstract": "To investigate the characteristics and prognostic factors in the elderly patients with COVID-19.\nConsecutive cases over 60 years old with COVID-19 in Renmin Hospital of Wuhan University from Jan 1 to Feb 6, 2020 were included. The primary outcomes were death and survival till March 5. Data of demographics, clinical features, comorbidities, laboratory tests and complications were collected and compared for different outcomes. Cox regression was performed for prognostic factors.\n339 patients with COVID-19 (aged 71\u00b18 years,173 females (51%)) were enrolled, including 80 (23.6%) critical, 159 severe (46.9%) and 100 moderate (29.5%) cases. Common comorbidities were hypertension (40.8%), diabetes (16.0%) and cardiovascular disease (15.7%). Common symptoms included fever (92.0%), cough (53.0%), dyspnea (40.8%) and fatigue (39.9%). Lymphocytopenia was a common laboratory finding (63.2%). Common complications included bacterial infection (42.8%), liver enzyme abnormalities (28.7%) and acute respiratory distress syndrome (21.0%). Till Mar 5, 2020, 91 cases were discharged (26.8%), 183 cases stayed in hospital (54.0%) and 65 cases (19.2%) were dead. Shorter length of stay was found for the dead compared with the survivors (5 (3-8) vs. 28 (26-29), P < 0.001). Symptoms of dyspnea (HR 2.35, P\u202f=\u202f0.001), comorbidities including cardiovascular disease (HR 1.86, P\u202f=\u202f0.031) and chronic obstructive pulmonary disease (HR 2.24, P\u202f=\u202f0.023), and acute respiratory distress syndrome (HR 29.33, P < 0.001) were strong predictors of death. And a high level of lymphocytes was predictive of better outcome (HR\u202f0.10, P < 0.001).\nHigh proportion of severe to critical cases and high fatality rate were observed in the elderly COVID-19 patients. Rapid disease progress was noted in the dead with a median survival time of 5 days after admission. Dyspnea, lymphocytopenia, comorbidities including cardiovascular disease and chronic obstructive pulmonary disease, and acute respiratory distress syndrome were predictive of poor outcome. Close monitoring and timely treatment should be performed for the elderly patients at high risk.", "topics": ["Epid\u00e9miologique", "Transversale", "G\u00e9riatrie"], "author_list": [{"id": 230, "name": "Wang L"}], "publication_date": "2020-04-02"}, {"id": 384, "slug": "cardiac-injury-is-associated-with-mortality-and-critically-ill-pneumonia-in-covi", "title": "Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l\u2019association entre d\u00e9faillance cardiaque (exprim\u00e9e par une augmentation de la troponine) et mortalit\u00e9 (crit\u00e8res de jugement principal), recours aux soins intensifs, SDRA et forme s\u00e9v\u00e8re de la maladie (crit\u00e8res de jugement secondaire) chez les patients atteints de COVID-19", "verbose_date": "20.04.2020", "authors": "Santoso A", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 162, "name": "Am J Emerg Med"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0735675720302801?token=3E6319625858F694A0FA7ABF6FF582778192BDBA631EE681ECF663C0349082AC06650A0863728F88F1798FAAF5678251", "findings": "", "take_away": "", "relevance_level": "Une l\u00e9sion cardiaque d\u00e9finie dans l'\u00e9tude comme une augmentation de la troponine est associ\u00e9e \u00e0 une augmentation de la mortalit\u00e9, de la s\u00e9v\u00e9rit\u00e9 de la maladie et du recours aux soins intensifs, sans augmentation du risque de SDRA.", "objectives": "Peu d'essais n =13, d\u00e9faillance cardiaque d\u00e9finie que par la hausse de troponine, beaucoup d\u2019essai exclus, que des \u00e9tudes observationnelles r\u00e9trospectives, biais de publication", "methods": "D\u00e9crire l\u2019association entre d\u00e9faillance cardiaque (exprim\u00e9e par une augmentation de la troponine) et mortalit\u00e9 (crit\u00e8res de jugement principal), recours aux soins intensifs, SDRA et forme s\u00e9v\u00e8re de la maladie (crit\u00e8res de jugement secondaire) chez les patients atteints de COVID-19", "pubmed_id": "32331955\n14647384\n31668196\n26030634\n19451363\n32217556\n22390970\n31986264\n32192578\n26846643", "doi": "10.1016/j.ajem.2020.04.052", "abstract": "In this systematic review and meta-analysis, we aimed to explore the association between cardiac injury and mortality, the need for intensive care unit (ICU) care, acute respiratory distress syndrome (ARDS), and severe coronavirus disease 2019 (COVID-19) in patients with COVID-19 pneumonia.\nWe performed a comprehensive literature search from several databases. Definition of cardiac injury follows that of the included studies, which includes highly sensitive cardiac troponin I (hs-cTnl) >99th percentile.The primary outcome was mortality, and the secondary outcomes were ARDS, the need for ICU care, and severe COVID-19. ARDS and severe COVID-19 were defined per the World Health Organization (WHO) interim guidance of severe acute respiratory infection (SARI) of COVID-19.\nThere were a total of 2389 patients from 13 studies. This meta-analysis showed that cardiac injury was associated with higher mortality (RR 7.95 [5.12, 12.34], p\u00a0<\u00a00.001; I\nCardiac injury is associated with mortality, need for ICU care, and severity of disease in patients with COVID-19.", "topics": ["Pronostique", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 370, "name": "Santoso A"}], "publication_date": "2020-04-20"}, {"id": 570, "slug": "gastrointestinal-and-hepatic-manifestations-of-2019-novel-coronavirus-disease-in", "title": "Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la pr\u00e9valence des manifestations gastro-intestinales et h\u00e9patiques des patients COVID-19 et explorer leur effet sur les issues cliniques.", "verbose_date": "11.05.2020", "authors": "Hajifathalian K", "specialties": [{"id": 19, "name": "H\u00e9pato-gastro-ent\u00e9rologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 21, "name": "Gastroenterology"}, "link": "http://www.sciencedirect.com/science/article/pii/S0016508520306028", "findings": "", "take_away": "", "relevance_level": "La symptomatologie gastro-intestinale \u00e9tait fr\u00e9quente ainsi que les anomalies biologiques h\u00e9patiques.\nLes anomalies biologiques h\u00e9patiques \u00e9tait associ\u00e9e \u00e0 de mauvaises issues cliniques en analyse multivari\u00e9e. Cela devrait \u00eatre pris en compte dans la stratification du risque.", "objectives": "Pre-proof, \u00e9tude de cohorte r\u00e9trospectiven=1 058, dont 291 en ambulatoire et 768 hospitalis\u00e9sDeux centres hospitaliers de ManhattanPas de d\u00e9tail sur l'analyse multivari\u00e9eCrit\u00e8res composites avec admission en soins intensifs ou d\u00e9c\u00e8s", "methods": "Etudier la pr\u00e9valence des manifestations gastro-intestinales et h\u00e9patiques des patients COVID-19 et explorer leur effet sur les issues cliniques.", "topics": ["Epid\u00e9miologique", "H\u00e9pato-gastro-ent\u00e9rologie"], "author_list": [{"id": 535, "name": "Hajifathalian K"}], "publication_date": "2020-05-11"}, {"id": 372, "slug": "personal-protective-equipment-for-preventing-highly-infectious-diseases-due-to-e", "title": "Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body fluids in healthcare staff", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer quels sont les \u00e9quipements de protection individuelle et les techniques d'habillage/d\u00e9shabillage les moins \u00e0 risque de contamination et d'infection pour les soignants ainsi que les modalit\u00e9s de formation associ\u00e9es les plus efficaces", "verbose_date": "17.04.2020", "authors": "Verbeek JH", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 136, "name": "Cochrane Database Syst Rev"}, "link": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011621.pub4/epdf/full", "findings": "", "take_away": "", "relevance_level": "Des \u00e9quipements de protection individuelles (EPI) plus protecteurs sont aussi souvent plus difficiles \u00e0 ajuster et retirer et semblent moins confortables entra\u00eenant un plus haut risque de contamination. Plusieures pistes d'am\u00e9lioration existent mais se basent sur peu d'\u00e9tudes et de faible niveau de preuve et peu de suivi. Pour les \u00e9tudes de simulation, les m\u00e9thodes \u00e0 utiliser pour provoquer l'exposition et mesurer la contamination/infection sont \u00e0 pr\u00e9ciser. Les \u00e9tudes en pratique clinique r\u00e9elle sont aussi \u00e0 favoriser.", "objectives": "- peu d'\u00e9tudes- les effets mis en \u00e9vidence sont parfois indirects- biais possibles\"", "methods": "D\u00e9terminer quels sont les \u00e9quipements de protection individuelle et les techniques d'habillage/d\u00e9shabillage les moins \u00e0 risque de contamination et d'infection pour les soignants ainsi que les modalit\u00e9s de formation associ\u00e9es les plus efficaces", "pubmed_id": "32412096", "doi": "10.1002/14651858.CD011621.pub5", "abstract": "In epidemics of highly infectious diseases, such as Ebola, severe acute respiratory syndrome (SARS), or coronavirus (COVID-19), healthcare workers (HCW) are at much greater risk of infection than the general population, due to their contact with patients' contaminated body fluids. Personal protective equipment (PPE) can reduce the risk by covering exposed body parts. It is unclear which type of PPE protects best, what is the best way to put PPE on (i.e. donning) or to remove PPE (i.e. doffing), and how to train HCWs to use PPE as instructed.\nTo evaluate which type of full-body PPE and which method of donning or doffing PPE have the least risk of contamination or infection for HCW, and which training methods increase compliance with PPE protocols.\nWe searched CENTRAL, MEDLINE, Embase and CINAHL to 20 March 2020.\nWe included all controlled studies that evaluated the effect of full-body PPE used by HCW exposed to highly infectious diseases, on the risk of infection, contamination, or noncompliance with protocols. We also included studies that compared the effect of various ways of donning or doffing PPE, and the effects of training on the same outcomes.\nTwo review authors independently selected studies, extracted data and assessed the risk of bias in included trials. We conducted random-effects meta-analyses were appropriate.\nEarlier versions of this review were published in 2016 and 2019. In this update, we included 24 studies with 2278 participants, of which 14 were randomised controlled trials (RCT), one was a quasi-RCT and nine had a non-randomised design. Eight studies compared types of PPE. Six studies evaluated adapted PPE. Eight studies compared donning and doffing processes and three studies evaluated types of training. Eighteen studies used simulated exposure with fluorescent markers or harmless microbes. In simulation studies, median contamination rates were 25% for the intervention and 67% for the control groups. Evidence for all outcomes is of very low certainty unless otherwise stated because it is based on one or two studies, the indirectness of the evidence in simulation studies and because of risk of bias. Types of PPE The use of a powered, air-purifying respirator with coverall may protect against the risk of contamination better than a N95 mask and gown (risk ratio (RR) 0.27, 95% confidence interval (CI) 0.17 to 0.43) but was more difficult to don (non-compliance: RR 7.5, 95% CI 1.81 to 31.1). In one RCT (59 participants) coveralls were more difficult to doff than isolation gowns (very low-certainty evidence). Gowns may protect better against contamination than aprons (small patches: mean difference (MD) -10.28, 95% CI -14.77 to -5.79). PPE made of more breathable material may lead to a similar number of spots on the trunk (MD 1.60, 95% CI -0.15 to 3.35) compared to more water-repellent material but may have greater user satisfaction (MD -0.46, 95% CI -0.84 to -0.08, scale of 1 to 5). According to three studies that tested more recently introduced full-body PPE ensembles, there may be no difference in contamination. Modified PPE versus standard PPE The following modifications to PPE design may lead to less contamination compared to standard PPE: sealed gown and glove combination (RR 0.27, 95% CI 0.09 to 0.78), a better fitting gown around the neck, wrists and hands (RR 0.08, 95% CI 0.01 to 0.55), a better cover of the gown-wrist interface (RR 0.45, 95% CI 0.26 to 0.78, low-certainty evidence), added tabs to grab to facilitate doffing of masks (RR 0.33, 95% CI 0.14 to 0.80) or gloves (RR 0.22, 95% CI 0.15 to 0.31). Donning and doffing Using Centers for Disease Control and Prevention (CDC) recommendations for doffing may lead to less contamination compared to no guidance (small patches: MD -5.44, 95% CI -7.43 to -3.45). One-step removal of gloves and gown may lead to less bacterial contamination (RR 0.20, 95% CI 0.05 to 0.77) but not to less fluorescent contamination (RR 0.98, 95% CI 0.75 to 1.28) than separate removal. Double-gloving may lead to less viral or bacterial contamination compared to single gloving (RR 0.34, 95% CI 0.17 to 0.66) but not to less fluorescent contamination (RR 0.98, 95% CI 0.75 to 1.28). Additional spoken instruction may lead to fewer errors in doffing (MD -0.9, 95% CI -1.4 to -0.4) and to fewer contamination spots (MD -5, 95% CI -8.08 to -1.92). Extra sanitation of gloves before doffing with quaternary ammonium or bleach may decrease contamination, but not alcohol-based hand rub. Training The use of additional computer simulation may lead to fewer errors in doffing (MD -1.2, 95% CI -1.6 to -0.7). A video lecture on donning PPE may lead to better skills scores (MD 30.70, 95% CI 20.14 to 41.26) than a traditional lecture. Face-to-face instruction may reduce noncompliance with doffing guidance more (odds ratio 0.45, 95% CI 0.21 to 0.98) than providing folders or videos only.\nWe found low- to very low-certainty evidence that covering more parts of the body leads to better protection but usually comes at the cost of more difficult donning or doffing and less user comfort. More breathable types of PPE may lead to similar contamination but may have greater user satisfaction. Modifications to PPE design, such as tabs to grab, may decrease the risk of contamination. For donning and doffing procedures, following CDC doffing guidance, a one-step glove and gown removal, double-gloving, spoken instructions during doffing, and using glove disinfection may reduce contamination and increase compliance. Face-to-face training in PPE use may reduce errors more than folder-based training. We still need RCTs of training with long-term follow-up. We need simulation studies with more participants to find out which combinations of PPE and which doffing procedure protects best. Consensus on simulation of exposure and assessment of outcome is urgently needed. We also need more real-life evidence. Therefore, the use of PPE of HCW exposed to highly infectious diseases should be registered and the HCW should be prospectively followed for their risk of infection.", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 359, "name": "Verbeek JH"}], "publication_date": "2020-04-17"}, {"id": 596, "slug": "transmission-of-sars-cov-2-in-domestic-cats", "title": "Transmission of SARS-CoV-2 in Domestic Cats", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer le risque de transmission entre f\u00e9lins apr\u00e8s inoculation du SARS-CoV-2 ", "verbose_date": "15.05.2020", "authors": "Halfmann PJ", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMc2013400?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Contamination possible entre des chats avec une infection apr\u00e8s contact direct survenant d\u00e8s J1 et disparaissant \u00e0 J5, puis d\u00e9veloppement d'une immunit\u00e9 \u00e0 J24\nN\u00e9cessit\u00e9 de mieux explorer la cha\u00eene de transmission humain-f\u00e9lin, mais pas de preuve pour le moment d'un risque d'infection du f\u00e9lin vers l'homme\nLe chien peut \u00e9galement \u00eatre touch\u00e9, comme l'a montr\u00e9 l'article de Nature du 6 mai : \"Infection of dogs with SARS-CoV-2\"", "objectives": "- Exp\u00e9rience sur 3 paires de chats- N\u00e9cessit\u00e9 plus d'exp\u00e9rimentations pour comprendre la cha\u00eene de transmission", "methods": "Evaluer le risque de transmission entre f\u00e9lins apr\u00e8s inoculation du SARS-CoV-2", "pubmed_id": "32402157", "doi": "10.1056/NEJMc2013400", "abstract": null, "topics": ["Autres", "Infectiologie"], "author_list": [{"id": 560, "name": "Halfmann PJ"}], "publication_date": "2020-05-15"}, {"id": 6, "slug": "high-flow-nasal-oxygenation-assisted-fibreoptic-tracheal-intubation-in-criticall", "title": "High-flow nasal-oxygenation-assisted fibreoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'efficacit\u00e9 et la s\u00e9curit\u00e9 de l'oxyg\u00e9noth\u00e9rapie nasale \u00e0 haut d\u00e9bit durant l'IOT par vid\u00e9o laryngoscopie chez les patients COVID-19 s\u00e9v\u00e8res VS oxyg\u00e9nation standard au masque", "verbose_date": "25.03.2020", "authors": "Wu CN", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 5, "name": "Br J Anaesth"}, "link": "https://www.dropbox.com/s/ktdc96l2ioapivh/PIIS0007091220301355.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L'oxyg\u00e9nation \u00e0 haut d\u00e9bit nasal semble int\u00e9ressante pour l'IOT sous vid\u00e9o-laryngoscope des patients COVID-19 : permet de r\u00e9duire le temps d'intubation, moins de d\u00e9saturation, moins de recours au masque facial pour d\u00e9saturation", "objectives": "Faible :1) Lettre \u00e0 l'\u00e9diteur2) Randomisation, mais technique de randomisation non d\u00e9crite / pas d'aveugle / calcul du nombre de sujet n\u00e9cessaire mais hypoth\u00e8ses non d\u00e9crites donc non argument\u00e9es", "methods": "Evaluer l'efficacit\u00e9 et la s\u00e9curit\u00e9 de l'oxyg\u00e9noth\u00e9rapie nasale \u00e0 haut d\u00e9bit durant l'IOT par vid\u00e9o laryngoscopie chez les patients COVID-19 s\u00e9v\u00e8res VS oxyg\u00e9nation standard au masque", "pubmed_id": "32200994\n26577199\n28320436\n32014114\n25578684\n30666367\n22563403\n32007143\n30336170", "doi": "10.1016/j.bja.2020.02.020", "abstract": null, "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 17, "name": "Wu CN"}], "publication_date": "2020-03-25"}, {"id": 587, "slug": "covid19-in-people-living-with-human-immunodeficiency-virus-a-case-series-of-33-p", "title": "COVID\u201019 in people living with human immunodeficiency virus: a case series of 33 patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Le Covid-19 entraine une d\u00e9ficience immune transitoire indiquant que le VIH et COVID-19 peuvent tous deux avoir des cons\u00e9quences immunologiques et cliniques d\u00e9l\u00e9t\u00e8res. D'autre part, l'immunit\u00e9 cellulaire chez les patients HIV pourrait paradoxalement \u00eatre protectrice pour une dysr\u00e9gulation s\u00e9v\u00e8re des cytokines.\r\n\r\nDans cette \u00e9tude, les auteurs d\u00e9crivent les caract\u00e9ristiques cliniques chez les patients HIV ayant une infection concomitante Covid-19.", "verbose_date": "14.05.2020", "authors": "Harter G", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 234, "name": "Infection"}, "link": "https://link.springer.com/content/pdf/10.1007/s15010-020-01438-z.pdf", "findings": "", "take_away": "", "relevance_level": "Cette \u00e9tude pr\u00e9liminaire ne d\u00e9montre pas une mortalit\u00e9 et morbidit\u00e9 excessive parmi les patients HIV symptomatiques du Covid-19 et avec une suppression virale sous traitement anti-retroviral.\nDes infections par le SRAS-CoV-2 peuvent survenir lors d'un rappel \u00e0 base de darunavir et/ou sous traitement anti-retroviral contenant du T\u00e9nofovir.\nD'autres \u00e9tudes sont n\u00e9cessaires pour \u00e9lucider tout effet protecteur ou d\u00e9l\u00e9t\u00e8re du VIH et de la th\u00e9rapie antir\u00e9trovirale.", "objectives": "- Petite \u00e9tude r\u00e9trospective et incontr\u00f4l\u00e9e avec suivi limit\u00e9.- Tous les cas \u00e9taient symptomatiques donc risque d'omission de patients asymptomatiques.- Des informations d\u00e9taill\u00e9es sur le d\u00e9but, la dur\u00e9e, l'intensit\u00e9 des sympt\u00f4mes et d\u00e9tails radiologiques des scanners \u00e9taient limit\u00e9s ou non obtenus.- D'autres donn\u00e9es \u00e9taient incompl\u00e8tes incluant les conditions de transmission et d'exposition.", "methods": "Le Covid-19 entraine une d\u00e9ficience immune transitoire indiquant que le VIH et COVID-19 peuvent tous deux avoir des cons\u00e9quences immunologiques et cliniques d\u00e9l\u00e9t\u00e8res. D'autre part, l'immunit\u00e9 cellulaire chez les patients HIV pourrait paradoxalement \u00eatre protectrice pour une dysr\u00e9gulation s\u00e9v\u00e8re des cytokines.\nDans cette \u00e9tude, les auteurs d\u00e9crivent les caract\u00e9ristiques cliniques chez les patients HIV ayant une infection concomitante Covid-19.", "pubmed_id": "32394344\n32188484\n30240813\n32037389\n32171076\n32275295\n7121484\n30414065\n32066541\n15075525\n32183930\n32289214\n32056407\n32304642\n32369286\n16095942\n32369209\n32220033\n32320003\n30650082\n25004134\n32282041\n32282022\n21342893", "doi": "10.1007/s15010-020-01438-z", "abstract": "Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population.\nRetrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome.\nThree out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir.\nThis preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART.", "topics": ["Pronostique", "Infectiologie"], "author_list": [{"id": 551, "name": "Harter G"}], "publication_date": "2020-05-14"}, {"id": 471, "slug": "association-of-inpatient-use-of-angiotensin-converting-enzyme-inhibitors-and-ang", "title": "Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer l'association entre l'utilisation \u00e0 l'h\u00f4pital des IECA / ARA II et la mortalit\u00e9 toutes causes des patients COVID-19 souffrant d'hypertension", "verbose_date": "28.04.2020", "authors": "Zhang P", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 191, "name": "Circ Res"}, "link": "https://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.120.317134", "findings": "", "take_away": "", "relevance_level": "Mortalit\u00e9 avec ajustement est plus basse dans le groupe avec IEC/ARAII que sans, avec des taux respectifs de 3,7% vs 9,8%.\r\nMais du fait des facteurs de confusion SURTOUT RETENIR que les patients HOSPITALISES n\u2019ont pas plus de SURMORTALITE avec les IEC/ARAII", "objectives": "Multicentrique mais une seule ville et que des patients hospitalis\u00e9sR\u00e9trospectifEffectif mod\u00e9r\u00e9 de patients utilisant des IEC ou ARAIIBonne m\u00e9thodologiePossible biais par le choix des crit\u00e8res d\u2019exclusionCONCLUSION : n\u00e9cessit\u00e9 d'une \u00e9tude PROSPECTIVE avec un plus grand effectif.", "methods": "D\u00e9terminer l'association entre l'utilisation \u00e0 l'h\u00f4pital des IECA / ARA II et la mortalit\u00e9 toutes causes des patients COVID-19 souffrant d'hypertension", "pubmed_id": "32302265", "doi": "10.1161/CIRCRESAHA.120.317134", "abstract": "Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension.\nTo determine the association between in-hospital use of ACEI/ARB and all-cause mortality in patients with hypertension and hospitalized due to COVID-19.\nThis retrospective, multi-center study included 1128 adult patients with hypertension diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [interquartile range, 55-68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [interquartile range 57-69]; 53.5% men), who were admitted to 9 hospitals in Hubei Province, China from December 31, 2019 to February 20, 2020. In mixed-effect Cox model treating site as a random effect, after adjusting for age, gender, comorbidities, and in-hospital medications, the detected risk for all-cause mortality was lower in the ACEI/ARB group versus the non-ACEI/ARB group (adjusted hazard ratio, 0.42 [95% CI, 0.19-0.92]; \nAmong hospitalized patients with COVID-19 and coexisting hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB nonusers. While study interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk.", "topics": ["Th\u00e9rapeutique", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 439, "name": "Zhang P"}], "publication_date": "2020-04-28"}, {"id": 157, "slug": "lianhuaqingwen-exerts-anti-viral-and-anti-inflammatory-activity-against-novel-co", "title": "Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SRAS-CoV-2)", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9montrer l'activit\u00e9 antivirale du Lianhuaqingwen contre le nouveau virus SRAS-CoV-2 et son effet potentiel dans la r\u00e9gulation de la r\u00e9ponse immunitaire", "verbose_date": "26.03.2020", "authors": "Runfeng L ", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 82, "name": "Pharmacol Res"}, "link": "https://www.dropbox.com/s/gx3tqrmshb1sp5d/1-s2.0-S104366182030743X-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le Lianhuaqingwen (LH) qui est issu de la m\u00e9decine chinoise semble diminuer la r\u00e9plication virale IN VITRO avec un profil assez proche du remdesivir en terme d'efficacit\u00e9", "objectives": "- Etude in vitro uniquement- Bas\u00e9 sur quelques exp\u00e9rimentations contr\u00f4l\u00e9es- N\u00e9cessite de conna\u00eetre la s\u00e9curit\u00e9 du produit et son efficacit\u00e9 in vivo", "methods": "D\u00e9montrer l'activit\u00e9 antivirale du Lianhuaqingwen contre le nouveau virus SRAS-CoV-2 et son effet potentiel dans la r\u00e9gulation de la r\u00e9ponse immunitaire", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 153, "name": "Runfeng L "}], "publication_date": "2020-03-26"}, {"id": 229, "slug": "isolation-and-full-length-genome-characterization-of-sars-cov-2-from-covid-19-ca", "title": "Isolation and Full-Length Genome Characterization of SARS-CoV-2 From COVID-19 Cases in Northern Italy", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "S\u00e9quen\u00e7age du g\u00e9nome du SARS-CoV-2 en Italie", "verbose_date": "02.04.2020", "authors": "Licastro D", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 111, "name": "J Virol"}, "link": "https://www.dropbox.com/s/rxb3l4gixuvdlmp/Journal%20of%20Virology-2020-Licastro-JVI.00543-20.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "1)Les 4 s\u00e9quences g\u00e9nomiques analys\u00e9es dans ce report montrent une couverture \u00e9lev\u00e9e du g\u00e9nome SARS-CoV-2.\n\r\n2)En analysant les 4 s\u00e9quences pour la variante marqueur S D614G, toutes les s\u00e9quences appartiennent \u00e0 la sous-classe racine Bavarian, qui domine en Europe, mais qui s'\u00e9loigne des s\u00e9quences chinoises connues au 16 mars 2020.\n\r\n3)Aucune preuve n'a \u00e9t\u00e9 trouv\u00e9e au cours du s\u00e9quen\u00e7age pour \u00e9tayer la d\u00e9l\u00e9tion 382-nt du g\u00e8ne ORF 8 d\u00e9termin\u00e9e \u00e0 Singapore, qui est propos\u00e9e comme variante d'un ph\u00e9notype att\u00e9nu\u00e9.", "objectives": "Case report", "methods": "S\u00e9quen\u00e7age du g\u00e9nome du SARS-CoV-2 en Italie", "pubmed_id": "32238585\n31992387\n28382917\n32022275\n32015508\n32015507\n29722887", "doi": "10.1128/JVI.00543-20", "abstract": null, "topics": ["Epid\u00e9miologique", "Virologie"], "author_list": [{"id": 219, "name": "Licastro D"}], "publication_date": "2020-04-02"}, {"id": 313, "slug": "detection-of-sars-cov-2-among-residents-and-staff-members-of-an-independent-and-", "title": "Detection of SARS-CoV-2 Among Residents and Staff Members of an Independent and Assisted Living Community for Older Adults - Seattle, Washington, 2020", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparer 3 m\u00e9thodes d'extraction de l'ARN du SARS-CoV-2 puis comparer les performances de 7 amorces/sondes et de un kit de test pour les tests par RT-PCR de d\u00e9tection du SARS-CoV-2", "verbose_date": "11.04.2020", "authors": "Roxby AC", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}, {"id": 13, "name": "G\u00e9riatrie"}, {"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 52, "name": "MMWR Morb Mortal Wkly Rep"}, "link": "https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6914e2-H.pdf", "findings": "", "take_away": "", "relevance_level": "Tous les 7 sets d'amorce/sonde test\u00e9s montrent une sp\u00e9cificit\u00e9 maximale de 100% dans cette exp\u00e9rimentation. N\u00e9anmoins les meilleures sensibilit\u00e9s/limites de d\u00e9tections sont obtenues avec les sets CDC N2 et Corman E-gene (d\u00e9tection du SARS-CoV-2 dans 10/10 \u00e9chantillons positifs et \u00e0 partir de 6 \u00e9quivalents g\u00e9nomiques d'ARN viral).", "objectives": "- exp\u00e9rimentation- peu de tests r\u00e9alis\u00e9s\"", "methods": "Comparer 3 m\u00e9thodes d'extraction de l'ARN du SARS-CoV-2 puis comparer les performances de 7 amorces/sondes et de un kit de test pour les tests par RT-PCR de d\u00e9tection du SARS-CoV-2", "pubmed_id": "32271726\n32004427\n32214083\n32240128", "doi": "10.15585/mmwr.mm6914e2", "abstract": "In the Seattle, Washington metropolitan area, where the first case of novel coronavirus 2019 disease (COVID-19) in the United States was reported (1), a community-level outbreak is ongoing with evidence of rapid spread and high morbidity and mortality among older adults in long-term care skilled nursing facilities (SNFs) (2,3). However, COVID-19 morbidity among residents of senior independent and assisted living communities, in which residents do not live as closely together as do residents in SNFs and do not require skilled nursing services, has not been described. During March 5-9, 2020, two residents of a senior independent and assisted living community in Seattle (facility 1) were hospitalized with confirmed COVID-19 infection; on March 6, social distancing and other preventive measures were implemented in the community. UW Medicine (the health system linked to the University of Washington), Public Health - Seattle & King County, and CDC conducted an investigation at the facility. On March 10, all residents and staff members at facility 1 were tested for SARS-CoV-2, the virus that causes COVID-19, and asked to complete a questionnaire about their symptoms; all residents were tested again 7 days later. Among 142 residents and staff members tested during the initial phase, three of 80 residents (3.8%) and two of 62 staff members (3.2%) had positive test results. The three residents had no symptoms at the time of testing, although one reported an earlier cough that had resolved. A fourth resident, who had negative test results in the initial phase, had positive test results 7 days later. This resident was asymptomatic on both days. Possible explanations for so few cases of COVID-19 in this residential community compared with those in several Seattle SNFs with high morbidity and mortality include more social distancing among residents and less contact with health care providers. In addition, early implementation of stringent isolation and protective measures after identification of two COVID-19 cases might have been effective in minimizing spread of the virus in this type of setting. When investigating a potential outbreak of COVID-19 in senior independent and assisted living communities, symptom screening is unlikely to be sufficient to identify all persons infected with SARS-CoV-2. Adherence to CDC guidance to prevent COVID-19 transmission in senior independent and assisted living communities (4) could be instrumental in preventing a facility outbreak.", "topics": ["Epid\u00e9miologique", "Virologie", "Infectiologie", "G\u00e9riatrie", "Hygi\u00e8ne"], "author_list": [{"id": 300, "name": "Roxby AC"}], "publication_date": "2020-04-11"}, {"id": 556, "slug": "tocilizumab-therapy-reduced-intensive-care-unit-admissions-andor-mortality-in-co", "title": "Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparer l'\u00e9volution de la COVID-19 entre patients trait\u00e9s et non trait\u00e9s par tocilizumab.", "verbose_date": "09.05.2020", "authors": "Klopfenstein T", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 219, "name": "M\u00e9decine et Maladies Infectieuses"}, "link": "https://www.dropbox.com/s/2gp0lyzva0sefjw/1-s2.0-S0399077X20301293-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Cette \u00e9tude montre une possible efficacit\u00e9 du tocilizumab pour am\u00e9liorer l'\u00e9volution de la COVID-19 chez des patients hospitalis\u00e9s et oxyg\u00e9norequ\u00e9rants en diminuant le nombre d'admissions en soins intensifs ainsi que le nombre de d\u00e9c\u00e8s. N\u00e9anmoins aucune recommandation ne peut \u00eatre tir\u00e9e de cette seule \u00e9tude et ce m\u00e9dicament devrait \u00eatre envisag\u00e9 dans des \u00e9tudes de meilleur niveau de preuve.", "objectives": "- Etude r\u00e9trospective- Faible effectif- Pas d'information concernant la comparabilit\u00e9 des groupes en terme d'antiviral du traitement dit \"standard\" re\u00e7u : y a-t-il une m\u00eame utilisation de l'hydroxychloroquine et du lopinavir/ritonavir entre les deux groupes?", "methods": "Comparer l'\u00e9volution de la COVID-19 entre patients trait\u00e9s et non trait\u00e9s par tocilizumab.", "pubmed_id": "32387320\n32234467\n32171076\n32197108\n32241792\n32243501", "doi": "10.1016/j.medmal.2020.05.001", "abstract": "No therapy has yet proven effective in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.\nWe conducted a retrospective case-control study in the Nord Franche-Comt\u00e9 Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: death and/or ICU admissions.\nPatients with TCZ (n=20) had a higher Charlson comorbidity index (5.3 [\u00b12.4] vs 3.4 [\u00b12.6], P=0.014), presented with more severe forms (higher level of oxygen therapy at 13L/min vs 6L/min, P<0.001), and had poorer biological findings (severe lymphopenia: 676/mm\nDespite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 522, "name": "Klopfenstein T"}], "publication_date": "2020-05-09"}, {"id": 121, "slug": "clinical-characteristics-of-coronavirus-disease-2019-in-china", "title": "Clinical Characteristics of Coronavirus Disease 2019 in China", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Description des caract\u00e9tistiques cliniques des patients atteints par le COVID-19 \u00e0 Wuhan", "verbose_date": "28.02.2020", "authors": "Guan WJ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.dropbox.com/s/crvl0mtzn6b7o4y/nejmoa2002032.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "M\u00e9diane d'\u00e2ge des patients infect\u00e9s de 47 ans, avec 5% de formes s\u00e9v\u00e8res et 2,3% d'intubation Fi\u00e8vre dans moins de la moiti\u00e9 des cas non hospitalis\u00e9s et toux pr\u00e9sente dans les 2/3 des casP\u00e9riode d'incubation m\u00e9diane de 4 jours (IQR: 2-7)A la radio : opacit\u00e9 en verre d\u00e9poli bilat\u00e9rale dans la moiti\u00e9 des cas, mais 18% de cas sans signes radio", "objectives": "Interm\u00e9diaire :1) Etude \u00e9pid\u00e9miologique de cohorte bien conduite sur de nombreux centres chinois avec nombreuses caract\u00e9ristiques \u00e9tudi\u00e9s2) Etude uniquement descriptive", "methods": "Description des caract\u00e9tistiques cliniques des patients atteints par le COVID-19 \u00e0 Wuhan", "pubmed_id": "32109013", "doi": "10.1056/NEJMoa2002032", "abstract": "Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in Wuhan city and rapidly spread throughout China, data have been needed on the clinical characteristics of the affected patients.\nWe extracted data regarding 1099 patients with laboratory-confirmed Covid-19 from 552 hospitals in 30 provinces, autonomous regions, and municipalities in mainland China through January 29, 2020. The primary composite end point was admission to an intensive care unit (ICU), the use of mechanical ventilation, or death.\nThe median age of the patients was 47 years; 41.9% of the patients were female. The primary composite end point occurred in 67 patients (6.1%), including 5.0% who were admitted to the ICU, 2.3% who underwent invasive mechanical ventilation, and 1.4% who died. Only 1.9% of the patients had a history of direct contact with wildlife. Among nonresidents of Wuhan, 72.3% had contact with residents of Wuhan, including 31.3% who had visited the city. The most common symptoms were fever (43.8% on admission and 88.7% during hospitalization) and cough (67.8%). Diarrhea was uncommon (3.8%). The median incubation period was 4 days (interquartile range, 2 to 7). On admission, ground-glass opacity was the most common radiologic finding on chest computed tomography (CT) (56.4%). No radiographic or CT abnormality was found in 157 of 877 patients (17.9%) with nonsevere disease and in 5 of 173 patients (2.9%) with severe disease. Lymphocytopenia was present in 83.2% of the patients on admission.\nDuring the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness. Patients often presented without fever, and many did not have abnormal radiologic findings. (Funded by the National Health Commission of China and others.).", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 127, "name": "Guan WJ"}], "publication_date": "2020-02-28"}, {"id": 50, "slug": "expert-consensus-for-managing-pregnant-women-and-neonates-born-to-mothers-with-s", "title": "Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection.", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Recommandations pour la prise en charge des femmes enceintes et des nouveau-n\u00e9s de m\u00e8res atteintes d'une infection COVID-19 confirm\u00e9e ou suspect\u00e9e", "verbose_date": "20.03.2020", "authors": "Chen D", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 7, "name": "Recommandations", "icon": "icon-reco"}, "journal": {"id": 44, "name": "Int J Gynaecol Obstet"}, "link": "https://www.dropbox.com/s/0d6brjwnesfjtzv/ijgo.13146.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "1) Les patientes COVID-19 suspect\u00e9es ou confirm\u00e9es doivent \u00eatre isol\u00e9es dans des chambres \u00e0 pression n\u00e9gative individuelles. Pr\u00e9voir des salles d'accouchement d\u00e9di\u00e9es.2) Traitement antibiotique \u00e0 large spectre pour pneumonie acquise dans la communaut\u00e9 en attente de diagnostic COVID-19+. Traitement antiviraux: Alpha-interf\u00e9ron par inhalation ou Lopinavir/Ritonavir.3) Radio thoracique et scanner pour le diagnostic de COVID-19 ne sont pas contre-indiqu\u00e9s pendant la grossesse.4) Assurer SpO2 maternelle >95%: oxyg\u00e9noth\u00e9rapie pr\u00e9coce, ECMO non recommand\u00e9e.5) Surveillance du rythme cardiaque f\u0153tal/\u00e9cographies. Amniocent\u00e8se n'est pas recommand\u00e9e.6) COVID-19 n'est pas une indication pour anticiper l'accouchement.7)) Modalit\u00e9s d'accouchement bas\u00e9es sur indications obst\u00e9tricales. Anesth\u00e9sie g\u00e9n\u00e9rale ou l'anesth\u00e9sie p\u00e9ridurale \u00e9tablie par l'anesth\u00e9siste pour le cas sp\u00e9cifique. Si intubation n\u00e9cessaire, pr\u00e9f\u00e9rez intubation endotrach\u00e9ale pendant l'accouchement par c\u00e9sarienne. 8) Consid\u00e9rer le placenta comme d\u00e9chet biologique dangereux.9)Prise en charge nouveau-n\u00e9: ne pas retarder le clampage du cordon ombilical. Isoler le nouveau-n\u00e9 pendant 14 jours (s\u00e9par\u00e9 de la m\u00e8re)10) Allaitement maternel n'est pas recommand\u00e9 (tirages de lait/ soutien psychologique de la m\u00e8re)", "objectives": "Faible", "methods": "Recommandations pour la prise en charge des femmes enceintes et des nouveau-n\u00e9s de m\u00e8res atteintes d'une infection COVID-19 confirm\u00e9e ou suspect\u00e9e", "pubmed_id": "32196655", "doi": "10.1002/ijgo.13146", "abstract": "To provide clinical management guidelines for novel coronavirus (COVID-19) in pregnancy.\nOn February 5, 2020, a multidisciplinary teleconference comprising Chinese physicians and researchers was held and medical management strategies of COVID-19 infection in pregnancy were discussed.\nTen key recommendations were provided for the management of COVID-19 infections in pregnancy.\nCurrently, there is no clear evidence regarding optimal delivery timing, the safety of vaginal delivery, or whether cesarean delivery prevents vertical transmission at the time of delivery; therefore, route of delivery and delivery timing should be individualized based on obstetrical indications and maternal-fetal status.", "topics": ["Recommandations", "P\u00e9diatrie"], "author_list": [{"id": 60, "name": "Chen D"}], "publication_date": "2020-03-20"}, {"id": 60, "slug": "a-doubt-of-multiple-introduction-of-sars-cov-2-in-italy-a-preliminary-overview", "title": "A doubt of multiple introduction of SARS-CoV-2 in Italy: a preliminary overview", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier les voies de transmission du SARS-CoV-2 en Italie par la g\u00e9nomique", "verbose_date": "19.03.2020", "authors": "Giovanetti M", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://www.dropbox.com/s/21gkfhu4yu2jk77/jmv.25773.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La circulation du SARS-CoV-2 aurait d\u00e9but\u00e9 par l'introduction du virus depuis 2 pays (Chine et Allemagne) suivi par une transmission autochtone en Italie.Les donn\u00e9es g\u00e9nomiques en temps r\u00e9el pourraient \u00eatre employ\u00e9es pour aider \u00e0 surveiller et \u00e0 comprendre l'\u00e9closion de nouveaux pathogenes \u00e9mergents", "objectives": "Faible :Etude g\u00e9nomique pr\u00e9liminaire", "methods": "Etudier les voies de transmission du SARS-CoV-2 en Italie par la g\u00e9nomique", "pubmed_id": "32190908\n31994738\n31978945\n23075143\n31133031\n31502247\n28968734\n15577937\n30531947\n25371430", "doi": "10.1002/jmv.25773", "abstract": "The emergence of the novel betacoronavirus, recently renamed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised serious concerns due to the virus's rapid dissemination worldwide. Nevertheless, there is limited information about the genomic epidemiology of SARS-CoV-2 circulating in Italy from surveillance studies. The shortage of complete genomic sequences available impairs our understanding of the SARS-CoV-2 introduction and establishment in the country. To better understand its dynamics in Italy, we analyzed complete genomes of SARS-CoV-2 isolates, obtained directly from clinical samples. Our phylogenetic reconstructions suggest possible multiple introduction of SARS-CoV-2. Continued genomic surveillance strategies are needed to improve monitoring and understanding of the current\u00a0SARS-CoV-2 epidemics, which might help to attenuate public health impact of infectious diseases.", "topics": ["Epid\u00e9miologique", "Virologie"], "author_list": [{"id": 70, "name": "Giovanetti M"}], "publication_date": "2020-03-19"}, {"id": 289, "slug": "considerations-for-drug-interactions-on-qtc-in-exploratory-covid-19-coronavirus-", "title": "Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Consid\u00e9rations sur les modifications de l'intervalle QT li\u00e9es au traitement combin\u00e9 de l'hydroxychloroquine et de l'azithromycine chez les patients COVID-19.", "verbose_date": "09.04.2020", "authors": "Roden DM", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 9, "name": "Circulation"}, "link": "https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.047521", "findings": "", "take_away": "", "relevance_level": "Chez les patients COVID-19 prenant simultan\u00e9ment de l'hydroxychloroquine et de l'azithromycine, il est n\u00e9cessaire de minimiser le risque d'arythmie (effets inconnus sur l'intervalle QT pour la combinaison des deux m\u00e9dicaments).\r\nMesures visant \u00e0 minimiser le risque d'arythmie :\u00a0\r\n1) \u00e9lectrocardiogramme et surveillance de l'intervalle QT : arr\u00eat du traitement si l'intervalle QTc > 500 msec ou chez les sujets pr\u00e9sentant un syndrome du QT long.\r\n2) \u00e9viter l'administration d'autres agents responsables de l'allongement de l'intervalle QT.\r\n3) correction de l'hypokali\u00e9mie jusqu'\u00e0 des valeurs >4 mEq/L et de l'hypomagn\u00e9s\u00e9mie jusqu'\u00e0 des valeurs >2mg/dL.", "objectives": "1) recommandation des experts2) aucune \u00e9tude sur l'utilisation combin\u00e9e de l'hydroxychloroquine et de l'azithromycine\"", "methods": "Consid\u00e9rations sur les modifications de l'intervalle QT li\u00e9es au traitement combin\u00e9 de l'hydroxychloroquine et de l'azithromycine chez les patients COVID-19.", "pubmed_id": "32267732", "doi": "10.1161/CIRCULATIONAHA.120.047521", "abstract": null, "topics": ["Th\u00e9rapeutique", "Transversale", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 277, "name": "Roden DM"}], "publication_date": "2020-04-09"}, {"id": 576, "slug": "qt-prolongation-torsades-de-pointes-and-sudden-death-with-short-courses-of-chlor", "title": "QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier l'effet arythmog\u00e9nique de la chloroquine et de l'hydroxychloroquine \u00e0 court terme chez les patients Covid-19.", "verbose_date": "12.05.2020", "authors": "Jankelson L", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 216, "name": "Heart Rythm"}, "link": "https://www.heartrhythmjournal.com/article/S1547-5271(20)30431-8/pdf", "findings": "", "take_away": "", "relevance_level": "Une part non n\u00e9gligeable des patients COVID-19 trait\u00e9s par hydroxychloroquine d\u00e9veloppent un allongement du segment QT.\r\nCertains patients Covid-19 ayant re\u00e7u de fortes doses de chloroquine ont d\u00e9velopp\u00e9 une arythmie ventriculaire.", "objectives": "Faible- Recherche large de la litt\u00e9rature, non limit\u00e9e \u00e0 l'anglais plus litt\u00e9rature industrielle-L'une des plus importantes \u00e9tudes incluses avait un suivi non clair avec de possibles perdus de vue-Biais de publication et de d\u00e9claration pouvant sous-estimer le risque-La plupart des donn\u00e9es issues de pr\u00e9-prints : possibles biais de ces \u00e9tudes", "methods": "Etudier l'effet arythmog\u00e9nique de la chloroquine et de l'hydroxychloroquine\u00a0\u00e0 court terme chez les patients Covid-19.", "pubmed_id": "32438018\n32187464\n17646028\n30400791\n14999113\n20185054\n32075761\n26660066\n21079043\n27212965\n32391667", "doi": "10.1016/j.hrthm.2020.05.008", "abstract": "Chloroquine and hydroxychloroquine are now being widely used for treatment of COVID-19. Both medications prolong the QT interval and accordingly may put patients at increased risk for torsades de pointes and sudden death. Published guidance documents vary in their recommendations for monitoring and managing these potential adverse effects. Accordingly, we set out to conduct a systematic review of the arrhythmogenic effect of short courses of chloroquine or hydroxychloroquine. We searched on MEDLINE and Embase, as well as in the gray literature up to April 17, 2020, for the risk of QT prolongation, torsades, ventricular arrhythmia, and sudden death with short-term chloroquine and hydroxychloroquine usage. This search resulted in 390 unique records, of which 14 were ultimately selected for qualitative synthesis and which included data on 1515 COVID-19 patients. Approximately 10% of COVID-19 patients treated with these drugs developed QT prolongation. We found evidence of ventricular arrhythmia in 2 COVID-19 patients from a group of 28 treated with high-dose chloroquine. Limitation of these results are unclear follow-up and possible publication/reporting bias, but there is compelling evidence that chloroquine and hydroxychloroquine induce significant QT-interval prolongation and potentially increase the risk of arrhythmia. Daily electrocardiographic monitoring and other risk mitigation strategies should be considered in order to prevent possible harms from what is currently an unproven therapy.", "topics": ["Th\u00e9rapeutique", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 540, "name": "Jankelson L"}], "publication_date": "2020-05-12"}, {"id": 540, "slug": "development-and-initial-validation-of-the-covid-stress-scales", "title": "Development and Initial Validation of the COVID Stress Scales", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9velopper et \u00e9valuer des \u00e9chelles de mesure des troubles psychiques associ\u00e9s \u00e0 la pand\u00e9mie de COVID-19 et plus largement \u00e0 de futures pand\u00e9mies : les COVID-19 Stress Scales.", "verbose_date": "06.05.2020", "authors": "Taylor S", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 214, "name": "J Anxiety Dis"}, "link": "https://www.dropbox.com/s/fta92z1pocdnfxs/1-s2.0-S0887618520300463-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les COVID-19 Stress Scales semblent \u00eatre utiles pour \u00e9tudier les troubles psychiques associ\u00e9s \u00e0 la COVID-19 et \u00e0 de futures pand\u00e9mies. Elles pourraient \u00e9galement aider \u00e0 identifier les sujets n\u00e9cessitant une aide psychologique et\u00a0les cibles d'interventions de sant\u00e9 publique. N\u00e9anmoins, ces \u00e9chelles devraient faire l'objet de validations suppl\u00e9mentaires dans d'autres populations.", "objectives": "- Etude pre-proof (-)- Bas\u00e9e sur un questionnaire auto-administr\u00e9 en ligne (-)- Echelle cr\u00e9\u00e9e \u00e0 partir de deux populations proches g\u00e9ographiquement et relativement proches culturellement (-)- Ajustement d'\u00e9chelles existantes (-)- Correction du risque alpha (+)- Pas d'\u00e9valuation de la validit\u00e9 via l'utilisation de diagnostics du DSM-5 par exemple (-)- Pas de comparaison \u00e0 d'autres mesures de l'anxi\u00e9t\u00e9 associ\u00e9e \u00e0 la COVID-19 alors non publi\u00e9es (-)", "methods": "D\u00e9velopper et \u00e9valuer des \u00e9chelles de mesure des troubles psychiques associ\u00e9s \u00e0 la pand\u00e9mie de COVID-19 et plus largement \u00e0 de futures pand\u00e9mies : les COVID-19 Stress Scales.", "pubmed_id": "32408047\n28029643\n32226353\n15697045\n32442880\n13813058\n19616305\n14992204\n15324539\n32214558\n19996233\n29902711\n12501574\n23129524\n32215365\n16621437\n32078967\n32155789\n17563199\n12171378\n25138528\n32179380\n19574308", "doi": "10.1016/j.janxdis.2020.102232", "abstract": "Research and clinical observations suggest that during times of pandemic many people exhibit stress- or anxiety-related responses that include fear of becoming infected, fear of coming into contact with possibly contaminated objects or surfaces, fear of foreigners who might be carrying infection (i.e., disease-related xenophobia), fear of the socio-economic consequences of the pandemic, compulsive checking and reassurance-seeking regarding possible pandemic-related threats, and traumatic stress symptoms about the pandemic (e.g., nightmares, intrusive thoughts). We developed the 36-item COVID Stress Scales (CSS) to measure these features, as they pertain to COVID-19. The CSS were developed to better understand and assess COVID-19-related distress. The scales were intentionally designed so they could be readily adapted for future pandemics. The CSS were developed and initially validated in population-representative samples from Canada (N = 3479) and the United States (N = 3375). A stable 5-factor solution was identified, corresponding to scales assessing COVID-related stress and anxiety symptoms: (1) Danger and contamination fears, (2) fears about economic consequences, (3) xenophobia, (4) compulsive checking and reassurance seeking, and (5) traumatic stress symptoms about COVID-19. The scales performed well on various indices of reliability and validity. The scales were intercorrelated, providing evidence of a COVID Stress Syndrome. The scales offer promise as tools for better understanding the distress associated with COVID-19 and for identifying people in need of mental health services.", "topics": ["Diagnostique", "Psychiatrie"], "author_list": [{"id": 506, "name": "Taylor S"}], "publication_date": "2020-05-06"}, {"id": 567, "slug": "covid-19-pcr-screening-of-asymptomatic-health-care-workers-at-london-hospital", "title": "COVID-19: PCR screening of asymptomatic health-care workers at London hospital", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier le taux de personnes positives au SARS-Cov-2 parmi les professionnels de sant\u00e9 asymptomatiques d'un groupe d'h\u00f4pitaux londoniens.\r\n\r\n ", "verbose_date": "11.05.2020", "authors": "Treibel T", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 70, "name": "The Lancet"}, "link": "https://doi.org/10.1016/S0140-6736(20)31100-4", "findings": "", "take_away": "", "relevance_level": "Le taux d'infection des professionnels de sant\u00e9 asymptomatiques a connu un pic \u00e0 7,1% au d\u00e9but du confinement puis s'est divis\u00e9 par 4 apr\u00e8s 4 semaines.", "objectives": "Faible : -Correspondance-Nombre d'inclus faible-Biais de s\u00e9lection", "methods": "Etudier le taux de personnes positives au SARS-Cov-2 parmi les professionnels de sant\u00e9 asymptomatiques d'un groupe d'h\u00f4pitaux londoniens.", "pubmed_id": "32401714", "doi": "10.1016/S0140-6736(20)31100-4", "abstract": null, "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 532, "name": "Treibel T"}], "publication_date": "2020-05-11"}, {"id": 440, "slug": "coronavirus-disease-2019-covid-19-in-pregnant-women-a-report-based-on-116-cases", "title": "Coronavirus disease 2019 (COVID-19) in pregnant women: A report based on 116 cases", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Rapporter le devenir maternel et n\u00e9onatal chez des femmes atteintes par le COVID-19 pendant leur grossesse", "verbose_date": "24.04.2020", "authors": "Yan J", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 175, "name": "Am J Obstet Gynecol"}, "link": "https://www.ajog.org/article/S0002-9378(20)30462-2/pdf", "findings": "", "take_away": "", "relevance_level": "Les caract\u00e9ristiques cliniques \u00e9taient similaires ici \u00e0 la population g\u00e9n\u00e9rale. Taux de pneumonies s\u00e9v\u00e8res identiques \u00e0 la population g\u00e9n\u00e9rale dans cette s\u00e9rie de cas. Le SARS-CoV-2 ne semble pas associ\u00e9 \u00e0 un risque accru d'avortement spontan\u00e9 ou d'accouchement pr\u00e9matur\u00e9 spontan\u00e9 selon les auteurs. Pas d'\u00e9vidence pour une transmission verticale lorsque l'infection se manifeste au troisi\u00e8me trimestre de la grossesse selon les auteurs.", "objectives": "1) Pre-proof2) Relecture des donn\u00e9es collect\u00e9es par deux investigateurs et en cas de d\u00e9saccord, consultation d'un troisi\u00e8me investigateur.3) 44% des cas \u00e9tudi\u00e9s n'ont pas \u00e9t\u00e9 confirm\u00e9s en RT-PCR4) Plus d'un tiers des patientes \u00e9taient encore hospitalis\u00e9es \u00e0 la date de point\"", "methods": "Rapporter le devenir maternel et n\u00e9onatal chez des femmes atteintes par le COVID-19 pendant leur grossesse", "topics": ["Epid\u00e9miologique", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 416, "name": "Yan J"}], "publication_date": "2020-04-24"}, {"id": 110, "slug": "prevalence-of-comorbidities-in-the-novel-wuhan-coronavirus-covid-19-infection-a-", "title": "Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematicreview and meta-analysis", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "M\u00e9ta-analyse 1. des facteurs de comorbidit\u00e9s pr\u00e9sents chez les patients Covid + \u00e0 Wuhan et 2. des diff\u00e9rences entre les patients s\u00e9veres ou non.", "verbose_date": "12.03.2020", "authors": "Yang J", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.dropbox.com/s/oydjhces1rcbs2y/1-s2.0-S1201971220301363-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Hypertension facteur de risque des cas graves.", "objectives": "Interm\u00e9diaire:-preproof-m\u00e9ta-analyse donc large \u00e9chantillon", "methods": "M\u00e9ta-analyse 1. des facteurs de comorbidit\u00e9s pr\u00e9sents chez les patients Covid + \u00e0 Wuhan et 2. des diff\u00e9rences entre les patients s\u00e9veres ou non.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 116, "name": "Yang J"}], "publication_date": "2020-03-12"}, {"id": 346, "slug": "spread-of-sars-cov-2-in-the-icelandic-population", "title": "Spread of SARS-CoV-2 in the Icelandic Population", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9crire les r\u00e9sultats de 3 strat\u00e9gies de d\u00e9pistage des personnes infect\u00e9es par le SARS-COV-2 en population pour d\u00e9crire la population infect\u00e9e et s\u00e9quencer le g\u00e9nome du SARS-COV-2 des personnes positives pour d\u00e9terminer les mutations du virus ainsi que sa diffusion", "verbose_date": "16.04.2020", "authors": "Gudbjartsson DF", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2006100?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude en population, les enfants de moins de 10 ans et les femmes ont une incidence plus faible d'infection par le SARS-COV-2 que les adolescents, adultes ou que les hommes.\r\nLa proportion de personnes infect\u00e9es n'a pas vari\u00e9 durant la p\u00e9riode de d\u00e9pistage. Seulement 13,3% des personnes \u00e0 risque ont \u00e9t\u00e9 test\u00e9es positives au SARS-CoV-2 et 0,8% de la population g\u00e9n\u00e9rale.", "objectives": "-D\u00e9pistage cons\u00e9quent en population g\u00e9n\u00e9rale (6% de la population du pays) mais-Biais de s\u00e9lection : volontariat (34 % de r\u00e9ponse des personnes invit\u00e9es) + la localisation du laboratoire de pr\u00e9l\u00e8vement \u00e0 Reykjavik : repr\u00e9sentation de la population de la capitale.-Pas de discussion autour des performances du test de d\u00e9pistage\"", "methods": "D\u00e9crire les r\u00e9sultats de 3 strat\u00e9gies de d\u00e9pistage des personnes infect\u00e9es par le SARS-COV-2 en population pour d\u00e9crire la population infect\u00e9e et s\u00e9quencer le g\u00e9nome du SARS-COV-2 des personnes positives pour d\u00e9terminer les mutations du virus ainsi que sa diffusion", "pubmed_id": "32289214", "doi": "10.1056/NEJMoa2006100", "abstract": "During the current worldwide pandemic, coronavirus disease 2019 (Covid-19) was first diagnosed in Iceland at the end of February. However, data are limited on how SARS-CoV-2, the virus that causes Covid-19, enters and spreads in a population.\nWe targeted testing to persons living in Iceland who were at high risk for infection (mainly those who were symptomatic, had recently traveled to high-risk countries, or had contact with infected persons). We also carried out population screening using two strategies: issuing an open invitation to 10,797 persons and sending random invitations to 2283 persons. We sequenced SARS-CoV-2 from 643 samples.\nAs of April 4, a total of 1221 of 9199 persons (13.3%) who were recruited for targeted testing had positive results for infection with SARS-CoV-2. Of those tested in the general population, 87 (0.8%) in the open-invitation screening and 13 (0.6%) in the random-population screening tested positive for the virus. In total, 6% of the population was screened. Most persons in the targeted-testing group who received positive tests early in the study had recently traveled internationally, in contrast to those who tested positive later in the study. Children under 10 years of age were less likely to receive a positive result than were persons 10 years of age or older, with percentages of 6.7% and 13.7%, respectively, for targeted testing; in the population screening, no child under 10 years of age had a positive result, as compared with 0.8% of those 10 years of age or older. Fewer females than males received positive results both in targeted testing (11.0% vs. 16.7%) and in population screening (0.6% vs. 0.9%). The haplotypes of the sequenced SARS-CoV-2 viruses were diverse and changed over time. The percentage of infected participants that was determined through population screening remained stable for the 20-day duration of screening.\nIn a population-based study in Iceland, children under 10 years of age and females had a lower incidence of SARS-CoV-2 infection than adolescents or adults and males. The proportion of infected persons identified through population screening did not change substantially during the screening period, which was consistent with a beneficial effect of containment efforts. (Funded by deCODE Genetics-Amgen.).", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 332, "name": "Gudbjartsson DF"}], "publication_date": "2020-04-16"}, {"id": 651, "slug": "ct-in-coronavirus-disease-2019-covid-19-a-systematic-review-of-chest-ct-findings", "title": "CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Identifier les l\u00e9sions scanographiques du COVID-19 et leur \u00e9volution temporelle.", "verbose_date": "03.06.2020", "authors": "Ojha V", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 155, "name": "Eur Radiol"}, "link": "https://link.springer.com/content/pdf/10.1007/s00330-020-06975-7.pdf", "findings": "", "take_away": "", "relevance_level": "Les l\u00e9sions scanographiques les plus observ\u00e9es chez les patients COVID-19 sont initialement des opacit\u00e9s en verre d\u00e9poli, susceptibles de s'accompagner par la suite de condensations. Ces l\u00e9sions sont majoritairement bilat\u00e9rales et p\u00e9riph\u00e9riques.\nLes atteintes semblent plus fr\u00e9quemment \u00e9tendues et multilobaires chez les patients au-del\u00e0 de 50-60 ans ou pr\u00e9sentant des formes graves.", "objectives": "Revue de la litt\u00e9rature \u00e0 consid\u00e9rer avec pr\u00e9caution!\nForces :- Revue syst\u00e9matique (anglophone uniquement) de la litt\u00e9rature.- Nombre d'\u00e9tudes incluses et population totale importantes.\nFaiblesses :- Exclusion probable d'un nombre non n\u00e9gligeable d'articles chinois non r\u00e9dig\u00e9s en anglais. - Les articles inclus sont uniquement des case series, pas de groupe contr\u00f4le. - Les articles inclus sont sujets \u00e0 de probables biais de classement des l\u00e9sions dus \u00e0 la subjectivit\u00e9 de l'interpr\u00e9tation et de la description de certains signes radiologiques. - Certains signes radiologiques ne semblent avoir \u00e9t\u00e9 recherch\u00e9s que dans un nombre limit\u00e9 d'\u00e9tudes avec une expression en % du nombre de scanners r\u00e9alis\u00e9s pouvant s'av\u00e9rer trompeuse (se basant sur une faible proportion du nombre total de scanners inclus). - Probable h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 forte des \u00e9tudes incluses (non \u00e9valu\u00e9e par les auteurs). - R\u00e9sultats de l'\u00e9valuation de la qualit\u00e9 des \u00e9tudes non donn\u00e9es.", "methods": "Identifier les l\u00e9sions scanographiques du COVID-19 et leur \u00e9volution temporelle.", "pubmed_id": "32474632\n32033513\n32204990\n32269085\n32229322\n18195376\n32125873\n32091414\n32232648\n32107577\n32085846\n32017661\n32246819\n19621072\n31978945\n32105637\n32077789\n32027573\n32055945\n32109443\n32100485\n32193037", "doi": "10.1007/s00330-020-06975-7", "abstract": "The objective of this systematic review was to evaluate the key imaging manifestations of COVID-19 on chest CT in adult patients by providing a comprehensive review of the published literature.\nWe performed a systematic literature search from the PubMed, Google Scholar, Embase, and WHO databases for studies mentioning the chest CT imaging findings of adult COVID-19 patients.\nA total of 45 studies comprising 4410 patients were included. Ground glass opacities (GGO), in isolation (50.2%) or coexisting with consolidations (44.2%), were the most common lesions. Distribution of GGOs was most commonly bilateral, peripheral/subpleural, and posterior with predilection for lower lobes. Common ancillary findings included pulmonary vascular enlargement (64%), intralobular septal thickening (60%), adjacent pleural thickening (41.7%), air bronchograms (41.2%), subpleural lines, crazy paving, bronchus distortion, bronchiectasis, and interlobular septal thickening. CT in early follow-up period generally showed an increase in size, number, and density of GGOs, with progression into mixed areas of GGOs plus consolidations and crazy paving, peaking at 10-11\u00a0days, before gradually resolving or persisting as patchy fibrosis. While younger adults more commonly had GGOs, extensive/multilobar involvement with consolidations was prevalent in the older population and those with severe disease.\nThis review describes the imaging features for diagnosis, stratification, and follow-up of COVID-19 patients. The most common CT manifestations are bilateral, peripheral/subpleural, posterior GGOs with or without consolidations with a lower lobe predominance. It is pertinent to be familiar with the various imaging findings to positively impact the management of these patients.\n\u2022 Ground glass opacities (GGOs), whether isolated or coexisting with consolidations, in bilateral and subpleural distribution, are the most prevalent chest CT findings in adult COVID-19 patients. \u2022 Follow-up CT shows a progression of GGOs into a mixed pattern, reaching a peak at 10-11\u00a0days, before gradually resolving or persisting as patchy fibrosis. \u2022 Younger people tend to have more GGOs. Older or sicker people tend to have more extensive involvement with consolidations.", "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 612, "name": "Ojha V"}], "publication_date": "2020-06-03"}, {"id": 523, "slug": "clinical-course-and-outcome-of-107-patients-infected-with-the-novel-coronavirus-", "title": "Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques d\u00e9mographiques, \u00e9pid\u00e9miologiques et paracliniques de patients hospitalis\u00e9s pour COVID-19 dans deux h\u00f4pitaux \u00e0 Wuhan ainsi que leur \u00e9volution et mettre en \u00e9vidence des facteurs de risque de d\u00e9c\u00e8s.", "verbose_date": "04.05.2020", "authors": "Wang D", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 59, "name": "Crit Care"}, "link": "https://ccforum.biomedcentral.com/track/pdf/10.1186/s13054-020-02895-6", "findings": "", "take_away": "", "relevance_level": "On peut faire l'hypoth\u00e8se\u00a0que l'\u00e9volution de la maladie se fait en 3 \u00e9tapes :\u00a0\r\n1\u00e8re semaine avec sympt\u00f4mes :\u00a0mise en \u00e9vidence\u00a0du g\u00e9nome viral (NAAT test) ce qui peut sugg\u00e9rer que la r\u00e9plication virale est corr\u00e9l\u00e9e \u00e0 la pr\u00e9sence des sympt\u00f4mes. Chez les\u00a0non-survivants, la r\u00e9ponse immunitaire syst\u00e9mique peut se manifester par des sympt\u00f4mes accrus et des anomalies de l'h\u00e9mogramme.\u00a0Durant la 2\u00e8me semaine le g\u00e9nome viral devient ind\u00e9tectable avec un d\u00e9lai d'environ 13 jours chez les survivants, en parall\u00e8le de la r\u00e9solution des sympt\u00f4mes\u00a0et des troubles de l'h\u00e9mogramme, avec une persistance tardive de baisse des lymphocytes\u00a0qui pourraient\u00a0\u00eatre une cible virale privil\u00e9gi\u00e9e. Chez les non-survivants, la d\u00e9faillance multi-visc\u00e9rale commence au cours de cette deuxi\u00e8me semaine et se poursuit durant la troisi\u00e8me semaine avec des complications telles que le SDRA r\u00e9fractaire, les \u00e9tats de choc, l'IRA, la cardiopathie aigue et la coagulopathie, alors que le tableau clinico-biologique se normalise pour les survivants.\u00a0\r\nLes deux facteurs de risque de mortalit\u00e9 identifi\u00e9s dans cette \u00e9tude sont l'\u00e2ge \u00e9lev\u00e9 et le sexe masculin.", "objectives": "Etude r\u00e9trospective, de faible effectif, avec seulement 2 centres dans la m\u00eame r\u00e9gion, quelques donn\u00e9es paracliniques manquantes.", "methods": "D\u00e9crire les caract\u00e9ristiques d\u00e9mographiques, \u00e9pid\u00e9miologiques et paracliniques de patients hospitalis\u00e9s pour COVID-19 dans deux h\u00f4pitaux \u00e0 Wuhan ainsi que leur \u00e9volution et mettre en \u00e9vidence des facteurs de risque de d\u00e9c\u00e8s.", "pubmed_id": "32354360\n32007145\n31995857\n32020029\n32094589\n32031570\n22797452\n32187464\n32007143\n32003551\n31986261\n32015507\n32171076\n31991079", "doi": "10.1186/s13054-020-02895-6", "abstract": "In December 2019, coronavirus disease 2019 (COVID-19) outbreak was reported from Wuhan, China. Information on the clinical course and prognosis of COVID-19 was not thoroughly described. We described the clinical courses and prognosis in COVID-19 patients.\nRetrospective case series of COVID-19 patients from Zhongnan Hospital of Wuhan University in Wuhan and Xishui Hospital, Hubei Province, China, up to February 10, 2020. Epidemiological, demographic, and clinical data were collected. The clinical course of survivors and non-survivors were compared. Risk factors for death were analyzed.\nA total of 107 discharged patients with COVID-19 were enrolled. The clinical course of COVID-19 presented as a tri-phasic pattern. Week 1 after illness onset was characterized by fever, cough, dyspnea, lymphopenia, and radiological multi-lobar pulmonary infiltrates. In severe cases, thrombocytopenia, acute kidney injury, acute myocardial injury, and adult respiratory distress syndrome were observed. During week 2, in mild cases, fever, cough, and systemic symptoms began to resolve and platelet count rose to normal range, but lymphopenia persisted. In severe cases, leukocytosis, neutrophilia, and deteriorating multi-organ dysfunction were dominant. By week 3, mild cases had clinically resolved except for lymphopenia. However, severe cases showed persistent lymphopenia, severe acute respiratory dyspnea syndrome, refractory shock, anuric acute kidney injury, coagulopathy, thrombocytopenia, and death. Older age and male sex were independent risk factors for poor outcome of the illness.\nA period of 7-13\u2009days after illness onset is the critical stage in the COVID-19 course. Age and male gender were independent risk factors for death of COVID-19.", "topics": ["Pronostique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie"], "author_list": [{"id": 489, "name": "Wang D"}], "publication_date": "2020-05-04"}, {"id": 403, "slug": "the-impact-of-2019-novel-coronavirus-on-heart-injury-a-systemic-review-and-meta-", "title": "The impact of 2019 novel coronavirus on heart injury: A systemic review and Meta-analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyser le lien entre la s\u00e9v\u00e9rit\u00e9 du COVID-19 et les caract\u00e9ristiques des l\u00e9sions myocardiques aigu\u00ebs \u00e0 partir des donn\u00e9es de la litt\u00e9rature.", "verbose_date": "21.04.2020", "authors": "Li JW", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 170, "name": "Progr Cardiovasc Dis"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0033062020300803?token=A026DB9776494BE60111BF89F7DC0F5C2CAE6E8F312E2CE1FE8C6102E71A2D47070FEFA53353AAA59DCE339A4149F9A7", "findings": "", "take_away": "", "relevance_level": "La s\u00e9v\u00e9rit\u00e9 du COVID-19 est associ\u00e9e \u00e0 l'intensit\u00e9 des l\u00e9sions myocardiques aigu\u00ebs, elles-m\u00eame associ\u00e9es aux d\u00e9c\u00e8s.\u00a0\r\nLes patients avec un ant\u00e9c\u00e9dent d'hypertension sont plus \u00e0 risque de souffrir de l\u00e9sions cardiaques.", "objectives": "- Nombre d'articles relativement cons\u00e9quent (n=28) et nombre de sujets important- M\u00e9ta-r\u00e9gression r\u00e9alis\u00e9e- R\u00e9sultats en accord avec la litt\u00e9rature- Cependant, bas\u00e9 sur des \u00e9tudes observationnelles r\u00e9trospectives- Sans \u00e9valuation m\u00e9thodologique de ces \u00e9tudes recueillies- H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 des donn\u00e9es, notamment des d\u00e9finition de la s\u00e9v\u00e9rit\u00e9 du COVID-19, des l\u00e9sions myocardiques et des biomarqueurs cardiaques, non explor\u00e9e\"", "methods": "Analyser le lien entre la s\u00e9v\u00e9rit\u00e9 du COVID-19 et les caract\u00e9ristiques des l\u00e9sions myocardiques aigu\u00ebs \u00e0 partir des donn\u00e9es de la litt\u00e9rature.", "topics": ["Epid\u00e9miologique", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 385, "name": "Li JW"}], "publication_date": "2020-04-21"}, {"id": 565, "slug": "kidney-manifestations-of-mild-moderate-and-severe-coronavirus-disease-2019-a-ret", "title": "Kidney manifestations of mild, moderate and severe coronavirus disease 2019: a retrospective cohort study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Cette \u00e9tude visait \u00e0 \u00e9valuer l'incidence, les facteurs de risque et les issues cliniques de l\u2019insuffisance r\u00e9nale aigu\u00eb chez les patients atteints de COVID-19.", "verbose_date": "11.05.2020", "authors": "Hong D", "specialties": [{"id": 20, "name": "N\u00e9phrologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 224, "name": "CKJ"}, "link": "https://doi.org/10.1093/ckj/sfaa083", "findings": "", "take_away": "", "relevance_level": "La prot\u00e9inurie et l'h\u00e9maturie microscopique ne sont pas rares chez les patients atteints d'une infection par COVID-19, en particulier dans les cas graves ou critiques. Des \u00e9chantillons plus importants sont n\u00e9cessaires pour clarifier la relation entre COVID-19 et l'atteinte r\u00e9nale, et un suivi \u00e0 long terme des patients atteints de COVID-19 doit \u00eatre effectu\u00e9 pour \u00e9tudier son impact sur l'atteinte r\u00e9nale.", "objectives": "-\t\u00c9tude de cohorte r\u00e9trospective-\tN=168-\tDeux h\u00f4pitaux-\tOn n'a pas pu obtenir les r\u00e9sultats des analyses d'urine effectu\u00e9es avant l'admission et, par cons\u00e9quent, on n'a pas pu confirmer la pr\u00e9sence ou non de prot\u00e9inurie et d'h\u00e9maturie microscopique avant l'admission. -\tOn n'a utilis\u00e9 la bandelette urinaire que pour tester l'h\u00e9maturie et n'a pas pu diff\u00e9rencier l'h\u00e9maturie r\u00e9elle de l'h\u00e9moglobinurie ou de la myoglobinurie. -\tLes donn\u00e9es de suivi \u00e9taient de petite taille et de courte dur\u00e9e, et il n'y avait pas de donn\u00e9es de suivi pour la prot\u00e9inurie ou l'h\u00e9maturie microscopique. -\tLa pr\u00e9valence de la prot\u00e9inurie et de l'h\u00e9maturie microscopique chez les patients de l\u2019\u00e9tude \u00e9tait beaucoup plus \u00e9lev\u00e9e que le 15,1% observ\u00e9 dans la population g\u00e9n\u00e9rale du Sichuan, mais les patients atteints de COVID-19 dans les deux cohortes \u00e9taient plus \u00e2g\u00e9s que la moyenne de la population. -\tLe RR a \u00e9t\u00e9 estim\u00e9 par une analyse univari\u00e9e ; il n'a pas pu \u00e9liminer l'influence des facteurs de confusion.", "methods": "Cette \u00e9tude visait \u00e0 \u00e9valuer l'incidence, les facteurs de risque et les issues cliniques de l\u2019insuffisance r\u00e9nale aigu\u00eb chez les patients atteints de COVID-19.", "topics": ["Epid\u00e9miologique", "N\u00e9phrologie"], "author_list": [{"id": 530, "name": "Hong D"}], "publication_date": "2020-05-11"}, {"id": 659, "slug": "effect-of-convalescent-plasma-therapy-on-time-to-clinical-improvement-in-patient", "title": "Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'efficacit\u00e9 et les effets ind\u00e9sirables de la th\u00e9rapie par plasma chez les patients COVID-19.", "verbose_date": "06.06.2020", "authors": "Li L", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://www.dropbox.com/s/qs2want334tsy6j/10.1001%40jama.2020.10044.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Chez les patients atteints de COVID-19 s\u00e9v\u00e8re ou mena\u00e7ant le pronostic vital, la th\u00e9rapie par plasma ajout\u00e9e au traitement standard, par rapport au traitement standard seul, n'a pas entra\u00een\u00e9 une am\u00e9lioration statistiquement significative du temps n\u00e9cessaire \u00e0 l'am\u00e9lioration clinique dans les 28 jours.", "objectives": "Essai contr\u00f4l\u00e9 randomis\u00e9, en ouvert, faible effectif n=103103 patients sur 200 pr\u00e9vus en nombre de sujets n\u00e9cessaires du fait du ralentissement de l'\u00e9pid\u00e9mie \u00e0 Wuhan fin marsPatients trait\u00e9s tardivement, l'intervalle m\u00e9dian entre le d\u00e9but des sympt\u00f4mes et la randomisation \u00e9tait de 30 joursTraitement concomittant possible par antiviraux, des antibiotiques, des corticost\u00e9ro\u00efdes, des immunoglobulines , des plantes m\u00e9dicinales chinoises.Patients trait\u00e9s plus s\u00e9v\u00e8res semblant plus s\u00e9v\u00e8re que groupe contr\u00f4le101 patients (98,1%) inclus dans l'analyse per protocole Ajout d'une analyse post hoc sur l'am\u00e9lioration clinique \u00e0 J7, J14, J28.Evaluation clinique par un investigateur en aveugleStandardisation dans la s\u00e9lection des plasmas des patients convalescents", "methods": "Evaluer l'efficacit\u00e9 et les effets ind\u00e9sirables de la th\u00e9rapie par plasma chez les patients COVID-19.", "pubmed_id": "32492084\n15616839\n16183666\n32423584\n26775794\n32031570\n27532807\n32253318\n25904375\n31582360\n15214887\n32219428\n32091533", "doi": "10.1001/jama.2020.10044", "abstract": "Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are needed.\nTo evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19.\nOpen-label, multicenter, randomized clinical trial performed in 7 medical centers in Wuhan, China, from February 14, 2020, to April 1, 2020, with final follow-up April 28, 2020. The trial included 103 participants with laboratory-confirmed COVID-19 that was severe (respiratory distress and/or hypoxemia) or life-threatening (shock, organ failure, or requiring mechanical ventilation). The trial was terminated early after 103 of a planned 200 patients were enrolled.\nConvalescent plasma in addition to standard treatment (n\u2009=\u200952) vs standard treatment alone (control) (n\u2009=\u200951), stratified by disease severity.\nPrimary outcome was time to clinical improvement within 28 days, defined as patient discharged alive or reduction of 2 points on a 6-point disease severity scale (ranging from 1 [discharge] to 6 [death]). Secondary outcomes included 28-day mortality, time to discharge, and the rate of viral polymerase chain reaction (PCR) results turned from positive at baseline to negative at up to 72 hours.\nOf 103 patients who were randomized (median age, 70 years; 60 [58.3%] male), 101 (98.1%) completed the trial. Clinical improvement occurred within 28 days in 51.9% (27/52) of the convalescent plasma group vs 43.1% (22/51) in the control group (difference, 8.8% [95% CI, -10.4% to 28.0%]; hazard ratio [HR], 1.40 [95% CI, 0.79-2.49]; P\u2009=\u2009.26). Among those with severe disease, the primary outcome occurred in 91.3% (21/23) of the convalescent plasma group vs 68.2% (15/22) of the control group (HR, 2.15 [95% CI, 1.07-4.32]; P\u2009=\u2009.03); among those with life-threatening disease the primary outcome occurred in 20.7% (6/29) of the convalescent plasma group vs 24.1% (7/29) of the control group (HR, 0.88 [95% CI, 0.30-2.63]; P\u2009=\u2009.83) (P for interaction\u2009=\u2009.17). There was no significant difference in 28-day mortality (15.7% vs 24.0%; OR, 0.65 [95% CI, 0.29-1.46]; P\u2009=\u2009.30) or time from randomization to discharge (51.0% vs 36.0% discharged by day 28; HR, 1.61 [95% CI, 0.88-2.93]; P\u2009=\u2009.12). Convalescent plasma treatment was associated with a negative conversion rate of viral PCR at 72 hours in 87.2% of the convalescent plasma group vs 37.5% of the control group (OR, 11.39 [95% CI, 3.91-33.18]; P\u2009<\u2009.001). Two patients in the convalescent plasma group experienced adverse events within hours after transfusion that improved with supportive care.\nAmong patients with severe or life-threatening COVID-19, convalescent plasma therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days. Interpretation is limited by early termination of the trial, which may have been underpowered to detect a clinically important difference.\nChinese Clinical Trial Registry: ChiCTR2000029757.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 71, "name": "Li L"}], "publication_date": "2020-06-06"}, {"id": 297, "slug": "four-cases-from-a-family-cluster-were-diagnosed-as-covid-19-after-14-day-of-quar", "title": "Four cases from a family cluster were diagnosed as COVID-19 after 14-day of quarantine period", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire 4 cas de contaminations au COVID-19 apr\u00e8s confinement de 14 jours", "verbose_date": "10.04.2020", "authors": "Chen D", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25849", "findings": "", "take_away": "", "relevance_level": "Alors que la p\u00e9riode d'incubation est aujourd'hui estim\u00e9e \u00e0 5 jours (2 \u00e0 14), il semblerait que cette p\u00e9riode de confinement de quatorze jours ne semble pas toujours suffisante pour s'assurer de l'absence d'infection, des cas d'apparition des premiers sypt\u00f4mes \u00e0 20 voire m\u00eame 30 jours apr\u00e8s infection ayant \u00e9t\u00e9 d\u00e9crit dans cet article.", "objectives": "- Case report- Peu de donn\u00e9es sur le mode de vie, les contacts potentiels et la situation \u00e9pid\u00e9mique dans cette province chinoise\"", "methods": "D\u00e9crire 4 cas de contaminations au COVID-19 apr\u00e8s confinement de 14 jours", "pubmed_id": "32270500", "doi": "10.1002/jmv.25849", "abstract": null, "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 60, "name": "Chen D"}], "publication_date": "2020-04-10"}, {"id": 462, "slug": "eculizumab-treatment-in-patients-with-covid-19-preliminary-results-from-real-lif", "title": "Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Rapporter les donn\u00e9es pr\u00e9liminaires obtenues avec la th\u00e9rapie anti compl\u00e9ment C5 \u00e0 l'eculizumab chez les patients COVID-19 admis \u00e0 l'unit\u00e9 de soins intensifs de l'ASL Napoli 2 Nord.", "verbose_date": "27.04.2020", "authors": "Diurno F", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 188, "name": "Eur Rev Med Pharmacol Sci"}, "link": "https://www.europeanreview.org/wp/wp-content/uploads/4040-4047.pdf", "findings": "", "take_away": "", "relevance_level": "L'eculizumab a le potentiel pour \u00eatre un acteur cl\u00e9 dans le traitement des cas graves de COVID-19. Les r\u00e9sultats de l'\u00e9tude soutiennent l'utilisation de l'eculizumab comme traitement hors \u00e9tiquette des cas graves de COVID-19, en attendant la confirmation par l'essai SOLID-C19 en cours.", "objectives": "-\ts\u00e9rie de cas, monocentrique -\t4 patients", "methods": "Rapporter les donn\u00e9es pr\u00e9liminaires obtenues avec la th\u00e9rapie anti compl\u00e9ment C5 \u00e0 l'eculizumab chez les patients COVID-19 admis \u00e0 l'unit\u00e9 de soins intensifs de l'ASL Napoli 2 Nord.", "pubmed_id": "32329881", "doi": "10.26355/eurrev_202004_20875", "abstract": "SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-related pneumonia, referred to as COVID-19 (Coronavirus Disease 19), is a public health emergency as it carries high morbidity, mortality, and has no approved specific pharmacological treatments. In this case series, we aimed to report preliminary data obtained with anti-complement C5 therapy with eculizumab in COVID-19 patients admitted to intensive care unit (ICU) of ASL Napoli 2 Nord.\nThis is a case series of patients with a confirmed diagnosis of SARS-CoV2 infection and severe pneumonia or ARDS who were treated with up to 4 infusions of eculizumab as an off-label agent. Patients were also treated with anticoagulant therapy with Enoxaparin 4000 IU/day via subcutaneous injection, antiviral therapy with Lopinavir 800 mg/day + Ritonavir 200 mg/day, hydroxychloroquine 400 mg/day, ceftriaxone 2 g/day IV, vitamine C 6 g/day for 4 days, and were on Non-Invasive Ventilation (NIV).\nWe treated four COVID-19 patients admitted to the intensive care unit because of severe pneumonia or ARDS. All patients successfully recovered after treatment with eculizumab. Eculizumab induced a drop in inflammatory markers. Mean C Reactive Protein levels dropped from 14.6 mg/dl to 3.5 mg/dl and the mean duration of the disease was 12.8 days.\nEculizumab has the potential to be a key player in treatment of severe cases of COVID-19. Our results support eculizumab use as an off-label treatment of COVID-19, pending confirmation from the ongoing SOLID-C19 trial.", "topics": ["Th\u00e9rapeutique", "Infectiologie"], "author_list": [{"id": 434, "name": "Diurno F"}], "publication_date": "2020-04-27"}, {"id": 188, "slug": "anticoagulant-treatment-is-associated-with-decreased-mortality-in-severe-coronav", "title": "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Effet des anticoagulants sur la mortalit\u00e9 des cas s\u00e9v\u00e8res d'infection \u00e0 SARS-CoV-2.", "verbose_date": "30.03.2020", "authors": "Ning T ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 96, "name": "J Thromb Haemostasis"}, "link": "https://www.dropbox.com/s/oknwbxc956v6bx6/jth.14817.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- En cas de score SIC \u2265 4 (21.6% des patients), le traitement par anticoagulant (h\u00e9parine) semble r\u00e9duire la mortalit\u00e9 \u00e0 28 jours.\r\n- Du fait de l'atteinte principalement pulmonaire de l'infection \u00e0 SARS-CoV-2, il est possible que la coagulopathie soit diff\u00e9rente de celle d'un sepsis classique. Les plaquettes pourraient ne pas \u00eatre un marqueur de coagulopathie du COVID-19.\r\n- Un marqueur indirect de l'activation de la coagulation (D-Dim\u00e8re > 6 ULN, 35.9% des patients) semble indiquer un effet b\u00e9n\u00e9fique du traitement par h\u00e9parine (groupe plus important que celui indiqu\u00e9 par le score SIC)\r\n- Les patients pouvant b\u00e9n\u00e9ficier d'un traitement par anticoagulant sont limit\u00e9s. Pas d'indication \u00e0 un traitement syst\u00e9matique chez les patients s\u00e9v\u00e8re sans coagulopathie.", "objectives": "- \u00c9tude r\u00e9trospective- Large cohorte bien men\u00e9e", "methods": "Effet des anticoagulants sur la mortalit\u00e9 des cas s\u00e9v\u00e8res d'infection \u00e0 SARS-CoV-2.", "pubmed_id": "32220112", "doi": "10.1111/jth.14817", "abstract": "A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, and the application of heparin in COVID-19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated.\nCoagulation results, medications, and outcomes of consecutive patients being classified as having severe COVID-19 in Tongji hospital were retrospectively analyzed. The 28-day mortality between heparin users and nonusers were compared, as was a different risk of coagulopathy, which was stratified by the\u00a0sepsis-induced coagulopathy (SIC) score or D-dimer result.\nThere were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin) for 7\u00a0days or longer. D-dimer, prothrombin time, and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference in 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P\u00a0=\u00a0.910). But the 28-day mortality of heparin users was lower than nonusers in patients with SIC score\u00a0\u22654 (40.0% vs 64.2%, P\u00a0=\u00a0.029), or D-dimer\u00a0>6-fold of upper limit of normal (32.8% vs 52.4%, P\u00a0=\u00a0.017).\nAnticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 181, "name": "Ning T "}], "publication_date": "2020-03-30"}, {"id": 470, "slug": "umifenovir-treatment-is-not-associated-with-improved-outcomes-in-patients-with-c", "title": "Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: A retrospective study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier l'efficacit\u00e9 et la s\u00e9curit\u00e9 de l'umifenovir dans le Covid-19.", "verbose_date": "28.04.2020", "authors": "Lian N", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 112, "name": "Clin Microbiol Infect"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1198743X20302342?token=845367DDB9226DA8446356DF9F11BE8ADD591EC0C49712E273B3520C83F07DDB86974EBD88FCD46D466C20DF08EEC45A", "findings": "", "take_away": "", "relevance_level": "L'umifenovir ne semble pas am\u00e9liorer le pronostic ou acc\u00e9l\u00e9rer l'\u00e9limination du SARS-COV 2 chez les patients hospitalis\u00e9s hors soins intensifs.", "objectives": "- \u00c9tude r\u00e9trospective monocentrique- Peu de patients (n=81)- Inclusion de patients mod\u00e9r\u00e9s \u00e0 s\u00e9v\u00e8res : \u00e0 l'h\u00f4pital mais hors soins intensifs : biais de s\u00e9lection- \u00c9chantillons pharyng\u00e9s collect\u00e9s tous les deux jours : biais d'information- Etude observationnelle : biais de confusion\"", "methods": "Etudier l'efficacit\u00e9 et la s\u00e9curit\u00e9 de l'umifenovir dans le Covid-19.", "topics": ["Th\u00e9rapeutique", "Infectiologie"], "author_list": [{"id": 438, "name": "Lian N"}], "publication_date": "2020-04-28"}, {"id": 299, "slug": "high-prevalence-of-obesity-in-severe-acute-respiratory-syndrome-coronavirus-2-sa", "title": "High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "\u00c9valuer la corr\u00e9lation entre la n\u00e9cessit\u00e9 de ventilation m\u00e9canique invasive et les caract\u00e9ristiques cliniques du patient, y compris l'indice de masse corporelle.", "verbose_date": "10.04.2020", "authors": "Simonnet A", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 139, "name": "Obesity"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.22831", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude a d\u00e9montr\u00e9 que le besoin de ventilation m\u00e9canique assist\u00e9e augmente progressivement avec l'augmentation de l'IMC et atteint 90 % pour les patients dont l'IMC est sup\u00e9rieur \u00e0 35 kg/m2.\r\nDes mesures suppl\u00e9mentaires doivent \u00eatre prises pour \u00e9viter l'infection SRAS-CoV-2 des personnes ob\u00e8ses.", "objectives": "1) \u00e9tude observationnelle2) petit \u00e9chantillon: 124 patients3) la majorit\u00e9 des patients \u00e9taient encore hospitalis\u00e9s au moment de l'analyse4) aucune information sur la mortalit\u00e9 en tant que r\u00e9sultat parce qu'il y a trop peu d'\u00e9v\u00e9nements (18 patients, 15%)\"", "methods": "\u00c9valuer la corr\u00e9lation entre la n\u00e9cessit\u00e9 de ventilation m\u00e9canique invasive et les caract\u00e9ristiques cliniques du patient, y compris l'indice de masse corporelle.", "pubmed_id": "32271993", "doi": "10.1002/oby.22831", "abstract": "The COVID-19 pandemic is rapidly spreading worldwide, notably in Europe and North America where obesity is highly prevalent. The relation between obesity and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has not been fully documented.\nThis retrospective cohort study analyzed the relationship between clinical characteristics, including BMI,\u00a0and the requirement for invasive mechanical ventilation (IMV) in 124 consecutive patients admitted in intensive care for SARS-CoV-2 in a single French center.\nObesity (BMI\u2009>\u200930) and severe obesity (BMI\u2009>\u200935) were present in 47.6% and 28.2% of cases, respectively. Overall, 85 patients (68.6%) required IMV. The proportion of patients who required IMV increased with BMI categories (P\u2009<\u20090.01, \u03c7\nThe present study showed a high frequency of obesity among patients admitted in intensive care for SARS-CoV-2. Disease severity increased with BMI. Obesity is a risk factor for SARS-CoV-2 severity, requiring increased attention to preventive measures in susceptible individuals.", "topics": ["Epid\u00e9miologique", "Transversale", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 287, "name": "Simonnet A"}], "publication_date": "2020-04-10"}, {"id": 99, "slug": "coronavirus-epidemic-and-extracorporeal-therapies-in-intensive-care-si-vis-pacem", "title": "Coronavirus Epidemic and Extracorporeal Therapies in Intensive Care: si vis pacem para bellum", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Accro\u00eetre les connaissances sur les th\u00e9rapies extracorporelles pour les patients avec VAHS atteints de dysfonctionnements multiples des organes", "verbose_date": "13.03.2020", "authors": "Ronco C", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 71, "name": "Blood Purif"}, "link": "https://www.dropbox.com/s/kwf5sy5v94h2m3t/507039.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les th\u00e9rapies extracorporelles (ECMO) telles que l'h\u00e9mofiltration et l'h\u00e9moperfusion peuvent compenser en cas de d\u00e9faillance multiple d'organe de type moyenne-s\u00e9v\u00e8re (c\u0153ur, poumons, reins, foie) chez les patients atteints de VAHS (rempla\u00e7ant la ventilation m\u00e9canique et le soutien h\u00e9modynamique).", "objectives": "Faible", "methods": "Accro\u00eetre les connaissances sur les th\u00e9rapies extracorporelles pour les patients avec VAHS atteints de dysfonctionnements multiples des organes", "pubmed_id": "32172242", "doi": "10.1159/000507039", "abstract": null, "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 105, "name": "Ronco C"}], "publication_date": "2020-03-13"}, {"id": 314, "slug": "comparative-performance-of-sars-cov-2-detection-assays-using-seven-different-pri", "title": "Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire la morbidit\u00e9 de la COVID-19 dans une r\u00e9sidence pour personnes \u00e2g\u00e9es autonomes mais avec besoin d'assistance", "verbose_date": "11.04.2020", "authors": "Nalla AK", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 141, "name": "J Clin Microbiol"}, "link": "https://jcm.asm.org/content/jcm/early/2020/04/06/JCM.00557-20.full.pdf", "findings": "", "take_away": "", "relevance_level": "Dans les r\u00e9sidences pour personnes \u00e2g\u00e9s autonomes, la moindre proximit\u00e9 des personnes pourrait permettre une moindre morbidit\u00e9 de la COVID-19. N\u00e9anmoins dans le cas d\u00e9cris, des mesures importantes de d\u00e9pistage biologique par RT-PCR et de pr\u00e9vention de la transmission mises en place rapidement ont probablement permis d'enrayer la propagation du virus. Il est \u00e0 noter que le d\u00e9pistage par les signes cliniques n'est pas fid\u00e8le et il est important de proc\u00e9der \u00e0 des tests biologiques.", "objectives": "- retour d'exp\u00e9rience d'un unique \u00e9tablissement- possible biais de m\u00e9moire lors de la d\u00e9claration des sympt\u00f4mes\"", "methods": "D\u00e9crire la morbidit\u00e9 de la COVID-19 dans une r\u00e9sidence pour personnes \u00e2g\u00e9es autonomes mais avec besoin d'assistance", "pubmed_id": "32511464", "doi": "10.1101/2020.03.13.20035618", "abstract": "More than 100,000 people worldwide are known to have been infected with SARS-CoV-2 beginning in December 2019. The virus has now spread to over 93 countries including the United States, with the largest cluster of US cases to date in the Seattle metropolitan area in Washington. Given the rapid increase in the number of local cases, the availability of accurate, high-throughput SARS-CoV-2 testing is vital to efforts to manage the current public health crisis. In the course of optimizing SARS-CoV-2 testing performed by the University of Washington Clinical Virology Lab (UW Virology Lab), we tested assays using seven different primer/probe sets and one assay kit. We found that the most sensitive assays were those the used the E-gene primer/probe set described by Corman et al. (Eurosurveillance 25(3), 2020, https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045) and the N2 set described by the CDC (Division of Viral Diseases, Centers for Disease Control and Prevention, 2020, https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer-probes.pdf). All assays tested were found to be highly specific for SARS-CoV-2, with no cross-reactivity with other respiratory viruses observed in our analyses regardless of the primer/probe set or kit used. These results will provide invaluable information to other clinical laboratories who are actively developing SARS-CoV-2 testing protocols at a time when increased testing capacity is urgently needed worldwide.", "topics": ["Diagnostique", "Virologie", "Infectiologie"], "author_list": [{"id": 301, "name": "Nalla AK"}], "publication_date": "2020-04-11"}, {"id": 507, "slug": "patients-with-cancer-appear-more-vulnerable-to-sars-cov-2-a-multi-center-study-d", "title": "Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques et la survenue de d\u00e9c\u00e8s, admission en soins intensifs, apparition de sympt\u00f4mes s\u00e9v\u00e8res ou critiques et recours \u00e0 une ventilation m\u00e9canique chez des patients porteurs de cancer hospitalis\u00e9s pour COVID-19.", "verbose_date": "02.05.2020", "authors": "Dai M", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 201, "name": "Cancer Discovery"}, "link": "https://cancerdiscovery.aacrjournals.org/content/candisc/early/2020/04/29/2159-8290.CD-20-0422.full.pdf", "findings": "", "take_away": "", "relevance_level": "- Les patients pr\u00e9sentant un cancer et hospitalis\u00e9s pour COVID-19 ont un risque significativement plus \u00e9lev\u00e9 de :\n* d\u00e9c\u00e8s\n* admission en soins intensifs\n* survenue de sympt\u00f4mes s\u00e9v\u00e8res ou critiques\n* recours \u00e0 la ventilation m\u00e9canique\npar rapport aux patients hospitalis\u00e9s pour COVID-19 non porteur d'un cancer, et ce apr\u00e8s ajustement sur l'\u00e2ge, le sexe, la pr\u00e9sence d'un diab\u00e8te, la pr\u00e9sence d'une HTA, le tabagisme, la pr\u00e9sence d'une BPCO \u00e0 l'admission.\n- Les patients pr\u00e9sentant un cancer h\u00e9matologique, un cancer du poumon ou un cancer \u00e0 un stade m\u00e9tastatique semblent \u00e0 sur-risque pour ces 4 complications.", "objectives": "- \u00c9tude cas-t\u00e9moins avec risque d'inflation du risque alpha", "methods": "D\u00e9crire les caract\u00e9ristiques et la survenue de d\u00e9c\u00e8s, admission en soins intensifs, apparition de sympt\u00f4mes s\u00e9v\u00e8res ou critiques et recours \u00e0 une ventilation m\u00e9canique chez des patients porteurs de cancer hospitalis\u00e9s pour COVID-19.", "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 475, "name": "Dai M"}], "publication_date": "2020-05-02"}, {"id": 656, "slug": "effects-of-non-pharmaceutical-interventions-on-covid-19-cases-deaths-and-demand-", "title": "Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer l'impact de diff\u00e9rentes mesures de contr\u00f4le pour att\u00e9nuer les cons\u00e9quences du COVID-19 au Royaume-Uni.", "verbose_date": "04.06.2020", "authors": "Davies NG", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 140, "name": "Lancet Public Health"}, "link": "https://www.thelancet.com/pdfs/journals/lanpub/PIIS2468-2667(20)30133-X.pdf", "findings": "", "take_away": "", "relevance_level": "En l'absence de mesures de contr\u00f4le, l'\u00e9pid\u00e9mie de COVID-19 pourrait rapidement submerger le syst\u00e8me de sant\u00e9.\nDans cette \u00e9tude, m\u00eame une combinaison d'interventions mod\u00e9r\u00e9es - telles que les fermetures d'\u00e9coles, la protection des personnes \u00e2g\u00e9es et l'auto-isolement des personnes symptomatiques - serait peu susceptible d'emp\u00eacher une \u00e9pid\u00e9mie exc\u00e9dant la capacit\u00e9 des unit\u00e9s de soins intensifs au Royaume-Uni.\nDes p\u00e9riodes intermittentes de mesures de verrouillage intensives devraient \u00eatre efficaces pour \u00e9viter que le syst\u00e8me de sant\u00e9 ne soit submerg\u00e9.", "objectives": "Prise en compte de la d\u00e9pl\u00e9tion des susceptibles dans le mod\u00e8leValeurs al\u00e9atoires de R0 ont \u00e9t\u00e9 choisies dans une distribution normale avec moyenne de 2,7Taux de l\u00e9talit\u00e9 de base stratifi\u00e9s par \u00e2ge issus de donn\u00e9es chinoises de d\u00e9but f\u00e9vrierAutres param\u00e8tres entr\u00e9s \u00e0 partir d'autres \u00e9tudes chinoises et contenant une forte approximation (d\u00e9finis dans les premiers stades de l\u2019\u00e9pid\u00e9mie)Hypoth\u00e8se d'une immunit\u00e9 protectrice d'1 \u00e0 2 ansHypoth\u00e8se de 0% de contact \u00e0 l'\u00e9cole lors de leur fermeture (ne prenant pas en compte la garde des enfants des travailleurs essentiels)200 simulations pour chacun des 8 mod\u00e8les test\u00e9sDate al\u00e9atoire d'introduction du SRAS-CoV-2 pour chaque unit\u00e9 administrative, les arrondissements de Londres \u00e9tant infect\u00e9s au cours de la premi\u00e8re semaine et toutes les autres unit\u00e9s administratives de Londres infect\u00e9es lors des 4 premi\u00e8res semaines de l'\u00e9pid\u00e9mie.Pas de structuration des individus par m\u00e9nagePas d'\u00e9v\u00e8nement de super-propagation dans le mod\u00e8lePas de prise en compte des infections li\u00e9es aux soinsHypoth\u00e8se probablement erron\u00e9e sur le taux de transmission des individus asymptomatiquesPas de donn\u00e9es suffisantes pour d\u00e9composer explicitement les mesures de distanciation physique, tels que rester \u00e0 2 m l'un de l'autre, augmenter le lavage des mains et le port du masque facial", "methods": "Evaluer l'impact de diff\u00e9rentes mesures de contr\u00f4le pour att\u00e9nuer les cons\u00e9quences du COVID-19 au Royaume-Uni.", "pubmed_id": "32502389\n32220655\n31995857\n16292310\n32171059\n31986264\n18252100\n18366252\n32119825\n32113505\n32164834\n32375776\n32311320", "doi": "10.1016/S2468-2667(20)30133-X", "abstract": "Non-pharmaceutical interventions have been implemented to reduce transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the UK. Projecting the size of an unmitigated epidemic and the potential effect of different control measures has been crucial to support evidence-based policy making during the early stages of the epidemic. This study assesses the potential impact of different control measures for mitigating the burden of COVID-19 in the UK.\nWe used a stochastic age-structured transmission model to explore a range of intervention scenarios, tracking 66\u00b74 million people aggregated to 186 county-level administrative units in England, Wales, Scotland, and Northern Ireland. The four base interventions modelled were school closures, physical distancing, shielding of people aged 70 years or older, and self-isolation of symptomatic cases. We also modelled the combination of these interventions, as well as a programme of intensive interventions with phased lockdown-type restrictions that substantially limited contacts outside of the home for repeated periods. We simulated different triggers for the introduction of interventions, and estimated the impact of varying adherence to interventions across counties. For each scenario, we projected estimated new cases over time, patients requiring inpatient and critical care (ie, admission to the intensive care units [ICU]) treatment, and deaths, and compared the effect of each intervention on the basic reproduction number, R\nWe projected a median unmitigated burden of 23 million (95% prediction interval 13-30) clinical cases and 350\u2008000 deaths (170\u2008000-480\u2008000) due to COVID-19 in the UK by December, 2021. We found that the four base interventions were each likely to decrease R\nThe characteristics of SARS-CoV-2 mean that extreme measures are probably required to bring the epidemic under control and to prevent very large numbers of deaths and an excess of demand on hospital beds, especially those in ICUs.\nMedical Research Council.", "topics": ["Mod\u00e9lisation", "Transversale"], "author_list": [{"id": 617, "name": "Davies NG"}], "publication_date": "2020-06-04"}, {"id": 393, "slug": "first-confirmed-detection-of-sars-cov-2-in-untreated-wastewater-in-australia-a-p", "title": "First confirmed detection of SARS-CoV-2 in untreated wastewater in Australia: A proof of concept for the wastewater surveillance of COVID-19 in the community", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyser les concentrations de SARS-COV-2 pr\u00e9sentes dans les eaux us\u00e9es et en d\u00e9duire le nombre de personnes infect\u00e9es en amont, dans le but d'explorer si la pr\u00e9sence de SARS-COV-2 dans les eaux non trait\u00e9es peut \u00eatre utilis\u00e9e comme un signal pr\u00e9curseur d'une \u00e9pid\u00e9mie dans la population.", "verbose_date": "20.04.2020", "authors": "Warish A", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 166, "name": "Science of The Total Environment"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0048969720322816?token=283E77812C1895BADEF084405C1CB265B52E20AAD0EE5421FA3B055ABB560FE1685F3F93FC5D387759389F565385EC5B", "findings": "", "take_away": "", "relevance_level": "La pr\u00e9sence du SARS-COV-2 peut \u00eatre d\u00e9tect\u00e9e dans les eaux us\u00e9es non trait\u00e9es.\r\nIl faudra d'autres \u00e9tudes pour \u00e9tablir le lien pr\u00e9cis entre les concentrations mesur\u00e9es et le nombre de cas.\u00a0\r\nD'autres \u00e9tudes sont \u00e9galement n\u00e9cessaires pour trouver les meilleures m\u00e9thodes de concentration et de test de RT-qPCR.", "objectives": "- Preuve de concept- Inconsistance des r\u00e9sultats selon les m\u00e9thodes employ\u00e9es- Pas de consensus sur les m\u00e9thodes \u00e0 employer pour la d\u00e9tection virale environnementale- Pas de comparaison possible  avec la pr\u00e9valence r\u00e9elle de ce bassin de population\"", "methods": "Analyser les concentrations de SARS-COV-2 pr\u00e9sentes dans les eaux us\u00e9es et en d\u00e9duire le nombre de personnes infect\u00e9es en amont, dans le but d'explorer si la pr\u00e9sence de SARS-COV-2 dans les eaux non trait\u00e9es peut \u00eatre utilis\u00e9e comme un signal pr\u00e9curseur d'une \u00e9pid\u00e9mie dans la population.", "pubmed_id": "32387778", "doi": "10.1016/j.scitotenv.2020.138764", "abstract": "Infection with SARS-CoV-2, the etiologic agent of the ongoing COVID-19 pandemic, is accompanied by the shedding of the virus in stool. Therefore, the quantification of SARS-CoV-2 in wastewater affords the ability to monitor the prevalence of infections among the population via wastewater-based epidemiology (WBE). In the current work, SARS-CoV-2 RNA was concentrated from wastewater in a catchment in Australia and viral RNA copies were enumerated using reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) resulting in two positive detections within a six day period from the same wastewater treatment plant (WWTP). The estimated viral RNA copy numbers observed in the wastewater were then used to estimate the number of infected individuals in the catchment via Monte Carlo simulation. Given the uncertainty and variation in the input parameters, the model estimated a median range of 171 to 1,090 infected persons in the catchment, which is in reasonable agreement with clinical observations. This work highlights the viability of WBE for monitoring infectious diseases, such as COVID-19, in communities. The work also draws attention to the need for further methodological and molecular assay validation for enveloped viruses in wastewater.", "topics": ["Autres", "Infectiologie", "Hygi\u00e8ne"], "author_list": [{"id": 377, "name": "Warish A"}], "publication_date": "2020-04-20"}, {"id": 52, "slug": "a-trial-of-lopinavirritonavir-in-adults-hospitalized-with-severe-covid-19", "title": "A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19", "has_other_authors": true, "impact_factor": {"id": 5, "name": "Fort", "posts_count": 5, "color": "green", "order": 1}, "goals_plain": "D\u00e9montrer l'effet th\u00e9rapeutique de Lopinavir + Ritonavir", "verbose_date": "19.03.2020", "authors": "Cao B", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.dropbox.com/s/6cmyvry595ciqm4/covid-19-a-trial-of-lopinavir-ritonavir-in-adults-hospitalized-with-severe-covid-19.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Pas d'effet prouv\u00e9 du lopinavir\u2013ritonavir sur l'am\u00e9lioration clinique, la r\u00e9duction de mortalit\u00e9 ou la r\u00e9duction de charge virale chez des patients avec forme s\u00e9v\u00e8re de Covid-19\r\nA confirmer par un essai randomis\u00e9 contr\u00f4l\u00e9 en aveugle de haut niveau de preuve", "objectives": "Interm\u00e9diaire haut (un des meilleurs essai \u00e0 ce jour) :1) Essai en ouvert2) Calcul d'effectif bas\u00e9 sur des hypoth\u00e8ses fausses3) Echantillon h\u00e9t\u00e9rog\u00e8ne4) Pas de tests syst\u00e9matiques au cours du temps pour v\u00e9rifier l'\u00e9limination du virus", "methods": "D\u00e9montrer l'effet th\u00e9rapeutique de Lopinavir + Ritonavir", "pubmed_id": "32187464", "doi": "10.1056/NEJMoa2001282", "abstract": "No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.\nWe conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao\nA total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group. Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events.\nIn hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 62, "name": "Cao B"}], "publication_date": "2020-03-19"}, {"id": 152, "slug": "rapid-response-to-covid-19-outbreak-in-northern-italy-how-to-convert-a-classic-i", "title": "Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Exposer la r\u00e9organisation d'un b\u00e2timent pour accueillir des patients COVID-19", "verbose_date": "26.03.2020", "authors": "Asperges E ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 6, "name": "J Hosp Infect"}, "link": "https://www.dropbox.com/s/17kqd91m0lj3cdk/PIIS0195670120301195.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Possibilit\u00e9 de modifier tr\u00e8s rapidement l'organisation et la fonction de service de soins ou d'autres services\r\nEn moins de deux semaines, un b\u00e2timent de maladies infectieuse a r\u00e9ussi \u00e0 plus que doubler son nombre de lits r\u00e9guliers de 44 \u00e0 94, \u00e0 cr\u00e9er un service infectieux sous-intensif et \u00e0 cr\u00e9er un service d'urgence infectieuses avec 16 lits pour les soins aigus.", "objectives": "1) Pre-proof2) Revue d'exp\u00e9rience", "methods": "Exposer la r\u00e9organisation d'un b\u00e2timent pour accueillir des patients COVID-19", "topics": ["Autres", "Transversale"], "author_list": [{"id": 148, "name": "Asperges E "}], "publication_date": "2020-03-26"}, {"id": 412, "slug": "sars-cov-2-and-viral-sepsis-observations-and-hypotheses", "title": "SARS-CoV-2 and viral sepsis: observations and hypotheses", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "A partir d'un ensemble d\u2019observations pr\u00e9c\u00e9demment faites sur l\u2019infection \u00e0 COVID-19, pr\u00e9senter et \u00e9mettre des hypoth\u00e8ses sur la pathog\u00e9nie du COVID-19 et sur un processus pathologique promu par les auteurs, celui de \u00ab sepsis viral \u00bb.", "verbose_date": "22.04.2020", "authors": "Li H", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30920-X.pdf", "findings": "", "take_away": "", "relevance_level": "Hypoth\u00e8ses principales :\r\n- Dans les formes mod\u00e9r\u00e9es d'infection \u00e0 COVID-19 une hypoth\u00e8se est que les macrophages alv\u00e9olaires contiennent de fa\u00e7on appropri\u00e9e le virus.\u00a0\r\n- Dans les formes s\u00e9v\u00e8res ou critiques d\u2019infection \u00e0 COVID-19 l'int\u00e9grit\u00e9 de la barri\u00e8re \u00e9pith\u00e9liale-endoth\u00e9liale est fortement alt\u00e9r\u00e9e. En plus de l'atteinte \u00e9pith\u00e9liale, l'atteinte de l'endoth\u00e9lium pulmonaire conduit \u00e0 une exsudation plasmatique dans les alv\u00e9oles.\u00a0\r\n- En r\u00e9ponse \u00e0 l\u2019infection par COVID-19 les macrophages alv\u00e9olaires ou endoth\u00e9liaux pourraient produire des cytokines et des chimiokines pro-inflammatoires multiples.\r\n- Par chimiotactisme, les monocytes et les neutrophiles seraient alors attir\u00e9s au site de l\u2019infection, conduisant \u00e0 une inflammation incontr\u00f4l\u00e9e. Du fait de la lymphop\u00e9nie et des dysfonctions lymphocytaires, la r\u00e9ponse immunitaire adaptative ne pourrait pas \u00eatre correctement initi\u00e9e. La r\u00e9plication incontr\u00f4l\u00e9e du virus m\u00e8ne \u00e0 une majoration de l\u2019infiltration macrophagique et donc de l'atteinte pulmonaire.\r\n- De fa\u00e7on concomitante, l'atteinte d'autres organes suite \u00e0 la diss\u00e9mination du COVID-19, la dysfonction immunitaire sous forme d\u2019orage cytokinique et les dysfonctions microcirculatoires d\u00e9clencherait ensemble le processus de \u00ab\u00a0sepsis viral\u00a0\u00bb, processus crucial dans la pathog\u00e9nie du COVID-19.\n\r\nPr\u00e9conisations :\r\n- de recherches in vivo en utilisant des mod\u00e8les animaux ou d'essais cliniques pour explorer les effets de l'action des inhibiteurs de l'enzyme de conversion de l'angiotensine ou des antagonistes des r\u00e9cepteurs de l'angiotensine II sur l'infection \u00e0 COVID-19.\r\n- d'\u00e9tudes pour tester l'hypoth\u00e8se d\u2019une infection directe des LT par le COVID-19, et l'influence de cette infection sur la r\u00e9ponse immunitaire adaptative\r\n- d'\u00e9tudes pour d\u00e9terminer la cin\u00e9tique de l\u00e9 r\u00e9ponse cytokinique au cours de l'infection par le COVID-19\r\n- d\u2019essais cliniques randomis\u00e9s pour tester l\u2019efficacit\u00e9 de traitements immunomodulateurs.", "objectives": "Avis d\u2019experts appuy\u00e9 par une revue de la litt\u00e9rature narrative", "methods": "A partir d'un ensemble d\u2019observations pr\u00e9c\u00e9demment faites sur l\u2019infection \u00e0 COVID-19, pr\u00e9senter et \u00e9mettre des hypoth\u00e8ses sur la pathog\u00e9nie du COVID-19 et sur un processus pathologique promu par les auteurs, celui de \u00ab\u00a0sepsis viral\u00a0\u00bb.", "pubmed_id": "32311318\n32007145\n32164092\n32171076\n32073213\n16043521\n15496474\n15141377\n18039138\n31986264\n22294047\n32361250\n32351056\n24762827\n30319615\n32015507\n32145190\n32085846\n28382038\n32172546\n26903338\n31978945\n32122468\n32109013\n15897343\n32043983\n32009228\n32114094\n32159775", "doi": "10.1016/S0140-6736(20)30920-X", "abstract": "Since the outbreak of coronavirus disease 2019 (COVID-19), clinicians have tried every effort to understand the disease, and a brief portrait of its clinical features have been identified. In clinical practice, we noticed that many severe or critically ill COVID-19 patients developed typical clinical manifestations of shock, including cold extremities and weak peripheral pulses, even in the absence of overt hypotension. Understanding the mechanism of viral sepsis in COVID-19 is warranted for exploring better clinical care for these patients. With evidence collected from autopsy studies on COVID-19 and basic science research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV, we have put forward several hypotheses about SARS-CoV-2 pathogenesis after multiple rounds of discussion among basic science researchers, pathologists, and clinicians working on COVID-19. We hypothesise that a process called viral sepsis is crucial to the disease mechanism of COVID-19. Although these ideas might be proven imperfect or even wrong later, we believe they can provide inputs and guide directions for basic research at this moment.", "topics": ["Autres", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie"], "author_list": [{"id": 393, "name": "Li H"}], "publication_date": "2020-04-22"}, {"id": 113, "slug": "are-patients-with-hypertension-and-diabetes-mellitus-atincreased-risk-for-covid-", "title": "Are patients with hypertension and diabetes mellitus atincreased risk for COVID-19 infection?", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'impact des traitements du diab\u00e8te et de l'HTA dans l'augmentation du risque li\u00e9 au COVID-19", "verbose_date": "11.03.2020", "authors": "Fang", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}, {"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 70, "name": "The Lancet"}, "link": "https://www.dropbox.com/s/qqgawoqmvekkkax/PIIS2213260020301168.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Attention aux patients trait\u00e9s par IEC et ARA2 :\r\nAugmentation possible du risque d'infection s\u00e9v\u00e8re (\u00e0 confirmer)\r\nPossibilit\u00e9 de remplacer par un antagoniste calcique qui ne serait pas associ\u00e9 \u00e0 un sur-risque", "objectives": "Faible : 1) Correspondance sans processus de blind reviewing2) Uniquement bas\u00e9 sur la bibliographie pr\u00e9c\u00e9dente et les hypoth\u00e8ses de l'auteur3) Pas de m\u00e9thodologie exp\u00e9rimentale permettant de confirmer ces propos", "methods": "Evaluer l'impact des traitements du diab\u00e8te et de l'HTA dans l'augmentation du risque li\u00e9 au COVID-19", "topics": ["Pronostique", "Cardiologie et maladies m\u00e9taboliques", "Transversale"], "author_list": [{"id": 119, "name": "Fang"}], "publication_date": "2020-03-11"}, {"id": 603, "slug": "first-experience-of-sars-cov-2-infections-in-solid-organ-transplant-recipients-i", "title": "First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'\u00e9pid\u00e9miologie, la pr\u00e9sentation clinique, le traitement et les r\u00e9sultats pour les patients adultes greff\u00e9s d'organes affect\u00e9s par COVID-19.", "verbose_date": "18.05.2020", "authors": "Tschopp J", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 20, "name": "N\u00e9phrologie"}, {"id": 19, "name": "H\u00e9pato-gastro-ent\u00e9rologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 237, "name": "Am J Transplant"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajt.16062", "findings": "", "take_away": "", "relevance_level": "Cette \u00e9tude montre que l'\u00e9volution clinique des patients COVID-19 transplant\u00e9s est similaire \u00e0 celle de la population g\u00e9n\u00e9rale.\nEn particulier, on constate que le taux d'incidence de l'infection est similaire entre les patients transplant\u00e9s (21 sur\u00a05000 patients) et la population g\u00e9n\u00e9rale (284 pour 100000 habitants au 6 avril 2020).\u00a0\nLa pr\u00e9sentation clinique et la mortalit\u00e9 sont\u00a0similaires \u00e0 celles de la population g\u00e9n\u00e9rale, mais le petit nombre de patients inclus dans l'\u00e9tude et l'\u00e2ge moyen inf\u00e9rieur \u00e0 celui de la population g\u00e9n\u00e9rale (56 ans vs 70 ans)\u00a0doivent \u00eatre pris en compte, car cela peut expliquer en partie les bons r\u00e9sultats des patients.\nL'\u00e9chantillon test\u00e9 pr\u00e9sentait des valeurs de param\u00e8tres inflammatoires inf\u00e9rieures \u00e0 celles de la population hospitalis\u00e9e (PCR 33mg/l vs 48 mg/l et D-dim\u00e8res 0.39\u00a0\u03bcg/ml vs 0-96 \u03bcg/ml).\nCes r\u00e9sultats devraient\u00a0\u00eatre \u00e9valu\u00e9s dans le cadre d'\u00e9tudes de cohortes plus grandes\u00a0avec des contr\u00f4les appropri\u00e9s.", "objectives": "Faible:1) Etude de cohorte observationnelle multicentrique2) Petit \u00e9chantillon (n=21)3) Suivi court (moyenne= 33 jours)4) Possible biais de s\u00e9lection : seuls les patients symptomatiques ont fait l'objet d'un d\u00e9pistage par RT-PCR", "methods": "D\u00e9crire l'\u00e9pid\u00e9miologie, la pr\u00e9sentation clinique, le traitement et les r\u00e9sultats pour les patients adultes greff\u00e9s d'organes affect\u00e9s par COVID-19.", "pubmed_id": "32412159", "doi": "10.1111/ajt.16062", "abstract": "Immunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Overall, 21 patients were included with a median age of 56\u00a0years (10 kidney, 5 liver, 1 pancreas, 1 lung, 1 heart and 3 combined transplantations). The most common presenting symptoms were fever (76%), dry cough (57%), nausea (33%), and diarrhea (33%). Ninety-five percent and 24% of patients required hospital and ICU admission, respectively, and 19% were intubated. After a median of 33\u00a0days of follow-up, 16 patients were discharged, 3 were still hospitalized and 2 patients died. These data suggest that clinical manifestations of SARS-CoV-2 infection in middle-aged SOT recipients appear to be similar to the general population without an apparent higher rate of complications. These results need to be confirmed in larger cohorts.", "topics": ["Epid\u00e9miologique", "Transversale", "N\u00e9phrologie", "H\u00e9pato-gastro-ent\u00e9rologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 567, "name": "Tschopp J"}], "publication_date": "2020-05-18"}, {"id": 103, "slug": "thrombocytopenia-is-associated-with-severe-coronavirus-disease-2019-covid-19-inf", "title": "Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9terminer si la num\u00e9ration plaquettaire peut diff\u00e9rencier les patients COVID-19 avec ou sans pathologie grave.Evaluer si la thrombocytop\u00e9nie est associ\u00e9e \u00e0 une forme grave de COVID-19", "verbose_date": "13.03.2020", "authors": "Lippi G", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 72, "name": "Clin Chim Acta"}, "link": "https://www.dropbox.com/s/e7d1qhqhy43cnnr/1-s2.0-S0009898120301248-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La r\u00e9duction du nombre de plaquettes est significativement diff\u00e9rente entre les patients pr\u00e9sentant une pathologie grave et ceux ne pr\u00e9sentant pas de pathologie grave.La thrombocytop\u00e9nie est associ\u00e9e \u00e0 un risque accru de pathologie grave (risque quintupl\u00e9)", "objectives": "Interm\u00e9diaire1) 9 \u00e9tudes dans la m\u00e9ta-analyse (dont 8 \u00e9tudes chinoises et 1 \u00e9tude de Singapore). Au totl 1779 patients / \u00e9chantillion varie entre 12 et 1099 patients par \u00e9tude2) 4 \u00e9tudes (sur 9) d\u00e9clarent la valeur de la trompocytop\u00e9nie (au total 1427 patients)3) 399 patients (22.4%) avec patologie grave", "methods": "D\u00e9terminer si la num\u00e9ration plaquettaire peut diff\u00e9rencier les patients COVID-19 avec ou sans pathologie grave.Evaluer si la thrombocytop\u00e9nie est associ\u00e9e \u00e0 une forme grave de COVID-19", "pubmed_id": "32178975\n21071526\n32125362\n32109013\n32171076\n15840177\n32125452\n16019455\n32118640\n32031570\n31986264\n8830480\n32154288\n29307969\n10890635\n29222318\n12837163\n32145275\n32048163\n32105632\n14765339", "doi": "10.1016/j.cca.2020.03.022", "abstract": "Coronavirus disease 2019 (COVID-19) is a novel infectious disease with lack of established laboratory markers available to evaluate illness severity. In this study, we investigate whether platelet count could differentiate between COVID-19 patients with or without severe disease. Additionally, we evaluate if thrombocytopenia is associated with severe COVID-19.\nAn electronic search in Medline, Scopus and Web of Science was performed to identify studies reporting data on platelet count in COVID-19 patients. A meta-analysis was performed, with calculation of weighted mean difference (WMD) of platelet number in COVID-19 patients with or without severe disease and odds ratio (OR) of thrombocytopenia for severe form of COVID-19.\nNine studies with 1779 COVID-19 patients, 399 (22.4%) with severe disease, were included in the meta-analysis. The pooled analysis revealed that platelet count was significantly lower in patients with more severe COVID-19 (WMD -31\u00a0\u00d7\u00a010\nLow platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 109, "name": "Lippi G"}], "publication_date": "2020-03-13"}, {"id": 641, "slug": "routine-venous-thromboembolism-prophylaxis-may-be-inadequate-in-the-hypercoagula", "title": "Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer la fr\u00e9quence des maladies thrombo-emboliques veineuses chez les patients COVID-19 graves et corr\u00e9ler ces \u00e9v\u00e8nements aux param\u00e8tres biologiques d'inflammation.", "verbose_date": "30.05.2020", "authors": "Maatman TK", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 217, "name": "Crit Care Med"}, "link": "https://journals.lww.com/ccmjournal/Abstract/9000/Routine_Venous_Thromboembolism_Prophylaxis_May_Be.95638.aspx", "findings": "", "take_away": "", "relevance_level": "Il semble que la mise en place d'une thrombo-prophylaxie dans ces conditions classiques de voie d'abord et de posologie soit insuffisante pour pr\u00e9venir le risque de survenue de thromboses veineuses profondes et d'embolies pulmonaires chez les patients atteints de COVID-19 grave. Des \u00e9tudes de meilleur niveau de preuve sont n\u00e9cessaires pour mieux caract\u00e9riser cette hypoth\u00e8se.", "objectives": "- \u00e9tude r\u00e9trospective (-)- inclusions de tous les patients cons\u00e9cutifs (+)- faible effectif pour l'\u00e9tude de la thrombo\u00e9lastrographie (-)- suivi incomplet pour 7 patients qui restaient hospitalis\u00e9s en fin d'\u00e9tude (dont 3 en soins intensifs) (-)- absence d'autopsie \u00e0 la recherche de caillots chez les patients d\u00e9c\u00e9d\u00e9s soudainement (-)- pas d'informations concernant les autres moyens de pr\u00e9vention de la maladie thrombo-embolique veineuse (-)", "methods": "D\u00e9terminer la fr\u00e9quence des maladies thrombo-emboliques veineuses chez les patients COVID-19 graves et corr\u00e9ler ces \u00e9v\u00e8nements aux param\u00e8tres biologiques d'inflammation.", "pubmed_id": "32459672", "doi": "10.1097/CCM.0000000000004466", "abstract": "The aim of this study was to determine the frequency of venous thromboembolism in critically ill coronavirus disease 2019 patients and associate a degree of inflammatory marker elevation to venous thromboembolism development.\nAn observational study that identified patients with severe coronavirus disease 2019 between March 12, 2020, and March 31, 2020. Data reported are those available through May 6, 2020.\nA multicenter study including three Indianapolis area academic hospitals.\nTwo-hundred forty consecutive patients with confirmed severe acute respiratory syndrome coronavirus 2 infection were admitted to one of three hospitals. One-hundred nine critically ill coronavirus disease 2019 patients admitted to the ICU were included in the analysis.\nAll patients received routine subcutaneous chemical venous thromboembolism prophylaxis.\nThe primary outcome of this study was to determine the frequency of venous thromboembolism and the degree of inflammatory and coagulation marker elevation associated with venous thromboembolism development. Descriptive statistics outlined the frequency of venous thromboembolism at any time during severe coronavirus disease 2019. Clinical course and laboratory metrics were compared between patients that developed venous thromboembolism and patients that did not develop venous thromboembolism. Hypercoagulable thromboelastography was defined as two or more hypercoagulable parameters.\nOne-hundred nine patients developed severe coronavirus disease 2019 requiring ICU care. The mean (\u00b1 SD) age was 61 \u00b1 16 years and 57% were male. Seventy-five patients (69%) were discharged home, 7 patients (6%) remain in the hospital, and 27 patients (25%) died. Venous thromboembolism was diagnosed in 31 patients (28%) 8 \u00b1 7 days after hospital admission, including two patients diagnosed with venous thromboembolism at presentation to the hospital. Elevated admission D-dimer and peak D-dimer were associated with venous thromboembolism development (p < 0.05). D-dimer greater than 2,600 ng/mL predicted venous thromboembolism with an area under the receiver operating characteristic curve of 0.760 (95% CI, 0.661-0.858; p < 0.0001), sensitivity of 89.7%, and specificity of 59.5%. Twelve patients (11%) had thromboelastography performed and 58% of these patients had a hypercoagulable study. The calculated coagulation index was hypercoagulable in 50% of patients with thromboelastography.\nThese data show that coronavirus disease 2019 results in a hypercoagulable state. Routine chemical venous thromboembolism prophylaxis may be inadequate in preventing venous thromboembolism in severe coronavirus disease 2019.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 603, "name": "Maatman TK"}], "publication_date": "2020-05-30"}, {"id": 80, "slug": "impact-of-non-pharmaceutical-interventions-npis-to-reduce-covid-19-mortality-and", "title": "Impact of non-pharmaceutical interventions (NPIs) to reduce COVID- 19 mortality and healthcare demand", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer l'impact des interventions non pharamaceutiques pour r\u00e9duire la mortalit\u00e9 du COVID-19 et la demande en soins en sant\u00e9 au Royaume-Uni et aux Etats-Unis", "verbose_date": "16.03.2020", "authors": "Ferguson NM", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 62, "name": "Imperial College COVID-19 Response Team"}, "link": "https://www.dropbox.com/s/w64zau2c5fvo1bk/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "N\u00e9cessit\u00e9 de combiner les mesures, strat\u00e9gie de suppression > strat\u00e9gie d'att\u00e9nuationPossibilit\u00e9 de mesures intermittentes de distanciation sociale g\u00e9n\u00e9rale +/- fermeture des \u00e9coles (effet sur l'absent\u00e9isme des professionnels de sant\u00e9 :\u00e0 d\u00e9clencher quand le nombre de nouveaux cas rebondit avec en continu isolation des cas et quarantaine des proches => jusqu'\u00e0 l'obtention d'un vaccinAttention \u00e0 la seconde vague \u00e0 la lev\u00e9e des mesures", "objectives": "Interm\u00e9diaire : 1) Mod\u00e8le utilis\u00e9 pour la grippe pand\u00e9mique avec ajustement par rapport au COVID2) Mesures \u00e9tudi\u00e9es parfois incoh\u00e9rentes: fermeture des \u00e9coles et universit\u00e9s (mais 25% des universit\u00e9s restent ouvertes), isolation des cas uniquement 7 jours", "methods": "Evaluer l'impact des interventions non pharamaceutiques pour r\u00e9duire la mortalit\u00e9 du COVID-19 et la demande en soins en sant\u00e9 au Royaume-Uni et aux Etats-Unis", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 90, "name": "Ferguson NM"}], "publication_date": "2020-03-16"}, {"id": 433, "slug": "the-profile-of-peripheral-blood-lymphocyte-subsets-and-serum-cytokines-in-childr", "title": "The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etude du profil de sous classes lymphocytaires et des cytokines chez l\u2019enfant atteint du COVID-19", "verbose_date": "22.04.2020", "authors": "Li H", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.journalofinfection.com/article/S0163-4453(20)30207-3/pdf", "findings": "", "take_away": "", "relevance_level": "1er : La r\u00e9ponse des lymphocyte CD8+ pourrait avoir un r\u00f4le dans la s\u00e9v\u00e9rit\u00e9 du coronavirus\r\n2\u00e8me : La modulation d\u2019IL10 pourrait pr\u00e9server les patients d\u2019une infection s\u00e9v\u00e8re\r\n3\u00e8me : Une co-infection bact\u00e9rienne pourrait \u00eatre un facteur de mauvais pronostic\u00a0\r\nSans que l'article soit assez probant pour en faire des certitudes.", "objectives": "Pre-proofEtude r\u00e9trospective, monocentriquePetit effectif et notamment un seul cas de pneumonie s\u00e9v\u00e8rePas de comparaison : -\tentre les diff\u00e9rents degr\u00e9s de s\u00e9v\u00e9rit\u00e9 du COVID -\tavec des enfants sainsEtude fait principalement de d\u00e9duction et de supposition devant l\u2019\u00e9tude de pourcentage", "methods": "Etude du profil de sous classes lymphocytaires et des cytokines chez l\u2019enfant atteint du COVID-19", "pubmed_id": "32325129", "doi": "10.1016/j.jinf.2020.04.001", "abstract": "The study was aimed at investigating the characteristics of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus (2019-nCoV) pneumonia.\nChildren with 2019-nCoV pneumonia or with respiratory syncytial virus (RSV) pneumonia were included. Data including lymphocyte subsets and serum cytokines were collected and analyzed.\n56 patients were included in the study, 40 children with 2019-nCoV pneumonia and 16 children with RSV pneumonia. Compared with children with RSV pneumonia, patients with 2019-nCoV pneumonia had higher count of CD3+8+ lymphocyte, higher percentages of CD3+, CD3+8+ lymphocytes and a lower percentage of CD19+ lymphocyte. The serum IL-10 level was significantly higher in children with RSV pneumonia. One 2019-nCoV pneumonia child who was with an obvious increase of IL-10 developed severe pneumonia.\nImmune response played a very important role in the development of 2019-nCoV pneumonia. The effective CD8+ T cell response might influence the severity of 2019-nCoV pneumonia. The adaptable change in IL-10 level might contribute to the relatively mild pneumonia symptoms in children with 2019-nCoV pneumonia and bacterial co-infection might be a risk factor of severe 2019-nCoV pneumonia.", "topics": ["Autres", "Infectiologie", "P\u00e9diatrie"], "author_list": [{"id": 393, "name": "Li H"}], "publication_date": "2020-04-22"}, {"id": 164, "slug": "favipiravir-versus-arbidol-for-covid-19-a-randomized-clinical-trial", "title": "Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9terminer l'efficacit\u00e9 et la s\u00e9curit\u00e9 du traitement par le Favipiravir pour les patients COVID-19 (groupe contr\u00f4le de l'\u00e9tude trait\u00e9 par Arbidol)", "verbose_date": "26.03.2020", "authors": "Chang C ", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/5pn004n7aac93ea/2020.03.17.20037432v1.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Taux de gu\u00e9rison clinique \u00e0 7 jours ou \u00e0 la fin du traitement: les patients mod\u00e9r\u00e9s 55.86%(62/111) pour le groupe Arbidol vs 71.43%(70/98) pour le groupe Favipiravir (p=0.0199).\u00a0\n\r\nD\u00e9lai entre la randomisation et la r\u00e9duction de la fi\u00e8vre et le soulagement de la toux: patients mod\u00e9r\u00e9s et patients avec HTA/diab\u00e8te: d\u00e9lai statistiquement plus court pour le groupe Favipiravir (p<0.0001)\n\r\nTaux de l'oxyg\u00e9noth\u00e9rapie auxiliaire ou ventilation m\u00e9canique non invasive: patients mod\u00e9r\u00e9s 17.12%(19/111) pour le groupe Arbidol vs 8.16%(8/98) pour le groupe Favipiravir (p=0.0541)\n\r\n==> Chez les patients COVID-19 mod\u00e9r\u00e9s non trait\u00e9s par antiviral auparavant, le Favipiravir peut \u00eatre consid\u00e9r\u00e9 comme un traitement privil\u00e9gi\u00e9 par rapport \u00e0 l'Arbidol en raison d'un taux de gu\u00e9rison clinique sup\u00e9rieur au jour 7 et plus efficacement r\u00e9duction de l'incidence de la fi\u00e8vre et de la toux.", "objectives": "1) \u00e9tude ex\u00e9rimental prospective, multicentrique, open-label, randomis\u00e9e2) \u00e9tude construite pour 240 pts : 120 groupe exp\u00e9rimental mais seulement 116 suivis (pourquoi ? pas motiv\u00e9) et 120 groupe de contr\u00f4le3) il n'existe aucun m\u00e9dicament antiviral dont l'efficacit\u00e9 contre le SRAS-CoV-2 est prouv\u00e9e, l'Arbidol est choisi pour le groupe de contr\u00f4le car il est utilis\u00e9 de mani\u00e8re empirique par les m\u00e9decins chinois4) pts suivis pendant une p\u00e9riode limit\u00e9e (20 f\u00e9vr 2020- 12 mars 2020), pas de suivi apr\u00e8s la d\u00e9charge5) recherche d'acides nucl\u00e9iques viraux non pris en compte dans les crit\u00e8res d'inclusion6) 18 pts graves dans le groupe exp\u00e9rimental et seulement 9 pts graves dans le groupe t\u00e9moin\nAttention : Pre-Prints (pas encore de reviewing)", "methods": "D\u00e9terminer l'efficacit\u00e9 et la s\u00e9curit\u00e9 du traitement par le Favipiravir pour les patients COVID-19 (groupe contr\u00f4le de l'\u00e9tude trait\u00e9 par Arbidol)", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 160, "name": "Chang C "}], "publication_date": "2020-03-26"}, {"id": 13, "slug": "systematic-review-of-covid19-in-children-show-milder-cases-and-a-better-prognosi", "title": "Systematic review of COVID\u201019 in children show milder cases and a better prognosis than adults", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00e9sumer les connaissances sur le COVID-19 chez l'enfant", "verbose_date": "25.03.2020", "authors": "Ludvigsson JF", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 10, "name": "Acta Paediatr"}, "link": "https://www.dropbox.com/s/h6nwwchgef2mxg9/apa.15270.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le 18/03/2020, 1 \u00e0 5% des cas de COVID-19 concernent des 0-19 ans avec une forme l\u00e9g\u00e8re la plupart du temps et tr\u00e8s peu de d\u00e9c\u00e8s ont \u00e9t\u00e9 notifi\u00e9s. Les sympt\u00f4mes sont globalement les m\u00eames que chez l'adulte mais on d\u00e9nombre moins de pneumopathies s\u00e9v\u00e8res. Par contre les marqueurs inflammatoires sont moins souvent augment\u00e9s chez l'enfant et la lymphop\u00e9nie est rare. Pas de preuve formelle d'une transmission verticale pendant la grossesse. Il faudrait d\u00e9sormais des \u00e9tudes dans d'autres pays pour pouvoir les comparer aux donn\u00e9es chinoises.", "objectives": "Faible:1) Revue syst\u00e9matique2) Relativement peu de cas chez l'enfant3) La plupart des \u00e9tudes des cas p\u00e9diatriques portent sur les enfants chinois4) Recoupement des cas entre \u00e9tudes5) Des articles chinois non traduits en anglais pour le moment6) Recommandations chinoises pour les enfants non adapt\u00e9es aux formes l\u00e9g\u00e8res (balance b\u00e9n\u00e9fice-risque du scanner thoracique dans ce cas?)7) Des cas non confirm\u00e9s par test du SARS-CoV-2", "methods": "R\u00e9sumer les connaissances sur le COVID-19 chez l'enfant", "topics": ["Autres", "P\u00e9diatrie"], "author_list": [{"id": 24, "name": "Ludvigsson JF"}], "publication_date": "2020-03-25"}, {"id": 357, "slug": "pediatric-airway-management-in-covid-19-patients-consensus-guidelines-from-the-s", "title": "Pediatric Airway Management in COVID-19 patients - Consensus Guidelines from the Society for Pediatric Anesthesia's Pediatric Difficult Intubation Collaborative and the Canadian Pediatric Anesthesia Society", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Recommandations, protection du personnel lors de la gestion de l'airway chez l'enfant COVID", "verbose_date": "16.04.2020", "authors": "Matava CT", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 154, "name": "Anesth Analg"}, "link": "https://www.dropbox.com/s/pye9v95kkdifzdu/Pediatric_Airway_Management_in_COVID_19_patients__.95683.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Anxiolyse avant induction, induction IV, sondes d'intubation avec ballonnet, utilisation du vid\u00e9olaryngoscope, syst\u00e8me d'aspiration endotrach\u00e9al clos, EPI, pression n\u00e9gative dans la pi\u00e8ce, temps de m\u00e9nage \u00e0 respecter", "objectives": "Avis d'expert bas\u00e9 sur la litt\u00e9rature actuelle", "methods": "Recommandations, protection du personnel lors de la gestion de l'airway chez l'enfant COVID", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "P\u00e9diatrie"], "author_list": [{"id": 344, "name": "Matava CT"}], "publication_date": "2020-04-16"}, {"id": 483, "slug": "prevalence-of-sars-cov-2-infection-in-residents-of-a-large-homeless-shelter-in-b", "title": "Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer la pr\u00e9valence de l'infection COVID-19 dans un refuge pour sans domiciles fixes.", "verbose_date": "29.04.2020", "authors": "Baggett TP", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://www.dropbox.com/s/wcy29wyfb6o83jl/10.1001%40jama.2020.6887.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Dans un foyer de sans-abris (USA), 36% des participants \u00e9taient positifs pour le COVID-19 avec une pr\u00e9dominance accrue des hommes et 88% d'asymptomatiques, sans lien apparent avec l'\u00e2ge ou l'origine ethnique.", "objectives": "Etude \u00e9pid\u00e9miologique transversale descriptive", "methods": "Evaluer la pr\u00e9valence de l'infection COVID-19 dans un refuge pour sans domiciles fixes.", "pubmed_id": "32338732", "doi": "10.1001/jama.2020.6887", "abstract": null, "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 451, "name": "Baggett TP"}], "publication_date": "2020-04-29"}, {"id": 475, "slug": "transmission-risk-of-sars-cov-2-to-healthcare-workers-observational-results-of-a", "title": "Transmission risk of SARS-CoV-2 to healthcare workers -observational results of a primary care hospital contact tracing", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'investigation de professionnels de sant\u00e9 contacts d'un patient COVID-19 diagnostiqu\u00e9 tardivement", "verbose_date": "28.04.2020", "authors": "Canova V", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 193, "name": "Swiss Med Weekly"}, "link": "https://www.dropbox.com/s/zn5fg2avms8r6p4/smw_2020_20257.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Pas d'infection retrouv\u00e9e chez 21 professionnels de sant\u00e9 expos\u00e9s \u00e0 un patient COVID-19 diagnostiqu\u00e9 apr\u00e8s son s\u00e9jour dans cet h\u00f4pital, m\u00eame si absence de port de masque et contacts proches (notamment \u00e9couvillonnage nasopharyng\u00e9). Mais les contacts ont \u00e9t\u00e9 relativement limit\u00e9s et le patient toussait peu.", "objectives": "1) Etude descriptive, revue de l'investigation de professionnels contacts2) Monocentrique3) Un test \u00e0 7 jours uniquement, p\u00e9riode de suivi de 14 jours4) Pas de donn\u00e9es sur PCR quantitative ou culture cellulaire\"", "methods": "D\u00e9crire l'investigation de professionnels de sant\u00e9 contacts d'un patient COVID-19 diagnostiqu\u00e9 tardivement", "pubmed_id": "32333603", "doi": "10.4414/smw.2020.20257", "abstract": "The coronavirus disease (COVID)-19 epidemic is evolving rapidly. Healthcare workers are at increased risk for infection, and specific requirements for their protection are advisable to ensure the functioning of the basic healthcare system, including the availability of general practitioners (GPs). Understanding the transmission risk is particularly important for guiding evidence-based protective measures in the primary healthcare setting.\nHealthcare worker contacts of an initially undiagnosed COVID-19 case, who were without personal protective equipment, in particular not wearing facemasks, were screened with nasopharyngeal swabs and polymerase chain reaction tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), irrespective of respiratory symptoms or fever seven days after initial contact. The details of exposure to the index case were obtained during routine contact investigation after unintentional pathogen exposure.\nTwenty-one healthcare workers reported contacts with the index case. Three healthcare workers reported respiratory symptoms (cough) or low-grade fever within 4 days. None of them tested positive for SARS-CoV-2 at the time of symptom onset. All 21 healthcare workers tested SARS-CoV-2 negative 7 days after initial index case contact, including the three healthcare workers with previous symptoms. Ten of the 21 healthcare workers reported a cumulative exposure time of &gt;15 minutes. Longer cumulative contact times were associated with more individual contacts, reduced contact time per contact and activities with physical patient contact. The closest relative of the index patient tested SARS-CoV-2 positive 2 days after the index case presented at the hospital emergency department.\nWe found a low risk of SARS-CoV-2 transmission in a primary care setting. These findings are compatible with previous reports of the highest transmission probability in household settings with prolonged close contacts. The current protective measures for healthcare workers, including strict adherence to basic standard hygiene and facemasks, offer considerable protection during short periods of contact with symptomatic COVID-19 cases by diminishing the risk of direct and indirect transmission.", "topics": ["Epid\u00e9miologique", "Hygi\u00e8ne"], "author_list": [{"id": 443, "name": "Canova V"}], "publication_date": "2020-04-28"}, {"id": 117, "slug": "how-health-anxiety-influences-responses-to-viral-outbreaks-like-covid-19-what-al", "title": "How health anxiety influences responses to viral outbreaks like COVID-19: What all decision-makers, health authorities, and health care professionals need to know", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00f4le de l\u2019anxi\u00e9t\u00e9 dans les prises de d\u00e9cision", "verbose_date": "10.03.2020", "authors": "Asmundson GJG", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 78, "name": "J Anxiety Disord"}, "link": "https://www.dropbox.com/s/eyeeu8wd48iysha/asmundson2020.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Anxi\u00e9t\u00e9 modif\u00e9e par l'\u00e9pid\u00e9mie avec 2 comportements d'adaptation inadapt\u00e9es :- Niveau d'anxi\u00e9t\u00e9 \u00e9lev\u00e9 avec conduites \u00e0 risques (stockage compulsif de produits de premi\u00e8re n\u00e9cessit\u00e9)- Niveau d'anxi\u00e9t\u00e9 insuffisament \u00e9lev\u00e9 avec sentiment d'invul\u00e9naribilit\u00e9 (peu d'hygi\u00e8ne, non respect des r\u00e8gles de distanciation ou de confinement)N\u00e9cessit\u00e9 d'idenditifier syst\u00e9matiquement l'\u00e9tat d'anxi\u00e9t\u00e9 des patients pour adapter la PEC en p\u00e9riode \u00e9pid\u00e9mique", "objectives": "Faible : 1) Editorial", "methods": "R\u00f4le de l\u2019anxi\u00e9t\u00e9 dans les prises de d\u00e9cision", "pubmed_id": "32179380\n22169014\n21476079\n21208765\n32125355\n32078967\n20549396\n23301849\n32172210", "doi": "10.1016/j.janxdis.2020.102211", "abstract": null, "topics": ["Autres", "Psychiatrie"], "author_list": [{"id": 123, "name": "Asmundson GJG"}], "publication_date": "2020-03-10"}, {"id": 545, "slug": "the-prevalence-of-olfactory-and-gustatory-dysfunction-in-covid-19-patients-a-sys", "title": "The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Pr\u00e9valence de la dysfonction gustative et olfactive chez les patients Covid-19.", "verbose_date": "07.05.2020", "authors": "Tong JY", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 133, "name": "Otorhinolaryngol"}, "link": "https://journals.sagepub.com/doi/pdf/10.1177/0194599820926473", "findings": "", "take_away": "", "relevance_level": "La dysfonction olfactive et gustative est fr\u00e9quente chez les patients atteints de COVID-19 et peut repr\u00e9senter des sympt\u00f4mes pr\u00e9coces au cours de l'infection. La pr\u00e9valence significativement plus \u00e9lev\u00e9e d\u00e9tect\u00e9e par des instruments valid\u00e9s sugg\u00e8re que la v\u00e9ritable pr\u00e9valence de dysfonctionnement olfactif et gustatif chez les patients COVID-19 peut rester sous-estim\u00e9e.", "objectives": "- M\u00e9thodologie claire et d\u00e9taill\u00e9e- Risque de biais mod\u00e9r\u00e9 pour la quasi totalit\u00e9 des 10 \u00e9tudes incluses (seulement une \u00e9tude avec un risque de biais \u00e9lev\u00e9)- Peu d'\u00e9tudes incluses", "methods": "Pr\u00e9valence de la dysfonction gustative et olfactive chez les patients Covid-19.", "pubmed_id": "32369429", "doi": "10.1177/0194599820926473", "abstract": "To determine the pooled global prevalence of olfactory and gustatory dysfunction in patients with the 2019 novel coronavirus (COVID-19).\nLiterature searches of PubMed, Embase, and Scopus were conducted on April 19, 2020, to include articles written in English that reported the prevalence of olfactory or gustatory dysfunction in COVID-19 patients.\nSearch strategies developed for each database contained keywords such as \nTen studies were analyzed for olfactory dysfunction (n = 1627), demonstrating 52.73% (95% CI, 29.64%-75.23%) prevalence among patients with COVID-19. Nine studies were analyzed for gustatory dysfunction (n = 1390), demonstrating 43.93% (95% CI, 20.46%-68.95%) prevalence. Subgroup analyses were conducted for studies evaluating olfactory dysfunction using nonvalidated and validated instruments and demonstrated 36.64% (95% CI, 18.31%-57.24%) and 86.60% (95% CI, 72.95%-95.95%) prevalence, respectively.\nOlfactory and gustatory dysfunction are common symptoms in patients with COVID-19 and may represent early symptoms in the clinical course of infection. Increased awareness of this fact may encourage earlier diagnosis and treatment, as well as heighten vigilance for viral transmission. To our knowledge, this is the first meta-analysis to report on the prevalence of these symptoms in COVID-19 patients.", "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 510, "name": "Tong JY"}], "publication_date": "2020-05-07"}, {"id": 44, "slug": "can-angiotensin-receptor-blocking-drugs-perhaps-be-harmful-in-the-covid-19-pande", "title": "Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'impact possible des antihypertenseurs", "verbose_date": "20.03.2020", "authors": "Murray E", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 38, "name": "J Hypertens"}, "link": "https://www.dropbox.com/s/bjqz4cvv80yxvh4/Can_angiotensin_receptor_blocking_drugs_perhaps_be.97003.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Hypothese : les m\u00e9dicaments bloqueurs des r\u00e9cepteurs \u00e0 l'angiotensine (ARB) augmentent l'expression des r\u00e9cepteurs ACE2, ce qui serait favorable pour l'infection \u00e0 SARS-CoV-2. La piste favorite pour un vaccin serait l'antagonisme immunologique du site de liaison des spikes de SARS-CoV-2 aux r\u00e9cepteurs ACE2.La prescription de ARB pendant l'\u00e9pid\u00e9mie pourrait donc \u00eatre nocive, d'autres classes d'antihypertenseur sont pr\u00e9f\u00e9r\u00e9es. Aucune augmentation de posologie de ARB ni instauration de traitement par ARB ne devrait \u00eatre faite chez des COVID19. Dans les formes s\u00e9v\u00e8res les ARB devraient peut \u00eatre \u00eatre switch\u00e9es pour d'autre antihypertenseurs. La d\u00e9croissance de l'expression des r\u00e9cepteurs ACE2 apr\u00e8s l'arr\u00eat des ARB n'est pas connue. Compte tenu de l'\u00e9pid\u00e9mie et de son \u00e9volution grandissante, il faudrait peut \u00eatre d\u00e9ja remplacer les ARB par d'autres anti hypertenseurs.Nos recommandations actuelles sont de ne PAS ARRETER les ARB AVANT CONFIRMATION DE CES HYPOTHESES. Le d\u00e9s\u00e9quilibre tensionnel qui pourrait survenir en cas de changement de traitement entrainerait des risques qui ne sont pas hypoth\u00e9tiques. La prise discontinue d'antihypertenseurs est fortement d\u00e9courag\u00e9e.", "objectives": "Faible :- lettre \u00e0 l'\u00e9diteur", "methods": "D\u00e9crire l'impact possible des antihypertenseurs", "pubmed_id": "32195824", "doi": "10.1097/HJH.0000000000002450", "abstract": null, "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 54, "name": "Murray E"}], "publication_date": "2020-03-20"}, {"id": 153, "slug": "identifying-locations-with-possible-undetected-imported-severe-acute-respiratory", "title": "Identifying Locations with Possible Undetected Imported Severe Acute Respiratory Syndrome Coronavirus 2 Cases by Using Importation Predictions.", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Identifier les emplacements qui pourraient avoir des cas de COVID-19 import\u00e9s de Wuhan et non d\u00e9tect\u00e9s", "verbose_date": "26.03.2020", "authors": "De Salazar PM ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 28, "name": "Emerg Infect Dis"}, "link": "https://wwwnc.cdc.gov/eid/article/26/7/20-0250_article", "findings": "", "take_away": "", "relevance_level": "Mod\u00e8le disponible sur github, estimant le nombre de cas import\u00e9s \u00e0 partir du nombre estim\u00e9 de passagers quotidiens des vols internationaux au d\u00e9part de Wuhan", "objectives": "1) Early release2) Mod\u00e8le relativement simple, avec des hypoth\u00e8ses non document\u00e9es, r\u00e9alis\u00e9 au d\u00e9but de l'\u00e9pid\u00e9mie avec peu de cas import\u00e9s dans les pays et modification du trafic a\u00e9rien3) Estimations du nombre de passagers dans les vols a\u00e9riens, avec donn\u00e9es manquantes", "methods": "Identifier les emplacements qui pourraient avoir des cas de COVID-19 import\u00e9s de Wuhan et non d\u00e9tect\u00e9s", "pubmed_id": "32207679", "doi": "10.3201/eid2607.200250", "abstract": "Cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection exported from mainland China could lead to self-sustained outbreaks in other countries. By February 2020, several countries were reporting imported SARS-CoV-2 cases. To contain the virus, early detection of imported SARS-CoV-2 cases is critical. We used air travel volume estimates from Wuhan, China, to international destinations and a generalized linear regression model to identify locations that could have undetected imported cases. Our model can be adjusted to account for exportation of cases from other locations as the virus spreads and more information on importations and transmission becomes available. Early detection and appropriate control measures can reduce the risk for transmission in all locations.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 149, "name": "De Salazar PM "}], "publication_date": "2020-03-26"}, {"id": 34, "slug": "intubation-and-ventilation-amid-the-covid-19-outbreak-wuhans-experience", "title": "Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan's Experience", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'exp\u00e9rience de Wuhan pour les intubations et ventilations des patients COVID-19", "verbose_date": "20.03.2020", "authors": "Meng", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 30, "name": "Anaesthesiology"}, "link": "https://www.dropbox.com/s/jdmyk60dmqdkx4v/aln.0000000000003296.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Des cas d\u00e9crits d'hypox\u00e9mie silencieuse :attention !Pr\u00e9paration pour IOT +++ Recommandations pour l'IOT d\u00e9taill\u00e9es dans l'article ainsi que recommandations pour la ventilation\u00e0 noter : privil\u00e9gier vid\u00e9olaryngoscope pour IOT, \u00e9viter auscultation post IOT et post extubationEviter ventilation oscillatoire \u00e0 HF, d\u00e9cubitus ventral conseill\u00e9 d\u00e8s le d\u00e9but et non comme ultime mesure", "objectives": "Faible 1) Article non corrig\u00e92) Retour d'exp\u00e9rience", "methods": "D\u00e9crire l'exp\u00e9rience de Wuhan pour les intubations et ventilations des patients COVID-19", "pubmed_id": "32195705", "doi": "10.1097/ALN.0000000000003296", "abstract": "The COVID-19 outbreak has led to 80,409 diagnosed cases and 3,012 deaths in mainland China based on the data released on March 4, 2020. Approximately 3.2% of patients with COVID-19 required intubation and invasive ventilation at some point in the disease course. Providing best practices regarding intubation and ventilation for an overwhelming number of patients with COVID-19 amid an enhanced risk of cross-infection is a daunting undertaking. The authors presented the experience of caring for the critically ill patients with COVID-19 in Wuhan. It is extremely important to follow strict self-protection precautions. Timely, but not premature, intubation is crucial to counter a progressively enlarging oxygen debt despite high-flow oxygen therapy and bilevel positive airway pressure ventilation. Thorough preparation, satisfactory preoxygenation, modified rapid sequence induction, and rapid intubation using a video laryngoscope are widely used intubation strategies in Wuhan. Lung-protective ventilation, prone position ventilation, and adequate sedation and analgesia are essential components of ventilation management.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 44, "name": "Meng"}], "publication_date": "2020-03-20"}, {"id": 225, "slug": "sars-cov-2-is-not-detectable-in-the-vaginal-fluid-of-women-with-severe-covid-19-", "title": "SARS-CoV-2 Is Not Detectable in the Vaginal Fluid of Women With Severe COVID-19 Infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer la pr\u00e9sence de SARS-CoV-2 dans les fluides vaginaux des patientes COVID-19", "verbose_date": "02.04.2020", "authors": "Qiu L", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 24, "name": "Clin Infect Dis"}, "link": "https://www.dropbox.com/s/ajebv5w3bawtt94/ciaa375.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Pr\u00e9levements vaginaux n\u00e9gatifs chez 10 femmes post-m\u00e9nopaus\u00e9es atteintes de formes s\u00e9v\u00e8res de COVID-19", "objectives": "1) Etude de cohorte monocentrique r\u00e9trospective, n=102) Pr\u00e9levements r\u00e9alis\u00e9s tardivement entre J17 et J40 du d\u00e9but des sympt\u00f4mes, \u00e0 des moments o\u00f9 la charge virale pouvait \u00eatre moins \u00e9lev\u00e9e. Toutes sous traitement antiviral.3) Triple v\u00e9rification des donn\u00e9es\"", "methods": "Evaluer la pr\u00e9sence de SARS-CoV-2 dans les fluides vaginaux des patientes COVID-19", "topics": ["Autres", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 216, "name": "Qiu L"}], "publication_date": "2020-04-02"}, {"id": 386, "slug": "comparison-of-nasopharyngeal-and-oropharyngeal-swabs-for-sars-cov-2-detection-in", "title": "Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Comparer les performances des pr\u00e9l\u00e8vements nasopharyng\u00e9s et oropharyng\u00e9s pour le diagnostic du SRAS-CoV-2 par test RT-PCR.", "verbose_date": "20.04.2020", "authors": "Wang X", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1201971220302356?token=513184ADCEDE1FA45FAA2990259650032869DF9044F5F579E60DB9217C4F0F7F53BCCC6724B701599B09753E4602FDE8", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude montre que 73,1% des cas d'\u00e9chantillons nasopharyng\u00e9s \u00e9taient n\u00e9gatifs pour l'\u00e9chantillon oropharyng\u00e9.\r\nLes pr\u00e9l\u00e8vements oropharyng\u00e9s sont corr\u00e9l\u00e9s avec un nombre plus \u00e9lev\u00e9 de r\u00e9sultats faux n\u00e9gatifs et il est donc recommand\u00e9 d'utiliser des pr\u00e9l\u00e8vements nasopharyng\u00e9s pour diagnostiquer la pr\u00e9sence du SRAS-CoV-2 par RT-PCR.\r\nCe r\u00e9sultat est particuli\u00e8rement important pour \u00e9valuer la sortie d'h\u00f4pital des patients sur la base de deux r\u00e9sultats n\u00e9gatifs de RT-PCR sur des \u00e9chantillons de voies a\u00e9riennes \u00e0 au moins un jour d'intervalle, comme le recommande l'OMS.", "objectives": "1) \u00e9tude observationnelle r\u00e9trospective bien men\u00e9e", "methods": "Comparer les performances des pr\u00e9l\u00e8vements nasopharyng\u00e9s et oropharyng\u00e9s pour le diagnostic du SRAS-CoV-2 par test RT-PCR.", "pubmed_id": "32315809\n32147628\n32075786\n32105609\n32091533\n32031570\n32105304\n32007143\n32105632\n32085850\n32227757\n32102856\n32034659\n32109013\n32058570\n19423873", "doi": "10.1016/j.ijid.2020.04.023", "abstract": "Since the outbreak of coronavirus disease (COVID-19) in Wuhan in December 2019, by March 10, 2020, a total of 80,932 confirmed cases have been reported in China. Two consecutively negative RT-PCR test results in respiratory tract specimens is required for the evaluation of discharge from hospital, and oropharyngeal swabs were the most common sample. However, false negative results occurred in the late stage of hospitalization, and avoiding false negative result is critical essential.\nWe reviewed the medical record of 353 patients who received tests with both specimens simultaneously, and compared the performance between nasopharyngeal and oropharyngeal swabs.\nOf the 353 patients (outpatients, 192; inpatients, 161) studied, the median age was 54 years, and 177 (50.1%) were women. Higher positive rate (positive tests/total tests) was observed in nasopharyngeal swabs than oropharyngeal swabs, especially in inpatients. Nasopharyngeal swabs from inpatients showed higher positive rate than outpatients. Nasopharyngeal swabs from male showed higher positive rate than female, especially in outpatients. Detection with both specimens slightly increased the positive rate than nasopharyngeal swab only. Moreover, the consistency between from nasopharyngeal and oropharyngeal swabs were poor (Kappa=0.308).\nIn conclusion, our study suggests that nasopharyngeal swabs may be more suitable than oropharyngeal swab at this stage of COVID-19 outbreak.", "topics": ["Diagnostique", "Transversale", "Virologie", "Infectiologie"], "author_list": [{"id": 372, "name": "Wang X"}], "publication_date": "2020-04-20"}, {"id": 571, "slug": "systematic-review-of-the-prevalence-of-current-smoking-among-hospitalized-covid-", "title": "Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "L'objectif de cette \u00e9tude \u00e9tait d'examiner syst\u00e9matiquement la pr\u00e9valence du tabagisme actuel parmi toutes les s\u00e9ries de cas publi\u00e9s de patients hospitalis\u00e9s atteints de COVID-19 en Chine, et de la comparer avec la pr\u00e9valence du tabagisme actuel dans la population.", "verbose_date": "12.05.2020", "authors": "Farsalinos K", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 228, "name": "Intern Emerg Med"}, "link": "https://doi.org/10.1007/s11739-020-02355-7", "findings": "", "take_away": "", "relevance_level": "La pr\u00e9valence estim\u00e9e du tabagisme actuel chez les patients atteints de COVID-19 en Chine \u00e9tait \u00e9tonnamment faible, environ un quart de la derni\u00e8re estimation de la pr\u00e9valence du tabagisme dans la population en Chine.\nCette analyse pr\u00e9liminaire, en supposant que les donn\u00e9es rapport\u00e9es soient exactes, sugg\u00e8re que le tabagisme actuel ne semble pas \u00eatre un facteur pr\u00e9disposant \u00e0 l'hospitalisation pour le COVID-19. Toutefois, il existe des limites qui ne peuvent \u00eatre abord\u00e9es avec les preuves et les donn\u00e9es actuellement disponibles.\r\nBien que le conseil g\u00e9n\u00e9ralis\u00e9 d'arr\u00eater de fumer comme mesure de r\u00e9duction du risque pour la sant\u00e9 reste valable, les r\u00e9sultats, ainsi que les effets immunomodulateurs bien \u00e9tablis de la nicotine, sugg\u00e8rent que la nicotine pharmaceutique devrait \u00eatre consid\u00e9r\u00e9e comme une option de traitement potentielle dans le cadre du COVID-19, et justifient une \u00e9tude des effets cliniques de la nicotine pharmaceutique sur le COVID-19 par le biais d'essais cliniques.", "objectives": "-\tRevue syst\u00e9matique de la litt\u00e9rature (PubMed) et m\u00e9ta-analyse-\tLimites : des facteurs de confusion, tels que le statut socio-\u00e9conomique, devraient \u00eatre pris en compte ; la pr\u00e9valence du tabagisme n'a pas \u00e9t\u00e9 ajust\u00e9e en fonction du sexe ; \u00e0 l'heure actuelle, il est impossible d'effectuer une analyse multivari\u00e9e ou d'examiner la pr\u00e9valence de l'hospitalisation COVID-19 en fonction du statut tabagique dans un \u00e9chantillon repr\u00e9sentatif de la population ; l'exactitude de la situation tabagique enregistr\u00e9e est \u00e9galement inconnue. Une autre limite est que des diff\u00e9rences dans la pr\u00e9valence du tabagisme dans la population peuvent exister entre les groupes d'\u00e2ge, \u00e9tant donn\u00e9 que l'\u00e2ge est un facteur pr\u00e9disposant aux COVID-19 graves et que l'hospitalisation serait plus probable pour les personnes \u00e2g\u00e9es.", "methods": "L'objectif de cette \u00e9tude \u00e9tait d'examiner syst\u00e9matiquement la pr\u00e9valence du tabagisme actuel parmi toutes les s\u00e9ries de cas publi\u00e9s de patients hospitalis\u00e9s atteints de COVID-19 en Chine, et de la comparer avec la pr\u00e9valence du tabagisme actuel dans la population.", "pubmed_id": "32385628\n16056392\n21691078\n32232552\n32293644\n32253888\n32253449\n18448662\n32173725\n32192578\n20625922\n32345613\n18800254\n27660401\n32187045\n32085846\n32336611\n32220206\n32344009\n32278362\n14571320\n17177960\n22718567\n15502843\n32125455\n17502850\n8114833\n32211844\n22232050\n32171067\n32311321\n17273548\n16001071\n27019629\n15898001\n32217556\n30088946\n32347972\n31986264\n32241833\n32341104\n16007097\n12508119\n32281110\n17941858\n32227760", "doi": "10.1007/s11739-020-02355-7", "abstract": "The effects of smoking on Corona Virus Disease 2019 (COVID-19) are currently unknown. The purpose of this study was to systematically examine the prevalence of current smoking among hospitalized patients with COVID-19 in China, considering the high-population smoking prevalence in China (26.6%). A systematic review of the literature (PubMed) was performed on April 1. Thirteen studies examining the clinical characteristics of hospitalized COVID-19 patients in China and presenting data on the smoking status were found. The pooled prevalence of current smoking from all studies was calculated by random-effect meta-analysis. To address the possibility that some smokers had quit shortly before hospitalization and were classified as former smokers on admission to the hospital, we performed a secondary analysis in which all former smokers were classified as current smokers. A total of 5960 patients were included in the studies identified. The current smoking prevalence ranged from 1.4% (95% CI 0.0-3.4%) to 12.6% (95% CI 10.6-14.6%). An unusually low prevalence of current smoking was observed from the pooled analysis (6.5%, 95% CI 4.9-8.2%) as compared to population smoking prevalence in China. The secondary analysis, classifying former smokers as current smokers, found a pooled estimate of 7.3% (95% CI 5.7-8.9%). In conclusion, an unexpectedly low prevalence of current smoking was observed among patients with COVID-19 in China, which was approximately 1/4th the population smoking prevalence. Although the generalized advice to quit smoking as a measure to reduce health risk remains valid, the findings, together with the well-established immunomodulatory effects of nicotine, suggest that pharmaceutical nicotine should be considered as a potential treatment option in COVID-19.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 536, "name": "Farsalinos K"}], "publication_date": "2020-05-12"}, {"id": 455, "slug": "covid-19-one-month-impact-of-the-french-lockdown-on-the-epidemic-burden", "title": "COVID-19: One-month impact of the French lockdown on the epidemic burden", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Analyser l'effet des mesures de confinement en France sur l'\u00e9pid\u00e9mie du COVID-19 apr\u00e8s 1 mois par mod\u00e9lisation", "verbose_date": "27.04.2020", "authors": "Roux J", "specialties": [{"id": 21, "name": "Confinement/D\u00e9confinement"}, {"id": 7, "name": "Transversale"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.ehesp.fr/wp-content/uploads/2020/04/Impact-Confinement-EHESP-20200322v1-1.pdf", "findings": "", "take_away": "", "relevance_level": "Bas\u00e9 sur des mod\u00e9lisations, le confinement en France aurait permis d'\u00e9viter 62 000 d\u00e9c\u00e8s (r\u00e9duction de moralit\u00e9 de 83,5%).\r\nLa r\u00e9duction du nombre d'hospitalisations n\u00e9cessaires atteint 88% soit 670 000 fran\u00e7ais et 91% pour les admissions en r\u00e9animation, soit 140 320 fran\u00e7ais.\u00a0\r\nLe confinement a ainsi \u00e9vit\u00e9 la saturation du syst\u00e8me hospitalier qui aurait \u00e9t\u00e9 atteinte d\u00e8s la fin mars avec pr\u00e8s d'un patient sur 2 qui n'aurait pas pu b\u00e9n\u00e9ficier d'un lit d'hospitalisation.", "objectives": "- Mod\u00e9lisation math\u00e9matique bien conduite avec mod\u00e8le compartimental bas\u00e9 sur des donn\u00e9es fiables et prenant en compte les diff\u00e9rents r\u00e9gionales ou li\u00e9es \u00e0 l'\u00e2ge- V\u00e9rification des pr\u00e9dictions du mod\u00e8le utilis\u00e9 par test sur la phase de pr\u00e9 confinement assurant d'une certaine robustesse du mod\u00e8le\"", "methods": "Analyser l'effet des mesures de confinement en France sur l'\u00e9pid\u00e9mie du COVID-19 apr\u00e8s 1 mois par mod\u00e9lisation", "topics": ["Mod\u00e9lisation", "Confinement/D\u00e9confinement", "Transversale"], "author_list": [{"id": 427, "name": "Roux J"}], "publication_date": "2020-04-27"}, {"id": 521, "slug": "second-trimester-miscarriage-in-a-pregnant-woman-with-sars-cov-2-infection", "title": "Second-Trimester Miscarriage in a Pregnant Woman With SARS-CoV-2 Infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etude de cas de fausse couche chez une femme enceinte au second trimestre et atteinte du COVID-19.\r\n\r\n ", "verbose_date": "04.05.2020", "authors": "Baud D", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://www.dropbox.com/s/auhn25ecvo7cg6a/10.1001%40jama.2020.7233.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Etude d'un cas de fausse couche du second trimestre chez une patiente infect\u00e9e par le COVID-19.\nDevant la mise en \u00e9vidence du virus sur le PLACENTA et l'absence d'autre cause retrouv\u00e9e, hypoth\u00e8se du r\u00f4le du COVID-19 dans la perte foetale.\nA fortiori, devant des cas similaires prouv\u00e9s pour le MERS et le SARS de 2002 (40% de malformations foetales et de fausses couches si pr\u00e9sence du virus sur la face maternelle du placenta).\nCette hypoth\u00e8se reste\u00a0\u00e0 prouver par des \u00e9tudes plus pouss\u00e9es.", "objectives": "Case report d'un seul cas. Etude de facteurs de confusion moyenne (patient ob\u00e8se, diab\u00e9tique)", "methods": "Etude de cas de fausse couche chez une femme enceinte au second trimestre et atteinte du COVID-19.", "topics": ["Epid\u00e9miologique", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 488, "name": "Baud D"}], "publication_date": "2020-05-04"}, {"id": 32, "slug": "rhabdomyolysis-as-potential-late-complication-associated-with-covid-19", "title": "Rhabdomyolysis as Potential Late Complication Associated with COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire le cas d'un patient COVID-19 avec SARS et rhabdomyolyse", "verbose_date": "21.03.2020", "authors": "Jin M", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 28, "name": "Emerg Infect Dis"}, "link": "https://wwwnc.cdc.gov/eid/article/26/7/20-0445_article", "findings": "", "take_away": "", "relevance_level": "Penser \u00e0 la rhabdomyolyse si douleurs musculaires localis\u00e9es / faiblesse musculaire localis\u00e9e pour un diagnostic rapide et un traitement rapide", "objectives": "Faible : 1) Case report2) Lettre \u00e0 l'\u00e9diteur", "methods": "D\u00e9crire le cas d'un patient COVID-19 avec SARS et rhabdomyolyse", "pubmed_id": "32197060", "doi": "10.3201/eid2607.200445", "abstract": "We describe a patient in Wuhan, China, with severe acute respiratory syndrome coronavirus 2 infection who had progressive pulmonary lesions and rhabdomyolysis with manifestations of lower limb pain and fatigue. Rapid clinical recognition of rhabdomyolysis symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection can be lifesaving.", "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 42, "name": "Jin M"}], "publication_date": "2020-03-21"}, {"id": 211, "slug": "the-effect-of-human-mobility-and-control-measures-on-the-covid-19-epidemic-in-ch", "title": "The effect of human mobility and control measures on the COVID-19 epidemic in China", "has_other_authors": true, "impact_factor": {"id": 5, "name": "Fort", "posts_count": 5, "color": "green", "order": 1}, "goals_plain": "Estimation de l'impact de la mobilit\u00e9 humaine et des mesures de restrictions de voyage sur l'\u00e9volution de l'\u00e9pid\u00e9mie de Covid 19 en Chine", "verbose_date": "31.03.2020", "authors": "Kraemer MUG ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 66, "name": "Science"}, "link": "https://www.dropbox.com/s/42vq9p3m26cdcik/science.abb4218.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Importance des restrictions de transports entre ville/\u00e9tat \u00e0 un stade pr\u00e9coce pour mitiger l'\u00e9pid\u00e9mie", "objectives": "Article Science, m\u00e9thodologie qui parait solide, avec donn\u00e9es de plusieurs types et analyses de sensibilit\u00e9", "methods": "Estimation de l'impact de la mobilit\u00e9 humaine et des mesures de restrictions de voyage sur l'\u00e9volution de l'\u00e9pid\u00e9mie de Covid 19 en Chine", "pubmed_id": "32511452\n24239323\n30139911\n15071187\n32019669\n32053479\n31836720\n32046819\n31986261\n10677276\n32023340\n31995857\n20808728\n16055564\n16574822\n31978945\n30833735\n27748685\n23894860\n32014114\n32105609\n27451336\n32064853\n32087115\n19393959", "doi": "10.1101/2020.03.02.20026708", "abstract": "The ongoing COVID-19 outbreak has expanded rapidly throughout China. Major behavioral, clinical, and state interventions are underway currently to mitigate the epidemic and prevent the persistence of the virus in human populations in China and worldwide. It remains unclear how these unprecedented interventions, including travel restrictions, have affected COVID-19 spread in China. We use real-time mobility data from Wuhan and detailed case data including travel history to elucidate the role of case importation on transmission in cities across China and ascertain the impact of control measures. Early on, the spatial distribution of COVID-19 cases in China was well explained by human mobility data. Following the implementation of control measures, this correlation dropped and growth rates became negative in most locations, although shifts in the demographics of reported cases are still indicative of local chains of transmission outside Wuhan. This study shows that the drastic control measures implemented in China have substantially mitigated the spread of COVID-19.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 202, "name": "Kraemer MUG "}], "publication_date": "2020-03-31"}, {"id": 631, "slug": "estimation-in-emerging-epidemics-biases-and-remedies", "title": "Estimation in emerging epidemics: Biases and remedies", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Ce travail porte sur l'estimation de param\u00e8tres \u00e9pid\u00e9miologiques clefs : taux de croissance, R0, distribution des temps li\u00e9s \u00e0 l'infection.", "verbose_date": "25.05.2020", "authors": "Britton T", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 243, "name": "J Royal Soc Interface"}, "link": "https://royalsocietypublishing.org/doi/10.1098/rsif.2018.0670", "findings": "", "take_away": "", "relevance_level": "L'estimation des param\u00e8tres clefs (R0...) dans le d\u00e9marrage de l'\u00e9pid\u00e9mie pr\u00e9sente diff\u00e9rents biais et difficult\u00e9s dus \u00e0 l'\u00e9chantillonnage, aux contacts multiples, \u00e0 la temporalit\u00e9... Leur impact et de premiers \u00e9l\u00e9ments de correction sont donn\u00e9s dans ce travail.", "objectives": "Ce travail est tr\u00e8s bien \u00e9crit et donne une premi\u00e8re vue globale int\u00e9ressante des difficult\u00e9s d'estimation, avec \u00e9l\u00e9ments th\u00e9oriques et exemples num\u00e9riques clairs. Le mod\u00e8le met l'accent sur le caract\u00e8re al\u00e9atoire du d\u00e9but de l'\u00e9pid\u00e9mie et des temps qui apparaissent et n\u00e9glige la question de l'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 de la population dont l'effet reste s\u00fbrement encore mal compris.", "methods": "Ce travail porte sur l'estimation de param\u00e8tres \u00e9pid\u00e9miologiques clefs : taux de croissance, R0, distribution des temps li\u00e9s \u00e0 l'infection.", "pubmed_id": "30958162\n3165683\n16494726\n16802088\n19718434\n19602714\n25260235\n26674948\n28193880\n16887892\n17476782\n27581480\n28396479\n29420641\n2497809\n24023679\n29102543\n28189386\n19854206\n2572017\n26477379\n21284013\n17174352\n20858771\n12781533\n25244186", "doi": "10.1098/rsif.2018.0670", "abstract": "When analysing new emerging infectious disease outbreaks, one typically has observational data over a limited period of time and several parameters to estimate, such as growth rate, the basic reproduction number R", "topics": ["Mod\u00e9lisation", "Transversale", "Infectiologie"], "author_list": [{"id": 594, "name": "Britton T"}], "publication_date": "2020-05-25"}, {"id": 150, "slug": "exuberant-plasmacytosis-in-bronchoalveolar-lavage-of-the-first-patient-requiring", "title": "Exuberant plasmacytosis in bronchoalveolar lavage of the first patient requiring Extracorporeal Membrane Oxygenation for SRAS-CoV-2 in Europe", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les r\u00e9sultats d'un LBA chez un COVID 19", "verbose_date": "20.03.2020", "authors": "Giani M ", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 37, "name": "J Thorac Oncol"}, "link": "https://www.dropbox.com/s/ydrjg9ykvah7aja/PIIS155608642030201X.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L'abondance de CD138+ retrouv\u00e9e chez les COVID 19 pourrait \u00eatre une piste vers la th\u00e9rapeutique\u00a0\u00e0 employer. Idem pour la r\u00e9ponse inflammatoire qui est importante chez les COVID 19, m\u00eame si les corticost\u00e9ro\u00efdes n'ont pas prouv\u00e9 leur efficacit\u00e9 pour les ARDS chez les A/H1N1", "objectives": "- lettre \u00e0 l'\u00e9diteur- se base sur 1 cas en Italie", "methods": "D\u00e9crire les\u00a0r\u00e9sultats d'un LBA chez un COVID 19", "topics": ["Autres", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 146, "name": "Giani M "}], "publication_date": "2020-03-20"}, {"id": 254, "slug": "d-dimer-is-associated-with-severity-of-coronavirus-disease-2019-a-pooled-analysi", "title": "D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier l'association entre des D-dim\u00e8res augment\u00e9s et la gravit\u00e9 du COVID-19", "verbose_date": "06.04.2020", "authors": "Lippi G", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 120, "name": "Thromb Haemost"}, "link": "https://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0040-1709650.pdf", "findings": "", "take_away": "", "relevance_level": "Des D-dim\u00e8res augment\u00e9s peuvent \u00eatre associ\u00e9s \u00e0 une \u00e9volution vers un tableau clinique plus d\u00e9favorable. Des \u00e9tudes suppl\u00e9mentaires devraient \u00e9tudier l'int\u00e9r\u00eat de l'ajout de traitements antithrombotiques dans les formes s\u00e9v\u00e8res de COVID-19.", "objectives": "1) Lettre \u00e0 l'\u00e9diteur2) 5 \u00e9tudes analys\u00e9es (dont 4 incluses pour le calcul de la diff\u00e9rence de moyenne standardis\u00e9e avec 3 \u00e9tudes \u00e9tudiant les formes s\u00e9v\u00e8res et 1 \u00e9tudiant les d\u00e9c\u00e8s), h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 \u00e9lev\u00e9e I\u00b2=94%\"", "methods": "Etudier l'association entre des D-dim\u00e8res augment\u00e9s et la gravit\u00e9 du COVID-19", "pubmed_id": "32246450", "doi": "10.1055/s-0040-1709650", "abstract": null, "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 109, "name": "Lippi G"}], "publication_date": "2020-04-06"}, {"id": 583, "slug": "association-of-treatment-with-hydroxychloroquine-or-azithromycin-with-in-hospita", "title": "Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'association entre la prise d'hydroxychloroquine et/ou d'azythromycine et la mortalit\u00e9 hospitali\u00e8re des patients COVID-19.\r\n\r\nD\u00e9crire l'association entre la prise d'HCQ et/ou AZT, les arr\u00eats cardiaques et des r\u00e9sultats d'\u00e9lectrocardiogramme anormaux (arythmie ou allongement de l'intervalle QT) chez les patients COVID-19.", "verbose_date": "13.05.2020", "authors": "Rosenberg ES", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://jamanetwork.com/journals/jama/fullarticle/2766117", "findings": "", "take_away": "", "relevance_level": "Chez les patients\u00a0COVID-19 hospitalis\u00e9s, pas d'association entre le traitement par HCQ, AZT ou les deux et la mortalit\u00e9 hospitali\u00e8re significativement plus faible.", "objectives": "Etude de cohorte r\u00e9trospective, multicentrique (repr\u00e9sentant 88,3% des patients COVID-19 de l'aire m\u00e9tropolitaine de New York sur la p\u00e9riode).Patients ayant re\u00e7u de la chloroquine exclus de l'analyse.\u00c9chantillon de 7914 patients COVID-19 admis dans les h\u00f4pitaux m\u00e9tropolitains de New York du 15 au 28 mars, un total de 2362 enregistrements ont \u00e9t\u00e9 s\u00e9lectionn\u00e9s au hasard, et 1438 ont \u00e9t\u00e9 r\u00e9sum\u00e9s et inclus dans les analyses.Traitement concomitant par aspirine ou un inhibiteur de l'enzyme de conversion.45 (3,1%) patients \u00e9taient hospitalis\u00e9s au moment de l'analyse finale.Les patients recevant de l'HCQ avec ou sans AZT \u00e9taient globalement plus malades \u00e0 l'admission.La mortalit\u00e9 \u00e9tait limit\u00e9e aux d\u00e9c\u00e8s \u00e0 l'h\u00f4pital, et les patients sortis \u00e9taient suppos\u00e9s \u00eatre encore en vie pendant la p\u00e9riode d'\u00e9tude.Les \u00e9v\u00e9nements ind\u00e9sirables ont \u00e9t\u00e9 collect\u00e9s \u00e0 n'importe quel moment de l'hospitalisation, potentiellement avant l'initiation du m\u00e9dicament", "methods": "D\u00e9crire l'association entre la prise d'hydroxychloroquine et/ou d'azythromycine\u00a0et la mortalit\u00e9 hospitali\u00e8re des patients COVID-19.\nD\u00e9crire l'association entre la prise d'HCQ et/ou AZT, les arr\u00eats cardiaques et des r\u00e9sultats d'\u00e9lectrocardiogramme anormaux (arythmie ou allongement de l'intervalle QT) chez les patients COVID-19.", "pubmed_id": "32392282\n31986257\n32298251\n32171076\n32194981\n32150618\n32240123\n32320003\n28693043\n32145363\n25288614\n32293639\n32302078\n29691971\n29652656\n32205204\n32379955\n12831814", "doi": "10.1001/jama.2020.8630", "abstract": "Hydroxychloroquine, with or without azithromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease 2019 (COVID-19). However, there are limited data on efficacy and associated adverse events.\nTo describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital inpatients diagnosed with COVID-19.\nRetrospective multicenter cohort study of patients from a random sample of all admitted patients with laboratory-confirmed COVID-19 in 25 hospitals, representing 88.2% of patients with COVID-19 in the New York metropolitan region. Eligible patients were admitted for at least 24 hours between March 15 and 28, 2020. Medications, preexisting conditions, clinical measures on admission, outcomes, and adverse events were abstracted from medical records. The date of final follow-up was April 24, 2020.\nReceipt of both hydroxychloroquine and azithromycin, hydroxychloroquine alone, azithromycin alone, or neither.\nPrimary outcome was in-hospital mortality. Secondary outcomes were cardiac arrest and abnormal electrocardiogram findings (arrhythmia or QT prolongation).\nAmong 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or both were more likely than those not receiving either drug to have diabetes, respiratory rate >22/min, abnormal chest imaging findings, O2 saturation lower than 90%, and aspartate aminotransferase greater than 40 U/L. Overall in-hospital mortality was 20.3% (95% CI, 18.2%-22.4%). The probability of death for patients receiving hydroxychloroquine\u2009+\u2009azithromycin was 189/735 (25.7% [95% CI, 22.3%-28.9%]), hydroxychloroquine alone, 54/271 (19.9% [95% CI, 15.2%-24.7%]), azithromycin alone, 21/211 (10.0% [95% CI, 5.9%-14.0%]), and neither drug, 28/221 (12.7% [95% CI, 8.3%-17.1%]). In adjusted Cox proportional hazards models, compared with patients receiving neither drug, there were no significant differences in mortality for patients receiving hydroxychloroquine\u2009+\u2009azithromycin (HR, 1.35 [95% CI, 0.76-2.40]), hydroxychloroquine alone (HR, 1.08 [95% CI, 0.63-1.85]), or azithromycin alone (HR, 0.56 [95% CI, 0.26-1.21]). In logistic models, compared with patients receiving neither drug cardiac arrest was significantly more likely in patients receiving hydroxychloroquine\u2009+\u2009azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]), but not hydroxychloroquine alone (adjusted OR, 1.91 [95% CI, 0.96-3.81]) or azithromycin alone (adjusted OR, 0.64 [95% CI, 0.27-1.56]), . In adjusted logistic regression models, there were no significant differences in the relative likelihood of abnormal electrocardiogram findings.\nAmong patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. However, the interpretation of these findings may be limited by the observational design.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 548, "name": "Rosenberg ES"}], "publication_date": "2020-05-13"}, {"id": 154, "slug": "covid-19-the-new-challenge-for-rheumatologists", "title": "COVID-19: the new challenge for rheumatologists", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00e9sumer les questions qui peuvent survenir \u00e0 la PEC d'un patient et formuler des hypoth\u00e8ses sur l'utilisation des ttt en rhumato", "verbose_date": "26.03.2020", "authors": "Ferro F ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 89, "name": "Clin Exp Rheumatol"}, "link": "https://www.dropbox.com/s/b34l3kii4j7bfdl/article.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les th\u00e8mes abord\u00e9s dans cet articles :\u00a0\r\n- est ce que le covid est juste une maladie infectieuse ou quelque chose d'autre ?\r\n- est ce qu'il y a une fen\u00eatre d'opportunit\u00e9 pour des traitements anti rhumatismaux?\r\n- Y a-t-il de la place pour th\u00e9rapie s\u00e9quentielle / combin\u00e9e\r\n- Le r\u00f4le du tocilizumab (TCZ) sur le SRAS-CoV-2?\r\n- Il y a t'il un r\u00f4le potentiel des immunoglobuline intraveineuses dans la prise en charge des infections COVID 19 ?\r\n- Est ce que l'adjonction de corticost\u00e9ro\u00efdes a un r\u00f4le dans la prise en charge des patients COVID 19\r\n- Est ce que les th\u00e9rapies immunosuppressives pour les maladies rhumatismales ont un r\u00f4le protecteur contre le COVID 19 ?\u00a0\r\n- Est ce que le COVID 19 va changer le screening des patient rhumato candidats \u00e0 commencer une th\u00e9rapie immunosuppressive ?\n\r\nDans le cas de patients devant commencer une th\u00e9rapie immunosuppressive et test\u00e9 positifs au COVID 19 : isolement 15 jours pour les patients asymptomatiques. SI le patient n'a pr\u00e9sent\u00e9 aucun signe, le ttt pourra \u00eatre mis en route.", "objectives": "- se base sur la biblio- tr\u00e8s peu de r\u00e9f\u00e9rence sur la rhumato", "methods": "R\u00e9sumer les questions qui peuvent survenir \u00e0 la PEC d'un patient et formuler des hypoth\u00e8ses sur l'utilisation des ttt en rhumato", "pubmed_id": "32207680", "doi": null, "abstract": null, "topics": ["Autres", "Transversale"], "author_list": [{"id": 150, "name": "Ferro F "}], "publication_date": "2020-03-26"}, {"id": 302, "slug": "clinical-outcomes-of-hydroxychloroquine-in-hospitalized-patients-with-covid-19-a", "title": "Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19 : a quasi-randomized comparative study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'effet clinique de l'hydroxychloroquine chez des patients hospitalis\u00e9s pour infection \u00e0 COVDI-19", "verbose_date": "12.04.2020", "authors": "Barbosa J", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/urzapkyij542qx5/NEJM_Clinical%20Outcomes%20of%20Hydroxychlorquine%20in%20Patients%20with%20COVID19.pdf.pdf.pdf.pdf.pdf.pdf.pdf.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L'hydroxychloroquine ne semble pas avoir d'efficacit\u00e9 clinique par rapport \u00e0 l'absence de traitement, sous r\u00e9serve des faiblesses m\u00e9thodologiques de l'\u00e9tude. Elle n'am\u00e9liore pas significativement l'\u00e9tat respiratoire des patients, ni le risque de d\u00e9c\u00e8s et la tendance est m\u00eame inverse avec un potentiel risque d'escalade th\u00e9rapeutique sur la fonction respiratoire dans le groupe traitement. Devant le potentiel risque d'aggravation des conditions cliniques des patients infect\u00e9s et en l'absence d'efficacit\u00e9 clinique notable, il convient donc de faire attention \u00e0 sa prescription en attendant des \u00e9tudes plus robustes.", "objectives": "- Etude non review\u00e9e pour le moment (soumission au NEJM)- Etude r\u00e9trospective sur faible effectif- Pas de randomisation des sujets- Etat respiratoire \u00e0 l'admission diff\u00e9rent entre les 2 bras d'\u00e9tude- Analyse statistique contenant des ajustements non d\u00e9taill\u00e9s sur les nombreux facteurs de confusion en l'absence de randomisation- Pas de prise en compte de l'inflation du risque alpha avec de multiples analyses\"", "methods": "Evaluer l'effet clinique de l'hydroxychloroquine chez des patients hospitalis\u00e9s pour infection \u00e0 COVDI-19", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie"], "author_list": [{"id": 290, "name": "Barbosa J"}], "publication_date": "2020-04-12"}, {"id": 167, "slug": "possible-vertical-transmission-of-sras-cov-2-from-an-infected-mother-to-her-newb", "title": "Possible Vertical Transmission of SRAS-CoV-2 From an Infected Mother to Her Newborn", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Description d'un cas possible de transmission in utero", "verbose_date": "27.03.2020", "authors": "Dong L ", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://www.dropbox.com/s/jh90my772phgvhs/10.1001%40jama.2020.4621.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Possible cas de transmission verticale (in utero) du coronavirus avec anticorps positifs et cytokines pro inflammatoires \u00e9lev\u00e9es \u00e0 la naissance sans aucun signes cliniques, radiographiques ou virologiques", "objectives": "1) Case Report2) Difficile appr\u00e9ciation des mesures de protection prises lors de cet accouchement", "methods": "Description d'un cas possible de transmission in utero", "topics": ["Diagnostique", "Gyn\u00e9cologie Obst\u00e9trique", "P\u00e9diatrie"], "author_list": [{"id": 162, "name": "Dong L "}], "publication_date": "2020-03-27"}, {"id": 593, "slug": "estimating-excess-1-year-mortality-associated-with-the-covid-19-pandemic-accordi", "title": "Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Les objectifs \u00e9taient de fournir des param\u00e8tres pour aider \u00e0 la mod\u00e9lisation et de fournir des estimations initiales de l'exc\u00e8s de d\u00e9c\u00e8s li\u00e9s \u00e0 COVID-19 sur une p\u00e9riode d'un an en fonction de diff\u00e9rents taux et niveaux relatifs d'impact de l'infection.", "verbose_date": "16.05.2020", "authors": "Banerjee A", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2930854-0", "findings": "", "take_away": "", "relevance_level": "On a produit un mod\u00e8le pour estimer l'exc\u00e8s de mortalit\u00e9 li\u00e9 au COVID-19 en incorporant le taux d'infection de la population dans diff\u00e9rents sc\u00e9narios relatifs au degr\u00e9 d'isolement social, diff\u00e9rents degr\u00e9s d'impact du COVID-19 sur les syst\u00e8mes de sant\u00e9, et la pr\u00e9valence de conditions sous-jacentes. Dans un sc\u00e9nario de suppression totale, m\u00eame si COVID-19 a un impact relatif \u00e9lev\u00e9 sur les syst\u00e8mes de sant\u00e9, la surmortalit\u00e9 sur un an peut \u00eatre minimis\u00e9e. Inversement, avec l'att\u00e9nuation (c'est-\u00e0-dire des mesures moins rigoureuses et volontaires), on pr\u00e9voie entre 18 000 et 37 000 d\u00e9c\u00e8s. On a fourni un prototype de calculateur de risques pour les chercheurs et les d\u00e9cideurs politiques. On souligne \u00e9galement l'int\u00e9r\u00eat des dossiers m\u00e9dicaux \u00e9lectroniques de routine et de l'utilisation de vastes ensembles de donn\u00e9es reli\u00e9es au niveau national pour faire face \u00e0 la pand\u00e9mie.\nCes mod\u00e8les permettent d'estimer les effets globaux (directs et indirects) de la pand\u00e9mie COVID-19 sur la surmortalit\u00e9. On fournisse un mod\u00e8le, un outil et des donn\u00e9es en libre acc\u00e8s pour individualiser la pr\u00e9diction des risques en fonction des conditions sous-jacentes, ce qui pr\u00e9sente des avantages cliniques, de sant\u00e9 publique et de recherche pour les contextes de la pand\u00e9mie et de la postpand\u00e9mie de COVID-19.\nCes r\u00e9sultats montrent la n\u00e9cessit\u00e9 de mesures de r\u00e9pression rigoureuses et durables ainsi que d'efforts soutenus pour cibler les personnes les plus \u00e0 risque en raison de conditions sous-jacentes gr\u00e2ce \u00e0 une s\u00e9rie d'interventions pr\u00e9ventives. Les pays devraient \u00e9valuer les effets globaux (directs et indirects) de la pand\u00e9mie sur la surmortalit\u00e9.", "objectives": "- \u00e9tude de cohorte bas\u00e9e sur la population britannique- n = 3 862 012", "methods": "Les objectifs \u00e9taient de fournir des param\u00e8tres pour aider \u00e0 la mod\u00e9lisation et de fournir des estimations initiales de l'exc\u00e8s de d\u00e9c\u00e8s li\u00e9s \u00e0 COVID-19 sur une p\u00e9riode d'un an en fonction de diff\u00e9rents taux et niveaux relatifs d'impact de l'infection.", "pubmed_id": "32405103\n23419635\n30999919\n30420026\n32214079\n32171390\n32203977\n28619959\n23386360\n29500026\n31748235\n32203360\n31986264\n32439095\n21872920\n24881994\n31329239\n31650125\n29474617", "doi": "10.1016/S0140-6736(20)30854-0", "abstract": "The medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19) pandemic has unknown effects on overall population mortality. Previous models of population mortality are based on death over days among infected people, nearly all of whom thus far have underlying conditions. Models have not incorporated information on high-risk conditions or their longer-term baseline (pre-COVID-19) mortality. We estimated the excess number of deaths over 1 year under different COVID-19 incidence scenarios based on varying levels of transmission suppression and differing mortality impacts based on different relative risks for the disease.\nIn this population-based cohort study, we used linked primary and secondary care electronic health records from England (Health Data Research UK-CALIBER). We report prevalence of underlying conditions defined by Public Health England guidelines (from March 16, 2020) in individuals aged 30 years or older registered with a practice between 1997 and 2017, using validated, openly available phenotypes for each condition. We estimated 1-year mortality in each condition, developing simple models (and a tool for calculation) of excess COVID-19-related deaths, assuming relative impact (as relative risks [RRs]) of the COVID-19 pandemic (compared with background mortality) of 1\u00b75, 2\u00b70, and 3\u00b70 at differing infection rate scenarios, including full suppression (0\u00b7001%), partial suppression (1%), mitigation (10%), and do nothing (80%). We also developed an online, public, prototype risk calculator for excess death estimation.\nWe included 3\u2008862\u2008012 individuals (1\u2008957\u2008935 [50\u00b77%] women and 1\u2008904\u2008077 [49\u00b73%] men). We estimated that more than 20% of the study population are in the high-risk category, of whom 13\u00b77% were older than 70 years and 6\u00b73% were aged 70 years or younger with at least one underlying condition. 1-year mortality in the high-risk population was estimated to be 4\u00b746% (95% CI 4\u00b741-4\u00b751). Age and underlying conditions combined to influence background risk, varying markedly across conditions. In a full suppression scenario in the UK population, we estimated that there would be two excess deaths (vs baseline deaths) with an RR of 1\u00b75, four with an RR of 2\u00b70, and seven with an RR of 3\u00b70. In a mitigation scenario, we estimated 18\u2008374 excess deaths with an RR of 1\u00b75, 36\u2008749 with an RR of 2\u00b70, and 73\u2008498 with an RR of 3\u00b70. In a do nothing scenario, we estimated 146\u2008996 excess deaths with an RR of 1\u00b75, 293\u2008991 with an RR of 2\u00b70, and 587\u2008982 with an RR of 3\u00b70.\nWe provide policy makers, researchers, and the public a simple model and an online tool for understanding excess mortality over 1 year from the COVID-19 pandemic, based on age, sex, and underlying condition-specific estimates. These results signal the need for sustained stringent suppression measures as well as sustained efforts to target those at highest risk because of underlying conditions with a range of preventive interventions. Countries should assess the overall (direct and indirect) effects of the pandemic on excess mortality.\nNational Institute for Health Research University College London Hospitals Biomedical Research Centre, Health Data Research UK.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 557, "name": "Banerjee A"}], "publication_date": "2020-05-16"}, {"id": 459, "slug": "the-impact-of-online-information-on-self-isolation-intention-during-the-covid-19", "title": "The Impact of Online Information on Self-isolation Intention during the COVID-19 Pandemic: A cross-sectional study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9tudier l'impact de l'information en ligne sur l'intention de se confiner, \u00e0 l\u2019\u00e9chelle individuelle, au cours de la pand\u00e9mie COVID-19. En appliquant la th\u00e9orie de la motivation de la protection, proposer un mod\u00e8le soulignant les effets de la cybercondrie et de la surcharge en informations sur les perceptions et la motivation individuelles.", "verbose_date": "27.04.2020", "authors": "Farooq A", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 187, "name": "J Med Internet Res"}, "link": "https://s3.ca-central-1.amazonaws.com/assets.jmir.org/assets/preprints/preprint-19128-accepted.pdf", "findings": "", "take_away": "", "relevance_level": "- la cybercondrie et la surcharge en informations sont plus \u00e9lev\u00e9es parmi ceux utilisant les r\u00e9seaux sociaux comme source d'informations sur le COVID-19\r\n- la cybercondrie a un impact positif sur l'intention d\u2019isolement volontaire\r\n- la surcharge en informations a un effet n\u00e9gatif sur l'intention d\u2019isolement volontaire", "objectives": "- \u00e9tude observationnelle descriptive transversale- preprint\"", "methods": "\u00c9tudier l'impact de l'information en ligne sur l'intention de se confiner, \u00e0 l\u2019\u00e9chelle individuelle, au cours de la pand\u00e9mie COVID-19. En appliquant la th\u00e9orie de la motivation de la protection, proposer un mod\u00e8le soulignant les effets de la cybercondrie et de la surcharge en informations sur les perceptions et la motivation individuelles.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 431, "name": "Farooq A"}], "publication_date": "2020-04-27"}, {"id": 116, "slug": "safety-and-efficacy-of-different-anesthetic-regimens-for-parturients-with-covid-", "title": "Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients.", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer la gestion et la s\u00e9curit\u00e9 de l'anesth\u00e9sie d'un accouchement par c\u00e9sarienne chez des parturientes COVID-19 + et chez les nouveaux n\u00e9s et \u0301valuer les proc\u00e9dures standardis\u00e9es visant la protection du personnel m\u00e9dical", "verbose_date": "10.03.2020", "authors": "Chen R", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 64, "name": "Can J Anaesth"}, "link": "https://www.dropbox.com/s/qml1fvabro6e92l/Chen2020_Article_SafetyAndEfficacyOfDifferentAn.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "12/14 patientes ont fait une hypotension per-op\u00e9ratoire significiative lors de l'anesth\u00e9sie p\u00e9riduraleBon d\u00e9roulement des c\u00e9sariennes en urgence, pas d'infection n\u00e9onatale, pas d'infection du personnel m\u00e9dical", "objectives": "Faible1) Monocentrique mais unique centre \u00e0 Wuhan de diagnostic et de prise en charge des femmes enceintes COVID-19 +2) n=173) Uniquement descriptif", "methods": "Evaluer la gestion et la s\u00e9curit\u00e9 de l'anesth\u00e9sie d'un accouchement par c\u00e9sarienne chez des parturientes COVID-19 + et chez les nouveaux n\u00e9s et \u0301valuer les proc\u00e9dures standardis\u00e9es visant la protection du personnel m\u00e9dical", "pubmed_id": "32180175", "doi": "10.1007/s12630-020-01630-7", "abstract": "To assess the management and safety of epidural or general anesthesia for Cesarean delivery in parturients with coronavirus disease (COVID-19) and their newborns, and to evaluate the standardized procedures for protecting medical staff.\nWe retrospectively reviewed the cases of parturients diagnosed with severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection disease (COVID-19). Their epidemiologic history, chest computed tomography scans, laboratory measurements, and SARS-CoV-2 nucleic acid positivity were evaluated. We also recorded the patients' demographic and clinical\u00a0characteristics, anesthesia and surgery-related data, maternal and neonatal complications, as well as the health status of the involved medical staff.\nThe clinical characteristics of 17 pregnant women infected with SARS-CoV-2 were similar to those previously reported in non-pregnant adult patients. All of the 17 patients underwent Cesarean delivery with anesthesia performed according to standardized anesthesia/surgery procedures. Fourteen of the patients underwent continuous epidural anesthesia with 12 experiencing significant intraoperative hypotension. Three patients received general anesthesia with tracheal intubation because emergency surgery was needed. Three of the parturients are still recovering from their Cesarean delivery and are receiving in-hospital treatment for COVID-19. Three neonates were born prematurely. There were no deaths or serious neonatal asphyxia events. All neonatal SARS-CoV-2 nucleic acid tests were negative. No medical staff were infected throughout the patient care period.\nBoth epidural and general anesthesia were safely used for Cesarean delivery in the parturients with COVID-19. Nevertheless, the incidence of hypotension during epidural anesthesia appeared excessive. Proper patient transfer, medical staff access procedures, and effective biosafety precautions are important to protect medical staff from COVID-19.", "topics": ["Th\u00e9rapeutique", "P\u00e9diatrie"], "author_list": [{"id": 122, "name": "Chen R"}], "publication_date": "2020-03-10"}, {"id": 28, "slug": "profiling-early-humoral-response-to-diagnose-novel-coronavirus-disease-covid-19", "title": "Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9crire la cin\u00e9tique des marqueurs de l'inflammation dans l'infection au COVID-19", "verbose_date": "21.03.2020", "authors": "Guo L", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 24, "name": "Clin Infect Dis"}, "link": "https://www.dropbox.com/s/val5qpb7nee8rlf/ciaa310.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La r\u00e9ponse humorale peut aider au diagnosic. \nDur\u00e9e m\u00e9diane de d\u00e9tection :- IgM et IgA = 5 jours (positif>85%)- IgG = 14 jours (positif>77%)\nM\u00e9thode de d\u00e9tection :- Privil\u00e9gier ELISA IgM plut\u00f4t que PCR- Ou combinaison des 2", "objectives": "Interm\u00e9diaire : 1) Exp\u00e9rimentation sur plus de 200 cas mais population tr\u00e8s h\u00e9t\u00e9rog\u00e8ne et caract\u00e9ristiques clinico-biologiques des patients mal connues2) Grand nombre de patients suspects inclus", "methods": "D\u00e9crire la cin\u00e9tique des marqueurs de l'inflammation dans l'infection au COVID-19", "pubmed_id": "32198501\n32007145\n31995857\n26165609\n32031570\n31986264\n32043978\n32007143\n32019667\n32003551\n32015508\n31992387\n31978945\n32004165\n32031568\n27012512\n32022836", "doi": "10.1093/cid/ciaa310", "abstract": "Emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. Current method of detection involves qPCR-based technique, which identifies the viral nucleic acids when present in sufficient quantity. False negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission. We here aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19.\nThe host humoral response against SARS-CoV-2 including IgA, IgM and IgG response were examined by using an ELISA based assay on the recombinant viral nucleocapsid protein. Total 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but had typical manifestation). The diagnostic value of IgM was evaluated in this cohort.\nThe median duration of IgM and IgA antibody detection were 5 days (IQR 3-6), while IgG was detected on 14 days (IQR 10-18) after symptom onset, with a positive rate of 85.4%, 92.7% and 77.9% respectively. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA is higher than that of qPCR method after 5.5 days of symptom onset. The positive detection rate is significantly increased (98.6%) when combined IgM ELISA assay with PCR for each patient compare with a single qPCR test (51.9%).\nHumoral response to SARS-CoV-2 can aid to the diagnosis of COVID-19, including subclinical cases.", "topics": ["Diagnostique", "Infectiologie"], "author_list": [{"id": 38, "name": "Guo L"}], "publication_date": "2020-03-21"}, {"id": 245, "slug": "respiratory-virus-shedding-in-exhaled-breath-and-efficacy-of-face-masks", "title": "Respiratory virus shedding in exhaled breath and efficacy of face masks", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Quantifier la quantit\u00e9 de virus respiratoires dans le souffle expir\u00e9 des patients avec des infections respiratoires aigu\u00ebs et d\u00e9terminer l'efficacit\u00e9 potentielle de masques chirurgicaux pour pr\u00e9venir la transmission des virus respiratoires", "verbose_date": "04.04.2020", "authors": "Leung NHL", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 115, "name": "Nature Med"}, "link": "https://www.nature.com/articles/s41591-020-0843-2.pdf", "findings": "", "take_away": "", "relevance_level": "Attention \u00e9tude sur coronavirus saisonnier et non SARS-Cov-2:\r\nCoronavirus d\u00e9tect\u00e9 \u00e0 partir de 30% des \u00e9chantillons de gouttelettes respiratoires et 40% des a\u00e9rosols sans masque (respectivement 26% et 35% pour la grippe, 28% et 56% pour le rhinovirus). Aucun virus dans les gouttelettes respiratoires ou les a\u00e9rosols collect\u00e9s avec masques (diff\u00e9rence significative dans les a\u00e9rosols). Diff\u00e9rence significative dans les gouttelettes pour la grippe. Pas de diff\u00e9rence significative dans les deux cas pour le rhinovirus. ARN viral identifi\u00e9 chez un petit nombre de participants qui n'ont pas touss\u00e9 du tout au cours des 30 minutes de respiration expir\u00e9e, ce qui sugg\u00e9rerait que les voies de transmission par gouttes et a\u00e9rosols sont possibles chez des individus sans signes ou sympt\u00f4mes \u00e9vidents", "objectives": "1) Concerne les coronavirus saisonniers et non SARS-CoV-2, ainsi que les grippes et les rhinovirus2) Crit\u00e8res d'inclusion non d\u00e9taill\u00e9s, uniquement la moiti\u00e9 des patients (n=123) avec infection respiratoire virale confirm\u00e9e par RT-PCR3) Pas de confirmation de la contagiosit\u00e9 des coronavirus saisonniers et des rhinovirus, test de culture virale uniquement pour les grippes4) Faible effectif : 17 patients avec coronavirus saisonnier, 43 avec une grippe, 54 avec un rhinovirus5) Recueil des donn\u00e9es et analyse r\u00e9alis\u00e9s par les m\u00eames personnes", "methods": "Quantifier la quantit\u00e9 de virus respiratoires dans le souffle expir\u00e9 des patients avec des infections respiratoires aigu\u00ebs et d\u00e9terminer l'efficacit\u00e9 potentielle de masques chirurgicaux pour pr\u00e9venir la transmission des virus respiratoires", "pubmed_id": "32371934", "doi": "10.1038/s41591-020-0843-2", "abstract": "We identified seasonal human coronaviruses, influenza viruses and rhinoviruses in exhaled breath and coughs of children and adults with acute respiratory illness. Surgical face masks significantly reduced detection of influenza virus RNA in respiratory droplets and coronavirus RNA in aerosols, with a trend toward reduced detection of coronavirus RNA in respiratory droplets. Our results indicate that surgical face masks could prevent transmission of human coronaviruses and influenza viruses from symptomatic individuals.", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 235, "name": "Leung NHL"}], "publication_date": "2020-04-04"}, {"id": 303, "slug": "compassionate-use-of-remdesivir-for-patients-with-severe-covid-19", "title": "Compassionate Use of Remdesivir for Patients with Severe Covid-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'efficacit\u00e9 du remdesivir dans une cohorte de patients hospitalis\u00e9s pour Covid-19 s\u00e9v\u00e8re qui ont \u00e9t\u00e9 trait\u00e9s avec du remdesivir sur une base compassionnelle.", "verbose_date": "11.04.2020", "authors": "Grein J", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2007016?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Sur cette cohorte de patient trait\u00e9e par remdesivir avec forme s\u00e9v\u00e8re de COVID-19, une am\u00e9lioration clinique respiratoire a \u00e9t\u00e9 retrouv\u00e9e dans 68% des cas \u00e0 J18 et \u00e0 84% \u00e0 J28. L'efficacit\u00e9 du traitement semble plus importante chez les personnes \u00e2g\u00e9es (plus de 70 ans), chez les patients avec ventilation invasive ou ceux mis sous ECMO. Le taux de d\u00e9c\u00e8s \u00e0 13% semblait bas. Mais de nombreux effets ind\u00e9sirables ont \u00e9t\u00e9 rapport\u00e9s sous traitement chez 60% des patients avec dans 23% des cas un effet ind\u00e9sirable grave.\u00a0\r\nL'efficacit\u00e9 du remdesivir semble prometteuse, mais doit encore \u00eatre confirm\u00e9e dans un essai contr\u00f4l\u00e9 randomis\u00e9 bien conduit, et il convient de faire attention \u00e0 la s\u00e9curit\u00e9 de ce m\u00e9dicament.", "objectives": "- Etude mulicentrique r\u00e9trospective sur petite cohorte sans groupe contr\u00f4le- Dur\u00e9e du traitement diff\u00e9rente entre les patients- Pas de calcul du nombre de sujets n\u00e9cessaires- Pas de d\u00e9tails sur les ajustements statistiques utilis\u00e9es pour prendre en compte les facteurs de confusion- Pas de prise en compte de l'inflation du risque alpha alors que multiples analtses statistiques\"", "methods": "Evaluer l'efficacit\u00e9 du remdesivir dans une cohorte de patients hospitalis\u00e9s pour Covid-19 s\u00e9v\u00e8re qui ont \u00e9t\u00e9 trait\u00e9s avec du remdesivir sur une base compassionnelle.", "pubmed_id": "32275812", "doi": "10.1056/NEJMoa2007016", "abstract": "Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2.\nWe provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day.\nOf the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.\nIn this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.).", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie"], "author_list": [{"id": 291, "name": "Grein J"}], "publication_date": "2020-04-11"}, {"id": 339, "slug": "dynamic-estimation-of-epidemiological-parameters-of-covid-19-outbreak-and-effect", "title": "Dynamic Estimation of Epidemiological Parameters of COVID-19 Outbreak and Effects of Interventions on Its Spread", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Estimer les param\u00e8tres de l'\u00e9pid\u00e9mie de Covid-19 \u00e0 Wuhan en fonction du temps entre le 19 Janvier et le 5 mars 2020 et analyser l'effet des diff\u00e9rentes interventions de sant\u00e9 publique sur la propagation de l'\u00e9pid\u00e9mie.", "verbose_date": "15.04.2020", "authors": "Zhang H", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.01.20050310v2.full.pdf", "findings": "", "take_away": "", "relevance_level": "-Diff\u00e9rences importantes entre le nombre officiel d'infections \u00e0 Wuhan et le nombre r\u00e9el d'infections, notamment dans la premi\u00e8re p\u00e9riode de l'\u00e9pid\u00e9mie.\r\n-Le nombre de reproduction effectif (Re) varie grandement au cours du temps, et suit l'\u00e9volution des mesures de sant\u00e9 publique.\r\n-Effet tr\u00e8s important des restrictions de transports non essentiels (confinement) et du d\u00e9pistage/hospitalisation massifs.", "objectives": "- Pr\u00e9 print- Etude \u00e9pid\u00e9miologique r\u00e9trospective- Utilisant les donn\u00e9es officielles chinoise pour les comparer \u00e0 leur r\u00e9sultats de mod\u00e9lisation\"", "methods": "Estimer les param\u00e8tres de l'\u00e9pid\u00e9mie de Covid-19 \u00e0 Wuhan en fonction du temps entre le 19 Janvier et le 5 mars 2020 et analyser l'effet des diff\u00e9rentes interventions de sant\u00e9 publique sur la propagation de l'\u00e9pid\u00e9mie.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 325, "name": "Zhang H"}], "publication_date": "2020-04-15"}, {"id": 541, "slug": "high-risk-of-thrombosis-in-patients-with-severe-sars-cov-2-infection-a-multicent", "title": "High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer si les complications thrombotiques sont plus \u00e9lev\u00e9es chez les patients hospitalis\u00e9s pour SDRA \u00e0 COVID-19 par rapport aux patients hospitalis\u00e9s pour SDRA ", "verbose_date": "06.05.2020", "authors": "Helms J", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 2, "name": "Intensive Care Med"}, "link": "https://link.springer.com/content/pdf/10.1007/s00134-020-06062-x.pdf", "findings": "", "take_away": "", "relevance_level": "La fr\u00e9quence des complications thrombotiques chez les patients atteints de SDRA \u00e0 COVID-19 semble \u00e9lev\u00e9e et on sugg\u00e8re qu'ils\u00a0d\u00e9veloppent plus de complications thrombotiques par rapport \u00e0 la m\u00eame population non atteinte de COVID-19, malgr\u00e9 une anticoagulation pr\u00e9ventive. Cependant, les\u00a0scores utilis\u00e9s n'ont pas mis en \u00e9vidence de CIVD plus fr\u00e9quente chez les patients atteints de COVID-19 malgr\u00e9 des modifications des param\u00e8tres biologiques de la coagulation.\u00a0\r\nEn comparant les deux populations, cette \u00e9tude met en \u00e9vidence des D-dim\u00e8res plus basses chez les patients atteints de COVID-19, alors que dans les pr\u00e9c\u00e9dentes \u00e9tudes ce marqueur est \u00e9lev\u00e9 et associ\u00e9 \u00e0 un mauvais pronostic.\u00a0\r\nLes m\u00e9canismes des thromboses restent non connus \u00e0 ce jour (hypoxie? pr\u00e9sence d'anticoagulant circulant? inflammation syst\u00e9mique?)\r\nIl pourrait \u00eatre pertinent de monitorer l'efficacit\u00e9 de l'anticoagulation pr\u00e9ventive dans cette population.", "objectives": "Etude de cohorte, seulement deux centres, effectif faible surtout apr\u00e8s appariement, pas de monitoring de l'anticoagulation pr\u00e9ventive", "methods": "D\u00e9terminer si les complications thrombotiques sont plus \u00e9lev\u00e9es chez les patients hospitalis\u00e9s pour SDRA \u00e0 COVID-19 par rapport aux patients hospitalis\u00e9s pour SDRA", "pubmed_id": "32367170", "doi": "10.1007/s00134-020-06062-x", "abstract": "Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection.\nAll patients referred to 4 intensive care units (ICUs) from two centers of a French tertiary hospital for acute respiratory distress syndrome (ARDS) due to COVID-19 between March 3rd and 31st 2020 were included. Medical history, symptoms, biological data and imaging were prospectively collected. Propensity score matching was performed to analyze the occurrence of thromboembolic events between non-COVID-19 ARDS and COVID-19 ARDS patients.\n150 COVID-19 patients were included (122 men, median age 63 [53; 71] years, SAPSII 49 [37; 64] points). Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%). 28/29 patients (96.6%) receiving continuous renal replacement therapy experienced circuit clotting. Three thrombotic occlusions (in 2 patients) of centrifugal pump occurred in 12 patients (8%) supported by ECMO. Most patients (>\u200995%) had elevated D-dimer and fibrinogen. No patient developed disseminated intravascular coagulation. Von Willebrand (vWF) activity, vWF antigen and FVIII were considerably increased, and 50/57 tested patients (87.7%) had positive lupus anticoagulant. Comparison with non-COVID-19 ARDS patients (n\u2009=\u2009145) confirmed that COVID-19 ARDS patients (n\u2009=\u200977) developed significantly more thrombotic complications, mainly pulmonary embolisms (11.7 vs. 2.1%, p\u2009<\u20090.008). Coagulation parameters significantly differed between the two groups.\nDespite anticoagulation, a high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications. Higher anticoagulation targets than in usual critically ill patients should therefore probably be suggested.", "topics": ["Pronostique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 369, "name": "Helms J"}], "publication_date": "2020-05-06"}, {"id": 557, "slug": "observational-study-of-hydroxychloroquine-in-hospitalized-patients-with-covid-19", "title": "Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier l'association entre l'utilisation d'hydroxychloroquine et l'intubation ou le d\u00e9c\u00e8s dans un h\u00f4pital de New York.", "verbose_date": "08.05.2020", "authors": "Galeris J", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2012410?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Le risque d'intubation ou de d\u00e9c\u00e8s n'\u00e9tait ni significativement plus \u00e9lev\u00e9 ni plus faible chez les patients trait\u00e9s par HCQ que ceux qui n'en ont pas re\u00e7u.", "objectives": "Etude observationnellePas de randomisation sur l'administration d'HCQ, Pas d'aveugle, Patients trait\u00e9s par HCQ plus gravesUtilisation d'un crit\u00e8re composite (intubation ou  d\u00e9c\u00e8s)70 patients exclus sur 1 446 patients cons\u00e9cutifs (4,8%)MonocentriqueDur\u00e9e m\u00e9diane de suivi de 22,5 jours, 119 patients toujours hospitalis\u00e9s \u00e0 la date de pointConseil d'associer l'azythromycine (AZT) initialement mais modification en cours d'\u00e9tude (486 patients HCQ + AZT, 127 patients AZT sans HCQ)Traitement concomittant possible par sarilumab (30 patients). Les patients ayant re\u00e7u de l'HCQ ont pu \u00eatre trait\u00e9s par la suite par remdesivir dans le cadre d'un essai contr\u00f4l\u00e9 randomis\u00e9 (27 patients)Donn\u00e9es extraites d'un stockage de donn\u00e9es du centre hospitalier, pas de v\u00e9rification dans le dossier m\u00e9dicaux Proposition d'une analyse par score de propension avec appariement par plus proche voisin mais nombre de patients non trait\u00e9s largement inf\u00e9rieur au nombre de patients trait\u00e9sParfois pr\u00e8s de 25% de donn\u00e9es manquantes sur certaines variables", "methods": "Etudier l'association entre l'utilisation d'hydroxychloroquine et l'intubation ou le d\u00e9c\u00e8s dans un h\u00f4pital de New York.", "pubmed_id": "32379955\n8278823\n32251731\n26836924\n28538439\n16640347\n32171740\n32205204\n32330277\n32150618", "doi": "10.1056/NEJMoa2012410", "abstract": "Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use.\nWe examined the association between hydroxychloroquine use and intubation or death at a large medical center in New York City. Data were obtained regarding consecutive patients hospitalized with Covid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation to the emergency department (study baseline). The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received hydroxychloroquine with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score.\nOf 1446 consecutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation and were excluded from the analysis. Of the remaining 1376 patients, during a median follow-up of 22.5 days, 811 (58.9%) received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours. Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive hydroxychloroquine (median ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen, 223 vs. 360). Overall, 346 patients (25.1%) had a primary end-point event (180 patients were intubated, of whom 66 subsequently died, and 166 died without intubation). In the main analysis, there was no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results were similar in multiple sensitivity analyses.\nIn this observational study involving patients with Covid-19 who had been admitted to the hospital, hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. Randomized, controlled trials of hydroxychloroquine in patients with Covid-19 are needed. (Funded by the National Institutes of Health.).", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 523, "name": "Galeris J"}], "publication_date": "2020-05-08"}, {"id": 137, "slug": "ventilatory-ratio-in-hypercapnic-mechanically-ventilated-patients-with-covid-19-", "title": "Ventilatory Ratio in Hypercapnic Mechanically Ventilated Patients with COVID-19 Associated ARDS", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire le rapport ventilatoire chez les patients COVID-19 avec SDRA hypercapniques ventil\u00e9s m\u00e9caniquement ", "verbose_date": "25.03.2020", "authors": "Liu X ", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 3, "name": "Am J Respir Crit Care Med"}, "link": "https://www.dropbox.com/s/8y12us68icgcx3v/rccm.202002-0373le.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Hypercapnie fr\u00e9quente\u00a0chez les patients COVID-19 avec SDRA ventil\u00e9s m\u00e9caniquement avec des\u00a0VC faibles\r\nUtilisation du ratio ventilatoire pour refl\u00e9ter l'espace mort\u00a0: Ratio ventilatoire = [ ventilation par minute (mL/min) x PaCO2 (mmHg) ] / [ poids pr\u00e9dit x 100 mL/min x 37,5 mmHg ]\r\nRecommandent des\u00a0VC interm\u00e9diaires (7-8 mL/kg poids pr\u00e9dit)", "objectives": "1) S\u00e9rie de 8 cas, monocentrique", "methods": "D\u00e9crire le rapport ventilatoire chez les patients COVID-19 avec SDRA hypercapniques ventil\u00e9s m\u00e9caniquement", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 134, "name": "Liu X "}], "publication_date": "2020-03-25"}, {"id": 590, "slug": "hyperinflammatory-shock-in-children-during-covid-19-pandemic", "title": "Hyperinflammatory shock in children during COVID-19 pandemic", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire une s\u00e9rie de cas de choc septique hyperinflammatoire chez des enfants infect\u00e9s dans le cadre du COVID-19 au Royaume-Uni", "verbose_date": "13.05.2020", "authors": "Riphagen S", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31094-1/fulltext", "findings": "", "take_away": "", "relevance_level": "Les auteurs alertent sur un tableau clinique repr\u00e9sentant potentiellement un nouveau ph\u00e9nom\u00e8ne affectant des enfants auparavant asymptomatiques atteints d'une infection par le SARS-CoV-2 se manifestant comme un syndrome hyperinflammatoire avec une d\u00e9faillance multiorganique similaire au choc de la maladie de Kawasaki", "objectives": "- S\u00e9rie d'uniquement 8 cas d'un h\u00f4pital anglais- Pour 6 enfants, le SARS-CoV-2 n'a pas \u00e9t\u00e9 retrouv\u00e9 et cela reste d\u00e8s lors uniquement des suspicions d'infection COVID-19- Correspondance donnant peu de d\u00e9tails sur les cas contacts, les signes biologiques et radiologiques \u00e9ventuels, ni m\u00eame l'\u00e9volution \u00e0 moyen terme", "methods": "D\u00e9crire une s\u00e9rie de cas de choc septique hyperinflammatoire chez des enfants infect\u00e9s dans le cadre du COVID-19 au Royaume-Uni", "pubmed_id": "32386565\n29176153\n30611297\n32293910", "doi": "10.1016/S0140-6736(20)31094-1", "abstract": null, "topics": ["Epid\u00e9miologique", "Anesth\u00e9sie-R\u00e9animation", "P\u00e9diatrie"], "author_list": [{"id": 554, "name": "Riphagen S"}], "publication_date": "2020-05-13"}, {"id": 414, "slug": "covid-19-and-thrombotic-or-thromboembolic-disease-implications-for-prevention-an", "title": "COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00e9sumer les connaissances (physiopathologie, \u00e9pid\u00e9miologie, traitement, \u00e9volution) relatives \u00e0 la prise en charge des patients COVID-19 avec pathologie thrombotique et thrombo embolique ant\u00e9rieure ou acquise avec l'infection, et au suivi de la maladie thrombotique chez des patients non infect\u00e9s", "verbose_date": "22.04.2020", "authors": "Bikdeli B", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 173, "name": "J Am Coll Cardiol"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0735109720350087?token=F668E9854131D7226D877D2D65D7E516971DB31C6DADDDC3D84AC14AFEE88CAE91584580408061D1B21B2C33AE5BF34B", "findings": "", "take_away": "", "relevance_level": "La COVID-19 peut favoriser les thromboses, en particulier veineuses chez les patients s\u00e9v\u00e8res. Une attention particuli\u00e8re doit \u00eatre port\u00e9e sur les risques d'interaction entre traitements de la COVID-19 et anti-thrombotiques. Encourager l'utilisation de la t\u00e9l\u00e9consultation pour le suivi des patients avec maladie thromboembolique dans ce contexte de pand\u00e9mie. Des \u00e9tudes de meilleur niveau de preuve sont n\u00e9cessaires sur le sujet.", "objectives": "- pr\u00e9-proof - inclusion d'articles non revus par les pairs - la plupart des \u00e9tudes sont de faible niveau de preuve (petits effectifs, \u00e9tudes r\u00e9trospectives)", "methods": "R\u00e9sumer les connaissances (physiopathologie, \u00e9pid\u00e9miologie, traitement, \u00e9volution) relatives \u00e0 la prise en charge des patients COVID-19 avec pathologie thrombotique et thrombo embolique ant\u00e9rieure ou acquise avec l'infection, et au suivi de la maladie thrombotique chez des patients non infect\u00e9s", "topics": ["Autres", "Infectiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 395, "name": "Bikdeli B"}], "publication_date": "2020-04-22"}, {"id": 257, "slug": "triage-considerations-for-patients-referred-for-structural-heart-disease-interve", "title": "Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Fournir un cadre aux \u00e9quipes pour trier les patients n\u00e9cessitant une intervention pour maladie cardiaque structurelle pendant la pand\u00e9mie de COVID-19 et pour discuter de l'\u00e9valuation et des consid\u00e9rations proc\u00e9durales pour ces patients.", "verbose_date": "07.04.2020", "authors": "Shah PB", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 7, "name": "Recommandations", "icon": "icon-reco"}, "journal": {"id": 123, "name": "Catheter Cardiovasc Interv"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/ccd.28910", "findings": "", "take_away": "", "relevance_level": "Voir r\u00e9sultats principaux.", "objectives": "- Avis d'expert\"", "methods": "Fournir un cadre aux \u00e9quipes pour trier les patients n\u00e9cessitant une intervention pour maladie cardiaque structurelle pendant la pand\u00e9mie de COVID-19 et pour discuter de l'\u00e9valuation et des consid\u00e9rations proc\u00e9durales pour ces patients.", "topics": ["Recommandations", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 246, "name": "Shah PB"}], "publication_date": "2020-04-07"}, {"id": 253, "slug": "difference-of-coagulation-features-between-severe-pneumonia-induced-by-sars-cov2", "title": "Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparer les param\u00e8tres de coagulation chez les formes s\u00e9v\u00e8res de COVID 19 et pneumonies non induites par SARS-CoV-2", "verbose_date": "06.04.2020", "authors": "Yin S", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 119, "name": "J Throm Thrombolysis"}, "link": "https://link.springer.com/content/pdf/10.1007/s11239-020-02105-8.pdf", "findings": "", "take_away": "", "relevance_level": "Les patients atteints de pneumonie s\u00e9v\u00e8re induite par le SARS-CoV2 avaient un nombre de plaquettes plus \u00e9lev\u00e9 que ceux induits par le non-SRAS-CoV2.\r\nChez les patients infect\u00e9s par le SRAS-CoV2, ceux dont les D-dim\u00e8res sont fortement \u00e9lev\u00e9s peuvent b\u00e9n\u00e9ficier du traitement anticoagulant.", "objectives": "- r\u00e9trospective, monocentrique - l'utilisation d'anticoagulant \u00e9tait peut \u00eatre li\u00e9e \u00e0 des comorbidit\u00e9s ou des sympt\u00f4mes qui ne sont pas pris en compte dans cette \u00e9tude - l'influence d'autres traitements sur ces patients n'a pas \u00e9t\u00e9 \u00e9valu\u00e9e\"", "methods": "Comparer les param\u00e8tres de coagulation chez les formes s\u00e9v\u00e8res de COVID 19 et pneumonies non induites par SARS-CoV-2", "pubmed_id": "32246317\n30701381\n31376606\n27886531\n16521285\n31986264\n24520253\n32007143\n28730545\n32172672\n29112544\n21068698\n27975101", "doi": "10.1007/s11239-020-02105-8", "abstract": "Severe coronavirus disease 2019 (COVID-19) is commonly complicated with coagulopathy, the difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 has not been analyzed. Coagulation results and clinical features of consecutive patients with severe pneumonia induced by SARS-CoV2 (COVID group) and non-SARS-CoV2 (non-COVID group) in Tongji hospital were retrospectively analyzed and compared. Whether patients with elevated D-dimer could benefit from anticoagulant treatment was evaluated. There were 449 COVID patients and 104 non-COVID patients enrolled into the study. The 28-day mortality in COVID group was approximately twofold of mortality in non-COVID group (29.8% vs. 15.4%, P\u2009=\u20090.003), COVID group were older (65.1\u2009\u00b1\u200912.0 vs. 58.4\u2009\u00b1\u200918.0, years, P\u2009<\u20090.001) and with higher platelet count (215\u2009\u00b1\u2009100 vs. 188\u2009\u00b1\u200998, \u00d710", "topics": ["Pronostique", "Transversale", "Infectiologie", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie"], "author_list": [{"id": 243, "name": "Yin S"}], "publication_date": "2020-04-06"}, {"id": 525, "slug": "effective-treatment-of-severe-covid-19-patients-with-tocilizumab", "title": "Effective treatment of severe COVID-19 patients with tocilizumab", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'efficacit\u00e9 du traitement avec Tocilizumab (anticorps monoclonal humanis\u00e9 qui bloque l'action des r\u00e9cepteurs de l'interleukine 6) chez les patients atteints de formes graves de COVID-19.", "verbose_date": "04.05.2020", "authors": "Xu X", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 36, "name": "Proc Natl Acad Sci USA"}, "link": "https://www.pnas.org/content/pnas/early/2020/04/27/2005615117.full.pdf", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude montre que chez les patients COVID-19 pr\u00e9sentant des manifestations graves et tr\u00e8s graves, le traitement par Tocilizumab permet le retour \u00e0 une temp\u00e9rature corporelle normale, r\u00e9tablit les valeurs correctes des lymphocytes et de la PCR (indicateurs de gravit\u00e9 pour la pathologie), permet l'am\u00e9lioration des l\u00e9sions pulmonaires.\nL'\u00e9tude pr\u00e9sente la forte limite d'\u00eatre une \u00e9tude d'observation, avec un tr\u00e8s petit \u00e9chantillon (n=21).\u00a0Des essais contr\u00f4l\u00e9s randomis\u00e9s \u00e9tudiant les m\u00e9canismes de l'IL-6 dans la pathogen\u00e8se du COVID-19 seront n\u00e9cessaires.", "objectives": "Faible:1) Etude observationnelle r\u00e9trospective2) Petit \u00e9chantillon (n=21)", "methods": "Evaluer l'efficacit\u00e9 du traitement avec Tocilizumab (anticorps monoclonal humanis\u00e9 qui bloque l'action des r\u00e9cepteurs de l'interleukine 6) chez les patients atteints de formes graves de COVID-19.", "pubmed_id": "32350134\n31986261\n23515142\n32085846\n24355866\n28234665\n24986424\n31986264\n15695582\n32105632\n23123977\n24077366\n29190287\n21881215\n22424201\n32031570\n24389239\n18358927\n32007143", "doi": "10.1073/pnas.2005615117", "abstract": "After analyzing the immune characteristics of patients with severe coronavirus disease 2019 (COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with large amount of interleukin 6 secreting may incite the inflammatory storm, which may potentially be curbed through monoclonal antibody that targets the IL-6 pathways. Here, we aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People's Hospital were given tocilizumab in addition to routine therapy between 5 and 14 February 2020. The changes of clinical manifestations, computerized tomography (CT) scan image, and laboratory examinations were retrospectively analyzed. Fever returned to normal on the first day, and other symptoms improved remarkably within a few days. Within 5 d after tocilizumab, 15 of the 20 patients (75.0%) had lowered their oxygen intake, and 1 patient needed no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral blood, which decreased in 85.0% of patients (17/20) before treatment (mean, 15.52 \u00b1 8.89%), returned to normal in 52.6% of patients (10/19) on the fifth day after treatment. Abnormally elevated C-reactive protein decreased significantly in 84.2% of patients (16/19). No obvious adverse reactions were observed. All patients have been discharged on average 15.1 d after giving tocilizumab. Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality.", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 491, "name": "Xu X"}], "publication_date": "2020-05-04"}, {"id": 495, "slug": "fdg-petct-findings-highly-suspicious-for-covid-19-in-an-italian-case-series-of-a", "title": "FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyser l'utilit\u00e9 des investigations diagnostiques telles que le FDG-TEP chez les patients COVID-19 asymptomatiques pour guider la prise en charge pr\u00e9coce des patients.", "verbose_date": "30.04.2020", "authors": "Setti L", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 27, "name": "Eur j Nucl Med Mol Imaging"}, "link": "https://link.springer.com/content/pdf/10.1007/s00259-020-04819-6.pdf", "findings": "", "take_away": "", "relevance_level": "Le FDG-TEP\u00a0 peut probablement identifier les patients COVID-19 aux premiers stades (asymptomatiques ou avant l'apparition des sympt\u00f4mes), ce qui a un impact important sur la prise en charge pr\u00e9coce des patients et la limitation de la propagation de SRAS-CoV-19.", "objectives": "Faible:1) s\u00e9rie de cas", "methods": "Analyser l'utilit\u00e9 des investigations diagnostiques telles que le FDG-TEP chez les patients COVID-19 asymptomatiques pour guider la prise en charge pr\u00e9coce des patients.", "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 464, "name": "Setti L"}], "publication_date": "2020-04-30"}, {"id": 155, "slug": "coronavirus-disease-covid-19-spectrum-of-ct-findings-and-temporal-progression-of", "title": "Coronavirus Disease (COVID-19): Spectrum of CT Findings and Temporal Progression of the Disease.", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les signes scannographiques des l\u00e9sions COVID 19 et leur temporalit\u00e9", "verbose_date": "26.03.2020", "authors": "Li M ", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 81, "name": "Acad Radiol"}, "link": "https://www.dropbox.com/s/2edszpxatcwr2ku/1-s2.0-S1076633220301446-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Scanner thoracique :\n\r\nphase pr\u00e9coce :\u00a0multiples \u00e9parses ombres et changements interstitiels avec une progression depuis la pl\u00e8vre et les bronches\n\r\nphase progressive\u00a0: les l\u00e9sions augmentent et s'\u00e9largissent, GGO, infiltration consolid\u00e9es\n\r\nphase s\u00e9v\u00e8re\u00a0: consolidation pulmonaire massive, poumons blancs (\u00e9panchement pleural rare).\n\r\nphase dissipative\u00a0: l\u00e9sions r\u00e9sorb\u00e9es et d\u00e9but de fibrose\n\r\nBeaucoup d'images pulmonaire dans l'article", "objectives": "- descriptif- pas de notion du nombre du scanners / patients vus", "methods": "D\u00e9crire les signes scannographiques des l\u00e9sions COVID 19 et leur temporalit\u00e9", "pubmed_id": "32204987", "doi": "10.1016/j.acra.2020.03.003", "abstract": "Coronavirus disease is an emerging infection caused by a novel coronavirus that is moving rapidly. High resolution computed tomography (CT) allows objective evaluation of the lung lesions, thus enabling us to better understand the pathogenesis of the disease. With serial CT examinations, the occurrence, development, and prognosis of the disease can be better understood. The imaging can be sorted into four phases: early phase, progressive phase, severe phase, and dissipative phase. The CT appearance of each phase and temporal progression of the imaging findings are demonstrated.", "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 151, "name": "Li M "}], "publication_date": "2020-03-26"}, {"id": 18, "slug": "global-epidemiology-of-coronavirus-disease-2019-disease-incidence-daily-cumulati", "title": "Global epidemiology of coronavirus disease 2019: disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9crire les donn\u00e9es \u00e9pid\u00e9miologiques de l'infection \u00e0 COVID-19 au niveau mondial et analyser leur association avec les ressources de soins de sant\u00e9 et le statut \u00e9conomique des pays touch\u00e9s, en date du 29/02/2020", "verbose_date": "24.03.2020", "authors": "Lai CC", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 14, "name": "Int J Antimicrob Agents"}, "link": "https://www.dropbox.com/s/wpn5aragew4m6a4/1-s2.0-S0924857920300960-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Ta\u00efwan a \u00e9t\u00e9 en mesure de limiter la propagation des cas sur son territoire au moyen de diverses mesures (information, \u00e9ducation, quarantaine, contr\u00f4le des masques, etc..).L'incidence du COVID-19 dans les diff\u00e9rents pays atteints fin f\u00e9vrier semble corr\u00e9l\u00e9e \u00e0 l'esp\u00e9rance de vie et \u00e0 la qualit\u00e9 du syst\u00e8me de sant\u00e9 mais ces r\u00e9sultats devraient \u00eatre v\u00e9rifi\u00e9s avec les donn\u00e9es \u00e9pid\u00e9miologiques plus r\u00e9centes.", "objectives": "Interm\u00e9diaire: 1) Analyse sur donn\u00e9es group\u00e9es2) Donn\u00e9es qui commence \u00e0 \u00eatre anciennes \u00e0 l'\u00e9chelle de la pand\u00e9mie (presque 1 mois)3) Se base sur le nombre de cas confirm\u00e9s", "methods": "D\u00e9crire les donn\u00e9es \u00e9pid\u00e9miologiques de l'infection \u00e0 COVID-19 au niveau mondial et analyser leur association avec les ressources de soins de sant\u00e9 et le statut \u00e9conomique des pays touch\u00e9s, en date du 29/02/2020", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 28, "name": "Lai CC"}], "publication_date": "2020-03-24"}, {"id": 458, "slug": "presymptomatic-sars-cov-2-infections-and-transmission-in-a-skilled-nursing-facil", "title": "Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer la transmission et l'ad\u00e9quation du d\u00e9pistage bas\u00e9 sur les sympt\u00f4mes pour identifier les infections chez les r\u00e9sidents d'une maisons de soins infirmiers sp\u00e9cialis\u00e9s, apr\u00e8s l'identification d'un cas de COVID-19.", "verbose_date": "27.04.2020", "authors": "Arons MM", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMoa2008457?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Transmission rapide du SARS-CoV-2 dans cette maison de soins infirmiers sp\u00e9cialis\u00e9s avec 48 r\u00e9sidents / 76 test\u00e9s (63%) 3 semaines environ apr\u00e8s le premier test positif chez un r\u00e9sident. Plus de la moiti\u00e9 des r\u00e9sidents dont les r\u00e9sultats des tests \u00e9taient positifs \u00e9taient asymptomatiques au moment du test et ont tr\u00e8s probablement contribu\u00e9 \u00e0 la transmission.\u00a0\r\nLa strat\u00e9gie de test uniquement sur les personnes symptomatiques n'a pas \u00e9t\u00e9 suffisante dans cet \u00e9tablissement.", "objectives": "1) Etude descriptive uniquement2) Monocentrique, une maison de soins infirmiers sp\u00e9cialis\u00e9s3) Faible effectif, 76 r\u00e9sidents test\u00e9s, 62 membres du personnel test\u00e9s4) Difficult\u00e9s de recueil de sympt\u00f4mes chez des patients avec parfois des troubles auditifs, cognitifs\u00a05) Pas de test chez les membres du personnels asymptomatiques", "methods": "\u00c9valuer la transmission et l'ad\u00e9quation du d\u00e9pistage bas\u00e9 sur les sympt\u00f4mes pour identifier les infections chez les r\u00e9sidents d'une maisons de soins infirmiers sp\u00e9cialis\u00e9s, apr\u00e8s l'identification d'un cas de COVID-19.", "topics": ["Epid\u00e9miologique", "Infectiologie"], "author_list": [{"id": 430, "name": "Arons MM"}], "publication_date": "2020-04-27"}, {"id": 443, "slug": "clinical-value-of-immune-inflammatory-parameters-to-assess-the-severity-of-coron", "title": "Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Explorer la valeur clinique des marqueurs immuno-inflammatoires pour \u00e9valuer la gravit\u00e9 de la maladie \u00e0 COVID-19.", "verbose_date": "24.04.2020", "authors": "Zhu Z", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.ijidonline.com/article/S1201-9712(20)30257-5/pdf", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude a montr\u00e9 qu'un niveau \u00e9lev\u00e9 d'IL-6, de CRP et d'hypertension \u00e9taient des facteurs de risque ind\u00e9pendants pour \u00e9valuer la gravit\u00e9 du COVID-19. Le mod\u00e8le de risque \u00e9tabli sur l'IL-6, la CRP et l'hypertension avait la plus grande pr\u00e9visibilit\u00e9 dans cette \u00e9tude. L'application de ce mod\u00e8le pourrait \u00eatre b\u00e9n\u00e9fique pour retarder ou stopper la progression de la maladie. En outre, l'IL-6 a jou\u00e9 un r\u00f4le essentiel dans la gravit\u00e9 du COVID-19 et a eu une valeur potentielle pour la surveillance du processus des cas graves. Il nous rappelle de mettre l'accent sur la temp\u00eate de cytokines dans la progression de COVID-19, et le traitement du blocage de l'IL-6 est peut-\u00eatre une nouvelle strat\u00e9gie de traitement des patients graves.", "objectives": "-        L'IL-6 n'est pas un test de laboratoire de routine-        La taille de l'\u00e9chantillon inclus dans cette \u00e9tude est relativement petite, en particulier pour les personnes appartenant au groupe \"\"graves\"\"-        Il s'agit d'une \u00e9tude r\u00e9trospective monocentrique-        Certaines analyses de laboratoire (par exemple, l'analyse des gaz du sang) ont \u00e9t\u00e9 effectu\u00e9es sur un nombre partiel de patients", "methods": "Explorer la valeur clinique des marqueurs immuno-inflammatoires pour \u00e9valuer la gravit\u00e9 de la maladie \u00e0 COVID-19.", "pubmed_id": "32334118", "doi": "10.1016/j.ijid.2020.04.041", "abstract": "To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19).\n127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, symptoms, underlying diseases and laboratory data were collected and assessed for predictive value.\nOf 127 COVID-19 patients, 16 cases (12.60%) were classified into the severe group. High level of interleukin-6 (IL-6), C-reaction protein (CRP) and hypertension were independent risk factors for the severity of COVID-19. The risk model based on IL-6, CRP and hypertension had the highest area under the receiver operator characteristic curve (AUROC). Additionally, the baseline IL-6 was positively correlated with other immune-inflammatory parameters and the dynamic change of IL-6 in the severe cases were parallel to the amelioration of the disease.\nOur study showed that high level of IL-6, CRP and hypertension were independent risk factors for assessing the severity of COVID-19. The risk model established upon IL-6, CRP and hypertension had the highest predictability in this study. Besides, IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases.", "topics": ["Pronostique", "Transversale", "Infectiologie"], "author_list": [{"id": 312, "name": "Zhu Z"}], "publication_date": "2020-04-24"}, {"id": 450, "slug": "association-of-renin-angiotensin-system-inhibitors-with-severity-or-risk-of-deat", "title": "Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier l'association entre la prise de traitements hypertenseurs de type inhibiteurs de l'enzyme (IEC) de conversion et antagonistes des r\u00e9cepteurs de l'angiotensine (ARA) et la s\u00e9v\u00e9rit\u00e9 et mortalit\u00e9 chez les patients hypertendus hospitalis\u00e9s pour COVID-19", "verbose_date": "25.04.2020", "authors": "Li J", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 99, "name": "JAMA Cardiol"}, "link": "https://www.dropbox.com/s/48qsnr3y5gzmmax/10.1001%40jamacardio.2020.1624.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Pas de diff\u00e9rence sur la s\u00e9v\u00e9rit\u00e9 de la maladie entre les patients, complications, et risque de d\u00e9c\u00e8s entre les patients hypertendus trait\u00e9s par inhibiteurs de l'enzyme de conversion (IEC) / antagonistes des r\u00e9cepteurs de l'angiotensine (ARA) et les patients non trait\u00e9s par ces classes de m\u00e9dicaments", "objectives": "1) S\u00e9rie de cas, monocentrique, analyse r\u00e9trospective2) 362 patients hypertendus dont 115 sous IEC ou ARA3) Comparaison avec patients non hypertendus, diff\u00e9rents en \u00e2ge, sexe, comorbidit\u00e9s \"", "methods": "Etudier l'association entre la prise de traitements hypertenseurs de type inhibiteurs de l'enzyme (IEC) de conversion et antagonistes des r\u00e9cepteurs de l'angiotensine (ARA) et la s\u00e9v\u00e9rit\u00e9 et mortalit\u00e9 chez les patients hypertendus hospitalis\u00e9s pour COVID-19", "pubmed_id": "32324209\n32170560\n32109013\n32125455\n32091533\n16001071\n32031570\n31986264\n15897343\n25766467\n29102084\n32171076\n32051365\n16007097\n32171062", "doi": "10.1001/jamacardio.2020.1624", "abstract": "Data are lacking whether patients with hypertension who are taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) have increased severity or risk of mortality during hospitalization for coronavirus disease 2019 (COVID-19).\nTo investigate the association between ACEIs/ARBs and severity of illness and mortality in patients with hypertension hospitalized for COVID-19 infection.\nRetrospective, single-center case series of the 1178 hospitalized patients with COVID-19 infections at the Central Hospital of Wuhan, China, from January 15 to March 15, 2020.\nCOVID-19 was confirmed by real-time reverse transcription-polymerase chain reaction and epidemiologic, clinical, radiologic, laboratory, and drug therapy data were analyzed in all patients. The percentage of patients with hypertension taking ACEIs/ARBs was compared between those with severe vs nonsevere illness and between survivors vs nonsurvivors.\nOf the 1178 patients with COVID-19, the median age was 55.5 years (interquartile range, 38-67 years) and 545 (46.3%) were men. The overall in-hospital mortality was 11.0%. There were 362 patients with hypertension (30.7% of the total group; median age, 66.0 years [interquartile range, 59-73 years]; 189 [52.2%] were men), of whom 115 (31.8%) were taking ACEI/ARBs. The in-hospital mortality in the patients with hypertension was 21.3%. The percentage of patients with hypertension taking ACEIs/ARBs did not differ between those with severe and nonsevere infections (32.9% vs 30.7%; P\u2009=\u2009.65) nor did it differ between nonsurvivors and survivors (27.3% vs 33.0%; P\u2009=\u2009.34). Similar findings were observed when data were analyzed for patients taking ACEIs and those taking ARBs.\nThis study provides clinical data on the association between ACEIs/ARBs and outcomes in patients with hypertension hospitalized with COVID-19 infections, suggesting that ACEIs/ARBs are not associated with the severity or mortality of COVID-19 in such patients. These data support current guidelines and societal recommendations for treating hypertension during the COVID-19 pandemic.", "topics": ["Pronostique", "Infectiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 255, "name": "Li J"}], "publication_date": "2020-04-25"}, {"id": 81, "slug": "coronavirus-fulminant-myocarditis-saved-with-glucocorticoid-and-human-immunoglob", "title": "Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Proposer un exemple de th\u00e9rapie m\u00e9dicamenteuse pour les patients atteints de myocardite du SARS-CoV-2", "verbose_date": "16.03.2020", "authors": "Hu H", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 34, "name": "Eur Heart J"}, "link": "https://www.dropbox.com/s/hteuqirpka5r3q8/ehaa190.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Cette \u00e9tude sugg\u00e8re qu'un traitement pr\u00e9coce avec des glucocortico\u00efdes anti-inflammatoires et des immunoglobulines a un effet imporant pour un patient jeune avec myocardite fulminante", "objectives": "Faible:-case report", "methods": "Proposer un exemple de th\u00e9rapie m\u00e9dicamenteuse pour les patients atteints de myocardite du SARS-CoV-2", "pubmed_id": "32176300", "doi": "10.1093/eurheartj/ehaa190", "abstract": null, "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 91, "name": "Hu H"}], "publication_date": "2020-03-16"}, {"id": 390, "slug": "longitudinal-characteristics-of-lymphocyte-responses-and-cytokine-profiles-in-th", "title": "Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etude de la corr\u00e9lation entre la cin\u00e9tique des lymphocytes, profil cytokinique et niveau de gravit\u00e9 clinique des patients COVID-19 positif.", "verbose_date": "20.04.2020", "authors": "Liu J", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 165, "name": "EBioMedicine"}, "link": "https://reader.elsevier.com/reader/sd/pii/S2352396420301389?token=63D64F8494420D14C858E62C172915645B81DB51FEA632728E22147AEBBF8FD7F8F686D6E9FC7CD4624F09D6EA714317", "findings": "", "take_away": "", "relevance_level": "v- Augmentation des neutrophiles et de fa\u00e7on prolong\u00e9e dans le groupe forme s\u00e9v\u00e8re\r\n- Augmentation marqu\u00e9e des cytokines IL2, IL6, IL10 et INFg avec pic \u00e0 J4-J6 dans le groupe forme s\u00e9v\u00e8re.\r\n- Baisse des lymphocytes de fa\u00e7on majeure dans le groupe forme s\u00e9v\u00e8re (44% vs 84%) avec pic \u00e0 J4-J6 touchant l\u2019ensemble des sous-classes des lymphocytes T mais pas les sous classe B, ni NK.\r\n- Possibilit\u00e9 du r\u00f4le de cytokines sur la baisse des lymphocytes T. Modalit\u00e9 restant \u00e0 \u00e9tudi\u00e9e.\u00a0\r\n- Possibilit\u00e9 de d\u00e9couverte d\u2019un facteur pr\u00e9dictif N8R (rapport neutrophile/lymphocyte T8+). A Evaluer.", "objectives": "-\tMonocentrique -\tFaible nombre de patient -\tR\u00e9trospective-\tBiais : o\tCrit\u00e8re de s\u00e9lection des patients graves discutables o\t5 patients s\u00e9v\u00e8res ont des co-infections (4 infections fongiques et 1 bact\u00e9rienne) qui peuvent \u00eatre de facteur de confusion", "methods": "Etude de la corr\u00e9lation entre la cin\u00e9tique des lymphocytes, profil cytokinique et niveau de gravit\u00e9 clinique des patients COVID-19 positif.", "pubmed_id": "32361250\n32227123\n32161940\n24065148\n17052299\n19635508\n17891146\n32031568\n28466096\n17917657\n27344959\n31986264\n24725946\n32007143\n31986261\n32217835", "doi": "10.1016/j.ebiom.2020.102763", "abstract": "The dynamic changes of lymphocyte subsets and cytokines profiles of patients with novel coronavirus disease (COVID-19) and their correlation with the disease severity remain unclear.\nPeripheral blood samples were longitudinally collected from 40 confirmed COVID-19 patients and examined for lymphocyte subsets by flow cytometry and cytokine profiles by specific immunoassays.\nOf the 40 COVID-19 patients enrolled, 13 severe cases showed significant and sustained decreases in lymphocyte counts [0\u00b76 (0\u00b76-0\u00b78)] but increases in neutrophil counts [4\u00b77 (3\u00b76-5\u00b78)] than 27 mild cases [1.1 (0\u00b78-1\u00b74); 2\u00b70 (1\u00b75-2\u00b79)]. Further analysis demonstrated significant decreases in the counts of T cells, especially CD8\nThe degree of lymphopenia and a proinflammatory cytokine storm is higher in severe COVID-19 patients than in mild cases, and is associated with the disease severity. N8R and NLR may serve as a useful prognostic factor for early identification of severe COVID-19 cases.\nThe National Natural Science Foundation of China, the National Science and Technology Major Project, the Health Commission of Hubei Province, Huazhong University of Science and Technology, and the Medical Faculty of the University of Duisburg-Essen and Stiftung Universitaetsmedizin, Hospital Essen, Germany.", "topics": ["Epid\u00e9miologique", "Infectiologie"], "author_list": [{"id": 339, "name": "Liu J"}], "publication_date": "2020-04-20"}, {"id": 330, "slug": "rapid-asymptomatic-transmission-of-covid-19-during-the-incubation-period-demonst", "title": "Rapid Asymptomatic Transmission of COVID-19 During the Incubation Period Demonstrating Strong Infectivity in a Cluster of Youngsters Aged 16-23 Years Outside Wuhan and Characteristics of Young Patients With COVID-19: A Prospective Contact-Tracing Study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Suivre et tracer tous les personnes qui ont \u00e9t\u00e9 en contact avec un homme de 22 ans (le patient 1) revenant de Wuhan et soup\u00e7onn\u00e9 d'\u00eatre infect\u00e9 par le COVID-19, et recueillir de mani\u00e8re prospective des informations sur les caract\u00e9ristiques d\u00e9mographiques, \u00e9pid\u00e9miologiques, cliniques, radiologiques et de laboratoire, ainsi que sur la prise en charge et les r\u00e9sultats pour les 8 jeunes avec COVID-19 confirm\u00e9 en laboratoire (y compris le patient 1) et pour les 9 contacts du patient 1 admis \u00e0 l'h\u00f4pital et n\u00e9gatifs pour le SARS-CoV-2.", "verbose_date": "14.04.2020", "authors": "Huang L", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0163445320301171?token=2F48CF0C05B593C50C76D2E22AA7A8523EC641B5131E5E41DF4CFD27C94D2F37BF7C186CEC138631965D176F0B5BC45B", "findings": "", "take_away": "", "relevance_level": "L'infection par le SARS-CoV-2 a pr\u00e9sent\u00e9 une forte infectiosit\u00e9 pendant la p\u00e9riode d'incubation avec une transmission rapide dans ce groupe de jeunes en dehors de Wuhan.\u00a0\r\nLes sympt\u00f4mes des jeunes atteints de COVID-19 \u00e9taient d'apparition rapide et \u00e9taient g\u00e9n\u00e9ralement l\u00e9gers, non sp\u00e9cifiques, atypiques et divers.", "objectives": "-        \u00c9tude de cohorte prospective de \u00ab contact-tracing \u00bb-        Tr\u00e8s petit \u00e9chantillon (23 sujets, et les informations ont \u00e9t\u00e9 recueillies pour seulement 17 sujets)", "methods": "Suivre et tracer tous les personnes qui ont \u00e9t\u00e9 en contact avec un homme de 22 ans (le patient 1) revenant de Wuhan et soup\u00e7onn\u00e9 d'\u00eatre infect\u00e9 par le COVID-19, et recueillir de mani\u00e8re prospective des informations sur les caract\u00e9ristiques d\u00e9mographiques, \u00e9pid\u00e9miologiques, cliniques, radiologiques et de laboratoire, ainsi que sur la prise en charge et les r\u00e9sultats pour les 8 jeunes avec COVID-19 confirm\u00e9 en laboratoire (y compris le patient 1) et pour les 9 contacts du patient 1 admis \u00e0 l'h\u00f4pital et n\u00e9gatifs pour le SARS-CoV-2.", "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie", "P\u00e9diatrie"], "author_list": [{"id": 317, "name": "Huang L"}], "publication_date": "2020-04-14"}, {"id": 282, "slug": "olfactory-and-gustatory-dysfunctions-as-a-clinical-presentation-of-mild-to-moder", "title": "Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9crire les troubles olfactifs et gustatifs chez les patients infect\u00e9s par le SARS-CoV-2", "verbose_date": "08.04.2020", "authors": "Lechien JR", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 133, "name": "Otorhinolaryngol"}, "link": "https://link.springer.com/content/pdf/10.1007/s00405-020-05965-1.pdf", "findings": "", "take_away": "", "relevance_level": "Les troubles olfactifs (anosmie, hyposmie, phantosmie et parosmie) et gustatifs (diminution et/ou modification du go\u00fbt) sont des sympt\u00f4mes importants \u00e0 rechercher car ils peuvent appara\u00eetre avant les autres sympt\u00f4mes de COVID-19 chez 12% des sujets d'apr\u00e8s cette \u00e9tude. Il semble que le sexe f\u00e9minin et la fi\u00e8vre sont associ\u00e9s \u00e0 la survenue de ces troubles. La quantification de la dur\u00e9e et de la r\u00e9solution de ces sympt\u00f4mes n\u00e9cessitera des \u00e9tudes particuli\u00e8res car le suivi \u00e9tait insuffisamment long dans cette \u00e9tude. Enfin la physiopathologie de ces sympt\u00f4mes sera \u00e0 explorer notamment pour expliquer leur diff\u00e9rence d'incidence entre la population asiatique et la population europ\u00e9enne, beaucoup plus touch\u00e9e.", "objectives": "- patients avec atteinte l\u00e9g\u00e8re ou mod\u00e9r\u00e9e (s\u00e9v\u00e8res non inclus)- peu de d\u00e9tail sur la traduction du questionnaire sQOD-NS : traduction valid\u00e9e? R\u00e9alis\u00e9e pour l'\u00e9tude?- effectif cons\u00e9quent mais certaines analyses sont r\u00e9alis\u00e9es dans des sous-groupes de petite taille- \u00e9valuation non objective- pas de suivi des patients pour estimer la dur\u00e9e des sympt\u00f4mes et leur r\u00e9solution- effet p\u00e9joratif potentiel des cortico\u00efdes PO et IN pris par certains patients de l'\u00e9tude\"", "methods": "D\u00e9crire les troubles olfactifs et gustatifs chez les patients infect\u00e9s par le SARS-CoV-2", "pubmed_id": "32253535", "doi": "10.1007/s00405-020-05965-1", "abstract": "To investigate the occurrence of olfactory and gustatory dysfunctions in patients with laboratory-confirmed COVID-19 infection.\nPatients with laboratory-confirmed COVID-19 infection were recruited from 12 European hospitals. The following epidemiological and clinical outcomes have been studied: age, sex, ethnicity, comorbidities, and general and otolaryngological symptoms. Patients completed olfactory and gustatory questionnaires based on the smell and taste component of the National Health and Nutrition Examination Survey, and the short version of the Questionnaire of Olfactory Disorders-Negative Statements (sQOD-NS).\nA total of 417 mild-to-moderate COVID-19 patients completed the study (263 females). The most prevalent general symptoms consisted of cough, myalgia, and loss of appetite. Face pain and nasal obstruction were the most disease-related otolaryngological symptoms. 85.6% and 88.0% of patients reported olfactory and gustatory dysfunctions, respectively. There was a significant association between both disorders (p\u2009<\u20090.001). Olfactory dysfunction (OD) appeared before the other symptoms in 11.8% of cases. The sQO-NS scores were significantly lower in patients with anosmia compared with normosmic or hyposmic individuals (p\u2009=\u20090.001). Among the 18.2% of patients without nasal obstruction or rhinorrhea, 79.7% were hyposmic or anosmic. The early olfactory recovery rate was 44.0%. Females were significantly more affected by olfactory and gustatory dysfunctions than males (p\u2009=\u20090.001).\nOlfactory and gustatory disorders are prevalent symptoms in European COVID-19 patients, who may not have nasal symptoms. The sudden anosmia or ageusia need to be recognized by the international scientific community as important symptoms of the COVID-19 infection.", "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 271, "name": "Lechien JR"}], "publication_date": "2020-04-08"}, {"id": 247, "slug": "favipiravir-pharmacokinetics-and-concerns-about-clinical-trials-for-2019-ncov-in", "title": "Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00e9sumer, en vue d'un possible essai clinique, les caract\u00e9ristiques pharmacocin\u00e9tiques et les \u00e9ventuelles interactions m\u00e9dicamenteuses du Favipiravir un antiviral envisag\u00e9 dans le traitement de la COVID-19", "verbose_date": "06.04.2020", "authors": "Du YX", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 116, "name": "Clin Pharmacol Ther"}, "link": "https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.1844", "findings": "", "take_away": "", "relevance_level": "Le favipiravir pourrait \u00eatre un bon antiviral pour le traitement de la COVID-19. Les auteurs estiment qu'il pourrait \u00eatre un candidat comme traitement compassionnel mais que davantage de preuves de son efficacit\u00e9 sont n\u00e9cessaires. Ce m\u00e9dicament a principalement \u00e9t\u00e9 utilis\u00e9 et \u00e9tudi\u00e9 dans la population japonaise et sa pharmacocin\u00e9tique doit \u00eatre \u00e9tudi\u00e9e dans d'autres populations.", "objectives": "- revue de petite taille- encore peu d'\u00e9tudes chez l'humain relativement aux \u00e9tudes in vitro ou chez l'animal", "methods": "R\u00e9sumer, en vue d'un possible essai clinique, les caract\u00e9ristiques pharmacocin\u00e9tiques et les \u00e9ventuelles interactions m\u00e9dicamenteuses du Favipiravir un antiviral envisag\u00e9 dans le traitement de la COVID-19", "pubmed_id": "32246834", "doi": "10.1002/cpt.1844", "abstract": "An outbreak of 2019-nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-\u0251, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.", "topics": ["Th\u00e9rapeutique", "Infectiologie", "Pneumologie"], "author_list": [{"id": 237, "name": "Du YX"}], "publication_date": "2020-04-06"}, {"id": 496, "slug": "antibody-responses-to-sars-cov-2-in-patients-with-covid-19", "title": "Antibody responses to SARS-CoV-2 in patients with COVID-19", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Etudier les catar\u00e9tisques des anticorps contre le SARS-COV-2 chez les patients atteints par le COVID-19.", "verbose_date": "01.05.2020", "authors": "Long QX", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 115, "name": "Nature Med"}, "link": "https://www.nature.com/articles/s41591-020-0897-1.pdf", "findings": "", "take_away": "", "relevance_level": "Test s\u00e9rologie pour le SARS-COV-2 compl\u00e9mentaire de la RT-PCR pour :\u00a0\n- le diagnostic (a\u00a0fortiori du fait de sa pr\u00e9cocit\u00e9 et de sa rapidit\u00e9 de r\u00e9sultats qui est important pour isoler les patients infect\u00e9s).\n- suivi\u00a0des personnes asymptomatiques et \"contact\" de patients infect\u00e9s", "objectives": "Etude de Cohorte Objectif multiple Bonne m\u00e9thodologie Mais : - effectif faible et surtout pour les formes s\u00e9v\u00e8res- absence d'\u00e9tude du r\u00f4le neutralisant des anticorps", "methods": "Etudier les catar\u00e9tisques des anticorps contre le SARS-COV-2 chez les patients atteints par le COVID-19.", "pubmed_id": "32350462", "doi": "10.1038/s41591-020-0897-1", "abstract": "We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT-PCR results and for the identification of asymptomatic infections.", "topics": ["Pronostique", "Virologie", "Infectiologie"], "author_list": [{"id": 465, "name": "Long QX"}], "publication_date": "2020-05-01"}, {"id": 351, "slug": "detection-of-sars-cov-2-by-rt-pcr-in-anal-from-patients-who-have-recovered-from-", "title": "Detection of SARS-CoV-2 by RT-PCR in anal from patients who have recovered from coronavirus disease 2019", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la d\u00e9tection de SARS-CoV-2 avec RT-PCR anales chez des patients r\u00e9tablis du COVID-19", "verbose_date": "16.04.2020", "authors": "Liu J", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25875", "findings": "", "take_away": "", "relevance_level": "4 patients / 69 avec RT-PCR positives en rectal pendant la quatorzaine post-sortie d'hospitalisation (valid\u00e9e par 2 tests n\u00e9gatifs en nasopharyng\u00e9 et 1 n\u00e9gatif en rectal). Cas notamment d'un gar\u00e7on de 8 ans avec \u00e9chantillons rectaux positifs pendant 9 jours.", "objectives": "1) Lettre \u00e0 l'\u00e9diteur2) Etude r\u00e9trospective, n=693) Pas de protocole d\u00e9crit de suivi par RT-PCR, \u00e0 quelle fr\u00e9quence ont ils \u00e9t\u00e9 r\u00e9alis\u00e9s?4) Pas de culture virale \u00e9tudiant la contagiosit\u00e9\"", "methods": "Etudier la d\u00e9tection de SARS-CoV-2 avec RT-PCR anales chez des patients r\u00e9tablis du COVID-19", "pubmed_id": "32285947", "doi": "10.1002/jmv.25875", "abstract": null, "topics": ["Diagnostique", "Virologie", "Infectiologie"], "author_list": [{"id": 339, "name": "Liu J"}], "publication_date": "2020-04-16"}, {"id": 527, "slug": "convalescent-plasma-transfusion-for-the-treatment-of-covid-19-systematic-review", "title": "Convalescent plasma transfusion for the treatment of COVID-19: Systematic review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Revue syst\u00e9matique de la litt\u00e9rature sur l'efficacit\u00e9 de la transfusion de plasma de patient convalescent (CPT) pour le traitement du COVID-19.", "verbose_date": "04.05.2020", "authors": "Ranjendran K", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://www.dropbox.com/s/4snxh0k562lchw0/10.1002%40jmv.25961.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le traitement par transfusion de plasma de patient convalescent pourrait \u00eatre une piste pour le traitement de patient atteint de COVID-19. De plus ample \u00e9tudes sont cependant n\u00e9cessaires pour pouvoir se prononcer sur le sujet.", "objectives": "- Pas d'attente de l'inscription du protocole.- Selon les lignes directrices PRISMA-P- Faible nombre d'article (n=5)- Faible nombre de patient (n=27)- Pas d'essai clinique (case report et s\u00e9rie de cas) / Absence de groupe contr\u00f4le- Risque \u00e9lev\u00e9 de biais dans les articles consid\u00e9r\u00e9s", "methods": "Revue syst\u00e9matique de la litt\u00e9rature sur l'efficacit\u00e9 de la transfusion de plasma de patient convalescent (CPT) pour le traitement du COVID-19.", "pubmed_id": "32356910\n21248066\n15616839\n16940336\n15214887\n32253318\n17914053\n32052466\n32281317\n32167489\n31502247\n25554246", "doi": "10.1002/jmv.25961", "abstract": "The recent emergence of coronavirus disease 2019 (COVID-19) pandemic has reassessed the usefulness of historic convalescent plasma transfusion (CPT). This review was conducted to evaluate the effectiveness of CPT therapy in COVID-19 patients based on the publications reported till date. To our knowledge, this is the first systematic review on convalescent plasma on clinically relevant outcomes in individuals with COVID-19. PubMed, EMBASE, and Medline databases were searched upto 19 April 2020. All records were screened as per the protocol eligibility criteria. We included five studies reporting CPT to COVID-19 patients. The main findings from available data are as follows: (a) Convalescent plasma may reduce mortality in critically ill patients, (b) Increase in neutralizing antibody titers and disappearance of SARS-CoV-2 RNA was observed in almost all the patients after CPT therapy, and (c) Beneficial effect on clinical symptoms after administration of convalescent plasma. Based on the limited scientific data, CPT therapy in COVID-19 patients appears safe, clinically effective, and reduces mortality. Well-designed large multicenter clinical trial studies should be conducted urgently to establish the efficacy of CPT to COVID-19 patients.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 494, "name": "Ranjendran K"}], "publication_date": "2020-05-04"}, {"id": 35, "slug": "clinical-features-of-severe-pediatric-patients-with-coronavirus-disease-2019-in-", "title": "Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques cliniques des patients s\u00e9v\u00e8res en p\u00e9diatrie", "verbose_date": "20.03.2020", "authors": "Sun D", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 31, "name": "World J Pediatr"}, "link": "https://www.dropbox.com/s/3zuhd46bkr7bcik/Sun2020_Article_ClinicalFeaturesOfSeverePediat.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Polypn\u00e9e, toux et fi\u00e8vre les plus fr\u00e9quentsImages pulmonaires d'opacit\u00e9s multiples et opacit\u00e9s en verre d\u00e9poliTemp\u00eate cytokinique avec ici IL6 et IL10 augment\u00e9s chez les patients critiques", "objectives": "Faible1) 8 patients, monocentrique2) uniquement descriptif", "methods": "D\u00e9crire les caract\u00e9ristiques cliniques des patients s\u00e9v\u00e8res en p\u00e9diatrie", "pubmed_id": "32193831\n32171026\n32164053\n32075786\n32051073\n32071063\n32181901\n28466096\n27344959\n32187464\n32083643\n32007143\n32159775\n32043842\n32112336\n32035018\n26808160\n32062875\n31986264\n32029004\n31981224\n32032682\n32105632", "doi": "10.1007/s12519-020-00354-4", "abstract": "An outbreak of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was first detected in Wuhan, Hubei, China. People of all ages are susceptible to SARS-CoV-2 infection. No information on severe pediatric patients with COVID-19 has been reported. We aimed to describe the clinical features of severe pediatric patients with COVID-19.\nWe included eight severe or critically ill patients with COVID-19 who were treated at the Intensive Care Unit (ICU), Wuhan Children's Hospital from January 24 to February 24. We collected information including demographic data, symptoms, imaging data, laboratory findings, treatments and clinical outcomes of the patients with severe COVID-19.\nThe onset age of the eight patients ranged from 2\u00a0months\u00a0to 15\u00a0years; six were boys. The most common symptoms were polypnea (8/8), followed by fever (6/8) and cough (6/8). Chest imaging showed multiple patch-like shadows in seven patients and ground-glass opacity in six. Laboratory findings revealed normal or increased whole blood counts (7/8), increased C-reactive protein, procalcitonin and lactate dehydrogenase (6/8), and abnormal liver function (4/8). Other findings included decreased CD16\u2009+\u2009CD56 (4/8) and Th/Ts*(1/8), increased CD3 (2/8), CD4 (4/8) and CD8 (1/8), IL-6 (2/8), IL-10 (5/8) and IFN-\u03b3 (2/8). Treatment modalities were focused on symptomatic and respiratory support. Two critically ill patients underwent invasive mechanical ventilation. Up to February 24, 2020, three patients remained under treatment in ICU, the other five recovered and were discharged home.\nIn this series of severe pediatric patients in Wuhan, polypnea was the most common symptom, followed by fever and cough. Common imaging changes included multiple patch-like shadows and ground-glass opacity; and\u00a0a cytokine storm was found in these patients, which appeared more serious in critically ill patients.", "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 45, "name": "Sun D"}], "publication_date": "2020-03-20"}, {"id": 401, "slug": "clinical-characteristics-of-older-patients-the-experience-of-a-geriatric-short-s", "title": "Clinical characteristics of older patients: The experience of a geriatric short-stay unit dedicated to patients with COVID-19 in France", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Pr\u00e9sentation d'un retour d'exp\u00e9rience sur une unit\u00e9 d'hospitalisation de courte dur\u00e9e de g\u00e9riatrie d\u00e9di\u00e9 au patient COVID-19.", "verbose_date": "21.04.2020", "authors": "Godaert L", "specialties": [{"id": 13, "name": "G\u00e9riatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.journalofinfection.com/article/S0163-4453(20)30217-6/pdf", "findings": "", "take_away": "", "relevance_level": "Les personnes ag\u00e9es sont fortement touch\u00e9es par le COVID-19, particuli\u00e8rement en fr\u00e9quence mais aussi en gravit\u00e9. Pr\u00e9sence de signe inhabituel chez les personnes ag\u00e9es (fr\u00e9quent pour beaucoup d'infection)", "objectives": "- Lettre \u00e0 l'\u00e9diteur- Faible effectif (n=17)\"", "methods": "Pr\u00e9sentation d'un retour d'exp\u00e9rience sur une unit\u00e9 d'hospitalisation de courte dur\u00e9e de g\u00e9riatrie d\u00e9di\u00e9 au patient COVID-19.", "pubmed_id": "32305489", "doi": "10.1016/j.jinf.2020.04.009", "abstract": null, "topics": ["Epid\u00e9miologique", "G\u00e9riatrie"], "author_list": [{"id": 384, "name": "Godaert L"}], "publication_date": "2020-04-21"}, {"id": 59, "slug": "should-patients-stop-their-biologic-treatment-during-the-covid-19-pandemic", "title": "Should patients stop their biologic treatment during the COVID-19 pandemic?", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Discuter la balance b\u00e9n\u00e9fice-risque de poursuivre des traitements par bioth\u00e9rapie chez des patients suivis pour des pathologies dermatologiques dans le contexte de la pand\u00e9mie \u00e0 SARS-CoV-2.", "verbose_date": "19.03.2020", "authors": "Bashyam AM", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 10, "name": "Dermatologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 50, "name": "J Dermatolog Treat"}, "link": "https://www.dropbox.com/s/mrr5dwnrjvg5agb/Should%20patients%20stop%20their%20biologic%20treatment%20during%20the%20COVID%2019%20pandemic.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "D'apr\u00e8s les auteurs, \u00e0 ce stade il ne faudrait pas \u00e9mettre une recommandation universelle d'arr\u00eat de leur traitement pour tous les patients sous bioth\u00e9rapie mais plut\u00f4t adopter une strat\u00e9gie au cas par cas en conseillant de stopper les bioth\u00e9rapies avant tout dans les groupes \u00e0 risque de COVID-19 s\u00e9v\u00e8re : patients \u00e2g\u00e9s, comorbidit\u00e9s cardiovasculaires et/ou pulmonaires.", "objectives": "Faible :Editorial, bas\u00e9 sur de la bibliographie", "methods": "Discuter la balance b\u00e9n\u00e9fice-risque de poursuivre des traitements par bioth\u00e9rapie chez des patients suivis pour des pathologies dermatologiques dans le contexte de la pand\u00e9mie \u00e0 SARS-CoV-2.", "pubmed_id": "32191143", "doi": "10.1080/09546634.2020.1742438", "abstract": null, "topics": ["Th\u00e9rapeutique", "Transversale", "Dermatologie"], "author_list": [{"id": 69, "name": "Bashyam AM"}], "publication_date": "2020-03-19"}, {"id": 424, "slug": "covid-19-related-severe-hypercoagulability-in-patients-admitted-to-intensive-car", "title": "COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer les anomalies de la coagulation via des tests traditionnels et des profils de thrombo\u00e9lastom\u00e9trie sur sang total chez les patients COVID-19, les comparer avec des personnes saines", "verbose_date": "23.04.2020", "authors": "Spiezia L", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 120, "name": "Thromb Haemost"}, "link": "https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0040-1710018.pdf", "findings": "", "take_away": "", "relevance_level": "Les patients COVID-19 pr\u00e9sentant une insuffisance respiratoire aigu\u00eb pr\u00e9sentent une hypercoagulabilit\u00e9 s\u00e9v\u00e8re plut\u00f4t qu'une coagulopathie de consommation. La formation et la polym\u00e9risation de la fibrine peuvent pr\u00e9disposer \u00e0 la thrombose et \u00eatre en corr\u00e9lation avec des issues plus d\u00e9favorables du COVID-19. La th\u00e9rapie par anticoagulant est \u00e0 explorer par d'autres \u00e9tudes.", "objectives": "1) Sch\u00e9ma d'\u00e9tude particulier: compare la coagulation de patients COVID-19 hospitalis\u00e9s en soins intensifs appel\u00e9s cas avec des t\u00e9moins sains appari\u00e9s sur l'\u00e2ge le sexe le poids. Mais pas r\u00e9elle \u00e9tude cas t\u00e9moins car pas de comparaison sur un facteur de risque2) On ne sait pas les modalit\u00e9s de recrutement des t\u00e9moins : hospitalis\u00e9s? 3) 22 patients COVID-19 inclus, 44 personnes saines appari\u00e9es. Les modifications observ\u00e9es sont-elles dues uniquement au COVID-19 ou une partie peut \u00eatre li\u00e9e \u00e0 l'hospitalisation en soins intensifs?4) Certains patients ont re\u00e7u de l'h\u00e9parine avant l'inclusion et les pr\u00e9l\u00e8vements sanguins (avec un d\u00e9lai susceptible d'\u00eatre inf\u00e9rieur \u00e0 4-6 heures), pas de mesure de l'activit\u00e9 anti-Xa.", "methods": "\u00c9valuer les anomalies de la coagulation via des tests traditionnels et des profils de thrombo\u00e9lastom\u00e9trie sur sang total chez les patients COVID-19, les comparer avec des personnes saines", "pubmed_id": "32316063", "doi": "10.1055/s-0040-1710018", "abstract": "In late December 2019 an outbreak of a novel coronavirus (SARS-CoV-2) causing severe pneumonia (COVID-19) was reported in Wuhan, Hubei Province, China. A common finding in most COVID-19 patients is high D-dimer levels which are associated with a worse prognosis. We aimed to evaluate coagulation abnormalities via traditional tests and whole blood thromboelastometry profiles in a group of 22 (mean age 67\u2009\u00b1\u20098 years, M:F 20:2) consecutive patients admitted to the Intensive Care Unit of Padova University Hospital for acute respiratory failure due to COVID-19. Cases showed significantly higher fibrinogen and D-dimer plasma levels versus healthy controls (", "topics": ["Epid\u00e9miologique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 404, "name": "Spiezia L"}], "publication_date": "2020-04-23"}, {"id": 480, "slug": "vaginal-delivery-in-sars-cov-2-infected-pregnant-women-in-northern-italy-a-retro", "title": "Vaginal delivery in SARS-CoV-2 infected pregnant women in Northern Italy: a retrospective analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Rapporter le mode d'accouchement et l'\u00e9volution imm\u00e9diate des nouveau-n\u00e9s de ces m\u00e8res infect\u00e9es.\r\n ", "verbose_date": "29.04.2020", "authors": "Ferrazzi E", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 195, "name": "Int J Obstet Gy"}, "link": "https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.16278", "findings": "", "take_away": "", "relevance_level": "Ces donn\u00e9es sugg\u00e8rent un faible risque de transmission aux nouveau-n\u00e9s apr\u00e8s un accouchement par voie basse. 60% d'accouchements par voie basse, mais un faible risque de transmission materno-foetale intrapartum ne peut \u00eatre exclu. Les femmes enceintes semblent avoir un tableau plut\u00f4t mod\u00e9r\u00e9 ou l\u00e9ger. Il faudrait r\u00e9server la c\u00e9sarienne aux d\u00e9tresses respiratoires aigu\u00ebs maternelles. D'autres donn\u00e9es sont n\u00e9cessaires pour la transmission possible lors d'un accouchement par voie basse.", "objectives": "Etude r\u00e9trospective \u00e0 faible effectif. Mais donn\u00e9es int\u00e9ressantes. A compl\u00e9ter sur de l'\u00e9volution \u00e0 plus long terme et sur les infections COVID avant le 3\u00e8me trimestre.", "methods": "Rapporter le mode d'accouchement et l'\u00e9volution imm\u00e9diate des nouveau-n\u00e9s de ces m\u00e8res infect\u00e9es.", "pubmed_id": "32339382\n25582523\n28729104\n32105680\n32151335", "doi": "10.1111/1471-0528.16278", "abstract": "To report mode of delivery and immediate neonatal outcome in women infected with COVID-19.\nRetrospective study.\nTwelve hospitals in northern Italy.\nPregnant women with COVID-19-confirmed infection who delivered.\nCOVID 19 infection in pregnancy.\nSARS-CoV-2-infected women who were admitted and delivered from 1 to 20 March 2020 were eligible. Data were collected from the clinical records using a standardised questionnaire on maternal general characteristics, any medical or obstetric co-morbidity, course of pregnancy, clinical signs and symptoms, treatment of COVID 19 infection, mode of delivery, neonatal data and breastfeeding.\nData on mode of delivery and neonatal outcome.\nIn all, 42 women with COVID-19 delivered at the participating centres; 24 (57.1%, 95% CI\u00a041.0-72.3) delivered vaginally. An elective caesarean section was performed in 18/42 (42.9%, 95% CI 27.7-59.0) cases: in eight cases the indication was unrelated to COVID-19 infection. Pneumonia was diagnosed in 19/42 (45.2%, 95% CI 29.8-61.3) cases: of these, 7/19 (36.8%, 95% CI 16.3-61.6) required oxygen support and 4/19 (21.1%, 95% CI\u00a06.1-45.6) were admitted to a critical care unit. Two women with COVID-19 breastfed without a mask because infection was diagnosed in the postpartum period: their newborns tested positive for SARS-Cov-2 infection. In one case, a newborn had a positive test after a vaginal operative delivery.\nAlthough postpartum infection cannot be excluded with 100% certainty, these findings suggest that vaginal delivery is\u00a0associated with a low risk of intrapartum SARS-Cov-2 transmission to the newborn.\nThis study suggests that vaginal delivery may be associated with a low risk of intrapartum SARS-Cov-2 transmission to the newborn.", "topics": ["Epid\u00e9miologique", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 448, "name": "Ferrazzi E"}], "publication_date": "2020-04-29"}, {"id": 321, "slug": "statins-in-coronavirus-outbreak-its-time-for-experimental-and-clinical-studies", "title": "Statins in coronavirus outbreak: it\u2019s time for experimental and clinical studies", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'int\u00e9r\u00eat du traitement par statines dans le cadre de l'infection \u00e0 SARS-CoV-2", "verbose_date": "14.04.2020", "authors": "Bifulco M", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 82, "name": "Pharmacol Res"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1043661820311117?token=270FE9607C9381077ABD676F369CC45E78351960EFD24A8C289E603259130F5A5A1BA0ABCCC56DF15EBA6B10BB2AFE15", "findings": "", "take_away": "", "relevance_level": "Les statines pourraient repr\u00e9senter une piste th\u00e9rapeutique int\u00e9ressante pour l'infection \u00e0 SARS-CoV-2 car facilement accessible et relativement s\u00fbres. En effet, ce traitement semble avoir un effet anti-viral par son action sur le cholest\u00e9rol : \u00e9chec de l'internalisation du virus par modification du cholest\u00e9rol de la membrase plasmatique notamment.\r\nToutefois, il n'y a pas d'\u00e9tude actuelle sp\u00e9cifique sur le SARS-CoV-2 (surtout sur des virus de la grippe A) et donc il y a un besoin d'\u00e9tudes compl\u00e9mentaires.", "objectives": "- Revue narrative sur tr\u00e8s peu de r\u00e9f\u00e9rences bibliographiques- Bas\u00e9 sur d'autres virus (pas de donn\u00e9es sur le SARS-CoV-2)- Bas\u00e9 sur des exp\u00e9rimentations in vitro notamment\"", "methods": "Evaluer l'int\u00e9r\u00eat du traitement par statines dans le cadre de l'infection \u00e0 SARS-CoV-2", "pubmed_id": "32289478", "doi": "10.1016/j.phrs.2020.104803", "abstract": null, "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 308, "name": "Bifulco M"}], "publication_date": "2020-04-14"}, {"id": 177, "slug": "early-low-dose-and-short-term-application-of-corticosteroid-treatment-in-patient", "title": "Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer l'efficacit\u00e9 et la s\u00e9curit\u00e9 de la corticoth\u00e9rapie dans le traitement des formes s\u00e9v\u00e8res de pneumopathies \u00e0 COVID-19", "verbose_date": "27.03.2020", "authors": "Wang Y ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/r3sgd7d3mod6leg/Wang%20et%20al%2C%20MedRxiv%202020.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Corticoth\u00e9rapie pourrait \u00eatre efficace sur la r\u00e9duction de la symptomatologie clinique des patients s\u00e9v\u00e8res avec une diminution significative de la dur\u00e9e de la fi\u00e8vre, de l'oxyg\u00e9nod\u00e9pendance et des images radiologiques.\r\nMais \u00e9tude de faible niveau de preuve, donc \u00e0 confirmer", "objectives": "- Pre-prints (non review\u00e9)- Absence de randomisation pour la constitution des groupes !- Absence d'aveugle- Moment du traitement non d\u00e9fini (au d\u00e9but de l'infection, pendant l'orage cytokinique ?)- Fr\u00e9quence des comorbidit\u00e9s faible par rapport \u00e0 la population g\u00e9n\u00e9ralement touch\u00e9e par le COVID 19- H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 des traitements concomitants re\u00e7us notamment antiviraux (a-interferon, Kaletra...)- Effets ind\u00e9sirables peu \u00e9tudi\u00e9s", "methods": "\u00c9valuer l'efficacit\u00e9 et la s\u00e9curit\u00e9 de la corticoth\u00e9rapie dans le traitement des formes s\u00e9v\u00e8res de pneumopathies \u00e0 COVID-19", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 171, "name": "Wang Y "}], "publication_date": "2020-03-27"}, {"id": 600, "slug": "reduction-of-hospitalizations-for-myocardial-infarction-in-italy-in-the-covid-19", "title": "Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Rechercher et caract\u00e9riser d'\u00e9ventuelles modifications des admissions en USIC et des complications pour les infarctus du myocarde en Italie durant la p\u00e9riode \u00e9pid\u00e9mique.", "verbose_date": "19.05.2020", "authors": "Rosa S", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 34, "name": "Eur Heart J"}, "link": "https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa409/5837572", "findings": "", "take_away": "", "relevance_level": "Sur la\u00a0semaine du 12 au 19 mars 2020, par rapport \u00e0 la semaine \u00e9quivalente en mars 2019, en Italie :\n- R\u00e9duction de 48,4% des admissions en USIC pour infarctus du myocarde avec une r\u00e9duction de 26,5% pour les STEMI (r\u00e9duction plus importante parmi les femmes de 41,2%) et une r\u00e9duction de 65,4% pour les NSTEMI.\n- Pour les STEMI : d\u00e9lais entre le premier sympt\u00f4me et la coronarographie et entre le premier contact m\u00e9dical et la coronarographie augment\u00e9s de 39,2% et de 31,5% respectivement.\n- Taux de coronarographie pour STEMI stable mais diminution de 13,3% des angioplasties percutan\u00e9es pour les NSTEMI.\n- Taux de mortalit\u00e9 des STEMI augment\u00e9 \u00e0 13,7% (RR=3,3), ce taux s'\u00e9levant \u00e0 28,6% pour les patients pr\u00e9sentant un STEMI et positifs au SARS-CoV-2. Taux de mortalit\u00e9 des NSTEMI augment\u00e9 \u00e0 3,3% (RR=1,9).\n- Taux de complications majeures major\u00e9 \u00e0 18,8% pour les STEMI (RR=1,8) et \u00e0 10,7% pour les NSTEMI (RR=2,1).", "objectives": "- \u00c9tude observationnelle descriptive transversale - Nombre modeste de cas, une seule semaine d'analyse- Plusieurs biais de confusion non pris en compte (\u00e9tendue de l'infarctus, comorbidit\u00e9s,...etc).", "methods": "Rechercher et caract\u00e9riser d'\u00e9ventuelles modifications des admissions en USIC et des complications pour les infarctus du myocarde en Italie durant la p\u00e9riode \u00e9pid\u00e9mique.", "pubmed_id": "32412631", "doi": "10.1093/eurheartj/ehaa409", "abstract": "To evaluate the impact of the COVID-19 pandemic on patient admissions to Italian cardiac care units (CCUs).\nWe conducted a multicentre, observational, nationwide survey to collect data on admissions for acute myocardial infarction (AMI) at Italian CCUs throughout a 1 week period during the COVID-19 outbreak, compared with the equivalent week in 2019. We observed a 48.4% reduction in admissions for AMI compared with the equivalent week in 2019 (P < 0.001). The reduction was significant for both ST-segment elevation myocardial infarction [STEMI; 26.5%, 95% confidence interval (CI) 21.7-32.3; P = 0.009] and non-STEMI (NSTEMI; 65.1%, 95% CI 60.3-70.3; P < 0.001). Among STEMIs, the reduction was higher for women (41.2%; P = 0.011) than men (17.8%; P = 0.191). A similar reduction in AMI admissions was registered in North Italy (52.1%), Central Italy (59.3%), and South Italy (52.1%). The STEMI case fatality rate during the pandemic was substantially increased compared with 2019 [risk ratio (RR) = 3.3, 95% CI 1.7-6.6; P < 0.001]. A parallel increase in complications was also registered (RR = 1.8, 95% CI 1.1-2.8; P = 0.009).\nAdmissions for AMI were significantly reduced during the COVID-19 pandemic across Italy, with a parallel increase in fatality and complication rates. This constitutes a serious social issue, demanding attention by the scientific and healthcare communities and public regulatory agencies.", "topics": ["Epid\u00e9miologique", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 563, "name": "Rosa S"}], "publication_date": "2020-05-19"}, {"id": 165, "slug": "clinical-and-microbiological-effect-of-a-combination-of-hydroxychloroquine-and-a", "title": "Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les r\u00e9sultats cliniques et microbiologiques des patients trait\u00e9s pendant au moins 3 jours par l'association hydroxychloroquine et azithromycine", "verbose_date": "27.03.2020", "authors": "Gautret P e", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/ncqyy26mzqrj1cg/COVID-IHU-2-1%281%29.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Description d'une efficacit\u00e9 clinique apparente du traitement par hydroxychloroquine et azithromycine avec une sortie d'hospitalisation sans complication pour 81% des patients.\u00a0\r\nSur le plan microbiologique, la charge virale \u00e9tait n\u00e9gative \u00e0 J9 dans 93% des cas et 97,5% des patients n'\u00e9taient plus consid\u00e9r\u00e9s comme contagieux \u00e0 J10", "objectives": "1) Attention : Pre-Prints (pas encore de reviewing)2) Etude uniquement observationnelle et descriptive (pas de groupe contr\u00f4le)3) Repr\u00e9sentativit\u00e9 de la population ?4) Pas de description des effets ind\u00e9sirables5) Charge virale se n\u00e9gative d\u00e9j\u00e0 physiologiquement vers j10 et l'orage cytokinique\"", "methods": "D\u00e9crire les r\u00e9sultats cliniques et microbiologiques des patients trait\u00e9s pendant au moins 3 jours par l'association hydroxychloroquine et azithromycine", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 85, "name": "Gautret P e"}], "publication_date": "2020-03-27"}, {"id": 363, "slug": "clinical-characteristics-of-3062-covid-19-patients-a-meta-analysis", "title": "Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques cliniques, biologique et d'imagerie du COVID-19", "verbose_date": "17.04.2020", "authors": "Zhu J", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25884", "findings": "", "take_away": "", "relevance_level": "Les sympt\u00f4mes les plus fr\u00e9quemment retrouv\u00e9s chez les patients Covid-19 \u00e9taient la fi\u00e8vre, l'asth\u00e9nie, la toux et les expectorations.\u00a0\r\nUne petite partie des patients \u00e9taient asymtomatiques.\u00a0\r\nChez la plupart des patients, la formule leukocytaire normale, la lymphop\u00e9nie et une \u00e9levation de la CRP et de la vitesse de s\u00e9dimentation \u00e9taient d\u00e9crite.\u00a0\r\nLes l\u00e9sions sur les deux poumons \u00e9taient fr\u00e9quentes.", "objectives": "-Nombre d'articles cons\u00e9quents (n=38), nombre de sujets important (>3000)-Bonne qualit\u00e9 des \u00e9tudes selectionn\u00e9es,-Mais que des articles rapportant des cas en Chine dans des \u00e9tudes monocentriques, biais de s\u00e9lection ++-Et qui sont r\u00e9trospectives, des biais de confusions sont donc possibles-De plus, elles d\u00e9crivaient mal les crit\u00e8res d'inclusion et de suivi-H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 mod\u00e9r\u00e9e \u00e0 consid\u00e9rable, explor\u00e9e par des analyses en sous groupe et de sensibilit\u00e9 mais qui n'ont pas pu \u00eatre r\u00e9alis\u00e9s pour chaque symtomes-P\u00e9riode d'analyse qui commence \u00e0 dater\"", "methods": "D\u00e9crire les caract\u00e9ristiques cliniques, biologique et d'imagerie du COVID-19", "pubmed_id": "32293716", "doi": "10.1002/jmv.25884", "abstract": "We aim to systematically review the clinical characteristics of Coronavirus disease 2019 (COVID-19).\nSeven datebases were searched to collect studies about the clinical characteristics of COVID-19 from 1 January 2020 to 28 February 2020. Then, meta-analysis was performed by using Stata12.0 software.\nA total of 38 studies involving 3 062 COVID-19 patients were included. Meta-analysis showed that a higher proportion of infected patients were male (56.9%). The incidence rate of respiratory failure or ARDS was 19.5% and the fatality rate was 5.5%. Fever (80.4%), fatigue (46%), cough (63.1%) and expectoration (41.8%) were the most common clinical manifestations. Other common symptoms included muscle soreness (33%), anorexia (38.8%), chest tightness (35.7%), shortness of breath (35%), dyspnea (33.9%). Minor symptoms included nausea and vomiting (10.2%), diarrhea (12.9%), headache (15.4%), pharyngalgia(13.1%), shivering (10.9%) and abdominal pain (4.4%). Patients with asymptomatic was 11.9%. Normal leukocytes counts (69.7%), lymphopenia (56.5%), elevated C-reactive protein levels (73.6%), elevated ESR (65.6%) and oxygenation index decreased (63.6%) were observed in most patients. About 37.2% of patients with elevated D-dimer, 25.9% of patients with leukopenia, along with abnormal levels of liver function (29%) and renal function (25.5%). Other findings included leukocytosis (12.6%) and elevated procalcitonin (17.5%). Only 25.8% of patients had lesions involving single lung and 75.7% of patients had lesions involving bilateral lungs.\nThe most commonly experienced symptoms of COVID-19 patients were fever, fatigue, cough and expectoration. A relatively small percentage of patients were asymptomatic. Most patients showed normal leucocytes counts, lymphopenia, elevated levels of C-reactive protein and ESR. Bilateral lungs involvement was common. This article is protected by copyright. All rights reserved.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 350, "name": "Zhu J"}], "publication_date": "2020-04-17"}, {"id": 369, "slug": "estimation-of-effects-of-nationwide-lockdown-for-containing-coronavirus-infectio", "title": "Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyser l'impact de la dur\u00e9e du confinement sur le contr\u00f4le de la glyc\u00e9mie et les complications chez les diab\u00e9tiques", "verbose_date": "18.04.2020", "authors": "Ghosal S", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 117, "name": "Diabetes Metab Syndr"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1871402120300540?token=83391CFF007159DF0FEFB58E427A3ED0A028EBD750DF1F04297AA02F7C04C024D6F88D3F1425691FA5FC12D0DA81AC3B", "findings": "", "take_away": "", "relevance_level": "La dur\u00e9e du confinement est li\u00e9e \u00e0 l'aggravation du contr\u00f4le glyc\u00e9mique et des complications chez les diab\u00e9tiques.", "objectives": "-Comparaison entre un confinement organis\u00e9 et des catastrophes naturelles ou non (tremblements de terres, ouragans, guerre) avec toutes les diff\u00e9rences en terme de cons\u00e9quences sur la sant\u00e9, de stress des populations et de planification que cela apporte-Nombre d'\u00e9tudes utilis\u00e9 faible (n=6)-Une \u00e9tude utilis\u00e9e pour le mod\u00e8le assez ancienne (il ya presque 30 ans), et presque toutes datent de plus de 10 ans : les techniques ont pu \u00e9volu\u00e9 depuis (t\u00e9l\u00e9consultations...)-Outlier ignor\u00e9 lors de la r\u00e9gression lin\u00e9aire-Calcul des complications par simple r\u00e8gle de trois par rapport \u00e0 l'augmentation de l'HBA1c-Pas de prise en compte de l'\u00e9volution de l'HBA1c au cours du temps, notamment apr\u00e8s le confinement\"", "methods": "Analyser l'impact de la dur\u00e9e du confinement sur le contr\u00f4le de la glyc\u00e9mie et les complications chez les diab\u00e9tiques", "pubmed_id": "32298984", "doi": "10.1016/j.dsx.2020.03.014", "abstract": "and aims: To prevent the spread of coronavirus disease (COVID19) total lockdown is in place in India from March 24, 2020 for 21 days. In this study, we aim to assess the impact of the duration of the lockdown on glycaemic control and diabetes-related complications.\nA systematic search was conducted using Cochrane library. A simulation model was created using glycemic data from previous disasters (taken as similar in impact to current lockdown) taking baseline HBA1c and diabetes-related complications data from India-specific database. A multivariate regression analysis was conducted to analyse the relationship between the duration of lockdown and glycaemic targets & diabetes-related complications.\nThe predictive model was extremely robust (R2\u00a0=\u00a00.99) and predicted outcomes for period of lockdown up to 90 days. The predicted increment in HBA1c from baseline at the end of 30 days and 45 days lockdown was projected as 2.26% & 3.68% respectively. Similarly, the annual predicted percentage increase in complication rates at the end of 30-day lockdown was 2.8% for non-proliferative diabetic retinopathy, 2.9% for proliferative diabetic retinopathy, 1.5% for retinal photocoagulation, 9.3% for microalbuminuria, 14.2% for proteinuria, 2.9% for peripheral neuropathy, 10.5% for lower extremity amputation, 0.9% for myocardial infarction, 0.5% for stroke and 0.5% for infections.\nThe duration of lockdown is directly proportional to the worsening of glycaemic control and diabetes-related complications. Such increase in diabetes-related complications will put additional load on overburdened healthcare system, and also increase COVID19 infections in patients with such uncontrolled glycemia.", "topics": ["Mod\u00e9lisation", "Immunit\u00e9", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 356, "name": "Ghosal S"}], "publication_date": "2020-04-18"}, {"id": 327, "slug": "high-prevalence-of-concurrent-gastrointestinal-manifestations-in-patients-with-s", "title": "High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-CoV-2: Early Experience from California", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Caract\u00e9riser les manifestations gastro-intestinales chez les patients atteints par le SARS-CoV-2", "verbose_date": "14.04.2020", "authors": "Cholankeril G", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 21, "name": "Gastroenterology"}, "link": "https://www.dropbox.com/s/850uggd8j9qpq2y/10.1053%40j.gastro.2020.04.008.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Pr\u00e8s d'un tiers des patients de cette cohorte de 116 patients ont eu des sympt\u00f4mes gastro-intestinaux (perte d'app\u00e9tit, naus\u00e9es ou vomissements, diarrh\u00e9e). Sur 65 patients avec \u00e9valuation de la fonction h\u00e9patique, 40% avaient des anomalies biologiques, avec \u00e9l\u00e9vation des transaminases (ASAT souvent plus hautes que les ALAT), pas de cas d'augmentation des phosphatases alcalines, bilirubine augment\u00e9e chez 2 patients avec des taux de base \u00e9lev\u00e9s. La s\u00e9v\u00e9rit\u00e9 de la maladie et le niveau de soins requis \u00e9taient associ\u00e9s au taux d'ASAT.", "objectives": "1) Cohorte r\u00e9trospective monocentrique2) Patients COVID-19 confirm\u00e9s en RT-PCR, mais souvent r\u00e9alis\u00e9s sur sympt\u00f4mes respiratoires, donc possiblement non inclusion de patients pr\u00e9sentant uniquement des sympt\u00f4mes gatro-intestinaux\"", "methods": "Caract\u00e9riser les manifestations gastro-intestinales chez les patients atteints par le SARS-CoV-2", "pubmed_id": "32283101", "doi": "10.1053/j.gastro.2020.04.008", "abstract": null, "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 314, "name": "Cholankeril G"}], "publication_date": "2020-04-14"}, {"id": 290, "slug": "neonatal-resuscitation-and-postresuscitation-care-of-infants-born-to-mothers-wit", "title": "Neonatal Resuscitation and Postresuscitation Care of Infants Born to Mothers with Suspected or Confirmed SARS-CoV-2 Infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Proposer une d\u00e9marche progressive de prise en charge p\u00e9ri-accouchement des nouveaux-n\u00e9s de m\u00e8res suspect\u00e9es/diagnostiqu\u00e9es de COVID-19", "verbose_date": "09.04.2020", "authors": "Chandrasekharan P", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 135, "name": "AM J Perinatol"}, "link": "https://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0040-1709688.pdf", "findings": "", "take_away": "", "relevance_level": "La prise en charge de nouveaux-n\u00e9s de m\u00e8res suspect\u00e9es ou diagnostiqu\u00e9es de COVID-19 n\u00e9cessite une r\u00e9organisation avec des \u00e9quipes d\u00e9di\u00e9es et une anticipation sans compter la protection optimale des soignants. Les principes de pr\u00e9caution peuvent se heurter au d\u00e9sir de favoriser le lien parent-enfant et sont \u00e0 discuter/n\u00e9gocier en amont si possible avec diff\u00e9rents niveaux de prise de risque dont des exemples sont fournis dans le tableau 1 de l'article.", "objectives": "- opinion personnelle d'experts- peu de retours d'exp\u00e9rience/d'\u00e9tudes sur le sujet \u00e0 ce stade\"", "methods": "Proposer une d\u00e9marche progressive de prise en charge p\u00e9ri-accouchement des nouveaux-n\u00e9s de m\u00e8res suspect\u00e9es/diagnostiqu\u00e9es de COVID-19", "pubmed_id": "32268381", "doi": "10.1055/s-0040-1709688", "abstract": "The first case of novel coronavirus disease of 2019 (COVID-19) caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was reported in November2019. The rapid progression to a global pandemic of COVID-19 has had profound medical, social, and economic consequences. Pregnant women and newborns represent a vulnerable population. However, the precise impact of this novel virus on the fetus and neonate remains uncertain. Appropriate protection of health care workers and newly born infants during and after delivery by a COVID-19 mother is essential. There is some disagreement among expert organizations on an optimal approach based on resource availability, surge volume, and potential risk of transmission. The manuscript outlines the precautions and steps to be taken before, during, and after resuscitation of a newborn born to a COVID-19 mother, including three optional variations of current standards involving shared-decision making with parents for perinatal management, resuscitation of the newborn, disposition, nutrition, and postdischarge care. The availability of resources may also drive the application of these guidelines. More evidence and research are needed to assess the risk of vertical and horizontal transmission of SARS-CoV-2 and its impact on fetal and neonatal outcomes. \u00b7 The risk of vertical transmission is unclear; transmission from family members/providers to neonates is possible.. \u00b7 Optimal personal-protective-equipment (airborne vs. droplet/contact precautions) for providers is crucial to prevent transmission.. \u00b7 Parents should be engaged in shared decision-making with options for rooming in, skin-to-skin contact, and breastfeeding..", "topics": ["Th\u00e9rapeutique", "P\u00e9diatrie"], "author_list": [{"id": 278, "name": "Chandrasekharan P"}], "publication_date": "2020-04-09"}, {"id": 481, "slug": "epidemiology-and-transmission-of-covid-19-in-391-cases-and-1286-of-their-close-c", "title": "Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Etude de cas index atteints de SARS-CoV-2 et de leurs cas contacts pour d\u00e9terminer des facteurs essentiels de l'histoire de la maladie tels que le taux d'attaque secondaire au sein des foyers, l'intervalle s\u00e9riel (d\u00e9lai entre premiers sympt\u00f4mes chez le cas index et premier sympt\u00f4mes chez le contact), et le R0.", "verbose_date": "29.04.2020", "authors": "Bi Q", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 74, "name": "Lancet Infect Dis"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1473309920302875?token=DC2B60F2A0C95DA64EDFBB263C7A76F903CB9B3E249AF4A063C94533A1174055832C14E13724E18713F12BC1BB1576AD", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude, le fait de tracer les contacts a permis de diminuer le d\u00e9lai entre l'isolement et le d\u00e9but des sympt\u00f4mes\u00a0(4,6 jours\u00a0vs 1,9 jours). Les contacts au sein du foyer ainsi que ceux par les voyages semblaient\u00a0les plus \u00e0 risque d'infection. Le taux d'attaque secondaire au sein des foyers \u00e9tait de\u00a011,2%, et de 6,6% parmi tous types de contact. Les enfants \u00e9taient autant \u00e0 risque de se faire infecter que les adultes, par contre les 60-69ans \u00e9taients plus \u00e0 risque.\u00a0Le R0 \u00e9tait de\u00a00,4, ce qui est plus bas que dans d'autres \u00e9tudes. Enfin l'intervalle s\u00e9riel \u00e9tait de\u00a06,3 jours.", "objectives": "Effectif important avec une qualit\u00e9 m\u00e9thodologique satisfaisante, cependant protocole ayant chang\u00e9 en cours d'\u00e9tude.", "methods": "Etude de cas index atteints de SARS-CoV-2 et de leurs cas contacts pour d\u00e9terminer des facteurs essentiels de l'histoire de la maladie tels que le taux d'attaque secondaire au sein des foyers, l'intervalle s\u00e9riel (d\u00e9lai entre premiers sympt\u00f4mes chez le cas index et premier sympt\u00f4mes chez le contact), et le R0.", "pubmed_id": "32353347\n31986261\n12766207\n31995857\n12781535\n32007143\n26851269\n32074444\n22276951\n20042754\n19598148", "doi": "10.1016/S1473-3099(20)30287-5", "abstract": "Rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, prompted heightened surveillance in Shenzhen, China. The resulting data provide a rare opportunity to measure key metrics of disease course, transmission, and the impact of control measures.\nFrom Jan 14 to Feb 12, 2020, the Shenzhen Center for Disease Control and Prevention identified 391 SARS-CoV-2 cases and 1286 close contacts. We compared cases identified through symptomatic surveillance and contact tracing, and estimated the time from symptom onset to confirmation, isolation, and admission to hospital. We estimated metrics of disease transmission and analysed factors influencing transmission risk.\nCases were older than the general population (mean age 45 years) and balanced between males (n=187) and females (n=204). 356 (91%) of 391 cases had mild or moderate clinical severity at initial assessment. As of Feb 22, 2020, three cases had died and 225 had recovered (median time to recovery 21 days; 95% CI 20-22). Cases were isolated on average 4\u00b76 days (95% CI 4\u00b71-5\u00b70) after developing symptoms; contact tracing reduced this by 1\u00b79 days (95% CI 1\u00b71-2\u00b77). Household contacts and those travelling with a case were at higher risk of infection (odds ratio 6\u00b727 [95% CI 1\u00b749-26\u00b733] for household contacts and 7\u00b706 [1\u00b743-34\u00b791] for those travelling with a case) than other close contacts. The household secondary attack rate was 11\u00b72% (95% CI 9\u00b71-13\u00b78), and children were as likely to be infected as adults (infection rate 7\u00b74% in children <10 years vs population average of 6\u00b76%). The observed reproductive number (R) was 0\u00b74 (95% CI 0\u00b73-0\u00b75), with a mean serial interval of 6\u00b73 days (95% CI 5\u00b72-7\u00b76).\nOur data on cases as well as their infected and uninfected close contacts provide key insights into the epidemiology of SARS-CoV-2. This analysis shows that isolation and contact tracing reduce the time during which cases are infectious in the community, thereby reducing the R. The overall impact of isolation and contact tracing, however, is uncertain and highly dependent on the number of asymptomatic cases. Moreover, children are at a similar risk of infection to the general population, although less likely to have severe symptoms; hence they should be considered in analyses of transmission and control.\nEmergency Response Program of Harbin Institute of Technology, Emergency Response Program of Peng Cheng Laboratory, US Centers for Disease Control and Prevention.", "topics": ["Epid\u00e9miologique", "Infectiologie"], "author_list": [{"id": 449, "name": "Bi Q"}], "publication_date": "2020-04-29"}, {"id": 329, "slug": "serological-immunochromatographic-approach-in-diagnosis-with-sars-cov-2-infected", "title": "Serological Immunochromatographic Approach in Diagnosis With SARS-CoV-2 Infected COVID-19 Patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la s\u00e9rologie par bande immunochromatographique \u00e0 base d'or collo\u00efdal ciblant les anticorps IgG et IgM et la comparer \u00e0 la RT-PCR", "verbose_date": "14.04.2020", "authors": "Pan Y", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.journalofinfection.com/article/S0163-4453(20)30175-4/pdf", "findings": "", "take_away": "", "relevance_level": "La s\u00e9rologie par bande immunochromatographique est \u00e0 explorer dans d'autres \u00e9tudes. Ici sensibilit\u00e9 \u00e0 plus de 90% apr\u00e8s le 7\u00e8me jour apr\u00e8s le d\u00e9but des sympt\u00f4mes sur 86 \u00e9chantillons de 67 patients. La d\u00e9tection des cas suspect\u00e9s n\u00e9gatifs en RT-PCR \u00e9tait de 43,6% en IgG ou IgM [ sur 39 \u00e9chantillons de 37 patients diagnostiqu\u00e9s cliniquement mais n\u00e9gatifs en RT-PCR]", "objectives": "1) Uniquement patients positifs confirm\u00e9s en RT-PCR ou cliniquement COVID-19, pas de patients t\u00e9moins n\u00e9gatifs2) Pas de notion d'\u00e9valuation ou d'analyse en aveugle3) Monocentrique, m\u00e9thodologie d'inclusion et d'exclusion peu d\u00e9taill\u00e9e4) Gold standard utilis\u00e9 ici RT-PCR oro-pharyng\u00e9\"", "methods": "Etudier la s\u00e9rologie par bande immunochromatographique \u00e0 base d'or collo\u00efdal ciblant les anticorps IgG et IgM et la comparer \u00e0 la RT-PCR", "pubmed_id": "32283141", "doi": "10.1016/j.jinf.2020.03.051", "abstract": "An outbreak of new coronavirus SARS-CoV-2 was occurred in Wuhan, China and rapidly spread to other cities and nations. The standard diagnostic approach that widely adopted in the clinic is nucleic acid detection by real-time RT-PCR. However, the false-negative rate of the technique is unneglectable and serological methods are urgently warranted. Here, we presented the colloidal gold-based immunochromatographic (ICG) strip targeting viral IgM or IgG antibody and compared it with real-time RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early stage (1-7 days after onset), intermediate stage (8-14 days after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative suspected cases was 43.6%. In addition, the concordance of whole blood samples and plasma showed Cohen's kappa value of 0.93, which represented the almost perfect agreement between two types of samples. In conclusion, serological ICG strip assay in detecting SARS-CoV-2 infection is both sensitive and consistent, which is considered as an excellent supplementary approach in clinical application.", "topics": ["Diagnostique", "Transversale", "Infectiologie"], "author_list": [{"id": 316, "name": "Pan Y"}], "publication_date": "2020-04-14"}, {"id": 171, "slug": "training-and-fit-testing-of-health-care-personnel-for-reusable-elastomeric-half-", "title": "Training and Fit Testing of Health Care Personnel for Reusable Elastomeric Half-Mask Respirators Compared With Disposable N95 Respirators", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "\u00c9valuer la faisabilit\u00e9 d'un entra\u00eenement rapide suivi d'essais d'ajustement pour l'utilisation de demi-masques respiratoires \u00e0 cartouche (EHMR : Elastomeric half-mask respirators) par les professionnels de sant\u00e9.", "verbose_date": "27.03.2020", "authors": "Pompeii LA ", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://www.dropbox.com/s/7swmseny0dyxgpj/10.1001%40jama.2020.4806.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les soignants peuvent \u00eatre form\u00e9s rapidement et efficacement \u00e0 l'utilisation des demi-masques respiratoires \u00e0 cartouches qui sont r\u00e9utilisables. Il est \u00e0 noter que l'efficacit\u00e9 de leur d\u00e9sinfection reste douteuse et ils repr\u00e9sentent un investissement financier initial potentiellement important.", "objectives": "1) Exp\u00e9rimentation2) Effectifs d\u00e9s\u00e9quilibr\u00e9s mais non n\u00e9gligeables3) Pas de calcul du nombre de sujets n\u00e9cessaires4) Pas de simulation en situation d'urgence\"", "methods": "\u00c9valuer la faisabilit\u00e9 d'un entra\u00eenement rapide suivi d'essais d'ajustement pour l'utilisation de demi-masques respiratoires \u00e0 cartouche (EHMR : Elastomeric half-mask respirators) par les professionnels de sant\u00e9.", "pubmed_id": "32211889\n20731598\n27462029\n28636443\n30638674", "doi": "10.1001/jama.2020.4806", "abstract": null, "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 166, "name": "Pompeii LA "}], "publication_date": "2020-03-27"}, {"id": 348, "slug": "comorbidities-in-covid-19-outcomes-in-hypertensive-cohort-and-controversies-with", "title": "Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Faire le point sur le COVID-19 chez les patients hypertendus et son lien avec l'utilisation des bloqueurs du syst\u00e8me r\u00e9nine-angiotensine", "verbose_date": "16.04.2020", "authors": "Singh AK", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 117, "name": "Diabetes Metab Syndr"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1871402120300564?token=948389CEAFACEC0CCBB8D7F1F362F8F4A822558F902439DD2E643B913701B276CCD03057B4FB0142D306CDF868857E28", "findings": "", "take_away": "", "relevance_level": "A ce jour, les preuves sont insuffisantes pour trancher entre un b\u00e9n\u00e9fice ou un pr\u00e9judice sur la survenue et la s\u00e9v\u00e9rit\u00e9 de la COVID-19 li\u00e9 \u00e0 l'utilisation des inhibiteurs du syst\u00e8me r\u00e9nine-angiotensine chez les patients hypertendus. Un grand nombre d'organisations recommandent la poursuite des IEC et des ARAII chez les patients d\u00e9j\u00e0 trait\u00e9s tout en leur apportant une attention particuli\u00e8re.", "objectives": "- peu de d\u00e9tails concernant la m\u00e9thode de revue- peu d'\u00e9tudes de bon niveau de preuve cit\u00e9es\"", "methods": "Faire le point sur le COVID-19 chez les patients hypertendus et son lien avec l'utilisation des bloqueurs du syst\u00e8me r\u00e9nine-angiotensine", "pubmed_id": "32283499", "doi": "10.1016/j.dsx.2020.03.016", "abstract": "COVID-19 is already a pandemic. Emerging data suggest an increased association and a heightened mortality in patients of COVID-19 with comorbidities. We aimed to evaluate the outcome in hypertensive patients with COVID-19 and its relation to the use of renin-angiotensin system blockers (RASB).\nWe have systematically searched the medical database up to March 27, 2020 and retrieved all the published articles in English language related to our topic using MeSH key words.\nFrom the pooled data of all ten available Chinese studies (n\u00a0=\u00a02209) that have reported the characteristics of comorbidities in patients with COVID-19, hypertension was present in nearly 21%, followed by diabetes in nearly 11%, and established cardiovascular disease (CVD) in approximately 7% of patients. Although the emerging data hints to an increase in mortality in COVID-19 patients with known hypertension, diabetes and CVD, it should be noted that it was not adjusted for multiple confounding factors. Harm or benefit in COVID-19 patients receiving RASB has not been typically assessed in these studies yet, although mechanistically and plausibly both, benefit and harm is possible with these agents, given that COVID-19 expresses to tissues through the receptor of angiotensin converting enzyme-2.\nSpecial attention is definitely required in patients with COVID-19 with associated comorbidities including hypertension, diabetes and established CVD. Although the role of RASB has a mechanistic equipoise, patients with COVID-19 should not stop these drugs at this point of time, as recommended by various world organizations and without the advice of health care provider.", "topics": ["Epid\u00e9miologique", "Transversale", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 336, "name": "Singh AK"}], "publication_date": "2020-04-16"}, {"id": 457, "slug": "characteristics-of-hospitalized-adults-with-covid-19-in-an-integrated-health-car", "title": "Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Pr\u00e9senter les caract\u00e9ristiques des patients adultes hospitalis\u00e9s pour infection COVID-19 pris en charge dans un large r\u00e9seau de soin californien", "verbose_date": "27.04.2020", "authors": "Myers L", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://www.dropbox.com/s/wytnhzqmyu4wdir/10.1001%40jama.2020.7202.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les hommes sont plus \u00e0 risques d'une hospitalisation dans le cadre d'une infection COVID-19 tout comme les hypertendus et les diab\u00e9tiques. Les co-infections virales semblent tr\u00e8s rares.\r\nEn Californie, le taux de mortalit\u00e9 des patients admis en r\u00e9animation atteignait 50%.", "objectives": "- Analyses uniquement descriptives- Manque un certain nombre de donn\u00e9es dans les caract\u00e9ristiques cliniques notamment le statut tabagique, l'IMC ou les ATCD cardiovasculaires- Echantillon am\u00e9ricain r\u00e9duit (377 hospitalis\u00e9s contre 16 000 test\u00e9s)\"", "methods": "Pr\u00e9senter les caract\u00e9ristiques des patients adultes hospitalis\u00e9s pour infection COVID-19 pris en charge dans un large r\u00e9seau de soin californien", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 429, "name": "Myers L"}], "publication_date": "2020-04-27"}, {"id": 589, "slug": "severe-covid-19-in-children-and-young-adults-in-the-washington-dc-metropolitan-r", "title": "Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "L'objectif de l'\u00e9tude \u00e9tait de d\u00e9terminer si des caract\u00e9ristiques \u00e9pid\u00e9miologiques et cliniques sp\u00e9cifiques des enfants et jeunes adultes \u00e9taient plus susceptibles d'\u00eatre associ\u00e9es \u00e0 l'hospitalisation et/ou aux soins intensifs.", "verbose_date": "14.05.2020", "authors": "DeBiasi RL", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 232, "name": "J Pediatr"}, "link": "https://www.sciencedirect.com/science/article/pii/S0022347620305813", "findings": "", "take_away": "", "relevance_level": "Cette \u00e9tude souligne le potentiel de maladies graves chez les enfants et les jeunes adultes.\nBien que tous les groupes d'\u00e2ge aient \u00e9t\u00e9 infect\u00e9s par le SARS-CoV-2, les enfants/jeunes adultes les plus jeunes (<1 an) et les plus \u00e2g\u00e9s (15-25 ans) \u00e9taient plus susceptibles d'\u00eatre hospitalis\u00e9s, et les plus \u00e2g\u00e9s \u00e9taient les plus susceptibles de n\u00e9cessiter des soins intensifs. Les conditions sous-jacentes \u00e9taient pr\u00e9sentes chez 39% des patients, mais les patients hospitalis\u00e9s et gravement malades \u00e9taient plus susceptibles de pr\u00e9senter des conditions sous-jacentes. Inversement, environ 55% dans l'ensemble, 37% des patients hospitalis\u00e9s et 22% des patients gravement malades ne pr\u00e9sentaient aucune affection sous-jacente, ce qui renforce le concept selon lequel la distanciation sociale et les mesures d'hygi\u00e8ne visant \u00e0 \u00e9viter l'infection doivent \u00eatre prises au s\u00e9rieux dans le groupe d'\u00e2ge p\u00e9diatrique, ainsi que chez les adultes. Seuls les diagnostics neurologiques, cardiaques, h\u00e9matologiques et oncologiques sous-jacents \u00e9taient significativement plus fr\u00e9quents dans la cohorte hospitalis\u00e9e par rapport \u00e0 la cohorte non hospitalis\u00e9e, et aucun n'\u00e9tait plus fr\u00e9quent dans la cohorte gravement malade par rapport \u00e0 la cohorte non gravement malade.", "objectives": "-\tPre-proof-\tEtude de cohorte r\u00e9trospective observationnelle monocentrique", "methods": "L'objectif de l'\u00e9tude \u00e9tait de d\u00e9terminer si des caract\u00e9ristiques \u00e9pid\u00e9miologiques et cliniques sp\u00e9cifiques des enfants et jeunes adultes \u00e9taient plus susceptibles d'\u00eatre associ\u00e9es \u00e0 l'hospitalisation et/ou aux soins intensifs.", "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 553, "name": "DeBiasi RL"}], "publication_date": "2020-05-14"}, {"id": 594, "slug": "variation-in-false-negative-rate-of-reverse-transcriptase-polymerase-chain-react", "title": "Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction\u2013Based SARS-CoV-2 Tests by Time Since Exposure", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Estimer le taux de faux n\u00e9gatifs de la RT-PCR vis-\u00e0-vis du SARS-CoV-2 par jour depuis le d\u00e9but de l'infection.", "verbose_date": "16.05.2020", "authors": "Kucirka LM", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 41, "name": "Ann Intern Med"}, "link": "https://www.acpjournals.org/doi/10.7326/M20-1495", "findings": "", "take_away": "", "relevance_level": "L'utilisation d'un r\u00e9sultat n\u00e9gatif de la RT-PCR pour \u00e9carter le diagnostic de COVID-19 est d\u00e9licate. En d\u00e9but d'infection particuli\u00e8rement, une suspicion clinique forte et des crit\u00e8res \u00e9pid\u00e9miologiques sont \u00e0 consid\u00e9rer prioritairement car la RT-PCR pr\u00e9sente un taux tr\u00e8s \u00e9lev\u00e9 de faux n\u00e9gatifs. Le moment id\u00e9al pour minimiser le risque de faux n\u00e9gatif de la RT-PCR semble \u00eatre 3 jours apr\u00e8s le d\u00e9but des sympt\u00f4mes / 8 jours apr\u00e8s l'exposition, mais il reste de 21%.", "objectives": "- \u00e9tude r\u00e9trospective (-)- inclusion de deux pre-print (-)- taux de faux-n\u00e9gatifs impr\u00e9cis en raison de l'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 de design des \u00e9tudes sources (-)- analyses de sensibilit\u00e9s en faveur d'une robustesse des r\u00e9sultats (+)- probable sous-estimation du taux de faux-n\u00e9gatifs puisque les patients COVID-19 n'ayant eu aucun test positif ne sont pas consid\u00e9r\u00e9s (-)", "methods": "Estimer le taux de faux n\u00e9gatifs de la RT-PCR vis-\u00e0-vis du SARS-CoV-2 par jour depuis le d\u00e9but de l'infection.", "pubmed_id": "32422057\n32101510\n9194271\n32277759\n32198501\n32425648\n32150748\n32235945\n28365331\n32221519\n32199474\n15934999\n31992387\n32242348", "doi": "10.7326/M20-1495", "abstract": "Tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse transcriptase polymerase chain reaction (RT-PCR) are being used to \"rule out\" infection among high-risk persons, such as exposed inpatients and health care workers. It is critical to understand how the predictive value of the test varies with time from exposure and symptom onset to avoid being falsely reassured by negative test results.\nTo estimate the false-negative rate by day since infection.\nLiterature review and pooled analysis.\n7 previously published studies providing data on RT-PCR performance by time since symptom onset or SARS-CoV-2 exposure using samples from the upper respiratory tract (\nA mix of inpatients and outpatients with SARS-CoV-2 infection.\nA Bayesian hierarchical model was fitted to estimate the false-negative rate by day since exposure and symptom onset.\nOver the 4 days of infection before the typical time of symptom onset (day 5), the probability of a false-negative result in an infected person decreases from 100% (95% CI, 100% to 100%) on day 1 to 67% (CI, 27% to 94%) on day 4. On the day of symptom onset, the median false-negative rate was 38% (CI, 18% to 65%). This decreased to 20% (CI, 12% to 30%) on day 8 (3 days after symptom onset) then began to increase again, from 21% (CI, 13% to 31%) on day 9 to 66% (CI, 54% to 77%) on day 21.\nImprecise estimates due to heterogeneity in the design of studies on which results were based.\nCare must be taken in interpreting RT-PCR tests for SARS-CoV-2 infection-particularly early in the course of infection-when using these results as a basis for removing precautions intended to prevent onward transmission. If clinical suspicion is high, infection should not be ruled out on the basis of RT-PCR alone, and the clinical and epidemiologic situation should be carefully considered.\nNational Institute of Allergy and Infectious Diseases, Johns Hopkins Health System, and U.S. Centers for Disease Control and Prevention.", "topics": ["Diagnostique", "Virologie", "Infectiologie"], "author_list": [{"id": 558, "name": "Kucirka LM"}], "publication_date": "2020-05-16"}, {"id": 405, "slug": "antibody-detection-and-dynamic-characteristics-in-patients-with-covid-19", "title": "Antibody Detection and Dynamic Characteristics in Patients with COVID-19", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Etudier les caract\u00e9ristiques dynamiques et l'ampleur de la r\u00e9ponse des anticorps sp\u00e9cifiques chez les patients atteints de COVID-19 ainsi que la valeur s\u00e9rodiagnostique des IgM et IgG. \r\n ", "verbose_date": "21.04.2020", "authors": "Xiang F", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 24, "name": "Clin Infect Dis"}, "link": "https://www.dropbox.com/s/6x4e5ov41b4j0ie/ciaa461.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les anticorps IgM et IgG sont d\u00e9tect\u00e9es environ apr\u00e8s 4 jours, de fa\u00e7on synchrone et restent d\u00e9tectables jusqu'\u00e0 J30 minimum (avec une d\u00e9croissance IgG \u00e0 J28)\r\nLes anticorps IgM ont :\u00a0\r\n- Bonne sp\u00e9cificit\u00e9 et VPP et se maintiennent apr\u00e8s J13 donc IgM positif bon outils pour diagnostic.\r\n- Sensibilit\u00e9, VPN et taux de concordance plus faible donc IgM n\u00e9gatif peut \u00eatre fauss\u00e9 et risque de passer \u00e0 c\u00f4t\u00e9 d'une infection surtout en p\u00e9riode aigu\u00eb.\r\nLes anticorps IgG ont :\u00a0\r\n- Bonne sp\u00e9cificit\u00e9, VPN et un bon taux de concordance. Diagnostic peut \u00eatre port\u00e9 sur un taux IgG positif.\r\nLes anticorps IgM et IgG ont une grande sp\u00e9cificit\u00e9 = argument fort pour test diagnostic (surtout \u00e0 un stade avanc\u00e9 de la maladie).\r\nEn cas de n\u00e9gativit\u00e9 et de doute, l'article conseille de refaire la s\u00e9rologie apr\u00e8s 10 jours.\r\nApproche compl\u00e9mentaire de la PCR pour le diagnostic des patients COVID", "objectives": "Etude prospective d'\u00e9valuation des propri\u00e9t\u00e9s diagnostiques contre gold standard admisEffectif mod\u00e9r\u00e9 (65 maximum) M\u00e9thodologie bonne", "methods": "Etudier les caract\u00e9ristiques dynamiques et l'ampleur de la r\u00e9ponse des anticorps sp\u00e9cifiques chez les patients atteints de COVID-19 ainsi que\u00a0la valeur s\u00e9rodiagnostique des IgM et IgG.", "pubmed_id": "32306047", "doi": "10.1093/cid/ciaa461", "abstract": "The corona virus disease 2019 (COVID-19) caused by the corona virus 2 (SARS-CoV-2) has been rapidly spreading nationwide and abroad. A serologic test to identify antibody dynamics and response to SARS-CoV-2 was developed.\nThe antibodies against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA) based on the recombinant nucleocapsid protein of SARS-CoV-2 in patients with confirmed or suspected COVID-19 at 3-40 days after symptom onset. The gold standard for COVID-19 diagnosis was nucleic acid testing for SARS-CoV-2 by RT-PCR. The serodiagnostic power of the specific IgM and IgG antibodies against SARS-CoV-2 was investigated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and consistency rate.\nThe seroconversion of specific IgM and IgG antibodies were observed as early as the 4th day after symptom onset. In the confirmed patients with COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 77.3% (51/66), 100%, 100%, 80.0%, and 88.1%, and those of IgG were 83.3.3% (55/66), 95.0%, 94.8%, 83.8%, and 88.9 %. In patients with suspected COVID-19, sensitivity, specificity, PPV, NPV, and consistency rate of IgM were 87.5% (21/24), 100%, 100%, 95.2%, and 96.4%, and those of IgG were 70.8% (17/24), 96.6%, 85.0%, 89.1%, and 88.1%. Both antibodies performed well in serodiagnosis for COVID-19 rely on great specificity.\nThe antibodies against SARS-CoV-2 can be detected in the middle and later stage of the illness. Antibody detection may play an important role in the diagnosis of COVID-19 as complement approach for viral nucleid acid assays.", "topics": ["Autres", "Virologie", "Infectiologie"], "author_list": [{"id": 387, "name": "Xiang F"}], "publication_date": "2020-04-21"}, {"id": 625, "slug": "factors-associated-with-hospital-admission-and-critical-illness-among-5279-peopl", "title": "Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les issues des personnes admises \u00e0 l'h\u00f4pital pour COVID-19 aux \u00c9tats-Unis, ainsi que les caract\u00e9ristiques cliniques et biologiques associ\u00e9es \u00e0 une forme grave de la maladie.", "verbose_date": "26.05.2020", "authors": "Petrilli CM", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 57, "name": "BMJ"}, "link": "https://www.bmj.com/content/bmj/369/bmj.m1966.full.pdf", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude prospective dans un syst\u00e8me de soins \u00e0 New York, le taux de mortalit\u00e9 global des patients admis \u00e0 l'h\u00f4pital se situait entre 24% et 30%.\n\u00c2ge, insuffisance cardiaque, sexe masculin, maladie r\u00e9nale chronique et ob\u00e9sit\u00e9 \u00e9taient associ\u00e9s \u00e0 l'hospitalisation et au d\u00e9veloppement d'une forme grave de la maladie.\nL'hypoxie et l'augmentation des marqueurs biologiques de l'inflammation \u00e0 l'admission \u00e9taient des facteurs indiquant une \u00e9volution p\u00e9jorative.", "objectives": "- Etude de cohorte prospective, dans un syst\u00e8me de sant\u00e9 \u00e0 New York, n=5 279- Les donn\u00e9es de l'\u00e9tude ont \u00e9t\u00e9 obtenues \u00e0 partir du dossier de sant\u00e9 \u00e9lectronique comprenant les donn\u00e9es des visites en hospitalisation et en ambulatoire dans le syst\u00e8me de sant\u00e9 - Admissions possibles dans d'autres centres, r\u00e9admissions ou d\u00e9c\u00e8s sans prise en compte dans l'\u00e9tude- Pas de donn\u00e9e clinique ou biologique chez les patients positifs suivis en ambulatoire.- Pas de protocole de biologie \u00e0 l'admission au d\u00e9but de l'\u00e9pid\u00e9mie- Modification des conditions de r\u00e9alisation des tests : apr\u00e8s le 16 mars r\u00e9alisation par le syst\u00e8me de soins, r\u00e9alisation uniquement de PCR nasopharyng\u00e9es, ajout d'un nouvel appareil de PCR le 31 mars, \u00e0 partir du 26 mars, restriction des tests auparavant r\u00e9alis\u00e9s sur des formes l\u00e9g\u00e8res ou mod\u00e9r\u00e9es- 172 patients toujours hospitalis\u00e9s (3,3% de la cohorte, 6,3% des hospitalis\u00e9s)", "methods": "D\u00e9crire les issues des personnes admises \u00e0 l'h\u00f4pital pour COVID-19 aux \u00c9tats-Unis, ainsi que les caract\u00e9ristiques cliniques et biologiques associ\u00e9es \u00e0 une forme grave de la maladie.", "pubmed_id": "32444366\n29930142\n32203977\n32171076\n32227120\n32167524\n32233161\n32181795\n32299776\n32251625\n28592801\n32227758\n32214079\n31390034\n10720501\n32219356\n25781614\n32176772\n32109013\n26903337\n12519925\n32250385\n22495079\n32240123\n32091533\n1355411\n29937192\n16236739\n32031570\n32320003", "doi": "10.1136/bmj.m1966", "abstract": "To describe outcomes of people admitted to hospital with coronavirus disease 2019 (covid-19) in the United States, and the clinical and laboratory characteristics associated with severity of illness.\nProspective cohort study.\nSingle academic medical center in New York City and Long Island.\n5279 patients with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection between 1 March 2020 and 8 April 2020. The final date of follow up was 5 May 2020.\nOutcomes were admission to hospital, critical illness (intensive care, mechanical ventilation, discharge to hospice care, or death), and discharge to hospice care or death. Predictors included patient characteristics, medical history, vital signs, and laboratory results. Multivariable logistic regression was conducted to identify risk factors for adverse outcomes, and competing risk survival analysis for mortality.\nOf 11\u2009544 people tested for SARS-Cov-2, 5566 (48.2%) were positive. After exclusions, 5279 were included. 2741 of these 5279 (51.9%) were admitted to hospital, of whom 1904 (69.5%) were discharged alive without hospice care and 665 (24.3%) were discharged to hospice care or died. Of 647 (23.6%) patients requiring mechanical ventilation, 391 (60.4%) died and 170 (26.2%) were extubated or discharged. The strongest risk for hospital admission was associated with age, with an odds ratio of >2 for all age groups older than 44 years and 37.9 (95% confidence interval 26.1 to 56.0) for ages 75 years and older. Other risks were heart failure (4.4, 2.6 to 8.0), male sex (2.8, 2.4 to 3.2), chronic kidney disease (2.6, 1.9 to 3.6), and any increase in body mass index (BMI) (eg, for BMI >40: 2.5, 1.8 to 3.4). The strongest risks for critical illness besides age were associated with heart failure (1.9, 1.4 to 2.5), BMI >40 (1.5, 1.0 to 2.2), and male sex (1.5, 1.3 to 1.8). Admission oxygen saturation of <88% (3.7, 2.8 to 4.8), troponin level >1 (4.8, 2.1 to 10.9), C reactive protein level >200 (5.1, 2.8 to 9.2), and D-dimer level >2500 (3.9, 2.6 to 6.0) were, however, more strongly associated with critical illness than age or comorbidities. Risk of critical illness decreased significantly over the study period. Similar associations were found for mortality alone.\nAge and comorbidities were found to be strong predictors of hospital admission and to a lesser extent of critical illness and mortality in people with covid-19; however, impairment of oxygen on admission and markers of inflammation were most strongly associated with critical illness and mortality. Outcomes seem to be improving over time, potentially suggesting improvements in care.", "topics": ["Pronostique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 588, "name": "Petrilli CM"}], "publication_date": "2020-05-26"}, {"id": 406, "slug": "objective-olfactory-testing-in-patients-presenting-with-sudden-onset-olfactory-d", "title": "Objective olfactory testing in patients presenting with sudden onset olfactory dysfunction as the first manifestation of confirmed COVID-19 infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier le statut COVID-19 des patients pr\u00e9sentant une anosmie olfactive soudaine initiale (ISOA) en utilisant des \u00e9couvillons naso pharyng\u00e9s pour l'analyse RT-PCR et explorer leurs dysfonctionnements olfactifs avec une \u00e9valuation olfactive psychophysique.", "verbose_date": "21.04.2020", "authors": "Lechien JR", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 18, "name": "Neurologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.15.20066472v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Les r\u00e9sultats de cette \u00e9tude confirment qu'une forte proportion des patients ISOA sont Covid+ et donc ils confirment la n\u00e9cessit\u00e9 urgente d'ajouter l'anosmie \u00e0 la liste des sympt\u00f4mes utilis\u00e9s dans les outils de d\u00e9pistage d'une \u00e9ventuelle infection par COVID-19. L'utilisation de la perte d'odorat - m\u00eame si elle se produit en l'absence de sympt\u00f4mes non oto-rhino-laryngologiques - comme marqueur sera une arme tr\u00e8s utile dans la lutte contre COVID-19, en particulier dans les pays o\u00f9 l'acc\u00e8s au d\u00e9pistage sera fortement limit\u00e9. De futures recherches cliniques et en sciences fondamentales sont n\u00e9cessaires pour mieux comprendre les m\u00e9canismes physiopathologiques qui sous-tendent le d\u00e9veloppement du dysfonctionnement olfactif chez les patients atteints de COVID-19.", "objectives": "-\tPreprint-\t\u00c9tude longitudinale prospective-\tN=78-\tDes tests de seuil et de discrimination et des tests simultan\u00e9s de la fonction olfactive \u00e9valu\u00e9s par le patient et objectifs n'ont pas \u00e9t\u00e9 effectu\u00e9s", "methods": "Etudier le statut COVID-19 des patients pr\u00e9sentant une anosmie olfactive soudaine initiale (ISOA) en utilisant des \u00e9couvillons naso pharyng\u00e9s pour l'analyse RT-PCR et explorer leurs dysfonctionnements olfactifs avec une \u00e9valuation olfactive psychophysique.", "topics": ["Diagnostique", "Transversale", "Infectiologie", "Neurologie"], "author_list": [{"id": 271, "name": "Lechien JR"}], "publication_date": "2020-04-21"}, {"id": 61, "slug": "artificial-intelligence-distinguishes-covid-19-from-community-acquired-pneumonia", "title": "Artificial Intelligence Distinguishes COVID-19 from Community Acquired Pneumonia on Chest CT", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9velopper un algorithme automatique de d\u00e9tection du COVID19 en utilisant le scanner thoracique", "verbose_date": "19.03.2020", "authors": "Li L", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 51, "name": "Radiology"}, "link": "https://www.dropbox.com/s/xfa0rcuk09ifxv4/radiol.2020200905.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Ce mod\u00e8le de deep learning peut detecter un COVID19 sur un scanner thoracique et le diff\u00e9rencier d'une pneumonie communautaire aigue ou d'autres pathologies pulmonaires (sensibilit\u00e9 et sp\u00e9cificit\u00e9 > 90%)", "objectives": "Intermediaire :- nombre d'examens important - Les PAC s\u00e9lectionn\u00e9es ne sont pas identifi\u00e9es virales ou bact\u00e9riennes, il se peut que les l\u00e9sions d'une pneumopathie virale soient identiques \u00e0 celles du SARS-CoV-2- Pas de transparence : on ne sait pas quelles l\u00e9sions font pencher la machine vers COVID ou PAC- aucune methode n'est capable de diff\u00e9rencier toutes les maladies pulmonaires simplement sur une image, il faut une approche multidisciplinaire (les pathologies d\u00e9pendent aussi de l'histoire m\u00e9dicale, traitements, comorbidit\u00e9s)- \u00e9chantillon training ne provient que du m\u00eame hopital", "methods": "D\u00e9velopper un algorithme automatique de d\u00e9tection du COVID19 en utilisant le scanner thoracique", "pubmed_id": "32191588\n32017661\n32073353\n26955021\n31041565\n31926366\n29474911\n3203132\n31995857\n32101510\n32031570\n25551822", "doi": "10.1148/radiol.2020200905", "abstract": "Background Coronavirus disease has widely spread all over the world since the beginning of 2020. It is desirable to develop automatic and accurate detection of COVID-19 using chest CT. Purpose To develop a fully automatic framework to detect COVID-19 using chest CT and evaluate its performances. Materials and Methods In this retrospective and multi-center study, a deep learning model, COVID-19 detection neural network (COVNet), was developed to extract visual features from volumetric chest CT exams for the detection of COVID-19. Community acquired pneumonia (CAP) and other non-pneumonia CT exams were included to test the robustness of the model. The datasets were collected from 6 hospitals between August 2016 and February 2020. Diagnostic performance was assessed by the area under the receiver operating characteristic curve (AUC), sensitivity and specificity. Results The collected dataset consisted of 4356 chest CT exams from 3,322 patients. The average age is 49\u00b115 years and there were slightly more male patients than female (1838 vs 1484; p-value=0.29). The per-exam sensitivity and specificity for detecting COVID-19 in the independent test set was 114 of 127 (90% [95% CI: 83%, 94%]) and 294 of 307 (96% [95% CI: 93%, 98%]), respectively, with an AUC of 0.96 (p-value<0.001). The per-exam sensitivity and specificity for detecting CAP in the independent test set was 87% (152 of 175) and 92% (239 of 259), respectively, with an AUC of 0.95 (95% CI: 0.93, 0.97). Conclusions A deep learning model can accurately detect COVID-19 and differentiate it from community acquired pneumonia and other lung diseases.", "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 71, "name": "Li L"}], "publication_date": "2020-03-19"}, {"id": 479, "slug": "vascular-skin-symptoms-in-covid-19-a-french-observational-study", "title": "Vascular skin symptoms in COVID-19: a french observational study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les l\u00e9sions dermatologiques et vasculaires en lien avec le COVID-19 en France", "verbose_date": "29.04.2020", "authors": "Bouaziz J", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 194, "name": "J Eur Acad Dermatol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.16544", "findings": "", "take_away": "", "relevance_level": "Des l\u00e9sions dermatologiques et vasculaires sont possibles dans le cadre d'une infection \u00e0 COVID-19 avec notamment des\u00a0exanth\u00e8mes, des purpuras ou des engelures. Elles apparaissent apr\u00e8s le d\u00e9but des sympt\u00f4mes g\u00e9n\u00e9raux de l'infection et jusqu'\u00e0 potentiellement 21 jours apr\u00e8s.\u00a0\nToutefois il est n\u00e9cessaire de continuer les \u00e9tudes pour d\u00e9terminer la pr\u00e9valence de ces sympt\u00f4mes, leur impact sur le pronostic et leur origine physiopathologique.", "objectives": "- Bas\u00e9e sur la description d'uniquement 14 cas- Etude ne permettant pas de conclure sur la pr\u00e9valence de ces l\u00e9sions- Donn\u00e9es d\u00e9claratives- Pas d'information sur les caract\u00e9ristiques cliniques des patients ou leur devenir", "methods": "D\u00e9crire les l\u00e9sions dermatologiques et vasculaires en lien avec le COVID-19 en France", "pubmed_id": "32339344", "doi": "10.1111/jdv.16544", "abstract": "Coronavirus 19 (COVID-19) was declared as a pandemic viral infection by the World Health organization on March 11", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 447, "name": "Bouaziz J"}], "publication_date": "2020-04-29"}, {"id": 173, "slug": "estimating-the-infection-and-case-fatality-ratio-for-coronavirus-disease-covid-1", "title": "Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Estimer les taux d'infectiosit\u00e9 et de mortalit\u00e9 corrig\u00e9s pour le COVID.", "verbose_date": "27.03.2020", "authors": "Russel TW ", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 46, "name": "Eurosurveillance"}, "link": "https://www.dropbox.com/s/l3v0pbft1wbeu9r/eurosurv-25-12-3.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "A partir des donn\u00e9es du paquebot Diamond princess, estimation d'un case\u00a0fatality ratio (=nombre de d\u00e9c\u00e8s/nombre de cas diagnostiqu\u00e9s) et d'un\u00a0infectious fatality ratio (=nombre de d\u00e9c\u00e8s/nombre de personnes\u00a0infect\u00e9es) corrig\u00e9s \u00e0 respectivement 1,2% et 0.6% sur la population\u00a0g\u00e9n\u00e9rale en Chine", "objectives": "M\u00e9thodologie solide; data du Diamond Princess parmi les meilleures disponibles.", "methods": "Estimer les taux d'infectiosit\u00e9 et de mortalit\u00e9 corrig\u00e9s pour le COVID.", "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 168, "name": "Russel TW "}], "publication_date": "2020-03-27"}, {"id": 454, "slug": "decontamination-of-face-masks-with-steam-for-mask-reuse-in-fighting-the-pandemic", "title": "Decontamination of face masks with steam for mask reuse in fighting the pandemic COVID-19: experimental supports med", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluation de l'efficacit\u00e9 de la d\u00e9contamination par vapeur et l'impact sur la capacit\u00e9 de filtration de masques chirurgicaux et FFP2 (N95).", "verbose_date": "26.04.2020", "authors": "Ma QX", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25921", "findings": "", "take_away": "", "relevance_level": "Cette \u00e9tude sugg\u00e8re qu'il est possible de d\u00e9contaminer des masques chirurgicaux et FFP2 par un traitement thermique vapeur, sans affecter sa capacit\u00e9 de filtration. Cette m\u00e9thode semble efficace sur les coronavirus mais pas de donn\u00e9es pr\u00e9sent\u00e9es pour d'autres pathog\u00e8nes.", "objectives": "- \u00c9tude sur un faible nombre de masque- Pas de pr\u00e9cision sur les masques utilis\u00e9- Pas d'information sur l'efficacit\u00e9 de la d\u00e9contamination sur d'autres pathog\u00e8nes- Pas d'information sur l'impact de d\u00e9contamination r\u00e9p\u00e9t\u00e9es sur la capacit\u00e9 de filtration des masques\"", "methods": "Evaluation de l'efficacit\u00e9 de la d\u00e9contamination par vapeur et l'impact sur la capacit\u00e9 de filtration de masques chirurgicaux et FFP2 (N95).", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 426, "name": "Ma QX"}], "publication_date": "2020-04-26"}, {"id": 493, "slug": "maternal-death-due-to-covid-19-disease", "title": "Maternal Death Due to COVID-19 Disease", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les r\u00e9sultats et les d\u00e9c\u00e8s maternels et p\u00e9rinataux dans une s\u00e9rie de cas de femmes enceintes atteintes de la maladie COVID-19.", "verbose_date": "30.04.2020", "authors": "Hantoushzadeh S", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 175, "name": "Am J Obstet Gynecol"}, "link": "https://www.dropbox.com/s/5udko2yzl6bmgqo/1-s2.0-S0002937820305160-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La d\u00e9termination du taux de l\u00e9talit\u00e9 proportionnel et du risque de morbidit\u00e9 grave pendant la grossesse n\u00e9cessitera des donn\u00e9es rigoureuses de surveillance \u00e0 l'\u00e9chelle de la population dans de nombreux pays, y compris des donn\u00e9es identifiant les modificateurs potentiels et les comorbidit\u00e9s ajustant le risque. Cependant, les cas que nous avons rapport\u00e9s ici d\u00e9montrent que la mortalit\u00e9 maternelle COVID-19 n'est pas nulle, et sugg\u00e8rent de mettre en garde contre la complaisance et les suppositions pr\u00e9coces de protection lors de la grossesse.\nJusqu'\u00e0 ce que des donn\u00e9es de surveillance rigoureusement collect\u00e9es soient disponibles, il est prudent d'\u00eatre conscient du risque de d\u00e9c\u00e8s maternel chez les femmes enceintes diagnostiqu\u00e9es avec la maladie COVID-19 au cours de leur(s) dernier(s) trimestre(s).", "objectives": "-\tPre-proof-\tS\u00e9rie de cas r\u00e9trospective-\tNombre limit\u00e9 de cas-\tCette s\u00e9rie est limit\u00e9e par le manque de donn\u00e9es de surveillance et elle est sujette au biais de constatation d'un r\u00e9sultat d\u00e9favorable.", "methods": "D\u00e9crire les r\u00e9sultats et les d\u00e9c\u00e8s maternels et p\u00e9rinataux dans une s\u00e9rie de cas de femmes enceintes atteintes de la maladie COVID-19.", "topics": ["Epid\u00e9miologique", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 461, "name": "Hantoushzadeh S"}], "publication_date": "2020-04-30"}, {"id": 606, "slug": "neurological-manifestations-and-neuro-invasive-mechanisms-of-the-severe-acute-re", "title": "Neurological manifestations and neuro-invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Description des manifestations neurologiques chez les patients atteints de COVID-19 et les m\u00e9canismes neuro-invasifs possibles de SARS-CoV-2.", "verbose_date": "19.05.2020", "authors": "Vonck K", "specialties": [{"id": 18, "name": "Neurologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 181, "name": "Eur J Neurol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.14329", "findings": "", "take_away": "", "relevance_level": "De plus en plus de preuves montrent que les infections par les COV ne se limitent pas toujours aux voies respiratoires.\u00a0\nPossibilit\u00e9 de manifestations neurologiques, y compris des maladies c\u00e9r\u00e9brovasculaires aigu\u00ebs, une alt\u00e9ration de la conscience, des manifestations des\u00a0nerfs cr\u00e2niens et des troubles auto-immuns tels que le syndrome de Guillain-Barr\u00e9.\nLes dysfonctionnements olfactifs et gustatifs sont tous deux fr\u00e9quents chez les patients atteints de COVID-19 l\u00e9ger \u00e0 mod\u00e9r\u00e9 qui peuvent ne pas pr\u00e9senter de sympt\u00f4mes nasaux. La plupart des autres sympt\u00f4mes neurologiques sont mis en \u00e9vidence chez les patients atteints d'une maladie COVID-19 plus s\u00e9v\u00e8re et sont potentiellement dus \u00e0 une d\u00e9r\u00e9gulation g\u00e9n\u00e9ralis\u00e9e de l'hom\u00e9ostasie caus\u00e9e par des dommages majeurs au syst\u00e8me organique. Cependant, une partie du spectre neurologique chez les patients COVID -19 peut \u00eatre due \u00e0 une l\u00e9sion neurologique virale directe ou \u00e0 des m\u00e9canismes neuroinflammatoires et auto-immuns indirects et peut survenir rapidement au cours de la maladie.\nLa d\u00e9tection de l'acide nucl\u00e9ique viral dans le LCR est rare jusqu'\u00e0 pr\u00e9sent; la d\u00e9tection de la synth\u00e8se intrath\u00e9cale d'anticorps antiviraux ou d'autopsies c\u00e9r\u00e9brales chez les patients COVID -19 pourrait clarifier la capacit\u00e9 virale d'invasion du SNC.", "objectives": "- Revue de litt\u00e9rature incluant des \u00e9tudes r\u00e9trospectives, observationnelles et des cases reports.", "methods": "Description des manifestations neurologiques chez les patients atteints de COVID-19 et les m\u00e9canismes neuro-invasifs possibles de SARS-CoV-2.", "pubmed_id": "32416028", "doi": "10.1111/ene.14329", "abstract": "Infections with coronaviruses are not always confined to the respiratory tract and various neurological manifestations have been reported. The aim of this study was to perform a review to describe neurological manifestations in patients with COVID-19 and possible neuro-invasive mechanisms of Sars-CoV-2.\nPubmed, WebOfScience and Covid-dedicated databases were searched for the combination of COVID-19 terminology and neurology terminology up to May 10\nNeurological manifestations potentially related to COVID-19 have been reported in large studies, case series and case reports and include acute cerebrovascular diseases, impaired consciousness, cranial nerve manifestations and auto-immune disorders such as Guillain-Barr\u00e9 Syndrome often present in patients with more severe COVID-19. Cranial nerve symptoms such as olfactory and gustatory dysfunctions are highly prevalent in patients with mild-to-moderate COVID-19 even without associated nasal symptoms and often present in an early stage of the disease.\nPhysicians should be aware of the neurological manifestations in patients with COVID-19, especially when rapid clinical deterioration occurs. The neurological symptoms in COVID-19 patients may be due to direct viral neurological injury or indirect neuroinflammatory and autoimmune mechanisms. No antiviral treatments against the virus or vaccines for its prevention are available and the long-term consequences of the infection on human health remain uncertain especially with regards to the neurological system.", "topics": ["Epid\u00e9miologique", "Neurologie"], "author_list": [{"id": 569, "name": "Vonck K"}], "publication_date": "2020-05-19"}, {"id": 598, "slug": "management-of-acute-kidney-injury-in-patients-with-covid-19", "title": "Management of acute kidney injury in patients with COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Discussion sur les connaissances actuelles des m\u00e9canismes de l'implication r\u00e9nale dans le Covid-19.\r\n\r\nFournir des s\u00e9ries de recommandations pour la pratique clinique sur base de l'exp\u00e9rience clinique actuelle, incluant la pr\u00e9vention et la gestion de l'insuffisance r\u00e9nale aigu\u00eb et des indications potentielles d'utilisation de th\u00e9rapies de remplacement r\u00e9nal.", "verbose_date": "16.05.2020", "authors": "Ronco C", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 20, "name": "N\u00e9phrologie"}], "category": {"id": 7, "name": "Recommandations", "icon": "icon-reco"}, "journal": {"id": 1, "name": "Lancet Repir Med"}, "link": "https://www.thelancet.com/action/showPdf?pii=S2213-2600%2820%2930229-0", "findings": "", "take_away": "", "relevance_level": "La d\u00e9cision d'utiliser des th\u00e9rapies extracorporelles devrait tenir compte de l'effort technique et des comp\u00e9tences d\u00e9di\u00e9es du personnel multidisciplinaire qui sont n\u00e9cessaires pour une prestation de th\u00e9rapie s\u00fbre et efficace. Une s\u00e9lection rigoureuse des patients pour les th\u00e9rapies extracorporelles s\u00e9quentielles est n\u00e9cessaire car l'\u00e2ge et les comorbidit\u00e9s semblent influencer les r\u00e9sultats chez les patients gravement malades atteints de COVID-19.\nDes recherches suppl\u00e9mentaires sont n\u00e9cessaires pour am\u00e9liorer la compr\u00e9hension de l'insuffisance r\u00e9nale secondaire au COVID-19, pour obtenir des preuves ad\u00e9quates pour soutenir les approches cliniques discut\u00e9es et pour d\u00e9velopper de nouvelles approches de surveillance et de gestion.", "objectives": "", "methods": "Discussion sur les connaissances\u00a0actuelles des m\u00e9canismes de l'implication r\u00e9nale dans le Covid-19.\nFournir des s\u00e9ries de recommandations pour la pratique clinique sur base\u00a0de l'exp\u00e9rience clinique actuelle, incluant la pr\u00e9vention et la gestion de\u00a0l'insuffisance r\u00e9nale aigu\u00eb et des indications potentielles d'utilisation de th\u00e9rapies de remplacement r\u00e9nal.", "pubmed_id": "32416769\n32203709\n32325026\n30043276\n32247631\n31820034\n29708394\n31777389\n32268022\n30470853\n31089920\n17563874\n32171076\n32035509", "doi": "10.1016/S2213-2600(20)30229-0", "abstract": "The outbreak of coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. Most patients with COVID-19 have mild symptoms, but about 5% develop severe symptoms, which can include acute respiratory distress syndrome, septic shock, and multiple organ failure. Kidney involvement is frequent, with clinical presentation ranging from mild proteinuria to progressive acute kidney injury (AKI) necessitating renal replacement therapy (RRT). An understanding of the pathophysiology and mechanisms of kidney damage and AKI in the setting of critical illness and COVID-19 is emerging, although further research is needed to identify patients at risk of AKI and to guide management strategies. As no specific treatment options exist for AKI secondary to COVID-19, intensive care is largely supportive. Current approaches to prevention and management of AKI, and identification of potential indications for use of RRT and sequential extracorporeal therapies, are based mainly on clinical experience, and AKI strategies are adapted empirically to patients with COVID-19. International collaborative and cross-disciplinary research is needed to obtain adequate evidence to support current clinical approaches and to develop new approaches to management.", "topics": ["Recommandations", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "N\u00e9phrologie"], "author_list": [{"id": 105, "name": "Ronco C"}], "publication_date": "2020-05-16"}, {"id": 438, "slug": "the-role-of-community-wide-wearing-of-face-mask-for-control-of-coronavirus-disea", "title": "The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluation de l'effet du port du masque par l'ensemble de la population sur la propagation du SRAS-CoV-2", "verbose_date": "24.04.2020", "authors": "Cheng VCC", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.journalofinfection.com/article/S0163-4453(20)30235-8/pdf", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude montre que l'utilisation du masque par la population g\u00e9n\u00e9rale pourrait avoir r\u00e9duit l'incidence du SRAS-CoV-2 \u00e0 HKSAR.\r\nLes auteurs recommandent l'utilisation de masques par la population en g\u00e9n\u00e9ral dans les lieux publics compatibles avec la fourniture de masques pour le personnel de sant\u00e9. L'utilisation de masques en tissu avec une efficacit\u00e9 de filtration r\u00e9duite est pr\u00e9f\u00e9rable \u00e0 l'absence totale de masque dans les endroits \u00e0 forte transmission.\r\nL'utilisation de masques par la population g\u00e9n\u00e9rale peut r\u00e9duire la transmission du SRAS-CoV-2 due \u00e0 des patients COVID-19 asymptomatiques.", "objectives": "1) \u00e9tude r\u00e9trospective sur tous les patients COVID-19 diagnostiqu\u00e9s \u00e0 HKSAR (n=961)2) article pre-proof3) aucune consid\u00e9ration n'a \u00e9t\u00e9 accord\u00e9e aux modes de transmission sans masque dans le cadre familier4) les types de masques utilis\u00e9s par la population et les r\u00e8gles d'hygi\u00e8ne adopt\u00e9es pour la mise en place et le retrait des masques n'ont pas \u00e9t\u00e9 v\u00e9rifi\u00e9es\"", "methods": "Evaluation de l'effet du port du masque par l'ensemble de la population sur la propagation du SRAS-CoV-2", "pubmed_id": "32335167", "doi": "10.1016/j.jinf.2020.04.024", "abstract": "Face mask usage by the healthy population in the community to reduce risk of transmission of respiratory viruses remains controversial. We assessed the effect of community-wide mask usage to control coronavirus disease 2019 (COVID-19) in Hong Kong Special Administrative Region (HKSAR).\nPatients presenting with respiratory symptoms at outpatient clinics or hospital wards were screened for COVID-19 per protocol. Epidemiological analysis was performed for confirmed cases, especially persons acquiring COVID-19 during mask-off and mask-on settings. The incidence of COVID-19 per million population in HKSAR with community-wide masking was compared to that of non-mask-wearing countries which are comparable with HKSAR in terms of population density, healthcare system, BCG vaccination and social distancing measures but not community-wide masking. Compliance of face mask usage in the HKSAR community was monitored.\nWithin first 100 days (31 December 2019 to 8 April 2020), 961 COVID-19 patients were diagnosed in HKSAR. The COVID-19 incidence in HKSAR (129.0 per million population) was significantly lower (p<0.001) than that of Spain (2983.2), Italy (2250.8), Germany (1241.5), France (1151.6), U.S. (1102.8), U.K. (831.5), Singapore (259.8), and South Korea (200.5). The compliance of face mask usage by HKSAR general public was 96.6% (range: 95.7% to 97.2%). We observed 11 COVID-19 clusters in recreational 'mask-off' settings compared to only 3 in workplace 'mask-on' settings (p\u202f=\u202f0.036 by Chi square test of goodness-of-fit).\nCommunity-wide mask wearing may contribute to the control of COVID-19 by reducing the amount of emission of infected saliva and respiratory droplets from individuals with subclinical or mild COVID-19.", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 299, "name": "Cheng VCC"}], "publication_date": "2020-04-24"}, {"id": 174, "slug": "potential-short-term-outcome-of-an-uncontrolled-covid-19-epidemic-in-lombardy-it", "title": "Potential short-term outcome of an uncontrolled COVID-19 epidemic in Lombardy, Italy", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Estimer le nombre de cas attendu en mars en Lombardie en absence d'intervention.", "verbose_date": "27.03.2020", "authors": "Guzzetta G ", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 46, "name": "Eurosurveillance"}, "link": "https://www.dropbox.com/s/0daalqxlejs9trc/eurosurv-25-12-1.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Si pas d'intervention en Lombardie,environ 250 000 cas dont 37 000 \u00e0 hospitaliser en r\u00e9animation aurait \u00e9t\u00e9 attendus entre le 8 et le 28 mars. N\u00e9cessit\u00e9 d'interventions.", "objectives": "Mod\u00e8le SIR classique mais cela reste de la mod\u00e9lisation. Le R (taux de reproduction) utilis\u00e9 est \u00e9lev\u00e9.", "methods": "Estimer le nombre de cas attendu en mars en Lombardie en absence d'intervention.", "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 169, "name": "Guzzetta G "}], "publication_date": "2020-03-27"}, {"id": 255, "slug": "covid-19-and-paediatric-inflammatory-bowel-diseases-global-experience-and-provis", "title": "COVID-19 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto group of ESPGHAN", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etablir des recommandations sur la prise en charge de cas p\u00e9diatrique de maladies inflammatoires digestives pendant la pand\u00e9mie de COVID-19", "verbose_date": "04.04.2020", "authors": "Turner D", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 121, "name": "J Pediatr Gastroenterol Nutr"}, "link": "https://www.dropbox.com/s/kx31k2lqktovk31/COVID_19_and_Paediatric_Inflammatory_Bowel.96116.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le COVID 19 chez les enfants, y compris avec maladie inflammatoire digestive, semble \u00eatre moins s\u00e9v\u00e8re que chez les adultes.\r\nLes traitements standards des maladies inflammatoires digestives devraient se poursuivre car un retard dans les perfusions d\u00fb \u00e0 la pand\u00e9mie a \u00e9t\u00e9 associ\u00e9 \u00e0 une pouss\u00e9e de maladie en Chine et Cor\u00e9e du Sud.", "objectives": "1) Pre-print2) Recommandations d'expert sans litt\u00e9rature3) Questionnaires en ligne aupr\u00e8s de plusieurs centres pour recenser le nombre de cas COVID-19 + maladies inflammatoires digestives\"", "methods": "Etablir des recommandations sur la prise en charge de cas p\u00e9diatrique de maladies inflammatoires digestives pendant la pand\u00e9mie de COVID-19", "topics": ["Autres", "P\u00e9diatrie"], "author_list": [{"id": 244, "name": "Turner D"}], "publication_date": "2020-04-04"}, {"id": 504, "slug": "renal-involvement-and-early-prognosis-in-patients-with-covid-19-pneumonia", "title": "Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les anomalies r\u00e9nales et leur \u00e9volution \u00e0 court terme dans la pneumonie \u00e0 COVID-19", "verbose_date": "02.05.2020", "authors": "Pei G", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 182, "name": "J Am Soc Nephrol"}, "link": "https://jasn.asnjournals.org/content/jnephrol/early/2020/04/27/ASN.2020030276.full.pdf", "findings": "", "take_away": "", "relevance_level": "Les anomalies r\u00e9nales surviennent chez la majorit\u00e9 des patients atteints de COVID, g\u00e9n\u00e9ralement spontan\u00e9ment r\u00e9solutives en 3 semaines. Les complications r\u00e9nales sont associ\u00e9es \u00e0 une mortalit\u00e9 augment\u00e9e. La s\u00e9v\u00e9rit\u00e9 de la pneumopathie est le facteur principal de survenue d'IRA.", "objectives": "Etude observationnellePeu de patients, donn\u00e9es manquantes, dur\u00e9e courte.Description int\u00e9ressante sur les statistiques de survenue d'anomalies r\u00e9nales (sans forc\u00e9ment de retentissement clinique).", "methods": "D\u00e9crire les anomalies r\u00e9nales et leur \u00e9volution \u00e0 court terme dans la pneumonie \u00e0 COVID-19", "pubmed_id": "32345702", "doi": "10.1681/ASN.2020030276", "abstract": "Some patients with COVID-19 pneumonia also present with kidney injury, and autopsy findings of patients who died from the illness sometimes show renal damage. However, little is known about the clinical characteristics of kidney-related complications, including hematuria, proteinuria, and AKI.\nIn this retrospective, single-center study in China, we analyzed data from electronic medical records of 333 hospitalized patients with COVID-19 pneumonia, including information about clinical, laboratory, radiologic, and other characteristics, as well as information about renal outcomes.\nWe found that 251 of the 333 patients (75.4%) had abnormal urine dipstick tests or AKI. Of 198 patients with renal involvement for the median duration of 12 days, 118 (59.6%) experienced remission of pneumonia during this period, and 111 of 162 (68.5%) patients experienced remission of proteinuria. Among 35 patients who developed AKI (with AKI identified by criteria expanded somewhat beyond the 2012 Kidney Disease: Improving Global Outcomes definition), 16 (45.7%) experienced complete recovery of kidney function. We suspect that most AKI cases were intrinsic AKI. Patients with renal involvement had higher overall mortality compared with those without renal involvement (28 of 251 [11.2%] versus one of 82 [1.2%], respectively). Stepwise multivariate binary logistic regression analyses showed that severity of pneumonia was the risk factor most commonly associated with lower odds of proteinuric or hematuric remission and recovery from AKI.\nRenal abnormalities occurred in the majority of patients with COVID-19 pneumonia. Although proteinuria, hematuria, and AKI often resolved in such patients within 3 weeks after the onset of symptoms, renal complications in COVID-19 were associated with higher mortality.", "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 472, "name": "Pei G"}], "publication_date": "2020-05-02"}, {"id": 599, "slug": "fibrinolysis-shutdown-correlates-to-thromboembolic-events-in-severe-covid-19-inf", "title": "Fibrinolysis Shutdown Correlates to Thromboembolic Events in Severe COVID-19 Infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etablir les qualit\u00e9s pr\u00e9dictives de mesures de d\u00e9pistage du risque de complications thrombo-emboliques dans le cadre des patients atteints de Covid-19 en unit\u00e9 de soins intensifs.", "verbose_date": "16.05.2020", "authors": "Wright FL", "specialties": [{"id": 15, "name": "H\u00e9matologie"}, {"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 145, "name": "J Am Coll Surg"}, "link": "https://www.journalacs.org/article/S1072-7515(20)30400-2/pdf", "findings": "", "take_away": "", "relevance_level": "La fibrinolyse incompl\u00e8te, objectiv\u00e9e par l'\u00e9l\u00e9vation des D-dim\u00e8res et la non-lyse du caillot \u00e0 30 minutes \u00e0 la thrombo\u00e9lastographie, pr\u00e9dit les \u00e9v\u00e8nements thromboemboliques et le recours \u00e0 l'h\u00e9modialyse des patients avec un Covid-19 critique.", "objectives": "- Etude r\u00e9trospective- Nombre de sujets faible- Variabilit\u00e9 des tests biologiques- Param\u00e8tres visco\u00e9lastiques et de coagulation analys\u00e9s \u00e0 diff\u00e9rents temps de progression de la maladie selon les patients.- Les \u00e9v\u00e8nements thromboemboliques \u00e9taient \u00e9tudi\u00e9s apr\u00e8s suspicion clinique sans d\u00e9pistage syst\u00e9matique- Certains patients encore hospitalis\u00e9s.", "methods": "Etablir les qualit\u00e9s pr\u00e9dictives de mesures de d\u00e9pistage du risque de complications thrombo-emboliques dans le cadre des patients atteints de Covid-19 en unit\u00e9 de soins intensifs.", "pubmed_id": "32422349\n28017804\n30701381\n32172546\n28650356\n32171076\n32073213\n14288611\n3553213\n22695409\n13952733\n30920409\n32312290\n32220112\n32105632\n11308009\n26770073\n3492876\n21216444\n13952731\n30376538\n31540685\n7614818\n13904589\n26741642\n28930589\n31425218\n15920177\n25594495\n32305883\n15599145\n25051384\n30239375\n28598908\n26920989", "doi": "10.1016/j.jamcollsurg.2020.05.007", "abstract": "Coronavirus disease 2019 (COVID-19) predisposes patients to a prothrombotic state with demonstrated microvascular involvement. The degree of hypercoagulability appears to correlate with outcomes, however optimal criteria to assess for the highest risk patients for thrombotic events remain unclear; we hypothesized that deranged thromboelastography (TEG) measurements of coagulation would correlate with thromboembolic events.\nPatients admitted to an intensive care unit with COVID-19 diagnoses that had TEG analyses performed were studied. Conventional coagulation assays, D-dimer levels, and viscoelastic parameters were analyzed using a receiver operating characteristic curve to predict thromboembolic outcomes and new onset renal failure.\nForty-four patients with COVID-19 were included in the analysis. Derangements in coagulation laboratory values including elevated D-Dimer, fibrinogen, PT, and PTT were confirmed; viscoelastic parameters showed an elevated maximum amplitude and low lysis at 30 minutes. A complete lack of lysis of clot at 30 minutes was seen in 57% of patients and predicted VTE with an AUROC of .742 (p=0.021). A D-Dimer cutoff of 2600 ng/ml predicted need for dialysis with an AUROC of .779 (p=0.005). Overall, patients with no lysis of clot at 30 minutes and a D-Dimer of greater than 2600 ng/ml had a rate of VTE of 50% compared to 0% for patients with neither risk factor (p=0.008) and had a hemodialysis rate of 80% compared to 14% (p=0.004).\nFibrinolysis shutdown, as evidenced by elevated D-Dimer and complete failure of clot lysis at 30 minutes on thromboelastography, predicts thromboembolic events and need for hemodialysis in critically ill patients with COVID-19. Further clinical trials are required to ascertain the need for early therapeutic anticoagulation or fibrinolytic therapy to address this state of fibrinolysis shutdown.", "topics": ["Pronostique", "H\u00e9matologie", "Transversale"], "author_list": [{"id": 562, "name": "Wright FL"}], "publication_date": "2020-05-16"}, {"id": 175, "slug": "in-vitro-testing-of-hydroxychloroquine-and-azithromycin-on-sras-cov-2-shows-syne", "title": "In vitro testing of Hydroxychloroquine and Azithromycin on SRAS-CoV-2 shows synergistic effect", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier l'effet synergique in vitro de l'association d'hydroxychloroquine et d'azythromycine sur le SARS Cov-2", "verbose_date": "27.03.2020", "authors": "Andreani J ", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/j98tqepzj84kmui/La-Scola-et-al-V1.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Effet mod\u00e9r\u00e9 de l'hydroxychloroquine seule sur SARS-CoV2 \u00e0 faible MOI avec des concentrations faibles\r\nEffet synergique de l'hydroxychloroquine et de l'azythromycine\r\nSynergie entre l'azithromycine et l'hydroxychloroquine observ\u00e9e correspond aux concentrations atteintes in vivo et d\u00e9tect\u00e9es dans les tissus pulmonaires", "objectives": "1) Pre-Prints (pas encore de reviewing)2) In vitro3) Pas d'aveugle d\u00e9crit4) Uniquement descriptif", "methods": "Etudier l'effet synergique in vitro de l'association d'hydroxychloroquine et d'azythromycine sur le SARS Cov-2", "topics": ["Th\u00e9rapeutique", "Virologie", "Infectiologie"], "author_list": [{"id": 170, "name": "Andreani J "}], "publication_date": "2020-03-27"}, {"id": 419, "slug": "cluster-of-covid-19-in-northern-france-a-retrospective-closed-cohort-study", "title": "Cluster of COVID-19 in northern France: A retrospective closed cohort study", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Description de l'infection COVID-19 et de l'immunit\u00e9 d\u00e9velopp\u00e9e dans le cluster du d\u00e9partement de l'Oise touch\u00e9 pr\u00e9cocemment par l'\u00e9pid\u00e9mie en France ", "verbose_date": "23.04.2020", "authors": "Fontanet A", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.18.20071134v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Le taux d'attaque de l\u2019infection (nombre de personnes infect\u00e9es parmi les participants \u00e0 l'\u00e9tude) dans l'Oise \u00e9tait estim\u00e9 \u00e0 25,9%.\r\nPlus pr\u00e9cis\u00e9ment, parmi les personnes ayant fr\u00e9quent\u00e9 le lyc\u00e9e, le taux d'attaque est de 41% contre 11% parmi les proches des lyc\u00e9ens. Le taux d'hospitalisation dans cette population jeune (\u00e2ge m\u00e9dian de 37 ans) est de 5,3%, et il n'y a pas eu de d\u00e9c\u00e8s.\r\nLa perte de l'odorat et la perte du go\u00fbt sont les deux sympt\u00f4mes qui ont une valeur pr\u00e9dictive tr\u00e8s forte en faveur d'une infection.\r\nLa proportion de personnes infect\u00e9es sans sympt\u00f4mes pendant la p\u00e9riode d'\u00e9tude est d'au moins 17%.\u00a0\r\nLes sujets fumeurs semblent significativement moins infect\u00e9s par le virus : 7,2% des fumeurs de l'\u00e9tude sont infect\u00e9s, contre 28% des non-fumeurs.", "objectives": "- Etude r\u00e9trospective sur grande cohorte : une des meilleures en France \u00e0 ce jour m\u00eame si plusieurs biais persistent- Donn\u00e9es \u00e9pid\u00e9miologiques pragmatiques avec test s\u00e9rologique fiable- Donn\u00e9es recueillies par auto-questionnaire apr\u00e8s plusieurs semaines (biais de m\u00e9morisation et de confirmation possibles)- Repr\u00e9sentativit\u00e9 de l'\u00e9chantillon ne correspond pas \u00e0 la population g\u00e9n\u00e9rale ni m\u00eame \u00e0 l'ensemble de la population cible (faible nombre de r\u00e9ponses)", "methods": "Description de l'infection COVID-19 et de l'immunit\u00e9 d\u00e9velopp\u00e9e dans le cluster du d\u00e9partement de l'Oise touch\u00e9 pr\u00e9cocemment par l'\u00e9pid\u00e9mie en France", "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 399, "name": "Fontanet A"}], "publication_date": "2020-04-23"}, {"id": 453, "slug": "acute-pulmonary-embolism-in-covid-19-patients-on-ct-angiography-and-relationship", "title": "Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9crire le taux d'embolie pulmonaire chez les patients COVID-19 soumis \u00e0 un scanner thoracique", "verbose_date": "26.04.2020", "authors": "Leonard-Lorant I", "specialties": [{"id": 3, "name": "Radiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 51, "name": "Radiology"}, "link": "https://pubs.rsna.org/doi/pdf/10.1148/radiol.2020201561", "findings": "", "take_away": "", "relevance_level": "Les soignants doivent \u00eatre particuli\u00e8rement vigilants au risque d'embolie pulmonaire chez les patients COVID-19 puisque son taux chez ceux ayant eu une angiographie pulmonaire semble sup\u00e9rieur par rapport aux non infect\u00e9s et serait autour de 30%. Il pourrait \u00eatre int\u00e9ressant dans leur cas d'augmenter la valeur seuil des D-dim\u00e8res \u00e0 2660 microgrammes/L ce qui permettrait de d\u00e9tecter l'ensemble des EP au scanner thoracique par la suite mais cela reste \u00e0 v\u00e9rifier sur de plus grands effectifs.", "objectives": "- \u00e9tude r\u00e9trospective monocentrique- images radiographiques analys\u00e9es par un seul radiologue- tous les patients cons\u00e9cutifs ont \u00e9t\u00e9 analys\u00e9s (+)- certains patients consid\u00e9r\u00e9s COVID-19 sans test positif mais sur les images radiologiques typiques et un \u00e9tat clinique concordant\"", "methods": "D\u00e9crire le taux d'embolie pulmonaire chez les patients COVID-19 soumis \u00e0 un scanner thoracique", "topics": ["Diagnostique", "Radiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 425, "name": "Leonard-Lorant I"}], "publication_date": "2020-04-26"}, {"id": 537, "slug": "preliminary-evidence-from-a-multicenter-prospective-observational-study-of-the-s", "title": "Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluation de l'efficacit\u00e9 et de la s\u00e9curit\u00e9 d'un traitement par chloroquine chez les patients COVID-19.", "verbose_date": "05.05.2020", "authors": "Huang M", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.26.20081059v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Cet article ne fait pas avancer les connaissances sur le traitement par chloroquine dans le COVID-19.", "objectives": "Attention pre-prints- Changement de protocole en cours de route du fait de la faible puissance initiale de l'\u00e9tude (trois groupes)- Pas d'informations d\u00e9taill\u00e9es sur le traitement re\u00e7u par le groupe contr\u00f4le- Etude observationnelle, groupe contr\u00f4le historique- Etude en per protocole- D\u00e9but du traitement par chloroquine plus tard apr\u00e8s le d\u00e9but des sympt\u00f4mes que pour le groupe non chloroquine- Groupe non comparable sur la classification clinique", "methods": "Evaluation de l'efficacit\u00e9 et de la s\u00e9curit\u00e9 d'un traitement par chloroquine chez les patients COVID-19.", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 503, "name": "Huang M"}], "publication_date": "2020-05-05"}, {"id": 538, "slug": "effect-of-non-pharmaceutical-interventions-to-contain-covid-19-in-china", "title": "Effect of non-pharmaceutical interventions to contain COVID-19 in China", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer l'effet de diff\u00e9rents types d'interventions non pharmaceutiques sur l'\u00e9pid\u00e9mie de Covid-19 en Chine continentale.", "verbose_date": "06.05.2020", "authors": "Lai S", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 189, "name": "Nature"}, "link": "https://www.nature.com/articles/s41586-020-2293-x_reference.pdf", "findings": "", "take_away": "", "relevance_level": "Les mesures non pharmaceutiques n'ont pas toutes la m\u00eame taille d'effet mais seraient essentielles pour r\u00e9duire la propagation de l'\u00e9pid\u00e9mie.\r\nPlus elles sont prises t\u00f4t, et plus l'\u00e9pid\u00e9mie serait contenue.", "objectives": "-Utilisation d'un nombre de donn\u00e9es tr\u00e8s important (plus de 7 milliards de positionnements par jour)-Validation des param\u00e8tres du mod\u00e8le avec les cas officiels-Plusieurs simulations avec hypoth\u00e8ses raisonnables-Mais bas\u00e9 sur des param\u00e8tres estim\u00e9s \u00e0 partir des cas symptomatiques du d\u00e9but de l'\u00e9pid\u00e9mie (biais de s\u00e9lection)-Possibilit\u00e9 de l'effet d'autres facteurs de confusions non pris en compte (saisonniers par exemple)-Utilisation des param\u00e8tres \u00e9pid\u00e9miologiques estim\u00e9s \u00e0 Wuhan et \u00e9tendu dans toute la Chine-La population ayant un smartphone (55%) correspond \u00e0 une sous-population bien particuli\u00e8re de la population (pas d'enfants par exemple) : biais de s\u00e9lection-Analyse de trois types d'intervention non pharmaceutiques, d'autres auraient pu \u00eatre prises en compte.", "methods": "Evaluer l'effet de diff\u00e9rents types d'interventions non pharmaceutiques sur l'\u00e9pid\u00e9mie de Covid-19 en Chine continentale.", "pubmed_id": "32365354", "doi": "10.1038/s41586-020-2293-x", "abstract": "On March 11, 2020, the World Health Organization declared COVID-19 a pandemic", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 504, "name": "Lai S"}], "publication_date": "2020-05-06"}, {"id": 642, "slug": "clinical-impact-of-covid-19-on-patients-with-cancer-ccc19-a-cohort-study", "title": "Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Caract\u00e9riser les issues d'une cohorte de patients atteints de cancer et de COVID-19 et identifier les facteurs de pronostic potentiels pour la mortalit\u00e9 et la maladie grave.", "verbose_date": "02.06.2020", "authors": "Kuderer NM", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931187-9", "findings": "", "take_away": "", "relevance_level": "Parmi les patients atteints de cancer et de COVID-19, la mortalit\u00e9 toutes causes confondues \u00e0 30 jours \u00e9tait \u00e9lev\u00e9e et associ\u00e9e \u00e0 des facteurs de risque g\u00e9n\u00e9raux et \u00e0 des facteurs de risque propres aux patients atteints de cancer. Un suivi plus long est n\u00e9cessaire pour mieux comprendre l'effet de COVID-19 sur les issues chez les patients atteints de cancer, y compris la capacit\u00e9 \u00e0 poursuivre des traitements anticanc\u00e9reux sp\u00e9cifiques.", "objectives": "-\tEtude de cohorte observationnelle prospective-\tN=928", "methods": "Caract\u00e9riser les issues d'une cohorte de patients atteints de cancer et de COVID-19 et identifier les facteurs de pronostic potentiels pour la mortalit\u00e9 et la maladie grave.", "pubmed_id": "32473681\n26135024\n32109013\n25890663\n25344526\n8668867\n11245484\n32171067\n32066541\n26659430\n32227760\n18929686\n32187459\n12690092\n10485450\n32298247\n23775961\n30523758\n32142651\n32206052\n3203132\n32214079", "doi": "10.1016/S0140-6736(20)31187-9", "abstract": "Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.\nIn this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.\nOf 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57-76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1\u00b784, 95% CI 1\u00b753-2\u00b721), male sex (1\u00b763, 1\u00b707-2\u00b748), smoking status (former smoker vs never smoked: 1\u00b760, 1\u00b703-2\u00b747), number of comorbidities (two vs none: 4\u00b750, 1\u00b733-15\u00b728), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3\u00b789, 2\u00b711-7\u00b718), active cancer (progressing vs remission: 5\u00b720, 2\u00b777-9\u00b777), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2\u00b793, 1\u00b779-4\u00b779; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0\u00b724, 0\u00b707-0\u00b784) or the US-Midwest (0\u00b750, 0\u00b728-0\u00b790) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.\nAmong patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments.\nAmerican Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 604, "name": "Kuderer NM"}], "publication_date": "2020-06-02"}, {"id": 347, "slug": "clinical-characteristics-of-covid-19-patients-with-digestive-symptoms-in-hubei-c", "title": "Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire la pr\u00e9valence des sympt\u00f4mes digestifs et les caract\u00e9ristiques cliniques de ces patients infect\u00e9s par le COVID-19", "verbose_date": "16.04.2020", "authors": "Pan L.", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 149, "name": "Am J Gastroenterol"}, "link": "https://journals.lww.com/ajg/Documents/COVID_Digestive_Symptoms_AJG_Preproof.pdf", "findings": "", "take_away": "", "relevance_level": "Les sympt\u00f4mes digestifs sont une pr\u00e9sentation clinique fr\u00e9quente dans le COVID-19, ils concernent 50% des patients. Ces sympt\u00f4mes sont l'anorexie (79%), la diarrh\u00e9e (34%), les vomissements (4%) et les douleurs abdominales (2%).\u00a0\r\nCes sympt\u00f4mes ne sont pas associ\u00e9s \u00e0 un sur-risque de d\u00e9c\u00e8s mais sont plus fr\u00e9quents dans les formes s\u00e9v\u00e8res. Ils sont associ\u00e9s \u00e0 des transaminases \u00e9lev\u00e9es.", "objectives": "- Etude r\u00e9trospective chinoise- M\u00e9thode de s\u00e9lection des patients non d\u00e9taill\u00e9es- Repr\u00e9sentativit\u00e9 perfectible de l'\u00e9chantillon (plut\u00f4t des sujets jeunes avec moins de comorbidit\u00e9s que la population habituelle)\"", "methods": "D\u00e9crire la pr\u00e9valence des sympt\u00f4mes digestifs et les caract\u00e9ristiques cliniques de ces patients infect\u00e9s par le COVID-19", "pubmed_id": "32287140", "doi": "10.14309/ajg.0000000000000620", "abstract": "Since the outbreak of Coronavirus Disease 2019 (COVID-19) in December 2019, various digestive symptoms have been frequently reported in patients infected with the virus. In this study, we aimed to further investigate the prevalence and outcomes of COVID-19 patients with digestive symptoms.\nIn this descriptive, cross-sectional, multicenter study, we enrolled confirmed patients with COVID-19 who presented to 3 hospitals from January 18, 2020, to February 28, 2020. All patients were confirmed by real-time polymerase chain reaction and were analyzed for clinical characteristics, laboratory data, and treatment. Data were followed up until March 18, 2020.\nIn the present study, 204 patients with COVID-19 and full laboratory, imaging, and historical data were analyzed. The average age was 52.9 years (SD \u00b1 16), including 107 men and 97 women. Although most patients presented to the hospital with fever or respiratory symptoms, we found that 103 patients (50.5%) reported a digestive symptom, including lack of appetite (81 [78.6%] cases), diarrhea (35 [34%] cases), vomiting (4 [3.9%] cases), and abdominal pain (2 [1.9%] cases). If lack of appetite is excluded from the analysis (because it is less specific for the gastrointestinal tract), there were 38 total cases (18.6%) where patients presented with a gastrointestinal-specific symptom, including diarrhea, vomiting, or abdominal pain. Patients with digestive symptoms had a significantly longer time from onset to admission than patients without digestive symptoms (9.0 days vs 7.3 days). In 6 cases, there were digestive symptoms, but no respiratory symptoms. As the severity of the disease increased, digestive symptoms became more pronounced. Patients with digestive symptoms had higher mean liver enzyme levels, lower monocyte count, longer prothrombin time, and received more antimicrobial treatment than those without digestive symptoms.\nWe found that digestive symptoms are common in patients with COVID-19. Moreover, these patients have a longer time from onset to admission, evidence of longer coagulation, and higher liver enzyme levels. Clinicians should recognize that digestive symptoms, such as diarrhea, are commonly among the presenting features of COVID-19 and that the index of suspicion may need to be raised earlier in at-risk patients presenting with digestive symptoms. However, further large sample studies are needed to confirm these findings.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 335, "name": "Pan L."}], "publication_date": "2020-04-16"}, {"id": 333, "slug": "in-vitro-antiviral-activity-of-doxycycline-against-sars-cov-2", "title": "In vitro antiviral activity of doxycycline against SARS-CoV-2", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'efficacit\u00e9 in vitro de la doxycycline contre le SARS-CoV-2 ", "verbose_date": "15.04.2020", "authors": "Gendrot M", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Dox_Covid_pre-print.pdf", "findings": "", "take_away": "", "relevance_level": "La doxycycline pourrait \u00eatre une piste th\u00e9rapeutique int\u00e9ressante dans la pr\u00e9vention (en association avec la chloroquine) ou le traitement de l'infection \u00e0 COVID-19 par son action antivirale mais aussi anti-inflammatoire.\u00a0\r\nCes r\u00e9sultats doivent \u00eatre confirm\u00e9s par des \u00e9tudes in vivo chez l'homme aussi bien sur l'efficacit\u00e9 que la s\u00e9curit\u00e9 du traitement.", "objectives": "- Etude exp\u00e9rimentale in vitro- Pas de comparaison de l'efficacit\u00e9 avec des cellules t\u00e9moins ou avec le traitement par chloroquine- Pas de quantification de la baisse de la r\u00e9plication virale ou de la production cytokiniques- Etude tr\u00e8s pr\u00e9liminaire\"", "methods": "Evaluer l'efficacit\u00e9 in vitro de la doxycycline contre le SARS-CoV-2", "topics": ["Th\u00e9rapeutique", "Transversale", "Virologie", "Infectiologie"], "author_list": [{"id": 320, "name": "Gendrot M"}], "publication_date": "2020-04-15"}, {"id": 194, "slug": "uv-sterilization-of-personal-protective-equipment-with-idle-laboratory-biosafety", "title": "UV Sterilization of Personal Protective Equipment with Idle Laboratory Biosafety Cabinets During the Covid-19 Pandemic", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluation de l'efficacit\u00e9 de la conversion de cabinet de s\u00e9curit\u00e9 biologique (BSC) pour la st\u00e9rilisation par UV de masques N95", "verbose_date": "31.03.2020", "authors": "Card KJ ", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/csyns3y68tq4za0/2020.03.25.20043489v1.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Possibilit\u00e9 de d\u00e9sinfecter les masques FFP2 et N95 par UVGI, en utilisant un cabinet de s\u00e9curit\u00e9 biologique (BSC), avec une exposition de 20 minutes par face (dur\u00e9e \u00e0 r\u00e9ajuster en fonction de la puissance du BSC).\r\n- N\u00e9cessit\u00e9 d'identifier chaque masque afin de pouvoir identifier le porteur du masque, et le nombre de cycles de d\u00e9sinfection effectu\u00e9\r\n- Transport des masques en paquet scell\u00e9\r\n- Pas de garantie sur la d\u00e9sinfection", "objectives": "- Pre-print- Besoin de pr\u00e9ciser l'impact de l'exposition r\u00e9p\u00e9t\u00e9 aux UV sur la structure.- Pas d'analyse bact\u00e9riologique directe, seulement un calcul de dose d'UV re\u00e7u.- Les UVs sont tr\u00e8s adapt\u00e9s aux surfaces, peu de donn\u00e9es sur des masques (possible probl\u00e8me li\u00e9 aux replis, \u00e0 la d\u00e9sinfection des couches internes du masque, si couche externes hydrophiles, etc...)\"", "methods": "Evaluation de l'efficacit\u00e9 de la conversion de cabinet de s\u00e9curit\u00e9 biologique (BSC) pour la st\u00e9rilisation par UV de masques N95", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 187, "name": "Card KJ "}], "publication_date": "2020-03-31"}, {"id": 316, "slug": "predictors-of-mortality-for-patients-with-covid-19-pneumonia-caused-by-sars-cov-", "title": "Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Identifier les facteurs associ\u00e9s au deces chez les COVID19", "verbose_date": "12.04.2020", "authors": "Du RH", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 142, "name": "Eur Respir J"}, "link": "https://erj.ersjournals.com/content/erj/early/2020/04/01/13993003.00524-2020.full.pdf", "findings": "", "take_away": "", "relevance_level": "Ils ont identifi\u00e9 quatre facteurs de risque, l'\u00e2ge \u2265 65 ans, des troubles cardiovasculaires ou\r\nmaladies c\u00e9r\u00e9brovasculaires, CD3 +CD8 +Cellules T \u2264 75 cellules / \u03bcL, et troponine cardiaque I \u2265 0,05 ng / mL, en particulier les deux derniers facteurs, \u00e9taient des pr\u00e9dicteurs de la mortalit\u00e9 des patients atteints de pneumonie au COVID-19.\n\r\nAnalyse de r\u00e9gression logistique univari\u00e9e et multivari\u00e9e a r\u00e9v\u00e9l\u00e9 que l'\u00e2ge \u2265 65 ans (OR 3,765; intervalle de confiance \u00e0 95%, 1,146\u201217,394; P = 0,023), les maladies cardiovasculaires ou c\u00e9r\u00e9brovasculaires concomitantes pr\u00e9existantes (2,464; 0,755\u20128,044; P = 0,007), les CD3 + CD8 + Cellules T \u2264 75 cellules / \u03bcL (3,982; 1,132\u201214,006; P <0,001), et troponine cardiaque I \u2265 0,05 ng / mL (4,077; 1,166\u201214,253; P <0,001) ont \u00e9t\u00e9 associ\u00e9s \u00e0 une augmentation du risque de mortalit\u00e9 de COVID-19.\n\r\nDans l'\u00e9tude de cas appari\u00e9e sur le sexe, l'\u00e2ge et la maladie comorbide, CD3 + CD8 + Cellules T \u2264 75 cell / \u03bcL et la troponine cardiaque I \u2265 0,05 ng / mL restent les pr\u00e9dicteurs d'une mortalit\u00e9 \u00e9lev\u00e9e chez les COVID-19", "objectives": "- pas de param\u00e8tres de performance ni de validation de leur mod\u00e8le de r\u00e9gression logistique - 76% des patients avaient un test SARS-CoV 2 positif, et 24% ont \u00e9t\u00e9 diagnostiqu\u00e9s cliniquement - pas de prise en compte des co infections - les patients critiques ont re\u00e7us plusieurs traitements (antibio,antifongiques, corticost\u00e9ro\u00efdes, immunoglobuline)", "methods": "Identifier les facteurs associ\u00e9s au deces chez les COVID19", "pubmed_id": "32269088\n24626235\n31995857\n31978945\n32109013\n31978944\n15156481\n32014114\n28724637\n32031570\n14585636\n31986264\n32048163\n15972696\n28177862\n32091533\n32007143\n31971553", "doi": "10.1183/13993003.00524-2020", "abstract": "The aim of this study was to identify factors associated with the death of patients with COVID-19 pneumonia caused by the novel coronavirus SARS-CoV-2.All clinical and laboratory parameters were collected prospectively from a cohort of patients with COVID-19 pneumonia who were hospitalised to Wuhan Pulmonary Hospital (Wuhan City, Hubei Province, China) between 25 December 2019 and 7 February 2020. Univariate and multivariate logistic regression was performed to investigate the relationship between each variable and the risk of death of COVID-19 pneumonia patients.In total, 179 patients with COVID-19 pneumonia (97 male and 82 female) were included in the present prospective study, of whom 21 died. Univariate and multivariate logistic regression analysis revealed that age \u226565\u2005years (OR 3.765, 95% CI 1.146\u201217.394; p=0.023), pre-existing concurrent cardiovascular or cerebrovascular diseases (OR 2.464, 95% CI 0.755\u20128.044; p=0.007), CD3", "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 303, "name": "Du RH"}], "publication_date": "2020-04-12"}, {"id": 451, "slug": "strong-associations-and-moderate-predictive-value-of-early-symptoms-for-sars-cov", "title": "Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Identifier les sympt\u00f4mes associ\u00e9s avec une positivit\u00e9 du test SARS-CoV-2 et d\u00e9velopper un mod\u00e8le diagnostique pour pr\u00e9dire la probabilit\u00e9 d'infection \u00e0 SARS-CoV-2 en se basant sur les sympt\u00f4mes pr\u00e9coces.", "verbose_date": "25.04.2020", "authors": "Tostmann A", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 46, "name": "Eurosurveillance"}, "link": "https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.16.2000508", "findings": "", "take_away": "", "relevance_level": "- les soignants test\u00e9s positifs au SARS-CoV-2 pr\u00e9sentaient le plus fr\u00e9quemment\u00a0: c\u00e9phal\u00e9es (71%), malaise diffus (63%), myalgies (63%)\r\n- association significative (<0,001) en analyse univari\u00e9e entre test SARS-CoV-2 positif et les sympt\u00f4mes suivants: anosmie (OR=23,0, 95% CI\u00a0: 8,2-64,8), myalgies (OR = 6,9, 95% CI\u00a0: 4,2-11,3), douleurs oculaires (OR = 4,5, 95% CI\u00a0: 2,7-7,4), malaise diffus (OR = 4,2, 95% CI\u00a0: 2,6-6,7), c\u00e9phal\u00e9es (OR = 3.5, 95% CI\u00a0: 2,1-5,7), asth\u00e9nie extr\u00eame (OR = 2,8, 95% CI\u00a0: 1,6-4,9), fi\u00e8vre (OR = 2,7, 95% CI\u00a0: 1,7-4,2)", "objectives": "- 2 \u00e9tudes de cohorte r\u00e9trospectives monocentriques \u00ab\u00a0combin\u00e9es\u00a0\u00bb en une- Effectifs modestes - Contr\u00f4le du biais de m\u00e9morisation (envoi du questionnaire dans les 24 heures apr\u00e8s test) mais probables biais de s\u00e9lection, biais de classement (fiabilit\u00e9 imparfaite du test?) et de confusion (analyse en univari\u00e9e)\"", "methods": "Identifier les sympt\u00f4mes associ\u00e9s avec une positivit\u00e9 du test SARS-CoV-2 et d\u00e9velopper un mod\u00e8le diagnostique pour pr\u00e9dire la probabilit\u00e9 d'infection \u00e0 SARS-CoV-2 en se basant sur les sympt\u00f4mes pr\u00e9coces.", "pubmed_id": "32347200\n18941266\n32146694\n32271722", "doi": "10.2807/1560-7917.ES.2020.25.16.2000508", "abstract": "Healthcare workers (n\u2009=\u2009803) with mild symptoms were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (n\u2009=\u200990 positive) and asked to complete a symptom questionnaire. Anosmia, muscle ache, ocular pain, general malaise, headache, extreme tiredness and fever were associated with positivity. A predictive model based on these symptoms showed moderate discriminative value (sensitivity: 91.2%; specificity: 55.6%). While our models would not justify presumptive SARS-CoV-2 diagnosis without molecular confirmation, it can contribute to targeted screening strategies.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 424, "name": "Tostmann A"}], "publication_date": "2020-04-25"}, {"id": 488, "slug": "neutralizing-antibody-responses-to-sars-cov-2-in-a-covid-19-recovered-2-patient-", "title": "Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered 2 patient cohort and their implications", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Explorer, chez des sujets gu\u00e9ris d'une forme l\u00e9g\u00e8re de COVID-19, les param\u00e8tres cliniques associ\u00e9s \u00e0 leur niveau d'anticorps neutralisants.", "verbose_date": "29.04.2020", "authors": "Fan W", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Il semble que la r\u00e9ponse immunitaire \u00e0 m\u00e9diation humorale dans la pand\u00e9mie COVID-19 se met en place \u00e0 partir de J10-J15 apr\u00e8s le d\u00e9but des sympt\u00f4mes. N\u00e9anmoins certains patients gu\u00e9rissent sans produire d'anticorps neutralisants anti-SARS-CoV-2 et il sera int\u00e9ressant d'\u00e9tudier chez eux les m\u00e9canismes de r\u00e9ponses \u00e0 l'infection et le risque de r\u00e9cidive. Les r\u00e9sultats de cette \u00e9tude font suspecter un r\u00f4le pr\u00e9pond\u00e9rant de l'immunit\u00e9 humorale lorsque l'immunit\u00e9 cellulaire fait d\u00e9faut. Le pouvoir protecteur du niveau d'anticorps neutralisants vis-\u00e0-vis d'une forme s\u00e9v\u00e8re reste \u00e0 d\u00e9montrer \u00e9galement. Enfin, avant d'\u00eatre utilis\u00e9es pour s\u00e9roth\u00e9rapie, les titrations d'anticorps devraient \u00eatre r\u00e9alis\u00e9es sur le s\u00e9rum des donneurs.", "objectives": "- \u00e9tude limit\u00e9e aux patients avec une forme l\u00e9g\u00e8re du COVID-19 car les sujets s\u00e9v\u00e8res avaient \u00e9t\u00e9 trait\u00e9s par s\u00e9roth\u00e9rapie- pas de suivi de la pr\u00e9sence du virus dans le sang- suivi post hospitalisation limit\u00e9 \u00e0 2 semaines- certaines analyses sur des sous-groupes de faible effectif", "methods": "Explorer, chez des sujets gu\u00e9ris d'une forme l\u00e9g\u00e8re de COVID-19, les param\u00e8tres cliniques associ\u00e9s \u00e0 leur niveau d'anticorps neutralisants.", "topics": ["Th\u00e9rapeutique", "Virologie", "Infectiologie"], "author_list": [{"id": 456, "name": "Fan W"}], "publication_date": "2020-04-29"}, {"id": 122, "slug": "severe-sars-cov-2-infections-practicalconsiderations-and-management-strategy-for", "title": "Severe SARS-CoV-2 infections: practicalconsiderations and management strategy for intensivists", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire la pr\u00e9sentation clinique, la prise en charge actuelle des patients s\u00e9v\u00e8res", "verbose_date": "26.02.2020", "authors": "Bouadma L", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 2, "name": "Intensive Care Med"}, "link": "https://www.dropbox.com/s/2w700hajd9e521t/Bouadma2020_Article_SevereSARS-CoV-2InfectionsPrac.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "LBA non recommand\u00e9 pour le diagnostic du fait des risques pour les professionnels de sant\u00e9 => examen du crachat ou aspiration endo trach\u00e9ale ou cath\u00e9ter t\u00e9l\u00e9scopique \u00e0 brosse prot\u00e9g\u00e9e Si test initial n\u00e9gatif, ne pas h\u00e9siter \u00e0 recommencer La valeur pronostique de l'excr\u00e9tion virale est encore inconnue", "objectives": "Faible : 1) r\u00e9dig\u00e9 \u00e0 partir de la litt\u00e9rature et l'exp\u00e9rience de 4 cas \u00e0 Bichat", "methods": "D\u00e9crire la pr\u00e9sentation clinique, la prise en charge actuelle des patients s\u00e9v\u00e8res", "pubmed_id": "32103284", "doi": "10.1007/s00134-020-05967-x", "abstract": null, "topics": ["Autres", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 128, "name": "Bouadma L"}], "publication_date": "2020-02-26"}, {"id": 671, "slug": "a-mathematical-model-for-the-spatiotemporal-epidemic-spreading-of-covid19", "title": "A mathematical model for the spatiotemporal epidemic spreading of COVID19", "has_other_authors": true, "impact_factor": {"id": 4, "name": "Ind\u00e9termin\u00e9", "posts_count": 12, "color": "gray", "order": 4}, "goals_plain": "Le but de cette \u00e9tude est d'introduire un mod\u00e8le individu-centr\u00e9 pour la mod\u00e9lisation et le suivi de l'\u00e9pid\u00e9mie de COVID-19.", "verbose_date": "08.06.2020", "authors": "Arenas A", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.03.21.20040022v1", "findings": "", "take_away": "", "relevance_level": "Cet article propose une mod\u00e9lisation individu-centr\u00e9e de l'\u00e9volution de l'\u00e9pid\u00e9mie de COVID-19, tenant compte de la structure g\u00e9ographique et d'\u00e2ge de la population, et permettant de simuler diff\u00e9rentes strat\u00e9gies d'isolement. Ce mod\u00e8le est appliqu\u00e9 \u00e0 la dynamique \u00e9pid\u00e9mique en Espagne jusqu'au 20 mars.", "objectives": "Le mod\u00e8le pr\u00e9sent\u00e9 dans cet article semble bien correspondre \u00e0 l'\u00e9volution observ\u00e9e de l'\u00e9pid\u00e9mie en Espagne. Cependant, ce mod\u00e8le d\u00e9pend d'un grand nombre de param\u00e8tres, il est donc complexe de se prononcer sur son caract\u00e8re pr\u00e9dictif.  Les codes utilis\u00e9s pour r\u00e9aliser ces simulations ne sont pas disponibles, mais les algorithmes correspondants sont bien d\u00e9crits dans le corps de l'article. Il serait probablement int\u00e9ressant de v\u00e9rifier si ce mod\u00e8le pr\u00e9dit de la m\u00eame fa\u00e7on l'\u00e9volution pr\u00e9coce de l'\u00e9pid\u00e9mie dans d'autres r\u00e9gions europ\u00e9ennes avant la mise en place de mesures de quarantaine.", "methods": "Le but de cette \u00e9tude est d'introduire un mod\u00e8le individu-centr\u00e9 pour la mod\u00e9lisation et le suivi de l'\u00e9pid\u00e9mie de COVID-19.", "topics": ["Mod\u00e9lisation", "Infectiologie"], "author_list": [{"id": 630, "name": "Arenas A"}], "publication_date": "2020-06-08"}, {"id": 95, "slug": "care-of-haematology-patients-in-a-covid-19-epidemic", "title": "Care of haematology patients in a COVID-19 epidemic", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Proposer des \u00e9tapes pratiques pour r\u00e9duire l'exposition et l'immunod\u00e9pression quand c'est possible des patients suivis en h\u00e9matologie.", "verbose_date": "15.03.2020", "authors": "Willan J", "specialties": [{"id": 15, "name": "H\u00e9matologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 68, "name": "Br J Haematol"}, "link": "https://www.dropbox.com/s/oipfr546p1fmyax/bjh.16620.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Faire au maximum \u00e0 distance, ou alors aller-vers les patientsPeser balance b\u00e9n\u00e9fice risque des traitements : contact avec d'autres patients, immunod\u00e9pression induite par les traitements et diff\u00e9rer quand c'est possible", "objectives": "Faible :1) Lettre \u00e0 l'\u00e9diteur2) Tr\u00e8s peu bas\u00e9 sur la litt\u00e9rature", "methods": "Proposer des \u00e9tapes pratiques pour r\u00e9duire l'exposition et l'immunod\u00e9pression quand c'est possible des patients suivis en h\u00e9matologie.", "topics": ["Autres", "H\u00e9matologie"], "author_list": [{"id": 101, "name": "Willan J"}], "publication_date": "2020-03-15"}, {"id": 300, "slug": "effect-of-throat-washings-on-detection-of-2019-novel-coronavirus", "title": "Effect of throat washings on detection of 2019 novel coronavirus", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer les lavages de gorge auto-collect\u00e9s comme moyen de diagnostic de COVID-19 et comparer aux pr\u00e9l\u00e8vement naso-pharyng\u00e9s.", "verbose_date": "10.04.2020", "authors": "Guo WL", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 24, "name": "Clin Infect Dis"}, "link": "https://www.dropbox.com/s/dt5ncqsr1epa8zg/ciaa416.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Des \u00e9tudes suppl\u00e9mentaires devraient \u00e9tudier le lavage de gorge auto-collect\u00e9 comme m\u00e9thode diagnostique alternative au pr\u00e9l\u00e8vement nasopharyng\u00e9.", "objectives": "1) Etude exploratoire2) 11 patients, 24 paires d'\u00e9chantillons3) \u00c9chantillons pr\u00e9lev\u00e9s en m\u00e9diane 53 jours apr\u00e8s le d\u00e9but des sympt\u00f4mes !4) Compar\u00e9 \u00e0 1 \u00e9chantillon de RT-PCR nasopharyng\u00e9e chez des patients COVID-19 tous confirm\u00e9s au d\u00e9but par RT-PCR\"", "methods": "\u00c9valuer les lavages de gorge auto-collect\u00e9s comme moyen de diagnostic de COVID-19 et comparer aux pr\u00e9l\u00e8vement naso-pharyng\u00e9s.", "pubmed_id": "32271374", "doi": "10.1093/cid/ciaa416", "abstract": "The 2019 novel coronavirus was detected in the self-collected throat washings. Positive testing rate of throat washing was much higher than that of Nasopharyngeal swabs. Throat washing is a promising candidate for 2019-nCoV screening and monitoring due to its noninvasive and reliability.", "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 288, "name": "Guo WL"}], "publication_date": "2020-04-10"}, {"id": 334, "slug": "covid-19-a-relationship-to-climate-and-environmental-conditions", "title": "COVID-19: A Relationship to Climate and Environmental Conditions?", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'effet des caract\u00e9ristiques climatiques et des processus m\u00e9t\u00e9orologiques dans les mod\u00e8les \u00e9pid\u00e9miologiques de propagation de SARS-CoV-2", "verbose_date": "15.04.2020", "authors": "Kroumpouzos G", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 127, "name": "Dermatol Ther"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/dth.13399", "findings": "", "take_away": "", "relevance_level": "La saisonnalit\u00e9 et la dynamique de diffusion du SARS-CoV-2 li\u00e9es aux conditions environnementales n'ont pas encore \u00e9t\u00e9 d\u00e9termin\u00e9es mais il a \u00e9t\u00e9 d\u00e9montr\u00e9 que des temp\u00e9ratures >38\u00b0C et une humidit\u00e9 relative > 95% r\u00e9duisent la viabilit\u00e9 du SARS-CoV-2.\r\nL'int\u00e9gration des caract\u00e9ristiques climatiques et des processus m\u00e9t\u00e9orologiques dans les mod\u00e8les \u00e9pid\u00e9miologiques de propagation de SARS-CoV-2 peut aider \u00e0 identifier les sc\u00e9narios d'interactions interhumaines les plus \u00e0 risque et \u00e0 am\u00e9liorer les mesures de surveillance ou de contr\u00f4le de la pand\u00e9mie en fonction de la r\u00e9gion g\u00e9ographique d'int\u00e9r\u00eat.", "objectives": "1) Lettre \u00e0 l'editeur2) Bas\u00e9 sur une litt\u00e9rature encore r\u00e9duite", "methods": "Evaluer l'effet des caract\u00e9ristiques climatiques et des processus m\u00e9t\u00e9orologiques dans les mod\u00e8les \u00e9pid\u00e9miologiques de propagation de SARS-CoV-2", "pubmed_id": "32276290\n20228108\n22312351\n31995857\n32112977", "doi": "10.1111/dth.13399", "abstract": null, "topics": ["Autres", "Transversale"], "author_list": [{"id": 321, "name": "Kroumpouzos G"}], "publication_date": "2020-04-15"}, {"id": 239, "slug": "use-of-siltuximab-in-patients-with-covid-19-pneumonia-requiring-ventilatory-supp", "title": "Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Donn\u00e9es pr\u00e9liminaires du traitement par anticorps monoclonal chim\u00e9rique bloquant l'effet de l'IL-6 (Siltuximab) dans les infections s\u00e9v\u00e8res \u00e0 SARS-CoV-2.", "verbose_date": "03.04.2020", "authors": "Gritti G", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.01.20048561v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "- CRP et IL-6 \u00e9lev\u00e9es initialement.\r\n- Retour de la CRP \u00e0 la normale 5 jours apr\u00e8s le traitement", "objectives": "- Pre-print- Pas de groupe contr\u00f4le- Petit effectif\"", "methods": "Donn\u00e9es pr\u00e9liminaires du traitement par anticorps monoclonal chim\u00e9rique bloquant l'effet de l'IL-6 (Siltuximab) dans les infections s\u00e9v\u00e8res \u00e0 SARS-CoV-2.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie"], "author_list": [{"id": 229, "name": "Gritti G"}], "publication_date": "2020-04-03"}, {"id": 301, "slug": "impact-of-school-closures-for-covid-19-on-the-us-health-care-workforce-and-net-m", "title": "Impact of school closures for COVID-19 on the US health-care workforce and net mortality: a modelling study", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Mod\u00e9liser l'impact des fermetures d'\u00e9cole sur les obligations de garde d'enfant pour le personnel soignant am\u00e9ricain et \u00e9valuer quel seuil de contribution des travailleurs de la sant\u00e9 \u00e0 la r\u00e9duction de la mortalit\u00e9 serait n\u00e9cessaire pour que leur absent\u00e9isme li\u00e9 aux fermetures suffisent pour annuler les avantages des fermetures d'\u00e9coles dans la r\u00e9duction du nombre de cas.", "verbose_date": "07.04.2020", "authors": "Bayham J", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 140, "name": "Lancet Public Health"}, "link": "https://www.thelancet.com/pdfs/journals/lanpub/PIIS2468-2667(20)30082-7.pdf", "findings": "", "take_away": "", "relevance_level": "La fermeture des \u00e9tablissements scolaires aux US est susceptible de causer 15% d'absence chez le personnel soignant am\u00e9ricain. Si l'absence de personnel soignant a un cout suffisament important en terme de diminution de probabilit\u00e9 de survie, les fermetures d'\u00e9coles sans mesures additionnelles pour assurer les gardes pourraient entra\u00eener un plus grand nombre de d\u00e9c\u00e8s qu'elles n'en pr\u00e9viennent.", "objectives": "Mod\u00e9lisation avec des hypoth\u00e8ses fortes (\u00e0 noter que n\u00e9anmoins les auteurs sont conscients des limites, et l'article a l'int\u00e9r\u00eat de pointer la n\u00e9cessit\u00e9 d'un compromis)", "methods": "Mod\u00e9liser l'impact des fermetures d'\u00e9cole sur les obligations de garde d'enfant pour le personnel soignant am\u00e9ricain et \u00e9valuer quel seuil de contribution des travailleurs de la sant\u00e9 \u00e0 la r\u00e9duction de la mortalit\u00e9 serait n\u00e9cessaire pour que leur absent\u00e9isme li\u00e9 aux fermetures suffisent pour annuler les avantages des fermetures d'\u00e9coles dans la r\u00e9duction du nombre de cas.", "pubmed_id": "32251626\n24830407\n20025205\n32164834\n27671169\n27273688\n19926697\n18401408\n21444809\n26511046\n32087115\n28003528\n23447463", "doi": "10.1016/S2468-2667(20)30082-7", "abstract": "The coronavirus disease 2019 (COVID-19) pandemic is leading to social (physical) distancing policies worldwide, including in the USA. Some of the first actions taken by governments are the closing of schools. The evidence that mandatory school closures reduce the number of cases and, ultimately, mortality comes from experience with influenza or from models that do not include the effect of school closure on the health-care labour force. The potential benefits from school closures need to be weighed against costs of health-care worker absenteeism associated with additional child-care obligations. In this study, we aimed to measure child-care obligations for US health-care workers arising from school closures when these are used as a social distancing measure. We then assessed how important the contribution of health-care workers would have to be in reducing mortality for their absenteeism due to child-care obligations to undo the benefits of school closures in reducing the number of cases.\nFor this modelling analysis, we used data from the monthly releases of the US Current Population Survey to characterise the family structure and probable within-household child-care options of US health-care workers. We accounted for the occupation within the health-care sector, state, and household structure to identify the segments of the health-care workforce that are most exposed to child-care obligations from school closures. We used these estimates to identify the critical level at which the importance of health-care labour supply in increasing the survival probability of a patient with COVID-19 would undo the benefits of school closures and ultimately increase cumulative mortality.\nBetween January, 2018, and January, 2020, the US Current Population Survey included information on more than 3\u00b71 million individuals across 1\u00b73 million households. We found that the US health-care sector has some of the highest child-care obligations in the USA, with 28\u00b78% (95% CI 28\u00b75-29\u00b71) of the health-care workforce needing to provide care for children aged 3-12 years. Assuming non-working adults or a sibling aged 13 years or older can provide child care, 15\u00b70% (14\u00b78-15\u00b72) of the health-care workforce would still be in need of child care during a school closure. We observed substantial variation within the health-care system. We estimated that, combined with reasonable parameters for COVID-19 such as a 15\u00b70% case reduction from school closings and 2\u00b70% baseline mortality rate, a 15\u00b70% decrease in the health-care labour force would need to decrease the survival probability per percent health-care worker lost by 17\u00b76% for a school closure to increase cumulative mortality. Our model estimates that if the infection mortality rate of COVID-19 increases from 2\u00b700% to 2\u00b735% when the health-care workforce declines by 15\u00b70%, school closures could lead to a greater number of deaths than they prevent.\nSchool closures come with many trade-offs, and can create unintended child-care obligations. Our results suggest that the potential contagion prevention from school closures needs to be carefully weighted with the potential loss of health-care workers from the standpoint of reducing cumulative mortality due to COVID-19, in the absence of mitigating measures.\nNone.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 289, "name": "Bayham J"}], "publication_date": "2020-04-07"}, {"id": 400, "slug": "multicenter-analysis-of-clinical-characteristics-and-outcome-of-covid-19-patient", "title": "Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier les caract\u00e9ristiques cliniques et le devenir des patients COVID-19 avec une atteinte h\u00e9patique.", "verbose_date": "21.04.2020", "authors": "Qi X", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 19, "name": "H\u00e9pato-gastro-ent\u00e9rologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 169, "name": "J Hepatology"}, "link": "https://www.journal-of-hepatology.eu/article/S0168-8278(20)30222-1/pdf", "findings": "", "take_away": "", "relevance_level": "Dans cette cohorte, 32 patients / 70 (455,7%) avaient une anomalie du bilan h\u00e9patique \u00e0 l'admission. Le d\u00e9lai entre le d\u00e9but de la maladie et l'admission \u00e9tait corr\u00e9l\u00e9 avec le risque de l\u00e9sion h\u00e9patique. La dur\u00e9e d'hospitalisation n'\u00e9tait pas diff\u00e9rente entre les patients avec atteinte h\u00e9patique \u00e0 l'admission et ceux sans.", "objectives": "1) Pre-proof & lettre \u00e0 l'\u00e9diteur2) Etude de cohorte multicentrique, n=70 dont 32 avec atteinte h\u00e9patique3) Uniquement biologie h\u00e9patique \u00e0 l'admission d\u00e9crite4) Crit\u00e8res d'inclusion et d'exclusion non d\u00e9taill\u00e9s5) Atteinte h\u00e9patique d\u00e9finie comme toute \u00e9l\u00e9vation des ASAT, ALAT ou bilirubine totale sup\u00e9rieure \u00e0 la normale \u00e0 l'admission6) Pas d'analyse prenant en compte le  traitement antiviral \"", "methods": "Etudier les caract\u00e9ristiques cliniques et le devenir des patients COVID-19 avec une atteinte h\u00e9patique.", "topics": ["Epid\u00e9miologique", "Transversale", "H\u00e9pato-gastro-ent\u00e9rologie"], "author_list": [{"id": 383, "name": "Qi X"}], "publication_date": "2020-04-21"}, {"id": 524, "slug": "contact-tracing-assessment-of-covid-19-transmission-dynamics-in-taiwan-and-risk-", "title": "Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9limiter la dynamique de transmission de COVID-19, \u00e9valuer le risque d\u2019infection \u00e0 diff\u00e9rentes fen\u00eatres d\u2019exposition et estimer la p\u00e9riode infectieuse.", "verbose_date": "04.05.2020", "authors": "Cheng HY", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 207, "name": "JAMA Intern Med"}, "link": "https://www.dropbox.com/s/lhokiw54pjpq2bj/10.1001%40jamainternmed.2020.2020.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Compte tenu de la contagiosit\u00e9 du virus avant l\u2019apparition des premiers sympt\u00f4mes, et des r\u00e9sultats sur le faible \u00e9cart dans le TACS entre les patients n\u2019ayant aucun contact post-sympt\u00f4me et ceux en ayant, les auteurs concluent que les mesures de quarantaine, m\u00eame coupl\u00e9es au contact tracing, ne seront pas suffisantes pour endiguer l\u2019\u00e9pid\u00e9mie et que des mesures d\u2019\u00e9loignement social seront n\u00e9cessaires.", "objectives": "Le contact tracing par enqu\u00eate, en particulier avant l\u2019apparition des sympt\u00f4mes est, par nature,non exhaustif. De plus, le choix des 4 jours avant l\u2019apparition de sympt\u00f4mes, bien qu\u2019en accord avec les recommandations de l\u2019OMS, est arbitraire et ne permet pas d\u2019observer les contaminations potentielles ant\u00e9rieures.Par ailleurs, on peut se demander si le nombre important d\u2019infections secondaires survenant rapidement n\u2019est pas fortement li\u00e9 au fait que ces contacts sont \u00e9galement des  contacts proches au sein du m\u00e9nage.Enfin, le fait que parmi les personnes en contact rapproch\u00e9, seuls ceux pr\u00e9sentant des sympt\u00f4mes ont b\u00e9n\u00e9fici\u00e9 d\u2019un test par PCR, dois inciter \u00e0 la prudence quant aux interpr\u00e9tations sur le nombre de personnes contamin\u00e9es secondairement.", "methods": "D\u00e9limiter la dynamique de transmission de COVID-19, \u00e9valuer le risque d\u2019infection \u00e0 diff\u00e9rentes fen\u00eatres d\u2019exposition et estimer la p\u00e9riode infectieuse.", "pubmed_id": "32356867\n32125371\n32091533\n32235945\n28418738\n31986264\n26679623\n32113824\n27090992\n32074416\n12766207\n32121356\n31995857\n32027631\n32125269\n31992387\n32129805\n31978945\n32119825\n32109372\n18064739\n32105638\n32145466\n32222336\n32074444\n32031570", "doi": "10.1001/jamainternmed.2020.2020", "abstract": "The dynamics of coronavirus disease 2019 (COVID-19) transmissibility are yet to be fully understood. Better understanding of the transmission dynamics is important for the development and evaluation of effective control policies.\nTo delineate the transmission dynamics of COVID-19 and evaluate the transmission risk at different exposure window periods before and after symptom onset.\nThis prospective case-ascertained study in Taiwan included laboratory-confirmed cases of COVID-19 and their contacts. The study period was from January 15 to March 18, 2020. All close contacts were quarantined at home for 14 days after their last exposure to the index case. During the quarantine period, any relevant symptoms (fever, cough, or other respiratory symptoms) of contacts triggered a COVID-19 test. The final follow-up date was April 2, 2020.\nSecondary clinical attack rate (considering symptomatic cases only) for different exposure time windows of the index cases and for different exposure settings (such as household, family, and health care).\nWe enrolled 100 confirmed patients, with a median age of 44 years (range, 11-88 years), including 56 men and 44 women. Among their 2761 close contacts, there were 22 paired index-secondary cases. The overall secondary clinical attack rate was 0.7% (95% CI, 0.4%-1.0%). The attack rate was higher among the 1818 contacts whose exposure to index cases started within 5 days of symptom onset (1.0% [95% CI, 0.6%-1.6%]) compared with those who were exposed later (0 cases from 852 contacts; 95% CI, 0%-0.4%). The 299 contacts with exclusive presymptomatic exposures were also at risk (attack rate, 0.7% [95% CI, 0.2%-2.4%]). The attack rate was higher among household (4.6% [95% CI, 2.3%-9.3%]) and nonhousehold (5.3% [95% CI, 2.1%-12.8%]) family contacts than that in health care or other settings. The attack rates were higher among those aged 40 to 59 years (1.1% [95% CI, 0.6%-2.1%]) and those aged 60 years and older (0.9% [95% CI, 0.3%-2.6%]).\nIn this study, high transmissibility of COVID-19 before and immediately after symptom onset suggests that finding and isolating symptomatic patients alone may not suffice to contain the epidemic, and more generalized measures may be required, such as social distancing.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 490, "name": "Cheng HY"}], "publication_date": "2020-05-04"}, {"id": 374, "slug": "amiodarone-as-a-possible-therapy-for-coronavirus-infection", "title": "Amiodarone as a possible therapy for coronavirus infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Explorer l'impact potentielle de l'amiodarone dans l'infection \u00e0 COVID-19", "verbose_date": "18.04.2020", "authors": "Aimo A", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 159, "name": "Eur J Prev Cardiol"}, "link": "https://journals.sagepub.com/doi/pdf/10.1177/2047487320919233", "findings": "", "take_away": "", "relevance_level": "Description d'une possible action antivirale de l'amiodarone pour lutter contre l'infection SARS-CoV-2 en bloquant l'entr\u00e9e du virus et en limitant sa propagation, via notamment le blocage de la fusion endosome/lysosome. Le mat\u00e9riel g\u00e9n\u00e9tique ne peut ainsi \u00eatre int\u00e9gr\u00e9 \u00e0 celui de la cellule.\r\nEtude \u00e0 r\u00e9aliser sur le virus SARS-CoV-2 in vivo pour confirmer cette piste th\u00e9rapeutique.", "objectives": "- Etude pharmacodynamique de l'amiodarone contre les infections virales sans exp\u00e9rimentations r\u00e9alis\u00e9es- Bas\u00e9 sur une revue narrative de la litt\u00e9rature concernant d'autres virus dont Ebola et le virus SARS-CoV-1\"", "methods": "Explorer l'impact potentielle de l'amiodarone dans l'infection \u00e0 COVID-19", "pubmed_id": "32295404", "doi": "10.1177/2047487320919233", "abstract": null, "topics": ["Th\u00e9rapeutique", "Transversale", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 361, "name": "Aimo A"}], "publication_date": "2020-04-18"}, {"id": 332, "slug": "no-evidence-of-clinical-efficacy-of-hydroxychloroquine-in-patients-hospitalized-", "title": "No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluation de l'effet de l'hydroxychloroquine sur une cohorte de patients hospitalis\u00e9s pour COVID-19 sous oxyh\u00e9noth\u00e9rapie ", "verbose_date": "15.04.2020", "authors": "Mahevas M", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.10.20060699v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Le traitement par hydroxychloroquine chez des patients COVID sous oxyg\u00e9noth\u00e9rapie ne semble pas avoir d'effet positif significatif sur l'\u00e9volution de la maladie (transfert en r\u00e9animation), sur l'apparition d'un SDRA ou sur la mortalit\u00e9 dans cette \u00e9tude observationnelle fran\u00e7aise.\r\nPar ailleurs, plusieurs cas de trouble du rythme ayant n\u00e9cessit\u00e9 l'arr\u00eat du traitement sont \u00e0 d\u00e9plorer. Il n'y a donc toujours\u00a0pas de preuve scientifique pour l'utilisation de l'hydroxychloroquine chez des patients COVID-19", "objectives": "- Analyse statistique robuste avec score de propension bien r\u00e9alis\u00e9 et plusieurs analyses de sensibilit\u00e9- Ne remplace toutefois pas un essai contr\u00f4l\u00e9 randomis\u00e9 mais s'en rapproche- Utilisation de donn\u00e9es r\u00e9elles pragmatiques- Comparabilit\u00e9 entre les groupes n'est pas parfaite : comorbidit\u00e9s moins pr\u00e9sentes dans le gorupe hydroxychloroquine- Pas de calcul de nombre de sujets n\u00e9cessaire, l'\u00e9tude manque s\u00fbrement de puissance", "methods": "Evaluation de l'effet de l'hydroxychloroquine sur une cohorte de patients hospitalis\u00e9s pour COVID-19 sous oxyh\u00e9noth\u00e9rapie", "topics": ["Th\u00e9rapeutique", "Transversale", "Virologie", "Infectiologie", "Pneumologie"], "author_list": [{"id": 319, "name": "Mahevas M"}], "publication_date": "2020-04-15"}, {"id": 550, "slug": "epidemiology-of-and-risk-factors-for-coronavirus-infection-in-health-care-worker", "title": "Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers: A Living Rapid Review", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Examiner l'implication du personnel de sant\u00e9 dans l'infection par SRAS-CoV-2 et les facteurs de risque associ\u00e9s.", "verbose_date": "07.05.2020", "authors": "Chou R", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 41, "name": "Ann Intern Med"}, "link": "https://annals.org/aim/fullarticle/2765801/epidemiology-risk-factors-coronavirus-infection-health-care-workers-living-rapid", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude montre que les travailleurs de\u00a0sant\u00e9 ont une incidence d'infection plus \u00e9lev\u00e9e que la population g\u00e9n\u00e9rale, mais des sympt\u00f4mes moins graves (qui pourraient \u00eatre li\u00e9s \u00e0 un \u00e2ge plus jeune et \u00e0 des comorbidit\u00e9s r\u00e9duites).\u00a0\nLes exp\u00e9riences de d\u00e9pression, d'anxi\u00e9t\u00e9 g\u00e9n\u00e9ralis\u00e9e et de stress psychologique sont courantes chez les professionnels de sant\u00e9 en contact avec des patients atteints de COVID-19, comme cela a \u00e9t\u00e9 constat\u00e9 pr\u00e9c\u00e9demment avec le SRAS-CoV.\nDes preuves ont \u00e9t\u00e9 \u00e9tablies entre l'utilisation correcte des EPI et la r\u00e9duction de l'incidence de l'infection ainsi que l'association entre l'exposition aux liquides biologiques des patients infect\u00e9s/intubation endotrach\u00e9ale et un risque accru d'infection.", "objectives": "Interm\u00e9diaire:1) Revue de la litt\u00e9rature non syst\u00e9matique2) Contraintes m\u00e9thodologiques 3) L'incertitude quant \u00e0 savoir si les donn\u00e9es du SRAS-CoV et du MERS-CoV peuvent \u00eatre appliqu\u00e9es au SRAS-CoV-24) La plupart des informations relatives \u00e0 Chine doivent \u00eatre examin\u00e9es dans d'autres contextes", "methods": "Examiner l'implication du personnel de sant\u00e9 dans l'infection par SRAS-CoV-2 et les facteurs de risque associ\u00e9s.", "topics": ["Epid\u00e9miologique", "Transversale", "Hygi\u00e8ne"], "author_list": [{"id": 515, "name": "Chou R"}], "publication_date": "2020-05-07"}, {"id": 566, "slug": "prognostic-value-of-leukocytosis-and-lymphopenia-for-coronavirus-disease-severit", "title": "Prognostic Value of Leukocytosis and Lymphopenia for Coronavirus Disease Severity", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluation de la valeur prognostique de la lymphop\u00e9nie et leucocytose sur les infections \u00e0 SARS-CoV-2.", "verbose_date": "11.05.2020", "authors": "Huang G", "specialties": [{"id": 15, "name": "H\u00e9matologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 225, "name": "EID"}, "link": "https://doi.org/10.3201/eid2608.201160", "findings": "", "take_away": "", "relevance_level": "La s\u00e9v\u00e9rit\u00e9 de l'infection \u00e0 SARS-CoV-2 semble corr\u00e9l\u00e9e \u00e0 la lymphop\u00e9nie / leucocytose. Le m\u00e9canisme de ce lien reste inconnu.", "objectives": "- M\u00e9ta analyse bien men\u00e9e portant sur 8 articles et regroupant 1289 cas.- H\u00e9t\u00e9rog\u00e9nicit\u00e9 de la d\u00e9finition de la s\u00e9v\u00e9rit\u00e9- H\u00e9t\u00e9rog\u00e9nicit\u00e9 des donn\u00e9es de lymphop\u00e9nie/leucocytose entre les \u00e9tudes (possiblement du \u00e0 leurs faible effectif)", "methods": "Evaluation de la valeur prognostique de la lymphop\u00e9nie et leucocytose sur les infections \u00e0 SARS-CoV-2.", "pubmed_id": "32384045", "doi": "10.3201/eid2608.201160", "abstract": "To evaluate lymphopenia as a marker for coronavirus disease severity, we conducted a meta-analysis of 10 studies. Severe illness was associated with lower lymphocyte and higher leukocyte counts. Using these markers for early identification of patients with severe disease may help healthcare providers prioritize the need to obtain therapy.", "topics": ["Pronostique", "H\u00e9matologie"], "author_list": [{"id": 531, "name": "Huang G"}], "publication_date": "2020-05-11"}, {"id": 359, "slug": "ct-image-visual-quantitative-evaluation-and-clinical-classification-of-coronavir", "title": "CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19)", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Explorer la relation entre les manifestations radiologiques et la classification clinique du COVID-19", "verbose_date": "16.03.2020", "authors": "Kunwei Li", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 155, "name": "Eur Radiol"}, "link": "https://www.dropbox.com/s/64vgp9e4ftmoflk/Li2020_Article_CTImageVisualQuantitativeEvalu.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le scanner n'est pas une m\u00e9thode fiable de d\u00e9pistage car plus de 30% des cas positifs n'ont pas de signes radiologiques.\r\nLes auteurs proposent un score de s\u00e9v\u00e9rit\u00e9 pour quantifier l'atteinte pulmonaire au scanner qui se r\u00e9v\u00e8le fiable (tr\u00e8s bonne reproductibilit\u00e9) et sp\u00e9cifique (Sp=100%) au seuil de 100% pour le diagnostic des cas s\u00e9v\u00e8res. Ce score pourrait donc \u00eatre int\u00e9ressant pour diff\u00e9rencier radiologiquement les cas s\u00e9v\u00e8res des autres cas (\u00e0 confirmer sur une plus large \u00e9tude).", "objectives": "- Cohorte chinoise monocentrique r\u00e9trospective avec peu d'effectif, surtout dans la cat\u00e9gorie des patients s\u00e9v\u00e8res (n=8)- Classification des patients en 3 groupes assez arbitraires- Repr\u00e9sentativit\u00e9 de l'\u00e9chantillon remise en doute (majorit\u00e9 de femmes, moyenne d'\u00e2ge de 60 ans et peu de comorbidit\u00e9s)\"", "methods": "Explorer la relation entre les manifestations radiologiques et la classification clinique du COVID-19", "pubmed_id": "32215691\n12376607\n14990845\n18195376\n29757717", "doi": "10.1007/s00330-020-06817-6", "abstract": "To explore the relationship between the imaging manifestations and clinical classification of COVID-19.\nWe conducted a retrospective single-center study on patients with COVID-19 from Jan. 18, 2020 to Feb. 7, 2020 in Zhuhai, China. Patients were divided into 3 types based on Chinese guideline: mild (patients with minimal symptoms and negative CT findings), common, and severe-critical (patients with positive CT findings and different extent of clinical manifestations). CT visual quantitative evaluation was based on summing up the acute lung inflammatory lesions involving each lobe, which was scored as 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%), or 4 (76-100%), respectively. The total severity score (TSS) was reached by summing the five lobe scores. The consistency of two observers was evaluated. The TSS was compared with the clinical classification. ROC was used to test the diagnosis ability of TSS for severe-critical type.\nThis study included 78 patients, 38 males and 40 females. There were 24 mild (30.8%), 46 common (59.0%), and 8 severe-critical (10.2%) cases, respectively. The median TSS of severe-critical-type group was significantly higher than common type (p\u00a0<\u20090.001). The ICC value of the two observers was 0.976 (95% CI 0.962-0.985). ROC analysis showed the area under the curve (AUC) of TSS for diagnosing severe-critical type was 0.918. The TSS cutoff of 7.5 had 82.6% sensitivity and 100% specificity.\nThe proportion of clinical mild-type patients with COVID-19 was relatively high; CT was not suitable for independent screening tool. The CT visual quantitative analysis has high consistency and can reflect the clinical classification of COVID-19.\n\u2022 CT visual quantitative evaluation has high consistency (ICC value of 0.976) among the observers. The median TSS of severe-critical type group was significantly higher than common type (p\u2009<\u20090.001). \u2022 ROC analysis showed the area under the curve (AUC) of TSS for diagnosing severe-critical type was 0.918 (95% CI 0.843-0.994). The TSS cutoff of 7.5 had 82.6% sensitivity and 100% specificity. \u2022 The proportion of confirmed COVID-19 patients with normal chest CT was relatively high (30.8%); CT was not a suitable screening modality.", "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 346, "name": "Kunwei Li"}], "publication_date": "2020-03-16"}, {"id": 382, "slug": "clinical-characteristics-and-prognosis-in-cancer-patients-with-covid-19-a-single", "title": "Clinical Characteristics and Prognosis in Cancer Patients with COVID-19: a Single Center's Retrospective Study", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques d\u00e9mographiques et cliniques ainsi que le pronostic de l'infection chez les patients COVID-19 atteints de cancer", "verbose_date": "19.04.2020", "authors": "Ma J", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.journalofinfection.com/article/S0163-4453(20)30214-0/pdf", "findings": "", "take_away": "", "relevance_level": "Il semble que de nombreux patients avec ant\u00e9c\u00e9dent de cancer hospitalis\u00e9s pour COVID-19 \u00e9voluent vers une forme s\u00e9v\u00e8re voire critique. D'apr\u00e8s ces donn\u00e9es, un traitement pour le cancer dans le mois pr\u00e9c\u00e9dent n'y est pas associ\u00e9. Plusieurs param\u00e8tres biologiques sont plus \u00e9lev\u00e9s dans les formes s\u00e9v\u00e8res. Ces r\u00e9sultats sont \u00e0 explorer avec des \u00e9tudes un niveau de preuve.", "objectives": "- pr\u00e9-proof- peu de d\u00e9tails sur les crit\u00e8res d'inclusion ou d'exclusion : patients en cours de traitement pour un cancer? ou r\u00e9cemment trait\u00e9s?- faible effectif", "methods": "D\u00e9crire les caract\u00e9ristiques d\u00e9mographiques et cliniques ainsi que le pronostic de l'infection chez les patients COVID-19 atteints de cancer", "pubmed_id": "32298677\n32164623", "doi": "10.1016/j.jinf.2020.04.006", "abstract": null, "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 368, "name": "Ma J"}], "publication_date": "2020-04-19"}, {"id": 226, "slug": "nervous-system-involvement-after-infection-with-covid-19-and-other-coronaviruses", "title": "Nervous System Involvement After Infection With COVID-19 and Other Coronaviruses", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier les recherches sur les complications neurologiques des infections \u00e0 coronavirus et sur les m\u00e9canismes possibles.", "verbose_date": "02.04.2020", "authors": "Wu Y ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 109, "name": "Brain Behav Immun"}, "link": "https://www.dropbox.com/s/044osu8xj99kivi/1-s2.0-S0889159120303573-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les coronavirus ont des effets neurologiques, la plupart pourrait \u00eatre caus\u00e9s par un effet direct du virus.\r\nM\u00e9canismes d'atteintes multiples", "objectives": "1) Pre-proof2) Revue non syst\u00e9matique de la litt\u00e9rature, m\u00e9thodologie de recherche non expliqu\u00e9e", "methods": "Etudier les recherches sur les complications neurologiques des infections \u00e0 coronavirus et sur les m\u00e9canismes possibles.", "pubmed_id": "32240762", "doi": "10.1016/j.bbi.2020.03.031", "abstract": "Viral infections have detrimental impacts on neurological functions, and even to cause severe neurological damage. Very recently, coronaviruses (CoV), especially severe acute respiratory syndrome CoV 2 (SARS-CoV-2), exhibit neurotropic properties and may also cause neurological diseases. It is reported that CoV can be found in the brain or cerebrospinal fluid. The pathobiology of these neuroinvasive viruses is still incompletely known, and it is therefore important to explore the impact of CoV infections on the nervous system. Here, we review the research into neurological complications in CoV infections and the possible mechanisms of damage to the nervous system.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 140, "name": "Wu Y "}], "publication_date": "2020-04-02"}, {"id": 378, "slug": "a-longitudinal-study-on-the-mental-health-of-general-population-during-the-covid", "title": "A Longitudinal Study on the Mental Health of General Population during the COVID-19 Epidemic in China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'impact psychologique temporel et l'\u00e9tat de sant\u00e9 mentale d\u00e9favorable pendant l'\u00e9pid\u00e9mie initiale et le pic de l'\u00e9pid\u00e9mie de COVID-19, ainsi que le risque identitaire et les facteurs de protection au sein de la population g\u00e9n\u00e9rale en Chine.", "verbose_date": "18.04.2020", "authors": "Wang C", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 109, "name": "Brain Behav Immun"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0889159120305110?token=6DEE3D192B2C1EF9B595FFFC85BFC0CD3BAD3B6C4FA87363D0C3979F14007CF6149D0992D57224E3A1E425AD348D0620", "findings": "", "take_away": "", "relevance_level": "Les diff\u00e9rents gouvernements devraient se concentrer sur des m\u00e9thodes efficaces de diffusion de connaissances impartiales sur la maladie, enseigner des m\u00e9thodes correctes de confinement, assurer la disponibilit\u00e9 des services et des produits essentiels, fournir un soutien financier suffisant pour le pr\u00e9sent et l'avenir.", "objectives": "-\t\u00c9tude longitudinale prospective-\tLa population g\u00e9n\u00e9rale \u00e9chantillonn\u00e9e lors des deux enqu\u00eates n'\u00e9tait pas la m\u00eame-\tL'auto-\u00e9valuation des niveaux d'impact psychologique, d'anxi\u00e9t\u00e9, de d\u00e9pression et de stress-\tOn ne peut pas exclure la possibilit\u00e9 que certaines des personnes interrog\u00e9es aient \u00e9t\u00e9 infect\u00e9es par le COVID-19 et aient pr\u00e9sent\u00e9 de l\u00e9gers sympt\u00f4mes de COVID-19-\tLa compr\u00e9hension du COVID-19 \u00e9tait limit\u00e9e lorsque nous avons con\u00e7u cette \u00e9tude (les sympt\u00f4mes neurologiques n'ont pas \u00e9t\u00e9 mesur\u00e9s)", "methods": "Evaluer l'impact psychologique temporel et l'\u00e9tat de sant\u00e9 mentale d\u00e9favorable pendant l'\u00e9pid\u00e9mie initiale et le pic de l'\u00e9pid\u00e9mie de COVID-19, ainsi que le risque identitaire et les facteurs de protection au sein de la population g\u00e9n\u00e9rale en Chine.", "pubmed_id": "32298802", "doi": "10.1016/j.bbi.2020.04.028", "abstract": "In addition to being a public physical health emergency, Coronavirus disease 2019 (COVID-19) affected global mental health, as evidenced by panic-buying worldwide as cases soared. Little is known about changes in levels of psychological impact, stress, anxiety and depression during this pandemic. This longitudinal study surveyed the general population twice - during the initial outbreak, and the epidemic's peak four weeks later, surveying demographics, symptoms, knowledge, concerns, and precautionary measures against COVID-19. There were 1738 respondents from 190 Chinese cities (1210 first-survey respondents, 861\u00a0s-survey respondents; 333 respondents participated in both). Psychological impact and mental health status were assessed by the Impact of Event Scale-Revised (IES-R) and the Depression, Anxiety and Stress Scale (DASS-21), respectively. IES-R measures PTSD symptoms in survivorship after an event. DASS -21 is based on tripartite model of psychopathology that comprise a general distress construct with distinct characteristics. This study found that there was a statistically significant longitudinal reduction in mean IES-R scores (from 32.98 to 30.76, p\u00a0<\u00a00.01) after 4\u00a0weeks. Nevertheless, the mean IES-R score of the first- and second-survey respondents were above the cut-off scores (>24) for PTSD symptoms, suggesting that the reduction in scores was not clinically significant. During the initial evaluation, moderate-to-severe stress, anxiety and depression were noted in 8.1%, 28.8% and 16.5%, respectively and there were no significant longitudinal changes in stress, anxiety and depression levels (p\u00a0>\u00a00.05). Protective factors included high level of confidence in doctors, perceived survival likelihood and low risk of contracting COVID-19, satisfaction with health information, personal precautionary measures. As countries around the world brace for an escalation in cases, Governments should focus on effective methods of disseminating unbiased COVID-19 knowledge, teaching correct containment methods, ensuring availability of essential services/commodities, and providing sufficient financial support.", "topics": ["Epid\u00e9miologique", "Psychiatrie"], "author_list": [{"id": 365, "name": "Wang C"}], "publication_date": "2020-04-18"}, {"id": 100, "slug": "covid-19-ecmo-and-lymphopenia-a-word-of-caution", "title": "COVID-19, ECMO, and lymphopenia: a word of caution", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Expliquer lien entre ECMO - taux lymphocytes, taux d'IL 6 et survie COVID", "verbose_date": "13.03.2020", "authors": "Henry BM", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 1, "name": "Lancet Repir Med"}, "link": "https://www.dropbox.com/s/m4rlafn0bldx4rr/PIIS2213260020301193.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les patients qui meurent du COVID19 pr\u00e9sentent un taux significativement inf\u00e9rieur de lymphocytes que les survivants.Sous ECMO, les taux d'IL-6 sont constamment \u00e9lev\u00e9s et inversement corr\u00e9l\u00e9s \u00e0 la survie chez les enfants et adultes. Ceux qui survivent \u00e0 l'ECMO sont capables de normaliser leur concentration d'IL-6 alors que ceux qui ne survivent pas pr\u00e9sentent des taux IL-6 \u00e9lev\u00e9s.Les cliniciens devraient consid\u00e9rer le compte de lymphocytes et d'IL-6 pendant l'ECMO pour suivre les patients et leur prognostic.Hypothese : la r\u00e9pl\u00e9tion des lymphocytes pourrait \u00eatre une cl\u00e9 pour gu\u00e9rir du COVID19, le compte de lymphocytes devrait \u00eatre suivi de pr\u00e8s chez les patients sous ECMO", "objectives": "Faible : 1) lettre \u00e0 l'\u00e9diteur", "methods": "Expliquer lien entre ECMO - taux lymphocytes, taux d'IL 6 et survie COVID", "pubmed_id": "32178774", "doi": "10.1016/S2213-2600(20)30119-3", "abstract": null, "topics": ["Pronostique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 106, "name": "Henry BM"}], "publication_date": "2020-03-13"}, {"id": 632, "slug": "individual-variation-in-susceptibility-or-exposure-to-sars-cov-2-lowers-the-herd", "title": "Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Quel est l'effet de l'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 de la population sur le seuil \u00e0 partir duquel l'immunit\u00e9 de groupe est atteinte ?", "verbose_date": "25.05.2020", "authors": "Gomes MGM", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 21, "name": "Confinement/D\u00e9confinement"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.27.20081893v3.full.pdf", "findings": "", "take_away": "", "relevance_level": "Quand on prend en compte l'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 de la population en termes de susceptibilit\u00e9, ou (infectivit\u00e9 et susceptibilit\u00e9), l'immunit\u00e9 de groupe est atteinte apr\u00e8s l'infection d'une proportion plus faible de la population que dans un mod\u00e8le homog\u00e8ne.", "objectives": "Le mod\u00e8le est un peu simpliste et la pr\u00e9sentation manque de rigueur. Il y a des coquilles (1/N en trop) dans  le calcul de R0. Les sources des donn\u00e9es ne sont pas pr\u00e9cis\u00e9es. Le code n'est pas fourni et il n'est pas possible de reproduire les r\u00e9sultats. On peut critiquer la forme de la force d'infection choisie dans la version du mod\u00e8le o\u00f9 infectivit\u00e9 et susceptibilit\u00e9 varient.", "methods": "Quel est l'effet de l'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 de la population sur le seuil \u00e0 partir duquel l'immunit\u00e9 de groupe est atteinte ?", "pubmed_id": "32511451", "doi": "10.1101/2020.04.27.20081893", "abstract": "As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads, the susceptible subpopulation is depleted causing the incidence of new cases to decline. Variation in individual susceptibility or exposure to infection exacerbates this effect. Individuals that are more susceptible or more exposed tend to be infected earlier, depleting the susceptible subpopulation of those who are at higher risk of infection. This selective depletion of susceptibles intensifies the deceleration in incidence. Eventually, susceptible numbers become low enough to prevent epidemic growth or, in other words, the herd immunity threshold (HIT) is reached. Although estimates vary, simple calculations suggest that herd immunity to SARS-CoV-2 requires 60-70% of the population to be immune. By fitting epidemiological models that allow for heterogeneity to SARS-CoV-2 outbreaks across the globe, we show that variation in susceptibility or exposure to infection reduces these estimates. Accurate measurements of heterogeneity are therefore of paramount importance in controlling the COVID-19 pandemic.", "topics": ["Mod\u00e9lisation", "Immunit\u00e9", "Confinement/D\u00e9confinement"], "author_list": [{"id": 595, "name": "Gomes MGM"}], "publication_date": "2020-05-25"}, {"id": 258, "slug": "potential-harmful-effects-of-discontinuing-ace-inhibitors-and-arbs-in-covid-19-p", "title": "Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Discuter l'effet d'un traitement par ARB ou ACEi discontinu", "verbose_date": "07.04.2020", "authors": "Rossi GP", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 124, "name": "Elife"}, "link": "https://www.dropbox.com/s/c9fm9ueysb8cxi6/elife-57278-v1.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le virus se lie aux enzymes ACE2, tr\u00e8s exprim\u00e9es dans les voies respiratoires inf\u00e9rieures. Les nouvelles ont par la suite annonc\u00e9 que les ACE inhibiteurs (ACEi) et les bloqueurs de r\u00e9cepteurs de l'angiotensine (ARB) pourraient \u00eatre dangereux chez les patients infect\u00e9s. Au contraire des preuves montrent que la voie ACE1/angiotensine 2/ATR1 est impliqu\u00e9 dans le SDRA provoqu\u00e9 par le virus, alors que la voie ACE2/angiotensine1\u00e07/ATR2/MasR et contrecarrent ainsi les actions n\u00e9fastes de l'angiotensine II dans le poumon.\u00a0\r\nUn ratio ACE1/ACE2 r\u00e9duit est une caract\u00e9ristique du SDRA qui peut etre r\u00e9duit par l'ACE2 recombinante humaine et l'administration d'angiotensine 1 \u00e0 7, pr\u00e9venant les l\u00e9sions pulmonaires caus\u00e9es par le SARS-CoV-2.\r\nLes ACEi et ARB permettent une protection cardiovasculaire et r\u00e9nale chez les patients diagnostiqu\u00e9s COVID19. Discontinuer ces traitements peut \u00eatre dangereux dans cette population.", "objectives": "- Revue narrative de la litt\u00e9rature - pas de m\u00e9thodo", "methods": "Discuter l'effet d'un traitement par ARB ou ACEi discontinu", "pubmed_id": "32250244\n25641619\n32117569\n32179701\n15141377\n27550352\n16001071\n22009550\n18448662\n23845795\n16908757\n32142651\n32139904\n32227760\n32015507\n32075877\n29288933\n15671045\n32208987\n24227843\n12459472\n22786934\n32212540\n31278346\n28619367\n21756232\n16581295\n25391767\n15007027\n32125455\n22929610\n28877748\n16282461\n22983755\n32009228\n16007097\n32171062\n32203970\n27343405\n24168260", "doi": "10.7554/eLife.57278", "abstract": "The discovery of angiotensin converting enzyme-2 (ACE-2) as the receptor for SARS- CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) has implicated the renin-angiotensin-aldosterone system in acute respiratory distress syndrome (ARDS) and respiratory failure in patients with coronavirus disease-19 (COVID-19). The angiotensin converting enzyme-1-angiotensin II-angiotensin AT", "topics": ["Th\u00e9rapeutique", "Transversale", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 247, "name": "Rossi GP"}], "publication_date": "2020-04-07"}, {"id": 214, "slug": "coincidence-of-covid-19-epidemic-and-olfactory-dysfunction-outbreak", "title": "Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluation du lien entre COVID-19 et anosmie/hyposmie", "verbose_date": "31.03.2020", "authors": "Bagheri SHR ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/ffxmsaejpvoywx1/2020.03.23.20041889v1.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Possible lien entre COVID-19 et anosmie/hyposmie\r\n- Pas de donn\u00e9e dans cette \u00e9tude sur le statut COVID-19 des patients atteints d'anosmie\r\n- Nombreux biais\r\n- R\u00e9sultats coh\u00e9rent avec le fait que l'infection virale des voies respiratoire haute est une des premi\u00e8res causes d'anosmie", "objectives": "\"Attention pre-prints- Questionnaire rempli par les patients- Recrutement bas\u00e9 sur le volontariat- Aucune id\u00e9e du statut COVID-19 des patients pr\u00e9sentant une anosmie- Pas de prise en compte du nombre d'habitant par province (facteur de confusion)- Possible biais de m\u00e9morisation\"", "methods": "Evaluation du lien entre COVID-19 et anosmie/hyposmie", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 205, "name": "Bagheri SHR "}], "publication_date": "2020-03-31"}, {"id": 389, "slug": "suppressed-t-cell-mediated-immunity-in-patients-with-covid-19-a-clinical-retrosp", "title": "Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etude du lien entre les modifications des sous populations de lymphocytes T au cours du infection \u00e0 SARS-CoV-2 et la gravit\u00e9 de la maladie", "verbose_date": "20.04.2020", "authors": "Bo X", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0163445320302231?token=A4D86BE835478E4EB08F535D1C50A8F34BB1BE105B3D4C1822C132250E03CFDB989D9597E29C176988A4E27AA134EF91", "findings": "", "take_away": "", "relevance_level": "- Diminution des sous populations de lymphocytes avec l'infection \u00e0 SARS-CoV-2 proportionnelle \u00e0 la s\u00e9v\u00e9rit\u00e9\r\n- Augmentation des SAA et de la CRP importante proportionnelle \u00e0 la s\u00e9v\u00e9rit\u00e9\r\n- Des niveaux bas de lymphocytes T, CD4+, CD3+, CD8+, et de lymphocytes B sont associ\u00e9s \u00e0 un sur risque de mortalit\u00e9", "objectives": "- Etude r\u00e9trospective- \u00c9tude monocentrique- Peu d'information sur les crit\u00e8res d'inclusion / exclusion- Multiplicit\u00e9 des tests statistiques- Pas de prise en compte des autres facteurs de risques\"", "methods": "Etude du lien entre les modifications des sous populations de lymphocytes T au cours du infection \u00e0 SARS-CoV-2 et la gravit\u00e9 de la maladie", "topics": ["Epid\u00e9miologique", "Immunit\u00e9", "Infectiologie"], "author_list": [{"id": 375, "name": "Bo X"}], "publication_date": "2020-04-20"}, {"id": 563, "slug": "a-comparison-study-of-sarscov2-igg-antibody-between-male-and-female-covid19-pati", "title": "A comparison study of SARS\u2010CoV\u20102 IgG antibody between male and female COVID\u201019 patients: a possible reason underlying different outcome between sex", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparer la diff\u00e9rence des anticorps IgG dirig\u00e9s contre le SARS-Cov-2 entre les hommes et les femmes. Au total, 331 patients infect\u00e9s ont \u00e9t\u00e9 inclus.", "verbose_date": "11.05.2020", "authors": "Zeng F", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://doi.org/10.1002/jmv.25989", "findings": "", "take_away": "", "relevance_level": "Les anticorps IgG de 331 patients dirig\u00e9s contre le SARS-Cov-2 ont \u00e9t\u00e9 d\u00e9tect\u00e9s et analys\u00e9s dans cette \u00e9tude. La plupart des femmes g\u00e9n\u00e8rent des taux \u00e9lev\u00e9s d'anticorps IgG suite \u00e0 une infection \u00e0 SARS-Cov-2 dans les \u00e9tats s\u00e9v\u00e8res. La production de ces anticorps chez les femmes est plus importante que chez les hommes dans la phase pr\u00e9coce de l'infection.\nIl est recommand\u00e9 d'\u00eatre vigilant quant aux patients qui ont des faibles taux d'anticorps IgG. Surveiller ces anticorps pourrait \u00eatre une m\u00e9thode potentielle pour pr\u00e9dire le pronostic du Covid-19.", "objectives": "Petit \u00e9chantillon.Peu ou pas de cas critiques enrol\u00e9s dans cette \u00e9tude.", "methods": "Comparer la diff\u00e9rence des anticorps IgG dirig\u00e9s contre le SARS-Cov-2 entre les hommes et les femmes. Au\u00a0total,\u00a0331 patients infect\u00e9s ont \u00e9t\u00e9 inclus.", "pubmed_id": "32383183\n31986261\n32147628\n32109013\n32164080\n32113510\n31502247\n32064853\n31986264\n32015508", "doi": "10.1002/jmv.25989", "abstract": "The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China at the end of 2019 has spread throughout the world and caused many thousands of deaths. The previous study reported a higher severe status rate and mortality rate in male patients in China. However, the reason underlying this difference has not been reported. The convalescent plasma containing a high level of SARS-CoV-2 immunoglobulin G (IgG) antibody has been used in clinical therapy and achieved good effects in China. In this study, to compare the differences of the SARS-CoV-2 IgG antibody between male and female patients, a total number of 331 patients confirmed SARS-CoV-2 infection were enrolled. The serum of these patients was collected during hospitalization and detected for the SARS-CoV-2 IgG antibody. Our data showed that the concentration of IgG antibody in mild, general, and recovering patients showed no difference between male and female patients. In severe status, compared with male patients, there were more female patients having a relatively high concentration of serum SARS-CoV-2 IgG antibody. In addition, the generation of IgG antibody in female patients was stronger than male patients in disease early phase. Our study identified a discrepancy in the SARS-CoV-2 IgG antibody level in male and female patients, which may be a potential cause leading to a different outcome of Coronavirus Disease 2019 between sex.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 528, "name": "Zeng F"}], "publication_date": "2020-05-11"}, {"id": 370, "slug": "successful-treatment-of-plasma-exchange-followed-by-intravenous-immunogloblin-in", "title": "Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9voquer la possible utilit\u00e9 des \u00e9changes plasmatiques et des IgIV chez les patients COVID-19 avec atteinte s\u00e9v\u00e8re de la maladie", "verbose_date": "18.04.2020", "authors": "Shi H", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 14, "name": "Int J Antimicrob Agents"}, "link": "https://reader.elsevier.com/reader/sd/pii/S092485792030131X?token=CF1B9496E9CFF280F978DD44738C6B0A12848F962E787465E01588FF8070122C3069E625FF272E6C72C39887F476B418", "findings": "", "take_away": "", "relevance_level": "Am\u00e9lioration significative et rapide de l'\u00e9tat clinique d'une patiente atteinte de COVID-19 class\u00e9e comme s\u00e9v\u00e8re (mais sans support ventilatoire invasif) apr\u00e8s 5 cures d\u2019 \u00e9changes plasmatiques et IgIV, sans effet secondaire objectiv\u00e9.\u00a0\r\nLe rationnel physiopathologique pourrait s'expliquer par la diminution de l\u2019orage cytokinique dans la course de la maladie.\r\nCe traitement pourrait-il permettre d'\u00e9viter le recours \u00e0 la ventilation m\u00e9canique chez les patients qui s'aggravent sur le plan respiratoire?", "objectives": "Case-report", "methods": "\u00c9voquer la possible utilit\u00e9 des \u00e9changes plasmatiques et des IgIV chez les patients COVID-19 avec atteinte s\u00e9v\u00e8re de la maladie", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 357, "name": "Shi H"}], "publication_date": "2020-04-18"}, {"id": 373, "slug": "ct-imaging-and-clinical-course-of-asymptomatic-cases-with-covid-19-pneumonia-at-", "title": "CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Caract\u00e9riser l'imagerie par tomodensitom\u00e9trie et l'\u00e9volution clinique des cas asymptomatiques de pneumonie COVID-19.", "verbose_date": "17.04.2020", "authors": "Meng H", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 3, "name": "Radiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 77, "name": "J infect"}, "link": "https://www.journalofinfection.com/article/S0163-4453(20)30211-5/pdf", "findings": "", "take_away": "", "relevance_level": "Les r\u00e9sultats ont indiqu\u00e9 que chez les patients asymptomatiques atteints de pneumonie COVID-19, avec l'\u00e9volution de la maladie, environ 25% des cas pr\u00e9sentent des sympt\u00f4mes, et l'\u00e9volution des l\u00e9sions \u00e0 la tomodensitom\u00e9trie a \u00e9t\u00e9 montr\u00e9e chez 17% des patients, dans le cadre du suivi \u00e0 court terme.\u00a0\r\nL'imagerie CT des cas asymptomatiques de pneumonie COVID-19 pr\u00e9sente des caract\u00e9ristiques bien d\u00e9finies. Les infections cach\u00e9es par le SARS-CoV-2 pourraient \u00eatre \u00e0 l'origine de nouveaux foyers (les patients asymptomatiques atteints de COVID-19 sont \"transmetteurs cach\u00e9s\"), et certains patients peuvent progresser rapidement \u00e0 court terme. Il est donc essentiel de pr\u00eater attention \u00e0 la surveillance des patients asymptomatiques atteints de COVID-19. La tomodensitom\u00e9trie est tr\u00e8s utile pour le d\u00e9pistage et la d\u00e9tection des patients atteints de pneumonie COVID-19, en particulier dans les cas asymptomatiques tr\u00e8s suspects avec test de l'acide nucl\u00e9ique du SARS-CoV-2 n\u00e9gatif.", "objectives": "-\tPr\u00e9-proof-\tEtude r\u00e9trospective, n=58", "methods": "Caract\u00e9riser l'imagerie par tomodensitom\u00e9trie et l'\u00e9volution clinique des cas asymptomatiques de pneumonie COVID-19.", "pubmed_id": "32294504", "doi": "10.1016/j.jinf.2020.04.004", "abstract": "Aimed to characterize the CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia.\nAsymptomatic cases with COVID-19 pneumonia confirmed by SARS-COV-2 nucleic acid testing in Renmin Hospital of Wuhan University were retrospectively enrolled. The characteristics of CT imaging and clinical feature were collected and analyzed.\n58 asymptomatic cases with COVID-19 pneumonia admitted to our hospital between Jan 1, 2020 and Feb 23, 2020 were enrolled. All patients had history of exposure to SARS-CoV-2. On admission, patients had no symptoms and laboratory findings were normal. The predominant feature of CT findings in this cohort was ground glass opacity (GGO) (55, 94.8%) with peripheral (44, 75.9%) distribution, unilateral location (34, 58.6%) and mostly involving one or two lobes (38, 65.5%), often accompanied by characteristic signs. After short-term follow-up, 16 patients (27.6%) presented symptoms with lower lymphocyte count and higher CRP, mainly including fever, cough and fatigue. The evolution of lesions on CT imaging were observed in 10 patients (17.2%). The average days of hospitalization was19.80\u00b110.82 days, and was significantly longer in progression patients (28.60\u00b17.55 day).\nCT imaging of asymptomatic cases with COVID-19 pneumonia has definite characteristics. Since asymptomatic infections as \"covert transmitter\", and some patients can progress rapidly in the short term. It is essential to pay attention to the surveillance of asymptomatic patients with COVID-19. CT scan has great value in screening and detecting patients with COVID-19 pneumonia, especially in the highly suspicious, asymptomatic cases with negative nucleic acid testing.", "topics": ["Epid\u00e9miologique", "Infectiologie", "Radiologie", "Pneumologie"], "author_list": [{"id": 360, "name": "Meng H"}], "publication_date": "2020-04-17"}, {"id": 186, "slug": "covid-19-face-masks-and-human-to-human-transmission", "title": "COVID-19 : Face Masks and Human-to-human Transmission", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Exposer le cas d'une personne COVID-19 ayant effectu\u00e9 2 trajets longs en bus dont l'un avec un masque et l'impact sur la transmission interhumaine", "verbose_date": "29.03.2020", "authors": "Liu X ", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 94, "name": "Influenza Other Respir Viruses"}, "link": "https://www.dropbox.com/s/3u1opnzq7e9cqoj/10.1111%40irv.12740.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "1 patient infect\u00e9 COVID-19 ayant effectu\u00e9 2 trajets en bus le m\u00eame jour (sans masque: 5 infect\u00e9s sur 39 passagers / masque: 0 infect\u00e9 sur 14 passagers)\r\nRecommandent le port d'un masque lors d'un trajet long en transport en commun avec 1 ou 2 masques de rechange lorsque celui-ci est d\u00e9form\u00e9 ou contamin\u00e9, d'\u00e9viter le trajet si toux ou fi\u00e8vre", "objectives": "1) Lettre \u00e0 l'\u00e9diteur mais dit avoir b\u00e9n\u00e9fici\u00e9 de full peer review2) Case review3) Peu de recul et de m\u00e9thodologie pour d\u00e9terminer les patients contamin\u00e9s par ce premier patient\"", "methods": "Exposer le cas d'une personne COVID-19 ayant effectu\u00e9 2 trajets longs en bus dont l'un avec un masque et l'impact sur la transmission interhumaine", "pubmed_id": "32223072\n19702582\n32043985\n21138542\n31986264\n25858901\n18042961\n31978945", "doi": "10.1111/irv.12740", "abstract": null, "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 134, "name": "Liu X "}], "publication_date": "2020-03-29"}, {"id": 510, "slug": "sex-specific-clinical-characteristics-and-prognosis-of-coronavirus-disease-19-in", "title": "Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Confirmer et explorer les m\u00e9canismes possibles des diff\u00e9rences entre les sexes dans les caract\u00e9ristiques cliniques des patients atteints de COVID-19.", "verbose_date": "02.05.2020", "authors": "Meng Y", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 203, "name": "PLoS Pathog"}, "link": "https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1008520&type=printable", "findings": "", "take_away": "", "relevance_level": "Les r\u00e9sultats mettent en \u00e9vidence des diff\u00e9rences sp\u00e9cifiques au sexe dans les caract\u00e9ristiques cliniques et le pronostic de COVID-19. On a \u00e9galement explor\u00e9 le m\u00e9canisme sous-jacent \u00e0 l'aide d'une analyse \u00e9pid\u00e9miologique. Six indicateurs de laboratoires candidats pr\u00e9sentant des diff\u00e9rences significatives entre les sexes ont \u00e9t\u00e9 consid\u00e9r\u00e9s comme des m\u00e9diateurs potentiels affectant le pronostic de COVID-19. La distribution des risques de COVID-19 en fonction de l'\u00e2ge a montr\u00e9 une corr\u00e9lation positive entre le pronostic et l'\u00e2ge/les comorbidit\u00e9s, qui \u00e9tait significativement influenc\u00e9e par le sexe. Le sexe est une variable biologique qui devrait \u00eatre prise en compte dans la pr\u00e9vention et la th\u00e9rapie du COVID-19. Des \u00e9tudes futures sont justifi\u00e9es pour \u00e9lucider les diff\u00e9rentes voies et r\u00e9ponses cellulaires entre les femmes et les hommes.", "objectives": "-\tUncorrected proof-\tEtude r\u00e9trospective monocentrique, qui incluait uniquement les patients hospitalis\u00e9s et excluait les patients asymptomatiques-\tSeuls les patients confirm\u00e9s ont \u00e9t\u00e9 inclus ; les patients suspects mais non diagnostiqu\u00e9s ont \u00e9t\u00e9 exclus-\tN=168", "methods": "Confirmer et explorer les m\u00e9canismes possibles des diff\u00e9rences entre les sexes dans les caract\u00e9ristiques cliniques des patients atteints de COVID-19.", "pubmed_id": "32343745\n32015507\n32007145\n32151334\n28373583\n27546235\n27352628\n32031570\n31986264\n32007143\n32105632\n32015508\n21953569\n31995857\n32077115\n32361250\n18192335\n32151335\n21829352\n14742282", "doi": "10.1371/journal.ppat.1008520", "abstract": "To confirm the relationship between sex and the progression of Coronavirus Disease-19 (COVID-19), and its potential mechanism, among severe patients. For this retrospective study, we included 168 consecutive severe patients with pathogen-confirmed COVID-19 who were hospitalized between January 16th and February 4th, 2020, at Tongji Hospital in Wuhan, China. Clinical characteristics, laboratory parameters, and outcomes were compared and analyzed between males and females. In the present study, we analyzed 168 severe patients with COVID-19, including 86 males and 82 females, and 48 patients (28.6%) were diagnosed as critically ill. Of 86 male patients, 12.8% (11/86) died and 75.6% (65/86) were discharged; of 82 female patients, 7.3% (6/82) died and 86.6% (71/82) were discharged. Eleven laboratory parameters showed significant differences between male and female patients, and six of them were higher during the whole clinical course in patients who died than in patients who were discharged. In adjusted logistic regression analysis, males with comorbidities presented a higher risk of being critically ill than males without comorbidities (OR = 3.824, 95% CI = 1.279-11.435). However, this association attenuated to null in female patients (OR = 2.992, 95% CI = 0.937-9.558). A similar sex-specific trend was observed in the relation between age and critically ill conditions. We highlighted sex-specific differences in clinical characteristics and prognosis. Male patients appeared to be more susceptible to age and comorbidities. Sex is an important biological variable that should be considered in the prevention and treatment of COVID-19.", "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 478, "name": "Meng Y"}], "publication_date": "2020-05-02"}, {"id": 187, "slug": "neonatal-early-onset-infection-with-sars-cov-2-in-33-neonates-born-to-mothers-wi", "title": "Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire le cas de nouveaux-n\u00e9s infect\u00e9s pr\u00e9cocement, n\u00e9s de m\u00e8re COVID-19", "verbose_date": "30.03.2020", "authors": "Zeng L ", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 95, "name": "JAMA Pediatrics"}, "link": "https://www.dropbox.com/s/orumwdg73mbfzpm/jamapediatrics_zeng_2020_ld_200013.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "3 nouveaux-n\u00e9s infect\u00e9s pr\u00e9cocement / 33 (9%)\r\nBonne \u00e9volution pour 2 nouveaux n\u00e9s sur 3, \u00e9volution plus compliqu\u00e9e pour le 3eme mais naissance pr\u00e9matur\u00e9e \u00e0 31SA + 2", "objectives": "1) Lettre \u00e0 l'\u00e9diteur2) Etude de cohorte monocentrique, n=33, uniquement descriptive3) Peu de recul sur le suivi", "methods": "D\u00e9crire le cas de nouveaux-n\u00e9s infect\u00e9s pr\u00e9cocement, n\u00e9s de m\u00e8re COVID-19", "pubmed_id": "32215598\n32058570\n32151335\n32154135\n32154287", "doi": "10.1001/jamapediatrics.2020.0878", "abstract": null, "topics": ["Epid\u00e9miologique", "Gyn\u00e9cologie Obst\u00e9trique", "P\u00e9diatrie"], "author_list": [{"id": 180, "name": "Zeng L "}], "publication_date": "2020-03-30"}, {"id": 608, "slug": "acute-heart-failure-in-multisystem-inflammatory-syndrome-in-children-mis-c-in-th", "title": "Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire un nouveau syndrome complexe chez des enfants f\u00e9briles admis pour insuffisance cardiaque aigu\u00eb, li\u00e9 \u00e0 une exposition ant\u00e9rieure au SARS-CoV-2 (syndrome inflammatoire multisyst\u00e9mique chez les enfants - MIS-C)", "verbose_date": "20.05.2020", "authors": "Belhadjer Z", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 9, "name": "Circulation"}, "link": "https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.048360", "findings": "", "take_away": "", "relevance_level": "Le syndrome inflammatoire multisyst\u00e9mique chez l'enfant (MIS-C) est un nouveau syndrome qui est temporairement li\u00e9 \u00e0 une exposition ant\u00e9rieure au SRAS-CoV-2. Similitudes avec la maladie de Kawasaki atypique, mais les signes cliniques importants sont diff\u00e9rents. L'atteinte myocardique avec une insuffisance cardiaque aigu\u00eb est probablement due \u00e0 une sid\u00e9ration myocardique ou \u00e0 un \u0153d\u00e8me plut\u00f4t qu'\u00e0 des l\u00e9sions inflammatoires du myocarde.\nAlors que la pr\u00e9sentation initiale peut \u00eatre s\u00e9v\u00e8re chez certains patients n\u00e9cessitant une assistance m\u00e9canique circulatoire et respiratoire, une r\u00e9cup\u00e9ration rapide avec l'utilisation d'immunoglobulines et de st\u00e9ro\u00efdes a \u00e9t\u00e9 observ\u00e9e.", "objectives": "S\u00e9rie de cas, n=35, multicentrique en France et 1 centre en Suisse7 patients toujours hospitalis\u00e9s ou avec une dysfonction ventriculaire gauche r\u00e9siduelleDonn\u00e9es manquantes du fait de l'absence de standardisation du suiviPas mal d'erreurs sur les pourcentages et incoh\u00e9rences sur le nombre de centres (14 / 12+1)", "methods": "D\u00e9crire un nouveau syndrome complexe chez des enfants f\u00e9briles admis pour insuffisance cardiaque aigu\u00eb, li\u00e9 \u00e0 une exposition ant\u00e9rieure au SARS-CoV-2 (syndrome inflammatoire multisyst\u00e9mique chez les enfants - MIS-C)", "pubmed_id": "32418446", "doi": "10.1161/CIRCULATIONAHA.120.048360", "abstract": "", "topics": ["Epid\u00e9miologique", "P\u00e9diatrie", "Anesth\u00e9sie-R\u00e9animation", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 571, "name": "Belhadjer Z"}], "publication_date": "2020-05-20"}, {"id": 376, "slug": "high-flow-nasal-cannula-is-a-good-treatment-option-for-covid-19", "title": "High flow nasal cannula is a good treatment option for COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'int\u00e9r\u00eat de l'oxyg\u00e9noth\u00e9rapie haut-d\u00e9bit par canule nasale dans l'infection COVID-19", "verbose_date": "18.04.2020", "authors": "Geng S", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 160, "name": "Heart Lung"}, "link": "https://www.heartandlung.org/article/S0147-9563(20)30113-8/pdf", "findings": "", "take_away": "", "relevance_level": "La canulation nasale haut d\u00e9bit peut fournir une une pression expiratoire positive sp\u00e9cifique qui a un effet important sur les d\u00e9tresses respiratoires dans le COVID-19. Cette m\u00e9thode pourrait r\u00e9duire le recours \u00e0 l'intubation, tout en am\u00e9liorant le pronostique et la clinique respiratoire des patients. Cette canulation nasale assure une oxyg\u00e9noth\u00e9rapie efficace rapidement et permet un retour \u00e0 une oxyg\u00e9noth\u00e9rapie conventionnelle en 7 jours en moyenne.", "objectives": "- \u00c9tude monocentrique chinoise dont on ne peut pas \u00eatre assur\u00e9 de la repr\u00e9sentativit\u00e9 de l'\u00e9chantillon- Tr\u00e8s petite cohorte (n=8)- Pas de comparaison \u00e0 une autre technique\"", "methods": "Evaluer l'int\u00e9r\u00eat de l'oxyg\u00e9noth\u00e9rapie haut-d\u00e9bit par canule nasale dans l'infection COVID-19", "pubmed_id": "32295710\n19467849\n23857440\n28947043", "doi": "10.1016/j.hrtlng.2020.03.018", "abstract": null, "topics": ["Th\u00e9rapeutique", "Infectiologie", "Pneumologie"], "author_list": [{"id": 363, "name": "Geng S"}], "publication_date": "2020-04-18"}, {"id": 661, "slug": "serodiagnostics-for-severe-acute-respiratory-syndromerelated-coronavirus-2-a-nar", "title": "Serodiagnostics for Severe Acute Respiratory Syndrome\u2013Related Coronavirus-2. A narrative review", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Proposer un recensement des principaux cas d'utilisation des tests de d\u00e9tection des anticorps du SRAS-CoV-2 et de leur application aux \u00e9tudes s\u00e9rologiques.\r\n\r\nPasser en revue les diff\u00e9rents tests actuellement disponibles, mettre en \u00e9vidence les principaux travaux de recherche en cours et proposer des strat\u00e9gies de mise en \u0153uvre des tests.", "verbose_date": "05.06.2020", "authors": "Cheng MP", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 41, "name": "Ann Intern Med"}, "link": "https://www.acpjournals.org/doi/10.7326/M20-2854", "findings": "", "take_away": "", "relevance_level": "Les tests mol\u00e9culaires sur les \u00e9chantillons respiratoires, l'\u00e9talon-or actuel pour le diagnostic de l'infection par le SRAS-CoV-2, pr\u00e9sentent une sensibilit\u00e9 imparfaite et une capacit\u00e9 de test limit\u00e9e.\nLes tests s\u00e9rologiques peuvent \u00eatre particuli\u00e8rement utiles pour le diagnostic de patients n\u00e9gatifs \u00e0 la RT-PCR. Cependant, le d\u00e9pistage des anticorps ne doit pas \u00eatre utilis\u00e9 comme seule base pour le diagnostic de COVID-19.\nDes \u00e9tudes s\u00e9ro-\u00e9pid\u00e9miologiques bien con\u00e7ues joueront un r\u00f4le essentiel dans la r\u00e9ponse des autorit\u00e9s de sant\u00e9 publique \u00e0 la pand\u00e9mie. Elles permettront en effet de caract\u00e9riser les dynamiques de transmission, en affinant les estimations de l\u2019impact de la maladie sur les population et de donner un aper\u00e7u de la cin\u00e9tique de l'immunit\u00e9 acquise \u00e0 SRAS-CoV-2.\nLa validation de nouveaux tests s\u00e9rologiques pour SARSCoV-2 devra pr\u00eater une attention particuli\u00e8re au choix des populations sources et des normes de r\u00e9f\u00e9rence, et \u00e0 une \u00e9ventuelle r\u00e9activit\u00e9 crois\u00e9e avec des anticorps dirig\u00e9s contre d'autres infections \u00e0 coronavirus. Des essais de s\u00e9roneutralisation par r\u00e9duction des plages de lyse, actuellement la norme de r\u00e9f\u00e9rence pour l\u2019identification des anticorps de l'h\u00f4te capables d'inhiber la r\u00e9plication virale, doivent \u00eatre effectu\u00e9s dans un laboratoire de niveau de bios\u00e9curit\u00e9 3.\nDes recherches urgentes sont n\u00e9cessaires pour d\u00e9terminer les corr\u00e9lations entre s\u00e9rologie et immunit\u00e9 contre le SRAS-CoV-2.", "objectives": "Revue de la litt\u00e9rature.", "methods": "Proposer un recensement des principaux cas d'utilisation des tests de d\u00e9tection des anticorps du SRAS-CoV-2 et de leur application aux \u00e9tudes s\u00e9rologiques.\nPasser en revue les diff\u00e9rents tests actuellement disponibles, mettre en \u00e9vidence les principaux travaux de recherche en cours et proposer des strat\u00e9gies de mise en \u0153uvre des tests.", "pubmed_id": "32496919\n32430429\n32416599\n32235945\n32398876\n32167489\n32221519\n32123347\n32213337\n17200218\n32402061\n3041855\n32015507\n20670286\n32301750\n31582358\n24274632\n32254064\n32353328\n15616839\n15229158\n32330439\n32400364\n30830861\n14647384\n32404476\n32238757\n27365041\n23331969\n19926660\n24670324\n22083674\n32179701\n32269100\n2170159\n32198501\n22311359\n18832706\n20956500\n32427334\n32219428\n26553825\n23386629\n30531947\n26633765\n32253318\n32132184\n32282894\n10655983\n32267220\n32350462\n30058403\n32207377\n32352484\n32159775\n29649602\n31582360\n32381641\n4406451\n32330441\n32265848", "doi": "10.7326/M20-2854", "abstract": "Accurate serologic tests to detect host antibodies to severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) will be critical for the public health response to the coronavirus disease 2019 pandemic. Many use cases are envisaged, including complementing molecular methods for diagnosis of active disease and estimating immunity for individuals. At the population level, carefully designed seroepidemiologic studies will aid in the characterization of transmission dynamics and refinement of disease burden estimates and will provide insight into the kinetics of humoral immunity. Yet, despite an explosion in the number and availability of serologic assays to test for antibodies against SARS-CoV-2, most have undergone minimal external validation to date. This hinders assay selection and implementation, as well as interpretation of study results. In addition, critical knowledge gaps remain regarding serologic correlates of protection from infection or disease, and the degree to which these assays cross-react with antibodies against related coronaviruses. This article discusses key use cases for SARS-CoV-2 antibody detection tests and their application to serologic studies, reviews currently available assays, highlights key areas of ongoing research, and proposes potential strategies for test implementation.", "topics": ["Diagnostique", "Virologie", "Infectiologie"], "author_list": [{"id": 621, "name": "Cheng MP"}], "publication_date": "2020-06-05"}, {"id": 580, "slug": "liver-injury-is-associated-with-severe-coronavirus-disease-2019-covid-19-infecti", "title": "Liver injury is associated with severe Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of retrospective studies", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00e9sumer les r\u00e9sultats des \u00e9tudes disponibles sur l'association entre les anomalies biologiques h\u00e9patiques et gravit\u00e9 de l'infection \u00e0 SARS-CoV-2", "verbose_date": "12.05.2020", "authors": "Parohan M", "specialties": [{"id": 19, "name": "H\u00e9pato-gastro-ent\u00e9rologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 231, "name": "Hepatol Res"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.13510", "findings": "", "take_away": "", "relevance_level": "Dans cette m\u00e9ta-analyse, une atteinte h\u00e9patique biologique \u00e9valu\u00e9e par les taux s\u00e9riques (ASAT, ALAT, bilirubine totale et albumine) a \u00e9t\u00e9 associ\u00e9e \u00e0 un pronostic s\u00e9v\u00e8re du COVID-19.", "objectives": "1) Pre-proof2) 20 \u00e9tudes r\u00e9trospectives incluses (n= 3 458 confirm\u00e9s en RT-PCR), toutes conduites en Chine, h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 moyenne \u00e0 \u00e9lev\u00e9e3) 2 \u00e9valuateurs ont extrait, \u00e9valuation de la qualit\u00e9 des \u00e9tudes, calcul de l'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 suivi des recommandations PRISMA4) L'\u00e9valuation de s\u00e9v\u00e9rit\u00e9 et la biologie n'\u00e9tait pas effectu\u00e9e de mani\u00e8re similaire dans toutes les \u00e9tudes (mais la plupart du temps \u00e0 l'admission)5) Pas de donn\u00e9e sur les ant\u00e9c\u00e9dents de pathologie chronique h\u00e9patique", "methods": "R\u00e9sumer les r\u00e9sultats des \u00e9tudes disponibles sur l'association entre les anomalies biologiques h\u00e9patiques et gravit\u00e9 de l'infection \u00e0 SARS-CoV-2", "pubmed_id": "32386449", "doi": "10.1111/hepr.13510", "abstract": "The Coronavirus disease 2019 (COVID-19) outbreak is a major threat to human beings. Lung injury has been reported as the major outcome of COVID-19 infection. However, liver damage has also been considered to occur in severe cases. Current meta-analysis of retrospective studies was done to summarize available findings on the association between liver injury and severity of COVID-19 infection.\nOnline databases including PubMed, Scopus, Web of Science and Cochrane Library were searched to detect relevant publications up to 1 April 2020, using relevant keywords. To pool data, a fixed- or random-effects model was used depending on the heterogeneity between studies. Furthermore, publication bias test and sensitivity analysis were also done.\nIn total, 20 retrospective studies with 3,428 COVID-19 infected patients (severe cases = 1,455 and mild cases = 1,973), were included in this meta-analysis. Higher serum levels of Aspartate aminotransferase (weighted mean difference = 8.84 U/L, 95% CI = 5.97 to 11.71, P<0.001), Alanine aminotransferase (weighted mean difference = 7.35 U/L, 95% CI = 4.77 to 9.93, P<0.001), total Bilirubin (weighted mean difference = 2.30 mmol/L, 95% CI = 1.24 to 3.36, P<0.001) and lower serum levels of Albumin (weighted mean difference = -4.24 g/L, 95% CI = -6.20 to -2.28, P<0.001), were associated with a significant increase in the severity of COVID-19 infection.\nThe incidence of liver injury, as assessed by serum analysis (AST, ALT, total Bilirubin and Albumin levels), seems to be higher in patients with severe COVID-19 infection.", "topics": ["Pronostique", "H\u00e9pato-gastro-ent\u00e9rologie"], "author_list": [{"id": 544, "name": "Parohan M"}], "publication_date": "2020-05-12"}, {"id": 431, "slug": "acute-onset-smell-and-taste-disorders-in-the-context-of-covid-19-a-pilot-multice", "title": "Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer si la pr\u00e9sence d'une perte du go\u00fbt et/ou de l'odorat est plus pr\u00e9sente dans l'infection \u00e0 COVID-19 que dans la grippe saisonni\u00e8re et \u00e9valuation des caract\u00e9ristiques associ\u00e9es", "verbose_date": "24.04.2020", "authors": "Beltran-Corbellini A", "specialties": [{"id": 18, "name": "Neurologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 181, "name": "Eur J Neurol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.14273", "findings": "", "take_away": "", "relevance_level": "Les troubles du go\u00fbt et de l'odorat semblent significativement plus fr\u00e9quents chez les patients COVID-19 en comparaison des patients infect\u00e9s par la grippe saisonni\u00e8re avec 39% des patients COVID touch\u00e9s contre 12,5% des patients gripp\u00e9s. L'odds-ratio ajust\u00e9 atteint 21,4.\r\nPar ailleurs, ces signes semblent toucher davantage les sujets jeunes et peuvent \u00eatre la pr\u00e9sentation clinique initiale de la maladie dans plus d'un tiers des cas.\r\nToutefois ces donn\u00e9es sont \u00e0 confirmer dans une \u00e9tude de plus haut niveau de preuve.", "objectives": "- \u00c9tude cas-t\u00e9moins- T\u00e9moins historiques avec recueil des donn\u00e9es plusieurs mois apr\u00e8s l'infection (biais de m\u00e9morisation)- Multiplicit\u00e9 des tests dans les recherches d'association avec les caract\u00e9ristiques des patients sans prise en compte de l'inflation du risque alpha- Seulement 5 t\u00e9moins ayant pr\u00e9sent\u00e9 des troubles du go\u00fbt et de l'odorat- Repr\u00e9sentativit\u00e9 de l'\u00e9chantillon difficile \u00e0 \u00e9valuer (pas assez de donn\u00e9es)", "methods": "Evaluer si la pr\u00e9sence d'une perte du go\u00fbt et/ou de l'odorat est plus pr\u00e9sente dans l'infection \u00e0 COVID-19 que dans la grippe saisonni\u00e8re et \u00e9valuation des caract\u00e9ristiques associ\u00e9es", "topics": ["Epid\u00e9miologique", "Neurologie"], "author_list": [{"id": 409, "name": "Beltran-Corbellini A"}], "publication_date": "2020-04-24"}, {"id": 536, "slug": "evaluating-the-serological-status-of-covid-19-patients-using-an-indirect-immunof", "title": "Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Proposer un test indirect par immunofluorescence pour d\u00e9terminer le statut s\u00e9rologique de patients COVID-19, confirm\u00e9s par PCR.", "verbose_date": "05.05.2020", "authors": "Edouard S", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.mediterranee-infection.com/wp-content/uploads/2020/05/Lire-larticle.pdf", "findings": "", "take_away": "", "relevance_level": "Les auteurs ont mis au point un test s\u00e9rologique dont ils estiment la sp\u00e9cificit\u00e9 entre 96,3 et 100\u00a0%\nPour les patients de la cohorte, la s\u00e9ropr\u00e9valence serait de 3\u00a0% 5jours apr\u00e8s l\u2019apparition des sympt\u00f4mes et 47\u00a0% apr\u00e8s plus de 15 jours.\nLa s\u00e9ropr\u00e9valence ainsi que le titrage en anticorps sp\u00e9cifiques serait plus hauts pour les patients ayant de mauvais r\u00e9sultats cliniques.", "objectives": "Etude pr\u00e9-printL\u2019\u00e9tude \u00e9value la sp\u00e9cificit\u00e9 du test mais pas sa sensibilit\u00e9, rendant l'utilisation de ce test pour le diagnostic du COVID-19 ainsi que les r\u00e9sultats de l'\u00e9tude concernant la s\u00e9ropr\u00e9valence p\u00e9rilleuses.La cohorte de d\u00e9part n\u2019est ni repr\u00e9sentative d\u2019une population quelconque (puisque tous \u00e9taient trait\u00e9s \u00e0 l\u2019HCQ et AZ), ni repr\u00e9sentative des patients atteint par le COVID-19 (moyenne d\u2019\u00e2ge 47 ans, majoritairement des femmes).La r\u00e9partition en sous-groupes d\u2019analyse (GO, PvirO, PClin01, PClinO2, PClinO3) ne semble pas adapt\u00e9e \u00e0 la probl\u00e9matique. Elle est pr\u00e9sent\u00e9e comme une \u00e9chelle de gravit\u00e9 dans les r\u00e9sultats, alors que plusieurs biais sont impliqu\u00e9s :- la diff\u00e9rence entre GP et PvorO r\u00e9side dans la charge virale et pas dans l\u2019\u00e9volution clinique- les patients du groupe PClin02, ont les m\u00eames sympt\u00f4mes et pr\u00e9sentent la n\u00e9cessit\u00e9 d\u2019hospitalisation prolong\u00e9e. Ils ont cependant re\u00e7u le traitement moins longtemps que ceux du groupe PClin01.\nEnfin, l\u2019h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 des dates de pr\u00e9l\u00e8vement des s\u00e9rums rend certains r\u00e9sultats observ\u00e9s contestables. En effet, un patient dont la s\u00e9rologie aura \u00e9t\u00e9 test\u00e9e n\u00e9gative au jour 1 et positive au jour 16 sera consid\u00e9r\u00e9 comme ayant eu une s\u00e9roconversion tardive (dans le groupe de 15 \u00e0 36 jours) alors que la conversion aura tr\u00e8s bien pu s\u2019effectuer le 2\u00e8me jour.", "methods": "Proposer un test indirect par immunofluorescence pour d\u00e9terminer le statut s\u00e9rologique de patients COVID-19, confirm\u00e9s par PCR.", "topics": ["Diagnostique", "Virologie"], "author_list": [{"id": 502, "name": "Edouard S"}], "publication_date": "2020-05-05"}, {"id": 672, "slug": "characteristics-and-outcomes-of-pregnant-women-admitted-to-hospital-with-confirm", "title": "Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire, \u00e0 l'\u00e9chelle d'une population, les caract\u00e9ristiques et les issues chez des femmes enceintes hospitalis\u00e9es pour une infection \u00e0 SARS-CoV-2 au Royaume-Uni.", "verbose_date": "11.06.2020", "authors": "Knight M", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 57, "name": "BMJ"}, "link": "https://www.bmj.com/content/bmj/369/bmj.m2107.full.pdf", "findings": "", "take_away": "", "relevance_level": "Plus de la moiti\u00e9 des femmes enceintes admises \u00e0 l'h\u00f4pital pour une infection par le SRAS-CoV-2 pendant la grossesse appartenaient \u00e0 des groupes ethniques noires ou d'autres minorit\u00e9s ethniques.\r\nLa plupart des femmes n'avaient pas de maladie grave et la plupart ont \u00e9t\u00e9 admises au troisi\u00e8me trimestre de la grossesse.\r\nLa transmission de l'infection aux nourrissons de m\u00e8res infect\u00e9es peut se produire mais est rare.", "objectives": "Etude de cohorte nationale prospective, n=427Uniquement descriptive25 (6%) femmes, 7 (28%) en pr\u00e9natal et 18 (72%) en postnatal, \u00e9taient encore hospitalis\u00e9es au moment de l'analyse.SARS-CoV-2 confirm\u00e9 biologiquement ou atteinte respiratoire + radiologique", "methods": "D\u00e9crire, \u00e0 l'\u00e9chelle d'une population, les caract\u00e9ristiques et les issues chez des femmes enceintes hospitalis\u00e9es pour une infection \u00e0 SARS-CoV-2 au Royaume-Uni.", "pubmed_id": "32513659", "doi": "10.1136/bmj.m2107", "abstract": "To describe a national cohort of pregnant women admitted to hospital with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the UK, identify factors associated with infection, and describe outcomes, including transmission of infection, for mothers and infants.\nProspective national population based cohort study using the UK Obstetric Surveillance System (UKOSS).\nAll 194 obstetric units in the UK.\n427 pregnant women admitted to hospital with confirmed SARS-CoV-2 infection between 1 March 2020 and 14 April 2020.\nIncidence of maternal hospital admission and infant infection. Rates of maternal death, level 3 critical care unit admission, fetal loss, caesarean birth, preterm birth, stillbirth, early neonatal death, and neonatal unit admission.\nThe estimated incidence of admission to hospital with confirmed SARS-CoV-2 infection in pregnancy was 4.9 (95% confidence interval 4.5 to 5.4) per 1000 maternities. 233 (56%) pregnant women admitted to hospital with SARS-CoV-2 infection in pregnancy were from black or other ethnic minority groups, 281 (69%) were overweight or obese, 175 (41%) were aged 35 or over, and 145 (34%) had pre-existing comorbidities. 266 (62%) women gave birth or had a pregnancy loss; 196 (73%) gave birth at term. Forty one (10%) women admitted to hospital needed respiratory support, and five (1%) women died. Twelve (5%) of 265 infants tested positive for SARS-CoV-2 RNA, six of them within the first 12 hours after birth.\nMost pregnant women admitted to hospital with SARS-CoV-2 infection were in the late second or third trimester, supporting guidance for continued social distancing measures in later pregnancy. Most had good outcomes, and transmission of SARS-CoV-2 to infants was uncommon. The high proportion of women from black or minority ethnic groups admitted with infection needs urgent investigation and explanation.\nISRCTN 40092247.", "topics": ["Epid\u00e9miologique", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 631, "name": "Knight M"}], "publication_date": "2020-06-11"}, {"id": 627, "slug": "clinical-features-of-rheumatic-patients-infected-with-covid-19-in-wuhan-china", "title": "Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques cliniques des patients atteints de maladies rhumatismales infect\u00e9s par le SARS-CoV-2", "verbose_date": "26.05.2020", "authors": "Ye C", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 242, "name": "Ann Rheum Dis"}, "link": "https://ard.bmj.com/content/annrheumdis/early/2020/05/22/annrheumdis-2020-217627.full.pdf", "findings": "", "take_away": "", "relevance_level": "Chez les patients atteints de maladies rhumatismales infect\u00e9s par le SARS-CoV-2, la dur\u00e9e d'hospitalisation ou la mortalit\u00e9 ne sont pas augment\u00e9s, malgr\u00e9 la fr\u00e9quence accrue de d\u00e9tresse respiratoire\nLa sympt\u00f4matologie clinique, biologique et radiologique est sinon tr\u00e8s proche des autres patients infect\u00e9s\nCes donn\u00e9es doivent \u00eatre confirm\u00e9es par une \u00e9tude plus robuste m\u00e9thodologiquement et sur un effectif plus important", "objectives": "- S\u00e9rie chinoise de cas avec faible effectif (puissance faible)- R\u00e9sultats pr\u00e9liminaires dont la m\u00e9thodologie d'\u00e9tude non comparative ne permet pas de tirer des conclusions - Analyse statistique simple, principalement descriptive", "methods": "D\u00e9crire les caract\u00e9ristiques cliniques des patients atteints de maladies rhumatismales infect\u00e9s par le SARS-CoV-2", "pubmed_id": "32444415", "doi": "10.1136/annrheumdis-2020-217627", "abstract": "The clinical features of rheumatic patients with coronavirus disease 2019 (COVID-19) have not been reported. This study aimed to describe the clinical features of COVID-19 in rheumatic patients and provide information for handling this situation in clinical practice.\nThis is a retrospective case series study. Deidentified data, including gender, age, laboratory and radiological results, symptoms, signs, and medication history, were collected from 2326 patients diagnosed with COVID-19, including 21 cases in combination with rheumatic disease, in Tongji Hospital between 13 January and 15 March 2020.\nLength of hospital stay and mortality rate were similar between rheumatic and non-rheumatic groups, while the presence of respiratory failure was more common in rheumatic cases (38% vs 10%, p<0.001). Symptoms of fever, fatigue and diarrhoea were seen in 76%, 43% and 23% of patients, respectively. There were four rheumatic patients who experienced a flare of rheumatic disease during hospital stay, with symptoms of muscle aches, back pain, joint pain or rash. While lymphocytopaenia was seen in 57% of rheumatic patients, only one patient (5%) presented with leucopenia in rheumatic cases. Rheumatic patients presented with similar radiological features of ground-glass opacity and consolidation. Patients with pre-existing interstitial lung disease showed massive fibrous stripes and crazy-paving signs at an early stage. Five rheumatic cases used hydroxychloroquine before the diagnosis of COVID-19 and none progressed to critically ill stage.\nRespiratory failure was more common in rheumatic patients infected with COVID-19. Differential diagnosis between COVID-19 and a flare of rheumatic disease should be considered.\nChiCTR2000030795.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 590, "name": "Ye C"}], "publication_date": "2020-05-26"}, {"id": 269, "slug": "a-case-of-exacerbation-of-psoriasis-after-oseltamivir-and-hydroxychloroquine-in-", "title": "A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire un cas d'exacerbation du psoriasis en r\u00e9action au traitement par oseltamivir et hydroxychloroquine chez un patient infect\u00e9 par le COVID-19", "verbose_date": "08.04.2020", "authors": "Kutlu O", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 127, "name": "Dermatol Ther"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/dth.13383", "findings": "", "take_away": "", "relevance_level": "Possible risque d'exacerbation de psoriasis sous traitement par hydroxychloroquine", "objectives": "- Case report unique", "methods": "D\u00e9crire un cas d'exacerbation du psoriasis en r\u00e9action au traitement par oseltamivir et hydroxychloroquine chez un patient infect\u00e9 par le COVID-19", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie"], "author_list": [{"id": 258, "name": "Kutlu O"}], "publication_date": "2020-04-08"}, {"id": 232, "slug": "a-simulation-on-potential-secondary-spread-of-novel-coronavirus-in-an-exported-c", "title": "A Simulation on Potential Secondary Spread of Novel Coronavirus in an Exported Country Using a Stochastic Epidemic SEIR Model", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Mod\u00e9liser de potentiels d\u00e9veloppements de foyer hors Chine (\u00e9tude faite d\u00e9but mars, alors que pas d'autres foyers signal\u00e9s)", "verbose_date": "02.04.2020", "authors": "Iwata K", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 98, "name": "J Clin Med"}, "link": "https://www.dropbox.com/s/8vke2visdfvzv2y/jcm-09-00944.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Simulation datant de d\u00e9but mars sur la possibilit\u00e9 de d\u00e9veloppement de foyer hors de Chine d'un int\u00e9r\u00eat assez faible car grande incertitude sur les param\u00e8tres. Une mesure potentiellement importante pour emp\u00eacher le d\u00e9veloppement d'un foyer est n\u00e9anmoins mise en avant : le raccourcissement du d\u00e9lai entre le d\u00e9but des symptomes et la consultation m\u00e9dicale.", "objectives": "Etude en date du 4 mars (donc pas de param\u00e8tre adapt\u00e9 pour des pays autre que la Chine)", "methods": "Mod\u00e9liser de potentiels d\u00e9veloppements de foyer hors Chine (\u00e9tude faite d\u00e9but mars, alors que pas d'autres foyers signal\u00e9s)", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 222, "name": "Iwata K"}], "publication_date": "2020-04-02"}, {"id": 230, "slug": "follow-up-of-the-asymptomatic-patients-with-sars-cov-2-infection", "title": "Follow-up of the Asymptomatic Patients With SARS-CoV-2 Infection", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Suivi de patients asymptomatiques afin de d\u00e9terminer si : infection asymptomatique possible, p\u00e9riode asymptomatique avant d\u00e9veloppement de sympt\u00f4me ou porteur sain", "verbose_date": "02.04.2020", "authors": "Zhou X", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 112, "name": "Clin Microbiol Infect"}, "link": "https://www.dropbox.com/s/k58j30xjgzh6rxj/PIIS1198743X20301695.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "- Certain patients ne pr\u00e9sentent aucun sympt\u00f4me, malgr\u00e9 une atteinte pulmonaire visible \u00e0 la radiologie\r\n- Pas de porteur sain d\u00e9couvert\r\n- Infection infra-clinique possible", "objectives": "- lettre \u00e0 l'\u00e9diteur", "methods": "Suivi de patients asymptomatiques afin de d\u00e9terminer si :\u00a0infection asymptomatique possible,\u00a0p\u00e9riode asymptomatique avant d\u00e9veloppement de sympt\u00f4me ou\u00a0porteur sain", "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 220, "name": "Zhou X"}], "publication_date": "2020-04-02"}, {"id": 220, "slug": "the-ace2-expression-in-human-heart-indicates-new-potential-mechanism-of-heart-in", "title": "The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9tudier l'expression du r\u00e9cepteur ACE2 au niveau des cellules cardiaques humaines d'un adulte en lien avec la capacit\u00e9 d'infection \u00e0 COVID-19 et d'atteinte cardiaque", "verbose_date": "01.04.2020", "authors": "Xiong TY ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 34, "name": "Eur Heart J"}, "link": "https://www.dropbox.com/s/kjmyoutrjx4wu3n/cvaa078.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L'atteinte cardiaque du SARS-CoV-2 pourrait s'expliquer par l'expression importante du r\u00e9cepteur ACE2 au niveau cardiaque, en particulier des p\u00e9ricytes, pouvant causer des dysfonctions micro-vasculaires s\u00e9v\u00e8res.\n\r\nIl est sugg\u00e9r\u00e9, par l'expression \u00e9lev\u00e9 de ce r\u00e9cepteur, que d'autres organes pourraient \u00eatre touch\u00e9s par ce coronavirus comme les intestins, les testicules et les reins.", "objectives": "- Etude pr\u00e9liminaire sur un effectif restreint de cellules cardiaques- Hypoth\u00e8ses physiopathologiques incertaines car poumon avec expression faible de l'ACE 2 alors que c'est l'organe le plus touch\u00e9 (plusieurs ph\u00e9nom\u00e8nes pathologiques concomitants)- Analyse biologique bien men\u00e9e- Analyses bas\u00e9es notamment sur une base de donn\u00e9es dont on ne conna\u00eet pas la fiabilit\u00e9 \"", "methods": "\u00c9tudier l'expression du r\u00e9cepteur ACE2 au niveau des cellules cardiaques humaines d'un adulte en lien avec la capacit\u00e9 d'infection \u00e0 COVID-19 et d'atteinte cardiaque", "pubmed_id": "32227090\n32109013\n15496474\n28665611\n32159775\n32105632\n32015507\n31429357", "doi": "10.1093/cvr/cvaa078", "abstract": "A new type of pneumonia caused by a novel coronavirus SARS-CoV-2 outbreaks recently in China and spreads into many other countries. This disease, named as COVID-19, is similar to patients infected by SARS-CoV and MERS-CoV, and nearly 20% of patients developed severe condition. Cardiac injury is a prevalent complication of severe patients, exacerbating the disease severity in coronavirus disease 2019 (COVID-19) patients. Angiotensin-converting enzyme 2 (ACE2), the key host cellular receptor of SARS-CoV-2, has been identified in multiple organs, but its cellular distribution in human heart is not illuminated clearly. This study performed the first state-of-art single cell atlas of adult human heart, and revealed that pericytes with high expression of ACE2 might act as the target cardiac cell of SARS-CoV-2. The pericytes injury due to virus infection may result in capillary endothelial cells dysfunction, inducing microvascular dysfunction. And patients with basic heart failure disease showed increased ACE2 expression at both mRNA and protein levels, meaning that if infected by the virus these patients may have higher risk of heart attack and critically ill condition. The finding of this study explains the high rate of severe cases among COVID-19 patients with basic cardiovascular disease; and these results also perhaps provide important reference to clinical treatment of cardiac injury among severe patients infected by SARS-CoV-2.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 211, "name": "Xiong TY "}], "publication_date": "2020-04-01"}, {"id": 460, "slug": "neurologic-manifestations-in-an-infant-with-covid-19", "title": "Neurologic manifestations in an infant with COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les manifestations neurologiques du Covid-19 chez les enfants", "verbose_date": "27.04.2020", "authors": "Dugue R", "specialties": [{"id": 18, "name": "Neurologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 171, "name": "Neurology"}, "link": "https://n.neurology.org/content/neurology/early/2020/04/22/WNL.0000000000009653.full.pdf", "findings": "", "take_away": "", "relevance_level": "Ce cas souligne la possibilit\u00e9 de rares, mais importantes manifestations neurologiques de Covid-19 chez les enfants ainsi que la coexistence avec d'autres infections virales chez eux.", "objectives": "- rapport d'un seul cas.\"", "methods": "D\u00e9crire les manifestations neurologiques du Covid-19 chez les enfants", "topics": ["Diagnostique", "Neurologie"], "author_list": [{"id": 432, "name": "Dugue R"}], "publication_date": "2020-04-27"}, {"id": 96, "slug": "comparison-of-clinical-characteristics-of-coronavirus-disease-covid-19-and-sever", "title": "Comparison of clinical characteristics of coronavirus disease (COVID-19) and severe acute respiratory syndrome (SARS) as experienced in Taiwan.", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparer les caract\u00e9ristiques cliniques, \u00e9pid\u00e9miologiques, biologiques du SRAS et COVID-19", "verbose_date": "14.03.2020", "authors": "Su YL", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 69, "name": "Travel Med Infect Dis"}, "link": "https://www.dropbox.com/s/j61x49vvhpsu07y/1-s2.0-S1477893920300934-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Patients COVID-19 plus \u00e2g\u00e9s que SRAS", "objectives": "Faible1) Lettre \u00e0 l'\u00e9diteur2) Comparaison de 10 cas COVID-19 \u00e0 50 cas SRAS mais non confirm\u00e9s3) Uniquement descriptif", "methods": "Comparer les caract\u00e9ristiques cliniques, \u00e9pid\u00e9miologiques, biologiques du SRAS et COVID-19", "pubmed_id": "32184131\n15520422", "doi": "10.1016/j.tmaid.2020.101625", "abstract": null, "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 102, "name": "Su YL"}], "publication_date": "2020-03-14"}, {"id": 477, "slug": "mild-or-moderate-covid-19", "title": "Mild or Moderate Covid-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Examiner la situation des cas l\u00e9gers et mod\u00e9r\u00e9s de COVID-19 : pr\u00e9sentation clinique et prise en charge, ainsi que les moyens de pr\u00e9vention et de contr\u00f4le de la transmission", "verbose_date": "27.04.2020", "authors": "Gandhi R", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 7, "name": "Recommandations", "icon": "icon-reco"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMcp2009249?articleTools=true", "findings": "", "take_away": "", "relevance_level": "La transmission par des sujets asymptomatiques est un r\u00e9el enjeu et devrait encourager la mise en place large de pr\u00e9cautions gouttelettes et contact. La plupart des sujets avec forme l\u00e9g\u00e8re de COVID-19 ne n\u00e9cessitent pas d'exploration particuli\u00e8re et restent habituellement \u00e0 domicile. Parmi eux, il faut identifier les patients avec facteurs de risque de forme s\u00e9v\u00e8re et assurer alors un suivi rapproch\u00e9. En cas de forme mod\u00e9r\u00e9e, l'hospitalisation est le plus souvent la r\u00e8gle avec des examens de base mais pas syst\u00e9matiquement de scanner thoracique.", "objectives": "- pas de d\u00e9tails concernant la m\u00e9thodologie de la revue- citation d'\u00e9tudes de faible niveau de preuve\"", "methods": "Examiner la situation des cas l\u00e9gers et mod\u00e9r\u00e9s de COVID-19 : pr\u00e9sentation clinique et prise en charge, ainsi que les moyens de pr\u00e9vention et de contr\u00f4le de la transmission", "pubmed_id": "32329974", "doi": "10.1056/NEJMcp2009249", "abstract": null, "topics": ["Recommandations", "Infectiologie", "Pneumologie"], "author_list": [{"id": 445, "name": "Gandhi R"}], "publication_date": "2020-04-27"}, {"id": 626, "slug": "incidence-clinical-outcomes-and-transmission-dynamics-of-severe-coronavirus-dise", "title": "Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Comprendre l'\u00e9pid\u00e9miologie et les cons\u00e9quences du Covid-19 s\u00e9v\u00e8re durant la premi\u00e8re vague \u00e9pid\u00e9mique sur la c\u00f4te Ouest des Etats-Unis", "verbose_date": "26.05.2020", "authors": "Lewnard JA", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 57, "name": "BMJ"}, "link": "https://www.bmj.com/content/bmj/369/bmj.m1923.full.pdf", "findings": "", "take_away": "", "relevance_level": "L'incidence d'hospitalisation pour Covid-19 est maximale pour les personnes les plus \u00e2g\u00e9es, de m\u00eame que la mortalit\u00e9. L'admission en unit\u00e9 de soins intensifs est plus importants chez les hommes.\r\nLe Re a d\u00e9cru avec les mesures de confinement.", "objectives": "- Cohorte prospective- Donn\u00e9es fiables d'un syst\u00e8me d'assurance, avec base de donn\u00e9es cons\u00e9quente- Absence de prise en compte de facteurs de confusion importants (comorbidit\u00e9s)- Biais d'information possibles pendant les premi\u00e8res phase de l'\u00e9pid\u00e9mie o\u00f9 les tests diagnostiques \u00e9taient moins r\u00e9pandus- Biais de s\u00e9lection \u00e9galement possible car les personnes appartenant \u00e0 ce syst\u00e8me de sant\u00e9 priv\u00e9 ont un statut socio-\u00e9conomique plus \u00e9lev\u00e9 que les personnes sans assurance", "methods": "Comprendre l'\u00e9pid\u00e9miologie et les cons\u00e9quences du Covid-19 s\u00e9v\u00e8re durant la premi\u00e8re vague \u00e9pid\u00e9mique sur la c\u00f4te Ouest des Etats-Unis", "pubmed_id": "32444358\n32297897\n31995857\n32178769\n32203977\n32404476\n32250385\n23012597\n32145466\n32058086\n32079150\n31050642\n27548806\n32213329\n32247326\n32046819\n32181807\n32269018\n32329797\n32109013\n15353409\n32298245\n32247381\n32171076\n32289150\n32240634\n32150748\n32191173\n32091533\n32031570\n32320003\n32188598\n32044814", "doi": "10.1136/bmj.m1923", "abstract": "To understand the epidemiology and burden of severe coronavirus disease 2019 (covid-19) during the first epidemic wave on the west coast of the United States.\nProspective cohort study.\nKaiser Permanente integrated healthcare delivery systems serving populations in northern California, southern California, and Washington state.\n1840 people with a first acute hospital admission for confirmed covid-19 by 22 April 2020, among 9\u2009596\u2009321 healthcare plan enrollees. Analyses of hospital length of stay and clinical outcomes included 1328 people admitted by 9 April 2020 (534 in northern California, 711 in southern California, and 83 in Washington).\nCumulative incidence of first acute hospital admission for confirmed covid-19, and subsequent probabilities of admission to an intensive care unit (ICU) and mortality, as well as duration of hospital stay and ICU stay. The effective reproduction number (\nAs of 22 April 2020, cumulative incidences of a first acute hospital admission for covid-19 were 15.6 per 100\u2009000 cohort members in northern California, 23.3 per 100\u2009000 in southern California, and 14.7 per 100\u2009000 in Washington. Accounting for censoring of incomplete hospital stays among those admitted by 9 April 2020, the estimated median duration of stay among survivors was 9.3 days (with 95% staying 0.8 to 32.9 days) and among non-survivors was 12.7 days (1.6 to 37.7 days). The censoring adjusted probability of ICU admission for male patients was 48.5% (95% confidence interval 41.8% to 56.3%) and for female patients was 32.0% (26.6% to 38.4%). For patients requiring critical care, the median duration of ICU stay was 10.6 days (with 95% staying 1.3 to 30.8 days). The censoring adjusted case fatality ratio was 23.5% (95% confidence interval 19.6% to 28.2%) among male inpatients and 14.9% (11.8% to 18.6%) among female inpatients; mortality risk increased with age for both male and female patients. Reductions in \nAmong residents of California and Washington state enrolled in Kaiser Permanente healthcare plans who were admitted to hospital with covid-19, the probabilities of ICU admission, of long hospital stay, and of mortality were identified to be high. Incidence rates of new hospital admissions have stabilized or declined in conjunction with implementation of social distancing interventions.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 589, "name": "Lewnard JA"}], "publication_date": "2020-05-26"}, {"id": 109, "slug": "patients-of-covid-19-may-benefit-from-sustained-lopinavir-combined-regimen-and-t", "title": "Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques \u00e9pid\u00e9miologique, cliniques, temporelles et \u00e9volution de patients trait\u00e9s par Lopinavir", "verbose_date": "12.03.2020", "authors": "Liu F", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.dropbox.com/s/t9nepwl1eg6zatj/1-s2.0-S1201971220301326-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Lopinavir a eu un effet positif selon les auteurs mais effets ind\u00e9sirables fr\u00e9quents (hypokali\u00e9mie et effets digestifs) Les \u00e9osinophiles pourraient \u00eatre un pr\u00e9dicteur de la progression de COVID-19 (abaiss\u00e9s initial pour remont\u00e9e)", "objectives": "Faible1) Pre-proof2) n=10 & monocentrique, pas control\u00e9 randomise, suivi court (issue non connues pour 3 patients transf\u00e9r\u00e9s", "methods": "D\u00e9crire les caract\u00e9ristiques \u00e9pid\u00e9miologique, cliniques, temporelles et \u00e9volution de patients trait\u00e9s par Lopinavir", "pubmed_id": "32173576", "doi": "10.1016/j.ijid.2020.03.013", "abstract": "To explore the epidemiological information, clinical characteristics, therapeutic outcomes and temporal progression of laboratory findings in 2019-coronavirus disease (COVID-19) patients exposed to lopinavir.\nWe collected data from ten COVID-19 patients admitted between January 22, 2020 and February 11, 2020 at Xixi hospital in Hangzhou, China.\nOf ten patients, secondary, tertiary and quartus patients emerged; the incubation period was 3-7 days. Mainly initial symptoms were cough and low fever (37.3-38.0\u00b0C). An asymptomatic case presented normal radiography, the others had ground glass opacities. All cases (three transferred, seven discharged) were exposed to lopinavir on initial hospitalization. Three patients stopped lopinavir because of adverse effects, two of them deteriorated, one was hospitalized longer than others who with sustained lopinavir use. Levels of potassium, albumin, and lymphocytes were low, but increased persistently after treatment. Eosinophil values were low on initial hospitalization, then all returned to normal before discharge. Viral load of SARS-CoV-2, radiography and eosinophil improved continuously in 3-14, 6-8 and 7-9 days, respectively.\nIncreasing eosinophils may be an indicator of COVID-19 improvement. The COVID-19 patients may benefit from sustained lopinavir use. More research on a larger scale is needed to verify these points.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 115, "name": "Liu F"}], "publication_date": "2020-03-12"}, {"id": 634, "slug": "the-disease-induced-herd-immunity-level-for-covid-19-is-substantially-lower-than", "title": "The disease-induced herd immunity level for Covid-19 is substantially lower than the classical herd immunity level", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "", "verbose_date": "24.05.2020", "authors": "Britton T", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 21, "name": "Confinement/D\u00e9confinement"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.05.06.20093336v2.full.pdf", "findings": "", "take_away": "", "relevance_level": "Dans une population structur\u00e9e (par \u00e2ge, niveau d'activit\u00e9), l'immunit\u00e9 collective suite \u00e0 la propagation d'une premi\u00e8re vague de l'\u00e9pid\u00e9mie est atteinte pour une fraction plus faible d'infect\u00e9s que dans une population consid\u00e9r\u00e9e homog\u00e8ne en contacts.", "objectives": "La question de l'immunit\u00e9 collective est apparue de fa\u00e7on centrale dans la crise du COVID19 et ce travail met l'accent sur un point important : l'importance de sa d\u00e9finition pr\u00e9cise et de celle du mod\u00e8le dans le niveau qui lui est associ\u00e9. La d\u00e9finition donn\u00e9e d'immunit\u00e9 induite par la maladie ou les \u00e9l\u00e9ments de preuves math\u00e9matiques pourraient \u00eatre d\u00e9taill\u00e9s et clarifi\u00e9s pour une meilleure lisibilit\u00e9 du papier.", "methods": "", "topics": ["Mod\u00e9lisation", "Immunit\u00e9", "Confinement/D\u00e9confinement"], "author_list": [{"id": 594, "name": "Britton T"}], "publication_date": "2020-05-24"}, {"id": 146, "slug": "sras-cov-2-turned-positive-in-a-discharged-patient-with-covid-19-arouses-concern", "title": "SRAS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire le cas d'un patient redevenu positif apr\u00e8s sa sortie d'hospitalisation ", "verbose_date": "24.03.2020", "authors": "Zhang JF ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.dropbox.com/s/ty4ooev964yrxpy/PIIS1201971220301260.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Crit\u00e8res de sortie\u00a0des patients COVID-19 \u00e0 \u00e9tudier\r\nN\u00e9cessit\u00e9 de\u00a0surveillance suppl\u00e9mentaire apr\u00e8s la sortie d'hospitalisation avec contr\u00f4le des pr\u00e9l\u00e8vements\r\nCas d'un\u00a0patient de nouveau positif et donc potentiellement infectant apr\u00e8s sa sortie d'hospitalisation\u00a0(avait \u00e9t\u00e9 transf\u00e9r\u00e9 en\u00a0unit\u00e9 de surveillance et de quarantaine pour encore 14 jours)", "objectives": "1) Case-report d'un patient", "methods": "D\u00e9crire le cas d'un patient redevenu\u00a0positif apr\u00e8s sa sortie d'hospitalisation", "topics": ["Autres", "Transversale"], "author_list": [{"id": 143, "name": "Zhang JF "}], "publication_date": "2020-03-24"}, {"id": 676, "slug": "pulmonary-post-mortem-findings-in-a-series-of-covid-19-cases-from-northern-italy", "title": "Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "L'analyse des caract\u00e9ristiques pathologiques du tissu pulmonaire de patients d\u00e9c\u00e9d\u00e9s du COVID-19", "verbose_date": "10.06.2020", "authors": "Carsana L", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 74, "name": "Lancet Infect Dis"}, "link": "https://www.thelancet.com/action/showPdf?pii=S1473-3099%2820%2930434-5", "findings": "", "take_away": "", "relevance_level": "La l\u00e9sion pulmonaire type chez les patients atteints de COVID-19 est la l\u00e9sion alv\u00e9olaire diffuse. La formation d'une membrane hyaline et l'hyperplasie atypique des pneumocytes sont fr\u00e9quentes. Il est important de noter que la pr\u00e9sence de thrombus plaquettaire dans les petits vaisseaux art\u00e9riels correspond \u00e0 une coagulopathie, qui semble \u00eatre fr\u00e9quente chez les patients atteints de COVID-19 et devrait \u00eatre l'une des principales cibles du traitement.", "objectives": "- Petite s\u00e9rie d'analyse pulmonaire de cas d\u00e9c\u00e9d\u00e9s - Manque des informations sur les donn\u00e9es d\u00e9mographiques, cliniques et radiologiques des sujets avant leur d\u00e9c\u00e8s- Pas de mention du d\u00e9lai post-mortem pour l'analyse", "methods": "L'analyse des caract\u00e9ristiques pathologiques du tissu pulmonaire de patients d\u00e9c\u00e9d\u00e9s du COVID-19", "topics": ["Epid\u00e9miologique", "Infectiologie", "Pneumologie"], "author_list": [{"id": 635, "name": "Carsana L"}], "publication_date": "2020-06-10"}, {"id": 445, "slug": "sars-cov-2-entry-factors-are-highly-expressed-in-nasal-epithelial-cells-together", "title": "SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluation du tropisme potentiel du SARS-CoV-2 en \u00e9tudiant l'expression des g\u00e8nes associ\u00e9s \u00e0 l'entr\u00e9e virale dans les donn\u00e9es de s\u00e9quen\u00e7age d'ARN provenant de plusieurs tissus humains sains. ", "verbose_date": "25.04.2020", "authors": "Sungnak W", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 115, "name": "Nature Med"}, "link": "https://www.nature.com/articles/s41591-020-0868-6.pdf", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude, constat que le r\u00e9cepteur d'entr\u00e9e ACE2 pour le SARS-CoV-2 et la prot\u00e9ase associ\u00e9e \u00e0 l'entr\u00e9e virale TMPRSS2 sont fortement exprim\u00e9s dans les fosses nasales (\u00e9pith\u00e9lium) et les cellules cili\u00e9es.\u00a0\r\nCette d\u00e9couverte implique que les cellules nasales peuvent \u00eatre \u00e0 l'origine de l'entr\u00e9e du virus et peuvent \u00eatre des r\u00e9servoirs possibles pour la diss\u00e9mination au sein de l'organisme ou entre les individus.\u00a0\r\nLa co-expression dans l'\u0153sophage, l'il\u00e9on et le c\u00f4lon pourrait expliquer l'excr\u00e9tion virale f\u00e9cale observ\u00e9e cliniquement, avec des implications pour la transmission f\u00e9cale-orale potentielle, tandis que la co-expression dans les cellules conjonctivales superficielles pourrait expliquer un ph\u00e9notype oculaire observ\u00e9 chez quelques patients COVID-19 avec propagation par le canal nasolacrymal.", "objectives": "- Etude exp\u00e9rimentale bien r\u00e9alis\u00e9e avec des \u00e9chantillons tissulaires sains- Manque des donn\u00e9es sur des tissus infect\u00e9s par le SARS-CoV-2- \u00c9tude encore pr\u00e9liminaire", "methods": "Evaluation du tropisme potentiel du SARS-CoV-2 en \u00e9tudiant l'expression des g\u00e8nes associ\u00e9s \u00e0 l'entr\u00e9e virale dans les donn\u00e9es de s\u00e9quen\u00e7age d'ARN provenant de plusieurs tissus humains sains.", "pubmed_id": "32327758", "doi": "10.1038/s41591-020-0868-6", "abstract": "We investigated SARS-CoV-2 potential tropism by surveying expression of viral entry-associated genes in single-cell RNA-sequencing data from multiple tissues from healthy human donors. We co-detected these transcripts in specific respiratory, corneal and intestinal epithelial cells, potentially explaining the high efficiency of SARS-CoV-2 transmission. These genes are co-expressed in nasal epithelial cells with genes involved in innate immunity, highlighting the cells' potential role in initial viral infection, spread and clearance. The study offers a useful resource for further lines of inquiry with valuable clinical samples from COVID-19 patients and we provide our data in a comprehensive, open and user-friendly fashion at www.covid19cellatlas.org.", "topics": ["Autres", "Immunit\u00e9", "Transversale"], "author_list": [{"id": 420, "name": "Sungnak W"}], "publication_date": "2020-04-25"}, {"id": 435, "slug": "early-description-of-coronavirus-2019-disease-in-kidney-transplant-recipients-in", "title": "Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Description de 15 cas de patients porteurs de greffe r\u00e9nale avec une infection \u00e0 COVID-19 av\u00e9r\u00e9e et hospitalis\u00e9s \u00e0 New York", "verbose_date": "24.04.2020", "authors": "Mohat S", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 182, "name": "J Am Soc Nephrol"}, "link": "https://jasn.asnjournals.org/content/jnephrol/early/2020/04/22/ASN.2020030375.full.pdf", "findings": "", "take_away": "", "relevance_level": "- Pr\u00e9sentation clinique domin\u00e9e par la fi\u00e8vre (87%) et la toux (67%) comme en population g\u00e9n\u00e9rale.\r\n- Radiographie thoracique initiale\u00a0: opacit\u00e9s multifocales ou bilat\u00e9rales (47%), pas d'atteinte (33%)\r\n- Interruption compl\u00e8te des antim\u00e9tabolites ou du L\u00e9flunomide chez 10 des 14 patients concern\u00e9s (71%)\r\n- Hydroxychloroquine chez 13 patients (87%), associ\u00e9e \u00e0 l\u2019Azithromycine chez 9 patients (60%)\r\n- N\u00e9cessit\u00e9 de ventilation m\u00e9canique invasive chez 4 patients (27%)\r\n- 2 d\u00e9c\u00e8s au terme du suivi, 8 sorties \u00e0 domicile, 5 toujours hospitalis\u00e9s dont 2 intub\u00e9s", "objectives": "- case series de 15 cas- monocentrique- donn\u00e9es censur\u00e9es \u00e0 droite chez 5 patients (33%)\"", "methods": "Description de 15 cas de patients porteurs de greffe r\u00e9nale avec une infection \u00e0 COVID-19 av\u00e9r\u00e9e et hospitalis\u00e9s \u00e0 New York", "pubmed_id": "32317402", "doi": "10.1681/ASN.2020030375", "abstract": "The novel SARS-CoV-2 virus has caused a global pandemic of coronavirus disease 2019 (COVID-19). Although immunosuppressed individuals are thought to be at an increased risk of severe disease, little is known about their clinical presentation, disease course, or outcomes.\nWe report 15 kidney transplant recipients from the Columbia University kidney transplant program who required hospitalization for confirmed COVID-19, and describe their management, clinical course, and outcomes.\nPatients presented most often with a fever (87%) and/or cough (67%). Initial chest x-ray most commonly showed bilateral infiltrates, but 33% had no acute radiographic findings. Patients were managed with immunosuppression reduction and the addition of hydroxychloroquine and azithromycin. Although 27% of our patients needed mechanical ventilation, over half were discharged home by the end of follow-up.\nKidney transplant recipients with COVID-19 have presentations that are similar to that of the general population. Our current treatment protocol appears to be associated with favorable outcomes, but longer follow-up of a larger cohort of patients is needed.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 412, "name": "Mohat S"}], "publication_date": "2020-04-24"}, {"id": 640, "slug": "hydroxychloroquine-or-chloroquine-for-treatment-or-prophylaxis-of-covid-19-a-liv", "title": "Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00e9sumer les preuves des b\u00e9n\u00e9fices et des risques de l'hydroxychloroquine et de la chloroquine pour le traitement ou la prophylaxie du COVID-19.", "verbose_date": "01.06.2020", "authors": "Hernandez AV", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 41, "name": "Ann Intern Med"}, "link": "https://www.acpjournals.org/doi/10.7326/M20-2496", "findings": "", "take_away": "", "relevance_level": "Les preuves sur les avantages et les inconv\u00e9nients de l'utilisation de l'hydroxychloroquine ou de la chloroquine pour traiter le COVID-19 sont tr\u00e8s faibles et contradictoires.", "objectives": "23 \u00e9tudes incluses (mais uniquement 4 essais contr\u00f4l\u00e9s randomis\u00e9s avec des risques de biais moyens \u00e0 \u00e9lev\u00e9s)Effectifs des essais randomis\u00e9s faibles de 30, 62, 81 et 150 patientsPas de m\u00e9ta-analyseRecherche non limit\u00e9e \u00e0 l'anglais", "methods": "R\u00e9sumer les preuves des b\u00e9n\u00e9fices et des risques de l'hydroxychloroquine et de la chloroquine pour le traitement ou la prophylaxie du COVID-19.", "pubmed_id": "32459529", "doi": "10.7326/M20-2496", "abstract": "Hydroxychloroquine and chloroquine have antiviral effects in vitro against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).\nTo summarize evidence about the benefits and harms of hydroxychloroquine or chloroquine for the treatment or prophylaxis of coronavirus disease 2019 (COVID-19).\nPubMed (via MEDLINE), EMBASE (via Ovid), Scopus, Web of Science, Cochrane Library, bioRxiv, Preprints, ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform, and the Chinese Clinical Trials Registry from 1 December 2019 until 8 May 2020.\nStudies in any language reporting efficacy or safety outcomes from hydroxychloroquine or chloroquine use in any setting in adults or children with suspected COVID-19 or at risk for SARS-CoV-2 infection.\nIndependent, dually performed data extraction and quality assessments.\nFour randomized controlled trials, 10 cohort studies, and 9 case series assessed treatment effects of the medications, but no studies evaluated prophylaxis. Evidence was conflicting and insufficient regarding the effect of hydroxychloroquine on such outcomes as all-cause mortality, progression to severe disease, clinical symptoms, and upper respiratory virologic clearance with antigen testing. Several studies found that patients receiving hydroxychloroquine developed a QTc interval of 500 ms or greater, but the proportion of patients with this finding varied among the studies. Two studies assessed the efficacy of chloroquine; 1 trial, which compared higher-dose (600 mg twice daily for 10 days) with lower-dose (450 mg twice daily on day 1 and once daily for 4 days) therapy, was stopped owing to concern that the higher dose therapy increased lethality and QTc interval prolongation. An observational study that compared adults with COVID-19 receiving chloroquine phosphate 500 mg once or twice daily with patients not receiving chloroquine found minor fever resolution and virologic clearance benefits with chloroquine.\nThere were few controlled studies, and control for confounding was inadequate in observational studies.\nEvidence on the benefits and harms of using hydroxychloroquine or chloroquine to treat COVID-19 is very weak and conflicting.\nAgency for Healthcare Research and Quality.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 602, "name": "Hernandez AV"}], "publication_date": "2020-06-01"}, {"id": 305, "slug": "quarantine-alone-or-in-combination-with-other-public-health-measures-to-control-", "title": "Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review", "has_other_authors": false, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9terminer les effets de la quarantaine seule ou en combinaison avec d'autres mesures visant \u00e0 contr\u00f4ler la propagation de la pand\u00e9mie de COVID-19 sur des sujets en contact avec des patients atteints de COVID-19 ou sur des sujets provenant d'\u00c9tats \u00e0 forte propagation ou vivant dans des r\u00e9gions pr\u00e9sentant une diffusion \u00e9pid\u00e9mique de la maladie.", "verbose_date": "09.04.2020", "authors": "Nussbaumer-Streit B", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 136, "name": "Cochrane Database Syst Rev"}, "link": "https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013574/epdf/full", "findings": "", "take_away": "", "relevance_level": "Les informations disponibles pour COVID-19 \u00e0 l'heure actuelle sont bas\u00e9es sur des \u00e9tudes de mod\u00e8les math\u00e9matiques et des preuves indirectes (\u00e9tudes SRAS et MERS), bien que la quarantaine soit efficace pour r\u00e9duire le nombre d'infections et de d\u00e9c\u00e8s pendant la pand\u00e9mie de COVID-19.\r\nLa mise en \u0153uvre pr\u00e9coce de la quarantaine et la combinaison avec d'autres strat\u00e9gies de sant\u00e9 publique sont n\u00e9cessaires pour limiter la propagation du SRAS-CoV-2.\r\nLes d\u00e9cisions relatives aux mesures prises doivent \u00eatre constamment actualis\u00e9es en fonction de la situation \u00e9pid\u00e9mique et de l'impact de ces mesures.\r\nLa reproduction des tests dans des \u00e9chantillons repr\u00e9sentatifs de la population pourrait fournir des donn\u00e9es sur la pr\u00e9valence r\u00e9elle de l'infection.", "objectives": "1) Revue syst\u00e9matique rapid: - pas de recherche de litt\u00e9rature grise,-  examen ind\u00e9pendant par deux chercheurs pour seulement 30% des articles- attribution du risque de biais par un seul examinateur2) Type d'\u00e9tude: aucune \u00e9tude d'observation sur les effets de la quarantaine seule ou en combinaison avec d'autres mesures pour contenir COVID-19 et 10 \u00e9tudes bas\u00e9es sur des mod\u00e8les math\u00e9matiques.4) 15 \u00e9tudes sur SRAS et  MERS : l'applicabilit\u00e9 \u00e0 l'\u00e9pid\u00e9mie de COVID-19 est limit\u00e9e par les diff\u00e9rentes dynamiques de transmission.5) Forte incertitude sur les donn\u00e9es concernant la transmissibilit\u00e9, la p\u00e9riode d'incubation et la pathog\u00e9nicit\u00e9 du SRAS-CoV-2.\"", "methods": "D\u00e9terminer les effets de la quarantaine seule ou en combinaison avec d'autres mesures visant \u00e0 contr\u00f4ler la propagation de la pand\u00e9mie de COVID-19 sur des sujets en contact avec des patients atteints de COVID-19 ou sur des sujets provenant d'\u00c9tats \u00e0 forte propagation ou vivant dans des r\u00e9gions pr\u00e9sentant une diffusion \u00e9pid\u00e9mique de la maladie.", "pubmed_id": "32267544\n15019504\n32219006\n17132339\n32164053\n32011472\n17464910\n16222170\n32046137\n29432858\n32048815\n16421244\n29716568\n32106216\n18436948\n15539347\n16102315\n15071187\n14561285\n22990086\n32109273\n16494711\n17413071\n17055533\n27733354\n14966229\n28703921\n28351976\n32091533\n15748730\n25186370\n32007643\n32061311\n32064853\n32108857\n14693874\n32141624\n20578793\n15752447\n32391661\n31972274\n15907545\n32112714\n14573569\n19631508", "doi": "10.1002/14651858.CD013574", "abstract": "Coronavirus disease 2019 (COVID-19) is a rapidly emerging disease that has been classified a pandemic by the World Health Organization (WHO). To support WHO with their recommendations on quarantine, we conducted a rapid review on the effectiveness of quarantine during severe coronavirus outbreaks.\nWe conducted a rapid review to assess the effects of quarantine (alone or in combination with other measures) of individuals who had contact with confirmed cases of COVID-19, who travelled from countries with a declared outbreak, or who live in regions with high transmission of the disease.\nAn information specialist searched PubMed, Ovid MEDLINE, WHO Global Index Medicus, Embase, and CINAHL on 12 February 2020 and updated the search on 12 March 2020. WHO provided records from daily searches in Chinese databases up to 16 March 2020.\nCohort studies, case-control-studies, case series, time series, interrupted time series, and mathematical modelling studies that assessed the effect of any type of quarantine to control COVID-19. We also included studies on SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome) as indirect evidence for the current coronavirus outbreak.\nTwo review authors independently screened 30% of records; a single review author screened the remaining 70%. Two review authors screened all potentially relevant full-text publications independently. One review author extracted data and assessed evidence quality with GRADE and a second review author checked the assessment. We rated the certainty of evidence for the four primary outcomes: incidence, onward transmission, mortality, and resource use.\nWe included 29 studies; 10 modelling studies on COVID-19, four observational studies and 15 modelling studies on SARS and MERS. Because of the diverse methods of measurement and analysis across the outcomes of interest, we could not conduct a meta-analysis and conducted a narrative synthesis. Due to the type of evidence found for this review, GRADE rates the certainty of the evidence as low to very low. Modeling studies consistently reported a benefit of the simulated quarantine measures, for example, quarantine of people exposed to confirmed or suspected cases averted 44% to 81% incident cases and 31% to 63% of deaths compared to no measures based on different scenarios (incident cases: 4 modelling studies on COVID-19, SARS; mortality: 2 modelling studies on COVID-19, SARS, low-certainty evidence). Very low-certainty evidence suggests that the earlier quarantine measures are implemented, the greater the cost savings (2 modelling studies on SARS). Very low-certainty evidence indicated that the effect of quarantine of travellers from a country with a declared outbreak on reducing incidence and deaths was small (2 modelling studies on SARS). When the models combined quarantine with other prevention and control measures, including school closures, travel restrictions and social distancing, the models demonstrated a larger effect on the reduction of new cases, transmissions and deaths than individual measures alone (incident cases: 4 modelling studies on COVID-19; onward transmission: 2 modelling studies on COVID-19; mortality: 2 modelling studies on COVID-19; low-certainty evidence). Studies on SARS and MERS were consistent with findings from the studies on COVID-19.\nCurrent evidence for COVID-19 is limited to modelling studies that make parameter assumptions based on the current, fragmented knowledge. Findings consistently indicate that quarantine is important in reducing incidence and mortality during the COVID-19 pandemic. Early implementation of quarantine and combining quarantine with other public health measures is important to ensure effectiveness. In order to maintain the best possible balance of measures, decision makers must constantly monitor the outbreak situation and the impact of the measures implemented. Testing in representative samples in different settings could help assess the true prevalence of infection, and would reduce uncertainty of modelling assumptions. This review was commissioned by WHO and supported by Danube-University-Krems.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 280, "name": "Nussbaumer-Streit B"}], "publication_date": "2020-04-09"}, {"id": 501, "slug": "estimating-the-effects-of-asymptomatic-and-imported-patients-on-covid19-epidemic", "title": "Estimating the Effects of Asymptomatic and Imported Patients on COVID\u201019 Epidemic Using Mathematical Modeling", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Mod\u00e9liser l'\u00e9pid\u00e9mie de Covid dans les provinces de Jiangsu et Anhui, en tenant compte des patients asymptomatiques et de la saturation des services hospitaliers pour pr\u00e9dire la survenue de seconde vague \u00e9pid\u00e9mique. ", "verbose_date": "27.04.2020", "authors": "Sun T", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 35, "name": "J Med Virol"}, "link": "https://www.dropbox.com/s/rexixa697o2nnsb/10.1002%40jmv.25939.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Mesures de distanciation fortes n\u00e9cessaires pour emp\u00eacher une seconde vague \u00e9pid\u00e9mique dans les provinces de Jiangsu et Anhui. La pr\u00e9sence de cas existants asymptomatiques est plus suceptible de mener \u00e0 une seconde vague que l'importation de nouveaux cas.", "objectives": "M\u00e9thodologie/objectifs peu d\u00e9taill\u00e9s", "methods": "Mod\u00e9liser l'\u00e9pid\u00e9mie de Covid dans les provinces de Jiangsu et Anhui, en tenant compte des patients asymptomatiques et de la saturation des services hospitaliers pour pr\u00e9dire la survenue de seconde vague \u00e9pid\u00e9mique.", "pubmed_id": "32330299\n32109013\n32181302\n32014114\n31502247\n18614583\n32190785\n32003551\n32133152\n32179137\n21771290\n32074444", "doi": "10.1002/jmv.25939", "abstract": "The epidemic of Coronavirus Disease 2019 has been a serious threat to public health worldwide. Data from 23 January to 31 March at Jiangsu and Anhui provinces in China were collected. We developed an adjusted model with two novel features: the asymptomatic population and threshold behavior in recovery. Unbiased parameter estimation identified faithful model fitting. Our model predicted that the epidemic for asymptomatic patients (ASP) was similar in both provinces. The latent periods and outbreak sizes are extremely sensitive to strongly controlled interventions such as isolation and quarantine for both asymptomatic and imported cases. We predicted that ASP serve as a more severe factor with faster outbreaks and larger outbreak sizes compared with imported patients. Therefore, we argued that the currently strict interventions should be continuously implemented, and unraveling the asymptomatic pool is critically important before preventive strategy such as vaccines.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 469, "name": "Sun T"}], "publication_date": "2020-04-27"}, {"id": 522, "slug": "clinical-and-epidemiological-characteristics-of-1420-european-patients-with-mild", "title": "Clinical and Epidemiological Characteristics of 1,420 European Patients with mild\u2010to\u2010moderate Coronavirus Disease 2019", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la pr\u00e9sentation clinique des cas l\u00e9gers \u00e0 mod\u00e9r\u00e9s de Covid-19 en Europe.", "verbose_date": "04.05.2020", "authors": "Lechien JR", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 101, "name": "J Intern Med"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13089", "findings": "", "take_away": "", "relevance_level": "Les 2 sympt\u00f4mes les plus fr\u00e9quents sont les\u00a0c\u00e9phal\u00e9es et l'anosmie (70% des cas chacun), puis l'obstruction nasale, la toux, l'asth\u00e9nie, les myalgies, la rhinorrh\u00e9e, l'agueusie (54%), la fi\u00e8vre (54%)\u00a0et les maux de gorge.\nLa pr\u00e9sentation varie selon l'\u00e2ge et le sexe.\nL'anosmie semble \u00eatre un sympt\u00f4me important des cas l\u00e9gers \u00e0 mod\u00e9r\u00e9s.", "objectives": "- Etude multicentrique- Nombre de patients importants (n=1 420)- Recueil des donn\u00e9es standardis\u00e9- Mais biais de s\u00e9lection : --patients jeunes avec peu de comorbidit\u00e9s--beaucoup de professionnels de sant\u00e9 dans la population--proportion \u00e9lev\u00e9e de femmes--sensibilit\u00e9 de la RT-PCR et diff\u00e9rences d'indication selon les pays-Sympt\u00f4mes subjectifs ne pouvant pas \u00eatre objectifi\u00e9s", "methods": "Etudier la pr\u00e9sentation clinique des cas l\u00e9gers \u00e0 mod\u00e9r\u00e9s de Covid-19 en Europe.", "pubmed_id": "32352202", "doi": "10.1111/joim.13089", "abstract": "The clinical presentation of European patients with mild-to-moderate Covid-19 infection is still unknown.\nTo study the clinical presentation of Covid-19 in Europe.\nPatients with positive diagnosis of Covid-19 were recruited from 18 European hospitals. Epidemiological and clinical data were obtained through a standardized questionnaire. Bayesian analysis was used for analyzing the relationship between outcomes.\n1,420 patients completed the study (962 females, 30.7% of health care workers). The mean age of patients was 39.17\u00b112.09 years. The most common symptoms were headache (70.3%), loss of smell (70.2%), nasal obstruction (67.8%), cough (63.2%), asthenia (63.3%), myalgia (62.5%), rhinorrhea (60.1%), gustatory dysfunction (54.2%) and sore throat (52.9%). Fever was reported by on 45.4%. The mean duration of Covid-19 symptoms of mild-to-moderate cured patients was 11.5\u00b15.7 days. The prevalence of symptoms significantly varied according to age and sex. Young patients more frequently had ear, nose, and throat complaints, whereas elderly individuals often presented fever, fatigue and loss of appetite. Loss of smell, headache, nasal obstruction and fatigue were more prevalent in female patients. The loss of smell was a key symptom of mild-to-moderate Covid19 patients and was not associated with nasal obstruction and rhinorrhea. Loss of smell persisted at least 7 days after the disease in 37.5% of cured patients.\nThe clinical presentation of mild-to-moderate Covid-19 substantially varies according to the age and the sex characteristics of patients. Olfactory dysfunction seems to be an important underestimated symptom of mild-to-moderate Covid-19 that needs to be recognized as such by the WHO.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 271, "name": "Lechien JR"}], "publication_date": "2020-05-04"}, {"id": 395, "slug": "central-nervous-system-manifestations-of-covid-19-a-systematic-review", "title": "Central nervous system manifestations of COVID-19: A systematic review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Discuter l\u2019implication du SNC et des manifestations neurologiques chez les patients atteints de covid-19.", "verbose_date": "18.04.2020", "authors": "Asadi-Pooya AA", "specialties": [{"id": 18, "name": "Neurologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 167, "name": "J Neurol Sci"}, "link": "https://www.jns-journal.com/article/S0022-510X(20)30168-4/pdf", "findings": "", "take_away": "", "relevance_level": "Dans cette \u00e9tude, implication su SNC et des manifestations neurologiques de covid19 sont rares et de faible qualit\u00e9. Ces derni\u00e8res n\u2019ont pas \u00e9t\u00e9 convenablement \u00e9tudi\u00e9 encore.N\u00e9c\u00e9ssit\u00e9 d\u2019une documentation cibl\u00e9e et pr\u00e9cise des sympt\u00f4mes neurologiques (c\u00e9phal\u00e9es, vertiges, etc) et signes (signes m\u00e9ning\u00e9s, etc), investigations cliniques, neurologiques et \u00e9lectrophysiologiques (EEG) d\u00e9taill\u00e9es de ces patients, tentative d\u2019isolation du virus dans le LCR ou encore une autopsie, afin de clarifier le r\u00f4le jou\u00e9 par ce virus dans les manifestations neurologiques.", "objectives": "Revue syst\u00e9matique de la litt\u00e9rature avec peu d'\u00e9tudes et h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9", "methods": "Discuter l\u2019implication du SNC et des manifestations neurologiques chez les patients atteints de covid-19.", "pubmed_id": "32299017\n15030709\n19622511\n32104915\n31861926\n32167747\n26030634\n27448521\n32007143\n26092326\n30416428\n14633896\n32031570\n32113704\n31986264\n25303830\n32105632\n28103598", "doi": "10.1016/j.jns.2020.116832", "abstract": "In this systematic review, we will discuss the evidence on the occurrence of central nervous system (CNS) involvement and neurological manifestations in patients with COVID-19.\nMEDLINE (accessed from PubMed) and Scopus from December 01, 2019 to March 26, 2020 were systematically searched for related published articles. In both electronic databases, the following search strategy was implemented and these key words (in the title/abstract) were used: \"COVID 19\" OR \"coronavirus\" AND \"brain\" OR \"CNS\" OR \"neurologic\".\nThrough the search strategy, we could identify two articles about neurological involvement by COVID-19. One of these publications was a narrative review and the other one was a viewpoint. However, the authors scanned the reference lists of the included studies and could identify multiple references. One study, specifically investigated the neurological manifestations of COVID-19 and could document CNS manifestations in 25% of the patients. Most of the studies investigated the manifestations of COVID-19 in general.\nWhile neurological manifestations of COVID-19 have not been studied appropriately, it is highly likely that some of these patients, particularly those who suffer from a severe illness, have CNS involvement and neurological manifestations. Precise and targeted documentation of neurological symptoms, detailed clinical, neurological, and electrophysiological investigations of the patients, attempts to isolate SARS-CoV-2 from cerebrospinal fluid, and autopsies of the COVID-19 victims may clarify the role played by this virus in causing neurological manifestations.", "topics": ["Epid\u00e9miologique", "Neurologie"], "author_list": [{"id": 379, "name": "Asadi-Pooya AA"}], "publication_date": "2020-04-18"}, {"id": 597, "slug": "impact-of-low-dose-tocilizumab-on-mortality-rate-in-patients-with-covid-19-relat", "title": "Impact of Low Dose Tocilizumab on Mortality Rate in Patients With COVID-19 Related Pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer l'impact du tocilizumab sur la mortalit\u00e9 des patients COVID-19", "verbose_date": "15.05.2020", "authors": "Capra R", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 12, "name": "Infectiologie"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 236, "name": "Eur J Intern Med"}, "link": "https://www.dropbox.com/s/imkzj2dtlez7mg4/1-s2.0-S0953620520301941-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le tocilizumab a montr\u00e9 un impact positif en termes de survie et d'\u00e9volution clinique avec son utilisation pr\u00e9coce dans cette \u00e9tude observationnelle r\u00e9trospective chez des patients COVID-19 avec syndrome respiratoire s\u00e9v\u00e8re.", "objectives": "Etude observationnelle r\u00e9trospective, monocentrique, 62 patients trait\u00e9s par tocilizumab, 23 \"contr\u00f4les\".Modalit\u00e9s diff\u00e9rentes d'administration du tocilizumab (2 ont re\u00e7u une dose de 800 mg en intra-veineux (IV), 33 ont re\u00e7u une dose de 400 mg en IV et 27 ont re\u00e7u une dose de 324 mg par voie sous-cutan\u00e9e).Patients du groupe Tocilizumab plus jeunes, plus souvent des femmes.", "methods": "Evaluer l'impact du tocilizumab sur la mortalit\u00e9 des patients COVID-19", "pubmed_id": "32405160", "doi": "10.1016/j.ejim.2020.05.009", "abstract": "Pneumonia with respiratory failure represents the main cause of death in COVID-19, where hyper inflammation plays an important role in lung damage. This study aims to evaluate if tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, reduces patients' mortality.\n85 consecutive patients admitted to the Montichiari Hospital (Italy) with COVID-19 related pneumonia and respiratory failure, not needing mechanical ventilation, were included if satisfying at least one among: respiratory rate \u2265 30 breaths/min, peripheral capillary oxygen saturation \u2264 93% or PaO2/FiO2<=300 mmHg. Patients admitted before March 13th (n=23) were prescribed the standard therapy (hydroxychloroquine, lopinavir and ritonavir) and were considered controls. On March 13th tocilizumab was available and patients admitted thereafter (n=62) received tocilizumab once within 4 days from admission, plus the standard care.\nPatients receiving tocilizumab showed significantly greater survival rate as compared to control patients (hazard ratio for death, 0.035; 95% confidence interval [CI], 0.004 to 0.347; p\u00a0=\u00a00.004), adjusting for baseline clinical characteristics. Two out of 62 patients of the tocilizumab group and 11 out of 23 in the control group died. 92% and 42.1% of the discharged patients in the tocilizumab and control group respectively, recovered. The respiratory function resulted improved in 64.8% of the observations in tocilizumab patients who were still hospitalized, whereas 100% of controls worsened and needed mechanical ventilation. No infections were reported.\nTocilizumab results to have a positive impact if used early during Covid-19 pneumonia with severe respiratory syndrome in terms of increased survival and favorable clinical course.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation", "Infectiologie", "Pneumologie"], "author_list": [{"id": 561, "name": "Capra R"}], "publication_date": "2020-05-15"}, {"id": 294, "slug": "cardiac-and-arrhythmic-complications-in-covid-19-patients", "title": "Cardiac and arrhythmic complications in Covid-19 patients", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Explorer les complications cardiaques du COVID-19 et comparer avec les donn\u00e9es disponibles sur le SARS-CoV-1, le MERS-CoV et la grippe H1N1", "verbose_date": "10.04.2020", "authors": "Kochi AN", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 137, "name": "J Cardiovasc Electrophysiol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/jce.14479", "findings": "", "take_away": "", "relevance_level": "Plusieurs \u00e9tudes soul\u00e8vent les atteintes cardiaques du SARS-CoV-2 avec des l\u00e9sions myocardiques et des troubles du rythme. Surveillance cardiovasculaire n\u00e9cessaire et plus particuli\u00e8rement les patients s\u00e9v\u00e8res et ceux avec des comorbidit\u00e9s cardiaques pr\u00e9-existantes. Attention particuli\u00e8re aux effets ind\u00e9sirables cardiaques des traitements empiriques utlis\u00e9s, attention \u00e9galement aux interactions m\u00e9dicamenteuses et \u00e0 la surveillance de l'intervalle QT.", "objectives": "1) Pre-proof2) Revue non syst\u00e9matique de la litt\u00e9rature\"", "methods": "Explorer les complications cardiaques du COVID-19 et comparer avec les donn\u00e9es disponibles sur le SARS-CoV-1, le MERS-CoV et la grippe H1N1", "topics": ["Epid\u00e9miologique", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 283, "name": "Kochi AN"}], "publication_date": "2020-04-10"}, {"id": 75, "slug": "hydroxychloroquine-and-azithromycin-as-a-treatment-of-covid-19-results-of-an-ope", "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9montrer l'effet th\u00e9rapeutique de l'hydroxychloroquine (600 mg par jour)", "verbose_date": "17.03.2020", "authors": "Gautret P e", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 60, "name": "International Journal of Antimicrobial Agents"}, "link": "https://www.dropbox.com/s/skr38h3hdkw1u9q/Hydroxychloroquine_final_DOI_IJAA.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Possible effet \u00e0 d\u00e9montrer de l'hydroxychloroquine potentialis\u00e9 par l'ajout d'azithromycine chez des patients atteints par le Covid-19N\u00e9cessite un essai clinique \u00e0 plus haut niveau de preuve pour application en pratique clinique (objet de l'essai europ\u00e9en d\u00e9butant le 20/03 avec un bras pour tester ce traitement)", "objectives": "Faible : 1) Essai non randomis\u00e9 en ouvert sur faible effectif2) Patients contr\u00f4les et trait\u00e9s dans h\u00f4pitaux diff\u00e9rents3) Multiplicit\u00e9 des tests statistiques (inflation risque alpha majeur)4) 10 patients t\u00e9moins sur 16 consid\u00e9r\u00e9s comme positif alors que non test\u00e9s5) Charge virale = mauvais crit\u00e8re de jugement car relation inverse entre charge virale et s\u00e9v\u00e9rit\u00e9 d\u00e9montr\u00e9e pour la famille des coronavirus dans une pr\u00e9c\u00e9dente \u00e9tude de 2016 publi\u00e9e dans Nature (\"SARS and MERS: recent insights into emerging coronaviruses\")", "methods": "D\u00e9montrer l'effet th\u00e9rapeutique de l'hydroxychloroquine (600 mg par jour)", "pubmed_id": "32205204\n27622822\n9927100\n26992838\n26575060\n30299363\n16640347\n32164085\n27911847", "doi": "10.1016/j.ijantimicag.2020.105949", "abstract": "Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.\nFrench Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16\nSix patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.\nDespite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.", "topics": ["Th\u00e9rapeutique", "Infectiologie"], "author_list": [{"id": 85, "name": "Gautret P e"}], "publication_date": "2020-03-17"}, {"id": 528, "slug": "prevalence-and-socio-demographic-correlates-of-psychological-health-problems-in-", "title": "Prevalence and socio-demographic correlates of psychological health problems in Chinese adolescents during the outbreak of COVID-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer la pr\u00e9valence de l'anxi\u00e9t\u00e9 et de la d\u00e9pression et leur corr\u00e9lations socio-d\u00e9mographiques parmi les adolescents chinois au cours de l'\u00e9pid\u00e9mie SARS-CoV-2.", "verbose_date": "05.05.2020", "authors": "Zhou SJ", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 208, "name": "European Child & Adolescent Psychiatry"}, "link": "https://link.springer.com/content/pdf/10.1007/s00787-020-01541-4.pdf", "findings": "", "take_away": "", "relevance_level": "- Pr\u00e9valence des sympt\u00f4mes d\u00e9pressifs : 43.7%, et des sympt\u00f4mes anxieux : 37.4% parmi une population de coll\u00e9giens et lyc\u00e9ens chinois.\n- Le\u00a0sexe f\u00e9minin appara\u00eet comme facteur de risque ind\u00e9pendant, de m\u00eame qu'habiter la province d'Hubei ou d'\u00eatre lyc\u00e9en.", "objectives": "- \u00c9tude observationnelle descriptive transversale- Probables biais de s\u00e9lection et de d\u00e9sirabilit\u00e9 sociale", "methods": "Evaluer la pr\u00e9valence de l'anxi\u00e9t\u00e9 et de la d\u00e9pression et leur corr\u00e9lations socio-d\u00e9mographiques parmi les adolescents chinois au cours de l'\u00e9pid\u00e9mie SARS-CoV-2.", "pubmed_id": "32363492\n17908376\n32027631\n29434331\n10568646\n32357513\n32043982\n24123859\n16676610\n17151166\n25023953\n30984663\n26966332\n27940701\n15342799\n12912767\n11556941\n27940726\n25360718\n21262472\n30967483\n16717171\n32172341\n18188442\n2751014\n10199117\n27231738\n22008427\n11437022\n30832200\n10360120\n24674239\n30579178\n17888804\n23952583\n32035030\n25532102\n25882127\n29921258\n26162484\n26412069", "doi": "10.1007/s00787-020-01541-4", "abstract": "Psychological health problems, especially emotional disorders, are common among adolescents. The epidemiology of emotional disorders is greatly influenced by stressful events. This study sought to assess the prevalence rate and socio-demographic correlates of depressive and anxiety symptoms among Chinese adolescents affected by the outbreak of COVID-19. We conducted a cross-sectional study among Chinese students aged 12-18\u00a0years during the COVID-19 epidemic period. An online survey was used to conduct rapid assessment. A total of 8079 participants were involved in the study. An online survey was used to collect demographic data, assess students' awareness of COVID-19, and assess depressive and anxiety symptoms with the Patient Health Questionnaire (PHQ-9) and the Generalized Anxiety Disorder (GAD-7) questionnaire, respectively. The prevalence of depressive symptoms, anxiety symptoms, and a combination of depressive and anxiety symptoms was 43.7%, 37.4%, and 31.3%, respectively, among Chinese high school students during the COVID-19 outbreak. Multivariable logistic regression analysis revealed that female gender was the higher risk factor for depressive and anxiety symptoms. In terms of grades, senior high school was a risk factor for depressive and anxiety symptoms; the higher the grade, the greater the prevalence of depressive and anxiety symptoms. Our findings show there is a high prevalence of psychological health problems among adolescents, which are negatively associated with the level of awareness of COVID-19. These findings suggest that the government needs to pay more attention to psychological health among adolescents while combating COVID-19.", "topics": ["Epid\u00e9miologique", "Psychiatrie"], "author_list": [{"id": 495, "name": "Zhou SJ"}], "publication_date": "2020-05-05"}, {"id": 323, "slug": "novel-approach-to-reduce-transmission-of-covid-19-during-tracheostomy", "title": "Novel Approach to Reduce Transmission of COVID-19 During Tracheostomy", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Pr\u00e9senter un protocole chirurgical de trach\u00e9otomie permettant de r\u00e9duire le risque de transmission du SARS-CoV-2", "verbose_date": "14.04.2020", "authors": "Foster P", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 145, "name": "J Am Coll Surg"}, "link": "https://reader.elsevier.com/reader/sd/pii/S1072751520303227?token=EA65C2D831AA5BBDE518B98F70DB631C8B703F4362E35FFF7024782B032807AD5C650CF71CECA0AF2D3B57D6E30A93C1", "findings": "", "take_away": "", "relevance_level": "Pr\u00e9sentation d'un protocole chirurgical pour accro\u00eetre la s\u00e9curit\u00e9 de l'op\u00e9rateur lors d'une trach\u00e9otomie via un champ plastique transparent tendu au-dessus du patient et l'utilisation de plusieurs filtres.\r\nToutefois, pas de v\u00e9rification de l'efficacit\u00e9 de ce dispositif.", "objectives": "- Retour d'exp\u00e9rience d'un seul centre- Absence d'exp\u00e9riementation sur la protection r\u00e9elle de ce dispositif, pas de pr\u00e9l\u00e8vements effectu\u00e9s\"", "methods": "Pr\u00e9senter un protocole chirurgical de trach\u00e9otomie permettant de r\u00e9duire le risque de transmission du SARS-CoV-2", "pubmed_id": "32283268\n32102726", "doi": "10.1016/j.jamcollsurg.2020.04.014", "abstract": null, "topics": ["Autres", "Anesth\u00e9sie-R\u00e9animation", "Hygi\u00e8ne"], "author_list": [{"id": 310, "name": "Foster P"}], "publication_date": "2020-04-14"}, {"id": 618, "slug": "hydroxychloroquine-or-chloroquine-with-or-without-a-macrolide-for-treatment-of-c", "title": "Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer le b\u00e9n\u00e9fice et la s\u00e9curit\u00e9 de l'utilisation de l'hydroxychloroquine, souvent utilis\u00e9e en association \u00e0 l'azythromycine, \u00e0 partir de registres multinationaux", "verbose_date": "23.05.2020", "authors": "Mehra MR", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 12, "name": "Lancet"}, "link": "https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31180-6.pdf", "findings": "", "take_away": "", "relevance_level": "Suite \u00e0 la r\u00e9tractation de 3 des 4 auteurs de l'\u00e9tude, les conclusions de celle-ci doivent \u00eatre prises avec pr\u00e9caution. La qualit\u00e9 et l'exactitude des donn\u00e9es sources utilis\u00e9es ne sont pas v\u00e9rifi\u00e9es. Toutefois, sur le volume des donn\u00e9es, les tendances mesur\u00e9es sont sans doute valables, \u00e9tant conformes aux tendances de la majorit\u00e9 des \u00e9tudes sur l'hydroxychloroquine : voir \"Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review\"\nCette \u00e9tude multinationale, observationnelle, r\u00e9trospective\u00a0sur donn\u00e9es de registre de\u00a0patients atteints de COVID-19 n\u00e9cessitant une hospitalisation a r\u00e9v\u00e9l\u00e9 que l'utilisation d'un traitement par hydroxychloroquine ou de la chloroquine (avec ou sans macrolide) n'\u00e9tait associ\u00e9e \u00e0 aucune preuve de b\u00e9n\u00e9fice, mais \u00e9tait plut\u00f4t associ\u00e9e \u00e0 une augmentation du risque d'arythmies ventriculaires et un risque accru de d\u00e9c\u00e8s \u00e0 l'h\u00f4pital avec COVID-19\nLe risque de d\u00e9c\u00e8s durant l'hospitalisation avec les traitements test\u00e9s passe de 9% \u00e0 16% minimum et m\u00eame 24% si association de l'hydroxychloroquine avec l'azythromycine\nCes r\u00e9sultats sugg\u00e8rent que ces sch\u00e9mas th\u00e9rapeutiques ne devraient pas \u00eatre utilis\u00e9s en dehors des essais cliniques et une confirmation urgente des essais cliniques randomis\u00e9s est n\u00e9cessaire", "objectives": "- Repr\u00e9sentation de l'utilisation pragmatique du traitement (vie r\u00e9elle)- Malgr\u00e9 la puissance de l'\u00e9tude et l'analyse statistique bien men\u00e9e avec score de propension, ne remplace pas un essai contr\u00f4l\u00e9 randomis\u00e9 en double-aveugle- On peut se poser la question de la fiabilit\u00e9 des donn\u00e9es extraites automatiquement par informatique depuis des dossiers m\u00e9dicaux remplis manuellement (m\u00eame si \"The Surgical Outcomes Collaborative\" est un registre r\u00e9guli\u00e8rement utilis\u00e9) : absence de v\u00e9rification possible de la qualit\u00e9 de ces donn\u00e9es primaires- Groupe contr\u00f4le non strictement comparable- Pas de mesure de l'intervalle QT ou d'enregistrement de torsades de pointe par exemple permettant de distinguer les arythmies les plus graves des autres", "methods": "Evaluer le b\u00e9n\u00e9fice et la s\u00e9curit\u00e9 de l'utilisation de l'hydroxychloroquine, souvent utilis\u00e9e en association \u00e0 l'azythromycine, \u00e0 partir de registres multinationaux", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 581, "name": "Mehra MR"}], "publication_date": "2020-05-23"}, {"id": 592, "slug": "the-incubation-period-of-coronavirus-disease-2019-covid-19-from-publicly-reporte", "title": "The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Estimer la dur\u00e9e de la p\u00e9riode d'incubation du COVID-19 et d\u00e9crire ses implications pour la sant\u00e9 publique", "verbose_date": "15.05.2020", "authors": "Lauer SA", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 41, "name": "Ann Intern Med"}, "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081172/pdf/aim-olf-M200504.pdf", "findings": "", "take_away": "", "relevance_level": "P\u00e9riode d'incubation moyenne de COVID-19 d'environ 5 jours. 97,5% de ceux qui d\u00e9veloppent des sympt\u00f4mes l'ont fait dans les 11,5 jours apr\u00e8s l'infection (IC95%, 8,2 \u00e0 15,6 jours).", "objectives": "n=181Etude bas\u00e9e sur reportages et communiqu\u00e9s de presse, cas hospitalis\u00e9sChaque rapport de cas est examin\u00e9 par deux auteurs, avec consensus sur les divergencesMod\u00e8le supposant un risque constant", "methods": "Estimer la dur\u00e9e de la p\u00e9riode d'incubation du COVID-19 et d\u00e9crire ses implications pour la sant\u00e9 publique", "pubmed_id": "32150748", "doi": "10.7326/M20-0504", "abstract": "A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in China in December 2019. There is limited support for many of its key epidemiologic features, including the incubation period for clinical disease (coronavirus disease 2019 [COVID-19]), which has important implications for surveillance and control activities.\nTo estimate the length of the incubation period of COVID-19 and describe its public health implications.\nPooled analysis of confirmed COVID-19 cases reported between 4 January 2020 and 24 February 2020.\nNews reports and press releases from 50 provinces, regions, and countries outside Wuhan, Hubei province, China.\nPersons with confirmed SARS-CoV-2 infection outside Hubei province, China.\nPatient demographic characteristics and dates and times of possible exposure, symptom onset, fever onset, and hospitalization.\nThere were 181 confirmed cases with identifiable exposure and symptom onset windows to estimate the incubation period of COVID-19. The median incubation period was estimated to be 5.1 days (95% CI, 4.5 to 5.8 days), and 97.5% of those who develop symptoms will do so within 11.5 days (CI, 8.2 to 15.6 days) of infection. These estimates imply that, under conservative assumptions, 101 out of every 10\u00a0000 cases (99th percentile, 482) will develop symptoms after 14 days of active monitoring or quarantine.\nPublicly reported cases may overrepresent severe cases, the incubation period for which may differ from that of mild cases.\nThis work provides additional evidence for a median incubation period for COVID-19 of approximately 5 days, similar to SARS. Our results support current proposals for the length of quarantine or active monitoring of persons potentially exposed to SARS-CoV-2, although longer monitoring periods might be justified in extreme cases.\nU.S. Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, and Alexander von Humboldt Foundation.", "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 556, "name": "Lauer SA"}], "publication_date": "2020-05-15"}, {"id": 185, "slug": "68-consecutive-patients-assessed-for-covid-19-infection-experience-from-a-uk-reg", "title": "68 Consecutive Patients Assessed for COVID-19 Infection; Experience From a UK Regional Infectious Disease Unit", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'exp\u00e9rience de l'\u00e9valuation cons\u00e9cutive de patients pour suspicion de COVID-19", "verbose_date": "29.03.2020", "authors": "Easom N ", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 94, "name": "Influenza Other Respir Viruses"}, "link": "https://www.dropbox.com/s/1s44ipxac45ovyp/irv.12739.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Sur 68 patients test\u00e9s, aucun coronavirus (mais au d\u00e9but de l'\u00e9pid\u00e9mie), pas de diagnostic retrouv\u00e9 dans 60,9% des cas sinon diagnostic diff\u00e9rentiel viral en majorit\u00e9\r\n15 patients ont \u00e9t\u00e9 hospitalis\u00e9s (22%) dont 5 pour impossibilit\u00e9 de s'isoler \u00e0 domicile\r\nLes patients n\u00e9cessitant une admission pour des raisons cliniques ou n\u00e9cessitant des antibiotiques ou antiviraux (14/68 ) \u00e9taient plus susceptibles d'avoir de la fi\u00e8vre ou une fr\u00e9quence respiratoire augment\u00e9e que ceux ne n\u00e9cessitant pas d'admission ou d'antibiotiques ou antiviraux.", "objectives": "1) S\u00e9rie de cas, \u00e0 l'\u00e9chelle r\u00e9gionale2) Etude r\u00e9alis\u00e9e au d\u00e9but de l'\u00e9pid\u00e9mie", "methods": "D\u00e9crire l'exp\u00e9rience de l'\u00e9valuation cons\u00e9cutive de patients pour suspicion de COVID-19", "topics": ["Epid\u00e9miologique", "Transversale", "Virologie"], "author_list": [{"id": 179, "name": "Easom N "}], "publication_date": "2020-03-29"}, {"id": 131, "slug": "epidemiological-clinical-characteristics-of-cases-of-sars-cov-2-infection-with-a", "title": "Epidemiological, clinical characteristics of cases of SARS- CoV-2 infection with abnormal imaging findings", "has_other_authors": false, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Identifier les caract\u00e9ristiques \u00e9pid\u00e9miologiques et cliniques des patients COVID-19 dont l'imagerie diagnostique est alt\u00e9r\u00e9e (Rx thoracique, TC scan pulmonaire).\r\n\r\nIdentifier les facteurs pr\u00e9dictifs de maladies graves ou critiques en croisant les donn\u00e9es cliniques et imaging score.", "verbose_date": "26.03.2020", "authors": "Zhang X", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.dropbox.com/s/socgx9fqqpa52ax/PIIS1201971220301727.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L\u00e9sions pulmonaires au imaging\r\nSur 645 pts: 72 nouvelles l\u00e9sions pulmonaires, 573 consolidations et/ou opacit\u00e9s en verre d\u00e9poli en au moins un lobe pulmonaire\r\n1) Corr\u00e9lation n\u00e9gative statistiquement significative entre le score radiographique et la PaO2/FiO2 : l'implication de multiples lobes pourrait entra\u00eener une d\u00e9t\u00e9rioration de la fonction pulmonaire (p<0.001)\n\r\nCaract\u00e9ristique \u00e9pidemiologiques\r\n1) Age moyen (46,65 ans) et pr\u00e9sence d'au moins une comorbidit\u00e9(28.8%) sont plus \u00e9lev\u00e9s pour les patients avec pneumonie(p age<0.0001, p com<0.05)\r\n2)\u00a0D\u00e9lai d'apparition des sympt\u00f4mes plus long pour les pts avec pneumonie (p<0,05)\r\n3) Pourcentage de sujets expos\u00e9s \u00e0 Wuhan ou contacts de cas confirm\u00e9s est plus faible pour les patients avec pneumonie (81.0% vs 91.7%, p<0.05)\n\r\nSympt\u00f4mes cliniques et resultas laboratoire\r\n1)\u00a0Fi\u00e9vre (85.9%), toux (68.4%), expectorations (36.3%) maux de gorge (14.0%), maux de t\u00eate (11.3%)\u00a0pour les patients avec pneumonie statistiquement\u00a0plus hauts\u00a0que pour les patients sans pneumonie (p<0.05).\u00a0Pour la\u00a0fatigue,\u00a0la\u00a0dyspn\u00e9e\u00a0et la\u00a0diarrh\u00e9e pas\u00a0des\u00a0diff\u00e9rences significatives\u00a0entre les deux groupes\r\n2) Pour\u00a0le patients avec pneumonie:\u00a0niveaux\u00a0plus faibles\u00a0de\u00a0lymphocytes,\u00a0d'albumine\u00a0et de\u00a0sodium s\u00e9rique\u00a0(p<0,05)\u00a0/\u00a0niveaux\u00a0plus \u00e9lev\u00e9s\u00a0de\u00a0bilirubine totale, de\u00a0cr\u00e9atinine kinase,\u00a0de\u00a0lactate d\u00e9shydrog\u00e9nase\u00a0et deprot\u00e9ine C r\u00e9active\u00a0(p<0,05)\r\n3) PaO2/FiO2 plus faible pour les patients avec pneumonie (381.46 vs 478.79, p<0.001)\n\r\nTraitements\r\n1) Glucocortico\u00efdes le plus souvent administr\u00e9s aux patients atteints de pneumonie (13.4% vs 0.0%, p<0.001),(glucocortico\u00efdes envisag\u00e9s si PaO2/FiO2<300mmHg et non recommand\u00e9s pour les sympt\u00f4mes l\u00e9gers)\r\n2) Oxyg\u00e9noth\u00e9rapie plus utilis\u00e9e pour les patients avec pneumonie (43,6% vs 11.1%, p<0.001), pourrait \u00eatre corr\u00e9l\u00e9 avec PaO2/FiO2 plus faible\n\r\nPossibles facteurs pr\u00e9dictifs de formes graves\r\n- douleurs musculaires (p=0,002)\r\n- dyspn\u00e9e (p=0,002)\r\n- naus\u00e9es et vomissements (p=0,001)\r\n- taux \u00e9lev\u00e9s de cr\u00e9atinine s\u00e9rique (p=0,004)\r\n- faibles taux de lymphocytes (p=0,008)\u00a0\u00a0\r\n- score radiographique \u00e9lev\u00e9", "objectives": "1) r\u00e9trospective2) donn\u00e9es entre 17 janvier 2020 et 8 f\u00e9vrier 2020, manque le suivi longitudinale des patients3) description des l\u00e9sions pulmonaires devrait \u00eatre plus d\u00e9taill\u00e9e\"", "methods": "Identifier les caract\u00e9ristiques\u00a0\u00e9pid\u00e9miologiques\u00a0et\u00a0cliniques\u00a0des patients COVID-19 dont l'imagerie diagnostique\u00a0est\u00a0alt\u00e9r\u00e9e\u00a0(Rx thoracique, TC scan pulmonaire).\n\r\nIdentifier les\u00a0facteurs pr\u00e9dictifs\u00a0de\u00a0maladies graves\u00a0ou critiques en croisant les donn\u00e9es cliniques et imaging score.", "pubmed_id": "32205284\n19834123\n32049601\n21561754\n32017662\n12759474\n32005675\n4813333\n32007143\n16778260\n32007145\n32107577\n32017661\n32006657\n20925450\n31996437\n15752436\n20349409\n26998804\n22797452\n31986264\n20007555\n23382162\n31226023\n32052466\n32007627", "doi": "10.1016/j.ijid.2020.03.040", "abstract": "To investigate the epidemiological and clinical characteristics of COVID-19 patients with abnormal imaging findings.\nPatients confirmed with SARS-CoV-2 infection in Zhejiang province from January 17 to February 8 who had undergone CT or X-ray were enrolled. Epidemiological and clinical data were analyzed among those with abnormal or normal imaging findings.\nExcluding 72 patients with normal images, 230 of 573 patients showed abnormalities affecting more than two lung lobes. The median radiographic score was 2.0, and there was a negative correlation between that score and the oxygenation index (\u03c1 = -0.657, P < 0.001). Patients with abnormal images were older (46.65 \u00b1 13.82), with a higher rate of coexisting condition (28.8%), a lower rate of exposure history, and longer time between onset and confirmation (5 days) than non-pneumonia patients (all P < 0.05). A higher rate of fever, cough, expectoration and headache, a lower level of lymphocytes, albumin, and serum sodium levels and a higher total bilirubin, creatine kinase, lactate dehydrogenase, and C-reactive protein levels and a lower oxygenation index were observed in pneumonia patients (all P < 0.05). Muscle ache, shortness of breath, nausea and vomiting, lower lymphocytes levels, and higher serum creatinine and radiographic score at admission were predictive factors for the severe/critical subtype.\nPatients with abnormal images have more obvious clinical manifestations and laboratory changes. Combing clinical features and radiographic scores can effectively predict severe/critical types.", "topics": ["Epid\u00e9miologique", "Radiologie"], "author_list": [{"id": 10, "name": "Zhang X"}], "publication_date": "2020-03-26"}, {"id": 432, "slug": "prevalence-and-characteristics-of-gastrointestinal-symptoms-in-patients-with-sar", "title": "Prevalence and Characteristics of Gastrointestinal Symptoms in Patients with SARS-CoV-2 Infection in the United States: A Multicenter Cohort Study", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Caract\u00e9riser la pr\u00e9valence et les caract\u00e9ristiques des sympt\u00f4mes gastro-intestinaux associ\u00e9s au COVID-19 dans une cohorte hospitali\u00e8re d'adultes \u00e9tats-uniens.", "verbose_date": "24.04.2020", "authors": "Redd W", "specialties": [{"id": 19, "name": "H\u00e9pato-gastro-ent\u00e9rologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 21, "name": "Gastroenterology"}, "link": "https://www.gastrojournal.org/article/S0016-5085(20)30564-3/pdf", "findings": "", "take_away": "", "relevance_level": "Pr\u00e8s de 2/3 des patients hospitalis\u00e9s au Massachusetts pour COVID-19 avaient des sympt\u00f4mes gastro-intestinaux. Parmis ceux les plus fr\u00e9quents \u00e9taient retrouv\u00e9s l'anorexie, la diarrh\u00e9e et la naus\u00e9e.\u00a0\r\nLes patients avec ce type de sympt\u00f4mes d\u00e9crivaient plus souvent de l'asth\u00e9nie, des myalgies et des maux de gorge. Leur trajectoire hospitali\u00e8re n'\u00e9tait pas diff\u00e9rente des autres patients.\u00a0\r\nLes patients avec anosmie et agueusie \u00e9taient plus \u00e0 risque d'avoir naus\u00e9e et anorexie.", "objectives": "- Cohorte r\u00e9trospective multicentrique- Une des premi\u00e8re et plus grosse \u00e9tude US \u00e9tudiant les manifestation gastro-intestinales- Manque d'instrument valid\u00e9 pour les sympt\u00f4mes- Biais de s\u00e9lection sur les patients hospitalis\u00e9s : non g\u00e9n\u00e9ralisable \u00e0 la population g\u00e9n\u00e9rale", "methods": "Caract\u00e9riser la pr\u00e9valence et les caract\u00e9ristiques des sympt\u00f4mes gastro-intestinaux associ\u00e9s au COVID-19 dans une cohorte hospitali\u00e8re d'adultes \u00e9tats-uniens.", "pubmed_id": "32333911", "doi": "10.1053/j.gastro.2020.04.045", "abstract": null, "topics": ["Epid\u00e9miologique", "H\u00e9pato-gastro-ent\u00e9rologie"], "author_list": [{"id": 410, "name": "Redd W"}], "publication_date": "2020-04-24"}, {"id": 108, "slug": "coronavirus-in-pregnancy-and-delivery-rapid-review", "title": "Coronavirus in pregnancy and delivery: rapid review", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Elaboration de raccomandations pour l'infection COVID-19 pendant la grossesse avec le consentement du RCPCH et du RCOG pour les sujets o\u00f9 les donn\u00e9es sont insuffisantes", "verbose_date": "12.03.2020", "authors": "Mullins E", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 75, "name": "Ultrasound Obstet Gynecol"}, "link": "https://www.dropbox.com/s/e3czacg38eif20c/10.1002%40uog.22014.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Sur 32 patientes \u00e9tudi\u00e9es, 7 \u00e9taient asymptomatiques, 23 symptomatiques et 2 ont n\u00e9cessit\u00e9 des soins intensifs. 27 de ces patientes ont accouch\u00e9s par c\u00e9sarienne et 47% ont n\u00e9cessit\u00e9 un accouchement avant terme.  Il n'y a pas de preuves pour une transmission materno-foetale du SARS-CoV-19.", "objectives": "Interm\u00e9diaire : 1) Revue de la litt\u00e9rature sur 23 \u00e9tudes", "methods": "Elaboration de raccomandations pour l'infection COVID-19 pendant la grossesse avec le consentement du RCPCH et du RCOG pour les sujets o\u00f9 les donn\u00e9es sont insuffisantes", "pubmed_id": "32180292", "doi": "10.1002/uog.22014", "abstract": "There are limited case series reporting the impact on women affected by coronavirus during pregnancy. In women affected by severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), the case fatality rate appears higher in those affected in pregnancy compared with non-pregnant women. We conducted a rapid review to guide health policy and management of women affected by COVID-19 during pregnancy, which was used to develop the Royal College of Obstetricians and Gynaecologists' (RCOG) guidelines on COVID-19 infection in pregnancy.\nSearches were conducted in PubMed and MedRxiv to identify primary case reports, case series, observational studies and randomized controlled trials describing women affected by coronavirus in pregnancy. Data were extracted from relevant papers. This review has been used to develop guidelines with representatives of the Royal College of Paediatrics and Child Health (RCPCH) and RCOG who provided expert consensus on areas in which data were lacking.\nFrom 9965 search results in PubMed and 600 in MedRxiv, 21 relevant studies, all of which were case reports or case series, were identified. From reports of 32 women to date affected by COVID-19 in pregnancy, delivering 30 babies (one set of twins, three ongoing pregnancies), seven (22%) were asymptomatic and two (6%) were admitted to the intensive care unit (ICU), one of whom remained on extracorporeal membrane oxygenation. No maternal deaths have been reported to date. Delivery was by Cesarean section in 27 cases and by vaginal delivery in two, and 15 (47%) delivered preterm. There was one stillbirth and one neonatal death. In 25 babies, no cases of vertical transmission were reported; 15 were reported as being tested with reverse transcription polymerase chain reaction after delivery. Case fatality rates for SARS and MERS were 15% and 27%, respectively. SARS was associated with miscarriage or intrauterine death in five cases, and fetal growth restriction was noted in two ongoing pregnancies affected by SARS in the third trimester.\nSerious morbidity occurred in 2/32 women with COVID-19, both of whom required ICU care. Compared with SARS and MERS, COVID-19 appears less lethal, acknowledging the limited number of cases reported to date and that one woman remains in a critical condition. Preterm delivery affected 47% of women hospitalized with COVID-19, which may put considerable pressure on neonatal services if the UK's reasonable worst-case scenario of 80% of the population being affected is realized. Based on this review, RCOG, in consultation with RCPCH, developed guidance for delivery and neonatal care in pregnancies affected by COVID-19, which recommends that delivery mode be determined primarily by obstetric indication and recommends against routine separation of affected mothers and their babies. We hope that this review will be helpful for maternity and neonatal services planning their response to COVID-19. \u00a9 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.", "topics": ["Autres", "P\u00e9diatrie"], "author_list": [{"id": 114, "name": "Mullins E"}], "publication_date": "2020-03-12"}, {"id": 68, "slug": "the-difference-in-the-incubation-period-of-2019-novel-coronavirus-sars-cov-2-inf", "title": "The difference in the incubation period of 2019 novel coronavirus (SARS- CoV-2) infection between travelers to Hubei and non-travelers: The need of a longer quarantine period", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Comparer la dur\u00e9e d'incubation de l'infection \u00e0 SARS-CoV-2 entre les sujets infect\u00e9s lors d'un voyage dans le Hubei et ceux s'\u00e9tant infect\u00e9 dans un autre contexte.", "verbose_date": "18.03.2020", "authors": "Leung C", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 55, "name": "Infect Control Hosp Emidemiol"}, "link": "https://www.dropbox.com/s/28dv97p662ti556/difference_in_the_incubation_period_of_2019_novel_coronavirus_sarscov2_infection_between_travelers_to_hubei_and_nontravelers_the_need_of_a_longer_quarantine_period.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La dur\u00e9e d'incubation du SARS-CoV-2 pourrait \u00eatre sup\u00e9rieure \u00e0 14jours, auquel cas les mesures de pr\u00e9vention de la transmission devraient \u00eatre adapt\u00e9es. Mais cette hypoth\u00e8se devrait \u00eatre confirm\u00e9e avec des donn\u00e9es plus fiables que celles de la pr\u00e9sente \u00e9tude.", "objectives": "Faible:1) Sources de donn\u00e9es non fiables : m\u00e9dias 2) Faible pr\u00e9cision des dur\u00e9es d'exposition, du fait de donn\u00e9es incompl\u00e8tes3) Manque cruel d'information sur la s\u00e9lection des non-expos\u00e9s durant un voyage dans le Hubei et sur leurs caract\u00e9ristiques", "methods": "Comparer la dur\u00e9e d'incubation de l'infection \u00e0 SARS-CoV-2 entre les sujets infect\u00e9s lors d'un voyage dans le Hubei et ceux s'\u00e9tant infect\u00e9 dans un autre contexte.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 78, "name": "Leung C"}], "publication_date": "2020-03-18"}, {"id": 381, "slug": "a-tool-to-early-predict-severe-coronavirus-disease-2019-covid-19-a-multicenter-s", "title": "A Tool to Early Predict Severe Coronavirus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9velopper un nomogramme pour pr\u00e9dire, \u00e0 l'\u00e9chelle individuelle, la probabilit\u00e9 de COVID-19 s\u00e9v\u00e8re", "verbose_date": "19.04.2020", "authors": "Gong J", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 24, "name": "Clin Infect Dis"}, "link": "https://www.dropbox.com/s/pgputmgr6ko8y18/ciaa443.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le nomogramme \u00e9labor\u00e9 dans cette \u00e9tude, bas\u00e9 sur 7 facteurs pronostiques principalement biologiques, pourrait \u00eatre un outil utile pour l'orientation et le suivi des patients mais reste \u00e0 valider dans d'autres populations en l'agr\u00e9mentant \u00e9ventuellement pour am\u00e9liorer sa sensibilit\u00e9 et sa sp\u00e9cificit\u00e9.", "objectives": "- \u00e9tude r\u00e9trospective- statut final non d\u00e9fini pour certains patients encore hospitalis\u00e9s \u00e0 la fin de l'\u00e9tude- risque de faux positifs li\u00e9 au choix du seuil- pas d'inclusion des Ig M et Ig G\"", "methods": "D\u00e9velopper un nomogramme pour pr\u00e9dire, \u00e0 l'\u00e9chelle individuelle, la probabilit\u00e9 de COVID-19 s\u00e9v\u00e8re", "pubmed_id": "32296824", "doi": "10.1093/cid/ciaa443", "abstract": "Due to no reliable risk stratification tool for severe coronavirus disease 2019 (COVID-19) patients at admission, we aimed to construct an effective model for early identification of cases at high risk of progression to severe COVID-19.\nIn this retrospective three-centers study, 372 non-severe COVID-19 patients during hospitalization were followed for more than 15 days after admission. Patients who deteriorated to severe or critical COVID-19 and patients who kept non-severe state were assigned to the severe and non-severe group, respectively. Based on baseline data of the two groups, we constructed a risk prediction nomogram for severe COVID-19 and evaluated its performance.\nThe training cohort consisted of 189 patients, while the two independent validation cohorts consisted of 165 and 18 patients. Among all cases, 72 (19.35%) patients developed severe COVID-19. We found that old age, and higher serum lactate dehydrogenase, C-reactive protein, the coefficient of variation of red blood cell distribution width, blood urea nitrogen, direct bilirubin, lower albumin, are associated with severe COVID-19. We generated the nomogram for early identifying severe COVID-19 in the training cohort (AUC 0.912 [95% CI 0.846-0.978], sensitivity 85.71%, specificity 87.58%); in validation cohort (0.853 [0.790-0.916], 77.5%, 78.4%). The calibration curve for probability of severe COVID-19 showed optimal agreement between prediction by nomogram and actual observation. Decision curve and clinical impact curve analysis indicated that nomogram conferred high clinical net benefit.\nOur nomogram could help clinicians to early identify patients who will exacerbate to severe COVID-19, which will enable better centralized management and early treatment of severe patients.", "topics": ["Pronostique", "Transversale"], "author_list": [{"id": 367, "name": "Gong J"}], "publication_date": "2020-04-19"}, {"id": 162, "slug": "meplazumab-treats-covid-19-pneumonia-an-open-labelled-concurrent-controlled-add-", "title": "Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer l'efficacit\u00e9 et la s\u00e9curit\u00e9 d'utilisation de l'anticorps anti-CD147 MEPLAZUMAB comme traitement d'appoint dans la pneumopathie \u00e0 COVID-19, bas\u00e9 sur des hypoth\u00e8ses de m\u00e9canisme \u00e0 la fois anti-viral et anti-inflammatoire.", "verbose_date": "26.03.2020", "authors": "Huijie B ", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/q7lkhsmcbsifp2k/2020.03.21.20040691v1.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Un traitement par 3 doses de MEPLAZUMAB IV en d\u00e9but de pneumopathie par le SRAS-CoV-2 pourrait am\u00e9liorer et acc\u00e9l\u00e9rer la clairance virale, la s\u00e9v\u00e9rit\u00e9 de la maladie, les constats radiologiques et le d\u00e9lai de sortie des patients mais ces r\u00e9sultats doivent \u00eatre confirm\u00e9s par un essai de plus grande ampleur.", "objectives": "\"Attention : Pre-Prints (pas encore de reviewing)1) Pas de randomisation2) Pas d'aveugle2) Crit\u00e8res d'exclusion \u00e0 pr\u00e9ciser4) Multiples tests mais sans correction de l'inflation du risque alpha5) Un seul centre, faibles effectifs6) M\u00eame si diff\u00e9rence non significative : plus de patients du groupe MEPLAZUMAB \u00e9taient trait\u00e9s par glucocortico\u00efdes (94% versus 64% des contr\u00f4les)7) Pas d'information sur le d\u00e9lai entre le d\u00e9but des sympt\u00f4mes et l'inclusion\"", "methods": "\u00c9valuer l'efficacit\u00e9 et la s\u00e9curit\u00e9 d'utilisation de l'anticorps anti-CD147 MEPLAZUMAB comme traitement d'appoint dans la pneumopathie \u00e0 COVID-19, bas\u00e9 sur des hypoth\u00e8ses de m\u00e9canisme \u00e0 la fois anti-viral et anti-inflammatoire.", "topics": ["Th\u00e9rapeutique", "Infectiologie"], "author_list": [{"id": 158, "name": "Huijie B "}], "publication_date": "2020-03-26"}, {"id": 274, "slug": "high-dose-intravenous-immunoglobulin-as-a-therapeutic-option-for-deteriorating-p", "title": "High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier l'effet des immunoglobulines IV dans des cas de formes s\u00e9v\u00e8res", "verbose_date": "08.04.2020", "authors": "Cao W", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 130, "name": "Open Forum Infect Dis"}, "link": "https://www.dropbox.com/s/ez9ofaey7nyv3y0/ofaa102.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les immunoglobulines IV pourraient \u00eatre une option th\u00e9rapeutique pour les patients COVID 19.\r\nLe timing de l'introduction est important (avant que les l\u00e9sions syst\u00e9miques ne soient install\u00e9es).", "objectives": "- 3 cas  - 2 patients prenaient d'autres antiviraux en plus des IVIg - 1 patient \u00e9tait sous st\u00e9ro\u00efdes - 1 patient sous valsartan (possible augmentation des ACE2)\"", "methods": "Etudier l'effet des immunoglobulines IV dans des cas de formes s\u00e9v\u00e8res", "pubmed_id": "32258207\n32007145\n32017661\n31978945\n15200814\n31996437\n28666326\n24474051\n10606875\n32129518\n28079912\n18685919\n31986264\n23840006\n18181739\n22454268", "doi": "10.1093/ofid/ofaa102", "abstract": "The outbreak of coronavirus disease 2019 (COVID-19) has spread rapidly in China. Until now, no definite effective treatment has been identified. We reported on 3 patients with severe COVID-19 who received high-dose intravenous immunoglobulin (IVIg) with satisfactory recovery. Based on these observations, randomized studies of high-dose IVIg should be considered in deteriorating patients infected with COVID-19.", "topics": ["Th\u00e9rapeutique", "Infectiologie", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie"], "author_list": [{"id": 263, "name": "Cao W"}], "publication_date": "2020-04-08"}, {"id": 210, "slug": "early-antiviral-treatment-contributes-to-alleviate-the-severity-and-improve-the-", "title": "Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "\u00c9valuer les facteurs associ\u00e9s \u00e0 la gravit\u00e9 et au pronostic des patients infect\u00e9s par le SARS-CoV-2", "verbose_date": "31.03.2020", "authors": "Wu J ", "specialties": [{"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 101, "name": "J Intern Med"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.13063", "findings": "", "take_away": "", "relevance_level": "Facteurs de risque de formes s\u00e9v\u00e8res :\r\n- \u00c2ge plus \u00e9lev\u00e9 (63 ans de m\u00e9diane)\r\n- trait\u00e9s plus tardivement par antiviraux (2,5 jours)\r\n- Avec plus de comorbidit\u00e9s : 86% d'entre eux avec diab\u00e8te ou maladie cardiovasculaire\r\n- IMC plus \u00e9lev\u00e9 (25 en m\u00e9diane)\n\r\nFacteurs pronostiques :\r\n- Comorbidit\u00e9s\r\n- D\u00e9lai d'instauration du traitement antiviral", "objectives": "- \u00c9tude de cohorte multicentrique mais h\u00f4pitaux de la m\u00eame r\u00e9gion chinoise- Multiplicit\u00e9 des tests statistiques (inflation du risque alpha)- Recrutement r\u00e9trospectif- D\u00e9finition des cas s\u00e9v\u00e8res peu claire", "methods": "\u00c9valuer les facteurs associ\u00e9s \u00e0 la gravit\u00e9 et au pronostic des patients infect\u00e9s par le SARS-CoV-2", "pubmed_id": "32220033", "doi": "10.1111/joim.13063", "abstract": "At present, the severity of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a focal point.\nTo assess the factors associated with severity and prognosis of patients infected with SARS-CoV-2, we retrospectively investigated the clinical, imaging and laboratory characteristics of confirmed 280 cases of novel coronavirus disease (COVID-19) from 20 January to 20 February 2020.\nThe median age of patients in the mild group was 37.55\u00a0years, whilst that in the severe group was 63.04\u00a0years. The proportion of patients aged over 65\u00a0years in the severe group was significantly higher than that of the mild group (59.04% vs. 10.15%, P\u00a0<\u00a00.05). 85.54% of severe patients had diabetes or cardiovascular diseases, which was significantly higher than that of the mild group (51.81% vs. 7.11%, P\u00a0=\u00a00.025; 33.73% vs. 3.05%, P\u00a0=\u00a00.042). Patients in the mild group experienced earlier initiation of antiviral treatment (1.19\u00a0\u00b1\u00a00.45 vs. 2.65\u00a0\u00b1\u00a01.06\u00a0days in the severe group, P\u00a0<\u00a00.001). Our study showed that comorbidity, time from illness onset to antiviral treatment and age >=65 were three major risk factors for COVID-19 progression, whilst comorbidity and time from illness onset to antiviral treatment were two major risk factors for COVID-19 recovery.\nThe elderly and patients with underlying diseases are more likely to experience a severe progression of COVID-19. It is recommended that timely antiviral treatment should be initiated to slow the disease progression and improve the prognosis.", "topics": ["Th\u00e9rapeutique", "Infectiologie"], "author_list": [{"id": 199, "name": "Wu J "}], "publication_date": "2020-03-31"}, {"id": 666, "slug": "estimating-the-effects-of-non-pharmaceutical-interventions-on-covid-19-in-europe", "title": "Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Etudier l'impact des interventions majeures dans 11 pays europ\u00e9ens (Autriche, Belgique, Danemark, France, Allemagne, Italie, Norv\u00e8ge, Espagne, Su\u00e8de, Suisse, Royaume-Uni) pour la p\u00e9riode allant du d\u00e9but de la COVID-19 jusqu'au 4 mai 2020, date \u00e0 laquelle les mesures de confinement ont commenc\u00e9 \u00e0 \u00eatre lev\u00e9es.", "verbose_date": "09.06.2020", "authors": "Flaxman S", "specialties": [{"id": 21, "name": "Confinement/D\u00e9confinement"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 189, "name": "Nature"}, "link": "https://www.nature.com/articles/s41586-020-2405-7_reference.pdf", "findings": "", "take_away": "", "relevance_level": "Les r\u00e9sultats de cette \u00e9tude montrent que les grandes interventions non pharmaceutiques et le confinement en particulier ont eu un effet important sur la r\u00e9duction de la transmission. Une intervention continue devrait \u00eatre envisag\u00e9e pour maintenir la transmission du SARS-CoV-2 sous contr\u00f4le.", "objectives": "- Accelerated Article Preview- \u00c9tude observationnelle- Mod\u00e9lisation bien men\u00e9e", "methods": "Etudier l'impact des interventions majeures dans 11 pays europ\u00e9ens\u00a0(Autriche, Belgique, Danemark, France, Allemagne, Italie, Norv\u00e8ge, Espagne, Su\u00e8de, Suisse, Royaume-Uni) pour la p\u00e9riode allant du d\u00e9but de la\u00a0COVID-19 jusqu'au 4 mai 2020, date \u00e0 laquelle les mesures de confinement ont commenc\u00e9 \u00e0 \u00eatre lev\u00e9es.", "pubmed_id": "32512579", "doi": "10.1038/s41586-020-2405-7", "abstract": "Following the emergence of a novel coronavirus", "topics": ["Mod\u00e9lisation", "Confinement/D\u00e9confinement", "Infectiologie"], "author_list": [{"id": 626, "name": "Flaxman S"}], "publication_date": "2020-06-09"}, {"id": 489, "slug": "acute-limb-ischemia-in-patients-with-covid-19-pneumonia", "title": "Acute limb ischemia in patients with COVID-19 pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'incidence, les caract\u00e9ristiques et les \u00e9volutions cliniques de patients Covid-19 avec une isch\u00e9mie aig\u00fce du membre inf\u00e9rieur.", "verbose_date": "30.04.2020", "authors": "Bellosta R", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 198, "name": "J Vasc Surg"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0741521420310806?token=534D06F002B528937C67A13B9E29A9D4F8A04C2B1DFBAF72ADCEA0C6CC63DC51389E6B61A51548069C8C435E1FA873D9", "findings": "", "take_away": "", "relevance_level": "En Lombardie, l'incidence de l'isch\u00e9mie art\u00e9rielle aig\u00fce du membre inf\u00e9rieur a augment\u00e9 par rapport \u00e0 l'ann\u00e9e derni\u00e8re.\r\nLe succ\u00e8s de la revascularisation est moins bon qu'escompt\u00e9 (hypercoagulabilit\u00e9 induite par le virus?).\r\nL'utilisation d'h\u00e9parine prolong\u00e9e pourrait am\u00e9liorer la mortalit\u00e9.", "objectives": "- Etude de cohorte prospective- Mais nombre du sujets limit\u00e9 (n=20)- P\u00e9riodes d'inclusion et de suivi courtes- L'incidence \u00e9lev\u00e9e pourrait \u00eatre due \u00e0 un retard au diagnostic dans ce contexte de pand\u00e9mie- Manque de donn\u00e9es sur l'hyper-coagulabilit\u00e9 induite par le virus \u00e9nonc\u00e9e dans l'article", "methods": "D\u00e9crire l'incidence, les caract\u00e9ristiques et les \u00e9volutions cliniques de patients Covid-19 avec une isch\u00e9mie aig\u00fce du membre inf\u00e9rieur.", "pubmed_id": "32360679\n24768362\n25971435\n15109406\n32145829\n19298930\n30583891\n16254381\n25961885\n28851596\n31315999\n25454806\n11400082\n26867832\n12756362\n32073213\n25638515\n27901322", "doi": "10.1016/j.jvs.2020.04.483", "abstract": "The aim of our study was to determine the incidence, characteristics, and clinical outcomes of patients with the novel coronavirus (COVID-19) infection who had presented with and been treated for acute limb ischemia (ALI) during the 2020 coronavirus pandemic.\nWe performed a single-center, observational cohort study. The data from all patients who had tested positive for COVID-19 and had presented with ALI requiring urgent operative treatment were collected in a prospectively maintained database. For the present series, successful revascularization of the treated arterial segment was defined as the absence of early (<30\u00a0days) re-occlusion or major amputation or death within 24\u00a0hours. The primary outcomes were successful revascularization, early (\u226430\u00a0days) and late (\u226530\u00a0days) survival, postoperative (\u226430\u00a0days) complications, and limb salvage.\nWe evaluated the data from 20 patients with ALI who were positive for COVID-19. For the period from January to March, the incidence rate of patients presenting with ALI in 2020 was significantly greater than that for the same months in 2019 (23 of 141 [16.3%] vs 3 of 163 [1.8%]; P\u00a0< .001)]. Of the 20 included patients, 18 were men (90%) and two were women (10%). Their mean age was 75\u00a0\u00b1 9\u00a0years (range, 62-95\u00a0years). All 20 patients already had a diagnosis of COVID-19 pneumonia. Operative treatment was performed in 17 patients (85%). Revascularization was successful in 12 of the 17 (70.6%). Although successful revascularization was not significantly associated with the postoperative use of intravenous heparin (64.7% vs 83.3%; P\u00a0= .622), no patient who had received intravenous heparin required reintervention. Of the 20 patients, eight (40%) had died in the hospital. The patients who had died were significantly older (81\u00a0\u00b1 10\u00a0years vs 71\u00a0\u00b1 5\u00a0years; P\u00a0= .008). The use of continuous postoperative systemic heparin infusion was significantly associated with survival (0% vs 57.1%; P\u00a0= .042).\nIn our preliminary experience, the incidence of ALI has significantly increased during the COVID-19 pandemic in the Italian Lombardy region. Successful revascularization was lower than expected, which we believed was due to a virus-related hypercoagulable state. The use of prolonged systemic heparin might improve surgical treatment efficacy, limb salvage, and overall survival.", "topics": ["Epid\u00e9miologique", "Infectiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 457, "name": "Bellosta R"}], "publication_date": "2020-04-30"}, {"id": 29, "slug": "the-emotional-impact-of-coronavirus-2019-ncov-new-coronavirus-disease", "title": "The emotional impact of Coronavirus 2019-nCoV (new Coronavirus disease)", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Pr\u00e9senter le risque de vuln\u00e9rabilit\u00e9 des patients et des soignants face au COVID-19", "verbose_date": "21.03.2020", "authors": "Lima CKT", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 25, "name": "Psychiatry Res"}, "link": "https://www.dropbox.com/s/n8e3r341yrpdqs2/1-s2.0-S0165178120305163-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Dispositif de soutien psychologique d\u00e9velopp\u00e9 en Chine via une plateforme internet pour agir avant tout en pr\u00e9vention primaire.\nAttention \u00e0 l'effet important de la quarantaine sur l'anxi\u00e9t\u00e9 qui d\u00e9cuple l'hyst\u00e9rie collective avant le virus.", "objectives": "Faible :1) lettre \u00e0 l'\u00e9diteur sans processus de blind reviewing2) bas\u00e9 sur une dizaine de r\u00e9f\u00e9rences de niveau de preuve assez faible", "methods": "Pr\u00e9senter le risque de vuln\u00e9rabilit\u00e9 des patients et des soignants face au COVID-19", "pubmed_id": "32199182", "doi": "10.1016/j.psychres.2020.112915", "abstract": "A novel form of Coronavirus (2019-nCoV) in Wuhan has created a confused and rapidly evolving situation. In this situational framework, patients and front-line healthcare workers are vulnerable.\nStudies were identified using large-circulation international journals found in two electronic databases: Scopus and Embase.\nPopulations of patients that may require tailored interventions are older adults and international migrant workers. Older adults with psychiatric conditions may be experiencing further distress. The COVID-19 epidemic has underscored potential gaps in mental health services during emergencies.\nMost health professionals working in isolation units and hospitals do not receive any training for providing mental health care. Fear seems more certainly a consequence of mass quarantine.", "topics": ["Autres", "Psychiatrie"], "author_list": [{"id": 39, "name": "Lima CKT"}], "publication_date": "2020-03-21"}, {"id": 249, "slug": "incidence-of-novel-coronavirus-2019-ncov-infection-among-people-under-home-quara", "title": "Incidence of novel coronavirus (2019-nCoV) infection among people under home quarantine in Shenzhen, China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Estimer l'incidence de l'infection par le SRAS-CoV-2 chez les personnes mises en quarantaine dans la ville de Shenzhen, Chine.", "verbose_date": "06.04.2020", "authors": "Wang J", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 69, "name": "Travel Med Infect Dis"}, "link": "https://www.dropbox.com/s/ev9cm3in2etrhml/1-s2.0-S1477893920301289-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "I) l'\u00e9tude a montr\u00e9 que la quarantaine r\u00e9duisait la transmission du SRAS-CoV-2 : 3 personnes positives sur 2004, aucun nouveau cas parmi les personnes incluses dans l'\u00e9tude et leurs contacts au 31 mars 2020.\n\r\nII) la supervision de la population par les agents de sant\u00e9, des instructions compr\u00e9hensibles et applicables doivent \u00eatre mises en place pour rendre la quarantaine efficace.", "objectives": "1) \u00e9tude d'observation prospective2) l'\u00e9chantillon nasopharyng\u00e9 n'a \u00e9t\u00e9 effectu\u00e9 qu'une seule fois pour chaque sujet, les faux n\u00e9gatifs ne peuvent \u00eatre exclus3) la population de l'\u00e9chantillon peut ne pas \u00eatre repr\u00e9sentative de la population totale \"", "methods": "Estimer l'incidence de l'infection par le SRAS-CoV-2 chez les personnes mises en quarantaine dans la ville de Shenzhen, Chine.", "pubmed_id": "32247931\n32027631\n31978945\n22611587\n21073672\n30828672\n31986264\n17662167", "doi": "10.1016/j.tmaid.2020.101660", "abstract": "Since the outbreak of 2019-nCoV in December, Chinese government has implemented various measures including travel bans, centralized treatments, and home quarantines to slowing the transmission across the country. In this study, we aimed to estimate the incidence of 2019-nCoV infection among people under home quarantine in Shenzhen, China.\nWe used a stratified multistage random sampling method to recruit participants and collected demographic information and laboratory results of people under home quarantine. We conducted descriptive analysis to estimate the basic characteristics and to calculate the incidence in out study population.\nA total of 2004 people under home quarantine participated in this study, of which 1637 participants finished the questionnaire with a response rate of 81.7%. Mean age of the participants was 33.7 years, ranging from 0.3 to 80.2 years. Of people who provided clear travel history, 129 people have traveled to Wuhan city and 1,046 people have traveled to other cities in Hubei province within 14 days before the home quarantine. Few (less than 1%) participants reported contact history with confirmed or suspected cases during their trip and most of these arrived at Shenzhen between Jan 24, 2020 to Jan 27, 2020. The incidence of COVID-19 in the sample was 1.5\u2030 (95% CI: 0.31\u2030-4.37\u2030).\nHome quarantine has been effective in preventing the early transmission of COVID-19, but that more needs to be done to improve early detection of COVID-19 infection.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 239, "name": "Wang J"}], "publication_date": "2020-04-06"}, {"id": 91, "slug": "covid-19-in-children-initial-characterization-of-the-pediatric-disease", "title": "COVID-19 in Children: Initial Characterization of the Pediatric Disease", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "R\u00e9sume l'article ci dessus", "verbose_date": "16.03.2020", "authors": "Cruz A", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 65, "name": "Pediatrics"}, "link": "https://www.dropbox.com/s/wv1k2xotbj3ighj/peds.2020-0834.full.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Voir ci dessus.Recommande un d\u00e9pistage large afin d'avoir de meilleures donn\u00e9es \u00e9pid\u00e9miologiques.", "objectives": "Faible :R\u00e9sume simplement l'article ci dessus et fait des propositions.", "methods": "R\u00e9sume l'article ci dessus", "pubmed_id": "32179659", "doi": "10.1542/peds.2020-0834", "abstract": null, "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 97, "name": "Cruz A"}], "publication_date": "2020-03-16"}, {"id": 283, "slug": "coagulopathy-and-antiphospholipid-antibodies-in-patients-with-covid-19", "title": "Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Description de cas COVID-19 pr\u00e9sentant une cogulopathie avec d\u00e9tection d'anticorps anti-phospholipides", "verbose_date": "09.04.2020", "authors": "Zhang Y", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 22, "name": "NEJM"}, "link": "https://www.nejm.org/doi/pdf/10.1056/NEJMc2007575?articleTools=true", "findings": "", "take_away": "", "relevance_level": "Risque potentiel de coagulopathie chez des patients avec forme s\u00e9v\u00e8re de COVID-19 avec l'apparition d'anticorps anti-phospholipides qui pourrait \u00eatre un signe biologique important dans ce cadre. Les \u00e9v\u00e8nements thrombotiques surviennent entre J10 et J33 avec des isch\u00e9mies des membres ou des infarctus c\u00e9r\u00e9braux par exemple.", "objectives": "- Description de 3 cas seulement- Patients avec risque cardio-vasculaire d\u00e9j\u00e0 tr\u00e8s \u00e9lev\u00e9\"", "methods": "Description de cas COVID-19 pr\u00e9sentant une cogulopathie avec d\u00e9tection d'anticorps anti-phospholipides", "pubmed_id": "32268022", "doi": "10.1056/NEJMc2007575", "abstract": null, "topics": ["Pronostique", "Infectiologie", "Anesth\u00e9sie-R\u00e9animation", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 223, "name": "Zhang Y"}], "publication_date": "2020-04-09"}, {"id": 569, "slug": "clinical-course-of-severe-and-critical-covid-19-in-hospitalized-pregnancies-a-us", "title": "Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire l'\u00e9volution de la COVID-19 chez des femmes enceintes avec forme s\u00e9v\u00e8re ou critique de l'infection.", "verbose_date": "11.05.2020", "authors": "Pierce-Williams R", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 227, "name": "AJOG MFM"}, "link": "https://doi.org/10.1016/j.ajogmf.2020.100134", "findings": "", "take_away": "", "relevance_level": "D'apr\u00e8s les donn\u00e9es de cette \u00e9tude, il semble que l'\u00e9volution de la COVID-19 chez les femmes enceintes avec forme s\u00e9v\u00e8re ou critique est la m\u00eame que chez les sujets non concern\u00e9s par une grossesse, m\u00eame si la dur\u00e9e d'hospitalisation et la l\u00e9talit\u00e9 paraissent moindre chez elles. N\u00e9anmoins plus d'\u00e9tudes sont n\u00e9cessaires pour conclure. Concernant les \u00e9v\u00e8nements obst\u00e9tricaux, les accouchements pr\u00e9matur\u00e9s et les d\u00e9clenchements semblent assez communs dans les cas de COVID-19 s\u00e9v\u00e8re ou critique et ces d\u00e9clenchements devraient faire l'objet d'une d\u00e9cision \u00e0 l'\u00e9chelle individuelle.", "objectives": "- effectif plut\u00f4t faible- des donn\u00e9es recueillies r\u00e9trospectivement- des femmes enceintes restaient hospitalis\u00e9es en fin d'\u00e9tude, certaines sous ventilation m\u00e9canique invasive, ou n'avaient pas encore accouch\u00e9 (50%)- pas de correction du risque alpha face \u00e0 la multiplicit\u00e9 des tests r\u00e9alis\u00e9s- pas de recueil des causes exactes de accouchements pr\u00e9-termes- prise en charge variable entre les h\u00f4pitaux", "methods": "D\u00e9crire l'\u00e9volution de la COVID-19 chez des femmes enceintes avec forme s\u00e9v\u00e8re ou critique de l'infection.", "pubmed_id": "32391519", "doi": "10.1016/j.ajogmf.2020.100134", "abstract": "The COVID-19 pandemic has had an impact on healthcare systems around the world with 3.0 million infected and 208,000 resultant mortalities as of this writing. Information regarding infection in pregnancy is still limited.\nTo describe the clinical course of severe and critical infection in hospitalized pregnant women with positive laboratory testing for SARS-CoV2.\nThis is a cohort study of pregnant women with severe or critical COVID-19 infection hospitalized at 12 US institutions between March 5, 2020 and April 20, 2020. Severe infection was defined according to published criteria by patient reported dyspnea, respiratory rate > 30 per minute, blood oxygen saturation \u2264 93% on room air, partial pressure of arterial oxygen to fraction of inspired oxygen <300 and/or lung infiltrates >50% within 24 to 48 hours on chest imaging. Critical disease was defined by respiratory failure, septic shock, and/or multiple organ dysfunction or failure. Women were excluded if they had presumed COVID-19 infection but laboratory testing was negative. The primary outcome was median duration from hospital admission to discharge. Secondary outcomes included need for supplemental oxygen, intubation, cardiomyopathy, cardiac arrest, death, and timing of delivery. The clinical courses are described by the median disease day on which these outcomes occurred after the onset of symptoms. Treatment and neonatal outcomes are also reported.\nOf 64 pregnant women hospitalized with COVID-19, 44 (69%) had severe and 20 (31%) critical disease. The following pre-existing comorbidities were observed: 25% had a pulmonary condition, 17% had cardiac disease and the mean BMI was 34 kg/m\nIn hospitalized pregnant women with severe or critical COVID-19 infection, admission typically occurred about 7 days after symptom onset, and the duration of hospitalization was 6 days (6 severe versus 12 critical). Critically ill women had a high rate of ARDS, and there was one case of cardiac arrest, but there were no cases of cardiomyopathy, or maternal mortality. Hospitalization for severe or critical COVID-19 infection resulted in delivery during the course of infection in 50% of this cohort, usually in the third trimester. There were no perinatal deaths in this cohort.", "topics": ["Pronostique", "Gyn\u00e9cologie Obst\u00e9trique"], "author_list": [{"id": 534, "name": "Pierce-Williams R"}], "publication_date": "2020-05-11"}, {"id": 118, "slug": "a-systematic-review-on-the-efficacy-and-safety-of-chloroquine-for-the-treatment-", "title": "A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer la s\u00e9curit\u00e9 et l'efficacit\u00e9 de la chloroquine", "verbose_date": "10.03.2020", "authors": "Cortegiani A", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 79, "name": "J Crit Care"}, "link": "https://www.dropbox.com/s/p10eq1pt587vvsj/10.1016%40j.jcrc.2020.03.005.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Effet chloroquine IN VIVO reste \u00e0 d\u00e9montrerEfficacit\u00e9 in vitro sur la r\u00e9plication viraleS\u00e9curit\u00e9 : attention \u00e0 l'allongement du QTN\u00e9cessit\u00e9 d'essais cliniques (en cours)", "objectives": "Interm\u00e9diaire :1) Revue syst\u00e9matique tr\u00e8s succinte avec nombreux essais et quelques lettres mais grande h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e92) Niveau de preuve de nombreuses \u00e9tudes inclues = faible", "methods": "Evaluer la s\u00e9curit\u00e9 et l'efficacit\u00e9 de la chloroquine", "pubmed_id": "32173110", "doi": "10.1016/j.jcrc.2020.03.005", "abstract": "COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chloroquine for the treatment of COVID-19.\nPubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in patients with COVID-19.\nWe included six articles (one narrative letter, one in-vitro study, one editorial, expert consensus paper, two national guideline documents) and 23 ongoing clinical trials in China. Chloroquine seems to be effective in limiting the replication of SARS-CoV-2 (virus causing COVID-19) in vitro.\nThere is rationale, pre-clinical evidence of effectiveness and evidence of safety from long-time clinical use for other indications to justify clinical research on chloroquine in patients with COVID-19. However, clinical use should either adhere to the Monitored Emergency Use of Unregistered Interventions (MEURI) framework or be ethically approved as a trial as stated by the World Health Organization. Safety data and data from high-quality clinical trials are urgently needed.", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 124, "name": "Cortegiani A"}], "publication_date": "2020-03-10"}, {"id": 452, "slug": "characteristic-ct-findings-distinguishing-2019-novel-coronavirus-disease-covid-1", "title": "Characteristic CT findings distinguishing 2019 novel coronavirus disease (COVID-19) from influenza pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9tudier les diff\u00e9rentes caract\u00e9ristiques de la tomodensitom\u00e9trie permettant de distinguer la grippe de la maladie \u00e0 COVID-19.", "verbose_date": "26.04.2020", "authors": "Wang H", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 155, "name": "Eur Radiol"}, "link": "https://link.springer.com/content/pdf/10.1007/s00330-020-06880-z.pdf", "findings": "", "take_away": "", "relevance_level": "Bien que les pneumonies virales pr\u00e9sentent g\u00e9n\u00e9ralement des caract\u00e9ristiques d'imagerie similaires, certains \u00e9l\u00e9ments caract\u00e9ristiques de la tomodensitom\u00e9trie, une m\u00e9thode pratique et non invasive, peuvent aider \u00e0 diff\u00e9rencier le COVID-19 de la pneumonie grippale. GGO (ground glass opacity) et GGO avec consolidation \u00e9taient les \u00e9l\u00e9ments communs de la tomodensitom\u00e9trie de la pneumonie virale. Le COVID-19 pr\u00e9sentait des opacit\u00e9s in\u00e9gales ou une combinaison de GGO et opacit\u00e9s de consolidation avec une distribution p\u00e9riph\u00e9rique et une pr\u00e9dominance \u00e9quilibr\u00e9e des lobes. Cependant, la pneumonie grippale avait tendance \u00e0 pr\u00e9senter un motif en grappe le long de l'arbre bronchique avec une distribution centrale, un \u00e9paississement de la paroi bronchique et une pr\u00e9dominance des lobes inf\u00e9rieurs.", "objectives": "-\t\u00e9tude r\u00e9trospective-\tla taille de l'\u00e9chantillon \u00e9tait modeste, en particulier pour la cohorte COVID-19 (n=13)-\tles 13 patients avec COVID-19 n'ont pas \u00e9t\u00e9 divis\u00e9s en diff\u00e9rents types selon les diff\u00e9rents processus pathologiques, qui pr\u00e9sentent g\u00e9n\u00e9ralement des manifestations diverses \u00e0 la tomodensitom\u00e9trie-\tles virus de la grippe A n'ont pas \u00e9t\u00e9 divis\u00e9s en sous-groupes-\tles \u00e9l\u00e9ments n'ont pas \u00e9t\u00e9 compar\u00e9s entre les sous-groupes de la grippe A et de la grippe B", "methods": "\u00c9tudier les diff\u00e9rentes caract\u00e9ristiques de la tomodensitom\u00e9trie permettant de distinguer la grippe de la maladie \u00e0 COVID-19.", "pubmed_id": "32323011", "doi": "10.1007/s00330-020-06880-z", "abstract": "To investigate the different CT characteristics which may distinguish influenza from 2019 coronavirus disease (COVID-19).\nA total of 13 confirmed patients with COVID-19 were enrolled from January 16, 2020, to February 25, 2020. Furthermore, 92 CT scans of confirmed patients with influenza pneumonia, including 76 with influenza A and 16 with influenza B, scanned between January 1, 2019, to February 25, 2020, were retrospectively reviewed. Pulmonary lesion distributions, number, attenuation, lobe predomination, margin, contour, ground-glass opacity involvement pattern, bronchial wall thickening, air bronchogram, tree-in-bud sign, interlobular septal thickening, intralobular septal thickening, and pleural effusion were evaluated in COVID-19 and influenza pneumonia cohorts.\nPeripheral and non-specific distributions in COVID-19 showed a markedly higher frequency compared with the influenza group (p\u2009<\u20090.05). Most lesions in COVID-19 showed balanced lobe localization, while in influenza pneumonia they were predominantly located in the inferior lobe (p\u2009<\u20090.05). COVID-19 presented a clear lesion margin and a shrinking contour compared with influenza pneumonia (p\u2009<\u20090.05). COVID-19 had a patchy or combination of GGO and consolidation opacities, while a cluster-like pattern and bronchial wall thickening were more frequently seen in influenza pneumonia (p\u2009<\u20090.05). The lesion number and attenuation, air bronchogram, tree-in-bud sign, interlobular septal thickening, and intralobular septal thickening were not significantly different between the two groups (all p\u2009>\u20090.05).\nThough viral pneumonias generally show similar imaging features, there are some characteristic CT findings which may help differentiating COVID-19 from influenza pneumonia.\n\u2022 CT can play an early warning role in the diagnosis of COVID-19 in the case of no epidemic exposure. \u2022 CT could be used for the differential diagnosis of influenza and COVID-19 with satisfactory accuracy. \u2022 COVID-19 had a patchy or combination of GGO and consolidation opacities with peripheral distribution and balanced lobe predomination.", "topics": ["Diagnostique", "Radiologie"], "author_list": [{"id": 84, "name": "Wang H"}], "publication_date": "2020-04-26"}, {"id": 487, "slug": "early-risk-factors-for-the-duration-of-sars-cov-2-viral-positivity-in-covid-19-p", "title": "Early risk factors for the duration of SARS-CoV-2 viral positivity in COVID-19 patients", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Etude des facteurs de risque pr\u00e9coces en lien avec la dur\u00e9e de positivit\u00e9 virale du SRAS-CoV-2 chez les patients COVID-19.", "verbose_date": "29.04.2020", "authors": "Lin A", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 24, "name": "Clin Infect Dis"}, "link": "https://www.dropbox.com/s/ugzuge2emxh5paf/ciaa490.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Un taux de lymphocytes CD8+\u00a0 (seuil 238/\u00b5L) est le seul facteur de risque en lien avec dur\u00e9e de positivit\u00e9 du COVID-19.", "objectives": "Etude de Cohorte Faible effectif R\u00e9sultats similaires \u00e0 d'autre \u00e9tudes pour la dur\u00e9e moyenne de positivit\u00e9 et similaire pour le facteur de risque de dur\u00e9e de positivit\u00e9", "methods": "Etude des facteurs de risque pr\u00e9coces en lien avec la dur\u00e9e de positivit\u00e9 virale du SRAS-CoV-2 chez les patients COVID-19.", "pubmed_id": "32337591", "doi": "10.1093/cid/ciaa490", "abstract": "Pneumonia COVID-19 has became a pandemic. However, information on early risk factors for the duration of SARS-CoV-2 viral positivity is unavailable yet.\nIn this prospective study, a cohort of 137 patients with confirmed SARS-CoV-2 infection were enrolled. Clinical information and laboratory data were retrieved from electronic medical records. Viral positivity duration was calculated by an interval from the day SARS-CoV-2 positive confirmed to the day SARS-CoV-2 returned to negative in these 137 COVID-19 patients. Early risk factors for the duration of SARS-CoV-2 viral positivity were evaluated.\nThe median SARS-CoV-2 viral positivity duration is 12 days (range: 4 days ~ 45 days) for this cohort. Cox regression results showed a significantly shorter viral positivity duration was related to younger [hazard ratio (HR) = 0.658, p = 0.017], not severe patient (HR = 0.653, p = 0.076), higher count of lymphocytes (HR = 1.464, p = 0.033), eosinophils (HR = 1.514, p = 0.020) and CD8+ T cells (HR=1.745, p=0.033), and lower IL-6 (HR = 0.664, p = 0.036) and IL-10 (HR = 0.631, p = 0.021). Multivariate analysis with covariables adjusted results showed that the count of CD8+ T cells (HR=2.376, p=0.114) was a predominant risk factor for the SARS-CoV-2 viral positivity duration.\nOur findings firstly provided early laboratory parameters such as count of CD8+ T cells, as risk factors for the duration of SARS-CoV-2 viral positivity, which have significance in control and prevention of the disease.", "topics": ["Pronostique", "Virologie", "Infectiologie"], "author_list": [{"id": 455, "name": "Lin A"}], "publication_date": "2020-04-29"}, {"id": 478, "slug": "do-psychiatric-patients-experience-more-psychiatric-symptoms-during-covid-19-pan", "title": "Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A Case-Control Study with Service and Research Implications for Immunopsychiatry", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer et comparer le stress imm\u00e9diat et l'impact psychologique v\u00e9cus chez des sujets avec des affections psychiatriques par rapport \u00e0 des sujets sans affection psychiatrique au cours du pic de COVID-19 et des mesures de confinement en Chine.", "verbose_date": "29.04.2020", "authors": "Hao F", "specialties": [{"id": 21, "name": "Confinement/D\u00e9confinement"}, {"id": 6, "name": "Psychiatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 109, "name": "Brain Behav Immun"}, "link": "https://reader.elsevier.com/reader/sd/pii/S0889159120306267?token=D435892FD92607209A382FF2280687EE15521ABE61AB394A1A26DA98D15E632C74D48086F4073A2B790AE5031C1E7456", "findings": "", "take_away": "", "relevance_level": "Les patients pr\u00e9sentant des troubles anxio-d\u00e9pressifs (F32, F33, F41 ou F41.8 selon CIM-10) semblent \u00e0 plus haut risque de pr\u00e9senter un tableau de stress post-traumatique, de d\u00e9pression, d'anxi\u00e9t\u00e9, d'insomnie et de stress et de pr\u00e9senter des id\u00e9ations suicidaires.", "objectives": "- \u00e9tude observationnelle descriptive transverse- probable biais de s\u00e9lection- biais de confusion majeur en l'absence d'analyse multivari\u00e9e pertinente", "methods": "Evaluer et comparer le stress imm\u00e9diat et l'impact psychologique v\u00e9cus chez des sujets avec des affections psychiatriques par rapport \u00e0 des sujets sans affection psychiatrique au cours du pic de COVID-19 et des mesures de confinement en Chine.", "pubmed_id": "32353518", "doi": "10.1016/j.bbi.2020.04.069", "abstract": "This study aimed to assess and compare the immediate stress and psychological impact experienced by people with and without psychiatric illnesses during the peak of 2019 coronavirus disease (COVID-19) epidemic with strict lockdown measures. Seventy-six psychiatric patients and 109 healthy control subjects were recruited from Chongqing, China and completed a survey on demographic data, physical symptoms during the past 14\u00a0days and a range of psychiatric symptoms using the Impact of Event Scale-Revised (IES-R), Depression, Anxiety and Stress Scale (DASS-21) and Insomnia Severity Index (ISI). IES-R measures PTSD symptoms in survivorship after an event. DASS-21 is based on tripartite model of psychopathology that comprise a general distress construct with distinct characteristics. The mean IES-R, DASS-21 anxiety, depression and stress subscale and ISI scores were higher in psychiatric patients than healthy controls (p\u00a0<\u00a00.001). Serious worries about their physical health, anger and impulsivity and intense suicidal ideation were significantly higher in psychiatric patients than healthy controls (p\u00a0<\u00a00.05). More than one-third of psychiatric patients might fulfil the diagnostic criteria post-traumatic stress disorder (PTSD). More than one-quarter of psychiatric patients suffered from moderately severe to severe insomnia. Respondents who reported no change, poor or worse physical health status and had a psychiatric illness were significantly more likely to have higher mean IES-R, DASS depression, anxiety and stress subscale scores and ISI scores (p\u00a0<\u00a00.05). This study confirms the severity of negative psychological impact on psychiatric patients during the COVID-19 epidemic with strict lockdown measures. Understanding the psychological impact on psychiatric patients during the COVID-19 pandemic has the potential to provide insight into how to develop a new immunopsychiatry service. Further research is required to compare pro-inflammatory cytokines between psychiatric patients and healthy controls during the pandemic.", "topics": ["Epid\u00e9miologique", "Confinement/D\u00e9confinement", "Psychiatrie"], "author_list": [{"id": 446, "name": "Hao F"}], "publication_date": "2020-04-29"}, {"id": 24, "slug": "the-characteristics-and-clinical-value-of-chest-ct-images-of-novel-coronavirus-p", "title": "The characteristics and clinical value of chest CT images of novel coronavirus pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Description des charact\u00e9ristiques et de la valeur clinique de scanner thoracique dans les infection COVID19", "verbose_date": "24.03.2020", "authors": "Zhao X", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 20, "name": "Clin Radiol"}, "link": "https://www.dropbox.com/s/5n72lgqjejixl7p/PIIS0009926020300866.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Les images de scaner thoracique chez les patients infect\u00e9 par le SARS-CoV-2 sont charact\u00e9ris\u00e9 par une atteinte majoritairement bilat\u00e9rale, avec des opacit\u00e9 en verre d\u00e9poli dans la r\u00e9gion sous pleurale. Les l\u00e9sions sont progressive et \u00e9voluent vers une consolidation.Des l\u00e9sions sont possible alors que les tests de d\u00e9pistage sont encore n\u00e9gatif", "objectives": "Faible :- Etude retrospective sur de faible effectif", "methods": "Description des charact\u00e9ristiques et de la valeur clinique de scanner thoracique dans les infection COVID19", "pubmed_id": "32199619", "doi": "10.1016/j.crad.2020.03.002", "abstract": "To investigate the characteristics and clinical value of chest computed tomography (CT) images of novel coronavirus pneumonia (NCP).\nClinical data and CT images of 80 cases of NCP were collected. The clinical manifestations and laboratory test results of the patients were analysed. The lesions in each lung segment of the patient's chest CT images were characterised. Lesions were scored according to length and diffusivity.\nThe main clinical manifestations were fever, dry cough, fatigue, a little white sputum, or diarrhoea. A total of 1,702 scored lesions were found in the first chest CT images of 80 patients. The lesions were located mainly in the subpleural area of the lungs (92.4%). Most of the lesions were ground-glass opacity, and subsequent fusions could increase in range and spread mainly in the subpleural area. Pulmonary consolidation accounted for 44.1% of all of the lesions. Of the 80 cases, 76 patients (95%) had bilateral lung disease, four (5%) patients had unilateral lung disease, and eight (10%) patients had cord shadow.\nThe chest CT of NCP patients is characterised by the onset of bilateral ground-glass lesions located in the subpleural area of the lung, and progressive lesions that result in consolidation with no migratory lesions. Pleural effusions and mediastinal lymphadenopathy are rare. As patients can have inflammatory changes in the lungs alongside a negative early nucleic acid test, chest CT, in combination with epidemiological and laboratory tests, is a useful examination to evaluate the disease and curative effect.", "topics": ["Epid\u00e9miologique", "Radiologie"], "author_list": [{"id": 34, "name": "Zhao X"}], "publication_date": "2020-03-24"}, {"id": 142, "slug": "characterization-of-the-receptor-binding-domain-rbd-of-2019-novel-coronavirus-im", "title": "Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Identifier le domaine de liaison du r\u00e9cepteur de la prot\u00e9ine S du SRAS-CoV-2 et \u00e9valuer sa capacit\u00e9 de liaison avec l'enzyme de conversion de l'angiotensine 2 dans l'optique d'orienter le d\u00e9veloppement des th\u00e9rapeutiques antivirales et d'un vaccin contre le COVID-19.", "verbose_date": "25.03.2020", "authors": "Tai W ", "specialties": [{"id": 22, "name": "Immunit\u00e9"}, {"id": 5, "name": "Virologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 11, "name": "Cell Mol Immunol"}, "link": "https://www.dropbox.com/s/83hnv9ymh47pgcx/10.1038%40s41423-020-0400-4.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le domaine de liaison du r\u00e9cepteur de la prot\u00e9ine S du SRAS-CoV-2 ou celui du SRAS-CoV avec l'enzyme de l'ACE 2 sont \u00e0 haut potentiel de d\u00e9veloppement de traitements antiviraux et de vaccin.", "objectives": "", "methods": "Identifier le domaine de liaison du r\u00e9cepteur de la prot\u00e9ine S du SRAS-CoV-2 et \u00e9valuer sa capacit\u00e9 de liaison avec l'enzyme de conversion de l'angiotensine 2 dans l'optique d'orienter le d\u00e9veloppement des th\u00e9rapeutiques antivirales et d'un vaccin contre le COVID-19.", "pubmed_id": "32203189", "doi": "10.1038/s41423-020-0400-4", "abstract": "The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection.", "topics": ["Th\u00e9rapeutique", "Immunit\u00e9", "Virologie"], "author_list": [{"id": 139, "name": "Tai W "}], "publication_date": "2020-03-25"}, {"id": 101, "slug": "teicoplanin-an-alternative-drug-for-the-treatment-of-coronavirus-covid-19", "title": "Teicoplanin: an alternative drug for the treatment of coronavirus COVID- 19?", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier la possibilit\u00e9 d'utiliser la teicoplanine comme traitement pour le COVID-19", "verbose_date": "13.03.2020", "authors": "Baron SA", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 14, "name": "Int J Antimicrob Agents"}, "link": "https://www.dropbox.com/s/qcfsfgphennquvw/1-s2.0-S0924857920300947-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Teicoplanine active sur le virus in vitroN\u00e9cessit\u00e9 d'un essai clinique randomis\u00e9 pour efficacit\u00e9 in vivo", "objectives": "Faible:1) Bas\u00e9 uniquement sur la bilbiographie2) In vitro uniquement", "methods": "Etudier la possibilit\u00e9 d'utiliser la teicoplanine comme traitement pour le COVID-19", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 107, "name": "Baron SA"}], "publication_date": "2020-03-13"}, {"id": 358, "slug": "efficacy-of-face-mask-in-preventing-respiratory-virus-transmission-a-systematic-", "title": "Efficacy of face mask in preventing respiratory virus transmission: a systematic review and meta-analysis", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer l'efficacit\u00e9 de l'utilisation de masques pour pr\u00e9venir la transmission de virus respiratoires", "verbose_date": "16.04.2020", "authors": "Liang M", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.03.20051649v2.full.pdf", "findings": "", "take_away": "", "relevance_level": "La m\u00e9ta-analyse sugg\u00e9rait un effet protecteur des masques avec un OR \u00e0 0,35 (IC 95% = 0,24 - 0,51). Le risque d'infection respiratoire virale \u00e9tait r\u00e9duit de 80% pour les professionnels de sant\u00e9 (OR = 0,20, IC 95% = 0,11-0,37) et de 47% pour les autres professionnels (OR = 0,53, IC 95% = 0,36-0,79). Etudes sur H1N1, SARS et SARS-CoV-2.", "objectives": "1) Pre-print2) 21 \u00e9tudes incluses, n=8 686, une seule \u00e9tude incluse \u00e9tudiant le SARS-CoV-23) H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 moyenne avec I\u00b2 \u00e0 60%4) \u00c9tudes incluses pour la grippe H1N1 avec des personnes vaccin\u00e9es5) Pas de distinction entre masques chirurgicaux et masque FFP2\"", "methods": "\u00c9valuer l'efficacit\u00e9 de l'utilisation de masques pour pr\u00e9venir la transmission de virus respiratoires", "pubmed_id": "32473312\n31986261\n21477136\n18042961\n23043536\n19522650\n9310563\n18326870\n23078163\n16022801\n15030692\n16014825\n27632416\n7786990\n24229526\n29140516\n32355904\n22264216\n15473141\n15018129\n15030700\n20061056\n25336079\n27481873\n28487207\n19652172\n15030685\n26952529", "doi": "10.1016/j.tmaid.2020.101751", "abstract": "Conflicting recommendations exist related to whether masks have a protective effect on the spread of respiratory viruses.\nThe Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement was consulted to report this systematic review. Relevant articles were retrieved from PubMed, Web of Science, ScienceDirect, Cochrane Library, and Chinese National Knowledge Infrastructure (CNKI), VIP (Chinese) database.\nA total of 21 studies met our inclusion criteria. Meta-analyses suggest that mask use provided a significant protective effect (OR\u202f=\u202f0.35 and 95% CI\u202f=\u202f0.24-0.51). Use of masks by healthcare workers (HCWs) and non-healthcare workers (Non-HCWs) can reduce the risk of respiratory virus infection by 80% (OR\u202f=\u202f0.20, 95% CI\u202f=\u202f0.11-0.37) and 47% (OR\u202f=\u202f0.53, 95% CI\u202f=\u202f0.36-0.79). The protective effect of wearing masks in Asia (OR\u202f=\u202f0.31) appeared to be higher than that of Western countries (OR\u202f=\u202f0.45). Masks had a protective effect against influenza viruses (OR\u202f=\u202f0.55), SARS (OR\u202f=\u202f0.26), and SARS-CoV-2 (OR\u202f=\u202f0.04). In the subgroups based on different study designs, protective effects of wearing mask were significant in cluster randomized trials and observational studies.\nThis study adds additional evidence of the enhanced protective value of masks, we stress that the use masks serve as an adjunctive method regarding the COVID-19 outbreak.", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 345, "name": "Liang M"}], "publication_date": "2020-04-16"}, {"id": 629, "slug": "scope-quality-and-inclusivity-of-clinical-guidelines-produced-early-in-the-covid", "title": "Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer la disponibilit\u00e9, la qualit\u00e9 et l'inclusivit\u00e9 des directives cliniques produites pendant les premiers temps de la pand\u00e9mie de Covid-19", "verbose_date": "27.05.2020", "authors": "Dagens A", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 57, "name": "BMJ"}, "link": "https://www.bmj.com/content/bmj/369/bmj.m1936.full.pdf", "findings": "", "take_away": "", "relevance_level": "Les directives cliniques pr\u00e9coces dans la pand\u00e9mie de Covid-19 \u00e9taient m\u00e9thodologiquement faibles et n\u00e9gligeaient les personnes vuln\u00e9rables.", "objectives": "- Rapide revue de la litt\u00e9rature- Biais de s\u00e9lection des recommandations publi\u00e9es hors des bases de donn\u00e9es bibliographiques, notamment pour celles non en anglais- Certaines \u00e9tudes ont \u00e9t\u00e9 traduites automatiquement, faisant perdre certaines nuances- L'outil AGREE II utilis\u00e9 pour \u00e9valuer la qualit\u00e9 des \u00e9tudes est destin\u00e9 \u00e0 des processus non \u00e9mergents.", "methods": "Evaluer la disponibilit\u00e9, la qualit\u00e9 et l'inclusivit\u00e9 des directives cliniques produites pendant les premiers temps de la pand\u00e9mie de Covid-19", "pubmed_id": "32457027\n22245450\n26957104\n27036638\n21951384\n31573350\n32043986\n26950335\n29847593\n26049252\n29161116\n18436948\n32122468\n30529647\n16968120\n32171076\n17202446\n23741299\n32043983\n32457027", "doi": "10.1136/bmj.m1936", "abstract": "To appraise the availability, quality, and inclusivity of clinical guidelines produced in the early stage of the coronavirus disease 2019 (covid-19) pandemic.\nRapid review.\nOvid Medline, Ovid Embase, Ovid Global Health, Scopus, Web of Science Core Collection, and WHO Global Index Medicus, searched from inception to 14 Mar 2020. Search strategies applied the CADTH database guidelines search filter, with no limits applied to search results. Further studies were identified through searches of grey literature using the ISARIC network.\nClinical guidelines for the management of covid-19, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS) produced by international and national scientific organisations and government and non-governmental organisations relating to global health were included, with no exclusions for language. Regional/hospital guidelines were excluded. Only the earliest version of any guideline was included.\nQuality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool. The quality and contents of early covid-19 guidelines were also compared with recent clinical guidelines for MERS and SARS.\n2836 studies were identified, of which 2794 were excluded after screening. Forty two guidelines were considered eligible for inclusion, with 18 being specific to covid-19. Overall, the clinical guidelines lacked detail and covered a narrow range of topics. Recommendations varied in relation to, for example, the use of antiviral drugs. The overall quality was poor, particularly in the domains of stakeholder involvement, applicability, and editorial independence. Links between evidence and recommendations were limited. Minimal provision was made for vulnerable groups such as pregnant women, children, and older people.\nGuidelines available early in the covid-19 pandemic had methodological weaknesses and neglected vulnerable groups such as older people. A framework for development of clinical guidelines during public health emergencies is needed to ensure rigorous methods and the inclusion of vulnerable populations.\nPROSPERO CRD42020167361.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 592, "name": "Dagens A"}], "publication_date": "2020-05-27"}, {"id": 484, "slug": "epidemiological-characteristics-and-incubation-period-of-7015-confirmed-cases-wi", "title": "Epidemiological characteristics and incubation period of 7,015 confirmed cases with Coronavirus Disease 2019 outside Hubei Province in China", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyser les caract\u00e9ristiques \u00e9pid\u00e9miologiques, l'incubation et les temps d'intervalle du Covid-19 au d\u00e9but de l'\u00e9pid\u00e9mie et \u00e9valuer l'effet des restrictions de trafic mis en place \u00e0 Hubei \u00e0 partir du 23 Janvier 2020.", "verbose_date": "29.04.2020", "authors": "Nie X", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 196, "name": "J Infect Dis"}, "link": "https://www.dropbox.com/s/nowwqyff2gd4dj5/jiaa211.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La p\u00e9riode d'incubation du COVID-19 est relativement courte et les temps d'intervalle diminuent au cours du temps.\r\nLes restrictions du trafic ont jou\u00e9 un r\u00f4le important dans la diminution du nombre de cas import\u00e9s.", "objectives": "- Etude r\u00e9trospective- Issue des bases de donn\u00e9es officielles chinoises- Donn\u00e9es du tout d\u00e9but de l'\u00e9pid\u00e9mie- Incubation calcul\u00e9e avec la date du dernier contact avec une personne infect\u00e9e : mais a pu \u00eatre en expos\u00e9 avant; ou apr\u00e8s sans que la personne ne soit identifi\u00e9e", "methods": "Analyser les caract\u00e9ristiques \u00e9pid\u00e9miologiques, l'incubation et les temps d'intervalle du Covid-19 au d\u00e9but de l'\u00e9pid\u00e9mie et \u00e9valuer l'effet des restrictions de trafic mis en place \u00e0 Hubei \u00e0 partir du 23 Janvier 2020.", "pubmed_id": "32339231", "doi": "10.1093/infdis/jiaa211", "abstract": "Disease caused by SARS-CoV-2 broke out in Wuhan in December 2019. We utilized confirmed cases outside Hubei Province to analyze epidemiologic characteristics and evaluate the effect of traffic restrictions implemented in Hubei beginning on January 23, 2020.\nInformation on 7,015 confirmed cases from January 19 to February 8, 2020, in all provinces outside Hubei was collected from the national and local health commissions in China. Incubation period and interval times were calculated using dates of the following events: contact with an infected person, onset, first visit and diagnosis. We evaluated changes in incubation period and interval times.\nThe average age of all cases was 44.24 years old. The median incubation period was 5 days and extended from 2 days on January 23 to 15 days on February 8. The proportion of imported cases decreased from 85.71% to 33.19% after January 23. In addition, the lengths of the intervals between onset and diagnosis, onset and first visit, and first visit and diagnosis decreased over time.\nRapidly transmitting COVID-19 has a short incubation period. The onset mainly occurs among young to middle-aged adults. Traffic restrictions played an important role in the decreased number of imported cases outside Hubei.", "topics": ["Epid\u00e9miologique", "Transversale", "Infectiologie"], "author_list": [{"id": 452, "name": "Nie X"}], "publication_date": "2020-04-29"}, {"id": 421, "slug": "a-cluster-randomised-trial-of-cloth-masks-compared-with-medical-masks-in-healthc", "title": "A cluster randomised trial of cloth masks compared with medical masks in healthcare workers", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Comparaison de l'efficacit\u00e9 des masques en tissu versus masques chirurgicaux sur la pr\u00e9vention des infections respiratoires.", "verbose_date": "23.04.2020", "authors": "Macintyre C", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 177, "name": "BMJ Open"}, "link": "https://bmjopen.bmj.com/content/bmjopen/5/4/e006577.full.pdf", "findings": "", "take_away": "", "relevance_level": "Il semblerait que les masques chirurgicaux offrent une meilleure protection que les masques en tissu.\n\r\nLe design de l'\u00e9tude ne permet pas de d\u00e9terminer si les masques chirurgicaux ont une efficacit\u00e9 ou si les masques en tissu sont m\u00eame d\u00e9l\u00e9t\u00e8res (possible du fait de la r\u00e9tention d'humidit\u00e9). Les r\u00e9sultats pourraient varier fortement en fonction du type de masques en tissu.\n\r\nLes auteurs recommandent de ne pas utiliser de masques en tissu dans des environnements \u00e0 haut risque d'infection.\n\r\nR\u00e9sultats ne portant pas sur le COVID-19. Les infections \u00e9taient principalement dues \u00e0 des rhinovirus (transmission a\u00e9roport\u00e9 et par gouttelettes).", "objectives": "- Essai prospectif- Randomis\u00e9- Pas d'aveugle- Effectif important- Pas sur le SARS-CoV-2", "methods": "Comparaison de l'efficacit\u00e9 des masques en tissu versus masques chirurgicaux sur la pr\u00e9vention des infections respiratoires.", "pubmed_id": "25903751\n1203649\n12620731\n14693874\n15031246\n16274752\n16388859\n17096360\n19193267\n20569111\n20827775\n20855230\n21477136\n21503394\n23078800\n23270612\n23413265\n23725338\n24593662\n25218265\n25564127\n25698835\n25858901\n28989404\n3039011\n7764001", "doi": "10.1136/bmjopen-2014-006577", "abstract": "The aim of this study was to compare the efficacy of cloth masks to medical masks in hospital healthcare workers (HCWs). The null hypothesis is that there is no difference between medical masks and cloth masks.\n14 secondary-level/tertiary-level hospitals in Hanoi, Vietnam.\n1607 hospital HCWs aged \u226518\u2005years working full-time in selected high-risk wards.\nHospital wards were randomised to: medical masks, cloth masks or a control group (usual practice, which included mask wearing). Participants used the mask on every shift for 4 consecutive weeks.\nClinical respiratory illness (CRI), influenza-like illness (ILI) and laboratory-confirmed respiratory virus infection.\nThe rates of all infection outcomes were highest in the cloth mask arm, with the rate of ILI statistically significantly higher in the cloth mask arm (relative risk (RR)=13.00, 95% CI 1.69 to 100.07) compared with the medical mask arm. Cloth masks also had significantly higher rates of ILI compared with the control arm. An analysis by mask use showed ILI (RR=6.64, 95% CI 1.45 to 28.65) and laboratory-confirmed virus (RR=1.72, 95% CI 1.01 to 2.94) were significantly higher in the cloth masks group compared with the medical masks group. Penetration of cloth masks by particles was almost 97% and medical masks 44%.\nThis study is the first RCT of cloth masks, and the results caution against the use of cloth masks. This is an important finding to inform occupational health and safety. Moisture retention, reuse of cloth masks and poor filtration may result in increased risk of infection. Further research is needed to inform the widespread use of cloth masks globally. However, as a precautionary measure, cloth masks should not be recommended for HCWs, particularly in high-risk situations, and guidelines need to be updated.\nAustralian New Zealand Clinical Trials Registry: ACTRN12610000887077.", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 401, "name": "Macintyre C"}], "publication_date": "2020-04-23"}, {"id": 238, "slug": "clinical-observations-of-low-molecular-weight-heparin-in-relieving-inflammation-", "title": "Clinical observations of low molecular weight heparin in relieving inflammation in COVID-19 patients: A retrospective cohort study", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer l'effet anti-inflammatoire des h\u00e9parines de bas poids mol\u00e9culaire (HBPM) dans la COVID-19", "verbose_date": "03.04.2020", "authors": "Shi C", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.03.28.20046144v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Possible effet b\u00e9n\u00e9fique des HBPM chez les patients COVID-19 s\u00e9v\u00e8res sur les param\u00e8tres inflammatoires et notamment l'IL-6 impliqu\u00e9e dans l'orage cytokinique. Pour ce qui est de l'augmentation des lymphocytes apr\u00e8s traitement par HBPM : les r\u00e9sultats \u00e9tant uniquement pr\u00e9sent\u00e9s en pourcentage de lymphocytes, ils sont difficilement interpr\u00e9tables.Pas de r\u00e9percussion clinique \u00e9vidente dans cette \u00e9tude, en tout cas non d\u00e9taill\u00e9e. Essai clinique en cours pour \u00e9valuer l'efficacit\u00e9 et la s\u00e9curit\u00e9 des HBPM dans cette indication.", "objectives": "- faibles effectifs (21 + 21)- crit\u00e8res de jugement non cliniques- population tr\u00e8s s\u00e9lectionn\u00e9e: s'int\u00e9resse aux patients s\u00e9v\u00e8res en excluant les patients atteints de certains facteurs de risque suspect\u00e9s de mauvaise \u00e9volution- pas de protocole pr\u00e9cis de traitement pour les HBPM\"", "methods": "\u00c9valuer l'effet anti-inflammatoire des h\u00e9parines de bas poids mol\u00e9culaire (HBPM) dans la COVID-19", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie"], "author_list": [{"id": 228, "name": "Shi C"}], "publication_date": "2020-04-03"}, {"id": 235, "slug": "breastfeeding-and-coronavirus-disease-2019-ad-interim-indications-of-the-italian", "title": "Breastfeeding and Coronavirus Disease-2019. Ad Interim Indications of the Italian Society of Neonatology Endorsed by the Union of European Neonatal & Perinatal Societies", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Recommandations pour la prise en charge de la m\u00e8re et du nouveau-n\u00e9 apr\u00e8s l'accouchement et pour l'allaitement", "verbose_date": "03.04.2020", "authors": "Davanzo R", "specialties": [{"id": 11, "name": "Gyn\u00e9cologie Obst\u00e9trique"}, {"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 7, "name": "Recommandations", "icon": "icon-reco"}, "journal": {"id": 113, "name": "Matern Child Nutr"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/mcn.13010", "findings": "", "take_away": "", "relevance_level": "Recommandations de la Soci\u00e9t\u00e9 Italienne de N\u00e9onatologie (donn\u00e9es de 28 f\u00e9vrier 2020):\r\n1) lorsque cela est possible, l'option \u00e0 privil\u00e9gier pendant l'hospitalisation est la prise en charge simultan\u00e9e de la m\u00e8re et du nouveau-n\u00e9 (m\u00e8re atteinte ou suspect\u00e9e d'\u00eatre atteinte de COVID-19 asymptomatique ou paucisymptomatique)\r\n2) si la m\u00e8re pr\u00e9sente des sympt\u00f4mes respiratoires graves (toux, fi\u00e8vre, s\u00e9cr\u00e9tions respiratoires), la m\u00e8re et le nouveau-n\u00e9 doivent \u00eatre s\u00e9par\u00e9s en attendant les r\u00e9sultats du d\u00e9pistage. En cas de r\u00e9sultat positif, le nourrisson doit \u00eatre s\u00e9par\u00e9 de sa m\u00e8re.\r\n3) la d\u00e9cision de s\u00e9parer la m\u00e8re et le nouveau-n\u00e9 doit \u00eatre prise en tenant compte des cas sp\u00e9cifiques, des souhaits de la m\u00e8re, de la logistique de l'h\u00f4pital et \u00e9ventuellement de la diffusion locale du SRAS-CoV-2.\r\n4) en cas de s\u00e9paration m\u00e8re-b\u00e9b\u00e9: le lait maternel est pr\u00e9f\u00e9r\u00e9, le lait maternel pasteuris\u00e9 n'est pas recommand\u00e9.\r\n5) dans le cas d'une m\u00e8re COVID-19, des mesures d'hygi\u00e8ne appropri\u00e9es doivent \u00eatre prises (lavage des mains, utilisation d'un masque chirurgical pendant l'allaitement et contact avec le nouveau-n\u00e9, interdire les visites, le nouveau-n\u00e9 doit dormir dans son berceau \u00e0 au moins deux m\u00e8tres de la m\u00e8re).\r\n6) \u00e9valuer au cas par cas la compatibilit\u00e9 de l'allaitement avec les m\u00e9dicaments administr\u00e9s aux m\u00e8res COVID-19.", "objectives": "1) recommandations europ\u00e9ennes2) peu de donn\u00e9es bibliographiques disponibles sur ce sujet", "methods": "Recommandations pour la prise en charge de la m\u00e8re et du nouveau-n\u00e9 apr\u00e8s l'accouchement et pour l'allaitement", "pubmed_id": "32243068", "doi": "10.1111/mcn.13010", "abstract": "The recent COVID-19 pandemic has spread to Italy with heavy consequences on public health and economics. Besides the possible consequences of COVID-19 infection on a pregnant woman and the fetus, a major concern is related to the potential effect on neonatal outcome, the appropriate management of the mother-newborn dyad, and finally the compatibility of maternal COVID-19 infection with breastfeeding. The Italian Society on Neonatology (SIN) after reviewing the limited scientific knowledge on the compatibility of breastfeeding in the COVID-19 mother and the available statements from Health Care Organizations has issued the following indications that have been endorsed by the Union of European Neonatal & Perinatal Societies (UENPS). If a mother previously identified as COVID-19 positive or under investigation for COVID-19 is asymptomatic or paucisymptomatic at delivery, rooming-in is feasible, and direct breastfeeding is advisable, under strict measures of infection control. On the contrary, when a mother with COVID-19 is too sick to care for the newborn, the neonate will be managed separately and fed fresh expressed breast milk, with no need to pasteurize it, as human milk is not believed to be a vehicle of COVID-19. We recognize that this guidance might be subject to change in the future when further knowledge will be acquired about the COVID-19 pandemic, the perinatal transmission of SARS-CoV-2, and clinical characteristics of cases of neonatal COVID-19.", "topics": ["Recommandations", "Gyn\u00e9cologie Obst\u00e9trique", "P\u00e9diatrie"], "author_list": [{"id": 225, "name": "Davanzo R"}], "publication_date": "2020-04-03"}, {"id": 9, "slug": "coronavirus-disease-2019-the-harms-of-exaggerated-information-and-non-evidence-b", "title": "Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Analyser l'effets des informations scientifiques inexactes sur le CVID-19 et leurs cons\u00e9quences sur les mesures prises", "verbose_date": "25.03.2020", "authors": "Ioannidis JPA", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 8, "name": "Eur J Clin Invest"}, "link": "https://www.dropbox.com/s/iqivzar311zhr0r/eci.13223.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Attention \u00e0 la grande h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 des publications scientifiques sur le COVID-19 : beaucoup d'\u00e9tudes \u00e0 faible niveau de preuve, parfois de fausses informations (m\u00eame dans des grandes revues) ou des informations tr\u00e8s impr\u00e9cises. Beaucoup de mesures ne sont pas bas\u00e9es sur des preuves solides : n\u00e9cessit\u00e9 d'une analyse critique de la litt\u00e9rature et de prendre du recul avant de prendre une d\u00e9cision sanitaire fond\u00e9e sur les preuves.", "objectives": "Faible :- analyse de quelques articles scientifiques- Expert reconnu en Sant\u00e9 Publique qui livre une analyse personnel mais tout \u00e0 fait pertinente", "methods": "Analyser l'effets des informations scientifiques inexactes sur le CVID-19 et leurs cons\u00e9quences sur les mesures prises", "pubmed_id": "32202659", "doi": "10.1111/eci.13223", "abstract": "The evolving coronavirus disease 2019 (COVID-19) pandemic", "topics": ["Autres", "Transversale"], "author_list": [{"id": 20, "name": "Ioannidis JPA"}], "publication_date": "2020-03-25"}, {"id": 338, "slug": "feasibility-of-controlling-covid-19-outbreaks-in-the-uk-by-rolling-interventions", "title": "Feasibility of Controlling COVID-19 Outbreaks in the UK by Rolling Interventions", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Estimer la faisabilit\u00e9 et l'efficacit\u00e9 de diff\u00e9rentes strat\u00e9gies de contr\u00f4le de l'\u00e9pid\u00e9mie (confinement total, partiel ou alternance entre les deux).", "verbose_date": "15.04.2020", "authors": "Yang P", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.05.20054429v2.full.pdf", "findings": "", "take_away": "", "relevance_level": "Selon les auteurs, une strat\u00e9gie de roulement entre suppression (confinement total) et limitation de la transmission (confinement partiel) \u00e0 haute intensit\u00e9 pourrait \u00eatre efficace et efficiente tout en minimisant les pertes en termes sociaux, \u00e9conomiques et psychologiques.\r\nLa meilleure strat\u00e9gie pourrait \u00eatre le confinement total prolong\u00e9 dans les zones dens\u00e9ment peupl\u00e9es (Londres ici) pendant 3 mois et une strat\u00e9gie de roulement de 3 semaines hors Londres, donc d'alternance de p\u00e9riode de confinement total et de confinement partiel.", "objectives": "- Pr\u00e9 Print- Etude \u00e9pid\u00e9miologique de mod\u00e9lisation- Utilisant entre autre les donn\u00e9es chinoises- Crit\u00e8res de jugements principaux multiples- Evoquent les risque \u00e9conomiques et psychosociaux dans les r\u00e9sultats sans les inclure dans les mod\u00e9lisation de l'\u00e9valuation\"", "methods": "Estimer la faisabilit\u00e9 et l'efficacit\u00e9 de diff\u00e9rentes strat\u00e9gies de contr\u00f4le de l'\u00e9pid\u00e9mie (confinement total, partiel ou alternance entre les deux).", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 324, "name": "Yang P"}], "publication_date": "2020-04-15"}, {"id": 69, "slug": "insight-into-covid-2019-for-pediatricians", "title": "Insight into COVID-2019 for pediatricians", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Discuter la prise en charge des enfants infect\u00e9s par le SARS-CoV-2, de la pr\u00e9vention au traitement.", "verbose_date": "18.03.2020", "authors": "Li Y", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 56, "name": "Pediatr Pumonol"}, "link": "https://www.dropbox.com/s/klveo23wamiefz8/ppul.24734.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Chez l'enfant la maladie est le plus souvent b\u00e9nigne m\u00eame si le scanner peut montrer une atteinte pulmonaire. La gu\u00e9rison se fait plus rapidement que chez l'adulte (mais pas forc\u00e9ment la diminution de la vir\u00e9mie). La RT-PCR peut \u00eatre n\u00e9gative alors que le sujet est infect\u00e9. Le diagnostic doit \u00eatre port\u00e9 quand : 1) il y a eu possiblit\u00e9 de contact dans les 14jours pr\u00e9c\u00e9dents 2) on retrouve 2/3 parmi : - fi\u00e8vre et/ou sympt\u00f4mes respiratoires - signes en faveur sur le scanner thoracique - diminution du nombre de leucocytes ou de lymphocytes dans le sang3) d\u00e9tection de l'acide nucl\u00e9ique du SARS-CoV-2 dans les pr\u00e9l\u00e8vements respiratoires ou sanguin OU sequencage viral dans les pr\u00e9l\u00e8vements respiratoires ou sanguins hautement compatible avec le SARS-CoV2", "objectives": "Faible:1) Seulement 2 cas d\u00e9crits, le reste des informations se basant sur de la bibliographie", "methods": "Discuter la prise en charge des enfants infect\u00e9s par le SARS-CoV-2, de la pr\u00e9vention au traitement.", "pubmed_id": "32187887\n15549175\n32102140\n32003551\n32102141\n31986261\n32187887\n32007143", "doi": "10.1002/ppul.24734", "abstract": "Since December 2019, patients with unexplained pneumonia have been found in Wuhan City, Hubei Province, China. The pathogen in these cases is a new type of coronavirus. The World Health Organization confirmed this diagnosis and named the pathogen SARSCoV-2. The disease caused by SARSCoV-2 is called Corona Virus Disease (COVID-2019). The virus is highly infectious and pathogenic, causing human-to-human transmission. At present, SARSCoV-2 is still rampant in the world. Zhengzhou City in Henan Province serves as an example, 102 people have been confirmed to be infected with SARSCoV-2 (at 24:00 on February 5th, 2020), including three children, the youngest is 4 years old. From the perspective of clinical pediatricians as the first line fighting the epidemic, this paper will discuss the clinical characteristics, prevention and control measures, outcomes, diagnosis, and treatment of pediatric cases.", "topics": ["Autres", "P\u00e9diatrie"], "author_list": [{"id": 79, "name": "Li Y"}], "publication_date": "2020-03-18"}, {"id": 637, "slug": "systematic-assessment-of-venous-thromboembolism-in-covid-19-patients-receiving-t", "title": "Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer l'incidence et les facteurs de risques associ\u00e9s \u00e0 la maladie thromboembolique veineuse chez les patients atteints de Covid-19 sous thromboprophylaxie.", "verbose_date": "28.05.2020", "authors": "Artifoni M", "specialties": [{"id": 15, "name": "H\u00e9matologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 245, "name": "J Thrombosis Thrombolysis"}, "link": "https://link.springer.com/content/pdf/10.1007/s11239-020-02146-z.pdf", "findings": "", "take_away": "", "relevance_level": "Malgr\u00e9 la thromboprophylaxie, le risque de MTEV est \u00e9lev\u00e9 chez les patients atteints de Covid-19 hors soins intensifs.\r\nUn taux de D-dim\u00e8res sup\u00e9rieur \u00e0 1.0 \u03bcg/ml pr\u00e9dit significativement le risque de MTEV.", "objectives": "- D\u00e9pistage syst\u00e9matique des Thromboses Veineuses Profondes - Mais \u00e9tude r\u00e9trospective- Multicentrique (2), de petite taille (n=71)- Biais de s\u00e9lection sur les patients qui n'ont pas eu de Doppler durant l'hospitalisation et qui ont \u00e9t\u00e9 exclus des analyses", "methods": "D\u00e9terminer l'incidence et les facteurs de risques associ\u00e9s \u00e0 la maladie thromboembolique veineuse chez les patients atteints de Covid-19 sous thromboprophylaxie.", "pubmed_id": "32451823\n32220206\n32271988\n32407255\n10477777\n32246317\n32381264\n32324103\n32344467\n27975101\n32379935\n32073213", "doi": "10.1007/s11239-020-02146-z", "abstract": "Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic events are debated and highly heterogeneous. The objective was to determine incidence and risk factors of venous thromboembolism (VTE) in COVID-19 inpatients receiving thromboprophylaxis. In this retrospective French cohort study, patients hospitalized in medical wards non-ICU with confirmed COVID-19 and adequate thromboprophylaxis were included. A systematic low limb venous duplex ultrasonography was performed at hospital discharge or earlier if deep venous thrombosis (DVT) was clinically suspected. Chest angio-CT scan was performed when pulmonary embolism (PE) was suspected. Of 71 patients, 16 developed VTE (22.5%) and 7 PE (10%) despite adequate thromboprophylaxis. D-dimers at baseline were significantly higher in patients with DVT (p\u2009<\u20090.001). Demographics, comorbidities, disease manifestations, severity score, and other biological parameters, including inflammatory markers, were similar in patients with and without VTE. The negative predictive value of a baseline D-dimer level\u2009<\u20091.0\u00a0\u00b5g/ml was 90% for VTE and 98% for PE. The positive predictive value for VTE was 44% and 67% for D-dimer level\u2009\u2265\u20091.0\u00a0\u00b5g/ml and\u2009\u2265\u20093\u00a0\u00b5g/ml, respectively. The association between D-dimer level and VTE risk increased by taking into account the latest available D-dimer level prior to venous duplex ultrasonography for the patients with monitoring of D-dimer. Despite thromboprophylaxis, the risk of VTE is high in COVID-19 non-ICU inpatients. Increased D-dimer concentrations of more than 1.0\u00a0\u03bcg/ml predict the risk of venous thromboembolism. D-dimer level-guided aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies.", "topics": ["Diagnostique", "H\u00e9matologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 599, "name": "Artifoni M"}], "publication_date": "2020-05-28"}, {"id": 658, "slug": "social-heterogeneity-and-the-covid-19-lockdown-in-a-multi-group-seir-model", "title": "Social heterogeneity and the COVID-19 lockdown in a multi-group SEIR model", "has_other_authors": true, "impact_factor": {"id": 4, "name": "Ind\u00e9termin\u00e9", "posts_count": 12, "color": "gray", "order": 4}, "goals_plain": "L'objectif de cet article est de montrer que les h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9s des interactions sociales ont un grand impact sur les caract\u00e9ristiques d'une \u00e9pid\u00e9mie (le R_0, la taille, le pic,...).\r\n ", "verbose_date": "01.06.2020", "authors": "Dolbeault J", "specialties": [{"id": 21, "name": "Confinement/D\u00e9confinement"}], "category": {"id": 8, "name": "Mod\u00e9lisation", "icon": "icon-all"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.05.15.20103010v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "La motivation principale de l'article vient du fait qu'apr\u00e8s le confinement bien qu'une majorit\u00e9 de la population ait consid\u00e9rablement r\u00e9duit ses contacts, une petite proportion de la population, comme les agents de sant\u00e9, ont d\u00fb garder un taux important de contacts. Ceci pourrait \u00eatre une explication parmi d'autres pour le fait qu'apr\u00e8s le confinement il y a eu un d\u00e9lai avant que le nombre des infect\u00e9s diminue.", "objectives": "Le mod\u00e8le est assez simple et ne prend pas en compte l\u2019ensemble des sp\u00e9cificit\u00e9s de l'\u00e9pid\u00e9mie de COVID 19. Mais cela est justifi\u00e9 par l'objectif de l'article qui est de mettre en avant, \u00e0 l'aide d'une \u00e9tude qualitative,  l'importance de l'impact de l'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 sur la dynamique et l'\u00e9quilibre d'une \u00e9pid\u00e9mie. Les param\u00e8tres dans les simulations sont aussi choisis dans un but illustratif. Les r\u00e9sultats sont bas\u00e9s sur des arguments th\u00e9oriques simples et des simulations. Ces arguments simples m\u00e8nent \u00e0 des conclusions importantes \u00e0 prendre en compte dans l'\u00e9tude de l'\u00e9pid\u00e9mie : n\u00e9gliger l'h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 des taux de contact pourrait mener \u00e0 des pr\u00e9dictions pessimistes. Par ailleurs, l'\u00e9tude souligne l'importance de prendre des mesures de pr\u00e9vention pour la partie de la population qui a un niveau \u00e9lev\u00e9 d'interactions sociales.", "methods": "L'objectif de cet article est de montrer que les h\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9s des interactions sociales ont un grand impact sur les caract\u00e9ristiques d'une \u00e9pid\u00e9mie (le R_0, la taille, le pic,...).", "topics": ["Mod\u00e9lisation", "Confinement/D\u00e9confinement"], "author_list": [{"id": 619, "name": "Dolbeault J"}], "publication_date": "2020-06-01"}, {"id": 436, "slug": "severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-infection-in-children", "title": "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Quelle est la pr\u00e9sentation clinique d'un enfant atteint du COVID 19?", "verbose_date": "24.04.2020", "authors": "Castagnoli R", "specialties": [{"id": 9, "name": "P\u00e9diatrie"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 95, "name": "JAMA Pediatrics"}, "link": "https://www.dropbox.com/s/i7czhttvje4nboz/10.1001%40jamapediatrics.2020.1467.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La plupart des enfants ont des sympt\u00f4mes l\u00e9gers et mod\u00e9r\u00e9s (fi\u00e8vre, toux, fatigue ou asymptomatique) qui gu\u00e9rissent en 1 \u00e0 2 semaines. Radiographie pulmonaire : \u00e9paississements bronchiques et opacit\u00e9s en verre d\u00e9poli. Retrouv\u00e9s aussi chez les enfants asymptomatiques. 1 seul cas s\u00e9v\u00e8re de 13 mois, pas de morts entre 0 et 9 ans. Besoin d'\u00e9tudes suppl\u00e9mentaires.", "objectives": "Revue de la litt\u00e9rature, peu de recul (3 mois) et peu d'\u00e9tudes. Uniquement des \u00e9tudes observationnelles et cases reports. Mais pas de biais de population, tous test\u00e9s positifs au SARS COV2.", "methods": "Quelle est la pr\u00e9sentation clinique d'un enfant atteint du COVID 19?", "pubmed_id": "32320004", "doi": "10.1001/jamapediatrics.2020.1467", "abstract": "The current rapid worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection justifies the global effort to identify effective preventive strategies and optimal medical management. While data are available for adult patients with coronavirus disease 2019 (COVID-19), limited reports have analyzed pediatric patients infected with SARS-CoV-2.\nTo evaluate currently reported pediatric cases of SARS-CoV-2 infection.\nAn extensive search strategy was designed to retrieve all articles published from December 1, 2019, to March 3, 2020, by combining the terms coronavirus and coronavirus infection in several electronic databases (PubMed, Cochrane Library, and CINAHL), and following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Retrospective cross-sectional and case-control studies, case series and case reports, bulletins, and national reports about the pediatric SARS-CoV-2 infection were included. The risk of bias for eligible observational studies was assessed according to the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline.\nA total of 815 articles were identified. Eighteen studies with 1065 participants (444 patients were younger than\u200910 years, and 553 were aged 10 to 19 years) with confirmed SARS-CoV-2 infection were included in the final analysis. All articles reflected research performed in China, except for 1 clinical case in Singapore. Children at any age were mostly reported to have mild respiratory symptoms, namely fever, dry cough, and fatigue, or were asymptomatic. Bronchial thickening and ground-glass opacities were the main radiologic features, and these findings were also reported in asymptomatic patients. Among the included articles, there was only 1 case of severe COVID-19 infection, which occurred in a 13-month-old infant. No deaths were reported in children aged 0 to 9 years. Available data about therapies were limited.\nTo our knowledge, this is the first systematic review that assesses and summarizes clinical features and management of children with SARS-CoV-2 infection. The rapid spread of COVID-19 across the globe and the lack of European and US data on pediatric patients require further epidemiologic and clinical studies to identify possible preventive and therapeutic strategies.", "topics": ["Epid\u00e9miologique", "P\u00e9diatrie"], "author_list": [{"id": 413, "name": "Castagnoli R"}], "publication_date": "2020-04-24"}, {"id": 535, "slug": "mitigating-the-psychological-impact-of-covid-19-on-healthcare-workers-a-digital-", "title": "Mitigating the Psychological Impact of COVID-19 on Healthcare Workers: A Digital Learning Package", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9veloppement et \u00e9valuation rapides d'un outil d'apprentissage num\u00e9rique pour aider les employeurs du secteur de la sant\u00e9 \u00e0 mettre en place des conditions favorables au bien-\u00eatre psychologique des professionnels de la sant\u00e9, \u00e0 \u00eatre mieux inform\u00e9s des besoins psychologiques et de leur impact pendant et apr\u00e8s la pand\u00e9mie, \u00e0 encourager les demandes d'aide fond\u00e9es sur des preuves scientifiques.", "verbose_date": "05.05.2020", "authors": "Blake H", "specialties": [{"id": 6, "name": "Psychiatrie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 212, "name": "Int J Environ Res Public Health"}, "link": "https://www.dropbox.com/s/abp1us7777x32fj/ijerph-17-02997-v2.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Le programme\u00a0\"Psychological Wellbeing in Healtcare Workers: Mitigating the Impacts of COVID-19\" a \u00e9t\u00e9 utilis\u00e9 17633 fois et a \u00e9t\u00e9 consult\u00e9 plus de 50 000 fois dans les\u00a0ressources sociaux au cours des 7 premiers jours suivant sa sortie.\u00a0\nSur les 55 travailleurs de la sant\u00e9 qui ont test\u00e9 la version finale 1.0 du programme, 82 % ont d\u00e9clar\u00e9 qu'ils avaient utilis\u00e9 les informations acquises gr\u00e2ce au programme sur leur lieu de travail et \u00e0 leur domicile et 100 % pr\u00e9voyaient de continuer \u00e0 les utiliser plus tard.\nLe programme a \u00e9t\u00e9 jug\u00e9 adapt\u00e9 \u00e0 tous les types de professionnels de la sant\u00e9 et utile\u00a0\u00e0 leurs besoins.\u00a0Les auteurs de l'\u00e9tude recommandent de diffuser le programme comme strat\u00e9gie suppl\u00e9mentaire pour assurer le bien-\u00eatre psychologique des professionnels de la sant\u00e9 pendant et apr\u00e8s la pand\u00e9mie COVID-19.", "objectives": "Interm\u00e9diaire:1) \u00e9tude sur le d\u00e9veloppement d'un syst\u00e8me d'apprentissage num\u00e9rique et son \u00e9valuation2) le syst\u00e8me a \u00e9t\u00e9 test\u00e9 sur un nombre limit\u00e9 de professionnels de la sant\u00e9 britanniques (n=55,  manque de preuves de l'efficacit\u00e9 internationale)", "methods": "D\u00e9veloppement et \u00e9valuation rapides d'un outil d'apprentissage num\u00e9rique pour aider les employeurs du secteur de la sant\u00e9 \u00e0 mettre en place des conditions favorables au bien-\u00eatre psychologique des professionnels de la sant\u00e9, \u00e0 \u00eatre mieux inform\u00e9s des besoins psychologiques et de leur impact pendant et apr\u00e8s la pand\u00e9mie, \u00e0 encourager les demandes d'aide fond\u00e9es sur des\u00a0preuves\u00a0scientifiques.", "pubmed_id": "32357424\n15133143\n32259193\n15345768\n32202646\n27745684\n31935985\n24609605\n32253133\n32271650\n32278298\n30366419\n32217624\n32276196\n19149392\n17457075\n22208464\n17500305\n21062471\n32272480", "doi": "10.3390/ijerph17092997", "abstract": "The coronavirus pandemic (COVID-19) will undoubtedly have psychological impacts for healthcare workers, which could be sustained; frontline workers will be particularly at risk. Actions are needed to mitigate the impacts of COVID-19 on mental health by protecting and promoting the psychological wellbeing of healthcare workers during and after the outbreak. We developed and evaluated a digital learning package using Agile methodology within the first three weeks of UK outbreak. This e-package includes evidence-based guidance, support and signposting relating to psychological wellbeing for all UK healthcare employees. A three-step rapid development process included public involvement activities (PPIs) (STEP 1), content and technical development with iterative peer review (STEP 2), and delivery and evaluation (STEP 3). The package outlines the actions that team leaders can take to provide psychologically safe spaces for staff, together with guidance on communication and reducing social stigma, peer and family support, signposting others through psychological first aid (PFA), self-care strategies (e.g., rest, work breaks, sleep, shift work, fatigue, healthy lifestyle behaviours), and managing emotions (e.g., moral injury, coping, guilt, grief, fear, anxiety, depression, preventing burnout and psychological trauma). The e-package includes advice from experts in mental wellbeing as well as those with direct pandemic experiences from the frontline, as well as signposting to public mental health guidance. Rapid delivery in STEP 3 was achieved via direct emails through professional networks and social media. Evaluation included assessment of fidelity and implementation qualities. Essential content was identified through PPIs (", "topics": ["Autres", "Psychiatrie"], "author_list": [{"id": 501, "name": "Blake H"}], "publication_date": "2020-05-05"}, {"id": 613, "slug": "arrhythmic-profile-and-24-hour-qt-interval-variability-in-covid-19-patients-trea", "title": "Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with Hydroxychloroquine and azithromycin", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Evaluer les modifications \u00e9lectrocardiographiques et d\u00e9terminer le profil sur 24h du QTc de patients COVID-19 trait\u00e9s par bith\u00e9rapie Hydroxychloroquine et Azithromycine.", "verbose_date": "20.05.2020", "authors": "Cipriani A", "specialties": [{"id": 12, "name": "Infectiologie"}, {"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 122, "name": "Int J Cardiol"}, "link": "https://www.internationaljournalofcardiology.com/article/S0167-5273(20)32223-3/pdf", "findings": "", "take_away": "", "relevance_level": "Sur 22 cas trait\u00e9s depuis au moins 3 jours par 200 mg x 2 d'Hydroxychloroquine et 500 mg par jour d'Azithromycine :\n- Allongement du QTc (450 vs 426 ms, p=0.02) entre l'ECG avant traitement et celui \u00e0 plus de 3 jours de traitement.\n- Les 5 patients avec un QTc > 480 ms pr\u00e9sentaient une \u00e9l\u00e9vation significative des transaminases par rapport \u00e0 ceux avec un QTc < 480 ms.\n- Sur holter ECG sur 24 heures : Valeur moyenne du QTc plus \u00e9lev\u00e9e chez les cas (453 vs 407 ms, p<0.01), sans variation significative sur la journ\u00e9e. Un seul enregistrement de TV non soutenue. Pas de ph\u00e9nom\u00e8ne R sur T constat\u00e9.", "objectives": "- \u00c9tude cas-t\u00e9moin - Tr\u00e8s faible effectif (22 cas)- Pre-proof", "methods": "Evaluer les modifications \u00e9lectrocardiographiques et d\u00e9terminer le profil sur 24h du QTc de patients COVID-19 trait\u00e9s par bith\u00e9rapie Hydroxychloroquine et Azithromycine.", "pubmed_id": "32439366", "doi": "10.1016/j.ijcard.2020.05.036", "abstract": "Hydroxychloroquine and azithromycin combination therapy is often prescribed for coronavirus disease 2019 (COVID-19). Electrocardiographic (ECG) monitoring is warranted because both medications cause corrected QT-interval (QTc) prolongation. Whether QTc duration significantly varies during the day, potentially requiring multiple ECGs, remains to be established.\nWe performed 12\u2011lead ECGs and 12\u2011lead 24-h Holter ECG monitoring in all patients aged <80\u00a0years admitted to our medical unit for COVID-19, in oral therapy with hydroxychloroquine (200\u00a0mg, twice daily) and azithromycin (500\u00a0mg, once daily) for at least 3\u00a0days. A group of healthy individuals matched for age and sex served as control.\nOut of 126 patients, 22 (median age 64, 82% men) met the inclusion criteria. ECG after therapy showed longer QTc-interval than before therapy (450 vs 426\u00a0ms, p\u00a0=\u00a0.02). Four patients had a QTc\u00a0\u2265\u00a0480\u00a0ms: they showed higher values of aspartate aminotransferase (52 vs 30\u00a0U/L, p\u00a0=\u00a0.03) and alanine aminotransferase (108 vs 33\u00a0U/L, p\u00a0<\u00a0.01) compared with those with QTc\u00a0<\u00a0480\u00a0ms. At 24-h Holter ECG monitoring, 1 COVID-19 patient and no control had \u22651 run of non-sustained ventricular tachycardia (p\u00a0=\u00a0.4). No patients showed \"R on T\" premature ventricular beats. Analysis of 24-h QTc dynamics revealed that COVID-19 patients had higher QTc values than controls, with no significant hourly variability.\nTherapy with hydroxychloroquine and azithromycin prolongs QTc interval in patients with COVID-19, particularly in those with high levels of transaminases. Because QTc duration remains stable during the 24\u00a0h, multiple daily ECG are not recommendable.", "topics": ["Pronostique", "Infectiologie", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 576, "name": "Cipriani A"}], "publication_date": "2020-05-20"}, {"id": 439, "slug": "presenting-characteristics-comorbidities-and-outcomes-among-5700-patients-hospit", "title": "Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les caract\u00e9ristiques cliniques et l'\u00e9volution pour des patients COVID-19 hospitalis\u00e9s dans le syst\u00e8me de soins am\u00e9ricain", "verbose_date": "24.04.2020", "authors": "Richardson S", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 23, "name": "JAMA"}, "link": "https://www.dropbox.com/s/t34avsyccyyx47j/10.1001%40jama.2020.6775.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "5 700 patients inclus : \u00e2ge m\u00e9dian de 63 ans, 39,7% de femmes, 84,4% de patients n'ayant jamais fum\u00e9. Les comorbidit\u00e9s les plus fr\u00e9quentes \u00e9taient l'hypertension art\u00e9rielle (56,6%), l'ob\u00e9sit\u00e9 (41,7%) et le diab\u00e8te (33,8%). 88% des patients avaient plus d'une comorbidit\u00e9.\u00a0\r\nPour les 2 634 patients sortis d'hospitalisation ou d\u00e9c\u00e9d\u00e9s \u00e0 la date de point, 14,2% pris en charge en soins intensifs, 12,2% ont eu une ventilation m\u00e9canique et 21% sont d\u00e9c\u00e9d\u00e9s.\r\nConcernant les r\u00e9admissions, 2,2% sur les 2 634 ont \u00e9t\u00e9 r\u00e9admis avec une m\u00e9diane de 3 jours apr\u00e8s leur sortie.", "objectives": "1) Large s\u00e9rie de cas, n=5 700 mais moins de la moiti\u00e9 (2 634) \u00e9taient \u00e9valuables pour l'issue du COVID-19 (sortie d'hospitalisation ou d\u00e9c\u00e8s)2) Multicentrique mais tr\u00e8s localis\u00e9 autour de New-York3) Uniquement descriptif, pas d'ajustement sur \u00e2ge, sexe, comorbidit\u00e9s, etc ...4) Donn\u00e9es extraites de la base de donn\u00e9es des dossiers m\u00e9dicaux, pas de revue possible du dossier5) La dur\u00e9e m\u00e9diane de suivi apr\u00e8s la sortie \u00e9tait tr\u00e8s br\u00e8ve \u00e0 4,4 jours\"", "methods": "D\u00e9crire les caract\u00e9ristiques cliniques et l'\u00e9volution pour des patients COVID-19 hospitalis\u00e9s dans le syst\u00e8me de soins am\u00e9ricain", "pubmed_id": "32320003\n32171076\n32233753\n3558716\n32004427\n15897343\n32191259\n26466050\n32148129", "doi": "10.1001/jama.2020.6775", "abstract": "There is limited information describing the presenting characteristics and outcomes of US patients requiring hospitalization for coronavirus disease 2019 (COVID-19).\nTo describe the clinical characteristics and outcomes of patients with COVID-19 hospitalized in a US health care system.\nCase series of patients with COVID-19 admitted to 12 hospitals in New York City, Long Island, and Westchester County, New York, within the Northwell Health system. The study included all sequentially hospitalized patients between March 1, 2020, and April 4, 2020, inclusive of these dates.\nConfirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive result on polymerase chain reaction testing of a nasopharyngeal sample among patients requiring admission.\nClinical outcomes during hospitalization, such as invasive mechanical ventilation, kidney replacement therapy, and death. Demographics, baseline comorbidities, presenting vital signs, and test results were also collected.\nA total of 5700 patients were included (median age, 63 years [interquartile range {IQR}, 52-75; range, 0-107 years]; 39.7% female). The most common comorbidities were hypertension (3026; 56.6%), obesity (1737; 41.7%), and diabetes (1808; 33.8%). At triage, 30.7% of patients were febrile, 17.3% had a respiratory rate greater than 24 breaths/minute, and 27.8% received supplemental oxygen. The rate of respiratory virus co-infection was 2.1%. Outcomes were assessed for 2634 patients who were discharged or had died at the study end point. During hospitalization, 373 patients (14.2%) (median age, 68 years [IQR, 56-78]; 33.5% female) were treated in the intensive care unit care, 320 (12.2%) received invasive mechanical ventilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died. Mortality for those requiring mechanical ventilation was 88.1%. The median postdischarge follow-up time was 4.4 days (IQR, 2.2-9.3). A total of 45 patients (2.2%) were readmitted during the study period. The median time to readmission was 3 days (IQR, 1.0-4.5) for readmitted patients. Among the 3066 patients who remained hospitalized at the final study follow-up date (median age, 65 years [IQR, 54-75]), the median follow-up at time of censoring was 4.5 days (IQR, 2.4-8.1).\nThis case series provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19 in the New York City area.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 415, "name": "Richardson S"}], "publication_date": "2020-04-24"}, {"id": 519, "slug": "status-of-sars-cov-2-in-cerebrospinal-fluid-of-patients-with-covid-19-and-stroke", "title": "Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Statut du SRAS-CoV-2 dans le liquide c\u00e9phalorachidien des patients ayant une infection COVID-19 et AVC concomitant.", "verbose_date": "04.05.2020", "authors": "Al Saiegh F", "specialties": [{"id": 18, "name": "Neurologie"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 205, "name": "J Neurol Neurosurg Psych"}, "link": "https://jnnp.bmj.com/content/jnnp/early/2020/04/30/jnnp-2020-323522.full.pdf", "findings": "", "take_away": "", "relevance_level": "Dans quelques cas, un \u00e9tat d'hypercoagulabilit\u00e9 et d'inflammation peut conduire \u00e0 une maladie c\u00e9r\u00e9brovasculaire avec une effraction de la barri\u00e8re h\u00e9mato-enc\u00e9phalique.\nLes auteurs encouragent l'analyse du LCR chez les patients avec une infection Covid-19 confirm\u00e9e afin de mieux comprendre le tropisme tissulaire du virus.", "objectives": "- Manque de donn\u00e9es notamment biologiques d'autant plus que d'autres cases reports mentionnent un lien potentiel entre l'\u00e9tat d'hypercoagulabilit\u00e9 et d'inflammation avec une maladie cerebro-vasculaire chez les patients Covid-19.- Faible \u00e9chantillon.", "methods": "Statut du SRAS-CoV-2 dans le liquide c\u00e9phalorachidien des patients ayant une infection COVID-19 et AVC concomitant.", "pubmed_id": "32354770", "doi": "10.1136/jnnp-2020-323522", "abstract": "Emergence of the novel corona virus (severe acute respiratory syndrome (SARS)-CoV-2) in December 2019 has led to the covid-19 pandemic. The extent of covid-19 involvement in the central nervous system is not well established, and the presence or the absence of SARS-CoV-2 particles in the cerebrospinal fluid (CSF) is a topic of debate.\nWe present two patients with covid-19 and concurrent neurological symptoms. Our first patient is a 31-year-old man who had flu-like symptoms due to covid-19 and later developed an acute-onset severe headache and loss of consciousness and was diagnosed with a Hunt and Hess grade 3 subarachnoid haemorrhage from a ruptured aneurysm. Our second patient is a 62-year-old woman who had an ischaemic stroke with massive haemorrhagic conversion requiring a decompressive hemicraniectomy. Both patients' CSF was repeatedly negative on real-time PCR analysis despite concurrent neurological disease.\nOur report shows that patients' CSF may be devoid of viral particles even when they test positive for covid-19 on a nasal swab. Whether SARS-CoV-2 is present in CSF may depend on the systemic disease severity and the degree of the virus' nervous tissue tropism and should be examined in future studies.", "topics": ["Diagnostique", "Neurologie"], "author_list": [{"id": 487, "name": "Al Saiegh F"}], "publication_date": "2020-05-04"}, {"id": 265, "slug": "extracorporeal-membrane-oxygenation-ecmo-does-it-have-a-role-in-the-treatment-of", "title": "Extracorporeal membrane oxygenation (ECMO): does it have a role in the treatment of severe COVID-19?", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les r\u00e9sultats cliniques de l'utilisation de l'ECMO dans le SDRA en g\u00e9n\u00e9ral, l'utilisation de l'ECMO dans les cas s\u00e9v\u00e8res de COVID-19 en Chine et discuter de ses indications", "verbose_date": "07.04.2020", "authors": "Hong X", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 18, "name": "Int J Infect Dis"}, "link": "https://www.ijidonline.com/article/S1201-9712(20)30191-0/pdf", "findings": "", "take_away": "", "relevance_level": "Le b\u00e9n\u00e9fice de l'ECMO dans le SDRA associ\u00e9 au COVID-19 n'est pas prouv\u00e9 \u00e0 ce jour mais de pr\u00e9c\u00e9dentes \u00e9tudes men\u00e9es dans le cadre des SDRA associ\u00e9s \u00e0 la gripe H1N1 ou au MERS-CoV semblent en faveur de son utilisation.", "objectives": "- pre-print- absence de d\u00e9tail sur la m\u00e9thodologie de la revue- peu de donn\u00e9es sp\u00e9cifiques \u00e0 la COVID-19 disponibles \u00e0 ce stade\"", "methods": "D\u00e9crire les r\u00e9sultats cliniques de l'utilisation de l'ECMO dans le SDRA en g\u00e9n\u00e9ral, l'utilisation de l'ECMO dans les cas s\u00e9v\u00e8res de COVID-19 en Chine et discuter de ses indications", "pubmed_id": "32251794\n29791822\n29330690\n21976615\n31986264\n30347031", "doi": "10.1016/j.ijid.2020.03.058", "abstract": "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged since December 2019 in Wuhan city, and has quickly spread throughout China and other countries. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. According to World Health Organization (WHO), management of coronavirus disease 19 (COVID-19) has mainly focused on infection prevention, case detection and monitoring, and supportive care. Given to the previous experience, extracorporeal membrane oxygenation (ECMO) has been proven to be an effective therapy in the treatment of respiratory failure or acute respiratory distress syndrome (ARDS). On the basis of similar principle, ECMO may be also an effective therapy in the treatment of severe COVID-19. In this study, we described and discussed the clinical outcomes of ECMO for ARDS patients, ECMO use for severe COVID-19 in China, the indications of ECMO use, and some important issues associated with ECMO.", "topics": ["Th\u00e9rapeutique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 254, "name": "Hong X"}], "publication_date": "2020-04-07"}, {"id": 396, "slug": "estimating-the-burden-of-sars-cov-2-in-france", "title": "Estimating the burden of SARS-CoV-2 in France", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Etudier l'impact du confinement en France sur l'\u00e9pid\u00e9mie de COVID-19 (hospitalisations, d\u00e9c\u00e8s) et sur le d\u00e9veloppement de l'immunit\u00e9", "verbose_date": "21.04.2020", "authors": "Salje H", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://hal-pasteur.archives-ouvertes.fr/pasteur-02548181/document", "findings": "", "take_away": "", "relevance_level": "\u00c0 l'aide de mod\u00e9lisations appliqu\u00e9es aux donn\u00e9es sur les hospitalisation et les d\u00e9c\u00e8s en France, les auteurs estiment l'impact du confinement et de l'immunit\u00e9 actuelle de la population.\u00a0\r\n2,6% des personnes infect\u00e9es sont hospitalis\u00e9es et 0,53% meurent, allant de 0,001% chez les <20 ans \u00e0 8,3% chez les> 80 ans. \u00c0 tous les \u00e2ges, les hommes sont plus susceptibles d'\u00eatre hospitalis\u00e9s, d'entrer en soins intensifs et de mourir que les femmes.\u00a0\r\nLe confinement a r\u00e9duit le taux de reproduction du virus (R0) de 3,3 \u00e0 0,5 (r\u00e9duction de 84%). D'ici le 11 mai, lorsque les mesures de restriction devraient \u00eatre assouplies, nous pr\u00e9voyons que 3,7 millions (IC: 2,3-6,7), soit 5,7% de la population, auront \u00e9t\u00e9 infect\u00e9s, avec une variabilit\u00e9 importante suivant les r\u00e9gions fran\u00e7aises, les plus touch\u00e9es \u00e9tant les plus immunis\u00e9es (jusqu'\u00e0 pr\u00e8s de 15% contre moins de 5%). L'immunit\u00e9 de la population semble insuffisante pour \u00e9viter une deuxi\u00e8me vague si toutes les mesures de contr\u00f4le sont lev\u00e9es \u00e0 la fin du confinement.", "objectives": "- Plus grosse \u00e9tude de mod\u00e9lisation \u00e9pid\u00e9miologique pour la France- Donn\u00e9es administratives fiables- Mod\u00e9lisations toujours critiquables mais relativement robustes- Mais pas de prise en compte des populations retrait\u00e9es vivant en EHPAD- Pas de prise en compte de l'impact des maladies chroniques ou des comorbidit\u00e9s sur la mortalit\u00e9 (bas\u00e9 sur les donn\u00e9es du Diamond Princess)- En partie bas\u00e9e sur les donn\u00e9es de contagiosit\u00e9 chinoise", "methods": "Etudier l'impact du confinement en France sur l'\u00e9pid\u00e9mie de COVID-19 (hospitalisations, d\u00e9c\u00e8s) et sur le d\u00e9veloppement de l'immunit\u00e9", "pubmed_id": "32404476\n17476782\n32234804\n19943919\n32234121\n32191173\n19718434\n32173574\n26176549\n32183930\n2117040\n21937658\n32353347\n32240634\n32213647\n26851269\n32229574", "doi": "10.1126/science.abc3517", "abstract": "France has been heavily affected by the SARS-CoV-2 epidemic and went into lockdown on the 17 March 2020. Using models applied to hospital and death data, we estimate the impact of the lockdown and current population immunity. We find 3.6% of infected individuals are hospitalized and 0.7% die, ranging from 0.001% in those <20 years of age (ya) to 10.1% in those >80ya. Across all ages, men are more likely to be hospitalized, enter intensive care, and die than women. The lockdown reduced the reproductive number from 2.90 to 0.67 (77% reduction). By 11 May 2020, when interventions are scheduled to be eased, we project 2.8 million (range: 1.8-4.7) people, or 4.4% (range: 2.8-7.2) of the population, will have been infected. Population immunity appears insufficient to avoid a second wave if all control measures are released at the end of the lockdown.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 380, "name": "Salje H"}], "publication_date": "2020-04-21"}, {"id": 474, "slug": "evaluation-of-ocular-symptoms-and-tropism-of-sarscov2-in-patients-confirmed-with", "title": "Evaluation of ocular symptoms and tropism of SARS\u2010CoV\u20102 in patients confirmed with COVID\u201019", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "\u00c9valuer les sympt\u00f4mes oculaires de SARS-CoV-2 dans un groupe de patients atteints de COVID-19.", "verbose_date": "28.04.2020", "authors": "Nan H", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 5, "name": "Epid\u00e9miologique", "icon": "icon-virus"}, "journal": {"id": 192, "name": "Acta Ophtalmol"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/aos.14445", "findings": "", "take_away": "", "relevance_level": "Dans une cohorte de 56 patients atteints de COVID-19, les sympt\u00f4mes oculaires avant et apr\u00e8s l'apparition de COVID-19 ont \u00e9t\u00e9 \u00e9valu\u00e9s. Chez environ 1 sujet sur 4, les sympt\u00f4mes oculaires se sont aggrav\u00e9s apr\u00e8s l'apparition de COVID-19. Chez environ 1 sujet sur 10, ces sympt\u00f4mes oculaires apparaissent plusieurs jours avant l'apparition de la fi\u00e8vre ou des sympt\u00f4mes respiratoires. La pr\u00e9sence de sympt\u00f4mes oculaires dans COVID-19 n\u00e9cessite une enqu\u00eate plus approfondie sur sa signification et a des implications en mati\u00e8re de s\u00e9curit\u00e9 au travail pour les professionnels des soins oculaires.", "objectives": "-\tEtude r\u00e9trospective-\tN=56-\tCette \u00e9tude ne dispose pas de donn\u00e9es d'\u00e9valuation clinique objective de la surface oculaire ant\u00e9rieure telles que les tests de volume et de stabilit\u00e9 des larmes. -\tL'\u00e9tude repose enti\u00e8rement sur des r\u00e9ponses subjectives", "methods": "\u00c9valuer les sympt\u00f4mes oculaires de SARS-CoV-2 dans un groupe de patients atteints de COVID-19.", "pubmed_id": "32336042\n18309341\n31994738\n31986257\n31039099\n14631402\n15141377\n32035510\n20502660\n32094336\n15219877\n31978945\n29321303\n31987001\n16102311\n28179131\n23471620\n15205225", "doi": "10.1111/aos.14445", "abstract": "The SARS-CoV-2 RNA has been detected in tears and conjunctival samples from infected individuals. Conjunctivitis is also reported in a small number of cases. We evaluated ocular symptoms and ocular tropism of SARS-CoV-2 in a group of patients with COVID-19.\nFifty-six patients infected with SARS-CoV-2 were recruited as subjects. Relevant medical histories were obtained from the electronic medical record system. Ocular history and ocular symptoms data were obtained by communicating directly with the subjects. The Ocular Surface Disease Index (OSDI) and Salisbury Eye Evaluation Questionnaire (SEEQ) were used to assess the anterior ocular surface condition before and after the onset of disease.\nPatients classified as severe COVID-19 cases were more likely to have hypertension compared to mild cases (p\u00a0=\u00a00.035). Of the 56 subjects, thirteen patients (23%) were infected in Wuhan, 32 patients (57%) were community-infected, 10 patients (18%) were unknown origin, 1 (2%) was a physician likely infected by a confirmed patient. Three patients wore face mask with precaution when contacting the confirmed patients. Fifteen (27%) had aggravated ocular symptoms, of which 6 (11%) had prodromal ocular symptoms before disease onset. The differences in mean scores of OSDI questionnaire and SEEQ between before and after onset of COVID-19 were all significant (p\u00a0<\u00a00.05 for both).\nOcular symptoms are relatively common in COVID-19 disease and may appear just before the onset of respiratory symptoms. Our data provided the anecdotal evidences of transmission of SARS-CoV-2 via ocular surface.", "topics": ["Epid\u00e9miologique", "Transversale"], "author_list": [{"id": 442, "name": "Nan H"}], "publication_date": "2020-04-28"}, {"id": 46, "slug": "perioperative-management-of-patients-infected-with-the-novel-coronavirus-recomme", "title": "Perioperative Management of Patients Infected with the Novel Coronavirus: Recommendation from the Joint Task Force of the Chinese Society of Anesthesiology", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Pr\u00e9senter les recommendations de prise en charge p\u00e9ri-op\u00e9ratoires dans le cadre du COVID-19", "verbose_date": "20.03.2020", "authors": "Chen X", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 7, "name": "Recommandations", "icon": "icon-reco"}, "journal": {"id": 40, "name": "Anesthesiology"}, "link": "https://www.dropbox.com/s/z3oudt27znb9x8g/aln.0000000000003301.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Recommandations chinoises, voici les grands titres : (version non corrig\u00e9e)\r\nEpid\u00e9mio : clinique et traitements :\r\nMesures de pr\u00e9caution\r\nPr\u00e9caution en p\u00e9ri op\u00e9ratoire pour des patients suspects ou confirm\u00e9s\r\n- \u00e9valuation clinique, anesth\u00e9sique pr\u00e9op\u00e9ratoire\r\n- pr\u00e9paration des patients pour chirurgies urgentes\r\n- Organisation de l'anesth\u00e9sie dans des lieux d\u00e9di\u00e9s : pr\u00e9paration pr\u00e9 op, anesth\u00e9sie (types d'anesth\u00e9sies, induction, salle de reveil (et transfert), gestion des \u00e9quipements post anesth\u00e9sie et \u00e9limination des d\u00e9chets m\u00e9dicaux (anesth\u00e9sie et blocs op\u00e9ratoires, dispositif de d\u00e9chets)\r\nIntubation oro trach\u00e9ale en urgence des cas suspects ou confirm\u00e9s en dehors des salle d'op\u00e9ration\r\n- indications IOT\r\n- pr\u00e9paration pr\u00e9 intubation\r\n- pr\u00e9cautions pour intubation\r\n- gestion des voies a\u00e9riennes apre\u00e8 intubation\r\nSurveillance des anesth\u00e9sistes apr\u00e8s avoir pris en charge un patient suspect ou confirm\u00e9", "objectives": "Consensus d'experts bas\u00e9 sur l'exp\u00e9rience chinoise", "methods": "Pr\u00e9senter les recommendations de prise en charge p\u00e9ri-op\u00e9ratoires dans le cadre du COVID-19", "topics": ["Recommandations", "Hygi\u00e8ne"], "author_list": [{"id": 56, "name": "Chen X"}], "publication_date": "2020-03-20"}, {"id": 553, "slug": "acute-physiology-and-chronic-health-evaluation-ii-score-as-a-predictor-of-hospit", "title": "Acute Physiology and Chronic Health Evaluation II Score as a Predictor of Hospital Mortality in Patients of Coronavirus Disease 2019", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer l'association entre le score Acute Physiology and Chronic Health Evaluation II (APACHE) et le taux de mortalit\u00e9 des patients COVID-19 hospitalis\u00e9s et comparer la valeur pr\u00e9dictive de la mortalit\u00e9 des scores Acute Physiology and Chronic Health Evaluaion II (APACHE), le score Sequential Organ Failure Assessment (SOFA) et le score Confusion, Urea, Respiratory rate, Blood pressure, Age 65 (CURB65)", "verbose_date": "09.05.2020", "authors": "Zou X", "specialties": [{"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 217, "name": "Crit Care Med"}, "link": "https://www.dropbox.com/s/x0fr0ekz6u6rzh2/Acute_Physiology_and_Chronic_Health_Evaluation_II.95659.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L'\u00e9tude a montr\u00e9 que le score APACHE II a une plus grande capacit\u00e9 \u00e0 pr\u00e9dire le risque de mortalit\u00e9 pour les patients COVID-19 que les scores SOFA et CRUB65 (p<0.001).\nLe score APACHE II est \u00e9galement utile pour guider les d\u00e9cisions m\u00e9dicales sachant que les patients \u00e0 faible risque (score<17) ont un taux de survie plus \u00e9lev\u00e9 que les patients \u00e0 haut risque (score>17).", "objectives": "Interm\u00e9diaire:1) Etude de cohorte r\u00e9trospective2) Petit \u00e9chantillon (n=154)3) L'h\u00f4pital de Tongji est un centre de r\u00e9f\u00e9rence pour le traitement du COVID-19, la gravit\u00e9 des sympt\u00f4mes des patients trait\u00e9s et le taux de mortalit\u00e9 peuvent ne pas refl\u00e9ter celui de la population g\u00e9n\u00e9rale", "methods": "Evaluer l'association entre le score Acute Physiology and Chronic Health Evaluation II (APACHE) et le taux de mortalit\u00e9 des patients COVID-19 hospitalis\u00e9s et comparer la valeur pr\u00e9dictive de la mortalit\u00e9 des scores Acute Physiology and Chronic Health Evaluaion II (APACHE), le score Sequential Organ Failure Assessment (SOFA) et le score Confusion, Urea, Respiratory rate, Blood pressure, Age 65 (CURB65)", "pubmed_id": "32371611\n31978945\n32171076\n28968972\n32167524\n32120458\n32141280\n12865378\n32031570\n31986264\n32217650\n21341394\n32007143\n32105632\n32239761\n32169400\n31276110\n31991541\n32125452\n32181903\n22797452\n32168464\n24474051\n25529395\n32015508", "doi": "10.1097/CCM.0000000000004411", "abstract": "Coronavirus disease 2019 has emerged as a major global health threat with a great number of deaths in China. We aimed to assess the association between Acute Physiology and Chronic Health Evaluation II score and hospital mortality in patients with coronavirus disease 2019, and to compare the predictive ability of Acute Physiology and Chronic Health Evaluation II score, with Sequential Organ Failure Assessment score and Confusion, Urea, Respiratory rate, Blood pressure, Age 65 (CURB65) score.\nRetrospective observational cohort.\nTongji Hospital in Wuhan, China.\nConfirmed patients with coronavirus disease 2019 hospitalized in the ICU of Tongji hospital from January 10, 2020, to February 10, 2020.\nNone.\nOf 178 potentially eligible patients with symptoms of coronavirus disease 2019, 23 patients (12.92%) were diagnosed as suspected cases, and one patient (0.56%) suffered from cardiac arrest immediately after admission. Ultimately, 154 patients were enrolled in the analysis and 52 patients (33.77%) died. Mean Acute Physiology and Chronic Health Evaluation II score (23.23 \u00b1 6.05) was much higher in deaths compared with the mean Acute Physiology and Chronic Health Evaluation II score of 10.87 \u00b1 4.40 in survivors (p < 0.001). Acute Physiology and Chronic Health Evaluation II score was independently associated with hospital mortality (adjusted hazard ratio, 1.07; 95% CI, 1.01-1.13). In predicting hospital mortality, Acute Physiology and Chronic Health Evaluation II score demonstrated better discriminative ability (area under the curve, 0.966; 95% CI, 0.942-0.990) than Sequential Organ Failure Assessment score (area under the curve, 0.867; 95% CI, 0.808-0.926) and CURB65 score (area under the curve, 0.844; 95% CI, 0.784-0.905). Based on the cut-off value of 17, Acute Physiology and Chronic Health Evaluation II score could predict the death of patients with coronavirus disease 2019 with a sensitivity of 96.15% and a specificity of 86.27%. Kaplan-Meier analysis showed that the survivor probability of patients with coronavirus disease 2019 with Acute Physiology and Chronic Health Evaluation II score less than 17 was notably higher than that of patients with Acute Physiology and Chronic Health Evaluation II score greater than or equal to 17 (p < 0.001).\nAcute Physiology and Chronic Health Evaluation II score was an effective clinical tool to predict hospital mortality in patients with coronavirus disease 2019 compared with Sequential Organ Failure Assessment score and CURB65 score. Acute Physiology and Chronic Health Evaluation II score greater than or equal to 17 serves as an early warning indicator of death and may provide guidance to make further clinical decisions.", "topics": ["Pronostique", "Anesth\u00e9sie-R\u00e9animation"], "author_list": [{"id": 519, "name": "Zou X"}], "publication_date": "2020-05-09"}, {"id": 183, "slug": "review-article-gastrointestinal-features-in-covid-19-and-the-possibility-of-faec", "title": "Review Article: Gastrointestinal Features in COVID-19 and the Possibility of Faecal Transmission", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9crire les r\u00e9sultats publi\u00e9s sur les manifestations digestives et discuter une possible transmission f\u00e9cale. ", "verbose_date": "29.03.2020", "authors": "Tian Y ", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 93, "name": "Aliment Pharmacol Ther"}, "link": "https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.15731", "findings": "", "take_away": "", "relevance_level": "Les patients peuvent pr\u00e9senter des\u00a0signes atypiques en premier symptomes\u00a0: c'est un indicateur pour les d\u00e9pister pr\u00e9cocement et inciter le gastroent\u00e9rologue \u00e0 se prot\u00e9ger pour r\u00e9duire le risque d'infection.\r\nLes patients ayant des\u00a0signes digestifs auraient un moins bon pronostic.\r\nDes\u00a0taux de formes s\u00e9v\u00e8res \u00e9lev\u00e9es indiqueraient une grande densit\u00e9 et virulence du virus,\u00a0qui endommagerait le syst\u00e8me digestif.\r\nChez les enfants : beaucoup plus de vomissement que chez les adultes\u00a0mais pas/peu de signes digestifs chez les formes critiques (seulement 1 patient sur 57). 10% des enfants ne pr\u00e9sentent que des signes digestifs et pas de signes respiratoires (taux plus \u00e9lev\u00e9 que chez les adultes (3%)).\r\nDifficile de dire si les signes digestifs chez les formes critiques sont primaires ou secondaires \u00e0 une hypoxie prolong\u00e9e/traitements administr\u00e9s.\r\nLe virus survivrait plus longtemps dans le syst\u00e8me digestif que dans le syst\u00e8me respiratoire. Le SARS-CoV-2 pourrait se propager via les selles. Une exposition \u00e0 un environnement contamin\u00e9 par les selles (toilettes publiques, poign\u00e9es de portes des toilettes \u00e0 la maison, ...) peut entra\u00eener une transmission muco/f\u00e9cale ou a\u00e9rosol/f\u00e9cale du virus. A confirmer par d'autres \u00e9tudes.\r\nDes \u00e9tudes indiquent que des patients SARS-CoV-2 pourraient transmettre le virus alors qu'ils sont asymptomatiques ou pr\u00e9-symptomatiques.\r\nLes chinois pr\u00e9cisent que les patients sont sortant de l'h\u00f4pital apr\u00e8s 2 PCR n\u00e9gatives \u00e0 1 jours d'intervalle et sont\u00a0confin\u00e9s pour encore 14 jours apr\u00e8s la sortie.\u00a0Compte tenu de la possible persistance du virus dans les selles, les patients devraient prendre\u00a0toutes les pr\u00e9cautions d'hygi\u00e8ne pour \u00e9viter une transmission f\u00e9cale\u00a0(lavage des mains, d\u00e9sinfection des toilettes et lavabo, \u00e9viter de partager le m\u00eame toilette avec les membres de la famille).\r\nLes auteurs proposent un\u00a0test de positivit\u00e9 des selles avant l'arr\u00eat de l'isolement.\r\nLes gastroent\u00e9rologues qui font des endoscopies pour les patients en isolement devraient consid\u00e9rer tous ces patients comme positifs et prendre des mesures de protection.", "objectives": "- la plupart des articles sont monocentriques r\u00e9trospectives et sur de faibles cohortes- certaines r\u00e9sultats contradictoires selon les \u00e9tudes- diff\u00e9rences des cas entre les premi\u00e8res phases et les phases plus avanc\u00e9es de l'\u00e9pid\u00e9mie car les m\u00e9thodes et crit\u00e8res diagnostiques ont \u00e9volu\u00e9s- manque de personnel m\u00e9dical, les anamn\u00e8se et donn\u00e9es cliniques incompl\u00e8tes aux stades pr\u00e9coces de l'\u00e9pid\u00e9mie peuvent avoir induit des biais de s\u00e9lection", "methods": "D\u00e9crire les r\u00e9sultats publi\u00e9s sur les manifestations digestives et discuter une possible transmission f\u00e9cale.", "pubmed_id": "32222988\n32109013\n32064853\n32163697\n32134205\n32031568\n32142773\n14517783\n31986264\n32222988\n32083643\n32105632\n32015508\n32118639\n32129805\n32171076\n12781535\n32146694\n32075786\n32124995\n32004427\n32091386\n32074444\n32031570\n32118389\n32007143\n32027573", "doi": "10.1111/apt.15731", "abstract": "There is little published evidence on the gastrointestinal features of COVID-19.\nTo report on the gastrointestinal manifestations and pathological findings of patients with COVID-19, and to discuss the possibility of faecal transmission.\nWe have reviewed gastrointestinal features of, and faecal test results in, COVID-19 from case reports and retrospective clinical studies relating to the digestive system published since the outbreak.\nWith an incidence of 3% (1/41)-79% (159/201), gastrointestinal symptoms of COVID-19 included anorexia 39.9% (55/138)-50.2% (101/201), diarrhoea 2% (2/99)-49.5% (146/295), vomiting 3.6% (5/138)-66.7% (4/6), nausea 1% (1/99)-29.4% (59/201), abdominal pain 2.2% (3/138)-6.0% (12/201) and gastrointestinal bleeding 4% (2/52)-13.7% (10/73). Diarrhoea was the most common gastrointestinal symptom in children and adults, with a mean duration of 4.1\u00a0\u00b1\u00a02.5\u00a0days, and was observed before and after diagnosis. Vomiting was more prominent in children. About 3.6% (5/138)-15.9% (32/201) of adult and 6.5% (2/31)-66.7% (4/6) of children patients presented vomiting. Adult and children patients can present with digestive symptoms in the absence of respiratory symptoms. The incidence of digestive manifestations was higher in the later than in the early stage of the epidemic, but no differences in digestive symptoms among different regions were found. Among the group of patients with a higher proportion of severe cases, the proportion of gastrointestinal symptoms in severe patients was higher than that in nonsevere patients (anorexia 66.7% vs 30.4%; abdominal pain 8.3% vs 0%); while in the group of patients with a lower severe rate, the proportion with gastrointestinal symptoms was similar in severe and nonsevere cases (nausea and vomiting 6.9% vs 4.6%; diarrhoea 5.8% vs 3.5%). Angiotensin converting enzyme 2 and virus nucleocapsid protein were detected in gastrointestinal epithelial cells, and infectious virus particles were isolated from faeces. Faecal PCR testing was as accurate as respiratory specimen PCR detection. In 36% (5/14)-53% (39/73) faecal PCR became positive, 2-5\u00a0days later than sputum PCR positive. Faecal excretion persisted after sputum excretion in 23% (17/73)-82% (54/66) patients for 1-11 days.\nGastrointestinal symptoms are common in patients with COVID-19, and had an increased prevalence in the later stage of the recent epidemic in China. SARS-CoV-2 enters gastrointestinal epithelial cells, and the faeces of COVID-19 patients are potentially infectious.", "topics": ["Autres", "Transversale", "Virologie", "Infectiologie"], "author_list": [{"id": 177, "name": "Tian Y "}], "publication_date": "2020-03-29"}, {"id": 349, "slug": "inactivation-of-severe-acute-respiratory-syndrome-coronavirus-2-by-who-recommend", "title": "Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 by WHO-Recommended Hand Rub Formulations and Alcohols", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "D\u00e9terminer l'activit\u00e9 virucide contre SRAS-CoV-2 des formulations de gel hydroalcoolique pour la friction des mains propos\u00e9es par l'OMS.", "verbose_date": "16.04.2020", "authors": "Kratzel A", "specialties": [{"id": 2, "name": "Hygi\u00e8ne"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 28, "name": "Emerg Infect Dis"}, "link": "https://wwwnc.cdc.gov/eid/article/26/7/20-0915_article", "findings": "", "take_away": "", "relevance_level": "Tous les formulations de gel hydroalcoolique propos\u00e9s par l'OMS (formulations I et II, formulations I et II modifi\u00e9es pour r\u00e9pondre aux normes europ\u00e9ennes 1500 et les r\u00e9actifs actifs de ces formulations tels que l'\u00e9thanol et le 2-propanol) se sont r\u00e9v\u00e9l\u00e9es efficaces pour r\u00e9duire la charge virale du SRAS-CoV-2 en un temps d'exposition de 30 secondes.\r\nIl est important de souligner que le\u00a0temps d'exposition doit \u00eatre d'au moins 30 secondes\u00a0(temps recommand\u00e9 par les recommandations mais pas toujours respect\u00e9 dans la pratique quotidienne).\r\nL'\u00e9tude d\u00e9montre que une\u00a0concentration \u2265 30 % (vol/vol) d'\u00e9thanol ou de 2-propanol est suffisante pour une inactivation virale compl\u00e8te.", "objectives": "1) Exp\u00e9rimentation ex vivo2) Utilisation d'une m\u00e9thode robuste pour normaliser les donn\u00e9es TCID50 (Prism version 8-0-3)3) Calcul de TCID50 moyenne bas\u00e9e sur la r\u00e9p\u00e9tition de 3 tests pour chaque formulation\"", "methods": "D\u00e9terminer l'activit\u00e9 virucide contre SRAS-CoV-2 des formulations de gel hydroalcoolique pour la friction des mains propos\u00e9es par l'OMS.", "pubmed_id": "32284092", "doi": "10.3201/eid2607.200915", "abstract": "Infection control instructions call for use of alcohol-based hand rub solutions to inactivate severe acute respiratory syndrome coronavirus 2. We determined the virucidal activity of World Health Organization-recommended hand rub formulations, at full strength and multiple dilutions, and of the active ingredients. All disinfectants demonstrated efficient virus inactivation.", "topics": ["Autres", "Hygi\u00e8ne"], "author_list": [{"id": 337, "name": "Kratzel A"}], "publication_date": "2020-04-16"}, {"id": 107, "slug": "sars-cov-2-rna-more-readily-detected-in-induced-sputum-than-in-throat-swabs-of-c", "title": "SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescentCOVID-19 patients", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9montrer laquelle des deux m\u00e9thodes de diagnostic est la plus sensible entre la d\u00e9tection de le RNA viral sur le pr\u00e9l\u00e8vement nasal pharyng\u00e9 et l'expectoration induite", "verbose_date": "12.03.2020", "authors": "Han H", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 3, "name": "Diagnostique", "icon": "icon-heat"}, "journal": {"id": 74, "name": "Lancet Infect Dis"}, "link": "https://www.dropbox.com/s/733zq3qbz81r8yt/10.1016%40S1473-30992030174-2.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "La d\u00e9tection de le RNA viral \u00e9tait plus sensible sur l'\u00e9chantillon obtenu par expectoration induite que sur le pr\u00e9l\u00e8vement nasal pharyng\u00e9 chez les patients d\u00e9j\u00e0 trait\u00e9s et asymptomatiques au moment de l'enqu\u00eate.", "objectives": "Faible", "methods": "D\u00e9montrer laquelle des deux m\u00e9thodes de diagnostic est la plus sensible entre la d\u00e9tection de le RNA viral sur le pr\u00e9l\u00e8vement nasal pharyng\u00e9 et l'expectoration induite", "pubmed_id": "32171389", "doi": "10.1016/S1473-3099(20)30174-2", "abstract": null, "topics": ["Diagnostique", "Transversale"], "author_list": [{"id": 113, "name": "Han H"}], "publication_date": "2020-03-12"}, {"id": 176, "slug": "viral-rna-load-as-determined-by-cell-culture-as-a-management-tool-for-discharge-", "title": "Viral RNA load as determined by cell culture as a management tool for discharge of SRAS-CoV-2 patients from infectious disease wards", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Explorer la charge virale par culture celllulaire comme outil pour la contagiosit\u00e9 et donc d\u00e9terminer la sortie des patients des services de maladies infectieuses", "verbose_date": "27.03.2020", "authors": "La Scola B ", "specialties": [{"id": 5, "name": "Virologie"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.dropbox.com/s/6a00hh1etucfd44/La-Scola-et-al.3-IHU-draft.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Propose la culture cellulaire pour d\u00e9terminer la sortie des patients COVID-19 : si Ct >= \u00e0 34, sortie possible", "objectives": "1) Pre-print (pas encore de reviewing)2) Non indiqu\u00e9 si \u00e9valuation en aveugle3) 129 cultures cellulaires possibles / 183 RT PCR + (70%)4) Dans d'autres \u00e9tudes, \u00e9chantillons de selles positifs plus longtemps (voir article Prolonged presence of SRAS-CoV-2 viral RNA in faecal samples)5) Co\u00fbt et faisabilit\u00e9 d'une telle m\u00e9thode (temps d'obtention des r\u00e9sultats, mat\u00e9riel dans les labos?)6) \"\"Sur la base de ces donn\u00e9es, nous pouvons d\u00e9duire qu'avec notre syst\u00e8me, les patients avec des valeurs Ct \u00e9gales ou sup\u00e9rieures \u00e0 34 n'excr\u00e8tent pas de particules virales infectieuses\"\" mais in vitro", "methods": "Explorer la charge virale par culture celllulaire comme outil pour la contagiosit\u00e9 et donc d\u00e9terminer la sortie des patients des services de maladies infectieuses", "topics": ["Pronostique", "Virologie"], "author_list": [{"id": 161, "name": "La Scola B "}], "publication_date": "2020-03-27"}, {"id": 560, "slug": "first-data-analysis-about-possible-covid-19-virus-airborne-diffusion-due-to-air-", "title": "First data analysis about possible COVID-19 virus airborne diffusion due to air particulate matter (PM): the case of Lombardy (Italy)", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer s\u2019il existe une corr\u00e9lation entre la concentration en particules fines (PM10) et la propagation du virus SARS Cov 2, et si ces particules peuvent constituer un vecteur de transmission du virus.", "verbose_date": "11.05.2020", "authors": "Bontempi E", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 221, "name": "Environ Res"}, "link": "https://doi.org/10.1016/j.envres.2020.109639", "findings": "", "take_away": "", "relevance_level": "Aucune corr\u00e9lation directe entre la pr\u00e9sence d\u2019une grande quantit\u00e9 de PM10 et la diffusion du virus n\u2019a pu \u00eatre mise en \u00e9vidence.", "objectives": "Pr\u00e9-Print.L\u2019analyse se limite \u00e0 quelques provinces d\u2019Italie et les nombreux facteurs de confusion (disparit\u00e9s entre les r\u00e9gions en termes de densit\u00e9 de population, mode de vie, niveau de vie, etc.) pourraient fausser les r\u00e9sultats des auteurs.", "methods": "D\u00e9terminer s\u2019il existe une corr\u00e9lation entre la concentration en particules fines (PM10) et la propagation du virus SARS Cov 2, et si ces particules peuvent constituer un vecteur de transmission du virus.", "topics": ["Autres", "Transversale"], "author_list": [{"id": 525, "name": "Bontempi E"}], "publication_date": "2020-05-11"}, {"id": 508, "slug": "clinical-characteristics-and-outcomes-of-patients-with-severe-covid-19-with-diab", "title": "Clinical characteristics and outcomes of patients with severe covid-19 with diabetes", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier les sp\u00e9cificit\u00e9s cliniques et l'\u00e9volution des patients diab\u00e9tiques atteints par une forme s\u00e9v\u00e8re de COVID-19.", "verbose_date": "02.05.2020", "authors": "Yan Y", "specialties": [{"id": 17, "name": "Cardiologie et maladies m\u00e9taboliques"}], "category": {"id": 6, "name": "Pronostique", "icon": "icon-chat"}, "journal": {"id": 202, "name": "BMJ open diabetes research & care"}, "link": "https://drc.bmj.com/content/bmjdrc/8/1/e001343.full.pdf", "findings": "", "take_away": "", "relevance_level": "Les patients COVID-19 s\u00e9v\u00e8res avec ant\u00e9c\u00e9dent de diab\u00e8te, plus \u00e2g\u00e9s que les non diab\u00e9tiques, semblent pr\u00e9senter une plus importante r\u00e9ponse inflammatoire, \u00eatre plus susceptibles d'\u00eatre admis en soins intensifs et d'\u00eatre ventil\u00e9s. Leur taux de survie est \u00e9galement moins \u00e9lev\u00e9 et pourrait s'expliquer par leur niveau de glyc\u00e9mie.", "objectives": "- \u00e9tude r\u00e9trospective monocentrique- biais de s\u00e9lection li\u00e9 \u00e0 cet h\u00f4pital d\u00e9sign\u00e9 pour le traitement des patients s\u00e9v\u00e8res- faible effectif- l'analyse de la dur\u00e9e d'hospitalisation n'exclue pas les patients d\u00e9c\u00e9d\u00e9s", "methods": "Etudier les sp\u00e9cificit\u00e9s cliniques et l'\u00e9volution des patients diab\u00e9tiques atteints par une forme s\u00e9v\u00e8re de COVID-19.", "pubmed_id": "32345579\n31986261\n21487074\n32125362\n9973685\n21169542\n16759303\n30805712\n21252989\n24002281\n32007143\n9272930\n32007145\n12734147\n31995857\n20587722\n23747244\n32004427\n27820698\n17029568\n30070331\n32031570\n24530745\n27612502\n31986264\n32105632\n28251163\n32003551\n23473035\n24077098", "doi": "10.1136/bmjdrc-2020-001343", "abstract": "This study explores the clinical characteristics of patients with diabetes with severe covid-19, and the association of diabetes with survival duration in patients with severe covid-19.\nIn this single-center, retrospective, observational study, the clinical and laboratory characteristics of 193 patients with severe covid-19 were collected. 48 patients with severe covid-19 had diabetes, and 145 patients (ie, the controls) did not have diabetes. A severe case was defined as including at least one of the following criteria: (1) Respiratory rate >30/min. (2) Oxygen saturation \u226493%. (3) PaO\nOf 193 patients with severe covid-19, 48 (24.9%) had diabetes. Compared with patients with severe covid-19 without diabetes, patients with diabetes were older, susceptible to receiving mechanical ventilation and admission to ICU, and had higher mortality. In addition, patients with severe covid-19 with diabetes had higher levels of leukocyte count, neutrophil count, high-sensitivity C reaction protein, procalcitonin, ferritin, interleukin (IL) 2 receptor, IL-6, IL-8, tumor necrosis factor \u03b1, D-dimer, fibrinogen, lactic dehydrogenase and N-terminal pro-brain natriuretic peptide. Among patients with severe covid-19 with diabetes, more non-survivors were men (30 (76.9%) \nThe mortality rate in patients with severe covid-19 with diabetes is considerable. Diabetes may lead to an increase in the risk of death.", "topics": ["Pronostique", "Cardiologie et maladies m\u00e9taboliques"], "author_list": [{"id": 476, "name": "Yan Y"}], "publication_date": "2020-05-02"}, {"id": 307, "slug": "timing-of-antiviral-treatment-initiation-is-critical-to-reduce-sars-cov-2-viral-", "title": "Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Mod\u00e9lisation de la dynamique virale de 13 patients infect\u00e9s non trait\u00e9s pour inf\u00e9rer les param\u00e8tres de croissance virale et pr\u00e9dire l'effet de traitements antiviraux.", "verbose_date": "10.04.2020", "authors": "Gon\u00e7alves A", "specialties": [{"id": 5, "name": "Virologie"}, {"id": 12, "name": "Infectiologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.04.20047886v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Pour r\u00e9duire le pic viral de plus de 2 log, l'efficacit\u00e9 des traitements doit \u00eatre de plus de 80% si les traitements sont administr\u00e9s au d\u00e9but des sympt\u00f4mes. Une efficacit\u00e9 de 50% pourrait \u00eatre suffisante si les traitements sont initi\u00e9s avant le d\u00e9but des sympt\u00f4mes.\n\r\nCompte tenu de leurs propri\u00e9t\u00e9s pharmacocin\u00e9tiques / pharmacodynamiques, les m\u00e9dicaments actuellement \u00e9tudi\u00e9s pourraient avoir une efficacit\u00e9 de 20 \u00e0 70%. Ils peuvent aider \u00e0 contr\u00f4ler le virus\r\nsi administr\u00e9 tr\u00e8s t\u00f4t, mais pourraient ne pas avoir d'effet chez les patients s\u00e9v\u00e8res.\n\r\nL'association de m\u00e9dicaments et une posologie plus agressive, y compris la prise en compte des doses de charge pour obtenir rapidement des expositions th\u00e9rapeutiques, peuvent \u00eatre b\u00e9n\u00e9fiques pour maximiser l'efficacit\u00e9 de ces agents antiviraux r\u00e9utilis\u00e9s. Cependant, ils peuvent \u00eatre pertinents dans l'administration prophylactique pr\u00e9 ou post-exposition pour r\u00e9duire la r\u00e9plication virale et donc le risque de progression de la maladie.", "objectives": "preprint - temps d'incubation d\u00e9fini \u00e0 5j pour tous les patients - seulement 13 patients - pas d'\u00e9tudes in vivo sur l'efficacit\u00e9 des traitements\"", "methods": "Mod\u00e9lisation de la dynamique virale de 13 patients infect\u00e9s non trait\u00e9s pour inf\u00e9rer les param\u00e8tres de croissance virale et pr\u00e9dire l'effet de traitements antiviraux.", "pubmed_id": "32511641", "doi": "10.1101/2020.04.04.20047886", "abstract": "We modeled the viral dynamics of 13 untreated patients infected with SARS-CoV-2 to infer viral growth parameters and predict the effects of antiviral treatments. In order to reduce peak viral load by more than 2 logs, drug efficacy needs to be greater than 80% if treatment is administered after symptom onset; an efficacy of 50% could be sufficient if treatment is initiated before symptom onset. Given their pharmacokinetic/pharmacodynamic properties, current investigated drugs may be in a range of 20-70% efficacy. They may help control virus if administered very early, but may not have a major effect in severe patients.", "topics": ["Th\u00e9rapeutique", "Virologie", "Infectiologie"], "author_list": [{"id": 294, "name": "Gon\u00e7alves A"}], "publication_date": "2020-04-10"}, {"id": 123, "slug": "time-course-of-lung-changes-on-chest-ct-during-recovery-from-2019-novel-coronavi", "title": "Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "D\u00e9terminer l'\u00e9volution des anomalies au scanner thoracique du diagnostic \u00e0 la gu\u00e9rison", "verbose_date": "13.02.2020", "authors": "Pan F", "specialties": [{"id": 3, "name": "Radiologie"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 51, "name": "Radiology"}, "link": "https://www.dropbox.com/s/n68mbzd6tiq356c/radiol.2020200370.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "4 stades d'\u00e9volution au scanner 1) stade pr\u00e9coce (J0-J4)2) stade progressif (J5-J8)3) stade maximal (J10-J13)4) phase d'absorption (>J14)", "objectives": "Faible : 1) monocentrique, majoritairement des femmes, patients jeunes2) patients graves exclus (FR>30, O2 ou VM, SpO2<90% en AA)3) \u00e9tude descriptive", "methods": "D\u00e9terminer l'\u00e9volution des anomalies au scanner thoracique du diagnostic \u00e0 la gu\u00e9rison", "topics": ["Autres", "Radiologie"], "author_list": [{"id": 129, "name": "Pan F"}], "publication_date": "2020-02-13"}, {"id": 178, "slug": "the-use-of-anti-inflammatory-drugs-in-the-treatment-of-people-with-severe-corona", "title": "The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Experience of Clinical Immunologists From China", "has_other_authors": true, "impact_factor": {"id": 3, "name": "Interm\u00e9diaire", "posts_count": 140, "color": "orange", "order": 2}, "goals_plain": "Evaluer l'int\u00e9r\u00eat de plusieurs traitements anti-inflammatoires pour les patients infect\u00e9s par le COVID-19", "verbose_date": "27.03.2020", "authors": "Zhang W ", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 90, "name": "Clin Immunol"}, "link": "https://www.dropbox.com/s/yqilb0gaob8gomc/1-s2.0-S1521661620301984-main.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "L'inflammation est une caract\u00e9ristique importante dans les formes s\u00e9v\u00e8res du COVID-19, c'est pourquoi de nombreuses th\u00e9rapeutiques anti-inflammatoires sont \u00e0 l'\u00e9tude actuellement.\r\nA l'heure d'aujourd'hui, aucun traitement anti-inflammatoire sp\u00e9cifique n'est recommand\u00e9 :\r\n- Corticoth\u00e9rapie : essais contradictoires et m\u00e9thodologiquement peu robustes\r\n- Tocilizumab : essais en cours\r\n- Inhibiteur JAK : essais en cours\r\n- Chloroquine : effet in vitro, mais efficacit\u00e9 et s\u00e9curit\u00e9 in vivo encore \u00e0 d\u00e9montrer", "objectives": "- Revue de la litt\u00e9rature existante et avis d'experts- Litt\u00e9rature h\u00e9t\u00e9rog\u00e8ne et d'un niveau de preuve encore faible pour pouvoir tirer des conclusions sur la prise en charge \u00e0 adopter", "methods": "Evaluer l'int\u00e9r\u00eat de plusieurs traitements anti-inflammatoires pour les patients infect\u00e9s par le COVID-19", "topics": ["Th\u00e9rapeutique", "Transversale"], "author_list": [{"id": 172, "name": "Zhang W "}], "publication_date": "2020-03-27"}, {"id": 231, "slug": "the-qt-interval-in-patients-with-sars-cov-2-infection-treated-with-hydroxychloro", "title": "The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine / Azithromycin", "has_other_authors": true, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Etudier l'allongement du QT dans le traitement par Hydroxychloroquine et Azithromycine en association ", "verbose_date": "03.04.2020", "authors": "Chorin E", "specialties": [{"id": 7, "name": "Transversale"}, {"id": 12, "name": "Infectiologie"}, {"id": 4, "name": "Anesth\u00e9sie-R\u00e9animation"}, {"id": 8, "name": "Pneumologie"}], "category": {"id": 4, "name": "Th\u00e9rapeutique", "icon": "icon-med"}, "journal": {"id": 85, "name": "Pre-prints"}, "link": "https://www.medrxiv.org/content/10.1101/2020.04.02.20047050v1.full.pdf", "findings": "", "take_away": "", "relevance_level": "Le traitement par hydroxychloroquine et azithromycine pourrait \u00eatre \u00e0 risque d'artythmie cardiaque provoquant le d\u00e9c\u00e8s. Le QTc a \u00e9t\u00e9 augment\u00e9 de 30 ms en moyenne chez les patients trait\u00e9s et pour 11% d'entre eux, le QTc a d\u00e9pass\u00e9 les 500 ms sans torsade de pointe.\r\nLe QTc de base ne permet pas de pr\u00e9dire l'\u00e9volution sous traitement.", "objectives": "- Pre-prints- Pas de structuration de type article scientifique avec une m\u00e9thodologie peu d\u00e9taill\u00e9e- H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 des patients- Temps de suivi ECG relativement court", "methods": "Etudier l'allongement du QT dans le traitement par Hydroxychloroquine et Azithromycine en association", "topics": ["Th\u00e9rapeutique", "Transversale", "Infectiologie", "Anesth\u00e9sie-R\u00e9animation", "Pneumologie"], "author_list": [{"id": 221, "name": "Chorin E"}], "publication_date": "2020-04-03"}, {"id": 124, "slug": "rapid-response-to-covid-19-outbreak-in-northern-italy-how-to-convert-a-classic-i", "title": "Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre", "has_other_authors": false, "impact_factor": {"id": 2, "name": "Faible", "posts_count": 485, "color": "red", "order": 3}, "goals_plain": "Exposer la r\u00e9organisation d'un batiment pour accueillir des patients COVID-19", "verbose_date": "26.03.2020", "authors": "Asperges E", "specialties": [{"id": 7, "name": "Transversale"}], "category": {"id": 2, "name": "Autres", "icon": "icon-other"}, "journal": {"id": 6, "name": "J Hosp Infect"}, "link": "https://www.dropbox.com/s/17kqd91m0lj3cdk/PIIS0195670120301195.pdf?dl=0", "findings": "", "take_away": "", "relevance_level": "Possibilit\u00e9 de modifier tr\u00e8s rapidement l'organisation et la fonction de service de soins ou d'autres services\r\nEn moins de deux semaines, un batiment de maladies infectieuse a r\u00e9ussi \u00e0 plus que doubler son nombre delits r\u00e9guliers de 44 \u00e0 94, \u00e0 cr\u00e9er un service infectieux sous-intensif et \u00e0 cr\u00e9er un service d'urgence infectieuses avec 16 lits pour les soins aigus.", "objectives": "1) Pre-proof2) Revue d'exp\u00e9rience\"", "methods": "Exposer la r\u00e9organisation d'un batiment pour accueillir des patients COVID-19", "topics": ["Autres", "Transversale"], "author_list": [{"id": 3, "name": "Asperges E"}], "publication_date": "2020-03-26"}]